GENE	Synonyms	EntrezId	MapLocation	NMID	Variant	TumorType	ResponseType	TherapyName	ApprovalStatus	EvidenceType	EfficacyEvidence	References
ABL1	ABL | bcr/abl | c-ABL | c-ABL1 | CHDSKM | JTK7 | p150 | v-abl	9q34.12	NM_005157	ABL1 R332W ABL1 T315I	lung adenocarcinoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 26758680).
ABL1	ABL | bcr/abl | c-ABL | c-ABL1 | CHDSKM | JTK7 | p150 | v-abl	9q34.12	NM_005157	ABL1 R332W ABL1 T315I	lung adenocarcinoma	resistant	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Gleevec (imatinib) in culture and in xenograft models (PMID: 26758680).
ABL1	ABL | bcr/abl | c-ABL | c-ABL1 | CHDSKM | JTK7 | p150 | v-abl	9q34.12	NM_005157	ABL1 G321L	lung adenocarcinoma	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680).
ABL1	ABL | bcr/abl | c-ABL | c-ABL1 | CHDSKM | JTK7 | p150 | v-abl	9q34.12	NM_005157	ABL1 G321L	lung adenocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680).
ABL1	ABL | bcr/abl | c-ABL | c-ABL1 | CHDSKM | JTK7 | p150 | v-abl	9q34.12	NM_005157	ABL1 G250R ABL1 G251D	oral cavity cancer	no benefit	Nilotinib	Clinical Study	Actionable	In a clinical study, Tasigna (nilotinib) treatment resulted in no benefit in a patient with oral cavity cancer harboring ABL1 G250R and G251D (PMID: 28514312).
ABL1	ABL | bcr/abl | c-ABL | c-ABL1 | CHDSKM | JTK7 | p150 | v-abl	9q34.12	NM_005157	ABL1 R332W	lung adenocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) in culture (PMID: 26758680).
ABL1	ABL | bcr/abl | c-ABL | c-ABL1 | CHDSKM | JTK7 | p150 | v-abl	9q34.12	NM_005157	ABL1 R332W	lung adenocarcinoma	sensitive	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 R332W (also reported as R351W) in culture, and inhibited tumor growth in xenograft models (PMID: 26758680).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 wild-type	ovarian cancer	predicted - sensitive	GSK2141795	Phase I	Actionable	In a Phase I trial, GSK2141795 treatment resulted in Akt inhibition and clinical benefit in 27% (3/11) of ovarian cancer patients (PMID: 26429956).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 wild-type	cancer	sensitive	GSK2141795	Preclinical	Actionable	In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 wild-type	clear cell renal cell carcinoma	sensitive	Everolimus + RX-0201	Phase Ib/II	Actionable	In a Phase I/II trial, RX-0201 and Afinitor (everolimus) combination therapy resulted in stable disease in 40% (2/5) of patients with metastatic clear cell renal carcinoma (J Clin Oncol 34, 2016 (suppl 2S; abstr 550)).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 act mut	lymphoma	no benefit	Sirolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) treatment did not improve survival in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 act mut	lymphoma	predicted - sensitive	Doxorubicin + Sirolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment resulted in improved survival and prolonged remission in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 act mut	Advanced Solid Tumor	no benefit	Triciribine	Phase I	Actionable	In a Phase I trial, Triciribine (API-2) demonstrated safety, but lacked efficacy as a monotherapy in advanced solid tumor patients with activated Akt (PMID: 20644979).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 act mut	lymphoma	decreased response	Doxorubicin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, lymphoma cells overexpressing constitutively active Akt demonstrated reduced sensitivity to Adriamycin (doxorubicin) treatment in cell line xenograft models (PMID: 18708578).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 amp	Advanced Solid Tumor	predicted - sensitive	ONC201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ONC201 (TIC-10) inhibited Akt activation and induced apoptosis and tumor regression in a variety of cell line xenograft models (PMID: 23390247).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 over exp PIK3CA H1047R	breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 over exp PIK3CA E545K	breast cancer	resistant	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 W80A	breast cancer	resistant	MK2206	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing AKT1 W80A were resistant to MK2206 in culture, resulting in repression of induced cell death when compared to wild-type AKT1 (PMID: 25551293).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 W80A	Advanced Solid Tumor	resistant	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, transformed mouse adipocytes expressing human Akt1 W80A were resistant to the AKT inhibitor, MK-2206 (PMID: 25856301).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K KRAS wild-type BRAF wild-type	colorectal cancer	resistant	Cetuximab + Irinotecan	Clinical Study	Actionable	In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K FGFR3 Y373C	urinary bladder cancer	sensitive	AZD5363 + AZD4547	Preclinical	Actionable	In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K NRAS G12D	prostate cancer	sensitive	BAY1125976	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	endometrial cancer	sensitive	Capivasertib	Clinical Study	Actionable	In a clinical study, two patients with endometrial cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	breast papillary carcinoma	sensitive	Capivasertib	Phase I	Actionable	In a Phase I clinical trial, a patient with ER-positive, ERBB2 (HER2)-negative papillary breast carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 (PMID: 26351323).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	ovarian endometrial cancer	sensitive	Capivasertib	Phase I	Actionable	In a Phase I clinical study, a patient with endometrioid ovarian carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 for more than two years (PMID: 26351323).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	Advanced Solid Tumor	sensitive	Capivasertib	Phase I	Actionable	In a Phase I clinical trial in patients with advanced solid tumors, AZD5363 demonstrated safety and preliminary antitumor activity, with stable disease in 27% (10/37) of patients and partial response in two patients, both of whom harbored an AKT1 E17K mutation (PMID: 26931343).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	Her2-receptor negative breast cancer	sensitive	Ipatasertib	Phase I	Actionable	In a Phase I trial, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring AKT1 E17K demonstrated a complete metabolic response when treated with Ipatasertib (GDC-0068) (PMID: 27872130).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	anal canal cancer	sensitive	BAY1125976	Preclinical - Pdx	Actionable	In a preclinical study, treatment with BAY1125976 reduced tumor growth and resulted in partial tumor regression or stable disease in anal cancer patient-derived xenograft (PDX) models harboring AKT1 E17K (PMID: 27699769).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	granulosa cell tumor	sensitive	Capivasertib	Phase I	Actionable	In a Phase I trial, a patient with ovarian granulosa cell tumor cancer harboring subclonal AKT E17K demonstrated an overall tumor regression of 24% when treated with AZD5363, which lasted 253 days (PMID: 28489509).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	meningothelial meningioma	sensitive	Capivasertib	Clinical Study	Actionable	In a clinical case study, a patient with meningothelial meningioma harboring AKT1 E17K demonstrated stable disease and some tumor regression when treated with AZD5363 (PMID: 28376212).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	cancer	sensitive	GSK2141795	Preclinical	Actionable	In a preclinical study, the pan AKT inhibitor GSK2141795 displayed similar levels of inhibition against ATK1 E17K (activating mutation) as ATK1 wild-type (PMID: 24978597).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	cervical cancer	sensitive	Capivasertib	Clinical Study	Actionable	In a clinical study, a patient with cervical cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	endometrial cancer	sensitive	ARQ 751	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ 751, demonstrating inhibition of tumor growth (PMID: 26469692).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	triple-receptor negative breast cancer	sensitive	Capivasertib	Clinical Study	Actionable	In a clinical study, a patient with triple-receptor negative breast cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	breast cancer	sensitive	BAY1125976	Preclinical - Pdx	Actionable	In a preclinical study, BAY1125976 induced complete tumor regression in a patient-derived xenograft (PDX) model of breast cancer harboring AKT E17K (PMID: 27699769).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	melanoma	sensitive	GSK2141795	Preclinical - Cell culture	Actionable	In a preclinical study, Uprosertib (GSK2141795) inhibited the growth of melanoma cells harboring AKT1 E17K in culture (PMID: 24735930).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	endometrial cancer	sensitive	ARQ092	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ092, demonstrating inhibition of tumor growth (PMID: 26469692).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	breast cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, AZD5363 inhibited growth and colony formation of breast cancer cells expressing AKT E17K in cell culture and in xenografts as well as breast cancer explant models harboring AKT E17K (PMID: 26351323).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	breast cancer	sensitive	Capivasertib	Clinical Study	Actionable	In a clinical study, four patients with ESR1-positive breast cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K	lung adenocarcinoma	sensitive	Capivasertib	Clinical Study	Actionable	In a clinical study, a patient with lung adenocarcinoma harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 E17K NRAS Q61R	bladder carcinoma	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 positive	ovarian clear cell carcinoma	predicted - sensitive	Perifosine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Perifosine (KRX-0401) inhibited Akt1 signaling, inhibited proliferation, and induced apoptosis in human ovarian clear cell cancer cells with activated Akt1 in culture and inhibited tumor growth in cell line xenografts (PMID: 25519148).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 positive	ovarian clear cell carcinoma	predicted - sensitive	Cisplatin + Perifosine	Preclinical - Cell culture	Actionable	In a preclinical study, Perifosine (KRX-0401) enhanced the sensitivity of human ovarian clear cell cancer cells with activated Akt1 to Platinol (cisplatin) treatment in culture (PMID: 25519148).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 P68_C77dup	breast cancer	sensitive	Capivasertib	Preclinical - Cell culture	Actionable	In a preclinical study, breast epithelial cells expressing AKT1 P68_C77dup demonstrated sensitivity by AZD5363 in culture, resulting in decreased cell survival (PMID: 29247016).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 mutant	endometrial cancer	sensitive	GDC-0980	Phase II	Actionable	In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 mutant	triple-receptor negative breast cancer	predicted - sensitive	Ipatasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 mutant	endometrial cancer	predicted - sensitive	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.16) and response rate (response difference 0.83) in advanced endometrial cancer patients harboring AKT1 mutations (PMID: 27016228).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 mutant	invasive bladder transitional cell carcinoma	predicted - resistant	Cisplatin + Gemcitabine + Sorafenib	Phase II	Actionable	In a Phase II trial, AKT1 mutations were more frequent in  muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 Q79K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 Q79K BRAF V600X PTEN pos	melanoma	sensitive	MK2206 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).
AKT1	AKT | CWS6 | PKB | PKB-ALPHA | PRKBA | RAC | RAC-ALPHA	14q32.33	NM_001014432	AKT1 Q79K	ovarian cancer	sensitive	Capivasertib	Clinical Study	Actionable	In a clinical study, an ovarian cancer patient harboring AKT1 Q79K demonstrated tumor regression that lasted 14 months when treated with AZD5363 (PMID: 28489509).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp ALK F1174V	neuroblastoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174V in culture (PMID: 29907598).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp ALK F1174V	neuroblastoma	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174V in culture (PMID: 29907598).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp Tp53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK amp	anaplastic large cell lymphoma	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK demonstrated a decreased response compared to parental cell lines harboring NPM1-ALK when treated with Alecensa (alectinib) in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp	neuroblastoma	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) was less efficient than Lorlatinib (PF-06463922) to induced growth inhibition in ALK-amplified neuroblastoma cells in culture (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp	neuroblastoma	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of ALK amplified neuroblastoma cells in culture (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp	neuroblastoma	sensitive	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 inhibited growth of ALK-amplified neuroblastoma cells in culture (PMID: 22203728).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp EML4-ALK EGFR L858R	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK partially responded to Xalkori (crizotinib) therapy, but progressed after four months, and was found to have acquired ALK amplification and EGFR L858R (PMID: 23344087).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp ALK F1174L	neuroblastoma	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174L in culture (PMID: 29907598).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp ALK F1174L	neuroblastoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174L in culture (PMID: 29907598).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp ALK rearrange	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, three patients with non-small cell lung carcinoma co-harboring an ALK rearrangement and ALK amplification demonstrated resistance to Xalkori (crizotinib) treatment (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK amp ALK rearrange	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, two non-small cell lung carcinoma patient harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed, and was found to have acquired ALK amplification (PMID: 25724526).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1152P	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1152P	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1152P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174V ALK G1202R	non-small cell lung carcinoma	sensitive	Ceritinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who was previously treated with Xalkori (crizotinib) and subsequently developed the resistance mutation, ALK G1269A, was treated with Zykadia (ceritinib), later progressed, and was found to have lost ALK G1269A, but gained ALK F1174V and ALK G1202R (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK G1202R	non-small cell lung carcinoma	predicted - resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, ALK G1202R was identified in a patient with ALK-rearranged non-small cell lung carcinoma after the disease progressed while on Xalkori (crizotinib) followed by Alecensa (alectinib) therapy (PMID: 27130468).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK G1202R	non-small cell lung carcinoma	predicted - resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, ALK G1202R was identified in a patient with ALK-rearranged non-small cell lung carcinoma after the disease progressed while on Zykadia (ceritinib) followed by Alecensa (alectinib) therapy (PMID: 28285684).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK G1202R	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1202R in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion ALK G1202R	non-small cell lung carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I trial, treatment with Lorlatinib (PF-06463922) demonstrated safety and resulted in durable responses in patients with ALK-positive non-small cell lung cancer, including patients harboring ALK G1202R (J Clin Oncol 34, 2016 (suppl; abstr 9009)).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK G1202R	Advanced Solid Tumor	sensitive	Ropotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TPX-0005 inhibited ALK G1202R and suppressed tumor growth in cell line xenograft models with ALK G1202R (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK G1202R ALK L1196M	non-small cell lung carcinoma	resistant	Lorlatinib	Clinical Study	Actionable	In a clinical study, ALK L1196M was identified as an acquired mutation in an ALK-positive non-small cell lung cancer patient harboring ALK G1202R who developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK G1202R ALK G1269A ALK L1204V	non-small cell lung carcinoma	resistant	Lorlatinib	Clinical Study	Actionable	In a clinical study, ALK G1269A and L1204V were identified as acquired mutations in an ALK-positive non-small cell lung cancer patient harboring ALK G1202R who developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	non-small cell lung carcinoma	resistant	Ceritinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who acquired the secondary drug resistance mutation, ALK S1206Y, when treated with Xalkori (crizotinib) was subsequently treated with Zykadia (ceritinib), developed drug resistance, and was then found to have lost the ALK S1206Y mutation, but gained ALK G1202R (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	non-small cell lung carcinoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, an ALK G1202R secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Ropotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor regression in cell line xenograft models (European Journal of Cancer , Volume 69, S32).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	non-small cell lung carcinoma	predicted - resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK, who had developed resistance to Xalkori (crizotinib), was found to harbor ALK G1202R following treatment with Alecensa (alectinib) (PMID: 24736079).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	lung cancer	conflicting	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	lung cancer	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK S1206Y	non-small cell lung carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK S1206Y in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK S1206Y	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed after 32 months, and was found to have acquired ALK S1206Y (PMID: 25724526).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK S1206Y	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, an ALK S1206Y secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture  (PMID: 26144315).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK G1128A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK G1128A was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK D1091N	neuroblastoma	sensitive	AZD3463 + Doxorubicin	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK D1091N	neuroblastoma	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 treatment in a neuroblastoma cell line harboring ALK D1091N resulted in inhibition of colony formation, repression of Pi3k signaling, and induction of apoptosis in culture (PMID: 26786851).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK D1091N	neuroblastoma	predicted - sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) treatment in a neuroblastoma cell line harboring ALK D1091N resulted in decreased cell viability, inhibition of colony formation, and inhibition of Pi3k pathway signaling in culture (PMID: 28455243).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK D1091N	neuroblastoma	predicted - sensitive	Alectinib + Doxorubicin	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V ALK L1196M	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK T1151dup ALK G1269A	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring an ALK rearrangement demonstrated a partial response with Xalkori (crizotinib) treatment, but then progressed after 10.8 months, and was found to harbor secondary resistance mutations, ALK T1151dup and ALK G1269A (PMID: 25724526).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22235099).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK in the context of EML4-ALK were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expression EML4-ALK with ALK G1269A in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited  growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	decreased response	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) compared to cells expressing wild-type EML4-ALK (PMID: 26939704).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In preclinical studies, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	non-small cell lung carcinoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated stable disease when treated with Xalkori (crizotinib), but then progressed, and was found to harbor a secondary resistance mutation, ALK G1269A (PMID: 22235099).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	non-small cell lung carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines expressing ALK G1269A in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	non-small cell lung carcinoma	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer  cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in cell line xenograft models (PMID: 26849637, PMID: 23344087).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	non-small cell lung carcinoma	sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1269A	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK E1210K ALK D1203N ALK G1269A	non-small cell lung carcinoma	resistant	Lorlatinib	Clinical Study	Actionable	In a clinical study, ALK G1269A was identified as an acquired mutation in an ALK-positive non-small cell lung cancer patient harboring ALK E1210K and D1203N who developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171T was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK G1269A was identified as a compound mutation in transformed cells expressing ALK F1174C in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were re-sensitized and became modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A ALK L1196M	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response when treated with Xalkori (crizotinib), however, after 6 months the patient progressed and was found to harbor two secondary resistance mutations, ALK G1269A and ALK L1196M (PMID: 23344087).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A ALK L1196M	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK G1269A was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK G1269A was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1269A ALK I1171N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171N was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151dup	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151dup	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151dup	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion	Advanced Solid Tumor	predicted - sensitive	Ropotrectinib	Phase I	Actionable	In a Phase I (TRIDENT-1) trial, Ropotrectinib (TPX-0005) treatment resulted in stable disease in 25% (4/16) of patient with advanced solid tumor harboring ALK fusions who completed 2 cycles of treatment (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion	non-small cell lung carcinoma	sensitive	Alectinib	Phase II	Actionable	In a Phase II trial, treatment with Alecensa (alectinib) resulted in a 49% (60/122) overall response rate in non-small cell lung cancer patients positive for an ALK fusion who had previously progressed on Xalkori (crizotinib) therapy (J Clin Oncol 33, 2015 (suppl; abstr 8008))
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion	non-small cell lung carcinoma	sensitive	Alectinib	Phase III	Actionable	In a Phase III trial, treatment with Alecensa (alectinib) resulted in improved progression-free survival compared to treatment with Xalkori (crizotinib) (HR=0.34)  in ALK-positive non-small cell lung cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 9008)).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion	colorectal cancer	sensitive	Entrectinib	Phase I	Actionable	In a Phase I clinical trial, Entrectinib (RXDX-101) treatment resulted in partial response for more than 3 months in a colorectal cancer patient harboring a CAD-ALK gene fusion (PMID: 26633560).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion	inflammatory myofibroblastic tumor	sensitive	Crizotinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 86% (12/14), with complete response in 36% (5/14), in patients with inflammatory myofibroblastic tumor harboring an ALK fusion (PMID: 28787259; NCT00939770).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion	non-small cell lung carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion	anaplastic large cell lymphoma	sensitive	Crizotinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 83% (5/6, all complete responses), at the 165 mg dose, and 90% (18/20, with complete response in 80% (16/20), at the recommended phase 2 dose of 280 mg, in patients with anaplastic large cell lymphoma harboring an ALK fusion, with 72% of tested patients harboring NPM1-ALK (PMID: 28787259; NCT00939770).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK fusion	non-small cell lung carcinoma	sensitive	Brigatinib	Phase Ib/II	Actionable	In a phase I/II clinical trial, Alunbrig (brigatinib) was determined to be safe and efficacious in patients with advanced, ALK-fusion positive NSCLC (PMID: 24091716).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK	F1245C TP53	wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Pdx	Actionable	In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1245C	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1245C	non-small cell lung carcinoma	sensitive	Ceritinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1245C	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1245C in culture (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1245C	neuroblastoma	resistant	Crizotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1245C in culture, and only delayed tumor growth in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1245C	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK F1245C was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1245C	neuroblastoma	sensitive	Lorlatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1245C in culture, and induced rapid and sustained complete tumor regression in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK D1203N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK D1203N was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F ALK D1203N	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N	Advanced Solid Tumor	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK D1203N in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK I1171N ALK D1203N	non-small cell lung carcinoma	resistant	Lorlatinib	Clinical Study	Actionable	In a clinical study, an ALK-positive non-small cell lung cancer patient harboring ALK I1171N and D1203N in cis developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	decreased response	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture compared to cells expressing wild-type EML4-ALK (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type EGFR wild-type	non-small cell lung carcinoma	predicted - sensitive	Carboplatin +  Pembrolizumab + Pemetrexed	FDA approved	Actionable	In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small-cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type EGFR wild-type	non-small cell lung carcinoma	predicted - sensitive	Cisplatin + Pembrolizumab + Pemetrexed	FDA approved	Actionable	In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small-cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK	wild-type TP53 H168R	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK	wild-type TP53 mutant	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type TP53 wild-type	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK	wild-type TP53 P177T	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type	head and neck cancer	predicted - sensitive	Dalantercept + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of Dalantercept (ACE-041) to Platinol (cisplatin) treatment resulted in increased cytoxicity and decreased tumor growth in cell line xenograft models of head and neck cancer (PMID: 26373572).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type	neuroblastoma	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type	breast cancer	predicted - sensitive	Dalantercept + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Dalantercept (ACE-041) in combination with Platinol (cisplatin) resulted in decreased tumor growth in cell line xenograft models of breast cancer (PMID: 26373572).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type	melanoma	sensitive	Dalantercept + Doxorubicin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Dalantercept (ACE-041) in combination with Adria (doxorubicin) resulted in decreased tumor growth in cell line xenograft models of melanoma, with increased efficacy over either agent alone (PMID: 26373572).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type	Advanced Solid Tumor	sensitive	Ropotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TPX-0005 inhibited cell proliferation in transformed cell lines over expressing wild-type ALK in culture and suppressed tumor growth in xenograft models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type	endometrial cancer	no benefit	dalantercept	Phase II	Actionable	In a Phase II clinical trial, treatment with Dalantercept (ACE-041) did not demonstrate activity as single agent in recurrent or persistent endometrial cancer, with a median progression-free survival (PFS) of 2.1 months, overall survival of 14.5 months, no objective responses, and stable disease in 57% (16/28) of patients (PMID: 25888978).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK wild-type	neuroblastoma	resistant	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 22203728).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK	wild-type TP53 C176F	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK I1179V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1179V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK act mut TP53 wild-type	neuroblastoma	predicted - sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1196M	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1196M	lung adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EML4-ALK achieved a partial response when treated with Xalkori (crizotinib), however, after 5 months, the patient progressed and was found to harbor secondary resistance mutations, ALK C1156Y and ALK L1196M (PMID: 20979473).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK C1156Y ALK L1198F	non-small cell lung carcinoma	resistant	Lorlatinib	Clinical Study	Actionable	In a clinical study, ALK D1203N was identified as an acquired mutation in an ALK-positive non-small cell lung cancer patient harboring ALK C1156Y who developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK F1174C	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK C1156Y	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed after 18.2 months, and was found to have acquired ALK C1156Y (PMID: 25724526).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK F1174V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1198F	non-small cell lung carcinoma	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1198F	non-small cell lung carcinoma	resistant	Lorlatinib	Phase I	Actionable	In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK C1156Y and ALK L1198F in the context of EML4-ALK were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156Y	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171T was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK F1174I	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174I was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	resistant	AUY922	Clinical Study	Actionable	In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing ALK C1156Y in the context of EML4-ALK demonstrated minimal sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	conflicting	Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	conflicting	Ceritinib	Clinical Study	Actionable	In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK C1156Y ALK L1256F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical	Actionable	In a preclinical study, ALK C1156Y was sensitive to Alecensa (alectinib) in an in vitro enzyme assay (PMID: 21575866).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	non-small cell lung carcinoma	sensitive	Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	non-small cell lung carcinoma	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of non-small cell lung cancer cells expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 21502504).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were insensitive to Xalkori (crizotinib) as demonstrated by a lack of growth inhibition and Alk phosphorylation in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ropotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity in culture (PMID: 26939704).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in cell line xenograft models (PMID: 21575866).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK L1256F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with  ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196M	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK F1174L	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174L was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK L1196M	Advanced Solid Tumor	sensitive	Ropotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0005 inhibited cell proliferation in transformed cell lines over expressing ALK L1196M in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK L1196M	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, four non-small cell lung carcinoma patients harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed, and was found to have acquired ALK L1196M (PMID: 25724526).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK L1196M	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, ALK L1196M was identified in biopsies from a non-small cell lung cancer patient harboring ALK rearrangement who developed resistance to Xalkori (crizotinib) (PMID: 22277784).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK F1174V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK I1171S	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171S was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK F1174C	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, introduction of an additional ALK mutation L1198F in transformed cells expressing ALK L1196M in the context of EML4-ALK reduced resistance to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK T1151M	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151M	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK R1192P	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK R1192P	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells overexpressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK R1192P was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK R1192P	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK R1192P	Advanced Solid Tumor	decreased response	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture compared to cells expressing wild-type NPM1-ALK (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK I1171T	lung adenocarcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a patient with a lung adenocarcinoma tumor harboring an ALK rearrangement with ALK I1171T progressed on Alecensa (alectinib) therapy after 4 months and resistance was confirmed using cell culture with cells derived from the patient’s tumor (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK I1171T	lung adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with a lung adenocarcinoma tumor harboring an ALK rearrangement and ALK I1171T progressed on Xalkori (crizotinib) therapy after 8 months and resistance was confirmed using cell culture with cells derived from the patient's tumor (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534), however, another study with comparable cells demonstrated sensitivity in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing ALK I1171T in the context of EML4-ALK but to a lesser degree than cells expressing EML4-ALK in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171T	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response with Xalkori (crizotinib) treatment, but after eight months showed progression, and was found to harbor a secondary resistance mutation, ALK I1171T (PMID: 25393798).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK I1171T	ganglioneuroblastoma	predicted - sensitive	Ceritinib	Clinical Study	Actionable	In a clinical case study, Zykadia (ceritinib) treatment resulted in a 43.6% decrease of the primary tumor after 6.5 months of treatment, and complete resolution of metastases at 21 months after initiation of treatment in a pediatric patient with ganglioneuroblastoma (PMID: 29907598).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171T	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171T	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, an anaplastic large-cell lymphoma cell line expressing ALK I1171T in the context of NPM1-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK L1198P	neuroblastoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to Xalkori (crizotinib) in culture (PMID: 21948233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK L1198P	neuroblastoma	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198P	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 21948233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198P	Advanced Solid Tumor	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174I	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174I	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171S	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859), however, another study with comparable cells demonstrated sensitivity (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171S	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859), however, in another study comparable cells demonstrated sensitivity (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171S	non-small cell lung carcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib) but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171S	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171S	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171S	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174V ALK I1171S	non-small cell lung carcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK F1174V initially responded to Alecensa (alectinib), but then demonstrated progression in one of two lung nodules, which was found to harbor a secondary resistance mutation, ALK I1171S, and upon resection of the nodule the patient continued Alecensa (alectinib) treatment and achieved complete remission (PMID: 26464158).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK I1171N ALK L1198F	non-small cell lung carcinoma	resistant	Lorlatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung cancer patient harboring ALK I1171N and L1198F in cis in the context of EML4-ALK demonstrated primary resistance to Lorlatinib (PF-06463922) (PMID: 29650534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F	Advanced Solid Tumor	decreased response	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing L1198F in the context of EML4-ALK in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V ALK L1198F	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK mut TP53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK mut	non-small cell lung carcinoma	sensitive	Ceritinib	Clinical Study	Actionable	In a retrospective analysis, patients with ALK-rearrangement positive non-small cell lung cancer that acquired ALK drug resistance mutations following Xalkori (crizotinib) treatment had a median progression-free survival (mPFS) of 5.4 months on Zykadia (ceritinib), which was not significantly different than the mPFS of 6.5 months for patients without ALK mutations (PMID: 25724526).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK positive	non-small cell lung carcinoma	sensitive	Ensartinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, Ensartinib (X-396) treatment resulted in partial response (PR) in 60% (19/30) and stable disease in 7% (2/30) of ALK positive non-small cell lung carcinoma patients, PR was 88% (7/8) in crizotinib-naïve patients and 83% (10/12) in patients with prior crizotinib treatment (J Clin Oncol 34, 2016 (suppl; abstr 9056)).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK positive	non-small cell lung carcinoma	no benefit	Crizotinib + Onalespib	Phase II	Actionable	In a Phase II trial, Onalespib (AT13387) and Xalkori (crizotinib) combination treatment did not significantly improve median progression free survival (269 vs 266 days) or objective response rate (55.4%, 38/68 vs 45.3%, 31/68) compared to Xalkori (crizotinib) single treatment in ALK positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9059); NCT01712217).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK positive	non-small cell lung carcinoma	sensitive	Alectinib	FDA approved	Actionable	In a Phase III trial supporting FDA approval (ALEX), Alecensa (alectinib) treatment resulted in improved rate of progression-free survival compared to Xalkori (crizotinib) (68.4% vs 48.7%, HR=0.47), and median progression-free survival (25.7 vs 10.4 months) in ALK-positive non-small cell lung cancer patients  (PMID: 28586279; NCT02075840).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK positive	non-small cell lung carcinoma	sensitive	Lorlatinib	Phase II	Actionable	In a Phase II trial, Lorlatinib (PF-06463922) treatment resulted in an objective response rate of 53% (120/227) in ALK positive non-small cell lung carcinoma patients (J Thorac Oncol. Nov 2017, 12(11); Suppl 2, S1756, abstract OA 05.06; NCT01970865).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK positive	Advanced Solid Tumor	sensitive	Belizatinib	Phase Ib/II	Actionable	In a Phase I trial, Belizatinib (TSR-011) treatment resulted in a response in 100% (3/3) of patients with ALK positive advanced solid tumors when administered at higher doses, and stable disease for 7 months or longer in 56% (5/9) of patients at lower dose (J Clin Oncol 33, 2015 (suppl; abstr 8063)).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK positive	neuroblastoma	sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in partial response in a patient with ALK-positive neuroblastoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK positive	non-small cell lung carcinoma	sensitive	Belizatinib	Phase I	Actionable	In a Phase I clinical trial, Belizatinib (TSR-011) treatment resulted in a partial response in 60% (3/5) of non-small cell lung cancer patients positive for Alk (J Clin Oncol 32, 2014 (suppl; abstr e19005)).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK positive	non-small cell lung carcinoma	sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in stable disease in a patient with ALK-positive non-small cell lung carcinoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1275Q	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a transformed cell line expressing ALK R1275Q was sensitive to Alunbrig (brigatinib) in culture and in cell line xenograft models, resulting in cell growth inhibition (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1275Q	neuroblastoma	sensitive	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 22203728).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1275Q	neuroblastoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 29907598).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1275Q	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in human neuroblastoma cell line xenograft models harboring ALK R1275Q and wild-type TP53 (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1275Q	neuroblastoma	sensitive	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, resulted in growth inhibition of neuroblastoma cells over expressing ALK R1275Q in culture and irapid and sustained complete tumor regression in cell line xenograft models (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1275Q	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK R1275Q in culture (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1275Q	neuroblastoma	conflicting	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK R1275Q in culture, and only delayed tumor growth in cell line xenograft models (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK R1275Q	neuroblastoma	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 29907598).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK G1123D	neuroblastoma	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of ALK G1123D in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK S1206F	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1245V	neuroblastoma	sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in partial response that lasted 8.3 months in a patient with neuroblastoma harboring ALK F1245V, who remained on treatment for over 3.5 years due to clinical benefit (PMID: 28183697).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1128S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK G1128S	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alunbrig (brigatinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202del	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated moderate resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202del	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK Y1278S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK Y1278S was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK E1210K ALK S1206C	non-small cell lung carcinoma	resistant	Brigatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK E1210K eventually progressed on treatment with Alunbrig (brigatinib) and was subsequently found to have acquired another resistance mutation, ALK S1206C (PMID: 29636358).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK S1206C	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK S1206C	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK S1206C	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK G1123S	neuroblastoma	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of ALK G1123S in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK G1123S ALK rearrange	lung adenocarcinoma	predicted - sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, Alecensa (alectinib) treatment resulted in rapid response in a patient with ALK-rearranged lung adenocarcinoma with an acquired an ALK G1123S mutation, whose disease had relapsed 2 years after initial response to Zykadia (ceritinib) (PMID: 26134233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK G1123S ALK rearrange	lung adenocarcinoma	predicted - resistant	Ceritinib	Clinical Study	Actionable	In a clinical study, ALK G1123S was identified as an acquired mutation in a patient with ALK-rearranged lung adenocarcinoma whose disease relapsed 2 years after initial response to Zykadia (ceritinib) (PMID: 26134233).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1152R	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a response to Xalkori (crizotinib) treatment, but after 3 months showed tumor progression, and was found to harbor the secondary resistance mutation, ALK L1152R (PMID: 21791641).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1152R	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture  (PMID: 26144315).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK neg ROS1 pos	non-small cell lung carcinoma	sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022); NCT01945021).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK negative	lymphoma	resistant	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative lymphoma cells in culture (PMID: 22203728).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK negative	leukemia	resistant	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative leukemia cells in culture (PMID: 22203728).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK negative	non-small cell lung carcinoma	resistant	CEP-28122	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ALK negative non-small cell lung carcinoma cells were resistant to CEP-28122 in culture and in cell line xenograft models (PMID: 22203728).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK negative	colon carcinoma	resistant	CEP-28122	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CEP-28122 did not inhibit tumor growth in cell line xenograft models of ALK-negative colon carcinoma (PMID: 22203728).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK V1180L	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK V1180L	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK V1180L	non-small cell lung carcinoma	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK V1180L	non-small cell lung carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring ALK V1180L  in the context of EML4-ALK was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing ALK V1180L  in the context of EML4-ALK in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK N1178H	Advanced Solid Tumor	decreased response	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK N1178H	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK N1178H	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK N1178H	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C demonstrated decreased sensitivity to Alecensa (alectinib) in culture compared to cells expressing EML4-ALK with wild-type ALK (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174C	non-small cell lung carcinoma	resistant	Ceritinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who developed resistance to Xalkori (crizotinib) treatment was subsequently treated with Zykadia (ceritinib), eventually progressed, and was found to have acquired ALK F1174C (PMID: 24675041).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196Q	anaplastic large cell lymphoma	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK L1196Q	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK I1171N was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171N	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK I1171N	non-small cell lung carcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated tumor regression when treated with Alecensa (alectinib), but progressed seven months later, and was found to harbor a secondary resistance mutation, ALK I1171N (PMID: 25393798).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171N	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange ALK I1171N	non-small cell lung carcinoma	predicted - resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a de novo ALK I1171N mutation was identified in the liver metastasis site and circulating DNA of a non-small cell lung cancer patient harboring an ALK rearrangement after disease progression on Alecensa (alectinib) treatment (PMID: 27565911).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L ALK L1198V	non-small cell lung carcinoma	resistant	Brigatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK progressed while being treated with Alunbrig (brigatinib) and was subsequently found to harbor two resistance mutations, ALK F1174L and ALK L1198V, which were both in cis (PMID: 29636358).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK P1139S in the context of NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK P1139S	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174V	non-small cell lung carcinoma	sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK initially responded to Xalkori (crizotinib), but then progressed due to acquisition of the secondary resistance mutation, ALK F1174V, and then responded to treatment with Alecensa (alectinib), demonstrating a complete response in one lung nodule and a 44% decrease in size in a second lung nodule (PMID: 26464158).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174V	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174V	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response to Xalkori (crizotinib) treatment after 3 months, but then progressed, and was found to harbor the secondary resistance mutation, ALK F1174V (PMID: 24736079).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174V	Advanced Solid Tumor	predicted - sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V, but to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1174V	neuroblastoma	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, neuroblastoma cells harboring ALK F1174V were sensitive to Alunbrig (brigatinib) in culture and in vivo, resulting in inhibition of both Alk activity and cell proliferation (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK E1210K	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK E1210K	Advanced Solid Tumor	conflicting	Crizotinib	Clinical Study	Actionable	In a clinical case study, a lung cancer patient harboring EML4-ALK demonstrated progression when treated with Xalkori (crizotinib) due to the secondary acquired resistance mutation, ALK E1210K, however, in vitro transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK E1210K	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EML4-ALK progressed on treatment with Xalkori (crizotinib) and was subsequently found to harbor a secondary resistance mutation, ALK E1210K (PMID: 29636358).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange MET amp	lung adenocarcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement developed resistance to Alecensa (alectinib)treatment, and subsequently was found to harbor amplification of MET (PMID: 24128725, PMID: 24518097).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange MET amp	lung adenocarcinoma	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement who developed resistance to Alecensa (alectinib) likely due to acquisition of MET amplification, responded well to treatment with Xalkori (crizotinib), demonstrating a radiological response after 12 days (PMID: 24128725, PMID: 24518097).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange MAP2K1 K57N	non-small cell lung carcinoma	sensitive	Ceritinib + Selumetinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of AZD6244, resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Ceritinib	Phase II	Actionable	In a Phase II trial (ASCEND-2), non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement and previously treated with Xalkori (crizotinib) and chemotherapy demonstrated an overall response rate of 38.6% (54/140),  a disease control rate of 77.1%, a median time to response of 1.8 months, a median duration of response of 9.7 months, and a median progression-free survival of 5.7 months when treated with Zykadia (ceritinib) (PMID: 27432917; NCT01685060).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Ceritinib	FDA approved	Actionable	In a Phase I trial that supported FDA approval, Zykadia (ceritinib) resulted in a blinded independent review committee (BIRC)-assessed objective response rate of 44% (72/163) and a duration of response of 7.1 months in ALK-rearranged non-small cell lung cancer patients (PMID: 25754348; NCT01283516).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Ceritinib	Clinical Study	Actionable	In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated a median overall survival of 49.5 months following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Zykadia (ceritinib), and radiotherapy (PMID: 26438117).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is included in guidelines as first-line therapy for ALK rearranged non-small cell lung cancer patients, and as subsequent therapy in patients whose disease progressed after Xalkori (crizotinib) therapy (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Ceritinib	Phase III	Actionable	In a Phase III trial, first-line treatment with Zykadia (ceritinib) resulted in an improved median progression-free survival of 16.6 months, compared to 8.1 months with chemotherapy, in patients with ALK-rearranged non-squamous non-small cell lung cancer (PMID: 28126333; NCT01828099).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I trial, Lorlatinib (PF-06463922) treatment resulted in an objective response in 46% (19/41) of patients with non-small cell lung carcinoma harboring an ALK rearrangement (PMID: 29074098; NCT03052608).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Nivolumab	Guideline	Actionable	Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Nivolumab	Clinical Study	Actionable	In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Durvalumab	Clinical Study	Actionable	In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Durvalumab	Guideline	Actionable	Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Afatinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Alectinib	Guideline	Actionable	Alecensa (alectinib) is included in guidelines as the preferred first-line therapy for patients with ALK-rearranged, metastatic non-small cell lung cancer, and as the subsequent therapy for patients who have progressed after Xalkori (crizotinib) (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Alectinib	FDA approved	Actionable	In a Phase III trial supporting FDA approval (ALEX), Alecensa (alectinib) treatment resulted in improved rate of progression-free survival compared to Xalkori (crizotinib) (68.4% vs 48.7%, HR=0.47), and median progression-free survival (25.7 vs 10.4 months) in non-small cell lung cancer patients harboring ALK rearrangement (PMID: 28586279; NCT02075840).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Alectinib	Clinical Study	Actionable	In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Alecensa (alectinib), and radiotherapy (PMID: 26438117).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Alectinib	Phase II	Actionable	In a Phase II trial, Alecensa (alectinib) treatment was effective in treating non-small cell lung cancer patients with ALK rearrangement, resulting in a 50% (61/122) objective response rate (ORR) in all patients, a 45% (43/96) ORR in Crizotinib-refractory patients, and an 83% (70/84) CNS disease control rate (PMID: 26598747).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Crizotinib	FDA approved	Actionable	In a Phase III trial (PROFILE 1014) that supported FDA approval, Xalkori (crizotinib) treatment resulted in improved progression-free survival (10.9 vs 7.0 months, HR=0.45, p<0.001) and objective response rate (74% vs 45%) relative to chemotherapy in NSCLC patients with ALK rearrangements (PMID: 25470694; NCT01154140).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Crizotinib	Phase III	Actionable	In a Phase III trial (PROFILE 1014), Xalkori (crizotinib) treatment resulted in improved progression-free survival (PFS) (PFS=10.9 months, n=172) relative to chemotherapy (PFS=7.0 months, n=171) in NSCLC patients with ALK rearrangements, including patients with and without brain metastases at baseline, and improved intracranial disease rate in patients with brain metastases at baseline (PMID: 27022118; NCT01154140).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Crizotinib	Phase III	Actionable	In a Phase III trial, Xalkori (crizotinib) treatment resulted in improved objective response (87.5%, 90/103 vs 45.6%, 47/103) and median progression free survival (11.1 vs 6.8 mo) compared to pemetrexed, cisplatin and carboplatinin combination treatment in treatment-naive ALK positive advanced non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9058); NCT01639001).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines as first-line and subsequent therapy for ALK rearranged non-small cell lung cancer (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Pembrolizumab	Clinical Study	Actionable	In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Pembrolizumab	Guideline	Actionable	Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Atezolizumab	Guideline	Actionable	Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Atezolizumab	Clinical Study	Actionable	In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Osimertinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	Advanced Solid Tumor	sensitive	Entrectinib	Phase I	Actionable	In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in an objective response rate of 57% (4/7) in patients with ALK rearranged advanced solid tumors that were treatment-naive, but no response (0/19) in patients received prior Alk inhibitor treatments (PMID: 28183697).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	Advanced Solid Tumor	sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in objective response in 67% (4/6) of patients with advanced solid tumors harboring rearrangement in ALK gene (AACR Apr 2016, Abstract # CT007).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Ceritinib + Crizotinib	Clinical Study	Actionable	In a retrospective analysis of patients with ALK-rearrangement positive non-small cell lung cancer, the combined median progression-free survival for sequential treatment with Xalkori (crizotinib) and Zykadia (ceritinib) without intervening treatments was 17.0 months, and overall survival was 49.4 months (PMID: 25724526).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	Advanced Solid Tumor	sensitive	ASP3026	Phase I	Actionable	In a Phase I trial, ASP3026 treatment resulted in a partial response in 50% (8/16) and stable disease in 44% (7/16) of patients with an advanced solid tumor harboring an ALK rearrangement or ALK F1174L (PMID: 26966027; NCT01284192).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is included in guidelines as subsequent therapy for ALK rearranged non-small cell lung cancer patients whose disease progressed after Xalkori (crizotinib) therapy (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Brigatinib	Clinical Study	Actionable	In a retrospective analysis, Alunbrig (brigatinib) demonstrated limited efficacy, resulted in objective response in 17% (3/18) and stable disease in 50% (9/18) of patients with alectinib-refractory, ALK-positive non-small cell lung cancer, with a median progression-free survival of 4.4 months (PMID: 29935304).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Brigatinib	Phase Ib/II	Actionable	In a Phase I/II trial, Alunbrig (brigatinib) treatment resulted in an objective response rate of 100% (8/8) in ALK inhibitor-naive ALK-rearranged non-small cell lung cancer (NSCLC) patients, 72% (51/71) in crizotinib-treated ALK-rearranged NSCLC patients, and 83% (5/6) in ALK-rearranged NSCLC patients with CNS metastases (PMID: 27836716).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Brigatinib	FDA approved	Actionable	In a Phase II trial (ALTA) that supported FDA approval, Alunbrig (brigatinib) treatment resulted an overall response rate of 45% (51/112) in the 90mg arm and 54% (59/110) in the 180mg arm, and median progression-free survival of 9.2 and 11.0 months respectively, in ALK-rearranged non-small cell lung carcinoma patients who progressed on Xalkori (crizotinib) (PMID: 28475456; NCT02094573).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Brigatinib	Clinical Study	Actionable	In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Alunbrig (brigatinib), and radiotherapy (PMID: 26438117).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Erlotinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Ensartinib	Phase Ib/II	Actionable	In a Phase I/II trial, Ensartinib (X-396) treatment resulted in partial response in 60% (36/60) and stable disease in 21.7 % (13/60) of patients with ALK-positive non-small cell lung cancer, with a median progression-free survival of 9.2 months (PMID: 29563138; NCT01625234).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	sensitive	Ensartinib	Clinical Study	Actionable	In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Ensartinib (X-396), and radiotherapy (PMID: 26438117).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange	non-small cell lung carcinoma	no benefit	Gefitinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange SRC pos	non-small cell lung carcinoma	sensitive	Saracatinib + Ceritinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Zykadia (ceritinib) demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK rearrange RB1 C706F TP53 loss	lung small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study	Actionable	In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK	F1174L TP53	wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174L	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1174L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK F1174L was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1174L	neuroblastoma	sensitive	AZD3463	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD3463 inhibited growth of neuroblastoma cells harboring ALK F1174L in culture, resulted in near complete tumor regression in cell line xenograft models (PMID: 26786851).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1174L	neuroblastoma	sensitive	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK F1174L in culture (PMID: 22203728).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1174L	neuroblastoma	sensitive	Lorlatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1174L in culture, and induced rapid and sustained complete tumor regression in both patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1174L	neuroblastoma	resistant	Crizotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1174L in culture, and only delayed tumor growth in patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	ALK F1174L	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1174L in culture (PMID: 26554404).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib)-mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture  (PMID: 26144315).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L	Advanced Solid Tumor	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L	Advanced Solid Tumor	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).
ALK	CD246 | NBLST3	2p23.2-p23.1	NM_004304	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC I1164fs	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC I1164fs	colorectal cancer	sensitive	G007-LK	Preclinical - Patient cell culture	Actionable	In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC Q1338*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell culture	Actionable	In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 27798265).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC Q1338*	colorectal cancer	sensitive	JW74	Preclinical	Actionable	In a preclinical study, JW74 inhibited Wnt signaling and decreased growth of colorectal cancer cells harboring APC Q1338* in culture and in xenograft models (PMID: 21199802).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC Q1338*	colorectal cancer	sensitive	JW67	Preclinical	Actionable	In a preclinical study, JW67 inhibited Wnt signaling and decreased proliferation of colorectal cancer cells harboring APC Q1338* in culture (PMID: 21199802).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC E1309*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E1309* in culture and in cell line xenograft models (PMID: 27798265).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC S1197* APC S1278*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC S1197* APC S1278*	colorectal cancer	sensitive	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC S1197* APC S1278*	colorectal cancer	sensitive	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC Q1131* APC Q1303*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell culture	Actionable	In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC Q1131* and Q1303* in culture (PMID: 27798265).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC S811*	colorectal cancer	sensitive	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC S811*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC S811*	colorectal cancer	sensitive	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC N1819fs APC wild-type	colorectal cancer	resistant	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC N1819fs APC wild-type	colorectal cancer	resistant	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC N1819fs	colorectal cancer	resistant	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC E853* APC K1555*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E853* and K1555* in culture and in cell line xenograft models (PMID: 27798265).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC L665* APC R1450*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC L665* APC R1450*	colorectal cancer	resistant	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC L665* APC R1450*	colorectal cancer	sensitive	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC L1488*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell culture	Actionable	In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC L1488* in culture (PMID: 27798265).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC W553*	colorectal cancer	sensitive	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC W553*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC E853* APC T1556fs	colorectal cancer	resistant	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC E853* APC T1556fs	colorectal cancer	resistant	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC E853* APC T1556fs	colorectal cancer	resistant	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC G1416*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell culture	Actionable	In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC G11416* in culture (PMID: 27798265).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC Q1429fs BRAF N581S ERBB2 L755S	rectum adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Trastuzumab	Clinical Study	Actionable	In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC R216*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC R216*	colorectal cancer	sensitive	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, a patient-derived colorectal cancer cell line harboring APC R216* demonstrated sensitivity to G007-LK in culture (PMID: 28179481).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC wild-type CTNNB1 wild-type	colon cancer	predicted - sensitive	Vantictumab	Preclinical - Pdx	Actionable	In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC wild-type	colorectal cancer	resistant	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 did not inhibit survival of APC wild-type colorectal cancer cells in culture or in cell line xenograft models (PMID: 27798265).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut KRAS G12D	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut KRAS G12D	colorectal cancer	sensitive	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut KRAS G12D	colorectal cancer	sensitive	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	Erlotinib + Ibuprofen	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	XAV939	Preclinical	Actionable	In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	MF tricyclic	Preclinical	Actionable	In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	iCRT-5	Preclinical	Actionable	In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	iCRT-3	Preclinical	Actionable	In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	CCT036477	Preclinical	Actionable	In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	G007-LK	Preclinical - Cell line xenograft	Actionable	In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	StAx-35	Preclinical	Actionable	In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	iCRT-14	Preclinical - Cell line xenograft	Actionable	In a preclinical study, iCRT-14 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture and decreased initial tumor growth in APC-mutant colon cancer cell line xenograft models (PMID: 21393571).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	Pyrvinium	Preclinical	Actionable	In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	Niclosamide	Preclinical	Actionable	In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	ICG-001	Preclinical	Actionable	In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	Celecoxib	Preclinical	Actionable	In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	CCT031374	Preclinical	Actionable	In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	CCT070535	Preclinical	Actionable	In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	Sulindac	Preclinical	Actionable	In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	JW55	Preclinical	Actionable	In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	NC043	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	CGP049090	Preclinical	Actionable	In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	Sirolimus	Preclinical	Actionable	In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	PKF118-310	Preclinical	Actionable	In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	PKF115-584	Preclinical	Actionable	In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colorectal cancer	sensitive	Celecoxib + Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon cancer	sensitive	Vinorelbine	Preclinical	Actionable	In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut	colon carcinoma	sensitive	FH535	Preclinical	Actionable	In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	no benefit	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	sensitive	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut PTEN inact mut	colorectal cancer	no benefit	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut PTEN inact mut	colorectal cancer	no benefit	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC inact mut PTEN inact mut	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC mutant	medulloblastoma	not applicable	N/A	Guideline	Prognostic	WNT-driven medulloblastomas, characterized by CTNNB1 or APC mutations, are associated with favorable prognosis (NCCN.org).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC mutant	colorectal cancer	sensitive	JW74	Preclinical	Actionable	In a preclinical study, JW74 reduced tumor formation and growth in a mouse model of colorectal cancer harboring an APC mutation (PMID: 21199802).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC mutant	colorectal cancer	no benefit	G-631	Preclinical - Cell line xenograft	Actionable	In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC mutant	colorectal cancer	predicted - sensitive	K-756	Preclinical	Actionable	In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC mutant	colon adenoma	predicted - sensitive	MYB vaccine	Preclinical	Actionable	In a preclinical study, TetMYB treatment resulted in improved median survival compared to control (356 vs 183 days) in APC-driven mouse models of colon adenoma (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC mutant KRAS mutant KDR R961W	colorectal cancer	sensitive	Regorafenib	Clinical Study	Actionable	In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).
APC	BTPS2 | DP2 | DP2.5 | DP3 | GS | PPP1R46	5q22.2	NM_000038	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 inact mut	myelodysplastic/myeloproliferative neoplasm	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, nonsense and frameshift mutations in ASXL1 were associated with decreased overall survival in patients with chronic myelomonocytic leukemia (PMID: 26849014, PMID: 23690417, PMID: 20880116).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 wild-type TET2 mutant	myelodysplastic/myeloproliferative neoplasm	sensitive	Decitabine	Clinical Study	Actionable	In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65%  vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 wild-type TET2 mutant	myelodysplastic/myeloproliferative neoplasm	sensitive	Azacitidine	Clinical Study	Actionable	In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65%  vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 wild-type CALR mut	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of a CALR mutation combined with wild-type ASXL1 is associated with longer survival in patients with myelofibrosis (NCCN.org).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 mut CALR wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of an ASXL1 mutation combined with wild-type CALR is associated with shorter survival in patients with myelofibrosis (NCCN.org).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 mut CALR mut	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of a CALR mutation combined with an ASXL1 mutation is associated with intermediate survival in patients with myelofibrosis (NCCN.org).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	ASXL1 mutations are associated with inferior overall survival and leukemia-free survival in patients with myelofibrosis (NCCN.org).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 mutant	chronic myelomonocytic leukemia	not applicable	N/A	Guideline	Prognostic	ASXL1 mutations are associated with a poor prognosis in patients with chronic myelomonocytic leukemia (NCCN.org).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	ASXL1 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
ASXL1	BOPS | MDS	20q11.21	NM_015338	ASXL1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in ASXL1 were associated with poor prognosis in patients with myelodysplastic syndrome (PMID: 24220272, PMID: 21714648).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM loss	head and neck cancer	predicted - sensitive	AZD6738 + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD6738 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating cell death in head and neck cancer cells harboring ATM loss in culture (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C60).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM loss	Advanced Solid Tumor	sensitive	YU238259	Preclinical	Actionable	In a preclinical study, YU238259 demonstrated increased cytotoxicity in ATM-deficient transformed human cell lines in culture (PMID: 26116172).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM loss	colorectal cancer	sensitive	VX-970	Phase I	Actionable	In a Phase I trial, VX-970 treatment resulted in complete response for more than 19 months in a colorectal cancer patient harboring ATM loss (J Clin Oncol 34, 2016 (suppl; abstr 2504)).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM loss	chronic lymphocytic leukemia	sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 induced cell death in ATM-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM loss	non-small cell lung carcinoma	sensitive	AZD6738 + Cisplatin	Preclinical	Actionable	In a preclinical study, AZD6738 and Platinol (cisplatin) synergistically induced cell death in ATM-deficient non-small cell lung carcinoma cell lines in culture, and caused rapid tumor regression in xenograft models (PMID: 26517239).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM loss	chronic lymphocytic leukemia	sensitive	AZD6738 + Ibrutinib	Preclinical	Actionable	In a preclinical study, AZD6738 sensitized ATM-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	Advanced Solid Tumor	sensitive	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ATM-deficient cell line demonstrated increased sensitivity to Veliparib (ABT-888) compared to an ATM-reconstituted cell line, in culture (PMID: 21300883).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	lymphoblastic leukemia	sensitive	Olaparib	Preclinical - Patient cell culture	Actionable	In a preclinical study, lymphoblastoid cell lines with ATM inactivation derived from ataxia-telangiectasia patients demonstrated increased sensitivity to Lynparza (olaparib) in culture, compared to ATM wild-type cell lines (PMID: 20739657).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	mantle cell lymphoma	sensitive	Bendamustine + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Treanda (bendamustine) in cell culture, resulting in growth inhibition (PMID: 20739657).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	prostate cancer	sensitive	Olaparib	Phase II	Actionable	In a Phase II clinical trial, 80% (4/5) of metastatic, castration-resistant prostate cancer patients harboring an ATM inactivating mutation responded to Lynparza (olaparib) (PMID: 26510020).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	mantle cell lymphoma	sensitive	Olaparib + Valproic Acid	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Lynparza (olaparib) and valproic acid worked synergistically to inhibit growth of a mantle cell lymphoma cell line harboring an ATM inactivating mutation in culture (PMID: 20739657).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	mantle cell lymphoma	sensitive	Fludarabine + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Fludara (fludarabine) in cell culture, resulting in decreased cell survival (PMID: 20739657).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	chronic lymphocytic leukemia	sensitive	Olaparib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived chronic lymphocytic leukemia cells with inactivating mutations in ATM, that had been induced to proliferate in culture, demonstrated increased sensitivity to growth inhibition by Lynparza (olaparib) compared to ATM wild-type cells (PMID: 20739657).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	Advanced Solid Tumor	sensitive	E7449	Preclinical	Actionable	In a preclinical study, E7449 inhibited proliferation of a ATM-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM inact mut	mantle cell lymphoma	sensitive	Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a mantle cell lymphoma cell line with ATM inactivation demonstrated sensitivity to Lynparza (olaparib) in culture and in xenograft models (PMID: 20739657).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM L804fs*4 ATM S978fs*12 RET M918T	thyroid medullary carcinoma	predicted - sensitive	Vandetanib + Everolimus	Clinical Study	Actionable	In a clinical case study, addition of Afinitor (everolimus)  to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM mutant	prostate cancer	sensitive	Olaparib	Phase II	Actionable	In a Phase II clinical trial, 80% (4/5) of metastatic castration-resistant prostate cancer patients with ATM truncation mutations demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM mut NRAS Q61R	melanoma	sensitive	Binimetinib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM dec exp	stomach cancer	sensitive	Veliparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, knockdown of ATM in a gastric cancer cell line resulted in increased sensitivity to Veliparib (ABT-888) in culture and in xenograft models (PMID: 27638859).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM dec exp	stomach cancer	predicted - sensitive	Olaparib + Paclitaxel	Phase II	Actionable	In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (5.29 vs 3.68 months) compared to Taxol alone, but did significantly prolong overall survival (HR = 0.35) in metastatic gastric cancer patients with decreased Atm expression (PMID: 26282658; NCT01063517).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM dec exp	breast cancer	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, knockdown of ATM expression sensitized breast cancer cells to treatment with Talazoparib (BMN-673) in culture (PMID: 23881923).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM over exp	stomach cancer	decreased response	Irinotecan	Preclinical - Cell culture	Actionable	In a preclinical study, high ATM expression was associated with decreased response to Camptosaur (irinotecan) in gastric cancer cell lines in culture (PMID: 27638859).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM over exp	stomach cancer	sensitive	Irinotecan + Veliparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Camptosar (irinotecan) and Veliparib (ABT-888) demonstrated synergy in gastric cancer cell lines with high ATM expression, resulting in increased apoptosis in culture, and enhanced tumor growth inhibition in cell line xenograft models (PMID: 27638859).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM over exp	stomach cancer	decreased response	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, high ATM expression was associated with decreased response to Veliparib (ABT-888) in gastric cancer cell lines in culture (PMID: 27638859).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM negative	stomach cancer	no benefit	Olaparib + Paclitaxel	Phase III	Actionable	In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (12.0 vs 10.0 months, HR=0.73, p=0.25) compared to Taxol (paclitaxel) alone in Asian patients with ATM-negative gastric cancer (PMID: 29103871; NCT01924533).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM positive	lung cancer	sensitive	AZD1390	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD1390 inhibited Atm activity, sensitized lung cancer cells to radiotherapy in culture, and demonstrated efficacy in cell line xenograft models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM positive	glioblastoma multiforme	sensitive	AZD1390	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD1390 inhibited Atm activity, sensitized glioblastoma cell lines to radiotherapy in culture, and demonstrated efficacy in mouse models of glioblastoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM del KRAS G12D	lung adenocarcinoma	sensitive	VX-970	Preclinical	Actionable	In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to VX-970, demonstrating decreased tumor volume and greater overall survival compared to control treated models (PMID: 28363999).
ATM	AT1 | ATA | ATC | ATD | ATDC | ATE | TEL1 | TELO1	11q22.3	NM_000051	ATM del KRAS G12D	lung adenocarcinoma	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999).
ATRX	JMS | MRX52 | RAD54 | RAD54L | XH2 | XNP | ZNF-HX	Xq21.1	NM_000489	ATRX loss IDH1 mut	astrocytoma	not applicable	N/A	Guideline	Diagnostic	ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).
ATRX	JMS | MRX52 | RAD54 | RAD54L | XH2 | XNP | ZNF-HX	Xq21.1	NM_000489	ATRX loss IDH1 mut	malignant glioma	predicted - sensitive	Gemcitabine + Radiotherapy	Phase I	Actionable	In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).
ATRX	JMS | MRX52 | RAD54 | RAD54L | XH2 | XNP | ZNF-HX	Xq21.1	NM_000489	ATRX loss	glioblastoma multiforme	sensitive	Irinotecan	Preclinical	Actionable	In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).
ATRX	JMS | MRX52 | RAD54 | RAD54L | XH2 | XNP | ZNF-HX	Xq21.1	NM_000489	ATRX loss	glioblastoma multiforme	sensitive	Doxorubicin	Preclinical	Actionable	In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).
ATRX	JMS | MRX52 | RAD54 | RAD54L | XH2 | XNP | ZNF-HX	Xq21.1	NM_000489	ATRX loss	glioblastoma multiforme	sensitive	Topotecan	Preclinical	Actionable	In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).
ATRX	JMS | MRX52 | RAD54 | RAD54L | XH2 | XNP | ZNF-HX	Xq21.1	NM_000489	ATRX loss IDH2 mut	astrocytoma	not applicable	N/A	Guideline	Diagnostic	ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).
ATRX	JMS | MRX52 | RAD54 | RAD54L | XH2 | XNP | ZNF-HX	Xq21.1	NM_000489	ATRX mutant	malignant glioma	not applicable	N/A	Guideline	Diagnostic	ATRX mutations aid in the diagnosis of gliomas (NCCN.org).
ATRX	JMS | MRX52 | RAD54 | RAD54L | XH2 | XNP | ZNF-HX	Xq21.1	NM_000489	ATRX inact mut	Advanced Solid Tumor	sensitive	E7449	Preclinical	Actionable	In a preclinical study, E7449 inhibited proliferation of a ATRX-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).
BCOR	ANOP2 | MAA2 | MCOPS2	Xp11.4	NM_001123385	BCOR-RARA	acute promyelocytic leukemia	sensitive	Tretinoin	Clinical Study	Actionable	In a clinical case study, a patient with acute promyelocytic leukemia harboring BCOR-RARA demonstrated sensitivity to treatment with Vesanoid (tretinoin) and achieved a complete response (PMID: 25790901).
BCOR	ANOP2 | MAA2 | MCOPS2	Xp11.4	NM_001123385	BCOR mutant	kidney clear cell sarcoma	not applicable	N/A	Clinical Study	Emerging	In multiple clinical analyses, internal tandem duplications of the BCOR gene were consistently found in clear cell sarcoma of the kidney (PMID: 26098867, PMID: 26516930, PMID: 26573325, PMID: 26150234), suggesting that this may serve as a future diagnostic biomarker.
BCOR	ANOP2 | MAA2 | MCOPS2	Xp11.4	NM_001123385	BCOR mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	BCOR mutations, including those at codon N1425, are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
BCORL1	BCoR-L1 | CXorf10	Xq26.1	NM_021946	BCORL1 over exp	hepatocellular carcinoma	not applicable	N/A	Clinical Study	Emerging	In a clinical study, BCORL1 over expression was associated with decreased overall survival and recurrence-free survival in patients with hepatocellular carcinoma (PMID: 26879601), suggesting that this may serve as a future prognostic biomarker.
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G464V	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464V (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G464V KRAS G13D	breast cancer	sensitive	Regorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G464V KRAS G13D	triple-receptor negative breast cancer	sensitive	DHM25	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G464V KRAS G13D	breast cancer	decreased response	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G464V KRAS G13D	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L485Y	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring BRAF L485Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	INC280 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G596R	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Erk and Mek in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G596R	colorectal cancer	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced Erk signaling and inhibited proliferation of a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G596R	colorectal cancer	sensitive	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 27577079).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G596R PIK3CA E545K	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466E	melanoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466E	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466E	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466E	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466E	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466E HRAS Q61K	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597R	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597R (PMID: 22798288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597R	Advanced Solid Tumor	sensitive	Vemurafenib	Preclinical	Actionable	In a preclinical study, treatment of cells expressing BRAF L597R with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V487_P492delinsA	pancreatic cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was sensitive to Mekinist (trametinib) in culture, resulting in cell growth inhibition (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V487_P492delinsA	pancreatic cancer	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to Tafinlar (dabrafenib) (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V487_P492delinsA	pancreatic cancer	resistant	Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a human pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to treatment with Zelboraf (vemurafenib) in both culture and xenograft models (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V487_P492delinsA	pancreatic cancer	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA were sensitive to LY3009120 in culture and in xenograft models, resulting in inhibition of tumor growth and partial tumor regression (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTPN11 dec exp	colorectal cancer	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut KRAS mut	melanoma	predicted - sensitive	BI-847325	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN wild-type	melanoma	sensitive	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + Binimetinib	Preclinical	Actionable	In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + LGX818	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + LGX818	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut RB1 loss	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut RB1 loss	melanoma	decreased response	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut RB1 loss	melanoma	decreased response	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN mut	melanoma	predicted - sensitive	ST-162	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ST-162 resulted in tumor regression in a melanoma cell line xenograft model co-harboring mutations in BRAF and PTEN (PMID: 28775144).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN mut	melanoma	decreased response	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN loss	melanoma	no benefit	Pembrolizumab	Preclinical	Actionable	In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN loss	melanoma	sensitive	SAR260301 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN loss	melanoma	sensitive	SAR260301	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN loss	melanoma	no benefit	GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN loss	melanoma	sensitive	SAR260301 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN loss	melanoma	sensitive	GSK2636771 + Pembrolizumab	Preclinical	Actionable	In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut KRAS mut CDKN2A mut	triple-receptor negative breast cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut NRAS wild-type	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut KRAS G12V	melanoma	resistant	AZ628 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut NRAS mut	melanoma	predicted - sensitive	BI-847325	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut NRAS mut	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	decreased response	Alpelisib	Preclinical	Actionable	In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482	Preclinical	Actionable	In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	no benefit	BYL719 + LGX818	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	BYL719 + GSK2636771 + LGX818	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	TGX-221	Preclinical	Actionable	In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	no benefit	BYL719 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	Pictilisib	Preclinical	Actionable	In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + LGX818 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	Binimetinib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + LGX818	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + LGX818 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + LGX818 + BYL719	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	LGX818 + unspecified IGF-1R antibody	Preclinical	Actionable	In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + Binimetinib	Preclinical	Actionable	In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	no benefit	BYL719 + MEK162	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + BYL719	Preclinical	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	BYL719 + GSK2636771	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + LGX818 + BYL719	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	NVP-AEW541 + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + LGX818 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + LGX818	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with BRAF mutations (PMID: 23039341).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	predicted - sensitive	Panitumumab + Trametinib + Dabrafenib	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with the triple combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vectibix (panitumumab) resulted in an objective response rate (ORR) of 21% and median progression-free survival (mPFS) of 4.2 mo, compared with 0% ORR and mPFS of 2.6 mo with Mekinist (trametinib) plus Vectibix (panitumumab), and 10% ORR and mPFS of 3.5 mo with Tafinlar (dabrafenib) plus Vectibix (panitumumab) in patients with BRAF-mutant colorectal cancer (PMID: 27770002; NCT01750918).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	pancreatic cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	predicted - sensitive	BI-847325	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of BRAF-mutant melanoma cell lines in culture, and inhibited tumor growth melanoma cell line xenograft models harboring BRAF mutations, including models with BRAF inhibitor resistance (PMID: 25873592).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring a BRAF mutation resulted in inhibition of brain tumor growth (PMID: 27307593).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	predicted - sensitive	ST-162	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ST-162 treatment resulted in tumor regression in BRAF mutant-melanoma cell line xenograft models (PMID: 28775144).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	sensitive	MLN2480	Preclinical	Actionable	In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture when compared to either agent alone (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	PLX8394	Preclinical	Actionable	In a preclinical study, PLX8394 blocked survival and growth of vemurafenib/PLX4720-resistant melanoma cells harboring BRAF V600E splice variants in culture (PMID: 24422853).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	E6201 + LY294002	Preclinical	Actionable	In a preclinical study, E6201 and LY294002 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations in culture, regardless of PTEN mutation status (PMID: 23039341).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	thyroid cancer	sensitive	HM95573	Preclinical - Cell culture	Actionable	In a preclinical study, HM95573 inhibited growth of BRAF mutant thyroid cancer cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	predicted - sensitive	MLN2480	Preclinical - Cell culture	Actionable	In a preclinical study, MLN2480 inhibited downstream signaling and proliferation of several BRAF mutant solid tumor cell lines in culture (EJC Supp, Nov 2010, Vol 8(7), p40-41).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	predicted - resistant	SYM004	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	Encorafenib + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Encorafenib (LGX818) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	predicted - sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a best response of stable disease in six melanoma patients and a partial response in three melanoma patients all harboring a BRAF mutation (PMID: 29247021).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	S63845 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of S63845 and Zelboraf (vemurafenib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Zelboraf (vemurafenib) alone (PMID: 27760111).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	lung adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of lung adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	sensitive	Dabrafenib	Phase I	Actionable	In a Phase I clinical trial, Tafinlar (dabrafenib) demonstrated safety and efficacy in patients with BRAF V600E positive solid tumors (PMID: 22608338).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colon cancer	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of BRAF mutant colon cancer (PMID: 26140595).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	PET-16 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PET-16 and Zelboraf (vemurafenib) synergistically inhibited growth of melanoma cell lines in culture, resulted in enhanced tumor growth inhibition in cell ine xenograft models (PMID: 26984758).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, a majority of human colorectal cancer cell lines (4/7) harboring mutant BRAF were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	MLN2480	Preclinical	Actionable	In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	MLN2480	Phase I	Actionable	In a Phase I trial, MLN2480 resulted in a median progression free survival of 4.6 months and a partial response in 50% (8/16) of melanoma patients harboring a BRAF mutation (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 410P; NCT01425008).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	sensitive	LGX818 + Cetuximab + BYL719	Phase Ib/II	Actionable	In a Phase Ib/II trial, the triple combination therapy of Encorafenib (LGX818), Erbitux (cetuximab), and Alpelisib (BYL719) resulted in an overall response rate of 18% (5/28), including 5 patients with a partial response, and led to a median progression free survival of 4.2 months and response duration of 12 weeks (PMID: 28363909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	pancreatic adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human pancreatic adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	sensitive	Cetuximab + Encorafenib	Phase Ib/II	Actionable	In a Phase Ib/II trial, the combination therapy of Erbitux (cetuximab) and Encorafenib (LGX818) in colorectal cancer patients harboring a BRAF mutation resulted in an overall response rate of 19% (5/26), including 1 patient with a complete response and 4 patients with a partial response, and led to a median progression free survival of 3.7 months and response duration of 46 weeks (PMID: 28363909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	Encorafenib	Phase I	Actionable	In a Phase I trial, Encorafenib (LGX818) treatment resulted in an overall response rate (ORR) of 60% (15/25) and a median progression-free survival (mPFS) of 12.4 months in BRAF inhibitor-naïve melanoma patients harboring BRAF mutations, and an ORR of 22% (6/29) and mPFS of 1.9 months in BRAF inhibitor-pretreated patients (PMID: 28611198; NCT01436656).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	Selumetinib	Phase II	Actionable	In a Phase II trial in patients with advanced melanoma, 5/6 patients exhibiting a response to selumetinib had BRAF-mutant tumors (PMID: 22048237).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	sensitive	AZ628 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in BRAF mutant colorectal cancer cell lines in culture (PMID: 26351322).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring BRAF mutations in culture and in cell line xenograft models (PMID: 26140595).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	non-small cell lung carcinoma	predicted - sensitive	Nivolumab	Clinical Study	Actionable	In a clinical study, mutant BRAF correlated with prolonged duration on Opdivo (nivolumab) therapy compared to wild-type BRAF in non-small cell lung carcinoma patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	thyroid cancer	sensitive	Selumetinib	Phase I	Actionable	In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	stomach carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	Binimetinib + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	decreased response	XL147	Preclinical	Actionable	In a preclinical study, tumor cell lines harboring BRAF mutations demonstrated limited sensitivity to XL147 treatment in culture (PMID: 25637314).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	sensitive	RAF709	Phase I	Actionable	In a preclinical study, cancer cell lines harboring BRAF mutations demonstrated increased sensitivity to RAF709 compared to BRAF wild-type cells in culture (PMID: 29343524).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	predicted - sensitive	Binimetinib	Phase I	Actionable	In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival of 1.4 months and overall survival of 7.1 months in colorectal cancer patients harboring BRAF mutations (PMID: 28152546).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	Tubastatin A	Preclinical	Actionable	In a preclinical study, Tubastatin A inhibited proliferation of BRAF mutant melanoma cell lines in culture (PMID: 25957812).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	no benefit	CC-90003	Phase I	Actionable	In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (AJ Clin Oncol 35, 2017 (suppl; abstr 2577)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	non-small cell lung carcinoma	predicted - sensitive	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis and enhanced ERK inhibition compared to either agent alone in non-small cell lung cancer cell lines harboring non-BRAF V600 mutations in culture (PMID: 27577079).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	sensitive	HM95573	Preclinical - Cell line xenograft	Actionable	In a preclinical study, HM95573 inhibited growth of BRAF mutant colorectal cancer cell lines in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	multiple myeloma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant BRAF in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	decreased response	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF mutant colorectal cancer cell lines demonstrated reduced sensitivity to PLX4720 in culture (PMID: 26351322).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	Advanced Solid Tumor	sensitive	Obatoclax	Preclinical	Actionable	In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with BRAF mutation in culture (PMID: 22460902).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	non-small cell lung carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant non-small cell lung cancer harboring (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colon cancer	predicted - sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) resulted in some reduced cell growth in colon cancer cells harboring a BRAF mutation in culture (PMID: 27655129).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	S63845 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	sensitive	Cetuximab + LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring BRAF mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	cervix carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	melanoma	sensitive	Vemurafenib + Voruciclib	Phase I	Actionable	In a Phase I trial, Voruciclib (P1446A-05) and Zelboraf (vemurafenib) combination therapy demonstrated safety and preliminary efficacy, resulted in complete response in 33% (1/3) and partial response in 67% (2/3) of BRAFi-naïve melanoma patients harboring BRAF mutations (J Clin Oncol 33, 2015 (suppl; abstr 9076)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mutant	colorectal cancer	predicted - sensitive	LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 resulted in a disease control rate of 8.3% (1/12) in BRAF mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut + TP53 wild-type	colorectal cancer	sensitive	ABT-263 + CGM097 + Dabrafenib + PF-04217903	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut + TP53 wild-type	melanoma	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut + TP53 wild-type	melanoma	sensitive	CGM097 + LGX818	Preclinical	Actionable	In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut STAG2 dec exp	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut STAG2 dec exp	melanoma	decreased response	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut STAG2 dec exp	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut STAG2 dec exp	melanoma	decreased response	Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF mut TP53 mut	colorectal cancer	sensitive	ABT-263 + Alpelisib + Dabrafenib + Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS G12D	pancreatic cancer	resistant	GDC0879	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS wild-type	colorectal cancer	decreased response	LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 demonstrated limited efficacy in BRAF and KRAS wild-type patient-derived xenograft models of colorectal cancer, resulted in a disease control rate of 3.8% (1/26) (PMID: 28611205).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS wild-type PIK3CA mutant	colorectal cancer	sensitive	Cetuximab	Clinical Study	Actionable	In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS G12V	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Pdx	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12V in patient-derived xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	Advanced Solid Tumor	resistant	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, a variety of BRAF wild-type tumor cell lines were insensitive to BGB-283 in culture (PMID: 26208524).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	melanoma	sensitive	Trametinib	Phase I	Actionable	In a Phase I study, 10% (4/39) of wild-type BRAF melanoma patients had a partial response to Mekinist (trametinib) (PMID: 22805292).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	melanoma	resistant	GDC0879	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells in cell culture, cell line xenograft models, and patient-derived xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	thyroid cancer	sensitive	CLM3	Preclinical	Actionable	In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression, in BRAF wild-type thyroid cancer cells in culture (PMID: 24423321).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	melanoma	no benefit	Selumetinib	Phase II	Actionable	In a Phase II trial, a favorable response rate to Selumetinib (AZD6244) was observed in mutant BRAF, but not BRAF wild-type, melanoma patients (PMID: 22048237).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	melanoma	predicted - sensitive	RAF265	Phase I	Actionable	In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	melanoma	predicted - sensitive	RAF265	Preclinical	Actionable	In a preclinical study, RAF265 inhibited the growth of melanoma tumors orthotopically implanted in mice, including tumors wild-type for BRAF (PMID: 22351689).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	melanoma	sensitive	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	melanoma	decreased response	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a BRAF wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	melanoma	resistant	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 did not inhibit growth of BRAF wild-type melanoma cells in culture or in cell line xenograft models (PMID: 18287029).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	malignant glioma	predicted - sensitive	Everolimus + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Afinitor (everolimus) and Selumetinib (AZD6244) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells in culture and in patient-derived xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type NRAS Q61K	melanoma	resistant	GDC0879	Preclinical - Pdx	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS wild-type NRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFIRI	Phase II	Actionable	In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Erbitux (cetuximab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 33.2 mo and response rate of 68% (40/59), however, resulted in a 10-mo PFS rate of 50.8% (30/59), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS wild-type NRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFIRI + Bevacizumab	Phase II	Actionable	In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by  Avastin (bevacizumab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 32.2 mo and response rate of 75% (43/57), however, resulted in a 10-mo PFS rate of 40.4% (23/57), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS Q61K	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS Q61K in culture and in cell line xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS G13D	colon cancer	resistant	GDC0879	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type NRAS wild-type	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type NRAS wild-type	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type NRAS wild-type	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type NRAS wild-type	melanoma	sensitive	Binimetinib + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type NRAS wild-type	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type NRAS wild-type	melanoma	resistant	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type NRAS mutant	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS G12C	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Pdx	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFOX	Phase II	Actionable	In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	AKT1 E17K KRAS wild-type BRAF wild-type	colorectal cancer	resistant	Cetuximab + Irinotecan	Clinical Study	Actionable	In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601N	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601N (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601N	hematologic cancer	sensitive	LY3009120	Preclinical - Cell culture	Actionable	In a preclinical study, a hematological tumor cell line harboring BRAF K601N demonstrated sensitivity to LY3009120 in culture (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K MAP2K1 P124L	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K MAP2K1 P124L	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K MAP2K1 P124L	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K NRAS Q61K	melanoma	sensitive	GSK2126458	Preclinical	Actionable	In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K NRAS Q61K	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K NRAS Q61K	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K	melanoma	sensitive	Trametinib + Dabrafenib	FDA approved	Actionable	In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K	melanoma	sensitive	Trametinib + Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, such as BRAF V600K, as adjuvant therapy for stage III disease and as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K	melanoma	sensitive	Vemurafenib + Cobimetinib	FDA approved	Actionable	In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, which included patients identified to harbor BRAF V600E or BRAF V600K (PMID: 27480103; NCT01689519).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K	melanoma	sensitive	GSK2126458	Preclinical	Actionable	In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K	melanoma	sensitive	Trametinib	FDA approved	Actionable	In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K	melanoma	sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600K, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K	melanoma	sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600K, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K MAP2K1 P124Q	melanoma	sensitive	VX-11e	Preclinical - Cell culture	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K MAP2K1 P124Q	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600K MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597Q	lung cancer	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in a lung cancer patient harboring BRAF L597Q (PMID: 29247021).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597Q	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597Q (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF N486_P490del	ovarian cancer	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, an ovarian cancer cell line harboring BRAF N486_P490del was resistant to Zelboraf (vemurafenib), resulting in minimal inhibition of both cell growth and phosphorylation of MEK and ERK in culture (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF N486_P490del	ovarian cancer	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to LY3009120, resulting in inhibition of cell growth and decreased phosphorylation of MEK and ERK in culture (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF N486_P490del	ovarian cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to Mekinist (trametinib), resulting in inhibition of cell growth in culture (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF N486_P490del	ovarian cancer	predicted - resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) resulted in minimal growth inhibitory activity of an ovarian cancer cell line harboring BRAF N486_P490del (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D PTEN loss	melanoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D	melanoma	sensitive	CCT196969	Preclinical	Actionable	In a preclinical study, CCT196969 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D	melanoma	sensitive	CCT241161	Preclinical	Actionable	In a preclinical study, CCT241161 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D	pilocytic astrocytoma	sensitive	Trametinib + Dabrafenib	Clinical Study	Actionable	In a clinical case study, single Tafinlar (dabrafenib) and subsequent Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in disease stablization in a patient with pilocytic astrocytoma harboring BRAF V600D (PMID: 28784858).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D	melanoma	sensitive	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, PLX7904 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600D	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601T	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601T (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529N	Advanced Solid Tumor	resistant	RAF265	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to RAF265 in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529N	Advanced Solid Tumor	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529N in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529N	Advanced Solid Tumor	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to PLX4720 in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529N	Advanced Solid Tumor	resistant	SB590885	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to SB590885 in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529N	Advanced Solid Tumor	conflicting	Sorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to Nexavar (sorafenib)-mediated inhibition of Erk phosphorylation but were equally as sensitive to Nexavar (sorafenib)-mediated growth inhibition as transformed cells expressing BRAF V600E in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594N	Advanced Solid Tumor	predicted - resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Mek in transformed cells expressing BRAF D594N in culture (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597S	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597S (PMID: 22798288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597S	melanoma	sensitive	TAK-733	Phase I	Actionable	In a Phase I trial, one metastatic melanoma patient carrying a BRAF L597S mutation, had a partial response to the MEK inhibitor, TAK-733 (PMID: 22798288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597S	Advanced Solid Tumor	sensitive	Vemurafenib	Preclinical	Actionable	In a preclinical study, treatment of cells expressing BRAF L597S with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469R NRAS Q61K	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469R NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469R NRAS Q61K	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594G NRAS G12D	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594G NRAS G12D	melanoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594G NRAS G12D	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594G NRAS G12D	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594G NRAS G12D	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF D594G	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF D594G in culture (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - sensitive	RAF265	Preclinical	Actionable	In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - resistant	PLX4720	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - resistant	SB590885	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L485_P490delinsY	non-small cell lung carcinoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to LY3009120 in both culture and xenograft models, resulting in significant tumor regression and inhibition of MEK and ERK phosphorylation (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L485_P490delinsY	non-small cell lung carcinoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was resistant to Tafinlar (dabrafenib) (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L485_P490delinsY	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to Mekinist (trametinib), resulting in cell growth inhibition (PMID: 26732095).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G464E	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464E (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469L	lung adenocarcinoma	no benefit	Vemurafenib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring BRAF G469L did not respond to Zelboraf (vemurafenib) therapy (PMID: 24035431).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF dec exp KRAS G12C	lung cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Braf expression through shRNA knockdown in culture (PMID: 27338794).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	APC Q1429fs BRAF N581S ERBB2 L755S	rectum adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Trastuzumab	Clinical Study	Actionable	In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF N581S	lung adenocarcinoma	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Patient cell culture	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from a lung adenocarcinoma patient harboring BRAF N581S in culture (PMID: 26140595).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G464R	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464R (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G596V NRAS G13R	colorectal cancer	sensitive	Cetuximab + LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF N581Y	colon cancer	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, colon cancer cells harboring BRAF N581Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V EGFR wild-type	non-small cell lung carcinoma	sensitive	Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	colorectal cancer	sensitive	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) delayed tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	non-small cell lung carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	non-small cell lung carcinoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring BRAF G466V in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of non-small cell lung cancer cell lines harboring BRAF G466V in culture (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	colorectal cancer	predicted - sensitive	Irinotecan + Panitumumab	Clinical Study	Actionable	In a clinical case study, a patient with metastatic colorectal cancer harboring BRAF G466V, and with wild-type RAS and NF1, demonstrated tumor regression following treatment with Vectibix (panitumumab) plus Camptosar (irinotecan) (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	colorectal cancer	sensitive	Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Erbitux (cetuximab) reduced ERK signaling and resulted in tumor regression in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	non-small cell lung carcinoma	sensitive	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a non-small cell lung cancer cell line harboring BRAF G466V in culture (PMID: 27577079).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	lung adenocarcinoma	sensitive	PLX8394	Preclinical - Cell culture	Actionable	In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G466V in culture (PMID: 27834212).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	non-small cell lung carcinoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring BRAF G466V demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	colorectal cancer	no benefit	Vemurafenib	Preclinical - Pdx	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit ERK signaling or tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V	non-small cell lung carcinoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung cancer cells expressing BRAF G466V in culture (PMID: 22649091).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G466V NRAS Q61K	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529I	Advanced Solid Tumor	predicted - resistant	SB590885	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529I	Advanced Solid Tumor	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529I	Advanced Solid Tumor	predicted - sensitive	RAF265	Preclinical	Actionable	In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529I	Advanced Solid Tumor	predicted - resistant	PLX4720	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF T529I	Advanced Solid Tumor	predicted - sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601E	melanoma	no benefit	Dabrafenib	Phase I	Actionable	In a Phase I trial, no responses were demonstrated among three melanoma patients with non-V600 BRAF mutations, including two patients harboring BRAF K601E, following treatment with Tafinlar (dabrafenib), compared to a confirmed response rate of 50% in patients harboring BRAF V600 mutations (PMID: 22608338).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601E	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the MEK inhibitor, Mekinist (trametinib) decreased activation of MEK and ERK in cells expressing BRAF K601E in culture (PMID: 22798288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601E	Advanced Solid Tumor	conflicting	Vemurafenib	Preclinical	Actionable	In a preclinical study, treatment of cells expressing BRAF K601E with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601E	Advanced Solid Tumor	conflicting	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601E (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601E	melanoma	sensitive	Trametinib	Clinical Study	Actionable	In a clinical case study, a melanoma patient with BRAF K601E demonstrated a 48% reduction in lymphadenopathy when treated with Mekinist (trametinib) and after more than 36 months of treatment showed a complete response (PMID: 28344857).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF K601E	melanoma	sensitive	Trametinib	Phase II	Actionable	In a Phase II trial, a melanoma patient harboring BRAF K601E demonstrated a partial response and a progression free survival of 32 weeks when treated with Mekinist (trametinib) (PMID: 23248257; NCT01037127).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF F247L	Advanced Solid Tumor	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Tafinlar (dabrafenib) in culture (PMID: 28512244).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF F247L	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Mekinist (trametinib) in culture (PMID: 28512244).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	lung adenocarcinoma	sensitive	PLX8394	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G469A in culture, and reduced tumor growth in xenograft models (PMID: 27834212).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	non-small cell lung carcinoma	sensitive	Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of  a non-small cell lung cancer cell line harboring BRAF G469A in culture, and prevented Mekinist (trametinib)-related activation of AKT and resulted in increased induction of apoptosis compared to either agent alone (PMID: 25706985).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	non-small cell lung carcinoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring BRAF G469A demonstrated resistance to induction of apoptosis by Zelboraf (vemurafenib,) and treatment with Zelboraf (vemurafenib) was not effective in inhibiting growth in culture (PMID: 25706985).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	non-small cell lung carcinoma	sensitive	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased viability and enhanced ERK inhibition compared to either agent alone, in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 27577079).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	non-small cell lung carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G469A mutation in culture (PMID: 26090892).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469A (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	small intestine carcinoma	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients harboring BRAF G469A, including one patient with head and neck cancer and one patient with small bowel cancer (PMID: 29247021).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	head and neck cancer	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients harboring BRAF G469A, including one patient with head and neck cancer and one patient with small bowel cancer (PMID: 29247021).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469A	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) induced apoptosis and inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 25706985).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L485W	gallbladder cancer	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (Ulixertinib) resulted in a complete response lasting almost 1 year in a gallbladder cancer patient harboring BRAF L485W (PMID: 29247016, PMID: 29247021).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600R	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600R	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600R	melanoma	sensitive	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, PLX7904 inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600R	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600R	melanoma	sensitive	Dabrafenib	Clinical Study	Actionable	In a clinical case study, a melanoma patient harboring BRAF V600R treated with Tafinlar (dabrafenib) demonstrated a reduction in lesion size after 2.5 months and at 5 months, stable disease, however, after 7 months progression ensued (PMID: 27255157).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600R	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF fusion	pilocytic astrocytoma	not applicable	N/A	Guideline	Diagnostic	BRAF fusions aid in the diagnosis of pilocytic astrocytoma (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF fusion	pilocytic astrocytoma	not applicable	N/A	Guideline	Prognostic	BRAF fusions are associated with indolent disease in patients with pilocytic astrocytoma (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P124L	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P124L	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P124S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P124S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P124S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P124S	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 I111N	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 I111N	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N  in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS G12V	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS G12V	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	conflicting	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T	colorectal cancer	resistant	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T	colorectal cancer	resistant	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF amp BRAF V600E	lung adenocarcinoma	decreased response	SCH772984	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived BRAF V600E mutant lung adenocarcinoma cells that acquired resistance to Erk inhibitor through BRAF amplification were less sensitive to SCH772984 in culture (PMID: 28714990).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF amp BRAF V600E	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired BRAF V600E amplification (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF amp BRAF V600E	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF amp BRAF V600E	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF amp BRAF V600E	lung adenocarcinoma	sensitive	Dabrafenib + SCH772984 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable tumor inhibition in cell line xenograft models of BRAF V600E mutated lung adenocarcinoma cells that acquired resistance to Erk inhibitors through BRAF amplification (PMID: 28714990).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E CSF1R positive	melanoma	sensitive	Pexidartinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Trametinib + Dabrafenib	Guideline	Actionable	Combination of Mekinist (trametinib) and Tafinlar (dabrafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Trametinib + Dabrafenib	FDA approved	Actionable	In a Phase II trial that supported FDA approval, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in patients with non-small cell lung cancer harboring BRAF V600E resulted in an overall response rate of 66.7% (38/57) in previously treated patients and 64% (23/36) in untreated patients, versus 33% (26/78) treated with Tafinlar (dabrafenib) alone (PMID: 27080216, PMID: 27283860, PMID: 28919011; NCT01336634).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	SBI-755199	Preclinical	Actionable	In a preclinical study, SBI-755199 induced cell death in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Cetuximab + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PLX4720 and Erbitux (cetuximab) inhibited tumor growth in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 22281684).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 inhibited growth of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	hairy cell leukemia	sensitive	Vemurafenib	Phase II	Actionable	In two Phase II clinical studies, patients with refractory hairy cell leukemia harboring BRAF V600E responded to Zelboraf (vemurafenib) with overall response rates of 96% (25/26) and 100% (24/24) as well as complete response rates of 35% (9/26) and 42% (10/24) with median follow up times of 8 and 12 weeks, respectively (PMID: 26352686).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Vemurafenib + Gefitinib	Preclinical	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Iressa (gefitinib) decreased the number of viable colorectal cancer cells harboring a BRAF V600E mutation in cell culture (PMID: 22448344).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	Advanced Solid Tumor	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell culture	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing BRAF V600E in culture, while single agent inhibition had no effect (PMID: 26140595).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Vemurafenib + Cobimetinib	FDA approved	Actionable	In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, which included patients identified to harbor BRAF V600E or BRAF V600K (PMID: 27480103; NCT01689519).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	CLM3	Preclinical	Actionable	In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression in thyroid cancer cells harboring BRAF V600E in culture (PMID: 24423321).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Ganetespib + TAK-733	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the Hsp90 inhibitor, Ganetespib, in combination with the MEK1/2 inhibitor TAK-733, caused the regression of tumors in vemurafenib-resistant cell line xenograft models of melanoma (PMID: 24398428).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Vemurafenib + Cetuximab	Clinical Study	Actionable	In a clinical case study, the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) was tolerated and showed clinical benefit in a patient with BRAF V600E mutant colorectal cancer (PMID: 24523613).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PLX4720 + Navitoclax	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 and navitoclax (ABT-263) worked synergistically to inhibit growth and increase apoptosis of BRAF V600E mutant melanoma cells in culture and in xenografts (PMID: 24983357).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Vemurafenib + Cobimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) inhibited tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 28649441).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	malignant glioma	predicted - sensitive	Selumetinib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600E, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Vemurafenib	FDA approved	Actionable	In a Phase III trial (BRIM-3) that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival (OS) (13.6 vs 9.7 months, HR=0.81, p=0.03) in patients with BRAF V600E-positive metastatic melanoma, with estimated OS rates of 56%, 30%, 21%, and 17% at 1, 2, 3, and 4 years, respectively (PMID: 28961848; NCT01006980).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PD-0325901 + Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in significant tumor regression in melanoma cell line xenograft models harboring BRAF V600E and demonstrated a 56% (5/9) complete response rate (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	PLX7904	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX7904 inhibited survival of colorectal cancer cells harboring BRAF V600E in culture and demonstrated anti-tumor activity in cell line xenograft models (PMID: 26466569).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Vemurafenib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring a BRAF V600E mutation had a complete response after treatment with Zelboraf (vemurafenib) (PMID: 23733758).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited Braf V600E in vitro and inhibited growth of human colon cancer cells harboring BRAF V600E in culture (PMID: 21325073, PMID: 24042735).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, thyroid cancer cells harboring BRAF V600E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	BGB-283	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in colorectal cancer cell lines harboring BRAF V600E in culture, and resulted in partial tumor regression in both cell line and patient-derived xenograft models (PMID: 26208524).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600E, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Dabrafenib	FDA approved	Actionable	In a Phase III clinical trial (BREAK-3) that supported FDA approval, Tafinlar (dabrafenib) improved median progression-free survival compared to Deticene (dacarbazine) (5.1 vs 2.7 months, HR=0.3, p<0.0001) in patients with BRAF V600E positive melanoma (PMID: 22735384; NCT01227889).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	predicted - sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a melanoma xenograft model harboring BRAF V600E demonstrated tumor regression when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	CCT241161	Preclinical - Pdx	Actionable	In a preclinical study, CCT241161 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	glioblastoma multiforme	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (Ulixertinib) resulted in a partial response in a patient with glioblastoma harboring BRAF V600E (PMID: 29247021).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Panitumumab + Dabrafenib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with the combination of Vectibix (panitumumab) and Tafinlar (dabrafenib) resulted in stable disease in 7/8 colorectal cancer patients harboring a BRAF V600E mutation (J Clin Oncol 32:5s, 2014 (suppl; abstr 3515)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Panitumumab + Dabrafenib	Phase I	Actionable	In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib) and Vectibix (panitumumab) resulted in an overall response rate of 10% (2/20, 1 complete response, 1 partial response), stable disease in 80% (16/20), and a median progression-free survival of 3.5 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Encorafenib	Phase I	Actionable	In a Phase I trial, Encorafenib (LGX818) showed activity in patients with advanced metastatic colorectal cancer harboring a BRAF V600E mutation, resulting in a median progression-free survival of 4 months and a best response of stable disease in 66.7% (12/18) (Ann Oncol (2014) 25 (suppl 4): iv182-iv183).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	conflicting	PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a melanoma cell line xenograft model harboring BRAF V600E treated with PD-0325901 demonstrated stable tumor growth, but by day 44, growth ensued and thus, demonstrated no benefit (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	conflicting	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, PD-0325901 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Regorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture and suppressed angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	Lapatinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and Zelboraf (vemurafenib) inhibited growth of thyroid cancer cells harboring a BRAF V600E mutation in culture and in BRAF-mutant mouse models of thyroid cancer (PMID: 23365119).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	skin melanoma	sensitive	Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	no benefit	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Ibrance (palbociclib) in a melanoma cell line xenograft model harboring BRAF V600E resulted in no benefit, demonstrating low but continuous growth (PMID: 27488531).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon adenocarcinoma	not applicable	N/A	Phase III	Emerging	In a post-hoc analysis of a Phase III trial, BRAF V600E mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that BRAF V600E may serve as a future prognostic biomarker in this patient population (PMID: 26768652).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	SB590885	Preclinical - Cell culture	Actionable	In a preclinical study, SB590885 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Refametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Refametinib (BAY86-9766) inhibited growth of melanoma cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited growth, downstream MAPK signaling and soft agar growth in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26343583).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Gefitinib + PLX4720	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) in combination with PLX4720 inhibited proliferation and tumorigenicity in human melanoma cell line harboring BRAF V600E and resistant to Braf inhibition in culture and in animal models (PMID: 23242808).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Imatinib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and PLX4720 enhanced antitumor efficacy of melanoma cells harboring BRAF V600E, demonstrating decreased cell survival in xenograft models, and decreased phosphorylation of Mapk1 in culture (PMID: 27924459).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	no benefit	Vemurafenib	Phase II	Actionable	In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate clinical activity as a single agent in patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	no benefit	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	no benefit	Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, colorectal cancer cell lines were not sensitive to growth inhibition by Zelboraf (vemurafenib) in culture or xenograft models, due to feedback activation of EGFR signaling (PMID: 22281684).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Selumetinib	Phase II	Actionable	In a Phase II trial, a favorable response rate to selumetinib (AZD6244) was observed in mutant BRAF but not BRAF wild-type melanoma patients (PMID: 22048237).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	Dasatinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	BI 882370 + Trametinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Mekinist (trametinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Refametinib	Preclinical	Actionable	In a preclinical study, Refametinib (BAY86-9766) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	EBI-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	no benefit	SHP099	Preclinical	Actionable	In a preclinical study, SHP099 did not inhibit proliferation or ERK activation in a melanoma cell line harboring BRAF V600E in culture (PMID: 27362227).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PLX4720 + Doxorubicin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PLX4720 and Adriamycin (doxorubicin) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and inhibition of cell growth in culture (PMID: 27924459).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Erlotinib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PLX4720 and Tarceva (erlotinib) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models and culture (PMID: 27924459).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Cobimetinib	Phase I	Actionable	In a Phase I trial, Cotellic (cobimetinib) treatment resulted in a confirmed partial response in six melanoma patients harboring BRAF V600E (PMID: 27424159).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Selumetinib + PLX4720	Preclinical	Actionable	In a preclinical study, PLX4720 and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	DEL-22379	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	CEP-32496	Preclinical - Cell line xenograft	Actionable	In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human melanoma cell line (PMID: 22319199).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) decreased tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 23942066).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 resulted in partial response in 1 thyroid cancer patient harboring BRAF V600E, who remained on treatment for over 481 days (AACR Annual Meeting, Apr 2016, abstract # CT005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Trametinib + TW-37	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PLX4720 + Tivozanib	Preclinical	Actionable	In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	predicted - sensitive	Binimetinib + Cetuximab + Encorafenib	Phase III	Actionable	In a Phase III (BEACON CRC) trial, Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab) combination treatment resulted in an objective response rate of 48% (14/29, 3 complete responses), and stable disease in 52% (15/29) of patients with BRAF V600E metastatic colorectal cancer, with a median progression-free survival of 8.0 months (Annals of Oncology, Volume 29, Issue suppl_5; NCT02928224).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	decreased response	Dabrafenib + SCH772984 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable inhibition of Erk signaling and proliferation of melanoma cells overexpressing BRAF V600E in culture (PMID: 28714990).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	Advanced Solid Tumor	sensitive	PLX8394	Preclinical	Actionable	In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF V600E splice variants (PMID: 24422853).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Navitoclax + Vemurafenib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Vemurafenib + TW-37	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	PD-0325901	Preclinical	Actionable	In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	predicted - sensitive	RAF265	Phase I	Actionable	In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Navitoclax + Vemurafenib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	INU-152	Preclinical - Cell line xenograft	Actionable	In a preclinical study, INU-152 reduced MEK and ERK phosphorylation and growth of a melanona cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 28645859).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Dabrafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation had increased sensitivity to Tafinlar (dabrafenib) in culture compared to cell lines with wild-type BRAF (PMID: 24885690).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	BI 882370 + Afatinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Gilotrif (afatinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Trametinib	FDA approved	Actionable	In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Lapatinib + Panobinostat	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) and Faridak (panobinostat) worked synergistically to inhibit growth of BRAF V600E mutant colorectal cancer cells in culture (PMID: 21464044).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Trametinib + TW-37	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Alpelisib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Alpelisib (BYL719) and PLX4720 enhanced antitumor activity in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Akt signaling in culture (PMID: 27924459).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	CCT241161	Preclinical	Actionable	In a preclinical study, CCT241161 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Encorafenib + Ribociclib	Phase Ib/II	Actionable	In a Phase Ib/II trial, Encorafenib (LGX818) and Kisqali (ribociclib) combination treatment resulted in confirmed partial response in 7.1% (2/28), unconfirmed partial response in 10.7% (3/28), and stable disease in 35.7% (10/28) of patients with melanoma harboring BRAF V600E (PMID: 28351928).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon carcinoma	sensitive	CEP-32496	Preclinical - Cell line xenograft	Actionable	In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human colon carcinoma cell line (PMID: 22319199).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	resistant	SHP099	Preclinical - Cell culture	Actionable	In a preclincial study, colorectal cancer cell lines harboring BRAF V600E demonstrated resistance to SHP099 in culture (PMID: 27362227).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with BRAF V600E unless it is given with a BRAF inhibitor (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	Advanced Solid Tumor	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	Advanced Solid Tumor	sensitive	RAF265	Preclinical	Actionable	In a preclinical study, RAF265 inhibited Erk phosphorylation and cell proliferation in BRAF V600E expressing cells in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	pilocytic astrocytoma	sensitive	Dabrafenib	Clinical Study	Actionable	In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a near complete response and resolution of leptomeningeal dissemination in a patient with pilocytic astrocytoma harboring BRAF V600E (PMID: 28784858).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	neuroendocrine tumor	sensitive	Trametinib + Dabrafenib	Clinical Study	Actionable	In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal adenocarcinoma	sensitive	DEL-22379	Preclinical - Pdx	Actionable	In a preclinical study, DEL-22379 inhibited tumor growth in a colorectal adenocarcinoma patient-derived xenograft model harboring BRAF V600E (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PAC-1 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PAC-1 and Zelboraf (vemurafenib) resulted in a synergistic effect when treating melanoma cells harboring BRAF V600E in culture and xenograft models, demonstrating increased apoptosis and decreased tumor volume (PMID: 27297867).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	sensitive	GDC0879	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC0879 inhibited survival of colon cancer cell lines harboring BRAF V600E in cell culture and cell line xenograft models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	sensitive	Vemurafenib + Cetuximab + Irinotecan	Guideline	Actionable	Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, RAF709 inhibited Erk signaling and proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 29343524).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	lung carcinoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) failed to induce apoptosis in lung carcinoma cells expressing BRAF V600E (PMID: 22649091).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Saracatinib	Preclinical	Actionable	In a preclinical study, saracatinib inhibited proliferation of human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	sensitive	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 inhibited growth of colon cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	predicted - sensitive	Cetuxmab + Sorafenib	Clinical Study	Actionable	In a clinical case report, a patient with metastatic colon cancer harboring BRAF V600E demonstrated a mixed radiographic response, with slight progression in some locations, however, response or stable disease for 7 months in other locations following treatment with the combination of Nexavar (sorafenib) and Erbitux (cetuximab) (PMID: 23792568).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	no benefit	Sorafenib	Phase II	Actionable	In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	Dasatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, PLX7904 inhibited survival of melanoma cell lines harboring monomeric BRAF V600E as well as cells harboring the Zelboraf (vemurafenib)-resistant dimeric BRAF V600E in culture (PMID: 26466569).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	SCH772984	Preclinical	Actionable	In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	CCT196969	Preclinical - Pdx	Actionable	In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PLX4720 + Vorinostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PLX4720 and Zolinza (vorinostat) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Rb phosphorylation in culture (PMID: 27924459).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	sensitive	PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PD-0325901 demonstrated antitumor activity against BRAF V600E colon cancer cell line xenografts (PMID: 16273091).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Vemurafenib + SBI-060756	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zelboraf (vemurafenib) in combination with SBI-0640756 inhibited the association of eIF4G1 and eIF4E in Zelboraf (vemurafenib) resistant human melanoma cell lines harboring BRAF V600E in culture and reduced tumor growth in xenograft models (PMID: 26603897).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	Advanced Solid Tumor	sensitive	PLX4720	Preclinical	Actionable	In a preclinical study, PLX4720 inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	BI-69A11	Preclinical	Actionable	In a preclinical study, BI-69A11 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	malignant glioma	predicted - sensitive	Everolimus + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and Afinitor (everolimus) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	glioblastoma multiforme	decreased response	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture (PMID: 26573800).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Trametinib + Navitoclax	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Vemurafenib + Panitumumab	Phase I	Actionable	In a Phase I trial, 83% (10/12) of patients with colorectal cancer carrying a BRAF V600E mutation demonstrated tumor regression when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 25589621).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Cediranib + Selumetinib + PLX4720	Preclinical	Actionable	In a preclinical study, PLX4720, Cediranib (AZD-2171) and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	hairy cell leukemia	not applicable	N/A	Guideline	Diagnostic	BRAF V600E is diagnostic and aids distinguishing classic hairy cell leukemia (HCL-C) from variant hairy cell leukemia (HCL-V) and other B-cell lymphomas and leukemias (PMID: 29118233).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	sensitive	Trametinib + Navitoclax	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	EBI-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of colorectal cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	Advanced Solid Tumor	sensitive	SB590885	Preclinical	Actionable	In a preclinical study, SB590885 inhibited inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	ovarian cancer	sensitive	CI-1040	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	BGB-283 + Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGB-283 in combination with Erbitux (cetuximab) demonstrated enhanced tumor suppression in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 26208524).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	Advanced Solid Tumor	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited viability of a variety of cancer cell lines harboring BRAF V600E in culture (PMID: 26208524).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	rectum cancer	sensitive	Vemurafenib + Cetuximab + Irinotecan	Guideline	Actionable	Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring a BRAF V600E mutation had increased sensitivity to Mekinist (trametinib) compared to other colorectal cancer lines in culture (PMID: 25309914).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Cediranib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 and Cediranib (AZD-2171) worked synergistically to inhibit cell growth and induce apoptosis in PLX4720-resistant human melanoma cell lines harboring BRAF V600E in culture and to suppress tumor growth in xenograft models (PMID: 26461489).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	DT01 + Fluorouracil + Oxaliplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DT01 increased sensitivity of human colorectal cancer (CRC) cells harboring BRAF V600E to Eloxatin (oxaliplatin) and Adrucil (5-fluorouracil), and the combination resulted in decreased liver tumor growth in CRC cell line xenograft metastasis models (PMID: 26637369).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	GDC0879	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, GDC0879 inhibited survival of melanoma cell lines harboring BRAF V600E in cell culture, cell line xenograft and patient-derived xenograft (PDX) models (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	lung cancer	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients with lung cancer each harboring BRAF V600E (PMID: 29247021).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	BI 882370 + Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Erbitux (cetuximab) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of thyroid cancer cells harboring BRAF V600E in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in melanoma cell lines harboring BRAF V600E in culture (PMID: 26208524).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 resulted in partial response in 1 of 2 melanoma patients harboring BRAF V600E, who remained on treatment for over 249 days (AACR Annual Meeting, Apr 2016, abstract # CT005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	glioblastoma multiforme	sensitive	BI2536	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated sensitivity to BI2536 in culture (PMID: 26573800).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	GSK2126458	Preclinical	Actionable	In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	SCH772984	Preclinical	Actionable	In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	BI-847325	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of melanoma cell lines harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models of BRAF V600E-positive melanoma, including models with BRAF-inhibitor resistance (PMID: 25873592).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Trametinib + Dabrafenib	FDA approved	Actionable	In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Trametinib + Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, such as BRAF V600E, as adjuvant therapy for stage III disease and as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Trametinib + Dabrafenib	Phase II	Actionable	In a Phase II trial, BRAF V600E positive melanoma patients who progressed on treatment with BRAF inhibitors or the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) were treated again with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) after 12 weeks off treatment, which resulted in a partial response in 35% (8/25) and stable disease in 40% (10/25) (PMID: 28268064).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	glioblastoma multiforme	decreased response	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PLX4720, demonstrating increased viability of CD133 positive cells in culture and in xenograft models (PMID: 26573800).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	pleomorphic xanthoastrocytoma	predicted - sensitive	Trametinib + Dabrafenib	Clinical Study	Actionable	In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in clinical benefit lasted for 16 months in a patient with pleomorphic xanthoastrocytoma harboring BRAF V600E (PMID: 29632053).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	DETD-35	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DETD-35 inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	SBI-0640756	Preclinical	Actionable	In a preclinical study, SBI-0640756 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	PAC-1 + Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of PAC-1 to Mekinist (trametinib) and Zelboraf (vemurafenib) led to greater levels of caspase-3 activity and apoptosis in melanoma cells harboring BRAF V600E when compared to Zelboraf (vemurafenib) and Mekinist (trametinib) treatment without PAC-1 (PMID: 27297867).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	INU-152	Preclinical - Cell line xenograft	Actionable	In a preclinical study, INU-152 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture, and reduced tumor growth in BRAF V600E-mutant colorectal cancer cell line xenograft models (PMID: 28645859).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	predicted - sensitive	LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 demonstrated modest efficacy in patient-derived xenograft models of colorectal cancer harboring BRAF V600E, resulted in tumor growth inhibition or regression, but relapse upon discontinuation of treatment (PMID: 28611205).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	sensitive	Navitoclax + Vemurafenib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Vemurafenib + Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Tarceva (erlotinib) resulted in improved inhibition of tumor growth in BRAF V600E mutant human colon cancer cell line xenograft models compared to either drug as monotherapy (PMID: 22448344).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	no benefit	Panitumumab + Trametinib	Phase I	Actionable	In a Phase I trial, combination therapy consisting of Vectibix (panitumumab) and Mekinist (trametinib) resulted in an overall response rate of 0% (0/31), stable disease in 55% (17/31), and a median progression-free survival of 2.6 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	rectum cancer	sensitive	Vemurafenib + Panitumumab + Irinotecan	Guideline	Actionable	Zelboraf (vemurafenib), Vectibix (panitumumab), and Irinotecan combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell lines harboring BRAF V600E mutation in culture (PMID: 24448821).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	predicted - sensitive	Panitumumab + Trametinib + Dabrafenib	Phase I	Actionable	In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib), Vectibix (panitumumab), and Mekinist (trametinib) resulted in an overall response rate of 21% (19/91, 1 complete response, 18 partial response), stable disease in 65% (59/91), and a median progression-free survival of 4.2 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	neuroendocrine tumor	sensitive	Trametinib + Vemurafenib	Clinical Study	Actionable	In a clinical case study, Mekinist (trametinib) and Zelboraf (vemurafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	Trametinib + Dabrafenib	FDA approved	Actionable	In a Phase II trial (ROAR) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an overall response rate of 69% (11/16; 1 complete response and 10 partial responses) in patients with anaplastic thyroid cancer harboring BRAF V600E (PMID: 29072975; NCT02034110).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	thyroid cancer	sensitive	Trametinib + Dabrafenib	Clinical Study	Actionable	In a clinical case report, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Vemurafenib + TW-37	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	SBI-0640726	Preclinical	Actionable	In a preclinical study, SBI-0640726 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	renal cell carcinoma	sensitive	Vemurafenib	Clinical Study	Actionable	In a clinical case study, a patient with metastatic renal cell carcinoma harboring BRAF V600E demonstrated a partial response following treatment with Zelboraf (vemurafenib) (PMID: 26918217).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	papillary thyroid carcinoma	sensitive	RO5126766	Preclinical	Actionable	In a preclinical study, RO5126766 inhibited Mek signaling and increased radioiodide uptake and response in transgenic animal models of papillary thyroid carcinoma driven by BRAF V600E (PMID: 27669459).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	S3I-201	Preclinical	Actionable	In a preclinical study, S3I-201 inhibited cell invasion and Stat3 signaling in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	PLX4720 + TAK-632	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Trametinib + Navitoclax	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	glioblastoma multiforme	predicted - sensitive	Trametinib + Dabrafenib	Clinical Study	Actionable	In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in stable disease lasted for more than 16 months in a patient with epithelioid glioblastoma harboring BRAF V600E (PMID: 29632053).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colorectal cancer	sensitive	CCT196969	Preclinical	Actionable	In a preclinical study, CCT196969 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	Encorafenib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, Encorafenib (LGX818) treatment of human melanoma xenograft models with BRAF V600E significantly decreased Mek activation and resulted in tumor regression (Cancer Res: 72(8) Suppl 1, Abstract #3790).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	malignant glioma	predicted - sensitive	Everolimus + PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Afinitor (everolimus) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Dabrafenib	Phase II	Actionable	In a Phase II trial, 33% (26/78) of previously treated non-small cell lung carcinoma patients harboring BRAF V600E demonstrated an overall response, which included all partial responses, when treated with Tafinlar (dabrafenib) while 67% (4/6) receiving Tafinlar (dabrafenib) as a first-line treatment achieved partial responses (PMID: 27080216; NCT01336634).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	non-small cell lung carcinoma	sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with BRAF V600E unless it is given with a BRAF inhibitor (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	DETD-35 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	melanoma	sensitive	BI 882370 + Trametinib	Preclinical	Actionable	In a preclinical study, xenograft models of melanoma harboring BRAF V600E treated with the combination of BI 882370 and Mekinist (trametinib) demonstrated tumor regression with no regrowth during the 5 weeks of treatment (PMID: 26916115).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	colon cancer	sensitive	Vemurafenib + Panitumumab + Irinotecan	Guideline	Actionable	Zelboraf (vemurafenib), Vectibix (panitumumab), and Irinotecan combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E	glioblastoma multiforme	sensitive	BI2536 + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of BI 2536 and PLX4720 resulted in suppression of downstream signaling, increased apoptotic activity, inhibition of cell proliferation, and tumor growth suppression in glioblastoma cell line xenograft models harboring BRAF V600E (PMID: 26573800).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	sensitive	Cetuximab + Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E TP53 Q192K	colon cancer	sensitive	Vemurafenib + Panitumumab	Clinical Study	Actionable	In a clinical study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E BRAF L505H	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical case study, a melanoma patient harboring BRAF V600E  treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K	melanoma	sensitive	XL888	Preclinical	Actionable	In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E ERBB2 over exp KRAS A146V	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS A146V and BRAF V600E in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K NRAS A146T	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	melanoma	resistant	CI-1040	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PTEN loss TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	MAP2K1 Q56P BRAF V600E	melanoma	sensitive	Selumetinib + PLX4720	Preclinical	Actionable	In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	MAP2K1 Q56P BRAF V600E	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor selumetinib (AZD6244) cell culture.
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	MAP2K1 Q56P BRAF V600E	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 H119P	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS amp	colorectal cancer	resistant	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS amp	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS amp	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS amp	colorectal cancer	resistant	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired KRAS amplification (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS amp	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS mutant	colorectal cancer	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS mutant	colorectal cancer	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G12D	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G12D	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquisition of KRAS G12D (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G12D	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G12D	colorectal cancer	resistant	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 E203K	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 E203K	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 E203K	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Vemurafenib + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	resistant	Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR G465R	colorectal cancer	resistant	Vemurafenib + Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 C121S	melanoma	decreased response	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Zelboraf (vemurafenib)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 C121S	melanoma	decreased response	Vemurafenib	Clinical Study	Actionable	In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 C121S	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 C121S	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 C121S	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 C121S	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 C121S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 C121S	melanoma	resistant	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V60E	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA P449T	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Regorafenib + Cetuximab	Preclinical	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA P449T	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA mut	colorectal cancer	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 G128V	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 G128V	melanoma	resistant	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 G128V	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 G128V	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	resistant	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to combination treatment consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture, likely due to the acquisition of KRAS A146V and A146T secondary resistance mutations (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquisition of KRAS G13D (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and SCH772984 in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PTEN mut	melanoma	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA H1047R	thyroid carcinoma	sensitive	Dabrafenib + Everolimus + Trametinib	Clinical Study	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA H1047R	thyroid carcinoma	resistant	Everolimus	Clinical Study	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA H1047R	thyroid carcinoma	resistant	Trametinib + Dabrafenib	Clinical Study	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	EGFR amp EGFR S492R BRAF V600E	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical study, a colorectal cancer patient harboring EGFR amplification, BRAF V600E, and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 I103N	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 I103N	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PTEN loss	melanoma	sensitive	Pictilisib + PLX4720	Preclinical	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PTEN loss	melanoma	sensitive	GDC0879 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PTEN loss	melanoma	sensitive	GSK2636771 + unspecified PD-1 antibody	Preclinical	Actionable	In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PTEN loss	melanoma	resistant	Everolimus	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PTEN loss	melanoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 Q56P	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 Q56P	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 Q56P	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	no benefit	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR over exp	colorectal cancer	sensitive	EBI-907	Preclinical - Cell culture	Actionable	In a preclinical study, EBI-907 inhibited growth of colorectal cancer cells harboring BRAF V600E and EGFR overexpression in culture (PMID: 26810733).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E EGFR over exp	colorectal cancer	resistant	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA P449T TP53 R273H	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E PIK3CA H1047K	melanoma	sensitive	ARQ092 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of ARQ092 and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E KRAS wild-type	colorectal cancer	no benefit	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring BRAF V600E (PMID: 26369631).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 K59del	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 K59del	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 K59del	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 K59del	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 K59del	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 K59del	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E MAP2K1 K59del	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF F595L	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Zelboraf (vemurafenib) did not reduce activation of Mek and Erk by BRAF F595L in transformed cells in culture (PMID: 26582644).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469V	non-small cell lung carcinoma	sensitive	Sorafenib	Clinical Study	Actionable	In a clinical case study, a patient with synchronous BRAF wild-type hepatocellular carcinoma and non-small cell lung cancer harboring BRAF G469V demonstrated a partial response in primary lung lesions and complete response in the lung metastasis following treatment with Nexavar (sorafenib) (PMID: 27388325).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF G469V	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469V (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X PTEN neg	melanoma	sensitive	GSK2141795	Preclinical - Cell culture	Actionable	In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	AKT1 Q79K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	AKT1 Q79K BRAF V600X PTEN pos	melanoma	sensitive	MK2206 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X PTEN H93D	melanoma	sensitive	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF amp BRAF V600X NRAS Q61K	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X PIK3CA H1047R PTEN Y86fs	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	PIK3CA H1047X BRAF V600X	ovarian carcinoma	sensitive	Bevacizumab + Temsirolimus + Doxil	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	AKT1 E17K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	AMG 232 + Trametinib + Dabrafenib	Phase I	Actionable	In a Phase I trial, the combination therapy of AMG 232, Mekinist (trametinib), and Tafinlar (dabrafenib) in 6 patients with metastatic cutaneous melanoma harboring a BRAF V600 mutation resulted in 4 patients with a partial response and 2 patients with stable disease, and of the 6 patients, all experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	cholangiocarcinoma	sensitive	Vemurafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in partial response in 12% (1/8) and stable disease in 50% (4/8) of cholangiocarcinoma patients with BRAF V600 mutations (PMID: 26287849).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	colorectal cancer	sensitive	Vemurafenib + Cetuximab + Irinotecan	Phase Ib/II	Actionable	In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	Trametinib + Dabrafenib	Phase Ib/II	Actionable	In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	Trametinib + Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, as adjuvant treatment for patients with Stage III disease, or as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	MK2206 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	colorectal cancer	no benefit	Vemurafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	colorectal cancer	sensitive	Vemurafenib + Cetuximab	Phase II	Actionable	In a Phase II clinical trial, treatment with the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) resulted in an overall response rate of 4% (1/26), stable disease in 69% (18/26), and a median progression-free survival of 3.7 months in patients with BRAF V600-mutant colorectal cancer (PMID: 26287849).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	colorectal cancer	sensitive	Trametinib + Dabrafenib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	Atezolizumab + Vemurafenib + Cobimetinib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Tecentriq (atezolizumab), Cotellic (cobimetinib), and Zelboraf (vemurafenib) resulted in antitumor efficacy in BRAF V600 positive melanoma patients, demonstrating an unconfirmed RECIST response in 85.3% (29/34) of patients, including 6 CRs and 23 PRs, and confirmed PRs in three patients (J Clin Oncol 35, 2017 (suppl; abstr 3063)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	predicted - sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	BKM120 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	MK2206 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	ASN003	Preclinical - Pdx	Actionable	In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	thyroid cancer	predicted - sensitive	Vemurafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in an overall response rate of 29% (2/7), with 1 complete response and 1 partial response, in patients with anaplastic thyroid cancer patients with BRAF V600 mutations (PMID: 26287849).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	Vemurafenib + Cobimetinib	Phase III	Actionable	In a Phase III trial, combination treatment with Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months compared to 7.2 months with Zelboraf (vemurafenib) alone among patients with BRAF V600-mutated metastatic melanoma (PMID: 27480103; NCT01689519).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	Vemurafenib + Cobimetinib	Guideline	Actionable	Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	BKM120 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	sensitive	BKM120 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600X	melanoma	predicted - sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF Y472C	non-small cell lung carcinoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung carcinoma cells harboring BRAF Y472C in culture (PMID: 22649091).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF act mut	Advanced Solid Tumor	sensitive	PLX8394	Preclinical	Actionable	In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF activating mutations (PMID: 24422853).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF act mut	colorectal cancer	no benefit	Venetoclax + VX-11e	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF act mut	non-small cell lung carcinoma	sensitive	RAF709	Preclinical - Pdx	Actionable	In a preclinical study, RAF709 inhibited tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring BRAF activating mutations (PMID: 29343524).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF act mut	melanoma	no benefit	Sorafenib	Phase II	Actionable	In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF act mut	Advanced Solid Tumor	sensitive	Binimetinib + Encorafenib	Phase Ib/II	Actionable	In a Phase Ib/II trial, Binimetinib (MEK162), in combination with Encorafenib (LGX818), demonstrated safety and efficacy in patients with BRAF mutant advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 9029)).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF act mut	colorectal cancer	predicted - sensitive	VX-11e + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF act mut	thyroid cancer	sensitive	Vemurafenib	Phase I	Actionable	In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF act mut	melanoma	sensitive	Cobimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cobimetinib (GDC-0973) induced cell death in human melanoma cell lines harboring BRAF activating mutations in culture and inhibited tumor growth in xenograft models (PMID: 22084396).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597V	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597V (PMID: 26343582).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PTEN loss	Advanced Solid Tumor	predicted - sensitive	PX-866 + Vemurafenib	Phase I	Actionable	In a Phase I trial, the combination therapy of PX-866 and Zelboraf (vemurafenib) demonstrated safety and resulted in an objective response in 28% (5/18) of advanced solid tumor patients harboring BRAF V600E or K, and of those five patients, 80% (4/5) also demonstrated loss of PTEN (PMID: 29051322).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K	melanoma	sensitive	Trametinib + Dabrafenib	FDA approved	Actionable	In a Phase III trial (COMBI-AD) that supported FDA approval, adjuvant treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved estimated 3-year relapse-free survival rate (58% vs 39%, HR=0.47, P<0.001) and 3-year overall survival rate (86% vs 77%, HR=0.57; 95% CI, 0.42 to 0.79, P=0.0006) compared to placebo in stage III melanoma patients harboring BRAF V600E or V600K mutations (PMID: 28891408; NCT01682083).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K	melanoma	sensitive	Trametinib + Dabrafenib	FDA approved	Actionable	In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K	melanoma	sensitive	Trametinib	Phase I	Actionable	In a Phase I trial, Mekinist (trametinib) resulted in complete response in 7% (2/30), partial response in 33% (10/30), and stable disease in 37% (11/30) of BRAF-mutant melanoma patients (PMID: 22805292).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K	melanoma	sensitive	Trametinib	FDA approved	Actionable	In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K positive metastatic melanoma (PMID: 22663011; NCT01245062).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K	melanoma	sensitive	Vemurafenib + Cobimetinib	FDA approved	Actionable	In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, which included patients identified to harbor BRAF V600E or BRAF V600K (PMID: 27480103; NCT01689519).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K	melanoma	sensitive	Binimetinib + Encorafenib	Guideline	Actionable	Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (NCCN.org).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K	melanoma	sensitive	Binimetinib + Encorafenib	FDA approved	Actionable	In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	TGX-221	Preclinical	Actionable	In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + ZSTK474	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Vemurafenib + ZSTK474	Preclinical	Actionable	In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	Idelalisib	Preclinical	Actionable	In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	BEZ235 + Vemurafenib	Preclinical	Actionable	In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	A66	Preclinical	Actionable	In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
BRAF	B-raf | B-RAF1 | BRAF1 | NS7 | RAFB1	7q34	NM_004333	BRAF L505H	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 dec exp MET dec exp	triple-receptor negative breast cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 dec exp MET over exp	triple-receptor negative breast cancer	no benefit	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 dec exp	triple-receptor negative breast cancer	sensitive	Cisplatin	Preclinical	Actionable	In a preclinical study, knockdown of BRCA1 increased sensitivity of triple-negative breast cancer cells to Platinol (cisplatin) under hypoxic conditions (PMID: 25193512).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 dec exp	triple-receptor negative breast cancer	sensitive	Chlorambucil	Preclinical	Actionable	In a preclinical study, BRCA1 knockdown enhanced growth inhibition by Ambochlorin (chlorambucil) in triple-receptor negative breast cancer cell lines in culture (PMID: 25193512).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 W1782*	ovarian carcinoma	sensitive	Rucaparib	Clinical Study	Actionable	In a clinical study, an ovarian carcinoma patient harboring a BRCA1 W1782* germline mutation demonstrated stable disease when treated with Rubraca (rucaparib) (PMID: 28588062).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 negative	Advanced Solid Tumor	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, BRCA1-deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, Talazoparib (BMN-673) (PMID: 23881923).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 E23Vfs*17 BRCA1 T37Qfs*13	ovarian cancer	predicted - resistant	Carboplatin	Clinical Study	Actionable	In a clinical study, an ovarian cancer patient harboring BRCA1 E23Vfs*17 progressed while being treated with platinum-based chemotherapy, and via cell-free DNA testing was found to have acquired a somatic reversion mutation, BRCA1 T37Qfs*13, which restored the open reading frame, resulting in wild-type BRCA1 protein function (PMID: 28765325).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 C61G TP53 loss	breast cancer	decreased response	Olaparib	Preclinical	Actionable	In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 E23Vfs*17 BRCA1 E29Sfs*2 BRCA1 K38Sfs*12	ovarian cancer	predicted - resistant	Carboplatin	Clinical Study	Actionable	In a clinical study, an ovarian cancer patient harboring BRCA1 E23Vfs*17 progressed while being treated with platinum-based chemotherapy, and via cell-free DNA testing was found to have acquired somatic reversion mutations, BRCA1 E29Sfs*2 and BRCA1 K38Sfs*12, which restored the open reading frame, resulting in wild-type BRCA1 protein function (PMID: 28765325).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 L392Qfs*5	ovarian carcinoma	sensitive	Rucaparib	Clinical Study	Actionable	In a clinical study, an ovarian carcinoma patient harboring a BRCA1 L392Qfs*5 germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 inact mut	Advanced Solid Tumor	predicted - sensitive	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 inact mut	ovarian cancer	sensitive	Niraparib	Phase I	Actionable	In a Phase I clinical trial, Zejula (niraparib) demonstrated safety and efficacy in ovarian cancer patients with BRCA1 inactivating mutations (PMID: 23810788).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 inact mut	breast cancer	predicted - sensitive	Carboplatin + Paclitaxel + Veliparib	Phase II	Actionable	In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 inact mut	breast cancer	sensitive	APTO-253	Preclinical - Cell culture	Actionable	In a preclinical study, APTO-253 treatment resulted in decreased viability of breast cancer cells expressing a BRCA1 inactivating mutation in culture (PMID: 29626126).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 inact mut	triple-receptor negative breast cancer	predicted - sensitive	E7449	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E7449 inhibited tumor growth in a triple-negative breast cancer cell line xenograft model harboring a BRCA1 splice donor site mutation (PMID: 26513298).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 inact mut	Advanced Solid Tumor	sensitive	E7449	Preclinical	Actionable	In a preclinical study, E7449 inhibited proliferation of a BRCA1-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 inact mut	ovarian cancer	no benefit	Veliparib + Cyclophosphamide	Phase II	Actionable	In a Phase II clinical trial, the combination of Veliparib (ABT-888) and Cytoxan (cyclophosphamide) did not demonstrate improved response rate or progression-free survival over Cytoxan (cyclophosphamide) alone in ovarian cancer patients harboring deleterious mutations in BRCA1 or BRCA2 (PMID: 25589624).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 L631Qfs*4	ovarian carcinoma	sensitive	Rucaparib	Clinical Study	Actionable	In a clinical study, an ovarian carcinoma patient harboring a BRCA1 L631Qfs*4 germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type	breast cancer	resistant	Olaparib	Preclinical	Actionable	In a preclinical study, BRCA1 proficient transgenic mouse models of breast cancer did not respond to Lynparza (olaparib) treatment (PMID: 27454287).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type	ovarian cancer	sensitive	Talazoparib + Temozolomide	Phase I	Actionable	In a Phase I trial, the combination of Talazoparib (BMN-673) and Temodar (temozolomide) resulted in a partial response in 50% (2/4) of ovarian cancer patients harboring wild-type BRCA1 (European Journal of Cancer, Sep 2015, 51:3, S60).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type	triple-receptor negative breast cancer	no benefit	Veliparib + Carboplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) provided no survival benefit in an intracranial human BRCA wild-type triple-negative breast cancer cell line xenograft model (PMID: 25824335).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type	triple-receptor negative breast cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study,  Lynparza (olaparib) inhibited the growth of triple-receptor negative breast cancer cell lines expressing wild-type BRCA1 under hypoxic conditions (PMID: 25193512).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	sensitive	Olaparib + KU-0063794	Preclinical	Actionable	In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	sensitive	Everolimus + Talazoparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN-673) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture and reduced tumor volume in xenograft models (PMID: 26546619).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	predicted - sensitive	Cisplatin + VX-970	Phase I	Actionable	In a Phase I trial, VX-970 in combination with Platinol (cisplatin) resulted in an objective response rate of 38.9% (7/18, all partial responses) and a disease control rate of 72.2% (13/18) in patients with BRCA1/2 wild-type triple-receptor negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 242PD; NCT02157792).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type BRCA2 wild-type	ovarian serous carcinoma	predicted - sensitive	Prexasertib	Phase II	Actionable	In a Phase II trial, Prexasertib (LY2606368) treatment resulted in a partial response in 33% (8/24) of BRCA wild-type patients with high-grade serous ovarian cancer (PMID: 29361470; NCT02203513).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	sensitive	Olaparib + Everolimus	Preclinical	Actionable	In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type BRCA2 wild-type	ovarian cancer	predicted - sensitive	Niraparib	Phase III	Actionable	In a Phase III trial (NOVA), Zejula (niraparib) maintenance therapy improved median progression-free survival compared to placebo (9.3 vs. 3.9 months, HR=0.45) in platinum-sensitive, recurrent ovarian cancer patients without germline BRCA mutations, with and without homologous recombination deficiency (12.9 vs. 3.8 months, HR=0.38) (PMID: 27717299; NCT01847274).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	sensitive	KU-0063794 + Talazoparib	Preclinical	Actionable	In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 N682*	ovarian carcinoma	sensitive	Rucaparib	Clinical Study	Actionable	In a clinical study, an ovarian carcinoma patient harboring a BRCA1 N682* germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 E23Vfs*17	breast cancer	decreased response	Olaparib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, breast cancer cells harboring BRCA1 E23Vfs*17 (referred to as BRCA1 185delAG) demonstrated reduced sensitivity, developed resistance to Lynparza (olaparib) in culture and in patient-derived xenograft models due to the expression of a RING-less form of Brca1 (PMID: 27454287).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 E23Vfs*17	invasive ductal carcinoma	resistant	Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast invasive ductal carcinoma cells harboring BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) acquired resistance to Platinol (cisplatin) both in culture and in cell line xenograft models through the expression of a RING-less Brca1 protein utilizing an in-frame translation start site downstream of the mutation (PMID: 27454289).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 E23Vfs*17	invasive ductal carcinoma	resistant	Rucaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast invasive ductal carcinoma cells harboring BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) acquired resistance to Rubraca (rucaparib) both in culture and in cell line xenograft models through the expression of a RING-less Brca1 protein utilizing an in-frame translation start site downstream of the mutation (PMID: 27454289).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	Her2-receptor negative breast cancer	sensitive	Cisplatin + Veliparib + Vinorelbine	Phase I	Actionable	In a Phase I trial, Veliparib (ABT-888), in combination with Platinol (cisplatin) and Navelbine (vinorelbine), resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	triple-receptor negative breast cancer	sensitive	Veliparib + Carboplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) induced DNA damage and decreased tumor growth in an intracranial human BRCA-mutant triple-negative breast cancer cell line xenograft model, but did not provide a significant survival benefit over Paraplatin (carboplatin) alone (PMID: 25824335).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	predicted - sensitive	Irinotecan + Veliparib	Phase I	Actionable	In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	predicted - sensitive	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	sensitive	NMS-P118	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NMS-P118 treatment resulted in antitumor activity in BRCA1 mutant breast cancer xenograft models, demonstrating tumor growth inhibition and induction of a complete response (PMID: 26222319).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	pancreatic cancer	predicted - sensitive	Rucaparib	Phase II	Actionable	In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19) and a disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	sensitive	AZD2461	Preclinical - Cell culture	Actionable	In a preclinical study, AZD2461 inhibited the growth of BRCA1 mutant breast cancer cells in culture (PMID: 27550455).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	predicted - sensitive	Talazoparib	Phase I	Actionable	In a Phase I clinical trial, Talazoparib (BMN-673) was well-tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including objective responses in 33% (2/6) of breast cancer patients carrying BRCA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	predicted - sensitive	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN-673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14) including one patient with a complete response and six patients with a partial response and a median progression free survival of 34.6 weeks (PMID: 28242752).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	triple-receptor negative breast cancer	decreased response	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN-673) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation resulted in a lower clinical benefit rate (56% vs 89%) compared to treatment in non-triple-receptor negative breast cancer patients carrying a BRCA1/2 mutation (PMID: 28242752).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	Her2-receptor negative breast cancer	sensitive	Olaparib	FDA approved	Actionable	In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a germline BRCA mutation (PMID: 28578601; NCT02000622).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	predicted - sensitive	Veliparib + Carboplatin	Phase I	Actionable	In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in  metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	sensitive	Rucaparib	FDA approved	Actionable	In a retrospective analysis of two Phase II trials (ARIEL2 and Study 10) that supported FDA approval, Rubraca (rucaparib) treatment resulted in an objective response rate of 54% (36/67) in high-grade ovarian cancer patients harboring BRCA1 mutations (PMID: 28751443).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	sensitive	Rucaparib	Guideline	Actionable	Rubraca (rucaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring BRCA1/2 germline mutations (NCCN.org).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	sensitive	Rucaparib	Phase II	Actionable	In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	sensitive	Rucaparib	Phase III	Actionable	In a Phase III trial (ARIEL3), Rubraca (rucaparib) treatment resulted in significantly improved progression-free survival compared to placebo (16.6 vs 5.4 months, HR=0.23, p=0.0001) in patients with BRCA-mutant, platinum-sensitive ovarian cancer (PMID: 28916367; NCT01968213).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline BRCA1/2 mutations are associated with increased risk of developing and early onset of pancreatic cancer (NCCN.org).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	Advanced Solid Tumor	predicted - sensitive	ABT-767	Phase I	Actionable	In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=14/79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	Advanced Solid Tumor	predicted - sensitive	CX-5461	Phase I	Actionable	In a Phase I trial, CX-5461 treatment resulted in partial response in a patient with advanced solid tumor harboring BRCA2 mutations, and stable disease in 5 additional patients, 4 of whom harboring BRCA1/2 mutations, and 1 with Li-Fraumeni syndrome (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 440; NCT02719977).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	not applicable	Denosumab	Clinical Study	Emerging	In a clinical study, Xgeva (denosumab) inhibited cell proliferation in normal breast tissues of BRCA1 mutation carriers, provided a potential strategy to prevent breast cancer in this population (PMID: 27322743).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	predicted - sensitive	Pamiparib	Phase I	Actionable	In a Phase I trial, BGB-290 treatment resulted in improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	sensitive	Pamiparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGB-290 inhibited PARylation and demonstrated anti-tumor activity in cell line xenograft models of breast cancer harboring BRCA1 mutations (Cancer Res 2015; 75(15 Suppl): Abstract nr 1653).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	predicted - sensitive	Niraparib	Phase III	Actionable	In a Phase III trial (NOVA), maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299; NCT01847274).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	sensitive	Olaparib	Phase II	Actionable	In a Phase II trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA1 mutations, with an objective response rate of 50% (9/18) in the maximum tolerated dose cohort and 19% (3/16) in the lower dose cohort (PMID: 20609467).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	triple-receptor negative breast cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, Lynparza (olaparib) inhibited the growth of triple-receptor negative BRCA1-mutant breast cancer cell lines under hypoxic conditions (PMID: 25193512).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	breast cancer	predicted - sensitive	Niraparib	Phase I	Actionable	In a Phase I clinical trial, Zejula (niraparib) was well-tolerated and demonstrated preliminary efficacy in advanced solid tumor patients, including partial responses in 50% (2/4) of breast cancer patients carrying BRCA1 or BRCA2 mutations (PMID: 23810788).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian carcinoma	no benefit	Bevacizumab + Carboplatin + Paclitaxel	Clinical Study	Actionable	In a clinical study, ovarian carcinoma patients harboring a mutation in either BRCA1, BRCA2, or another homologous recombination repair (HRR) gene did not demonstrate a significant difference in progression free survival when Avastin (bevacizumab) was added to the combined platinum therapy, Platinol (carboplatin) and Taxol (paclitaxel), versus the platinum therapy with placebo, suggesting HRR gene mutations do not impact the effect of Avastin (bevacizumab) (PMID: 29191972).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	sensitive	Olaparib	Phase III	Actionable	In a Phase III trial, ovarian cancer patients who are platinum-sensitive and relapsed and harbor either mutant BRCA1 or mutant BRCA2 demonstrated a greater progression-free survival (19.1 mo vs 5.5 mo) when treated with Lynparza (olaparib) tablets as maintenance therapy compared to placebo (PMID: 28754483; NCT01874353).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	sensitive	Olaparib	Guideline	Actionable	Lynparza (olaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring BRCA1/2 germline mutations (NCCN.org).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mutant	ovarian cancer	sensitive	Olaparib	FDA approved	Actionable	In a Phase II trial that supported FDA approval, treatment with Lynparza (olaparib) resulted in a tumor response rate of 34% (n=137) and median duration of response of 7.9 months in ovarian cancer patients harboring germline BRCA1/2 mutations that had received 3 or more lines of chemotherapy (PMID: 26187614, PMID: 25366685; NCT01078662).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mut TP53 E298*	ovarian cancer	predicted - sensitive	MK-1775 + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 E298* and mutations in BRCA1 (PMID: 27998224).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 mut TP53 Y220C	ovarian cancer	sensitive	Carboplatin + VX-970	Phase I	Actionable	In a Phase I trial, VX-970 and Paraplatin (carboplatin) combination treatment resulted in partial response for 6 months in a PARP inhibitor-resistant ovarian cancer patient harboring a germline BRCA1 mutation and TP53 Y220C (J Clin Oncol 34, 2016 (suppl; abstr 2504)).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 loss	breast cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, Lynparza (olaparib) treatment resulted in prolonged overall survival in BRCA1 deficient transgenic mouse models of breast cancer (PMID: 27454287).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 loss	breast cancer	sensitive	Carboplatin	Phase II	Actionable	In a Phase II trial, high dose Paraplatin (carboplatin) chemotherapy was more beneficial for breast cancer patients with BRCA1 loss than was conventional anthracycline-based chemotherapy (PMID: 21135055).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 loss TP53 loss	breast cancer	sensitive	AZD2461	Preclinical	Actionable	In a preclinical study, a breast cancer model lacking both BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 loss FGFR2-DNM3	triple-receptor negative breast cancer	predicted - sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring FGFR2-DNM3 were sensitive to treatment with BGJ398, demonstrating tumor regression, however, after 43 days on average, three out of six models developed resistance (PMID: 29203461).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 loss FGFR2-DNM3	triple-receptor negative breast cancer	decreased response	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models treated with BKM120 demonstrated only delayed tumor progression when compared to treatment with BGJ398, which resulted in tumor regression (PMID: 29203461).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 loss FGFR2-DNM3	triple-receptor negative breast cancer	sensitive	BGJ398 + Talazoparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models treated with a combination of BGJ398 and Talazoparib (BMN-673) demonstrated a complete response and no relapse within 80 days (PMID: 29203461).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 loss FGFR2-DNM3	triple-receptor negative breast cancer	sensitive	BGJ398 + Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring FGFR2-DNM3 treated with a combination of BGJ398 and Lynparza (olaparib) demonstrated a complete response and did not develop resistance as compared to those models treated with BGJ398 alone (PMID: 29203461).
BRCA1	BRCAI | BRCC1 | BROVCA1 | FANCS | IRIS | PNCA4 | PPP1R53 | PSCP | RNF53	17q21.31	NM_007294	BRCA1 L1795Pfs*3	breast cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, Lynparza (olaparib) inhibited growth of human breast cancer cells harboring BRCA1 L1795Pfs*3 (referred to as BRCA1 5382insC) in culture, and resulted in prolonged overall survival in transgenic mouse models of breast cancer (PMID: 27454287).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	colorectal cancer	sensitive	YU238259	Preclinical - Cell line xenograft	Actionable	In a preclinical study, YU238259 induced cytotoxicity in a human BRCA2-deficient colorectal cancer cell line in culture and slowed tumor growth in xenograft models (PMID: 26116172).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	colorectal cancer	sensitive	Etoposide + YU238259	Preclinical	Actionable	In a preclinical study, YU238259 and Eposin (etoposide) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	prostate cancer	sensitive	Olaparib	Phase II	Actionable	In a Phase II clinical trial, 100% (7/7) of metastatic castration-resistant prostate cancer patients with BRCA2 loss demonstrated response to Lynparza (olaparib) treatment (PMID: 26510020).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	ovarian cancer	predicted - sensitive	APTO-253	Preclinical - Cell culture	Actionable	In a preclinical study, APTO-253 treatment resulted in decreased viability in BRCA2-deficient ovarian cancer cells in culture (PMID: 29626126).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	colorectal cancer	sensitive	Olaparib + YU238259	Preclinical - Cell culture	Actionable	In a preclinical study, YU238259 and Lynparza (olaparib) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	ovary adenocarcinoma	sensitive	YU238259	Preclinical	Actionable	In a preclinical study, YU238259 demonstrated increased cytotoxicity compared to control in BRCA2-deficient ovarian adenocarcinoma cell lines in culture (PMID: 26116172).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	colorectal cancer	sensitive	Radiotherapy + YU238259	Preclinical	Actionable	In a preclinical study, YU238259 and radiotherapy synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	colorectal adenocarcinoma	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line deficient for BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 loss	pancreatic cancer	sensitive	NMS-P118 + Temozolomide	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NMS-P118 enhanced the effects of Temodar (temozolomide) in BRCA2-deficient pancreatic cancer xenograft models, demonstrating inhibition of tumor growth and a complete response in 50% (3/6) of the models (PMID: 26222319).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 D244Efs*10 BRCA2 D244Rfs*7 BRCA2 D252Vfs*24 BRCA2 E260Sfs*15 BRCA2 I247_E254del BRCA2 I247Yfs*8 BRCA2 N255Tfs*21 BRCA2 N257Efs*19 BRCA2 R245_D252del BRCA2 T256Kfs*19	breast cancer	predicted - resistant	Carboplatin + Olaparib	Clinical Study	Actionable	In a clinical study, a breast cancer patient harboring BRCA2 D252Vfs*24 progressed while being treated with Carboplatin and a PARP inhibitor, and via cell-free DNA testing was found to have acquired nine somatic reversion mutations, BRCA2 D244Efs*10, BRCA2 D244Rfs*7, BRCA2 E260Sfs*15, BRCA2 I247_E254del, BRCA2 I247Yfs*8, BRCA2 N255Tfs*21, BRCA2 N257Efs*19, BRCA2 R245_D252del, BRCA2 T256Kfs*19, which restored the open reading frame, resulting in wild-type BRCA2 protein function (PMID: 28765325).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 N136_L139del BRCA2 N136Ifs*16 BRCA2 V130_N136delinsD	breast cancer	resistant	Talazoparib	Clinical Study	Actionable	In a clinical study, a patient with breast cancer harboring the germline mutation, BRCA2 N136Ifs*16, acquired two BRCA2 reversion mutations, V130_N136delinsD and N136_L139del, as detected in cell-free DNA post treatment with Paraplatin (carboplatin), and subsequently, did not respond to treatment with Talazoparib (BMN-673) (PMID: 28765325).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	pancreatic cancer	sensitive	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN-673) treatment in pancreatic cancer patients resulted in four patients with a clinical benefit including a partial response in one patient harboring a BRCA2 mutation (PMID: 28242752).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	breast cancer	sensitive	Olaparib	Phase II	Actionable	In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 mutations (PMID: 20609467).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	prostate cancer	sensitive	Veliparib	Phase II	Actionable	In a Phase II clinical trial, Veliparib (ABT-888) demonstrated preliminary clinical activity in patients with BRCA2-mutant metastatic castration resistant prostate cancer, with an overall response rate of 66% (2/3) and clinical benefit rate of 100% (3/3) (J Clin Oncol 33, 2015 (suppl 7; abstr 170)).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	breast cancer	predicted - sensitive	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14), including one patient with a complete response and six patients with a partial response, and resulted in a median progression free survival of 34.6 weeks (PMID: 28242752).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	Her2-receptor negative breast cancer	sensitive	Olaparib	FDA approved	Actionable	In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a germline BRCA mutation (PMID: 28578601; NCT02000622).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	Advanced Solid Tumor	predicted - sensitive	CX-5461	Phase I	Actionable	In a Phase I trial, CX-5461 treatment resulted in partial response in a patient with advanced solid tumor harboring BRCA2 mutations, and stable disease in 5 additional patients, 4 of whom harboring BRCA1/2 mutations, and 1 with Li-Fraumeni syndrome (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 440; NCT02719977).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	Advanced Solid Tumor	predicted - sensitive	ABT-767	Phase I	Actionable	In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=14/79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	sensitive	Rucaparib	FDA approved	Actionable	In a retrospective analysis of two Phase II trials (ARIEL 2 and Study 10) that supported FDA approval, Rubraca (rucaparib) treatment resulted in an objective response rate of 54% (21/39) in high-grade ovarian cancer patients harboring BRCA2 mutations (PMID: 28751443).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	sensitive	Rucaparib	Phase III	Actionable	In a Phase III trial (ARIEL3), Rubraca (rucaparib) treatment resulted in significantly improved progression-free survival compared to placebo (16.6 vs 5.4 months, HR=0.23, p=0.0001) in patients with BRCA-mutant, platinum-sensitive ovarian cancer (PMID: 28916367; NCT01968213).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	sensitive	Rucaparib	Phase II	Actionable	In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	sensitive	Rucaparib	Guideline	Actionable	Rubraca (rucaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring BRCA1/2 germline mutations (NCCN.org).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian carcinoma	no benefit	Bevacizumab + Carboplatin + Paclitaxel	Clinical Study	Actionable	In a clinical study, ovarian carcinoma patients harboring a mutation in either BRCA1, BRCA2, or another homologous recombination repair (HRR) gene did not demonstrate a significant difference in progression free survival when Avastin (bevacizumab) was added to the combined platinum therapy, Platinol (carboplatin) and Taxol (paclitaxel), versus the platinum therapy with placebo, suggesting HRR gene mutations do not impact the effect of Avastin (bevacizumab) (PMID: 29191972).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	breast cancer	predicted - sensitive	Veliparib + Carboplatin	Phase I	Actionable	In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in  metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	Her2-receptor negative breast cancer	predicted - sensitive	Cisplatin + Veliparib + Vinorelbine	Phase I	Actionable	In a Phase I trial, Veliparib (ABT-888) in combination with Platinol (cisplatin) and Navelbine (vinorelbine) resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	predicted - sensitive	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	predicted - sensitive	Pamiparib	Phase I	Actionable	In a Phase I trial, BGB-290 treatment resulted in an improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	predicted - sensitive	Niraparib	Phase III	Actionable	In a Phase III trial (NOVA), maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299; NCT01847274).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	pancreatic cancer	predicted - sensitive	Rucaparib	Phase II	Actionable	In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19) and a disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline BRCA1/2 mutations are associated with increased risk of developing and early onset of pancreatic cancer (NCCN.org).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	predicted - sensitive	Irinotecan + Veliparib	Phase I	Actionable	In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	sensitive	Olaparib	Guideline	Actionable	Lynparza (olaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring BRCA1/2 germline mutations (NCCN.org).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	sensitive	Olaparib	Preclinical - Pdx	Actionable	In a preclinical study, Lynparza (olaparib) decreased tumor growth in patient-derived xenografts carrying BRCA2 mutation (PMID: 21097693).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	sensitive	Olaparib	FDA approved	Actionable	In a Phase II trial that supported FDA approval, treatment with Lynparza (olaparib) resulted in a tumor response rate of 34% (n=137) and median duration of response of 7.9 months in ovarian cancer patients harboring germline BRCA1/2 mutations that had received 3 or more lines of chemotherapy (PMID: 26187614, PMID: 25366685; NCT01078662).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	ovarian cancer	sensitive	Olaparib	Phase III	Actionable	In a Phase III trial, ovarian cancer patients who are platinum-sensitive and relapsed and harbor either mutant BRCA1 or mutant BRCA2 demonstrated a greater progression-free survival (19.1 mo vs 5.5 mo) when treated with Lynparza (olaparib) tablets as maintenance therapy compared to placebo (PMID: 28754483; NCT01874353).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 mutant	triple-receptor negative breast cancer	decreased response	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN-673) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation resulted in a lower clinical benefit rate (56% vs 89%) compared to treatment in non-triple-receptor negative breast cancer patients carrying a BRCA1/2 mutation (PMID: 28242752).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 del	colorectal adenocarcinoma	sensitive	Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Platinol (cisplatin) inhibited growth of a human colorectal adenocarcinoma cell line harboring BRCA2 deletion in culture, and inhibited tumor growth in xenograft models (PMID: 25193512).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 del	colorectal adenocarcinoma	sensitive	Chlorambucil	Preclinical	Actionable	In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Ambochlorin (chlorambucil) compared to cells with intact BRCA2 in culture  (PMID: 25193512).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 del	colorectal adenocarcinoma	sensitive	PR-104	Preclinical - Cell line xenograft	Actionable	In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to PR-104 compared to cells with intact BRCA2 in culture and in cell line xenograft models (PMID: 25193512)
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 del	colorectal adenocarcinoma	sensitive	Evofosfamide	Preclinical - Cell line xenograft	Actionable	In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Evofosfamide (TH-302) compared to cells with intact BRCA2 in culture and human cell line xenograft models (PMID: 25193512).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 negative	Advanced Solid Tumor	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, BRCA2-deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, Talazoparib (BMN-673) (PMID: 23881923).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 wild-type	colorectal adenocarcinoma	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line harboring wild-type BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	sensitive	KU-0063794 + Talazoparib	Preclinical	Actionable	In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	predicted - sensitive	Cisplatin + VX-970	Phase I	Actionable	In a Phase I trial, VX-970 in combination with Platinol (cisplatin) resulted in an objective response rate of 38.9% (7/18, all partial responses) and a disease control rate of 72.2% (13/18) in patients with BRCA1/2 wild-type triple-receptor negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 242PD; NCT02157792).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	sensitive	Olaparib + KU-0063794	Preclinical	Actionable	In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA1 wild-type BRCA2 wild-type	ovarian cancer	predicted - sensitive	Niraparib	Phase III	Actionable	In a Phase III trial (NOVA), Zejula (niraparib) maintenance therapy improved median progression-free survival compared to placebo (9.3 vs. 3.9 months, HR=0.45) in platinum-sensitive, recurrent ovarian cancer patients without germline BRCA mutations, with and without homologous recombination deficiency (12.9 vs. 3.8 months, HR=0.38) (PMID: 27717299; NCT01847274).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	sensitive	Everolimus + Talazoparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN-673) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture and reduced tumor volume in xenograft models (PMID: 26546619).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA1 wild-type BRCA2 wild-type	ovarian serous carcinoma	predicted - sensitive	Prexasertib	Phase II	Actionable	In a Phase II trial, Prexasertib (LY2606368) treatment resulted in a partial response in 33% (8/24) of BRCA wild-type patients with high-grade serous ovarian cancer (PMID: 29361470; NCT02203513).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA1 wild-type BRCA2 wild-type	triple-receptor negative breast cancer	sensitive	Olaparib + Everolimus	Preclinical	Actionable	In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 inact mut	breast cancer	sensitive	AZD2461	Preclinical - Cell culture	Actionable	In a preclinical study, a BRCA2-deficient breast cancer cell line resistant to Lynparza (olaparib) demonstrated sensitivity to treatment with AZD2461 in culture, resulting in reduced cell viability (PMID: 27550455).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 inact mut	breast cancer	predicted - sensitive	Carboplatin + Paclitaxel + Veliparib	Phase II	Actionable	In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 inact mut	ovarian cancer	no benefit	Veliparib + Cyclophosphamide	Phase II	Actionable	In a Phase II clinical trial, the combination of Veliparib (ABT-888) and Cytoxan (cyclophosphamide) did not demonstrate improved response rate or progression-free survival over Cytoxan (cyclophosphamide) alone in ovarian cancer patients harboring deleterious mutations in BRCA1 or BRCA2 (PMID: 25589624).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 inact mut	Advanced Solid Tumor	predicted - sensitive	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN-673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 inact mut	Advanced Solid Tumor	sensitive	E7449	Preclinical	Actionable	In a preclinical study, E7449 inhibited proliferation of a BRCA2-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair mutations (PMID: 26513298).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 inact mut	breast cancer	sensitive	Olaparib	Phase II	Actionable	In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 inactivating mutations (PMID: 20609467).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 inact mut	prostate cancer	predicted - sensitive	Talazoparib	Phase I	Actionable	In a Phase I trial, Talazoparib (BMN-673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including one patient with prostate cancer (J Clin Oncol 31, 2013 (suppl; abstr 2580)).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 dec exp MET dec exp	triple-receptor negative breast cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 dec exp	breast cancer	sensitive	NU1025	Preclinical - Cell culture	Actionable	In a preclinical study, knockdown of Brca2 with siRNA sensitized breast cancer cell lines to NU1025 in culture (PMID: 15829966).
BRCA2	BRCC2 | BROVCA2 | FACD | FAD | FAD1 | FANCD | FANCD1 | GLM3 | PNCA2 | XRCC11	13q13.1	NM_000059	BRCA2 dec exp MET over exp	triple-receptor negative breast cancer	no benefit	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Brca2 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met overexpression to Rubraca (rucaparib) in culture (PMID: 26779812).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR K385fs	hematologic cancer	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells expressing CALR L385fs in culture (PMID: 26668133).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	ASXL1 mut CALR wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of an ASXL1 mutation combined with wild-type CALR is associated with shorter survival in patients with myelofibrosis (NCCN.org).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR wild-type JAK2 wild-type MPL wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of concurrent wild-type JAK2, MPL, and CALR in myelofibrosis patients is associated with inferior leukemia-free survival compared to patients with JAK2 and/or CALR mutations, and is associated with inferior overall survival when compared to patients with CALR mutations (NCCN.org).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	ASXL1 wild-type CALR mut	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of a CALR mutation combined with wild-type ASXL1 is associated with longer survival in patients with myelofibrosis (NCCN.org).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	ASXL1 mut CALR mut	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of a CALR mutation combined with an ASXL1 mutation is associated with intermediate survival in patients with myelofibrosis (NCCN.org).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR mutant	bone marrow cancer	not applicable	N/A	Clinical Study	Diagnostic	CALR mutations are used in the diagnosis of myeloproliferative neoplasms, especially of essential thrombocythemia and primary myelofibrosis (PMID: 26697989, PMID: 26449662, PMID: 26071474, PMID: 25873496).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR mutant	bone marrow cancer	predicted - sensitive	Alpha 2 Interferon	Clinical Study	Actionable	In a clinical study, Roferon-A (Alpha 2 Interferon) treatment resulted in hematologic response in 100% (31/31) and complete molecular response in 6% (2/31) of essential thrombocythemia (ET) patients harboring CALR mutations (PMID: 26486786).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	CALR mutations are associated with improved survival when compared to JAK2 mutations or concurrent wild-type CALR, MPL, and JAK2 in patients with primary myelofibrosis (NCCN.org).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR L367fs	hematologic cancer	sensitive	Ruxolitinib + Temsirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Torisel (temsirolimus) acted synergistically to inhibit growth of transformed cells expressing CALR L367fs in culture (PMID: 26668133).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR L367fs	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of the CALR type 1 mutation, L367fs, or a type 1-like mutation is associated with improved overall survival compared to a CALR type 2 (K385fs) or CALR type 2-like mutation and JAK2 V617F in patients with myelofibrosis (NCCN.org).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR L367fs	hematologic cancer	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells expressing CALR L367fs in culture (PMID: 26668133).
CALR	cC1qR | CRT | HEL-S-99n | RO | SSA	19p13.13	NM_004343	CALR L367fs	myelofibrosis	predicted - sensitive	SAR302503	Clinical Study	Actionable	In a clinical study, 2 myelofibrosis patients harboring CALR L367fs (reported as L367fs*46 for patient 1 and L367fs*48 for patient 2) and wild-type JAK2 demonstrated a greater than 50% reduction in spleen size following treatment with Fedratinib (SAR302503) (PMID: 24645956).
CBL	C-CBL | CBL2 | FRA11B | NSLL | RNF55	11q23.3	NM_005188	CBL mutant	myelodysplastic/myeloproliferative neoplasm	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108).
CBL	C-CBL | CBL2 | FRA11B | NSLL | RNF55	11q23.3	NM_005188	CBL mutant	bone marrow cancer	sensitive	Quizartinib	Preclinical	Actionable	In a preclinical study, Quizartinib (AC220) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016).
CBL	C-CBL | CBL2 | FRA11B | NSLL | RNF55	11q23.3	NM_005188	CBL dec exp	pancreatic ductal carcinoma	predicted - sensitive	Erlotinib + Gemcitabine	Preclinical - Cell line xenograft	Emerging	In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515).
CBL	C-CBL | CBL2 | FRA11B | NSLL | RNF55	11q23.3	NM_005188	CBL del CBLB del	bone marrow cancer	predicted - sensitive	Fasudil	Preclinical	Actionable	In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in a mouse model of myeloproliferative disorder (PMID: 26177294).
CBLB	Cbl-b | Nbla00127 | RNF56	3q13.11	NM_170662	CBLB dec exp	stomach cancer	decreased response	Fluorouracil	Preclinical	Actionable	In a preclinical study, gastric cancer cell lines with decreased Cblb expression level via shRNA knockdown demonstrated reduced sensitivity to Adrucil (fluorouracil) in cell culture (PMID: 24351824).
CBLB	Cbl-b | Nbla00127 | RNF56	3q13.11	NM_170662	CBL del CBLB del	bone marrow cancer	predicted - sensitive	Fasudil	Preclinical	Actionable	In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in a mouse model of myeloproliferative disorder (PMID: 26177294).
CBLC	CBL-3 | CBL-SL | RNF57	19q13.32	NM_012116	CBLC over exp	non-small cell lung carcinoma	not applicable	N/A	Clinical Study	Emerging	In a clinical study, over expression of Cblc was identified as a promising diagnostic biomarker for non-small cell lung cancer (PMID: 17671213).
CBLC	CBL-3 | CBL-SL | RNF57	19q13.32	NM_012116	CBLC dec exp	breast cancer	predicted - sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured breast cancer cell lines (PMID: 25883215).
CBLC	CBL-3 | CBL-SL | RNF57	19q13.32	NM_012116	CBLC dec exp	osteosarcoma	predicted - sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured osterosarcoma cell lines (PMID: 25883215).
CDH1	Arc-1 | BCDS1 | CD324 | CDHE | ECAD | LCAM | UVO	16q22.1	NM_004360	CDH1 over exp	non-small cell lung carcinoma	resistant	Volasertib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to volasertib in culture (PMID: 26597303).
CDH1	Arc-1 | BCDS1 | CD324 | CDHE | ECAD | LCAM | UVO	16q22.1	NM_004360	CDH1 over exp	non-small cell lung carcinoma	resistant	BI2536	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to BI2536 in culture (PMID: 26597303).
CDH1	Arc-1 | BCDS1 | CD324 | CDHE | ECAD | LCAM | UVO	16q22.1	NM_004360	CDH1 over exp	pancreatic ductal adenocarcinoma	sensitive	Erlotinib + Selumetinib	Phase II	Actionable	In a Phase II clinical trial, patients with pancreatic ductal adenocarcinoma tumors expressing high levels of Cdh1 were more likely to respond to a combination therapy of Tarceva (erlotinib) and Selumetinib (AZD6244) (PMID: 26251290).
CDH1	Arc-1 | BCDS1 | CD324 | CDHE | ECAD | LCAM | UVO	16q22.1	NM_004360	CDH1 mutant	stomach cancer	not applicable	N/A	Clinical Study	Diagnostic	Pathogenic germline CDH1 mutations are used in the diagnosis of hereditary diffuse gastric cancer (PMID: 26380059, PMID: 26182300).
CDH1	Arc-1 | BCDS1 | CD324 | CDHE | ECAD | LCAM | UVO	16q22.1	NM_004360	CDH1 mutant	stomach cancer	not applicable	N/A	Guideline	Risk Factor	Germline truncating mutations in CDH1 are associated with hereditary diffuse gastric cancer, which is characterized by increased risk of developing gastric cancer (NCCN.org).
CDH1	Arc-1 | BCDS1 | CD324 | CDHE | ECAD | LCAM | UVO	16q22.1	NM_004360	CDH1 R63* ERBB2 L869Q	breast cancer	sensitive	Lapatinib + Capecitabine	Clinical Study	Actionable	In a clinical case study, treatment with the combination of  Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A del	glioblastoma multiforme	sensitive	Palbociclib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A in culture and prolonged survival in patient-derived xenograft models (PMID: 22711607).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A del	lung cancer	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of CDKN2A-deleted lung cancer (PMID: 26140595).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A R80*	stomach carcinoma	sensitive	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a gastric carcinoma cell line harboring CDKN2A R80* was sensitive to Ibrance (palbociclib) both in culture and in cell line xenograft models (PMID: 26380006, PMID: 20952405).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	pancreatic cancer	decreased response	ON-01910 + PD0332991	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of ON-01910 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	non-small cell lung carcinoma	sensitive	Palbociclib	Phase II	Actionable	In a Phase II trial, treatment with Ibrance (palbociclib) resulted in and stable disease in 50% (8/16) of non-small cell lung cancer patients with CDKN2A loss (J Clin Oncol 32:5s, 2014 (suppl; abstr 8077)).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	pancreatic cancer	decreased response	PD0332991 + Gemcitabine	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of Gemzar (gemcitabine) in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line with CDKN2A loss demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in inhibition of cell growth (PMID: 27488531).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	neuroendocrine tumor	sensitive	ZK304709	Preclinical	Actionable	In a preclinical study, an orthotopic mouse model treated with ZK 304709 demonstrated an 80% tumor growth reduction in neuroendocrine tumor cells with CDKN2A loss (PMID: 18829975).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	chordoma	sensitive	Abemaciclib	Preclinical - Cell culture	Actionable	In a preclinical study, Abemaciclib (LY2835219) inhibited growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	chordoma	sensitive	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited expression of phosphorylated Rb and growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	pancreatic cancer	decreased response	GSK461364 + PD0332991	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of GSK461364 in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	melanoma	resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line deficient for CDKN2A demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 27488531).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	pancreatic cancer	decreased response	HMN-214 + PD0332991	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) antagonized the activity of HMN-214 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	brain glioblastoma multiforme	sensitive	Milciclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Milciclib (PHA-848125AC) resulted in tumor regression in glioma cell line xenograft models with CDKN2A loss (PMID: 23347136).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	Advanced Solid Tumor	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell culture	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of multiple cancer cell lines harboring CDKN2A loss and in Cdkn2a-depleted transformed cells in culture (PMID: 26140595).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	melanoma	sensitive	Alvocidib	Preclinical	Actionable	In a preclinical study, melanoma cell lines with CDKN2A loss demonstrated a greater sensitivity to Alvocidib (flavopiridol) as compared to melanoma cell lines positive for CDKN2A (PMID: 12777976).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss	renal cell carcinoma	sensitive	Palbociclib	Preclinical	Actionable	In a preclinical study, renal cell carcinoma cell lines with CDKN2A loss were sensitive to Palbociclib (PD-0332991) (PMID: 23898052).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss NRAS mutant	melanoma	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A loss KRAS wild-type	non-small cell lung carcinoma	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	NRAS Q61K CDKN2A loss	melanoma	sensitive	SBI-0640756	Preclinical	Actionable	In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	NRAS Q61K CDKN2A loss	melanoma	sensitive	Palbociclib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A pos RB1 inact mut	glioblastoma multiforme	resistant	Palbociclib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H	melanoma	sensitive	Imatinib + Carboplatin + Paclitaxel	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	NRAS mut CDKN2A mut	acute lymphocytic leukemia	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	PIK3CA mutant CDKN2A mutant	breast cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in CDKN2A results in familial malignant melanoma syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	BRAF mut KRAS mut CDKN2A mut	triple-receptor negative breast cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
CDKN2A	ARF | CDK4I | CDKN2 | CMM2 | INK4 | INK4A | MLM | MTS-1 | MTS1 | P14 | P14ARF | P16 | P16-INK4A | P16INK4 | P16INK4A | P19 | P19ARF | TP16	9p21.3	NM_000077	CDKN2A over exp SMARCB1 negative	rhabdoid cancer	decreased response	Palbociclib	Preclinical	Actionable	In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).
CEBPA	C/EBP-alpha | CEBP	19q13.11	NM_004364	CEBPA mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, biallelic CEBPA mutations were associated with favorable clinical outcome in patients with cytogenetically normal acute myeloid leukemia (PMID: 26601784, PMID: 19171880, PMID: 20038735, PMID: 22915647).
CEBPA	C/EBP-alpha | CEBP	19q13.11	NM_004364	CEBPA mutant	acute myeloid leukemia	predicted - sensitive	Ruxolitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Jakafi (ruxolitinib) compared to control AML cells in culture (PMID: 27034432).
CEBPA	C/EBP-alpha | CEBP	19q13.11	NM_004364	CEBPA mutant	acute myeloid leukemia	predicted - sensitive	Tofacitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Xeljanz (tofacitinib) compared to control AML cells in culture (PMID: 27034432).
CEBPA	C/EBP-alpha | CEBP	19q13.11	NM_004364	CEBPA mutant	acute myeloid leukemia	predicted - sensitive	Momelotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Momelotinib (CYT387) compared to control AML cells in culture (PMID: 27034432).
CEBPA	C/EBP-alpha | CEBP	19q13.11	NM_004364	CEBPA mutant	acute myeloid leukemia	predicted - sensitive	AZD1480	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to AZD1480 compared to control AML cells in culture (PMID: 27034432).
CEBPA	C/EBP-alpha | CEBP	19q13.11	NM_004364	CEBPA mutant GATA2 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).
CEBPA	C/EBP-alpha | CEBP	19q13.11	NM_004364	CEBPA positive	hepatocellular carcinoma	predicted - sensitive	CEBPA-51	Preclinical - Cell culture	Actionable	In a preclinical study, CEBPA-51 treatment resulted in induced expression of CEBPA mRNA and inhibited proliferation of hepatocellular carcinoma cells in culture (PMID: 28882451).
CSF1R	C-FMS | CD115 | CSF-1R | CSFR | FIM2 | FMS | HDLS | M-CSF-R	5q32	NM_005211	CSF1R positive	Hodgkin's lymphoma	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, elevated levels of CSF1R expression were associated with a worse survival in patients with Hodgkin's lymphoma (PMID: 24619759, PMID: 26066800, PMID: 22955918).
CSF1R	C-FMS | CD115 | CSF-1R | CSFR | FIM2 | FMS | HDLS | M-CSF-R	5q32	NM_005211	CSF1R positive	Hodgkin's lymphoma	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited CSF1R phosphorylation and induced apoptosis in Hodgkin's lymphoma cells in culture (PMID: 21517818)
CSF1R	C-FMS | CD115 | CSF-1R | CSFR | FIM2 | FMS | HDLS | M-CSF-R	5q32	NM_005211	BRAF V600E CSF1R positive	melanoma	sensitive	Pexidartinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).
CSF1R	C-FMS | CD115 | CSF-1R | CSFR | FIM2 | FMS | HDLS | M-CSF-R	5q32	NM_005211	CSF1R over exp	tenosynovial giant cell tumor	sensitive	Pexidartinib	Phase I	Actionable	In a Phase I trial, PLX3397 reduced tenosynovial giant cell tumor volume in patients with overexpression of Csf1r (PMID: 26222558).
CSF1R	C-FMS | CD115 | CSF-1R | CSFR | FIM2 | FMS | HDLS | M-CSF-R	5q32	NM_005211	CSF1R Y571D	myeloid leukemia	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, CSFR1 Y571D conferred sensitivity to Gleevec (imatinib) in myeloid cell lines in culture (PMID: 18971950).
CSF3R	CD114 | GCSFR | SCN7	1p34.3	NM_000760	CSF3R T640N	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T640N in culture (PMID: 26475333).
CSF3R	CD114 | GCSFR | SCN7	1p34.3	NM_000760	CSF3R T618I	Advanced Solid Tumor	sensitive	Ibrutinib + Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Imbruvica (ibrutinib) and Jakafi (ruxolitinib) resulted in a synergistic effect in cells expressing CSF3R T618I, demonstrating greater decreased cell viability as compared to either agent alone (PMID: 29977015).
CSF3R	CD114 | GCSFR | SCN7	1p34.3	NM_000760	CSF3R T618I	Advanced Solid Tumor	sensitive	Ibrutinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing CSF3R T618I were sensitive to treatment with Imbruvica (ibrutinib) in culture, demonstrating a reduced cell proliferation (PMID: 29977015).
CSF3R	CD114 | GCSFR | SCN7	1p34.3	NM_000760	CSF3R T618I	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) reduced colony formation of cells expressing CSF3R T618I in culture (PMID: 26475333, PMID: 29977015).
CSF3R	CD114 | GCSFR | SCN7	1p34.3	NM_000760	CSF3R mutant	bone marrow cancer	not applicable	N/A	Clinical Study	Emerging	In clinical studies, high frequency of CSF3R mutations was identified in patients with chronic neutrophilic leukemia (PMID: 23656643, PMID: 24081659), suggesting that this may serve as a future diagnostic biomarker (PMID: 24441292).
CSF3R	CD114 | GCSFR | SCN7	1p34.3	NM_000760	CSF3R Q741*	Advanced Solid Tumor	sensitive	Ibrutinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing CSF3R Q741* were sensitive to treatment with Imbruvica (ibrutinib) in culture, demonstrating a reduced cell proliferation (PMID: 29977015).
CSF3R	CD114 | GCSFR | SCN7	1p34.3	NM_000760	CSF3R Q741*	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing CSF3R Q741* were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased total colony formation (PMID: 29977015).
CSF3R	CD114 | GCSFR | SCN7	1p34.3	NM_000760	CSF3R Q741*	Advanced Solid Tumor	sensitive	Ibrutinib + Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Imbruvica (ibrutinib) and Jakafi (ruxolitinib) resulted in a synergistic effect in cells expressing CSF3R Q741*, demonstrating greater decreased cell viability as compared to either agent alone (PMID: 29977015).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	APC wild-type CTNNB1 wild-type	colon cancer	predicted - sensitive	Vantictumab	Preclinical - Pdx	Actionable	In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 T41A	lung cancer	predicted - sensitive	Mps1-IN-1	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 T41A	lung cancer	predicted - sensitive	BAY1217389	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 T41A	sarcoma	sensitive	Imatinib	Clinical Study	Actionable	In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 T41A demonstrated a greater progression arrest rate at 6 months (70%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 T41A	lung cancer	predicted - sensitive	NMS-P715	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 T41A	lung cancer	predicted - sensitive	BAY1161909	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 T41A	lung cancer	predicted - sensitive	NTRC 0066-0	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1, in culture and in xenograft models (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 T41A	lung cancer	predicted - sensitive	Mps-BAY2b	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 T41A	lung cancer	predicted - sensitive	MPI-0479605	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45F	sarcoma	sensitive	Imatinib	Clinical Study	Actionable	In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 S45F demonstrated a greater progression arrest rate at 6 months (85%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	Mps1-IN-1	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	NTRC 0066-0	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal carcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	MPI-0479605	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	BAY1217389	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	NMS-P715	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	Mps-BAY2b	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	NTRC 0066-0	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal carcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	MPI-0479605	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	Mps-BAY2b	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	BAY1161909	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	NMS-P715	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	Mps1-IN-1	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	BAY1217389	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 mut NRAS mut	liver cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 mutant	medulloblastoma	not applicable	N/A	Guideline	Prognostic	WNT-driven medulloblastomas, characterized by CTNNB1 or APC mutations, are associated with favorable prognosis (NCCN.org).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 mutant	hepatocellular carcinoma	sensitive	PMED-1	Preclinical	Actionable	In a preclinical study, PMED-1 decreased Wnt expression and decreased proliferation of hepatocellular carcinoma cells with Ctnnb1 mutations (PMID: 2481996).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 mutant	endometrial cancer	predicted - sensitive	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.46) but not response rate (response difference 0.00) in advanced endometrial cancer patients harboring CTNNB1 mutations (PMID: 27016228).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 mutant	colorectal cancer	sensitive	BC21	Preclinical	Actionable	In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45del	colon carcinoma	predicted - sensitive	Mps-BAY2b	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45del	colon carcinoma	predicted - sensitive	BAY1161909	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45del	colorectal adenocarcinoma	predicted - sensitive	BAY1161909	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45del	colon carcinoma	predicted - sensitive	NTRC 0066-0	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1 or an isogenic cell line lacking the CTNNB1 mutation, in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45del	colon carcinoma	predicted - sensitive	Mps1-IN-1	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45del	colon carcinoma	predicted - sensitive	BAY1217389	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45del	colon carcinoma	predicted - sensitive	NMS-P715	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 S45del	colon carcinoma	predicted - sensitive	MPI-0479605	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 act mut	sarcoma	sensitive	Imatinib	Clinical Study	Actionable	In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 activating mutations demonstrated a greater progression arrest rate at 6 months compared to patients with CTNNB1 wild-type when treated with Gleevec (imatinib) (PMID: 26861905).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 amp	acute myeloid leukemia	predicted - sensitive	CWP232291	Phase I	Actionable	In a Phase I trial, CWP232291 reduced beta-catenin expression and demonstrated safety and preliminary efficacy in acute myeloid leukemia (J Clin Oncol (Meeting Abstracts) 2015 33: 7044)).
CTNNB1	armadillo | CTNNB | EVR7 | MRD19	3p22.1	NM_001098210	CTNNB1 over exp	colon cancer	predicted - sensitive	NVP-TNKS656 + Triciribine	Preclinical - Pdx	Actionable	In a preclinical study, the combination of NVP-TNKS656 and Triciribine (API-2) inhibited tumor growth in Triciribine (API-2)-resistant patient-derived xenograft (PDX) models of colon cancer with high nuclear CTNNB1 (Beta-catenin) levels (PMID: 26224873).
DNMT3A	DNMT3A2 | M.HsaIIIA | TBRS	2p23.3	NM_022552	DNMT3A mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448).
DNMT3A	DNMT3A2 | M.HsaIIIA | TBRS	2p23.3	NM_022552	DNMT3A mut	acute myeloid leukemia	predicted - sensitive	Decitabine	Clinical Study	Actionable	In a clinical study, acute myeloid leukemia patients harboring DNMT3A mutations demonstrated a greater complete response rate (60% vs 33%) compared to acute myeloid leukemia patients with wild-type DNMT3A when treated with hypomethylating agents such as Dacogen (decitabine) (PMID: 27418649).
DNMT3A	DNMT3A2 | M.HsaIIIA | TBRS	2p23.3	NM_022552	DNMT3A mut FLT3 mut NPM1 mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Emerging	In a retrospective analysis, the combination of DNMT3A, FLT3, and NPM1 mutations in patients with acute myeloid leukemia was highly associated with decreased event-free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A750P EGFR L747_E749del	non-small cell lung carcinoma	sensitive	WZ4002 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR A750P and EGFR L747_E749del in culture (PMID: 26036643).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719X	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR G719 mutations demonstrated a response rate of 58% and disease control rate of 73.68%, and a median progression-free survival of 2.8 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719X	non-small cell lung carcinoma	decreased response	Osimertinib	Phase Ib/II	Actionable	In a Phase I/II trial (AURA), Tagrisso (osimertinib) demonstrated limited clinical efficacy, resulted in partial response in 14% (1/7) and stable disease in 43% (3/7) of non-small cell lung cancer patients harboring EGFR G719 mutations, with 3 patients also harboring EGFR T790M (PMID: 29285266; NCT01802632).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719X	non-small cell lung carcinoma	sensitive	Afatinib	FDA approved	Actionable	In a post-hoc analysis of Phase II and Phase III trials that supported FDA approval (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective response rate of 77.8% (14/18) in non-small cell lung cancer patients harboring EGFR G719X (alone or in combination with other EGFR mutations), with a mean progression-free survival of 13.8 months, and an overall survival of 26.9 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719X	non-small cell lung carcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 14% (1/7), stable disease in 43% (3/7), and progressive disease in 43% (3/7) of non-small cell lung carcinoma patients carrying an EGFR G719 mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719X	non-small cell lung carcinoma	sensitive	Afatinib	Phase III	Actionable	In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719X	non-small cell lung carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719X	non-small cell lung carcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719X	non-small cell lung carcinoma	sensitive	Neratinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Nerlynx (neratinib) resulted in partial response in 75% (3/4) and stable disease in 25% (1/4) of non-small cell lung cancer patients harboring EGFR G719 mutations (PMID: 20479403).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L62R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L62R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R were sensitive to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L62R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L62R	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR act mut	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR act mut	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR act mut	non-small cell lung carcinoma	resistant	Naquotinib	Phase I	Actionable	In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR act mut	Advanced Solid Tumor	resistant	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR act mut	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Tagrisso (osimertinib) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770delinsGY EGFR C797S	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to dacomitinib in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770delinsGY EGFR C797S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S + EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Tagrisso (osimertinib) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S + EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	resistant	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S + EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S + EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S + EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	resistant	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a combination of EGFR C797S, EGFR L747_P753delinsS, and EGFR T790M were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR C797S	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR C797S	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR C797S	non-small cell lung carcinoma	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring EGFR DelE746_A750 and expressing EGFR DelE746_A750/C797S demonstrated resistance to growth inhibition by Rociletinib (CO1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR C797S	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR C797S	non-small cell lung carcinoma	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iressa (gefitinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR C797S	non-small cell lung carcinoma	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR C797S	non-small cell lung carcinoma	resistant	WZ4002	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by WZ4002 in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR C797S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	resistant	Osimertinib	Phase I	Actionable	In a Phase I clinical trial, 40% (6/15) of non-small cell lung cancer patients harboring an EGFR exon 19 deletion and EGFR T790M  developed resistance to Tagrisso (osimertinib) due to acquired EGFR C797S mutations (PMID: 25939061).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	conflicting	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of EGFR C797S on the same allele as an EGFR exon 19 deletion and EGFR T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	conflicting	Gefitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	lung adenocarcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	lung adenocarcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	conflicting	Gefitinib + WZ4002	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and WZ4002 combination treatment resulted in complete inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	lung adenocarcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	conflicting	Gefitinib + WZ4002	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to the combination of Iressa (gefitinib) and WZ4002 when T790M and C797S were in cis, but were sensitive when EGFR T790M and EGFR C797S were in trans (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR D770_N771insNPG EGFR T790M	Advanced Solid Tumor	predicted - resistant	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR D770_N771insNPG, and EGFR T790M did not respond to treatment with OBX1-012 in culture (PMID: 29754184).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon19 del, and EGFR T854A were sensitive to treatment with Alunbrig (brigatinib) in culture, demonstrating reduced cell growth (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Gilotrif (afatinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Iressa (gefitinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A were resistant to treatment with Tagrisso (osimertinib) (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR T790M	Advanced Solid Tumor	sensitive	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S and EGFR T790M were sensitive to treatment with OBX1-012 in culture, demonstrating decreased cell viability (PMID: 29754184).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR C797S	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR C797S	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR C797S demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 27913578).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR C797S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR C797S double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR C797S	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR C797S	Advanced Solid Tumor	resistant	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R with EGFR C797S demonstrated resistance to inhibition by Poziotinib (HM781-36B) in culture (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut EGFR C797S EGFR T790M	non-small cell lung carcinoma	resistant	Naquotinib	Phase I	Actionable	In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del	lung adenocarcinoma	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del	Advanced Solid Tumor	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, transformed human cells harboring EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del	lung adenocarcinoma	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del	lung adenocarcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR exon 19 del	Advanced Solid Tumor	resistant	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR exon 19 deletion with EGFR C797S demonstrated resistance to inhibition by Poziotinib (HM781-36B) in culture (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266)
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as EGFR L858R and T790M in transformed cells in culture (PMID: 25939061).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of EGFR C797S on the same allele as both EGFR L858R and T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited growth of transformed cells expressing a EGFR L858R/T790M/C797S triple mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	predicted - resistant	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T790M did not respond to treatment with OBX1-012 in culture (PMID: 29754184).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266)
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	lung cancer	sensitive	Cetuximab + EAI045	Preclinical	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors concomitant C797S, L858R and T790M mutations in culture (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a combination of EGFR C797S, EGFR L858R, and EGFR T790M were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Gilotrif (afatinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Alunbrig (brigatinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Iressa (gefitinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L858R EGFR T854A	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated resistance to treatment with Tagrisso (osimertinib) (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L792H EGFR L858R	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L792H EGFR L858R	Advanced Solid Tumor	predicted - sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R demonstrated some efficacy to treatment with Iressa (gefitinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L792H EGFR L858R	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Alunbrig (brigatinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR C797S EGFR L792H EGFR L858R	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR C797S	Advanced Solid Tumor	no benefit	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit growth of transformed cells expressing a EGFR E746_A750del/T790M/C797S triple mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR dec exp KRAS wild-type	colorectal cancer	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR dec exp KRAS wild-type	colorectal cancer	sensitive	GA201 + Irinotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR dec exp KRAS mut	non-small cell lung carcinoma	sensitive	GA201	Preclinical	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR dec exp KRAS mut	non-small cell lung carcinoma	sensitive	ER2 + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model with low expression of wild-type EGFR, that also harbors a KRAS mutation (PMID: 27040853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR dec exp KRAS mut	colorectal cancer	sensitive	GA201	Preclinical	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR dec exp KRAS mut	lung adenocarcinoma	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS-mutant lung adenocarcinoma with low EGFR expression in culture and improved overall survival in low EGFR expressing, KRAS-mutant lung adenocarcinoma cell line xenograft models, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR I744_K745insKIPVAI	non-small cell lung carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a clinical study, two patients with non-small cell lung carcinoma each harboring EGFR I744_K745insKIPVAI demonstrated some efficacy when treated with Iressa (gefitinib), including a partial response and stable disease (PMID: 28089594).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR I744_K745insKIPVAI	non-small cell lung carcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR I744_K745insKIPVAI demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 22190593).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A702S	non-small cell lung carcinoma	no benefit	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient carrying an EGFR A702S mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were moderately sensitive to Alunbrig (brigatinib) in culture, demonstrating reduced cell growth (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T854A	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, expression of EGFR T854A decreased sensitivity of transformed cells expressing EGFR L858R to Tarceva (erlotinib) in culture (PMID: 19010870).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T854A	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating decreased cell growth (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T854A	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating decreased cell growth (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were mildly resistant to Iressa (gefitinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	predicted - sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR exon 19 del and EGFR T854A were moderately resistant to Alunbrig (brigatinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	predicted - resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR exon 19 del and EGFR T854A were moderately resistant to Iressa (gefitinib) in culture (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR exon 19 del and EGFR T854A were sensitive to treatment with Gilotrif (afatinib), demonstrating reduced cell growth (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR exon 19 del and EGFR T854A were sensitive to treatment with Tagrisso (osimertinib), demonstrating reduced cell growth (PMID: 29702287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A763_Y764insFQEA were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	non-small cell lung carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	non-small cell lung carcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In contrast to other known exon 20 insertions, EGFR A763_Y764insFQEA is sensitive to tyrosine kinase inhibitors, such as Tarceva (erlotinib), in cells, in animal models and in NSCLC patients (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	non-small cell lung carcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR A763_Y764insFQEA demonstrated a partial response after treatment with Tarceva (erlotinib), however, another patient with the same mutation and tumor type demonstrated progressive disease when treated with Tarceva (erlotinib) (PMID: 28089594).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited growth of non-small cell lung cancer cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited EGFR phosphorylation and growth of a transformed cell line expressing EGFR A763_Y764insFQEA in culture (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	non-small cell lung carcinoma	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Iressa (gefitinib) in culture, in contrast to other Egfr exon 20 insertions, and consistent with clinical observations (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	non-small cell lung carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR A763_Y764insFQEA demonstrated a partial response when treated with Iressa (gefitinib) (PMID: 28089594).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29467275, PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR A763_Y764insFQEA, in culture (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	non-small cell lung carcinoma	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Gilotrif (afatinib) in cell culture, in contrast to other EGFR exon 20 insertion mutations (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A763_Y764insFQEA	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A763_Y764insFQEA were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_P753delinsS were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR L747_P753delinsS in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465E EGFR G465R	colorectal cancer	sensitive	MM-151	Phase I	Actionable	In a Phase I trial, MM-151 treatment resulted in marked reduction of EGFR G465E in circulating cell-free tumor DNA and reduced tumor size in a colorectal cancer patient harboring both EGFR G465E and EGFR G465R (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465E	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465E in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465E	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465E	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751del EGFR S752I	non-small cell lung carcinoma	sensitive	WZ4002 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR L747_T751del and EGFR S752I in culture (PMID: 26036643).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A EGFR L861Q	lung adenocarcinoma	predicted - sensitive	Erlotinib	Clinical Study	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in partial response lasting for 18 months in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q (PMID: 28343545).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A EGFR L861Q EGFR T790M	lung adenocarcinoma	predicted - resistant	Erlotinib	Clinical Study	Actionable	In a clinical case study, EGFR T790M was detected at the time of progression in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q that was treated with Tarceva (erlotinib) (PMID: 28343545).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A EGFR L861Q EGFR T790M	lung adenocarcinoma	predicted - sensitive	Osimertinib	Clinical Study	Actionable	In a clinical case study, Tagrisso (osimertinib) treatment resulted in partial response for over 8 months in a patient with lung adenocarcinoma harboring EGFR G719A, L861Q, and T790M that has progressed while on Tarceva (erlotinib) treatment (PMID: 28343545).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L861Q	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L861Q demonstrated a response rate of 23.53% and disease control rate of 64.71%, and a median progression-free survival of 2.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L861Q	esophagus squamous cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L861Q	non-small cell lung carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, a catalog of tyrosine kinase inhibitor responses of NSCLC patients harboring EGFR mutations determined that EGFR L861Q responded to Iressa (gefitinib), but possibly not as favorably as EGFR L858R, exon 19 deletion, and G719X mutations (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L861Q	non-small cell lung carcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (2/6), stable disease in 50% (3/6), and progressive disease in 17% (1/6) of non-small cell lung carcinoma patients harboring EGFR L861Q (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L861Q	non-small cell lung carcinoma	sensitive	Afatinib	FDA approved	Actionable	In a post-hoc analysis of Phase II and Phase III trials that supported FDA approval (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective rate of 56.3% (9/16) in non-small cell lung cancer patients harboring EGFR L861Q (alone or in combination with EGFR L719X or exon 19 deletion), with a mean progression-free survival of 8.2 months, and an overall survival of 17.1 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L861Q	esophagus squamous cell carcinoma	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, esophageal squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L861Q	non-small cell lung carcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In an analysis of published clinical data, non-small cell cancer patients harboring EGFR L861Q were demonstrated to respond to treatment with Tarceva (erlotinib), but possibly not as favorably as EGFR L858R, exon 19 deletion, and G719X mutations (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L861Q	esophagus squamous cell carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in esophagus squamous carcinoma cells harboring EGFR L861Q in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P772_H773insPNP	lung adenocarcinoma	sensitive	Dacomitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P772_H773insPNP	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719C	non-small cell lung carcinoma	predicted - sensitive	Erlotinib	Clinical Study	Actionable	In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719C	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719C	non-small cell lung carcinoma	sensitive	Afatinib	Phase III	Actionable	In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719C	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E719C were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719C	non-small cell lung carcinoma	predicted - sensitive	Gefitinib	Clinical Study	Actionable	In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719C	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719C were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR-SEPT14	glioblastoma multiforme	sensitive	Lapatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR-SEPT14	glioblastoma multiforme	sensitive	Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR exon 19 ins	non-small cell lung carcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR exon 19 deletion and insertion (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L833V EGFR H835L	lung adenocarcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring a compound EGFR L833V/H835L mutation responded to treatment with Iressa (gefitinib), with disease progression after 34 weeks of treatment (PMID: 21422421).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR I941R EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing EGFR that harbors concomitant L858R, T790M and I941R mutations demonstrated increased sensitivity to EAI045 induced growth inhibition in culture (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut EGFR amp	glioblastoma multiforme	predicted - sensitive	Depatuxizumab mafodotin + Temozolomide + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 in combination with Temodar (temozolomide) and radiotherapy inhibited tumor growth and resulted in tumor growth delay in a glioblastoma multiforme cell line xenograft model harboring amplified EGFR vIII (exon 2-7 deletion), with increased efficacy compared to the combination of Temodar (temozolomide) and radiotherapy (PMID: 26846818).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut EGFR amp	glioblastoma multiforme	predicted - sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 induced cytoxicity in a glioblastoma cell line harboring amplified EGFR vIII (exon 2-7 deletion) in culture, and induced complete tumor regression in cell line xenograft models of glioblastoma harboring amplified EGFR vIII (PMID: 26846818).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp ERBB2 amp	urinary bladder cancer	sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp PTEN loss	glioblastoma multiforme	decreased response	Dacomitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Dacomitinib induced growth inhibition in culture and in xenograft models (PMID: 25939761).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR wild-type EGFR act mut	glioblastoma multiforme	predicted - sensitive	Depatuxizumab mafodotin	Preclinical - Pdx	Actionable	In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	gastric adenocarcinoma	predicted - sensitive	ABT-806	Clinical Study	Actionable	In a clinical analysis, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in objective response in 57% (4/7, 3 complete response, 1 partial response) and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma (PMID: 29449271).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	gastroesophageal junction adenocarcinoma	predicted - sensitive	Cetuximab	Clinical Study	Actionable	In a clinical analysis, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in objective response in 57% (4/7, 3 complete response, 1 partial response) and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma (PMID: 29449271).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	penile cancer	sensitive	ABT-806	Phase I	Actionable	In a Phase I trial, ABT-806 treatment resulted in stable disease for more than 2.5 years in a penile cancer patient harboring EGFR amplification (PMID: 25895099).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	urinary bladder cancer	no benefit	Afatinib	Phase II	Actionable	In a Phase II clinical trial, three urothelial carcinoma  patients with EGFR amplification in the absence of other ERBB family member alterations, received no benefit from Gilotrif (afatinib) therapy (PMID: 27044931).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	triple-receptor negative breast cancer	sensitive	Gefitinib + PF-573228	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Iressa (gefitinib) and PF-573228 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating decreased colony formation in culture (PMID: 27793840).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	triple-receptor negative breast cancer	sensitive	Gefitinib + PF-431396	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Iressa (gefitinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating a decrease in colony formation in culture (PMID: 27793840).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	malignant glioma	no benefit	Temsirolimus + Erlotinib	Phase Ib/II	Actionable	In a Phase I/II clinical trial, Torisel (temsirolimus) in combination with Tarceva (erlotinib) demostrated minimal efficacy at the maximum tolerated dosage in high-grade glioma patients, with no correlation between EGFR amplification and survival (PMID: 24470557).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	esophagus squamous cell carcinoma	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	non-small cell lung carcinoma	sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, Ganetespib inhibited growth of a non-small cell lung cancer cell line with EGFR amplification and overexpression in culture (PMID: 25077897).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	gastric adenocarcinoma	predicted - sensitive	Cetuximab	Clinical Study	Actionable	In a clinical analysis, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in objective response in 57% (4/7, 3 complete response, 1 partial response) and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma (PMID: 29449271).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	head and neck cancer	sensitive	unspecified EGFR antibody + unspecified ERBB3 antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	head and neck squamous cell carcinoma	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	triple-receptor negative breast cancer	sensitive	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of an EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 27362227).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	head and neck squamous cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to  Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	non-small cell lung carcinoma	predicted - sensitive	Docetaxel + Vandetanib	Phase III	Actionable	In a Phase III trial (ZODIAC), Caprelsa (vandetanib) and Taxotere (docetaxel) combination treatment resulted in improved progression-free survival (HR=0.61), overall survival (HR=0.48), and objective response (odd ratio=3.90) in non-small cell lung cancer patients harboring EGFR amplification compared to the overall study population (PMID: 25057173; NCT00312377).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	colorectal cancer	sensitive	Panitumumab	Phase III	Actionable	In a Phase III study, response to Vectibix (pantitumumab) was associated with EGFR amplification in colorectal cancer patients (PMID: 17664472).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	triple-receptor negative breast cancer	sensitive	Erlotinib + PF-431396	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tarceva (erlotinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating inhibition of cell growth in culture (PMID: 27793840).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	triple-receptor negative breast cancer	sensitive	Depatuxizumab mafodotin	Phase Ib/II	Actionable	In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in a patient with EGFR amplified triple-receptor negative breast cancer (PMID: 29533458; NCT01741727).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	triple-receptor negative breast cancer	sensitive	Depatuxizumab mafodotin	Preclinical	Actionable	In a preclinical study, ABT-414 demonstrated cytotoxicity against a EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 26846818).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	head and neck squamous cell carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of head and neck squamous cell carcinoma (HNSCC) cell lines in culture, and inhibited tumor growth in HNSCC cell line xenograft models, with highest efficacy against EGFR-amplified cell lines (PMID: 25559287).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	head and neck cancer	sensitive	unspecified EGFR antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr resulted in Egfr degradation and inhibition of proliferation in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	glioblastoma multiforme	no benefit	Vandetanib + Temozolomide	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS in glioblastoma patients harboring EGFR amplification versus glioblastoma patients without EGFR amplification (PMID: 25910950).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	head and neck squamous cell carcinoma	sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 demonstrated cytoxicity against an EGFR-amplified head and neck squamous cell carcinoma (HNSCC) cell line in culture and induced tumor regression in EGFR-amplified HNSCC cell line xenograft models (PMID: 26846818).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	esophagus squamous cell carcinoma	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Gilotrif (afatinib) in a cell viability assay (PMID: 27207775).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	gastrointestinal system cancer	sensitive	Cetuximab	Preclinical - Pdx	Actionable	In preclinical studies, Erbitux (cetuximab) promoted tumor growth inhibition in several patient-derived xenograft models of gastric cancers with EGFR amplification (PMID: 24141978).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	glioblastoma multiforme	sensitive	Dacomitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Dacomitinib inhibited Egfr signaling and survival of patient-derived EGFR amplified glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	glioblastoma multiforme	sensitive	Depatuxizumab mafodotin	Phase I	Actionable	In a Phase I trial, treatment with Depatuxizumab mafodotin (ABT-414) resulted in an overall response rate of 6.7% (3/59; 1 complete response and 2 partial responses), stable disease in 41% (27/66), and a progression-free survival rate of 28.8% (95% CI 18.5, 39.9%) at 6 months in patients with EGFR-amplified recurrent glioblastoma (PMID: 29075855; NCT01800695).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	Advanced Solid Tumor	sensitive	Depatuxizumab mafodotin	Phase I	Actionable	In a Phase I trial, ABT-414 displayed safety and preliminary efficacy in advanced solid tumor patients with EGFR amplification (J Clin Oncol 33, 2015 (suppl; abstr 2510)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	Advanced Solid Tumor	sensitive	Depatuxizumab mafodotin	Phase Ib/II	Actionable	In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in 1.8% (1/56) and stable disease in 23% (13/56) of patients with advanced solid tumor harboring EGFR amplification, overexpression, or mutated EGFR variant III (PMID: 29533458; NCT01741727).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	gastroesophageal junction adenocarcinoma	predicted - sensitive	ABT-806	Clinical Study	Actionable	In a clinical analysis, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in objective response in 57% (4/7, 3 complete response, 1 partial response) and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma (PMID: 29449271).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	esophagus adenocarcinoma	resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with esophageal adenocarcinoma progressed on AMG 337 therapy upon outgrowth of EGFR amplified tumor cells (PMID: 26432108).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	esophagus squamous cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	esophagus squamous cell carcinoma	sensitive	SHP099	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of EGFR-amplified esophageal squamous cell carcinoma cells in culture, and inhibited tumor growth in EGFR-amplified esophageal squamous cell carcinoma cell line xenograft models (PMID: 27362227).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	Advanced Solid Tumor	predicted - sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 antagonized EGFR activity and inhibited proliferation in several tumor cell lines in culture (PMID: 25911688).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	head and neck cancer	sensitive	unspecified EGFR antibody + unspecified IGF-1R antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in growth inhibition in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp	head and neck cancer	sensitive	EGFR antibody + ERBB3 antibody + IGF-1R antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR S492R BRAF V600E	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical study, a colorectal cancer patient harboring EGFR amplification, BRAF V600E, and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp MET amp	esophagus adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR act mut PTEN R308C	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR act mut PTEN R308C	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR over exp	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment resulted in tumor regression in patient-derived xenograft (PDX) models of esophageal cancer with both EGFR amplification and Egfr overexpression (PMID: 28881608)
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp FGFR1 amp KRAS G13C	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	sensitive	Cetuximab + Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR amp	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR E746_A750del	lung adenocarcinoma	sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 demonstrated cytotoxicity against a lung adenocarcinoma cell line that harbored EGFR amplification and EGFR E746_A750del in culture and induced tumor regression in cell line xenograft models (PMID: 26846818).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EML4-ALK EGFR amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, EGFR amplification (PMID: 29636358).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	PDGFRA amp EGFR amp	glioblastoma multiforme	sensitive	Gefitinib + Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR S492R	colorectal cancer	sensitive	Panitumumab	Clinical Study	Actionable	In a clinical study, a colorectal cancer patient harboring both EGFR amplification and EGFR S492R demonstrated a 50% tumor reduction when treated with Vectibix (panitumumab) (PMID: 22270724).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR S492R	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical study, a colorectal cancer patient harboring EGFR amplification and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR G719A	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR G719A	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp FGFR1 amp	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp ERBB2 over exp	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified EGFR amplification in 2 patients demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR amp EGFR G696_P1033dup	lung adenocarcinoma	resistant	Afatinib	Clinical Study	Actionable	In a clinical case study, a patient with EGFR G696_P1033dup expressing lung adenocarcinoma had a partial response after two cycles of Gilotrif (afatinib), but subsequently developed resistance to the therapy after amplification of EGFR (PMID: 26286086).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	head and neck squamous cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	lung cancer	sensitive	Tarloxotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR N771_H773dup in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	head and neck squamous cell carcinoma	resistant	Erlotinib	Preclinical	Actionable	In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	lung cancer	predicted - resistant	Afatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) decreased Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR N771_H773dup in culture, bud did not affect tumor growth in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	head and neck squamous cell carcinoma	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup in culture (PMID: 25931286).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	non-small cell lung carcinoma	sensitive	Poziotinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Poziotinib (HM781-36B) decreased tumor burden by greater than 85% in 8/9 mice in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring EGFR N771_H773dup (reported as EGFR H773insNPH) (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited EGFR phosphorylation and growth of a transformed cell line expressing EGFR N771_H773dup (reported as H773insNPH) in culture (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_H773dup	lung adenocarcinoma	sensitive	Dacomitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insNPG	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770_N771insNPG were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insNPG	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited EGFR phosphorylation and growth of a transformed cell line expressing EGFR D770_N771insNPG in culture (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insNPG	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR D770_N771insNPG in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insNPG	Advanced Solid Tumor	predicted - resistant	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770_N771insNPG did not respond to treatment with OBX1-012 in culture (PMID: 29754184).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insNPG	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR D770_N771insNPG in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insNPG	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR D770_N771insNPG in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insNPG	non-small cell lung carcinoma	sensitive	Poziotinib	Preclinical	Actionable	In a preclinical study, treatment with Poziotinib (HM781-36B) decreased tumor burden by greater than 85% in a mouse model of non-small cell lung cancer expressing EGFR D770_N771insNPG (WCLC 2017, Abstract OA 12.01).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insNPG	lung cancer	sensitive	Poziotinib	Preclinical	Actionable	In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring EGFR D770_N771insNPG, with no signs of progression at 12 weeks (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_T751delinsS were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsS	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR V765_M766delinsHH	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing both EGFR L858R and EGFR V765_M766delinsHH were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR V765_M766delinsHH	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing both EGFR L858R and EGFR V765_M766delinsHH were resistant to Gilotrif (afatinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_P772insN	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771_P772insN were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_P772insN	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771_P772insN were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_P772insN	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771_P772insN were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_P772insN	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771_P772insN were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771_P772insN	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771_P772insN were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR G719A in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	non-small cell lung carcinoma	predicted - sensitive	Erlotinib	Clinical Study	Actionable	In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	non-small cell lung carcinoma	sensitive	Afatinib	Phase III	Actionable	In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	decreased response	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	non-small cell lung carcinoma	predicted - sensitive	Gefitinib	Clinical Study	Actionable	In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	decreased response	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719A EGFR T790M	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquisition of EGFR T790M was associated with resistance to Gilotrif (afatinib) in transformed cells expressing EGFR G719A in culture (PMID: 27913578).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S752_I759del	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S752_I759del	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  S752_I759del were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R222C	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R222C were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R222C	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R222C were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747P	lung adenocarcinoma	predicted - resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, Tagrisso (osimertinib) treatment resulted in disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747P	lung adenocarcinoma	no benefit	Bevacizumab + Erlotinib	Clinical Study	Actionable	In a clinical case study, Tarceva (erlotinib) and Avastin (bevacizumab) combination treatment resulted in stable disease for 7 months until disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747P	lung adenocarcinoma	predicted - resistant	Gefitinib	Clinical Study	Actionable	In a clinical case study, Iressa (gefitinib) treatment resulted in disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750del were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_A750del were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750del were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_A750del were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750del	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_A750del were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750del	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_A750del were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsP	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_T751delinsP were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsP	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsP	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsP	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsP	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsP	lung adenocarcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, 3 patients with lung adenocarcinoma harboring EGFR L747_T751delinsP were found to respond to Iressa (gefitinib) therapy (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsP EGFR T790M	lung adenocarcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP and EGFR T790M was found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751delinsP EGFR T790M	lung adenocarcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP that had developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768_D770dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of transformed cell lines expressing EGFR S768_D770dup (also reported as EGFR D770insSVD) in culture (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768_D770dup	lung cancer	sensitive	Tarloxotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR S768_D770dup in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768_D770dup	head and neck squamous cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768_D770dup	head and neck squamous cell carcinoma	resistant	Erlotinib	Preclinical	Actionable	In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768_D770dup	head and neck squamous cell carcinoma	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited EGFR signaling and reduced growth of sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup in culture (PMID: 25931286).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768_D770dup	non-small cell lung carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR S768_D770dup (PMID: 29686424; NCT03066206).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768_D770dup	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768_D770dup (also referred to as D770_N771insSVD) demonstrated resistance to dacomitinib in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L833F	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L833F demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 4.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mut MET amp	lung adenocarcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of MET was identified in a lung adenocarcinoma cell line harboring EGFR mutation that acquired resistance to Tarceva (erlotinib) in culture (PMID: 28630215).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mut MET amp	lung adenocarcinoma	sensitive	Erlotinib + EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) and EMD 1214063 synergistically inhibited growth of lung carcinoma cells harboring EGFR mutation and Met amplification in culture (PMID: 28630215).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	no benefit	Lapatinib	Phase II	Actionable	In a Phase II trial, Tykerb (lapatinib) demonstrated safety in patients with non-small cell lung cancer, but demonstrated minimal antitumor activity with no responses in patients harboring EGFR mutations (PMID: 20215545).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	decreased response	Durvalumab	Clinical Study	Actionable	In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	lung adenocarcinoma	not applicable	N/A	Clinical Study	Emerging	In a clinical study, lung adenocarcinoma patients with compound EGFR mutations had inferior overall survival when compared to patients with single EGFR mutations (PMID: 26785607), suggesting that the presence of compound EGFR mutations may be have prognostic significance in lung adenocarcinoma.
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines for patients with EGFR mutant non-small cell lung cancer who have progressive leptomeningeal disease (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	decreased response	Nivolumab	Clinical Study	Actionable	In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate  (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	lung adenocarcinoma	sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) displayed modest efficacy in lung adenocarcinoma patients with mutant EGFR (J Clin Oncol 33, 2015 (suppl; abstr 8085).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	predicted - sensitive	NGI-1	Preclinical - Cell culture	Actionable	In a preclinical study, NGI-1 inhibited EGFR phosphorylation and proliferation and induced cell cycle arrest in non-small cell lung cancer cell lines harboring kinase domain mutations in EGFR in culture (PMID: 27694802).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	predicted - sensitive	BMS-690514	Phase II	Actionable	In a Phase IIa clinical trial, BMS-690514 demonstrated safety and preliminary anti-tumor activity in patients with non-small cell lung cancer, with patients harboring EGFR mutations achieving a disease control rate (DCR) of 70% (7/10), compared to a DCR of 29% (6/21) in EGFR-wild type patients (PMID: 23490650).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	sensitive	Erlotinib + S63845	Preclinical - Cell culture	Actionable	In a preclinical study, combination of S63845 and Tarceva (erlotinib) resulted in potent cytotoxic effects in EGFR mutated non-small cell lung cancer cells in culture compared to the cytostatic effect of Tarceva (erlotinib) alone (PMID: 27760111).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	sensitive	Brigatinib	Phase I	Actionable	In a Phase I trial, Alunbrig (brigatinib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including NSCLC patients harboring EGFR mutations (J Clin Oncol 31, 2013 (suppl; abstr 8031)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	Advanced Solid Tumor	no benefit	N/A	Clinical Study	Emerging	In a clinical study, 87.5% (7/8) of solid tumor patients harboring EGFR alterations experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	predicted - sensitive	DS-1205b + Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with the combination of DS-1205b and Tagrisso (osimertinib) delayed the onset of therapeutic resistance compared to Tagrisso (osimertinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	predicted - sensitive	DS-1205b + Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with the combination of DS-1205b and Tarceva (erlotinib) delayed the onset of therapeutic resistance compared to Tarceva (erlotinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model, and overcame resistance to Tarceva (erlotinib) in a Tarceva (erlotinib)-resistant xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	sensitive	Sorafenib	Phase III	Actionable	In a Phase III trial, treatment with Nexavar (sorafenib) in non-small cell lung cancer patients harboring an EGFR mutation resulted in a greater overall survival and progression free survival when compared to placebo (PMID: 26743856).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	decreased response	Atezolizumab	Clinical Study	Actionable	In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	sensitive	Naquotinib	Phase I	Actionable	In a Phase I trial, ASP8273 treatment resulted in partial response in 36% (16/45) and stable disease in 27% (12/45) of non-small cell lung carcinoma patients harboring EGFR mutations, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	decreased response	Pembrolizumab	Clinical Study	Actionable	In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	sensitive	Pelitinib	Phase I	Actionable	In a Phase I study, Pelitinib (EKB-569) demonstrated efficacy in 2 patients with non-small cell lung cancer with EGFR mutations and acquired resistance to gefitinib (PMID: 16364494).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	lung cancer	sensitive	CO1686	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rociletinib (CO-1686) induced tumor regression in EGFR-mutant human non-small cell lung cancer cell line xenograft models, while slightly inhibiting tumor growth in xenograft models of a wild-type EGFR human squamous carcinoma cell line (PMID: 24065731).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 22% (22/58), stable disease in 47% (27/58), and progressive disease in 31% (18/58) of non-small cell lung carcinoma patients carrying an EGFR mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant	non-small cell lung carcinoma	predicted - sensitive	Docetaxel + Vandetanib	Phase III	Actionable	In a Phase III trial (ZODIAC), Caprelsa (vandetanib) and Taxotere (docetaxel) combination treatment resulted in improved progression-free survival (HR=0.51), overall survival (HR=0.46), and objective response (odd ratio=3.34) in non-small cell lung cancer patients harboring EGFR mutations compared to the overall study population (PMID: 25057173; NCT00312377).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M EGFR mut	non-small cell lung carcinoma	decreased response	Nivolumab	Clinical Study	Actionable	In a retrospective study, Opdivo (nivolumab) treatment after disease progression during EGFR tyrosine kinase inhibitors resulted in longer median progression-free survival (2.1 vs 1.3 months, HR=0.48, p=0.099) in T790M-negative, EGFR mutant non-small cell lung cancer patients compared to T790M-positive patients (PMID: 28407039).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mut TP53 mut	non-small cell lung carcinoma	decreased response	unspecified EGFR tyrosine kinase inhibitor	Clinical Study	Actionable	In a clinical study, non-small cell lung cancer patients harboring both EGFR and TP53 mutations demonstrated a disease control rate of 70.3% (26/37) following first-line treatment with an EGFR inhibitor such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Dacomitinib, compared to a DCR of 88.2% (75/85) in TP53 wild-type, EGFR-mutant patients (PMID: 27780855).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mutant FGFR1 wild-type	non-small cell lung carcinoma	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR mut TP53 exon 8	non-small cell lung carcinoma	decreased response	unspecified EGFR tyrosine kinase inhibitor	Clinical Study	Actionable	In a clinical study, EGFR-mutant non-small cell lung cancer patients with TP53 exon 8 mutations demonstrated a disease control rate (DCR) of 42% (5/12), median progression-free survival (mPFS) of 4.2 mo and median overall survival (mOS) of 16.2 mo with first-line EGFR tyrosine kinase inhibitor treatment (such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Dacomitinib), vs a DCR of 87% (97/111), mPFS of 12.5 mo, and mOS of 32.3 mo in TP53 exon 8 wild-type patients (PMID: 27780855).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR L792F	Advanced Solid Tumor	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750del and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing E746_A750del alone (PMID: 27913578).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD EGFR L792F	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquisition of EGFR L792F was associated with resistance to Gilotrif in transformed cells expressing EGFR E709_T710delinsD in culture (PMID: 27913578).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD EGFR L792F	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, dacomitinib inhibited growth of transformed cells expressing EGFR E709_T710delinsD and EGFR L792F in culture (PMID: 27913578).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L792F EGFR L858R	Advanced Solid Tumor	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing EGFR L858R alone (PMID: 27913578).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	lung cancer	predicted - resistant	Afatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) decreased Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR A767_V769dup in culture, bud did not affect tumor growth in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A767_V769dup in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of transformed cell lines expressing EGFR A767_V769dup (reported as V769insASV) in culture (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	lung cancer	sensitive	Tarloxotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR A767_V769dup in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	non-small cell lung carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR A767_V769dup (PMID: 29686424; NCT03066206).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	lung adenocarcinoma	sensitive	Poziotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited EGFR phosphorylation and growth of a lung adenocarcinoma patient cell line harboring EGFR A767_V769dup in culture (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A767_V769dup in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A767_V769dup in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767_V769dup	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup (also referred to as V769_D770insASV) demonstrated resistance to dacomitinib in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insNPH	lung cancer	predicted - sensitive	TAS6417	Preclinical - Pdx	Actionable	In a preclinical study, TAS6417 inhibited tumor growth in lung cancer patient-derived xenograft (PDX) models harboring EGFR H773_V774insNPH (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insNPH	Advanced Solid Tumor	sensitive	TAS6417	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR H773_V774insNPH, in culture, and inhibited tumor growth in EGFR H773_V774insNPH-expressing cell line xenograft models (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insNPH	non-small cell lung carcinoma	sensitive	Nazartinib	Preclinical - Pdx	Actionable	In a preclinical study, EGF816 inhibited tumor growth in patient-derived xenograft models of non-small cell lung cancer harboring EGFR H773_V774insNPH (PMID: 26825170).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insNPH	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical - Pdx	Actionable	In a preclinical study, Tagrisso (osimertinib) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring EGFR H773_V774insNPH (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insNPH	Advanced Solid Tumor	sensitive	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR H773_V774insNPH in culture (PMID: 26825170).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR M766_A767insASV	non-small cell lung carcinoma	resistant	Afatinib	Preclinical - Pdx	Actionable	In a preclinicl study, patient-derived xenograft (PDX) models of non-small cell lung cancer harboring EGFR M766_A767insASV were resistant to Gilotrif (afatinib) (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR M766_A767insASV	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical - Pdx	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring EGFR M766_A767insASV (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R776H	non-small cell lung carcinoma	no benefit	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient carrying an EGFR R776H mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709G	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709G	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709G	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709G	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E734Q	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, cells expressing EGFR E734Q demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 20942962).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L718Q EGFR T790M	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L718Q EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR L718Q	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR L718Q	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR L718Q	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR L718Q	non-small cell lung carcinoma	resistant	CO1686	Preclinical	Actionable	In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L718Q	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L718Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L718Q	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L718Q	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L718Q	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L718Q	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L718Q	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L718Q	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L718Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L718Q double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR L718Q	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR L718Q	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR L718Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N826S	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Iressa (gefitinib) in cell culture (PMID: 19147750).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N826S	Advanced Solid Tumor	resistant	AEE788	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to AEE788 in cell culture (PMID: 19147750).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N826S	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Tarceva (erlotinib) in cell culture (PMID: 19147750).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	sensitive	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR D770_N771insSVD in culture (PMID: 26825170).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR D770_N771insSVD, demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160, PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited Egfr phosphorylation in transformed cells expressing EGFR D770_N771insSVD in culture (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770_N771insSVD were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770_N771insSVD were insensitive to Tarceva (erlotinib)-mediated inhibition of Egfr phosphorylation in culture (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770_N771insSVD were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited Egfr phosphorylation, resulted in growth inhibition of non-small cell lung carcinoma cells expressing EGFR D770_N771insSVD in culture and tumor growth inhibition in cell line xenograft models (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	non-small cell lung carcinoma	resistant	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cells expressing EGFR D770_N771insSVD were resistant to Gilotrif (afatinib)-mediated growth inhibition in culture and in cell line xenograft models (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770_N771insSVD were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	non-small cell lung carcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR D770_N771insSVD, displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770_N771insSVD were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	lung cancer	sensitive	TAS6417	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS6417 inhibited growth and induced apoptotic markers in a lung cancer cell line expressing EGFR D770_N771insSVD in culture, inhibited tumor growth and induced tumor regression in subcutaneous xenograft models, and prolonged survival in intrapulmonary xenograft models (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insSVD	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR D770_N771insSVD, in culture (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769L	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769L	non-small cell lung carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR V769L (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769L	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769L	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769L	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R252C	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R252C were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iressa (gefitinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and inhibition of downstream targets, including Cbl, in EGFR wild-type expressing compared to EGFR L858R expressing transformed cells in culture (PMID: 25573954).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	sensitive	Sorafenib	Phase II	Actionable	In a Phase II clinical trial, Nexavar (sorafenib) demonstrated efficacy in NSCLC patients with wild-type EGFR (PMID: 24166906).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	decreased response	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment demonstrated reduced potency inhibiting proliferation of non-small cell lung carcinoma cell lines harboring wild-type EGFR in culture (PMID: 26090892).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	squamous cell carcinoma	no benefit	Avitinib maleate	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Avitinib maleate (AC0010) resulted in no antitumor activity when treating a squamous cell carcinoma cell line xenograft model harboring wild-type EGFR (PMID: 27573423).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	sensitive	Erlotinib + MK2206	Phase II	Actionable	In a Phase II trial, EGFR wild-type non-small cell lung cancer patients treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a clinical benefit as indicated by a disease control rate of 43% (15/43), thus, exceeding the primary endpoint rate of 20% (PMID: 26106072).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	colon cancer	sensitive	Decitabine + Gefitinib	Preclinical	Actionable	In a preclinical study, the combined treatment of DNA methyltransferase inhibitor decitabine and EGFR inhibitor gefitinib on EGFR wild-type colon cancer cell lines resulted in synergistic effects in inhibiting cell growth and migration (PMID: 24874286).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	lung carcinoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) did not inhibit growth of lung carcinoma cells with activated wild-type EGFR signaling via EGF stimulation in culture (PMID: 27780853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	no benefit	Gefitinib	Phase III	Actionable	In a Phase III trial, postoperative adjuvant Iressa (gefitinib) did not provide prolonged disease-free survival nor increased overall survival in NSCLC patients with wild-type EGFR (PMID: 23980091).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	predicted - sensitive	Pembrolizumab	Clinical Study	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P?=?0.54) non-small cell lung carcinoma patients (PMID: 29270615).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	sensitive	Icotinib	Phase III	Actionable	In Phase II and III clinical trials, Chinese patients with advanced NSCLC have shown Conmana (icotinib) to be safe and effective, with indication that patients with EGFR wild-type may receive some benefit  (PMID: 23372346, PMID: 2394835, PMID: 24438614, PMID: 25261231).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	unknown	Cabozantinib + Erlotinib	Phase II	Actionable	In a Phase II trial, the combination of Cometriq (cabozantinib) and Tarceva (erlotinib) resulted in an improved median progression-free survival of 4.7 mo vs. 1.8 mo with Tarceva (erlotinib) alone, and an improved median overall survival of 13.3 months vs 5.1 mo with Tarceva (erlotinib) in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	sensitive	ER2 + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and resulted in decreased inhibition of downstream targets, including Stat5, in transformed cells expressing wild-type EGFR, compared to EGFR L858R expressing cells in culture (PMID: 25573954).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	Advanced Solid Tumor	resistant	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 did not inhibit proliferation of transformed cells harboring wild type EGFR in culture (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	predicted - sensitive	Docetaxel	Guideline	Actionable	Taxotere (docetaxel) is included in guidelines for EGFR wild-type non-small cell lung cancer patients (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	predicted - sensitive	Atezolizumab	Clinical Study	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P?=?0.54) non-small cell lung carcinoma patients (PMID: 29270615).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	sensitive	K-756 + Gefitinib	Preclinical	Actionable	In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	glioblastoma multiforme	no benefit	Dacomitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Dacomitinib did not inhibit Egfr signaling or survival of patient-derived EGFR wild-type glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	sensitive	ER2	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ER2 inhibited EGFR signaling and proliferation and induced apoptosis of EGFR wild-type non-small cell lung cancer cells in culture and delayed tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	unknown	Cabozantinib	Phase II	Actionable	In a Phase II trial, treatment with Cometriq (cabozantinib) resulted in an improved median progression-free survival of 4.3 months, compared to 1.8 months with Tarceva (erlotinib), and an improved median overall survival of 9.2 months, versus 5.1 with Tarceva (erlotinib), in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	predicted - sensitive	Nivolumab	Clinical Study	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P?=?0.54) non-small cell lung carcinoma patients (PMID: 29270615).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type	non-small cell lung carcinoma	sensitive	Erlotinib + Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Tarceva (erlotinib) and Ganetespib led to tumor regression in cell line xenograft models of EGFR wild-type non-small cell lung cancer, and demonstrated improved efficacy over either agent alone (PMID: 25077897).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR wild-type MET over exp	non-small cell lung carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF G466V EGFR wild-type	non-small cell lung carcinoma	sensitive	Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	ALK wild-type EGFR wild-type	non-small cell lung carcinoma	predicted - sensitive	Carboplatin +  Pembrolizumab + Pemetrexed	FDA approved	Actionable	In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small-cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	ALK wild-type EGFR wild-type	non-small cell lung carcinoma	predicted - sensitive	Cisplatin + Pembrolizumab + Pemetrexed	FDA approved	Actionable	In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small-cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR N771delinsFH	lung adenocarcinoma	sensitive	Poziotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) growth of a lung adenocarcinoma patient-derived cell line harboring EGFR N771delinsFH in culture, and decreased tumor burden in xenograft models (PMID: 29686424).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S492R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S492R were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S492R	lung squamous cell carcinoma	predicted - sensitive	Necitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, Portrazza (necitumumab) bound EGFR S492R, and reduced ligand-induced EGFR phosphorylation in lung squamous cell carcinoma cells expressing EGFR S492R (referred to as S468R) in cell culture (PMID: 29158469).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S492R	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR S492R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S492R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S492R were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S492R	colorectal cancer	sensitive	Panitumumab	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S492R	colorectal cancer	sensitive	SYM004	Phase I	Actionable	In a Phase I study, a colorectal cancer patient harboring EGFR S492R demonstrated a partial response when treated with SYM004 (PMID: 25962717).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S492R	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S492R were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S492R	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G735S	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G735S were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G735S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G735S were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G735S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G735S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S306L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S306L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S306L	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S306L	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were sensitive to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S306L	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were sensitive to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T751_I759delinsN	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  T751_I759delinsN were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insPH	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR H773_V774insPH, in culture (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K714R	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K714R were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K714R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K714R were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R831H	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR R831H in culture (PMID: 20942962).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465R EGFR S464L	colorectal cancer	sensitive	MM-151	Phase I	Actionable	In a Phase I trial, MM-151 treatment resulted in reduction of EGFR S464L and stabilization of EGFR G465R in circulating cell-free tumor DNA and prolonged stable disease in a colorectal cancer patient harboring both EGFR G465R and EGFR S464L (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S464L	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S464L in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S464L	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S464L	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR V769_D770insASV, in culture (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited Egfr phosphorylation, resulted in growth inhibition of non-small cell lung carcinoma cells expressing EGFR V769_D770insASV in culture, and tumor regression in cell line and patient-derived xenograft (PDX) models (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited Egfr phosphorylation in transformed cells expressing EGFR V769_D770insASV in culture (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769_D770insASV were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR exon 20 insertions, including EGFR V769_D770insASV (also known as A767_V769dupASV), demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160, PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769_D770insASV were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769_D770insASV were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	non-small cell lung carcinoma	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells expressing EGFR V769_D770insASV were resistant to Gilotrif (afatinib)-mediated growth inhibition in culture and in cell line xenograft models (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	non-small cell lung carcinoma	resistant	Erlotinib	Phase I	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR V769_D770insASV (also referred to as A767_V769dup), displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	non-small cell lung carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR V769_D770insASV (also referred to as A767_V769dup), displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769_D770insASV were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR EGFR V769_D770insASV were insensitive to Tarceva (erlotinib)-mediated inhibition of Egfr phosphorylation in culture (PMID: 29483211).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	Advanced Solid Tumor	sensitive	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR V769_D770insASV in culture (PMID: 26825170).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769_D770insASV	lung cancer	sensitive	TAS6417	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth and induced apoptotic markers in a lung cancer patient-derived xenograft (PDX) model-derived cell line harboring EGFR V769_D770insASV in culture, and inhibited tumor growth and induced tumor regression in PDX models (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR I491M	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR I491M in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR I491M	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR I491M	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D761Y EGFR L858R	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R and EGFR D716Y in culture (PMID: 17085664).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D761Y EGFR L858R	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR D761Y demonstrated decreased sensitivity to Iressa (gefitinib) in culture (PMID: 17085664).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D761Y EGFR L858R	Advanced Solid Tumor	decreased response	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and D761Y demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D761Y EGFR L858R	non-small cell lung carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, a patient with EGFR L858R-mutant non-small lung cancer that developed resistance to Iressa (gefitinib) was demonstrated to have acquired a secondary EGFR D761Y mutation (PMID: 17085664).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T	olfactory neuroblastoma	sensitive	Cetuximab + Sunitinib	Clinical Study	Actionable	In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769M	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR V769M demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 3.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769M	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769M were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769M were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769M	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769M were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V769M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769M were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR-PURB	lung adenocarcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In a clinical study, a patient with lung adenocarcinoma harboring EGFR-PURB demonstrated a partial response when treated with Tarceva (erlotinib), resulting in a 48% decrease in lesion size and ongoing therapy for 20 months without indication of progression (PMID: 27102076).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V292L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V292L were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V292L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V292L were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V292L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V292L were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289V	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289V	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR A289V in culture (PMID: 17177598).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289V	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR K754E	lung adenocarcinoma	decreased response	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of EGFR K754E in lung adenocarcinoma cells harboring EGFR exon 19 deletion mutations led to decreased response to Tarceva (erlotinib) compared to control cells in culture (PMID: 27478040).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR I744M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR I744M were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR I744M	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR I744M were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T263P	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR T263P in culture (PMID: 17177598).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V765M	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V765M were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V765M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V765M were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V765M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V765M were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR V765M	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V765M were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709X	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR E709 mutations demonstrated a response rate of 66.66% and a median progression-free survival of 3.1 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709X	non-small cell lung carcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (2/4) and stable disease in 50% (2/4) of non-small cell lung carcinoma patients carrying an EGFR E709 mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T751I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751I were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K745_E746insIPVAIK	non-small cell lung carcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR K745_E746insIPVAIK demonstrated a partial response when treated with Gilotrif (afatinib) (PMID: 22190593).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K745_E746insVPVAIK	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K745_E746insVPVAIK	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K745_E746insVPVAIK	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H304Y	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H304Y were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H304Y	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H304Y were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H304Y	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H304Y were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR E884K	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition by Iressa (gefitinib) compared to cells expressing EGFR L858R alone (PMID: 20942962).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR E884K	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, cells expressing the double EGFR L858R/E844K mutation demonstrated decreased sensitivity to Tarceva (erlotinib) in culture compared to cells expressing EGFR L858R alone (PMID: 19015641).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR E884K	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition of Egfr phosphorylation by EKI-285 compared to cells expressing EGFR L858R alone (PMID: 20942962).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747S were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747S	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747S were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L747S	lung adenocarcinoma	decreased response	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR L747S had an initial partial response to Tarceva (erlotinib), but was found to progress after 6 months (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L747S	lung adenocarcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R that had developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR L747S mutation (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770delinsGY	Advanced Solid Tumor	resistant	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770delinsGY demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770delinsGY	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of transformed cells expressing EGFR D770delinsGY in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770delinsGY	non-small cell lung carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR D770delinsGY (PMID: 29686424; NCT03066206).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770delinsGY EGFR T790M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR T790M double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770delinsGY EGFR T790M	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquisition of EGFR T790M was associated with resistance to dacomitinib in transformed cells expressing EGFR D770delinsGY (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750delinsP	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_A750delinsP were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750delinsP	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_A750delinsP were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750delinsP	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_A750delinsP were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750delinsP	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_A750delinsP	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P741L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P741L were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P741L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P741L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P741L	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P741L were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T34_A289del	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in transformed cells over expressing EGFR T34_A289del in culture (PMID: 27216155).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T34_A289del	neuroblastoma	resistant	Etoposide	Preclinical - Cell culture	Actionable	In a preclinical study, neuroblastoma cells over expressing EGFR T34_A289del were resistant to Eposin (etoposide) in culture (PMID: 27216155).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T34_A289del	neuroblastoma	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in neuroblastoma cells over expressing EGFR T34_A289del in culture (PMID: 27216155).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T34_A289del	Advanced Solid Tumor	decreased response	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) did not efficiently inhibit Egfr phosphorylation in transformed cells over expressing T34_A289del in culture (PMID: 27216155).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709V	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709V	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_A750delinsIP were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_A750delinsIP were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750delinsIP	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_A750delinsIP were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750delinsIP were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_A750delinsIP were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750delinsIP were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751del	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751del	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751del	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_T751del were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_T751del	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  L747_P753delinsQ were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsQ	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719S were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	non-small cell lung carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, Iressa (gefitinib) (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	non-small cell lung carcinoma	sensitive	Gefitinib	Preclinical	Actionable	In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Iressa (gefitinib) (PMID: 17349580).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	non-small cell lung carcinoma	sensitive	Erlotinib	Preclinical	Actionable	In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Gilotrif (afatinib) (PMID: 17349580).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	non-small cell lung carcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	non-small cell lung carcinoma	sensitive	Afatinib	Phase III	Actionable	In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S	non-small cell lung carcinoma	sensitive	Afatinib	Preclinical	Actionable	In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Gilotrif (afatinib) (PMID: 17349580).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S EGFR T790M	lung adenocarcinoma	predicted - resistant	Osimertinib	Clinical Study	Actionable	In a clinical study, Tagrisso (osimertinib) treatment resulted in disease progression in a patient with lung adenocarcinoma harboring EGFR G719S and an acquired EGFR T790M, after her disease progressed while on Tarceva (erlotinib) and then on Gilotrif (afatinib) treatments (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G719S EGFR T790M	lung adenocarcinoma	predicted - resistant	Afatinib	Clinical Study	Actionable	In a clinical study, EGFR T790M was identified as an acquired mutation in the tumor of a patient with lung adenocarcinoma harboring EGFR G719S, after her disease progressed while on Tarceva (erlotinib) and then on Gilotrif (afatinib) treatments (PMID: 29285266).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G EGFR G719S	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR Y764_V765insHH	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR Y764_V765insHH in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR Y764_V765insHH	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR Y764_V765insHH in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR Y764_V765insHH	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR Y764_V765insHH were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR Y764_V765insHH	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR Y764_V765insHH in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR Y764_V765insHH	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR Y764_V765insHH demonstrated resistance to dacomitinib in culture (PMID: 28363995).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465R	colorectal cancer	sensitive	SYM004	Clinical Study	Actionable	In a clinical study, a patient with Erbitux (cetuximab)-resistant metastatic colorectal cancer harboring EGFR G465R demonstrated stable disease for 15 weeks following treatment with SYM004 (PMID: 26888827).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465R	colorectal cancer	sensitive	SYM004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYM004 inhibited EGFR downstream signaling and proliferation of a colorectal cancer cell line harboring EGFR G465R in culture, and induced tumor regression in xenograft models (PMID: 26888827).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465R	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465R	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G465R	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465R in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	resistant	Vemurafenib + Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Vemurafenib + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR G465R	colorectal cancer	resistant	Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_S752del EGFR T790M EGFR P794L	non-small cell lung carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a clinical case study, Gilotrif (afatinib) treatment resulted in rapid clinical response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion (E746_S752del), EGFR T790M and EGFR P794L (PMID: 29704676).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_S752del EGFR T790M EGFR P794L	non-small cell lung carcinoma	predicted - resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, Tagrisso (osimertinib) treatment resulted in initial response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion (E746_S752del) and T790M, however, the disease progressed 20 months after treatment started, and EGFR P794L was identified by liquid biopsy at the time of progression (PMID: 29704676).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858M	non-small cell lung carcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 100% (2 of 2) of non-small cell lung carcinoma patients carrying EGFR L858M mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K467T	colorectal cancer	sensitive	Panitumumab	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K467T	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR K467T were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K467T	Advanced Solid Tumor	predicted - sensitive	SYM004	Preclinical - Cell culture	Actionable	In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR K467T in culture (PMID: 26888827).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K467T	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR S645C	lung adenocarcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of EGFR S645C in lung adenocarcinoma cells harboring EGFR exon 19 deletion mutations led to resistance to Tarceva (erlotinib) in culture (PMID: 27478040).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R451C	colorectal cancer	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R451C	Advanced Solid Tumor	predicted - sensitive	SYM004	Preclinical - Cell culture	Actionable	In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR R451C in culture (PMID: 26888827).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R451C	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R451C	colorectal cancer	sensitive	Panitumumab	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709A	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709A	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709A	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709A	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709A	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	Advanced Solid Tumor	decreased response	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	Advanced Solid Tumor	decreased response	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to the first-generation EGFR inhibitor Iressa (gefitinib) in culture, when compared to second-generation inhibitors, with an IC90 concentration approximately two-times the estimated trough concentration at the recommended dose (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	lung adenocarcinoma	sensitive	Afatinib	Phase I	Actionable	In a clinical case study, treatment with Gilotrif (afatinib) in a lung adenocarcinoma patient harboring EGFR E709_T710delinsD resulted in tumor shrinkage, while prior treatment with Tarceva (erlotinib) had achieved stable disease (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709_T710delinsD	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L703P	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703P were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L703P	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703P were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L703P	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703P were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insG	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR D770_N771insG, in culture (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D770_N771insG	non-small cell lung carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR D770delinsGY (PMID: 29686424; NCT03066206).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S720F	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S720F	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S720F	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S720F	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S720F	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S720F	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289D	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289D were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289D	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289D were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P753S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P753S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P753S	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P753S were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P753S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P753S were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR-RAD51	Advanced Solid Tumor	predicted - sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated some sensitivity to treatment with Tagrisso (osimertinib) in culture, resulting in decreased cell viability (PMID: 27102076).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR-RAD51	lung adenocarcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In a clinical study, three patients with lung adenocarcinoma harboring EGFR-RAD51 demonstrated partial responses as indicated by tumor regression, when treated with Tarceva (erlotinib) (PMID: 27102076).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR-RAD51	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Gilotrif (afatinib) in culture, resulting in decreased cell viability and inhibition of downstream MAPK and PI3K signaling (PMID: 27102076).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR-RAD51	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Erbitux (cetuximab) in culture, resulting in decreased cell viability (PMID: 27102076).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L703I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703I were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L703I	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703I were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L703I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703I were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR neg FGFR1 over exp	head and neck squamous cell carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR K745_E746insTPVAIK	non-small cell lung carcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR K745_E746insTPVAIK demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 22190593).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut MET amp	lung cancer	sensitive	SYM015	Preclinical - Pdx	Actionable	In a preclinical study, SYM015 treatment resulted in tumor growth inhibition in patient-derived xenograft (PDX) models of MET-amplified lung cancer harboring EGFR activating mutations (PMID: 28679766).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut EGFR A289T PTEN I253N PTEN N69D	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut EGFR A289T PTEN I253N PTEN N69D	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Amlexanox + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Sapitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapitinib (AZD8931) inhibited EGFR, ERBB2, and ERBB3 kinase activity, and inhibited growth in several non-small cell lung cancer cell lines and xenograft models, including those with EGFR activating mutations (PMID: 20145185).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Naquotinib	Phase I	Actionable	In a Phase I trial, ASP8273 demonstrated preliminary antitumor activity in non-small cell lung patients harboring EGFR activating mutations (J Clin Oncol 33, 2015 (suppl; abstr 8014).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	no benefit	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	predicted - sensitive	Glesatinib + Erlotinib	Phase I	Actionable	In a Phase I trial, Glesatinib (MGCD265) and Tarceva (erlotinib) combination treatment resulted in partial response in a non-small cell lung carcinoma patient harboring an EGFR activating mutation (J Clin Oncol 30, 2012 (suppl; abstr e13602)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line, but not subsequent therapy for metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib) treatment, when compared to Iressa (gefitinib), resulted in statistically significant improvement of progression free survival (11.0 vs 10.9 months, HR 0.74, p=0.0178), time-to-treatment failure (13.7 vs 11.5 months, HR 0.75, p=0.0136), and objective response rate (72.5% vs 56%, odd ratio 2.121, p=0.0018) (PMID: 28169392).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	no benefit	Alectinib	Guideline	Actionable	Alecensa (alectinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In a Phase III (ARCHER 1050) trial, Dacomitinib demonstrated superior efficacy compared to Iressa (gefitinib) as first-line therapy in non-small cell lung cancer patients harboring EGFR activating mutations (exon 19 deletion or L858R), resulting in prolonged overall survival (34.1 vs 26.8 months, HR=0.76, p=0.0438) (PMID: 29864379; NCT01774721).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II clinical trial, progression-free survival at 4 months was 95.5% in patients with EGFR-mutant non-small cell lung cancer following treatment with dacomitinib, compared to 76.8% in the overall treatment population (PMID: 25456362).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR activating mutations in culture, regardless of the presence or absence of EGFR T790M (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	Advanced Solid Tumor	predicted - sensitive	ABT-806	Phase I	Actionable	In a Phase I trial, ABT-806 treatment in patients with advanced solid tumors that often express EGFR amplification or EGFR vIII was well-tolerated, demonstrated safety, and resulted in stable disease in two patients (PMID: 25895099).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	CO1686	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in xenograft models of human non-small cell lung cancer cell lines harboring EGFR activating mutations (PMID: 24065731).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	no benefit	Erlotinib + MK2206	Phase II	Actionable	In a Phase II trial, non-small cell lung cancer patients harboring EGFR activating mutations treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a 9% (4/45) response rate, which did not reach the primary endpoint rate of 20% or more, therefore, indicating no benefit (PMID: 26106072).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	decreased response	Neratinib	Phase I	Actionable	In a Phase I trial, Nerlynx (neratinib) demonstrated limited clinical activity in EGFR-mutant non-small cell lung cancer patients with prior EGFR TKI therapy, with a response rate of 3.4% (3/88), stable disease as best response in 50% (44/88), and prolonged stable disease in 10%, (9/88) (PMID: 20479403).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	XL647	Phase II	Actionable	In a Phase II study, XL647 demonstrated antitumor activity and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 22722787).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Gefitinib	Phase III	Actionable	In a Phase III trial, adjuvant Iressa (gefitinib) treatment resulted in prolonged disease-free survival (28.7 vs 18.0 months) compared to Navelbine (vinorelbine) and Platinol (cisplatin) combination in completely resected non-small cell lung cancer patients harboring EGFR-activating mutations (J Clin Oncol 35, 2017 (suppl; abstr 8500)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefitinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Gefitinib	Phase III	Actionable	In a Phase III clinical trial, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 19692680).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	predicted - sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	predicted - sensitive	Erlotinib	Phase III	Actionable	In a Phase III trial, a trend toward disease free survival was observed in non-small cell lung cancer patients harboring EGFR activating mutations when treated with Tarceva (erlotinib) vs placebo in the adjuvant setting, but significance was not demonstrated due to study design (PMID: 26324372).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	predicted - sensitive	Erlotinib	Phase II	Actionable	In a Phase II trial, non-small cell lung cancer patients with EGFR mutations demonstrated a median progression-free survival of 10.8 months, overall survival of 31.0 months, an overall response rate of 66.2% (137/207), and a disease control rate of 82.6% (2 complete responses; 135 partial responses, and 34 stable disease) following treatment with Tarceva (erlotinib) (PMID: 26720423).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as first-line therapy for locally advanced or metastatic non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	no benefit	AUY922 + Erlotinib	Phase Ib/II	Actionable	In a Phase Ib/II clinical trial, the combination of AUY922 and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, with 16% (4/25) patients achieving partial response (PMID: 25870087).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	non-small cell lung carcinoma	no benefit	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut	lung adenocarcinoma	sensitive	Bevacizumab + Erlotinib	Phase II	Actionable	In a Phase II trial, Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 13.2 months and a 12 month progression-free survival of 55% (60/109) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) (PMID: 28408243).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut EGFR T790M	non-small cell lung carcinoma	sensitive	Naquotinib	Phase I	Actionable	In a Phase I trial, treatment with ASP8273 resulted in a partial response in 41% (19/46) of non-small cell lung carcinoma patients co-harboring EGFR T790M and an EGFR activating mutation, demonstrating almost undetectable levels of the mutations in cell-free DNA (PMID: 28954786; NCT02113813).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut EGFR T790M	non-small cell lung carcinoma	no benefit	AUY922 + Erlotinib	Phase Ib/II	Actionable	In a Phase Ib/II clinical trial, the combination of AUY922 and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, including patients with EGFR T790M, with 16% (4/25) patients achieving partial response (PMID: 25870087).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR act mut EGFR T790M	lung adenocarcinoma	sensitive	Bevacizumab + Erlotinib	Phase II	Actionable	In a Phase II trial, Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 16.0 months and a 12 month progression-free survival of 68% (25/37) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) and EGFR T790M (PMID: 28408243).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M KRAS amp	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M KRAS amp	non-small cell lung carcinoma	sensitive	Osimertinib + Selumetinib	Preclinical	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib increased Parp cleavage, and highly suppressed phosphorylated Erk in human non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and a gain in KRAS in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M KRAS amp	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del ERBB2 wild-type	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, transgenic mouse models with ERBB2 (HER2)-wild-type cells expressing EGFR exon 19 deletion demonstrated tumor growth inhibition and an improved progression-free survival when treated with Tagrisso (osimertinib) compared to treatment with Tarceva (erlotinib) (PMID: 29298799).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS E63K	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS E63K	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS E63K	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - sensitive	Osimertinib + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Tagrisso (osimertinib) and Saracatinib (AZD0530) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Tagrisso (osimertinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Gilotrif (afatinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased expression and phosphorylation of Met, were associated with resistance to Tarceva (erlotinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - sensitive	Afatinib + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in MET, leading to increased Met phosphorylation, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Xalkori (crizotinib) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del KRAS amp	non-small cell lung carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del KRAS amp	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS G12V	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS amp	non-small cell lung carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS amp	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS amp	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del TP53 wild-type	non-small cell lung carcinoma	sensitive	unspecified EGFR tyrosine kinase inhibitor	Clinical Study	Actionable	In a clinical study, non-small cell lung carcinoma patients harboring an EGFR exon 19 deletion and TP53 wild-type exon 8 demonstrated a median progression-free survival of 16.8 months following first-line treatment with an EGFR tyrosine kinase inhibitor, such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Dacomitinib, compared with 4.2 months in patients harboring a TP53 exon 8 mutation and EGFR exon 19 deletion (PMID: 27780855).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	sensitive	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	lung cancer	sensitive	Osimertinib + Bosutinib + PF-573328	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Bosulif (bosutinib) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	sensitive	CO1686	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 64.3% (18/28) in non-small cell lung cancer patients harboring both EGFR exon 19 deletions and EGFR T790M (PMID: 25923550).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	lung adenocarcinoma	resistant	Afatinib	Clinical Study	Actionable	In an analysis of lung adenocarcinoma patients treated with Gilotrif (afatinib), second-site EGFR T790M mutations were detected in 47.6% (20/42) of patients with acquired resistance, with 9/20 patients harboring primary EGFR exon 19 deletion mutations (PMID: 26862733).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of EGFR T790M in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	sensitive	TAE226	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring both EGFR T790M and EGFR Exon 19 deletion mutations (PMID: 26090892).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	lung cancer	resistant	Cetuximab + EAI045	Preclinical	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	lung cancer	sensitive	BKM120 + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	lung cancer	sensitive	Osimertinib + PF-573328 + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Saracatinib (AZD0530) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	sensitive	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 inhibited EGFR signaling and cell growth in 1st generation TKI-resistant non-small cell lung carcinoma cells harboring EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	resistant	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing both EGFR exon 19 deletion mutation and T790M in culture (PMID: 26208524).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	predicted - sensitive	Osimertinib + Ramucirumab	Phase I	Actionable	In a Phase I trial, Cyramza (ramucirumab) and Tagrisso (osimertinib) combination treatment resulted in an objective response rate of 76% (19/25, 1 complete response, 18 partial response), and stable disease in 16% (4/25) of EGFR-mutant (exon 19 deletion or L858R) non-small cell lung cancer patients harboring EGFR T790M, who progressed on first-line EGFR TKI therapy (J Clin Oncol 36, 2018 (suppl; abstr 9053); NCT02789345).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	lung cancer	sensitive	GSK2334470 + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of GSK2334470 and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a clinical case study, Iressa (gefitinib) treatment resulted in initial response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion, however, the disease progressed 3 years after initial treatment and EGFR T790M was identified at the time of progression (PMID: 29704676).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancercarcinoma cells harboring EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	resistant	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Clinical Study	Actionable	In a clinical case study, Tagrisso (osimertinib) resulted in a partial response and stable disease of brain metastases in a NSCLC patient harboring EGFR exon 19 deletion and a secondary resistance mutation, EGFR T790M, which occurred post Iressa (gefitinib) therapy (PMID: 27435396).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Phase III	Actionable	In a Phase III trial, third-line treatment with Tagrisso (osimertinib) resulted in improved median progression-free survival compared to treatment with the combination of Taxotere (docetaxel) and Avastin (bevacizumab) (10.2 mo vs. 2.95 mo., HR=0.23), and a an overall response rate of 61.6% (45/73) compared to 8.3% (6/72), in patients with non-squamous non-small cell lung cancer harboring EGFR T790M with either EGFR L858R or an EGFR exon 19 deletion (PMID: 29858027, NCT02959749).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, AZD9291 treatment resulted in a response rate of 64% (49/77) in NSCLC patients that harbored both EGFR exon 19 deletions and T790M mutations (PMID: 25923549).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon 19 EGFR T790M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del KRAS G12S	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of KRAS G12S in lung adenocarcinoma cells harboring EGFR exon 19 deletion resulted in resistance to Tagrisso (osimertinib) in culture, consistent with KRAS G12S identified in tumor samples of a lung adenocarcinoma patient harboring EGFR exon 19 deletion who developed resistance to Tagrisso (osimertinib) (PMID: 27252416).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M NRAS Q61K	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR del exon19 MET amp	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET amp	lung adenocarcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET amp	non-small cell lung carcinoma	sensitive	JNJ-61186372	Preclinical - Cell line xenograft	Actionable	In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET amp	lung adenocarcinoma	sensitive	Osimertinib + Savolitinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib), however, after 36 weeks presented with progression (PMID: 27694386).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS G12R	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS G12R	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del MET amp MET D1228V	lung adenocarcinoma	sensitive	Cabozantinib + Erlotinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size (PMID: 27694386).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS Q61K	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS Q61K	non-small cell lung carcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del NRAS Q61K	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	no benefit	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	K-756 + Gefitinib	Preclinical	Actionable	In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	TAE226	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring EGFR Exon 19 deletion mutation (PMID: 26090892).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a clinical study, a comparison of  the clinical outcomes of  non-small cell lung cancer patients harboring either EGFR exon 19 deletion or L858R demonstrated similar responses to treatment with Iressa (gefitinib) or Tarceva (erlotinib), with overall response rates of 76.9% with Iressa (gefitinib) and 74.4% with  Tarceva (erlotinib) (PMID: 24736073).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Gefitinib	FDA approved	Actionable	In a Phase III trial that supported FDA approval, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) compared to 47.3% (61/129) with Paraplatin (carboplatin) plus Taxol (paclitaxel) and prolonged progression-free survival (HR=0.48) in non-small cell lung cancer patients harboring EGFR activating mutations, including EGFR exon 19 deletions (PMID: 19692680, NCT00322452).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefitinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	predicted - sensitive	Erlotinib + GLPG0634	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion in culture that had, over time, acquired resistance to Tarceva (erlotinib) showed decreased drug resistance when treatment was combined with Filgotinib (GLPG0634), demonstrating reduced expression of Osmr and phosphorylated-Stat3, and decreased cell viability (PMID: 28729401).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	lung adenocarcinoma	sensitive	Gefitinib + Golvatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, addition of Golvatinib (E7050) overcame Hgf-induced Iressa (gefitinib)-resistance in lung adenocarcinoma cell lines harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 22789825).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	Advanced Solid Tumor	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR exon 19 deletion mutation in culture (PMID: 26208524).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	no benefit	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In a Phase III trial, treatment with dacomitinib as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 12.3 months with dacomitnib vs. 9.8 months with Iressa (gefitinib) among patients with EGFR exon 19 deletions (PMID: 28958502; NCT01777421).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Nazartinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring an exon 19 deletion in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring an exon 19 deletion (PMID: 26825170).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Icotinib	Phase III	Actionable	In a meta-analysis of 12 Phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	JNJ-61186372	Preclinical - Cell line xenograft	Actionable	In a preclinical study, JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion, with increased efficacy following treatment cessation compared to Tarceva (erlotinib) (PMID: 27216193).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	lung adenocarcinoma	sensitive	JNJ-61186372	Preclinical - Pdx	Actionable	In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring an EGFR exon 19 deletion, with continued response following treatment cessation (PMID: 27216193).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	lung adenocarcinoma	sensitive	Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion demonstrated a partial response when treated with Tagrisso (osimertinib), which lasted for nearly 16 months (PMID: 29596911).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	TH-4000	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TH-4000 induced tumor regression in erlotinib-resistant human cell line xenograft models of non-small cell lung cancer harboring EGFR exon 19 deletion mutations (J Clin Oncol 33, 2015 (suppl; abstr e13548)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Erlotinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 11.0 months for patients harboring EGFR exon 19 deletions (PMID: 26720423).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Erlotinib	FDA approved	Actionable	In a Phase III trial (EURTAC) that supported FDA approval, treatment with Tarceva (erlotinib) resulted in improved progression-free survival compared to treatment with platinum-based chemotherapy in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27) (PMID: 24868098).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	lung cancer	sensitive	Dasatinib + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Osimertinib	FDA approved	Actionable	In a Phase III (FLAURA) trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in a longer median progression-free survival compared to treatment with either Tarceva (erlotinib) or Iressa (gefitinib) (18.9 mo vs 10.2 mo) in non-small cell lung carcinoma patients harboring either EGFR L858R or EGFR exon 19 deletion (PMID: 29151359; NCT02296125).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a human NSCLC cell line xenograft model with brain metastases harboring an EGFR exon 19 deletion demonstrated tumor regression and improved survival benefit when treated with Tagrisso (osimertinib) (PMID: 27435396).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as first-line therapy for locally advanced or metastatic non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, non-small cell lung cancer patients harboring EGFR exon 19 deletions demonstrated a response rate of 30% (8/27) following treatment with Tagrisso (osimertinib) (PMID: 25923549).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	lung cancer	sensitive	AZD3759	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring an EGFR exon 19 deletion in culture and induced tumor regression in subcutaneous xenograft models, and inhibited tumor growth in brain and leptomeningeal xenograft models (PMID: 27928026).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	OBX1-012	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 del were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29754184).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Vandetanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Egfr activation, resulting in growth inhibition of non-small cell lung cancer cells harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 19447865).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	no benefit	CO1686	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rociletinib (CO-1686) did not result in tumor regression or a survival benefit when treating a NSCLC cell line xenograft model harboring an EGFR exon 19 deletion (PMID: 27435396).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	lung cancer	sensitive	Osimertinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Ibrutinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Imbruvica (ibrutinib) inhibited Egfr activity and downstream signaling, resulting in cell cycle arrest in culture and delayed tumor progression in cell line xenograft models of non-small cell lung cancer harboring EGFR exon 19 deletions (PMID: 26375053).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	no benefit	Alectinib	Guideline	Actionable	Alecensa (alectinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line, but not subsequent therapy for metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Afatinib	FDA approved	Actionable	In a Phase III trial supporting FDA approval (LUX-Lung 3), Gilotrif (afatinib) treatment resulted in improved median progression-free survival compared to chemotherapy (HR=0.28) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (PMID: 23816960; NCT00949650).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del	non-small cell lung carcinoma	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months) and time-to-treatment failure (13.7 vs 11.5 months) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M MET amp	lung adenocarcinoma	resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with Xalkori (crizotinib) treatment (PMID: 27393507).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Osimertinib + TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of TAK-632 and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Dasatinib + Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tagrisso (osimertinib) and Sprycel (dasatinib) in combination resulted in increased PARP cleavage and inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M compared to Tagrisso (osimertinib) alone, and inhibited tumor growth in xenograft models, with 3 out of 7 models demonstrating no tumor rebound after cessation of therapy (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M	non-small cell lung carcinoma	sensitive	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 del and EGFR T790M , resistant to Iressa (gefitinib) and Tarceva (erlotinib), were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro (PMID: 29754184).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Osimertinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 19 del EGFR T790M	non-small cell lung carcinoma	predicted - sensitive	Avitinib maleate	Phase I	Actionable	In a Phase I trial, Avitinib maleate (AC0010) treatment resulted in an overall response rate of 36.5% (19/52) and a disease control rate of 75% (39/52) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (33/52) or L858R (19/52) with acquired resistance to first generation Egfr tyrosine kinase inhibitors, 87% (45/52) of the patients also harbored EGFR T790M (PMID: 29626621).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR L844V	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR L844V	non-small cell lung carcinoma	resistant	CO1686	Preclinical	Actionable	In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR L844V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR L844V	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del SMO amp	non-small cell lung carcinoma	no benefit	Sonidegib	Preclinical	Actionable	In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del SMO amp	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del SMO amp	non-small cell lung carcinoma	sensitive	PHA-665752 + Sonidegib	Preclinical	Actionable	In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del SMO amp	non-small cell lung carcinoma	sensitive	Gefitinib + Sonidegib	Preclinical	Actionable	In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	non-small cell lung carcinoma	sensitive	Gefitinib + NPS-1034	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	non-small cell lung carcinoma	sensitive	Gefitinib + PHA-665752	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	lung adenocarcinoma	no benefit	Afatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	lung adenocarcinoma	resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841)
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	lung adenocarcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	non-small cell lung carcinoma	resistant	CO1686	Preclinical - Cell line xenograft	Actionable	In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	non-small cell lung carcinoma	sensitive	CO1686 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del MET amp	lung adenocarcinoma	sensitive	Afatinib + Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR Q791R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M EGFR Q791R	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750del demonstrated increased sensitivity to Caprelsa (vandetanib) in culture (PMID: 15604279).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR E746_A750del demonstrated resistance to growth inhibition by Tykerb (lapatinib) in cell culture (PMID: 18199554).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring  EGFR E746_A750del in culture (PMID: 21325073, PMID: 16731747).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR E746_A750del in culture (PMID: 27780853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	ER2 + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model harboring EGFR E746_A750del (PMID: 27040853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	Erlotinib + Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Ganetespib and Tarceva (erlotinib) demonstrated improved antitumor activity compared to either agent alone in cell line xenograft models of non-small cell lung cancer harboring EGFR E746_A750del (PMID: 25077897).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	WZ4002 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of WZ4002 and Mekinist (trametinib) inhibited tumor growth, and resulted in reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 26036643).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	lung carcinoma	sensitive	BGB-283	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGB-283 inhibited Egfr phosphorylation and cell proliferation in lung carcinoma cells harboring EGFR E746_A750del in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26208524).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	lung adenocarcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, treatment with Iressa (gefitinib) was found to result in partial response in 7 patients, stable disease in 1 patient, and progressive disease in 1 patient with lung adenocarcinoma harboring EGFR E746_A750del (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	lung cancer	sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of lung cancer cell lines harboring EGFR E746_A750del in culture (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR E746_A750del demonstrated increased sensitivity to Caprelsa (vandetanib) in culture (PMID: 15604279).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	lung adenocarcinoma	sensitive	Avitinib maleate	Preclinical - Cell line xenograft	Actionable	In a preclinical study, lung adenocarcinoma cells harboring EGFR E746_A750del demonstrated sensitivity to treatment with Avitinib maleate (AC0010), which resulted in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del	non-small cell lung carcinoma	sensitive	ER2	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with ER2 resulted in decreased proliferation and increased apoptosis of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del in culture, and delayed tumor growth in NSCLC cell line xenograft models with EGFR E746_A750del (PMID: 27040853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR L844V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR L844V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR L844V	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M	non-small cell lung carcinoma	sensitive	WZ4002 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib)  inhibited tumor growth, and resulted in increased ERK inhibition and reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring both EGFR E746_A750del and EGFR T790M (PMID: 26036643).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M	non-small cell lung carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M	non-small cell lung carcinoma	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR E746_A750del and T790M in culture (PMID: 27780853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M	lung adenocarcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, 3 of 4 patients with lung adenocarcinoma harboring EGFR E746_A750del and EGFR T790M were found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M	lung adenocarcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, 4 patients with lung adenocarcinoma harboring EGFR E746_A750del that had developed Iressa (gefitinib) resistance were found to have acquired EGFR T790M mutations (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_A750del EGFR T790M	non-small cell lung carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R KRAS G12V	lung adenocarcinoma	resistant	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, KRAS G12V was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	sensitive	Pimasertib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M MET amp	lung adenocarcinoma	predicted - resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M progressed after 19 months on Tagrisso (osimertinib), and was found to have acquired MET amplification (PMID: 29128427).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib + Osimertinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient with EGFR L858R, EGFR T790M, and MET amplification demonstrated a partial response in her lung lesions and an approximately 90% reduction in the retroperitoneal lymph node and right adrenal gland, and progression-free survival lasting 3 months following treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) (PMID: 29128427).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R KRAS G12D	lung adenocarcinoma	resistant	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R MET amp	non-small cell lung carcinoma	sensitive	CO1686 + Crizotinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR Q791R EGFR T790M	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR Q791R EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M NRAS Q61K	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H	lung adenocarcinoma	unknown	Cabozantinib + Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M, MET amplification and MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement, decreased pleural effusion, and lung nodule shrinkage following treatment with the combination of Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) (PMID: 29128427).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H	lung adenocarcinoma	predicted - resistant	Crizotinib + Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M and MET amplification demonstrated progressive disease after 3 months of treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) and was found to have acquired 4 MET mutations: MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y (PMID: 29128427).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L844V EGFR T790M	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L844V EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple-mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R KRAS G12R	lung adenocarcinoma	resistant	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, KRAS G12R was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M MET amp MET D1231Y	lung adenocarcinoma	predicted - resistant	Cabozantinib + Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R, EGFR T790M, MET amplification, MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement and lung nodule shrinkage following treatment Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) in combination, but progressed after 1 month and was found to have lost MET D1228H, MET D1228N, and MET Y1230H, and to have an increased allele fraction of MET D1231Y (PMID: 29128427).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L844V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L844V	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR L844V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring EGFR L858R EGFR T790M in culture (PMID: 21325073, PMID: 19238632).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung cancer	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of a lung cancer cell line harboring EGFR L858R and EGFR T790M in culture (PMID: 29748209).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	decreased response	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, AZD9291 treatment resulted in a response rate of 57% (24/24) in patients harboring both EGFR L858R and T790M mutations (PMID: 25923549).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Phase III	Actionable	In a Phase III trial, third-line treatment with Tagrisso (osimertinib) resulted in improved median progression-free survival compared to treatment with the combination of Taxotere (docetaxel) and Avastin (bevacizumab) (10.2 mo vs. 2.95 mo., HR=0.23), and a an overall response rate of 61.6% (45/73) compared to 8.3% (6/72), in patients with non-squamous non-small cell lung cancer harboring EGFR T790M with either EGFR L858R or an EGFR exon 19 deletion (PMID: 29858027, NCT02959749).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Clinical Study	Actionable	In a clinical case study, Tagrisso (osimertinib) resulted in a partial response and stable disease of brain metastases in a NSCLC patient harboring EGFR L858R and a secondary resistance mutation, EGFR T790M, which occurred post Tarceva (erlotinib) therapy (PMID: 27435396).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Avitinib maleate	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cells harboring the double mutation, EGFR L858R and EGFR T790M, demonstrated sensitivity to treatment with Avitinib maleate (AC0010), resulting in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Avitinib maleate	Phase I	Actionable	In a Phase I trial, Avitinib maleate (AC0010) treatment resulted in an overall response rate of 36.5% (19/52) and a disease control rate of 75% (39/52) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (33/52) or L858R (19/52) with acquired resistance to first generation Egfr tyrosine kinase inhibitors, 87% (45/52) of the patients also harbored EGFR T790M (PMID: 29626621).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung adenocarcinoma	sensitive	Afatinib + Cetuximab + Sirolimus	Preclinical	Actionable	In a preclinical study, addition of Rapamune (sirolimus) to Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment restored sensitivity in transgenic animal models of lung adenocarcinoma driven by EGFR L858R and T790M that acquired resistance to the combination treatment, resulted in tumor shrinkage (PMID: 24813888).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung cancer	resistant	AZD3759	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M did not demonstrate sensitivity to AZD3759 in culture (PMID: 27928026).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung cancer	sensitive	Osimertinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	OBX1-012	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR L858R and EGFR T790M were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29754184).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	CO1686	Preclinical - Pdx	Actionable	In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in human non-small cell lung cancer cell line and patient-derived xenograft models of non-small cell lung cancer harboring both EGFR L858R and EGFR T790M (PMID: 24065731).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	CO1686	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 53.3% (8/15) in non-small cell lung cancer patients harboring both EGFR L858R and EGFR T790M (PMID: 25923550).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung cancer	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Gilotrif (afatinib) in a lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 28145866).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	predicted - sensitive	Ibrutinib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Imbruvica (ibrutinib) and Mekinist (trametinib) combination treatment enhanced growth inhibition of non-small cell lung cancer cells harboring EGFR L858R and T790M compared to monotherapy in culture, but did not improve tumor suppression in cell line xenograft models (PMID: 26375053).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Nazartinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring both EGFR L858R and EGFR T790M in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring both EGFR L858R and EGFR T790M (PMID: 26825170).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, non-small cell carcinoma cancer cell lines harboring EGFR L858R and T790M mutations demonstrated resistance to growth inhibition by Tykerb (lapatinib) in culture (PMID: 18199554).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Afatinib + Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Ganetespib and Gilotrif (afatinib) demonstrated improved antitumor activity compared to either agent alone in  cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	WZ4002 + Trametinib	Preclinical	Actionable	In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib) resulted in tumor regression, and decreased tumor rebound and increased survival compared to WZ4002 alone in non-small cell lung cancer mouse models expressing EGFR L858R and EGFR T790M (PMID: 26036643).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung adenocarcinoma	resistant	Afatinib	Clinical Study	Actionable	In a clinical study, acquired EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib), with 10/20 of those patients harboring EGFR L858R as their primary EGFR mutation (PMID: 26862733).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung adenocarcinoma	resistant	Erlotinib	Preclinical	Actionable	In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which occurred after repeated treatments with Tarceva (erlotinib) and resulted in drug resistance (PMID: 26341921).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Erlotinib + Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of Ganetespib overcame resistance to Tarceva (erlotinib) in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung adenocarcinoma	resistant	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed  after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	predicted - sensitive	Osimertinib + Ramucirumab	Phase I	Actionable	In a Phase I trial, Cyramza (ramucirumab) and Tagrisso (osimertinib) combination treatment resulted in an objective response rate of 76% (19/25, 1 complete response, 18 partial response), and stable disease in 16% (4/25) of EGFR-mutant (exon 19 deletion or L858R) non-small cell lung cancer patients harboring EGFR T790M, who progressed on first-line EGFR TKI therapy (J Clin Oncol 36, 2018 (suppl; abstr 9053); NCT02789345).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing both EGFR L858R and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung cancer	sensitive	Cetuximab + EAI045	Preclinical	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M-mutant-driven lung cancer mouse model (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung adenocarcinoma	sensitive	Osimertinib + Selumetinib	Preclinical	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R and EGFR T790M that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	decreased response	EKI-285	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to EKI-285 (CL-387,785) in culture (PMID: 17085664).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Gedatolisib + Neratinib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) and Nerlynx (neratinib) in combination worked syngerstically to inhibit Akt phosphorylation in a human non-small cell lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 21325073).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	AV-412	Preclinical	Actionable	In a preclinical study, AV-412 inhibited EGFR signaling in a NSCLC cell line carrying the double EGFR mutant, L858R and T790M (PMID: 17888033).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung adenocarcinoma	sensitive	JNJ-61186372	Preclinical - Pdx	Actionable	In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring EGFR L858R and EGFR T790M, with response continuing up to 2 months post-treatment cessation (PMID: 27216193).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR L858R and T790M in culture (PMID: 27780853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	Ibrutinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Imbruvica (ibrutinib) inhibited Egfr activity and down stream signaling, resulting in cell cycle arrest in culture and delayed tumor progression in cell line xenograft models of non-small cell lung cancer harboring both EGFR L858R and T790M (PMID: 26375053).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung cancer	sensitive	Dasatinib + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a clinical study, EGFR T790M mutations were associated with acquired resistance to Iressa (gefitinib) in non-small cell lung cancer patients harboring EGFR L858R (PMID: 22263058).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a clinical case report, a non-small cell lung cancer patient that progressed on Iressa (gefitinib) was demonstrated to harbor EGFR L858R and a secondary EGFR T790M mutation (PMID: 15737014).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	predicted - resistant	Vandetanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Caprelsa (vandetanib) did not inhibit Egfr activation and growth of non-small cell lung cancer cells harboring EGFR L858R and T790M in culture, but delayed the emergence of resistance in cell line xenograft models compared to EGFR tyrosine kinase inhibitors (PMID: 19447865).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	lung cancer	sensitive	BKM120 + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	AZD9291 + JNJ-61186372	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) and JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R and EGFR T790M, and resulted in durable response following treatment cessation (PMID: 27216193).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	no benefit	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR with both L858R and T790M mutations in culture (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R EGFR T790M	non-small cell lung carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring both EGFR L858R and EGFR T790M mutations in culture (PMID: 26090892).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 27780853).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung cancer	sensitive	AZD3759	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring EGFR L858R in culture, and inhibited tumor growth in xenograft models (PMID: 27928026).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung cancer	sensitive	AZD3759	Clinical Study	Actionable	In two clinical case studies, treatment with AZD3759 inhibited EGFR activity and demonstrated antitumor activity in patients harboring EGFR L858R, resulting in decreased CSF tumor cell number in the patient with leptomeningeal metastasis, and decreased brain tumor growth in the patient with brain metastasis (PMID: 27928026).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a clinical study, a network meta-analysis of 12 Phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including Iressa (gefitinib), were superior to standard chemotherapy (PMID: 24533047).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Gefitinib	FDA approved	Actionable	In a Phase III trial that supported FDA approval, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) compared to 47.3% (61/129) with Paraplatin (carboplatin) plus Taxol (paclitaxel) and prolonged progression-free survival (HR=0.48) in non-small cell lung cancer patients harboring EGFR activating mutations, including EGFR L858R (PMID: 19692680, NCT00322452).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefitinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Icotinib	Phase III	Actionable	In a meta-analysis of 12 phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	no benefit	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Afatinib	FDA approved	Actionable	In a Phase III trial supporting FDA approval (LUX-Lung 3), Gilotrif (afatinib) treatment resulted in improved median progression-free survival compared to chemotherapy (HR=0.73) in non-small cell lung carcinoma patients harboring EGFR L858R (PMID: 23816960; NCT00949650).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line, but not subsequent therapy for metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months) and time-to-treatment failure (13.7 vs 11.5 months) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, treatment with AZD9291 resulted in a response rate of 11% (2/19) in NSCLC patients harboring EGFR L858R without EGFR T790M (PMID: 25923549).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as first-line therapy for locally advanced or metastatic non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Osimertinib	FDA approved	Actionable	In a Phase III (FLAURA) trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in a longer median progression-free survival compared to treatment with either Tarceva (erlotinib) or Iressa (gefitinib) (18.9 mo vs 10.2 mo) in non-small cell lung carcinoma patients harboring either EGFR L858R or EGFR exon 19 deletion (PMID: 29151359; NCT02296125).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	no benefit	Alectinib	Guideline	Actionable	Alecensa (alectinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Erlotinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 9.2 months for patients harboring EGFR L858R (PMID: 26720423).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Erlotinib	FDA approved	Actionable	In a Phase III trial (EURTAC) that supported FDA approval, treatment with Tarceva (erlotinib) resulted in improved progression-free survival compared to treatment with platinum-based chemotherapy in non-small cell lung cancer patients harboring EGFR L858R (HR= 0.52) (PMID: 24868098).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR L858R in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and inhibited phosphorylation of downstream signaling molecules Cbl, Erk, Akt, phospholipase C gamma, Stat3, and Stat5 in EGFR L858R expressing transformed cells to a greater degree than EGFR wild-type expressing transformed cells in culture (PMID: 25573954).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EGFR L858R mutation in culture (PMID: 26090892).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of transformed human cell lines harboring EGFR L858R mutation in culture (PMID: 26090892).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In a Phase III trial, treatment with dacomitinib as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 16.5 months with dacomitnib vs. 9.2 months with Iressa (gefitinib) among patients with EGFR L858R (PMID: 28958502; NCT01777421).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	no benefit	PF3644022 + PF-477736	Preclinical - Cell culture	Actionable	In a preclinical study, neither single agent or combination of Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 inhibited growth of transformed cells over expressing EGFR L858R in culture (PMID: 26140595).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	AV-412	Preclinical	Actionable	In a preclinical study, AV-412 inhibited the kinase activity of EGFR L858R (PMID: 17888033).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR L858R in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Ibrutinib	Preclinical - Cell culture	Actionable	In a preclinical study, Imbruvica (ibrutinib) inhibited Egfr activity and down stream signaling, resulting in cell cycle arrest in non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 26375053).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Egfr activation, resulting in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 19447865).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung adenocarcinoma	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited tumor growth in mouse lung adenocarcinoma models expressing EGFR L858R (PMID: 24063894).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung adenocarcinoma	sensitive	CO1686	Preclinical	Actionable	In a preclinical study, CO-1686 demonstrated efficacy in treating transgenic mouse models of lung adenocarcinoma expressing EGFR L858R (PMID: 24065731).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR L858R in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung cancer	sensitive	Osimertinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung cancer	sensitive	BKM120 + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	sensitive	Nazartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGF816 inhibited tumor growth and induced tumor regression in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R (Cancer Res 2014;74(19 Suppl):Abstract nr 1733).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung adenocarcinoma	sensitive	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment resulted in the least tumor recurrence after treatment cessation, and delayed development of treatment resistance compared to single drug treatment in animal models of EGFR L858R-induced lung adenocarcinoma (PMID: 26341921).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iressa (gefitinib) inhibited Egfr phosphorylation and inhibited phosphorylation of downstream signaling molecules Cbl, Erk, Akt, phospholipase C gamma, and Stat5 in EGFR L858R expressing transformed cells to a greater degree than EGFR wild-type expressing transformed cells in culture (PMID: 25573954).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	no benefit	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 27251290).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR L858R in culture (PMID: 29467275).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	lung adenocarcinoma	sensitive	Osimertinib + Selumetinib	Preclinical	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	Advanced Solid Tumor	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR L858R in culture (PMID: 26208524).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L858R	non-small cell lung carcinoma	no benefit	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	ALK amp EML4-ALK EGFR L858R	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK partially responded to Xalkori (crizotinib) therapy, but progressed after four months, and was found to have acquired ALK amplification and EGFR L858R (PMID: 23344087).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P596L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P596L were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P596L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P596L were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P596L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P596L were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A750V	non-small cell lung carcinoma	no benefit	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR A750V mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R108K	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) treatment resulted in decreased cell viability in transformed cells expressing EGFR R108K  in culture and led to tumor growth inhibition in mouse models (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R108K	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R108K were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R108K	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR R108K in culture (PMID: 17177598).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR R108K	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R108K were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D761_E762insEAFQ	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D761_E762insEAFQ were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D761_E762insEAFQ	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D761_E762insEAFQ were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR D761_E762insEAFQ	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  D761_E762insEAFQ were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_T751delinsV	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_T751delinsV were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_T751delinsV	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_T751delinsV were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_T751delinsV	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_T751delinsV were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_T751delinsV	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_T751delinsV were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_T751delinsV	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_T751delinsV were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709K	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709K were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709K	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709K	Advanced Solid Tumor	decreased response	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709K	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709K	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709K	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709K	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E709K	Advanced Solid Tumor	decreased response	CO1686	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G696_P1033dup	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing the kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G696_P1033dup	lung adenocarcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a clinical study, a patient with EGFR G696_P1033dup expressing lung adenocarcinoma had a partial response after two cycles of Gilotrif (afatinib) after failing first line chemotherapy (PMID: 26286086).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G696_P1033dup	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G696_P1033dup	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	INC280 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp FGFR2 amp	head and neck squamous cell carcinoma	sensitive	AZD4547 + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp FGFR2 amp	head and neck squamous cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp FGFR1 amp	head and neck squamous cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp FGFR1 amp	head and neck squamous cell carcinoma	sensitive	AZD4547 + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp FGFR1 over exp	esophageal cancer	sensitive	AZD4547	Preclinical - Pdx	Actionable	In a preclinical study, AZD4547 treatment resulted in tumor regression in patient-derived xenograft (PDX) models, with both Egfr and Fgfr1 overexpression (PMID: 28881608),
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp FGFR1 over exp	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment demonstrated decreased efficcacy in patient-derived xenograft (PDX) models of esophageal cancer with both Egfr and Fgfr1 overexpression compared to models with only Egfr overexpression (PMID: 28881608).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp KRAS wild-type	pancreatic adenocarcinoma	sensitive	Afatinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gilotrif (afatinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp KRAS wild-type	pancreatic adenocarcinoma	sensitive	Trametinib + Triciribine	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Triciribine (API-2) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp	squamous cell carcinoma	sensitive	TAK-285	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAK-285 inhibited growth of squamous cell carcinoma cells harboring EGFR over expression in culture and in cell line xenograft models (PMID: 23983820).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp	lung squamous cell carcinoma	sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 demonstrated cytoxicity against a lung squamous cell carcinoma cell line with EGFR over expression in culture and induced tumor regression in EGFR over expressing lung squamous cell carcinoma cell line xenograft models (PMID: 26846818).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp	lung cancer	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of Egfr over expressing lung cancer cells in culture (PMID: 26208524).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp	squamous cell carcinoma	sensitive	BGB-283	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGB-283 inhibited Egfr phosphorylation in Egfr over expressing squamous cell carcinoma cells in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26208524).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment resulted in significant tumor growth inhibition in patient-derived xenograft (PDX) models of esophageal cancer with Egfr overexpression (PMID: 28881608)
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp	Advanced Solid Tumor	predicted - sensitive	Depatuxizumab mafodotin	Phase Ib/II	Actionable	In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in 1.8% (1/56) and stable disease in 23% (13/56) of patients with advanced solid tumor harboring EGFR amplification, overexpression, or mutated EGFR variant III (PMID: 29533458; NCT01741727).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp	squamous cell carcinoma	sensitive	GA201	Preclinical	Actionable	In a preclinical study, treatment with GA201 resulted in inhibition of EGFR signaling and induced antibody-dependent cell-mediated cytotoxicity towards EGFR-over expressing squamous cell carcinoma cells in culture (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR over exp	colorectal cancer	sensitive	EBI-907	Preclinical - Cell culture	Actionable	In a preclinical study, EBI-907 inhibited growth of colorectal cancer cells harboring BRAF V600E and EGFR overexpression in culture (PMID: 26810733).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	BRAF V600E EGFR over exp	colorectal cancer	resistant	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp PIK3CA E542K	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment demonstrated decreased efficcacy in patient-derived xenograft (PDX) models of esophageal cancer with Egfr overexpression and PIK3CA E542K compared to models with only Egfr overexpression (PMID: 28881608).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp ERBB2 dec exp	inflammatory breast carcinoma	sensitive	Sapitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR over exp ERBB2 dec exp	inflammatory breast carcinoma	sensitive	Sapitinib + Paclitaxel	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_S752del	lung adenocarcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del had a partial response to Iressa (gefitinib) therapy (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_S752del EGFR T790M	lung adenocarcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del and EGFR T790M was found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L747_S752del EGFR T790M	lung adenocarcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del that developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L844V	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L844V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR L844V	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	non-small cell lung carcinoma	sensitive	Afatinib	FDA approved	Actionable	In a post-hoc analysis of Phase II and Phase III trials that supported FDA approval (LUX-Lung 2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in partial response in 100% (8/8) of non-small cell lung cancer patients harboring EGFR S768I (alone or in combination with EGFR L719X or L858R), with a mean progression-free survival of 14.7 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	non-small cell lung carcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR S768I (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	non-small cell lung carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR S768I (PMID: 29686424; NCT03066206).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I had decreased sensitivity to Tarceva (erlotinib) in cell culture (PMID: 19147750).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	Advanced Solid Tumor	decreased response	Erlotinib	Clinical Study	Actionable	In a retrospective clinical study, non-small lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (PMID: 27468240).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	non-small cell lung carcinoma	decreased response	Gefitinib	Clinical Study	Actionable	In a retrospective clinical study, non-small lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions  (PMID: 27468240).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR S768I demonstrated a response rate of 25% and disease control rate of 80%, and a median progression-free survival of 3.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR S768I	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective clinical study, non-small cell lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or icotinib, compared to 10.8 months in patients with EGFR L858R  and EGFR exon 19 deletions (PMID: 27468240).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR P772_H773insDNP	non-small cell lung carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR P772_H773insDNP (PMID: 29686424; NCT03066206).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_P753delinsVS were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_P753delinsVS were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_P753delinsVS	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_P753delinsVS were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_P753delinsVS were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_P753delinsVS were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR  E746_P753delinsVS were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions demonstrated a response rate of 11.11%  and disease control rate of 44.44%, and a median progression-free survival of 1.9 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or icotinib compared to patients with EGFR L858R or exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	sensitive	AUY922	Phase II	Actionable	In a Phase II trial, AUY922 demonstrated safety and preliminary efficacy in EGFR TKI-resistant non-small cell lung cancer patients harboring EGFR exon 20 insertions, with 10% (1/10) of patients achieving partial response and 30% of (3/10) patients achieving stable disease, and a median progression-free survival of 6.1 months (J Clin Oncol 33, 2015 (suppl; abstr 8015)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective clinical study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib compared to patients with EGFR L858R and exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in an overall response rate of 73% (8/11) in non-small cell lung carcinoma patients harboring EGFR exon 20 insertions (PMID: 29162564).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	predicted - resistant	Erlotinib	Clinical Study	Actionable	In a retrospective clinical study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib compared to patients with EGFR L858R and exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	predicted - resistant	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, cells expressing an EGFR exon 20 insertion mutation were resistant to AZD9291 in culture (PMID: 24893891).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	Advanced Solid Tumor	resistant	CO1686	Preclinical	Actionable	In a preclinical study, cells expressing an EGFR exon 20 insertion demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 24065731).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	Advanced Solid Tumor	predicted - sensitive	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, EGF816 inhibited growth of transformed cell lines expressing three different EGFR exon 20 insertions in culture (PMID: 26825170).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR exon 20 insertion mutation had decreased response to Dacomitinib compared to other EGFR activating mutations, with inhibitory doses exceeding clinically attainable levels (PMID: 18089823, PMID: 21764376).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	lung cancer	predicted - sensitive	Tarloxotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR exon 20 insertions in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	resistant	Afatinib	Phase II	Actionable	In a post-hoc analysis of Phase II and Phase III trials (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective response rate of 8.7% (2/23) in non-small cell lung cancer patients harboring EGFR exon 20 insertions, with a mean progression-free survival of 2.7 months, and an overall survival of 9.2 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR exon 20 ins	non-small cell lung carcinoma	resistant	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (1/3), stable disease in 33% (1/3), and progressive disease in 337% (1/3) in non-small cell lung carcinoma patients carrying an EGFR exon 20 insertion mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G598V	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G598V were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G598V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G598V were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G598V	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G598V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR G598V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G598V were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insH	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773_V774insH were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insH	non-small cell lung carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions, including EGFR H773_V774insH, demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insH	non-small cell lung carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773_V774insH, displayed progressive disease following treatment with Iressa (gefitinib) (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insH	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773_V774insH were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insH	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773_V774insH were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR H773_V774insH	non-small cell lung carcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773_V774insH, displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E868G	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR E868G in culture (PMID: 20942962).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M MET amp	non-small cell lung carcinoma	resistant	CO1686	Clinical Study	Actionable	In an analysis of EGFR T790M-positive non-small cell lung cancer patients, emergence of MET amplification was identified in 26% (28/43) of patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M MET amp	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M MET amp	lung adenocarcinoma	resistant	CO1686	Preclinical	Actionable	In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M ERBB2 over exp	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M ERBB2 over exp	lung adenocarcinoma	resistant	CO1686	Preclinical	Actionable	In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	CO1686	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in a response rate of 59% (27/46) and a disease control rate of 93% (43/46) in non-small cell lung cancer patients harboring EGFR T790M (PMID: 25923550).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	CO1686	Phase I	Actionable	In a Phase I trial, CO-1686 has demonstrated safety and efficacy in NSCLC patients carrying EGFR T790M mutations (J Clin Oncol 31, 2013 (suppl; abstr 2524)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	predicted - resistant	Afatinib	Clinical Study	Actionable	In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 15% (4/27), stable disease in 56% (15/27), and progressive disease in 30% (8/27) of non-small cell lung carcinoma patients carrying an EGFR T790M mutation (PMID: 26354527).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	predicted - resistant	Afatinib	Phase II	Actionable	In a post-hoc analysis of Phase II and Phase III trials (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective response rate of 14.3% (2/14) in non-small cell lung cancer patients harboring EGFR T790M, with a mean progression-free survival of 2.9 months, and an overall survival of 14.9 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Avitinib maleate	Clinical Study	Actionable	In a clinical study, two patients with non-small cell lung cancer harboring EGFR T790M demonstrated tumor reductions of 31% and 36% when treated with Avitinib maleate (AC0010) (PMID: 27573423).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Avitinib maleate	Phase I	Actionable	In a Phase I trial, Avitinib maleate (AC0010) treatment resulted in decreased EGFR T790M allele frequency in cell free DNA of non-small cell lung carcinoma patients with acquired resistance to first generation Egfr tyrosine kinase inhibitor, and resulted in partial response or stable disease (PMID: 29626621).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	predicted - sensitive	Epitinib	Phase I	Actionable	In a Phase I clinical trial, HMPL-813 (Epitinib) demonstrated safety and preliminary efficacy in patients with NSCLC, including a patient with EGFR T790M (J Clin Oncol 31, 2013 (suppl; abstr e19042).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	no benefit	Brigatinib	Phase Ib/II	Actionable	In a Phase I/II trial, Alunbrig (brigatinib) treatment did not result in objective response in EGFRT790M-positive non-small cell lung cancer patients resistant to one previous EGFR tyrosine kinase inhibitor (PMID: 27836716).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Naquotinib	Phase I	Actionable	In a Phase I trial, ASP8273 treatment resulted in partial response in 38% (15/40) and stable disease in 28% (11/40) of non-small cell lung carcinoma patients harboring EGFR T790M, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	lung adenocarcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a clinical study, EGFR T790M mutations were associated with resistance to Iressa (gefitinib) in lung adenocarcinoma patients (PMID: 15737014).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	predicted - sensitive	Alflutinib	Phase I	Actionable	In a Phase I trial, Alflutinib (AST2818) treatment resulted in an objective response rate of 58.3% (7/12) and a disease control rate of 91.7% (11/12) in patents with non-small cell lung cancer harboring EGFR T790M whose disease progressed on EGFR tyrosine kinase inhibitor therapy (J Thorac Oncol. Nov 2017, Vol 12, Issue 11, Suppl. 2, pS2138).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	lung cancer	sensitive	CUDC-101	Preclinical	Actionable	In a preclinical study, CUDC-101 inhibited the growth of lung cancer cells expressing EGFR T790M (PMID: 20388807).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR T790M demonstrated a response rate of 4.76% and disease control rate of 47.62%, and a median progression-free survival of 1.6 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, AZD9291 demonstrated efficacy in 50% (9/18) of NSCLC patients carrying EGFR T790M mutations (PMID: 24410791).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Phase II	Actionable	In Phase II clinical trials (AURA extension and AURA2), Tagrisso (osimertinib) treatment resulted in a central nervous system (CNS) overall response rate of 54% (24/50), including 6 complete responses, and a CNS disease control rate of 92% (46/50) in non-small cell lung cancer patients with CNS metatstases harboring EGFR T790M (PMID: 29293889; NCT01802632, NCT02094261).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Phase III	Actionable	In a Phase III trial (AURA3), treatment with Tagrisso (osimertinib) resulted in an improved median progression-free survival of 10.1 months vs. 4.4 months with platinum plus pemetrexed, and an objective response rate of 71% (95% CI, 65 to 76) compared to 31% (95% CI, 24 to 40) with platinum plus pemetrexed therapy in patients with EGFR T790M-positive non-small cell lung cancer (PMID: 27959700; NCT02151981).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as subsequent therapy in patients with EGFR T790M-positive, metastatic non-small cell lung cancer who have progressed on Tarceva (erlotinib), Iressa (gefitinib), or Gilotrif (afatinib), and in patients who have progression with symptomatic brain metastases (NCCN.org).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	FDA approved	Actionable	In a Phase I extension trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in in an objective response rate of 58% (115/119) and disease control rate of 92%  in patients with EGFR-TKI resistant non-small cell lung cancer harboring EGFR T790M mutations (World Conf on Lung Cancer 2015. Abst MINI16.06).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, AZD9291 treatment resulted in an objective response rate of 61% (78/127) and a disease control rate of 95% (121/127) in NSCLC patients harboring EGFR T790M mutations (PMID: 25923549).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a clinical study, 83% (5/6) of non-small cell lung cancer patients that had progressed on prior treatment with Iressa (gefinitib) with secondary EGFR T790M mutations had progressive disease as best response to treatment with Tarceva (erlotinib) (PMID: 18981003).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	lung adenocarcinoma	resistant	Afatinib	Clinical Study	Actionable	In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib) (PMID: 26862733).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	Advanced Solid Tumor	sensitive	AV-412	Preclinical	Actionable	In a preclinical study, AV-412 inhibited the kinase activity of EGFR T790M (PMID: 17888033).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Selumetinib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of Iressa (gefitinib)-resistant NSCLC cells harboring EGFR T790M in culture and in cell line xenograft models (PMID: 24939055).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Amlexanox + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations, including EGFR T790M, demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	Nazartinib	Phase I	Actionable	In a Phase I study, EGF816 treatment resulted in an objective response rate of 44% (56/127), disease control rate of 91% (115/127), and an estimated progression-free survival of 9.2 months in non-small cell lung carcinoma patients harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9044); NCT02108964).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR T790M	non-small cell lung carcinoma	sensitive	HM61713	Phase II	Actionable	In a Phase II trial, BI 1482694 (HM61713) treatment resulted in a disease control rate of 90% (64/71), and objective response with a median duration of 8.3 months in 56% (40/71) of patients with EGFR tyrosine kinase inhibitor-resistant non-small cell lung carcinoma harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9055)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289T	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289T were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289T	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289T were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A289T	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289T were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767V were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767V were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A767V	Advanced Solid Tumor	resistant	CO1686	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos KRAS wild-type	colorectal cancer	sensitive	Cetuximab + FOLFIRI	Phase III	Actionable	In a Phase III trial that supported FDA approval, the combination of Erbitux (cetuximab) and FOLFIRI resulted in a greater tumor response rate in EGFR positive, KRAS wild-type colorectal cancer patients (59% (102/172)) compared to EGFR positive, KRAS mutant colorectal cancer patients (36.2% (38/105)) (PMID: 19339720; NCT00154102).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos ERBB2 pos	lung cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos ERBB2 pos	urinary bladder cancer	predicted - sensitive	Afatinib + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos ERBB2 pos	colon cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos ERBB2 pos	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos ERBB2 pos	stomach cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos ERBB2 pos	breast cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	Advanced Solid Tumor	predicted - sensitive	AVID100	Preclinical - Cell culture	Actionable	In a preclinical study, AVID100 demonstrated activity against several EGFR-positive tumor cell lines in culture (Eur J Cancer, Dec 2016, Vol 69, S147).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	colorectal cancer	sensitive	SYM004	Phase I	Actionable	In a Phase I study, 13% (5/39) of patients with metastatic colorectal cancer resistant to EGFR therapy had a partial response to SYM004 while 44% (17/39) demonstrated tumor regression (PMID: 25962717).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	Advanced Solid Tumor	sensitive	AFM24	Preclinical - Cell culture	Actionable	In a preclinical study, tumor cell lines expressing EGFR  demonstrated efficacy in culture when treated with the bispecific antibody, AFM24 (J Clin Oncol 35, 2017 (suppl; abstr e14001)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	kidney cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited tumor growth of human kidney cancer cells expressing EGFR in cell line xenograft models (PMID: 24837299).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	Advanced Solid Tumor	predicted - sensitive	ABBV-221	Phase I	Actionable	In a Phase I trial, ABBV-221 demonstrated safety and preliminary efficacy, resulting in stable disease in 38% (16/42) of patients with EGFR-dependent solid tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510; NCT02365662).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	non-small cell lung carcinoma	no benefit	Erlotinib	Phase III	Actionable	In a Phase III trial, no difference in disease free survival was observed in non-small cell lung cancer patients positive for Egfr treated with Tarceva (erlotinib) vs placebo in the adjuvant setting (PMID: 26324372).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	non-small cell lung carcinoma	predicted - sensitive	SYM004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYM004 demonstrated efficacy in cell line xenograft models of Erbitux (cetuximab)-resistant non-small cell lung cancer (PMID: 24204198).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	Advanced Solid Tumor	predicted - sensitive	AC480	Phase I	Actionable	In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	Advanced Solid Tumor	predicted - sensitive	S-222611	Phase I	Actionable	In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	Advanced Solid Tumor	sensitive	EGFRBi-armed autologous activated T cells	Preclinical - Cell culture	Actionable	In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells of a variety of EGFR positive tumor types (PMID: 16397041).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	head and neck cancer	predicted - sensitive	ABBV-221	Phase I	Actionable	In a Phase I trial, ABBV-221 demonstrated safety and preliminary efficacy, resulting in unconfirmed partial response in a patient with head and neck cancer that expressed high level of Egfr and its ligand (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510; NCT02365662).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	pancreatic adenocarcinoma	sensitive	EGFRBi-armed autologous activated T cells	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells and cell line mouse xenograft models of a variety of EGFR positive tumor types including pancreatic adenocarcinoma (PMID: 16397041).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	colorectal cancer	predicted - sensitive	GC1118	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GC1118 inhibited EGFR ligand binding and reduced ligand-induced downstream signaling and proliferation of colorectal cancer cell lines exposed to a variety of EGFR ligands in culture, and inhibited tumor growth in colorectal cancer cell line xenograft models expressing high-affinity EGFR ligands (PMID: 26586721).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	Advanced Solid Tumor	no benefit	Pelitinib	Phase I	Actionable	In a Phase I study, patients with advanced solid tumors that were positive for EGFR expression demonstrated no complete or partial responses when treated with Pelitinib (EKB-569) (PMID: 16710023).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib demonstrated efficacy associated with Egfr expression level in patient-derived xenograft (PDX) models, with highest anti-tumor activity in models harboring both EGFR amplification and overexpression, and low to moderate efficacy in models with low or medium Egfr expression (PMID: 28881608),
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	non-small cell lung carcinoma	predicted - sensitive	SYM004 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYM004 enhanced sensitivity to radiation therapy in non-small cell lung cancer cells in culture and in cell line xenografts (PMID: 24130052).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	non-small cell lung carcinoma	sensitive	ABBV-221	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGFR-positive non-small cell lung carcinoma cell line xenograft models were sensitive to ABBV-221 treatment, demonstrating tumor regression (PMID: 29483208).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	biliary tract cancer	predicted - sensitive	anti-EGFR CAR T	Phase I	Actionable	In a Phase I trial, treatment with EGFR-specific CAR T cells demonstrated safety and preliminary efficacy, resulted in complete response in 6% (1/17) and stable disease in 59% (10/17) of patients with Egfr-positive biliary tract cancer (PMID: 29138340; NCT01869166).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	stomach cancer	predicted - sensitive	Irinotecan + Nimotuzumab	Phase II	Actionable	In a Phase II trial, addition of Nimotuzumab to Camptosar (irinotecan) improved median progression-free survival (118.5 vs 59.0 days), median overall survival (358.5 vs 229.5 days) and response rate (33.3% vs 0.0 %) compared to Camptosar alone in EGFR positive gastric cancer patients (PMID: 25185971).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR positive	colorectal cancer	predicted - sensitive	MM-151	Phase I	Actionable	In a Phase I clinical trial in patients with advanced solid tumors, MM-151 demonstrated safety and preliminary antitumor activity in patients with colorectal cancer (CRC), with 2 partial responses and 30% (8/26) of CRC patients demonstrating stable disease for greater than 4 months (J Clin Oncol 32:5s, 2014 (suppl; abstr 2518)).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos KRAS mut	renal cell carcinoma	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos KRAS mut	pancreatic cancer	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR pos KRAS mut	triple-receptor negative breast cancer	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 resulted in increased tumor growth inhibition in EGFR-positive triple-negative breast cancer cell line xenograft models harboring KRAS mutations when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR loss KRAS G12S	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGFR-deficient lung adenocarcinoma cells harboring KRAS G12S were sensitive to treatment with Gilotrif (afatinib), demonstrating decreased cell proliferation and inhibition of Erbb2 (Her2) and Erbb3 (Her3) in culture, and blocked tumor growth in cell line xenograft models (PMID: 29925635).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR loss KRAS G12S	lung adenocarcinoma	no benefit	Gefitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGFR-deficient lung adenocarcinoma cells harboring KRAS G12S did not respond to treatment with Iressa (gefitinib) in culture and in cell line xenograft models (PMID: 29925635).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A216T	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Iressa (gefitinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A216T	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A216T	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A216T	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR A216T	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_S752delinsV	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EGFR	ERBB | ERBB1 | HER1 | mENA | NISBD2 | PIG61	7p11.2	NM_005228	EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	resistant	AUY922	Clinical Study	Actionable	In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing ALK C1156Y in the context of EML4-ALK demonstrated minimal sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	conflicting	Ceritinib	Clinical Study	Actionable	In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	conflicting	Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	non-small cell lung carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK E1210K ALK S1206C	non-small cell lung carcinoma	resistant	Brigatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK E1210K eventually progressed on treatment with Alunbrig (brigatinib) and was subsequently found to have acquired another resistance mutation, ALK S1206C (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151M	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A ALK I1171N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171N was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198P	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 21948233).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198P	Advanced Solid Tumor	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK EGFR amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, EGFR amplification (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK HRAS amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, HRAS amplification (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171T was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture  (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK S1206Y	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, an ALK S1206Y secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK E1210K	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EML4-ALK progressed on treatment with Xalkori (crizotinib) and was subsequently found to harbor a secondary resistance mutation, ALK E1210K (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK E1210K	Advanced Solid Tumor	conflicting	Crizotinib	Clinical Study	Actionable	In a clinical case study, a lung cancer patient harboring EML4-ALK demonstrated progression when treated with Xalkori (crizotinib) due to the secondary acquired resistance mutation, ALK E1210K, however, in vitro transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK F1174V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A ALK L1196M	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response when treated with Xalkori (crizotinib), however, after 6 months the patient progressed and was found to harbor two secondary resistance mutations, ALK G1269A and ALK L1196M (PMID: 23344087).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A ALK L1196M	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK G1269A was identified as a compound mutation in transformed cells expressing ALK F1174C in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing ALK V1180L  in the context of EML4-ALK in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK V1180L	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK V1180L	non-small cell lung carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring ALK V1180L  in the context of EML4-ALK was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK V1180L	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK V1180L	non-small cell lung carcinoma	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK SRC pos	lung cancer	sensitive	Ropotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK SRC pos	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Zykadia (ceritinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK SRC pos	lung cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK NOTCH1 D1538A	non-small cell lung carcinoma	predicted - resistant	Brigatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated resistance to treatment with Alunbrig (brigatinib), and was subsequently found to have acquired NOTCH1 D1538A (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK F1174I	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174I was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK G1269A was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity in culture (PMID: 26939704).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	non-small cell lung carcinoma	sensitive	Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	non-small cell lung carcinoma	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of non-small cell lung cancer cells expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 21502504).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ropotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were insensitive to Xalkori (crizotinib) as demonstrated by a lack of growth inhibition and Alk phosphorylation in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in cell line xenograft models (PMID: 21575866).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response with Xalkori (crizotinib) treatment, but after eight months showed progression, and was found to harbor a secondary resistance mutation, ALK I1171T (PMID: 25393798).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing ALK I1171T in the context of EML4-ALK but to a lesser degree than cells expressing EML4-ALK in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534), however, another study with comparable cells demonstrated sensitivity in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171T	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK I1171S	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171S was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK FGFR1 amp	non-small cell lung carcinoma	predicted - resistant	Brigatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Alunbrig (brigatinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, FGFR1 amplification (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK D1203N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK D1203N was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1152P	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1152P	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1152P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L ALK L1198V	non-small cell lung carcinoma	resistant	Brigatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK progressed while being treated with Alunbrig (brigatinib) and was subsequently found to harbor two resistance mutations, ALK F1174L and ALK L1198V, which were both in cis (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1152R	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a response to Xalkori (crizotinib) treatment, but after 3 months showed tumor progression, and was found to harbor the secondary resistance mutation, ALK L1152R (PMID: 21791641).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture  (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1152R	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	ALK amp EML4-ALK EGFR L858R	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK partially responded to Xalkori (crizotinib) therapy, but progressed after four months, and was found to have acquired ALK amplification and EGFR L858R (PMID: 23344087).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK F1174V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK KRAS G12C	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK and KRAS G12C demonstrated a minimal response when treated with Xalkori (crizotinib), and eventually progressed (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK L1256F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1198F	non-small cell lung carcinoma	resistant	Lorlatinib	Phase I	Actionable	In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1198F	non-small cell lung carcinoma	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK C1156Y and ALK L1198F in the context of EML4-ALK were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK F1174C	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174V ALK G1202R	non-small cell lung carcinoma	sensitive	Ceritinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who was previously treated with Xalkori (crizotinib) and subsequently developed the resistance mutation, ALK G1269A, was treated with Zykadia (ceritinib), later progressed, and was found to have lost ALK G1269A, but gained ALK F1174V and ALK G1202R (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK F1174L	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174L was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171T was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alunbrig (brigatinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202del	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated moderate resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202del	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1256F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK F1174C	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK I1179V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1179V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK G1202R	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1202R in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK NOTCH1 D1533A	non-small cell lung carcinoma	predicted - resistant	Ceritinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated resistance to treatment with Zykadia (ceritinib), and was subsequently found to have acquired NOTCH1 D1533A (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, introduction of an additional ALK mutation L1198F in transformed cells expressing ALK L1196M in the context of EML4-ALK reduced resistance to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1245C	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1245C	non-small cell lung carcinoma	sensitive	Ceritinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N	Advanced Solid Tumor	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK D1203N in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C demonstrated decreased sensitivity to Alecensa (alectinib) in culture compared to cells expressing EML4-ALK with wild-type ALK (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C	non-small cell lung carcinoma	resistant	Ceritinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who developed resistance to Xalkori (crizotinib) treatment was subsequently treated with Zykadia (ceritinib), eventually progressed, and was found to have acquired ALK F1174C (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174C	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK GNAS amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, GNAS amplification (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture  (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L	Advanced Solid Tumor	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L	Advanced Solid Tumor	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib)-mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were re-sensitized and became modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171S	non-small cell lung carcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib) but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171S	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859), however, another study with comparable cells demonstrated sensitivity (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171S	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171S	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859), however, in another study comparable cells demonstrated sensitivity (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK S1206F	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	decreased response	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture compared to cells expressing wild-type EML4-ALK (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174V ALK I1171S	non-small cell lung carcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK F1174V initially responded to Alecensa (alectinib), but then demonstrated progression in one of two lung nodules, which was found to harbor a secondary resistance mutation, ALK I1171S, and upon resection of the nodule the patient continued Alecensa (alectinib) treatment and achieved complete remission (PMID: 26464158).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1196M	lung adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EML4-ALK achieved a partial response when treated with Xalkori (crizotinib), however, after 5 months, the patient progressed and was found to harbor secondary resistance mutations, ALK C1156Y and ALK L1196M (PMID: 20979473).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK C1156Y ALK L1196M	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F	Advanced Solid Tumor	decreased response	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing L1198F in the context of EML4-ALK in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expression EML4-ALK with ALK G1269A in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated stable disease when treated with Xalkori (crizotinib), but then progressed, and was found to harbor a secondary resistance mutation, ALK G1269A (PMID: 22235099).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	non-small cell lung carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines expressing ALK G1269A in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In preclinical studies, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited  growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22235099).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK in the context of EML4-ALK were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	non-small cell lung carcinoma	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer  cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in cell line xenograft models (PMID: 26849637, PMID: 23344087).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	non-small cell lung carcinoma	sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	non-small cell lung carcinoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	decreased response	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) compared to cells expressing wild-type EML4-ALK (PMID: 26939704).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK KRAS G13D	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK eventually progressed while on treatment with Xalkori (crizotinib) and was subsequently found to harbor a presumed resistance mutation, KRAS G13D (PMID: 29636358).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	neuroblastoma	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells harboring EML4-ALK in culture (PMID: 26554404).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited Alk phosphorylation and growth in non-small cell lung cancer cell lines harboring EML4-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, non-small cell lung carcinoma patients harboring an EML4-ALK fusion, in which exon 13 of EML4 is fused to exon 20 of ALK, demonstrated a significantly longer PFS compared to patients with an EML4-ALK fusion that includes either exon 20 or exon 6a/6b fused to ALK, when treated with Xalkori (crizotinib) (PMID: 27354483).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Crizotinib	Phase I	Actionable	In a Phase I trial, Xalkori (crizotinib) inhibited tumor growth by at least 30% from baseline in 90% (18/20) of patients with EML4-ALK positive non-small cell lung carcinoma (PMID: 20979469; NCT00585195; NCT00585195).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	lung cancer	sensitive	X-376	Preclinical - Cell line xenograft	Actionable	In a preclinical study, X-376 inhibited Alk signaling, resulted in growth inhibition in lung cancer cells harboring EML4-ALK fusion in culture and in cell line xenograft models (PMID: 21613408).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Entrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation and complete tumor regression in cell line xenograft models (PMID: 26939704).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Afatinib + Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination of Gilotrif (afatinib) and Alecensa (alectinib) restored sensitivity to Alecensa (alectinib) in non-small cell lung cancer cells harboring EML4-ALK fusion that acquired resistance to Alecensa (alectinib) through up-regulating Egfr signaling in culture, inhibited tumor progression in cell line xenograft models (PMID: 26682573).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited phosphorylation of Alk and inhibited growth of human non-small cell lung cancer cell lines harboring EML4-ALK in culture (PMID: 25173427).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EML4-ALK fusion in culture (PMID: 26090892).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells harboring EML4-ALK fusion, and reduced intracranial tumor size in cell line xenograft models (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	inflammatory myofibroblastic tumor	predicted - sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in complete remission in a patient with inflammatory myofibroblastic tumor harboring EML4-ALK three years after starting treatment (PMID: 26808369).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited Alk phosphorylation and growth of a human non-small cell lung cancer cell line harboring EML4-ALK in culture and in cell line xenograft models (PMID: 21575866).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	CEP-28122	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CEP-28122 inhibited growth of non-small cell lung carcinoma cell lines harboring EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 22203728).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	sensitive	Sirolimus + X-396	Preclinical	Actionable	In a preclinical study, transformed non-small cell lung cancer cells harboring EML4-ALK demonstrated enhanced growth inhibition to a combination treatment with Afinitor (sirolimus) and Ensartinib (X-396) (PMID: 21613408).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	non-small cell lung carcinoma	predicted - sensitive	Crizotinib + GLPG0634	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK in culture that had, over time, acquired resistance to Xalkori (crizotinib) showed decreased drug resistance when treatment was combined with Filgotinib (GLPG0634), demonstrating reduced expression of Osmr and phosphorylated-Stat3, and decreased cell viability (PMID: 28729401).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK	neuroblastoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing EML4-ALK in culture (PMID: 26554404).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151dup	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151dup	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK T1151dup	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	non-small cell lung carcinoma	resistant	Ceritinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who acquired the secondary drug resistance mutation, ALK S1206Y, when treated with Xalkori (crizotinib) was subsequently treated with Zykadia (ceritinib), developed drug resistance, and was then found to have lost the ALK S1206Y mutation, but gained ALK G1202R (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	non-small cell lung carcinoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, an ALK G1202R secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	non-small cell lung carcinoma	predicted - resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK, who had developed resistance to Xalkori (crizotinib), was found to harbor ALK G1202R following treatment with Alecensa (alectinib) (PMID: 24736079).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Ropotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor regression in cell line xenograft models (European Journal of Cancer , Volume 69, S32).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	lung cancer	conflicting	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK G1202R	lung cancer	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171N	non-small cell lung carcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated tumor regression when treated with Alecensa (alectinib), but progressed seven months later, and was found to harbor a secondary resistance mutation, ALK I1171N (PMID: 25393798).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK I1171N	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174V	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174V	non-small cell lung carcinoma	sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK initially responded to Xalkori (crizotinib), but then progressed due to acquisition of the secondary resistance mutation, ALK F1174V, and then responded to treatment with Alecensa (alectinib), demonstrating a complete response in one lung nodule and a 44% decrease in size in a second lung nodule (PMID: 26464158).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174V	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response to Xalkori (crizotinib) treatment after 3 months, but then progressed, and was found to harbor the secondary resistance mutation, ALK F1174V (PMID: 24736079).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK R1192P	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells overexpressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK R1192P	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).
EML4	C2orf2 | ELP120 | EMAP-4 | EMAPL4 | ROPP120	2p21	NM_019063	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_S779insCPG	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) G778_S779insCPG in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L768S	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L768S	breast cancer	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L768S	breast cancer	sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776_V777insVGC	non-small cell lung carcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 1 patient and progressive disease in 2 patients with non-small cell lung cancer harboring ERBB2 (HER2) G776_V777insVGC (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 exon 20 ins	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1, partial response in 1, and stable disease in 3 of the 5 patients with Erbb2 (Her2)-receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) exon 20 insertion mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 exon 20 ins	non-small cell lung carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 exon 20 ins	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 exon 20 ins	non-small cell lung carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 10 and progressive disease in 5 of the 15 patients with non-small cell lung cancer harboring ERBB2 (HER2) exon 20 insertion mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 exon 20 ins	non-small cell lung carcinoma	predicted - sensitive	Trastuzumab	Clinical Study	Actionable	In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 exon 20 ins	lung adenocarcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a clinical study, treatment with pulse Gilotrif (afatinib) resulted in an objective response rate of 33.3% (1/3) in lung adenocarcinoma patients with ERBB2 (HER2) exon 20 insertion mutations (PMID: 26964772).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V773L	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Nerlynx (nerlatinib) in culture, resulting in decreased colony formation (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V773L	breast cancer	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V773L	breast cancer	sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsVC	non-small cell lung carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of a non-small cell lung cancer (NSCLC) cell line harboring ERBB2 (HER2) G776delinsVC in culture and inhibited tumor growth in NSCLC cell line xenografts carrying ERBB2 (HER2) G776delinsVC (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsVC	non-small cell lung carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 8.5 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) G776delinsVC (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsVC	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsVC	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring ERBB2 (HER2) G776delinsVC demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsVC	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsVC	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 29686424).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR over exp ERBB2 dec exp	inflammatory breast carcinoma	sensitive	Sapitinib + Paclitaxel	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR over exp ERBB2 dec exp	inflammatory breast carcinoma	sensitive	Sapitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	CDH1 R63* ERBB2 L869Q	breast cancer	sensitive	Lapatinib + Capecitabine	Clinical Study	Actionable	In a clinical case study, treatment with the combination of  Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S ERBB2 R1153* ERBB2 V777L	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) L755S, R1153*, and V777L (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsLC	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsLC	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 P761del	endometrial cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with endometrial cancer harboring ERBB2 (HER2) P761del (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L726F	Advanced Solid Tumor	sensitive	XL647	Preclinical - Cell culture	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L726F in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L726F	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) L726F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L726F	breast cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L726F demonstrated resistance to Tykerb (lapatinib) in both culture and xenograft models (PMID: 25435280).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755_E757delinsS	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 9.0 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755_E757delinsS (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR amp ERBB2 amp	urinary bladder cancer	sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CH5132799 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA H1047R	ovarian cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA C420R	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 over exp	stomach cancer	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) induced tumor regression in a gastric cancer cell line xenograft model with HER2 (ERBB2) amplification and over expression (PMID: 23578997).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 over exp	stomach cancer	sensitive	trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Neratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA mut	breast cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA mut	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	Copanlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	Ipatasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	CDX-3379	Preclinical	Actionable	In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer (PMID: 26880266).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	stomach cancer	sensitive	Lapatinib	Preclinical	Actionable	In preclinical studies, Tykerb (lapatinib) demonstrated antiproliferative activity in HER2-amplified gastric cancer in cell assays and in xenograft models (PMID: 20179222).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	S63845 + Trastuzumab	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, S63845 and Herceptin (trastuzumab) demonstrated synergy in ERBB2 (HER2)-amplified breast cancer cells in culture and in ERBB2 (HER2)-amplified breast cancer patient-derived xenograft (PDX) models, resulting in enhanced tumor growth inhibition and overall survival compared to either agent alone (PMID: 28768804).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	vulva squamous cell carcinoma	sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 demonstrated cytoxicity against a EGFR-amplified vulvar epidermoid carcinoma cell line in culture and induced tumor regression in EGFR-amplified vulvar epidermoid carcinoma cell line xenograft models (PMID: 26846818).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells with ERBB2 (HER2) amplification in culture (PMID: 21558396).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	uterine corpus serous adenocarcinoma	sensitive	SYD985	Preclinical	Actionable	In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-amplified primary uterine serous carcinoma (USC) cell lines in culture and inhibited tumor growth and improved survival in ERBB2 (HER2)-amplified USC primary cell line xenografts (PMID: 27256376).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	FDA approved	Actionable	In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) resulted in a synergistic effect, demonstrating greater cell growth inhibitory activity in uterine serous carcinoma cells harboring ERBB2 (HER2) amplification compared to either agent alone (PMID: 26333383).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	gastroesophageal junction adenocarcinoma	no benefit	Lapatinib	Phase III	Actionable	In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastroesophageal junction adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	Trastuzumab + Pertuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and Perjeta (pertuzumab), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	Lapatinib + S63845	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of S63845 and Tykerb (lapatinib) resulted in potent cytotoxic effects in ERBB2 (HER2)-amplified breast cancer cells in culture compared to the cytostatic effect of Tykerb (lapatinib) alone (PMID: 27760111).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	colorectal cancer	no benefit	Pertuzumab	Preclinical - Pdx	Actionable	In a preclinical study, Perjeta (pertuzumab) did not inhibit tumor growth in patient-derived xenograft (PDX) models of ERBB2 (HER2)-amplified colorectal cancer (PMID: 22586653).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	gastric adenocarcinoma	predicted - sensitive	Lapatinib + Oxaliplatin + Capecitabine	Phase II	Actionable	In a Phase II trial, Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment resulted in a disease control rate of 81.3% (26/32, 7 complete response, 15 partial response, 4 stable disease) in patients with Erbb2 (Her2)-positive (defined as IHC3+ or IHC 2+ with ERBB2 amplification) gastric adenocarcinoma (PMID: 29409051; NCT02015169).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	predicted - sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of ERBB2 (HER2) amplified breast cancer cells in culture (PMID: 26208524).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	uterine corpus serous adenocarcinoma	sensitive	Taselisib	Preclinical - Cell culture	Actionable	In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Taselisib (GDC-0032) in culture, resulting in inhibition of cell growth (PMID: 26333383).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	predicted - sensitive	Temsirolimus + Neratinib	Phase I	Actionable	In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-amplified breast cancer resistant to (Herceptin) trastuzumab (PMID: 24323026).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	Lapatinib + Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Tykerb (lapatinib) and Torkinib (PP242) in ERBB2 (HER2) amplified breast cancer cells in culture blocked cell growth, inhibited phosphorylation of Akt and S6, and led to greater caspase activity when compared to each agent alone (PMID: 27197158).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	colorectal cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, colorectal cancer tumorgrafts with ERBB2 (HER2) amplification demonstrated resistance to Herceptin (trastuzumab) treatment in animal models (PMID: 26296355).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	colorectal cancer	sensitive	Lapatinib + Pertuzumab	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Perjeta (pertuzumab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	esophageal cancer	sensitive	Ibrutinib	Preclinical - Cell culture	Actionable	In a preclinical study, esophageal cancer cells with ERBB2 (HER2) amplification demonstrated sensitivity to Imbruvica (ibrutinib), resulting in decreased survival in culture (PMID: 28830912).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	colorectal cancer	decreased response	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Tykerb (lapatinib) resulted in initial disease stabilization with subsequent progression, in patient-derived colorectal cancer tumorgraft models with ERBB2 (HER2) amplification (PMID: 26296355).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	Neratinib + Pertuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Perjeta (pertuzumab) and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	duodenum adenocarcinoma	sensitive	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin	Clinical Study	Actionable	In a clinical case study, a patient with duodenal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated a complete pathologic response after treatment with a combination of Herceptin (trastuzumab), Adrucil (fluorouracil), Wellcovorin (leucovorin), and Eloxatin (oxaliplatin) (PMID: 28784859).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	gastroesophageal junction adenocarcinoma	sensitive	Trastuzumab	FDA approved	Actionable	In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric cancer or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	decreased response	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Tykerb (lapatinib) demonstrated decreased phosphorylation of Erbb2 (her2) and Akt, however, after 4-8 hours, Akt-driven Rictor showed upregulation, thereby resulting in a decreased treatment response (PMID: 27197158).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Advanced Solid Tumor	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib), demonstrated safety and efficacy in various advanced solid tumor patients with ERBB2 (HER2) amplification (PMID: 23775486).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	gastric adenocarcinoma	sensitive	Trastuzumab	FDA approved	Actionable	In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	stomach cancer	sensitive	BMS-690514	Preclinical	Actionable	In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Advanced Solid Tumor	predicted - sensitive	trastuzumab emtansine	Phase II	Actionable	In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine)  treatment resulted in partial response in 8.1% (3/37) and stable disease in 43% (16/37) of patients with ERBB2 (HER2) amplified advanced solid tumors, with a 6-month progression-free survival rate of 24.8% (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	CDX-3379 + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer, with increased efficacy compared to KTN3379 alone (PMID: 26880266).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	parotid gland cancer	predicted - sensitive	trastuzumab emtansine	Phase II	Actionable	In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine)  treatment resulted in partial response in a patient with ERBB2 (HER2) amplified salivary duct carcinoma of the parotid gland and a patient with ERBB2 (HER2) amplified squamous cell carcinoma of the parotid gland (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	esophagus adenocarcinoma	no benefit	Lapatinib	Phase III	Actionable	In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in esophagus adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	gastrointestinal system cancer	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, dacomitinib demonstrated significant growth-inhibitory effects in HER2- amplified gastric cancer cells (PMID: 18606718).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Lapatinib + S63845	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and S63845 demonstrated synergy in an ERBB2 (HER2)-amplified breast cancer cell line in culture, resulting in decreased cell viability (PMID: 28768804).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	colorectal adenocarcinoma	sensitive	trastuzumab emtansine	Clinical Study	Actionable	In a clinical case study, a patient with metastatic colorectal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated clinical benefit with stable disease in the primary tumor for 7 months following treatment with Kadcyla (trastuzumab emtansine) (PMID: 28040715).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	stomach carcinoma	no benefit	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of ERBB2 (HER2) amplified gastric carcinoma (PMID: 26438159).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	colorectal cancer	sensitive	Cetuximab + Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	LJM716 + Neratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of LJM716 and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	uterine corpus serous adenocarcinoma	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Nerlynx (neratinib) in culture, resulting in inhibition of cell growth (PMID: 26333383).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	urinary bladder cancer	sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, patients with ERBB2 (HER2) amplified urothelial carcinoma had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	stomach cancer	sensitive	Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Herceptin (trastuzumab) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification (PMID: 26296355).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Trastuzumab	Clinical Study	Actionable	In a meta-analysis, breast cancer patients with >12 copies of ERBB2 (HER2) had a better response to Herceptin (trastuzumab) than patients with 6-12 copies of ERBB2 (HER2) (PMID: 24691421).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	scrotum Paget's disease	predicted - sensitive	trastuzumab emtansine	Phase II	Actionable	In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine)  treatment resulted in partial response in a patient with ERBB2 (HER2) amplified Paget’s disease of the scrotum (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Palbociclib + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Herceptin (trastuzumab) worked synergistically to inhibit growth of ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 19874578).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited proliferation of breast cancer cell lines with ERBB2 (HER2) amplification in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	LJM716 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and LJM716, resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical study, ERBB2 (HER2) amplification was associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 21900593).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line xenograft model harboring ERBB2 (HER2) amplification demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	stomach cancer	sensitive	Trastuzumab + Lapatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in ERBB2 (HER2)-amplified cell line xenograft models of gastric cancer (PMID: 26296355).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	Her2-receptor positive breast cancer	predicted - sensitive	KRIBB11 + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK-2206 and KRIBB11 synergistically inhibited growth of ERBB2 (HER2)-amplified breast cancer cell lines in culture (PMID: 28598816).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Torkinib (PP242) demonstrated some efficacy in culture including reduced phosphorylation of S6 and Akt, apoptosis, and decreased cell growth (PMID: 27197158).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	colorectal cancer	sensitive	Trastuzumab + Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in patient-derived colorectal cancer tumorgraft models harboring ERBB2 (HER2) amplification (PMID: 26296355).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	non-small cell lung carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of non-small cell lung cancer (NSCLC) cell lines with ERBB2 (HER2) amplification in culture, and inhibited tumor growth in ERBB2 (HER2)-amplified NSCLC cell line xenograft models (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	lung squamous cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, a lung squamous cell carcinoma cell line with ERBB2 (HER2) amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	stomach cancer	sensitive	Poziotinib	Preclinical	Actionable	In a preclinical study, Poziotinib suppressed cell growth, decreased phosphorylation of downstream signaling molecules, and induced apoptosis of human gastric cancer cells harboring ERBB2 (HER2) amplification (PMID: 21306821).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	breast cancer	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, dacomitinib was more effective in preventing proliferation in ERBB2 (HER2) amplified breast cancer cells than in wild-type ERBB2 (HER2) breast cancer cells (PMID: 22761403).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp	gastric adenocarcinoma	no benefit	Lapatinib	Phase III	Actionable	In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastric adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp SRC E527K	gastroesophageal junction adenocarcinoma	sensitive	Lapatinib + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and Saracatinib (AZD0530) inhibited growth of ERBB2 (HER2)-amplified gastroesophageal adenocarcinoma cells harboring SRC E527K in culture (PMID: 25350844).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp SRC E527K	gastroesophageal junction adenocarcinoma	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, an ERBB2 (HER2)-amplified gastroesophageal cancer cell line initially sensitive to treatment with Tykerb (lapatinib) in culture developed resistance and was subsequently found to have acquired a secondary drug resistant mutation, SRC E527K (PMID: 25350844).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L866M	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) treatment resulted in stable tumor size in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L866M	colorectal cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) had no effect on tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L866M	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification were resistant to Erbitux (cetuximab) (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L866M	colorectal cancer	sensitive	Neratinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in sustained tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Trastuzumab + Pertuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Perjeta (pertuzumab) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	decreased response	trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ERBB2 (HER2) L755S resulted in decreased sensitivity to treatment with Kadcyla (trastuzumab emtansine) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Lapatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2) L755S was associated with reactivation of ERBB2 (HER2) signaling and acquired resistance to Tykerb (lapatinib) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification in culture and in xenograft models (PMID: 28487443).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture, and inhibited tumor growth in xenograft models (PMID: 28487443).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Trastuzumab + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture (PMID: 28487443).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA E545K PIK3CA K567R	Her2-receptor positive breast cancer	sensitive	Gedatolisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp ERBB2 T798M	breast cancer	resistant	Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a human ERBB2-amplified breast cancer cell line expressing ERBB2 (HER2) T798M was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA E545K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA E545K	breast cancer	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA N345K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp TP53 R158H	gastric adenocarcinoma	predicted - resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp FGFR2 amp	esophagus adenocarcinoma	sensitive	AZD4547 + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PIK3CA K111N	breast cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	FGFR2 wild-type ERBB2 amp	stomach cancer	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, gastric cancer cells with wild-type FGFR2  and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	esophageal carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	gastric adenocarcinoma	resistant	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	gastroesophageal junction adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) inhibited the growth of gastroesophageal adenocarcinoma cells with ERBB2 (HER2) and MET amplification in culture (PMID: 25350844).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	esophagus adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	esophageal carcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	esophageal carcinoma	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	gastric adenocarcinoma	resistant	Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	gastric adenocarcinoma	sensitive	Crizotinib + Trastuzumab + Paclitaxel	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp MET amp	gastric adenocarcinoma	resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 amp PTEN dec exp	Her2-receptor positive breast cancer	decreased response	CDX-3379	Preclinical	Actionable	In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ROS1 fusion ERBB2 amp FGFR3 amp RET amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L841V	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L841V	Her2-receptor negative breast cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.8 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L ERBB2 V842I	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L and V842I (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	colorectal cancer	conflicting	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	colorectal cancer	conflicting	Neratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	colon cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	Advanced Solid Tumor	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 6.9 months in a patient with endometrial cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	colorectal cancer	resistant	Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, human colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Erbitux (cetuximab) in culture and in patient-derived xenograft models (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	gastroesophageal junction adenocarcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.1 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in one patient, and progressive disease in 4 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in one patient, and progressive disease with a progression-free survival of 0.8 months in another patient with biliary tract cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 6.9 months in a patients with bladder cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V777L	colorectal cancer	sensitive	Neratinib + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769Y	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769Y	gastroesophageal junction adenocarcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769Y	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769Y reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769Y	urinary bladder cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with bladder cancer harboring both ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769Y	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) C805S and ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) demonstrated resistance to dacomitinib in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 M774delinsWLV ERBB2 C805S	Advanced Solid Tumor	resistant	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 M774delinsWLV ERBB2 C805S	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquisition of ERBB2 (HER2) C805S in transformed cells expressing ERBB2 (HER2) M774delinsWLV conferred resistance to dacomitinib in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 M774delinsWLV ERBB2 C805S	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776V	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) G776V in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L786V	non-small cell lung carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.7 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L786V (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F ERBB2 G660D	ampulla of Vater carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a clinical case study, Gilotrif (afatinib) treatment resulted in stable disease with slight lymph node metastasis reduction in a patient with ampulla of Vater carcinoma harboring ERBB2 S310F and G660D, but the disease eventually progressed after 4 months (PMID: 29146616).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) decreased cell survival of transformed human cells expressing ERBB2 (HER2) S310F (PMID: 22908275).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in one and progressive disease in another patient with biliary tract cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	urinary bladder cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	non-small cell lung carcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	colorectal cancer	conflicting	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	colorectal cancer	conflicting	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with colorectal cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	urinary bladder cancer	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	cervical cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in 1 patient, stable disease in 1 patient, and progressive disease in 1 patient with cervical cancer harboring ERBB2 (HER2) D769N (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 4 patients and progressive disease in 1 patient with bladder cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	Advanced Solid Tumor	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cells expressing ERBB2 S310F in culture (PMID: 22908275).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	urinary bladder cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	gastroesophageal junction adenocarcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.9 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	colon cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response with a progression-free survival of 14.6 months in one patient, and stable disease with a progression-free survival of 3.7 months in another patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D277H ERBB2 S310F	urinary bladder cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D277H ERBB2 S310F	urinary bladder cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D277H ERBB2 S310F	urinary bladder cancer	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310F ERBB2 V842I	breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) S310F and V842I (PMID: 28679771).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D277G ERBB2 S310F	urinary bladder cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with bladder cancer harboring both ERBB2 (HER2) D277G and S310F (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y803N	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) Y803N in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y803N	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) Y803N demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 P780L	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) P780L demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 P780L	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) P780L in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L869R	breast cancer	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tarceva (erlotinib) in culture (PMID: 27900369).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L869R	lung adenocarcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L869R	breast cancer	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L869R	lung adenocarcinoma	resistant	Lapatinib	Clinical Study	Actionable	In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L869R	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L869R (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L869R	breast cancer	resistant	Lapatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L869R	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L869R	breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) L869R (PMID: 28679771).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S653C	urinary bladder cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S653C	urinary bladder cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S653C	urinary bladder cancer	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S653C demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 E717K	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) E717K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 E717K	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E717K in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	colorectal cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y were resistant to Erbitux (cetuximab) (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 9.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 2 patients and progressive disease in 2 patients with bladder cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	cervical cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 0.5 month in a patient with cervical cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	gastroesophageal junction adenocarcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 0.8 month in a patient with gastroesophageal cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	colorectal cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	colorectal cancer	sensitive	Trastuzumab + Lapatinib	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) and Tykerb (lapatinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S310Y	colorectal cancer	sensitive	Neratinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg ERBB2 pos	Her2-receptor negative breast cancer	sensitive	RO4929097 + Paclitaxel	Preclinical	Actionable	In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of RO4929097 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone  (PMID: 27556950).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg ERBB2 pos	Her2-receptor negative breast cancer	sensitive	LY411575 + Paclitaxel	Preclinical	Actionable	In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg MET pos	esophagus adenocarcinoma	no benefit	Onartuzumab + mFOLFOX6	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	AMG102	Phase III	Actionable	In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Onartuzumab + mFOLFOX6	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg MET pos	gastroesophageal junction adenocarcinoma	no benefit	Onartuzumab	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg MET pos	gastroesophageal junction adenocarcinoma	no benefit	AMG102	Phase III	Actionable	In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Onartuzumab	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg	Her2-receptor negative breast cancer	predicted - sensitive	Exemestane + Seribantumab	Phase II	Actionable	In a Phase II trial, Seribantumab (MM-12) and Aromasin (exemestane) combination treatment resulted in a 74% decrease in risk of progression (HR 0.26) and a a 59% decrease in risk of death (HR 0.436) compared to exemestane alone in ERBB2-negative, hormone receptor positive breast cancer patients (AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, May 2016, Abstract # A14).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg	Her2-receptor negative breast cancer	no benefit	Ramucirumab + Docetaxel	Phase III	Actionable	In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 neg	Her2-receptor negative breast cancer	predicted - sensitive	Sorafenib + Vinorelbine	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Navelbine (vinorelbine) and Nexavar (sorafenib) resulted in a response rate of 30% (8/27), median progression free survival of 5.7 months, and a clinical benefit rate (absence of disease progression at 6 months) of 48% (13/27) in patients with ERBB2 (HER2)-negative metastatic breast cancer (PMID: 27992451).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 H878Y	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) H878Y demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 H878Y	Advanced Solid Tumor	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited proliferation of  transformed cell lines expressing ERBB2 (HER2) H878Y in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 E812K	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E812K in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 E812K	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) E812K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G660D	lung cancer	sensitive	Afatinib	Clinical Study	Actionable	In a clinical case study, Gilotrif (afatinib) treatment resulted in partial response in the lung lesion and stable bone metastasis for over 16 months in a patient with familial lung cancer harboring germline ERBB2 G660D mutation (PMID: 29146616).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G660D	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G660D in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G660D	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells cells expressing ERBB2 (HER2) G660D did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	Advanced Solid Tumor	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as ERBB2 A775_G776insYVMA) in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	lung cancer	sensitive	Poziotinib	Preclinical	Actionable	In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA), with no signs of progression at 12 weeks (PMID: 29686424).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	non-small cell lung carcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 5 patients and progressive disease in 4 patients with non-small cell lung cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	urinary bladder cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) Y722_A775dup (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	lung adenocarcinoma	conflicting	Afatinib	Clinical Study	Actionable	In a clinical study, a lung adenocarcinoma patient harboring ERBB2 Y772_A775dup (also referred to as A775_G776insYVMA and E740_A741insAYVM) achieved a partial response for 5 months following treatment with pulse Gilotrif (afatinib), however, a second patient harboring ERBB2 Y772_A775dup treated with pulse Gilotrif (afatinib) demonstrated progressive disease (PMID: 26964772).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited ERBB2 (HER2) phosphorylation and growth of a transformed cell line expressing (HER2) Y772_A775dup (reported as A775_G776insYVMA)  in culture (PMID: 29686424).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in one patient, and stable disease in 2 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 Y772_A775dup	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp KRAS G13D	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS G13D in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047L	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA mut	breast cancer	sensitive	ARQ092 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	PKI-179	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA mut	breast cancer	sensitive	ARQ092 + Paclitaxel	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA N345T	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA N345T (PMID: 29208673).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR T790M ERBB2 over exp	lung adenocarcinoma	resistant	CO1686	Preclinical	Actionable	In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR T790M ERBB2 over exp	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	BRAF V600E ERBB2 over exp KRAS A146V	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS A146V and BRAF V600E in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	BKM120 + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	no benefit	BKM120 + Trastuzumab + Lapatinib	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Trastuzumab + Lapatinib	Preclinical	Actionable	In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	BKM120 + Bevacizumab	Preclinical	Actionable	In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	BKM120 + Trastuzumab + Pertuzumab	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Trastuzumab + Pertuzumab	Preclinical	Actionable	In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR amp ERBB2 over exp	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified EGFR amplification in 2 patients demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-over expressing breast carcinoma cell lines in culture (PMID: 27450453).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-amplified and HER2-over expressing gastric cancer cell lines in culture (PMID: 18774637).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	MM-302 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) resulted in improved tumor growth inhibition in cell line xenograft models of Erbb2 (Her2)-over expressing gastric cancer (PMID: 26759238).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	ADXS31-164	Preclinical	Actionable	In a preclinical study, ADXS31-164 prevented development of spontaneous mammary tumors in Erbb2 (Her2)-over expressing transgenic animal models (PMID: 20725099).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	HER2 CAR-T cells	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2)-specific CAR-T cells induced cell death in ERBB2 (HER2)-over expressing gastric cancer cell lines in culture, and inhibited tumor growth and improved survival in a ERBB2 (HER2)-over expressing gastric cancer cell line xenograft model (PMID: 28284008).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	gastroesophageal junction adenocarcinoma	sensitive	S-222611	Phase I	Actionable	In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient over expressing ERBB2 (HER2) and a partial response in a gastric cancer patient also over expressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	KU004	Preclinical	Actionable	In a preclinical study, KU004 inhibited growth and induced apoptosis in gastric cancer cell lines over expressing ERBB2 in culture and suppressed growth in a dose dependent manner in xenograft models (PMID: 26437915).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	pancreatic carcinoma	predicted - sensitive	HER2 CAR-T cells	Phase I	Actionable	In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	gastric adenocarcinoma	sensitive	VS-5584	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VS-5584 inhibited tumor growth in human gastric cancer cell line xenograft models overexpressing ERBB2 (HER2) (PMID: 23270925).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	S-222611	Phase I	Actionable	In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient overexpressing ERBB2 (HER2) and a partial response in a gastric cancer patient also overexpressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	carcinoma	predicted - sensitive	MGAH22	Phase I	Actionable	In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	TAK-285	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAK-285 inhibited tumor growth in gastric cancer cell line xenograft models over expressing ERBB2 (HER2)  (PMID: 23983820).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	TAK-285	Preclinical	Actionable	In a preclinical study, the N87 gastric cancer cell line, which has been demonstrated to have ERBB2 (HER2) amplification and over expression, was sensitive to TAK-285, inhibiting phosphorylation of ERBB2 (HER2) and ERBB3 (HER3) (PMID: 25594012, PMID: 18441328).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	Paclitaxel + Trastuzumab + MM-111	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MM-111, in combination with Herceptin (trastuzumab) and Taxol (paclitaxel), resulted in a synergistic effect thereby inhibiting ErbB2 in ERBB2 (HER2) over expressing gastric cancer cell line xenograft models (J Clin Oncol 31, 2013 (suppl 4; abstr 48)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	varlitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Varlitinib (ARRY-334543) resulted in a 74%  tumor growth inhibition and tumor regression in 88% (7/8) of human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tucatinib (ARRY-380) inhibited proliferation of an ERBB2 (HER2) over expressing gastric cancer cell line in culture (Cancer Res April 15, 2010 70:3610).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	BMS-690514	Preclinical	Actionable	In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	NAX014	Preclinical	Actionable	In a preclinical study, NAX014 induced cellular senescence, prevented tumor growth, and decreased tumor volume in a Her2 positive breast cancer mouse model (PMID: 26168818).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	predicted - sensitive	MM-302	Preclinical	Actionable	In a preclinical study, ERBB2 (HER2) over expressing gastric cancer xenograft models demonstrated anti-tumor activity when treated with MM-302 (Cancer Res December 15, 2010 70; P3-14-09).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	gastric adenocarcinoma	sensitive	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines as first-line therapy for Erbb2 (Her2)-overexpressing metastatic gastric adenocarcinoma patients (NCCN.org)
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	breast cancer	sensitive	AV-412	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AV-412 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cell lines in culture, and inhibited tumor growth in a ERBB2 (HER2)-over expressing breast cancer cell line xenograft model (PMID: 17888033).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	gastric adenocarcinoma	predicted - sensitive	Lapatinib + Oxaliplatin + Capecitabine	Phase II	Actionable	In a Phase II trial, Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment resulted in a disease control rate of 81.3% (26/32, 7 complete response, 15 partial response, 4 stable disease) in patients with Erbb2 (Her2)-positive (defined as IHC3+ or IHC 2+ with ERBB2 amplification) gastric adenocarcinoma (PMID: 29409051; NCT02015169).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	PF-05280014	Preclinical	Actionable	In a preclinical study, PF-05280014 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cells with activity comparable to Herceptin (trastuzumab) in culture (PMID: 25001079).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	breast cancer	sensitive	KU004	Preclinical	Actionable	In a preclinical study, KU004 inhibited growth and induced apoptosis in breast cancer cell lines over expressing ERBB2 in culture (PMID: 26437915).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	biliary tract cancer	predicted - sensitive	HER2 CAR-T cells	Phase I	Actionable	In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	esophagus adenocarcinoma	sensitive	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines for Erbb2 (Her2)-overexpressing metastatic esophageal adenocarcinoma patients (NCCN.org)
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	trastuzumab + varlitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Varlitinib (ARRY-334543), in combination with Herceptin (trastuzumab), resulted in a 91% tumor growth inhibition and tumor regression in human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	gastroesophageal junction adenocarcinoma	sensitive	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines for Erbb2 (Her2)-overexpressing metastatic esophagogastric junction adenocarcinoma patients (NCCN.org)
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	CUDC-101	Phase I	Actionable	In a Phase I clinical trial, a breast cancer patient with ERBB2 (HER2) over expression that had progressed on Herceptin (trastuzumab) demonstrated stable disease for more than 12 weeks following treatment with CUDC-101 (PMID: 25107918).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	TAK-285	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAK-285 inhibited growth of breast cancer cell line harboring ERBB2 (HER2) over expression in culture and in cell line xenograft models (PMID: 23983820).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	FDA approved	Actionable	In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	colorectal cancer	resistant	Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2) over expression was associated with resistance to Erbitux (cetuximab) treatment in a human cell line xenograft model of colorectal cancer (PMID: 26296355).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	CDX-3379	Preclinical	Actionable	In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth by 43% in N87 gastric cancer xenograft model, which has been demonstrated to have ERBB2 (HER2) amplification and overexpression (AACR; 2015. Abstract nr 1558, PMID: 18441328).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	Her2-receptor positive breast cancer	predicted - sensitive	MGAH22	Phase Ib/II	Actionable	In Phase I clinical trial, Margetuximab (MGAH22) displayed safety and had initial efficacy in patients with ERBB2 (HER2) positive breast cancer (J Clin Oncol 31, 2013 (suppl; abstr 3004)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	breast cancer	sensitive	MM-302 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) synergistically inhibited tumor growth in cell line xenograft models of Erbb2 (Her2)-over expressing breast cancer (PMID: 26759238).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II trial, Dacomitinib resulted in a 7.4% (2/27) response rate and 40.7% (11/27) disease control rate when treating advanced gastric cancer patients with ERBB2 (HER2) over expression (J Clin Oncol 30, 2012 (suppl 4; abstr 54)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, ERBB2 (HER2) over expressing gastric cancer cells were sensitive to Dacomitinib, resulting in inhibition of ERBB2 (HER2)/ERBB3 (HER3) heterodimers (PMID: 22135232).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	stomach cancer	sensitive	trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp	cholangiocarcinoma	predicted - sensitive	HER2 CAR-T cells	Phase I	Actionable	In a Phase I trial, a patient with perihilar cholangiocarcinoma over expressing ERBB2 achieved a partial response and progression-free survival for 4.5 months following treatment with ERBB2 (HER2)-specific CAR-T cells (PMID: 28710747, NCT01935843).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp MET amp MET R988C	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study, assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Ponatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 over exp MET amp	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tissue from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified MET amplification in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L726I	breast cancer	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, an ERBB2 (HER2) L726I mutation was detected in a murine breast cancer cell line that acquired resistance to Iressa (gefitinib) in culture (PMID: 17638894).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 R896C	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 R896C	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 R896C	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R896C reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755A	non-small cell lung carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.6 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755A (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L915M	Advanced Solid Tumor	sensitive	XL647	Preclinical - Cell culture	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L915M in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T733I	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) T733I demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T733I	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.7 months in a patient with biliary tract cancer harboring ERBB2 (HER2) T733I (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T733I	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T733I in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776_V777insYVMA	Advanced Solid Tumor	sensitive	Canertinib	Preclinical	Actionable	In a preclinical study, Canertinib inhibited Erbb2 (Her2) phosphorylation and cell growth in transformed human cell lines expressing ERBB2 (HER2) G776_V777insYVMA (PMID: 16843263).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	Her2-receptor positive breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) treatment resulted in complete response in 12.5% (3/24) and partial response in 20.8% (5/24) of ERBB2 (HER2) mutant but not amplified breast cancer patients (Cancer Res 2017;77(4 Suppl):Abstract nr PD2-08).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	colorectal cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 8.3% (1/12), and a median progression-free survival of 1.8 months in patients with colorectal cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 28.6% (2/7), and a median progression-free survival of 2.6 months in patients with endometrial cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	non-small cell lung carcinoma	sensitive	Pyrotinib	Phase II	Actionable	In a Phase II trial, Pyrotinib treatment in non-small cell lung cancer patients harboring an ERBB2 (HER2) mutation resulted in a partial response in 54.5% (6/11) of patients and stable disease in 27.3% (3/11) of patients, and a PFS of 6.2 months (Journal of Thoracic Oncology, Vol. 12, Issue 1, S359).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	lung squamous cell carcinoma	predicted - sensitive	Afatinib	Phase III	Actionable	In a Phase III trial (LUX-Lung 8), secondary analysis demonstrated favorable outcomes with Gilotrif (afatinib) treatment compared to Tarceva (erlotinib) in lung squamous cell carcinoma patients with ERBB (HER) family mutations, and ERBB2 (HER2) mutations predicted an OS (HR=0.06, p=0.02) and PFS (HR=0.06, p=0.02) benefit for Gilotrif (afatinib) over Tarceva (erlotinib) treatment (PMID: 29902295; NCT01523587).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	Her2-receptor negative breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an object response rate of 24% (6/25), a clinical benefit rate of 40% (10/25), and a median progression-free survival of 3.5 months in patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	non-small cell lung carcinoma	sensitive	trastuzumab emtansine	Guideline	Actionable	Kadcyla (trastuzumab emtansine) is included in guidelines for non-small cell lung cancer patients with ERBB2 (HER2) mutations (NCCN.org).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 18.8% (3/16), and a median progression-free survival of 1.8 months in patients with bladder cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	gastroesophageal junction adenocarcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 20% (1/5), and a median progression-free survival of 1.7 months in patients with gastroesophageal cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	lung adenocarcinoma	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, treatment with Gilotrif (afatinib) resulted in objective response in 3 lung adenocarcinoma patients harboring ERBB2 (HER2) mutations (PMID: 22325357).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	non-small cell lung carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a clinical study, treatment with Gilotrif (afatinib) resulted in an objective response rate of 33% (2/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	cervical cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate of 20% (1/5), a clinical benefit rate of 60% (3/5), and a median progression-free survival of 20.1 months in patients with cervical cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	non-small cell lung carcinoma	predicted - sensitive	Trastuzumab	Clinical Study	Actionable	In a clinical study, treatment with Herceptin (trastuzumab) in combination with chemotherapy resulted in an objective response rate of 67% (4/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	lung cancer	sensitive	Neratinib	Phase I	Actionable	In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-mutant non-small-cell lung cancer (PMID: 24323026).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	non-small cell lung carcinoma	sensitive	AV-412	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring an ERBB2 (HER2) mutation demonstrated sensitivity to AV-412, resulting in decreased phosphorylation of Erbb2, Akt, and Erk (PMID: 19459856).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	non-small cell lung carcinoma	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate of 3.8% (1/26), a clinical benefit rate of 42.3% (11/26), and a median progression-free survival of 5.5 months in patients with non-small cell lung cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	non-small cell lung carcinoma	sensitive	Neratinib	Phase I	Actionable	In a Phase I study, Nerlynx (neratinib) administered with temsirolimus was tolerable and demonstrated antitumor activity in ERBB2-mutant non-small-cell lung cancer (PMID: 24323026).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, with treatment resulting in a clinical benefit rate of 31% (5/16; 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more) and a median progression-free survival of 16 weeks (PMID: 28679771).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	ovarian cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, no clinical benefit, and a median progression-free survival of 2.1 months in patients with ovarian cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	biliary tract cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate at 8 weeks of 22.2% (2/9), a clinical benefit rate of 33.3% (3/9), and a median progression-free survival of 2.8 months in patients with biliary tract cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 mutant	invasive bladder transitional cell carcinoma	predicted - sensitive	Cisplatin + Gemcitabine + Sorafenib	Phase II	Actionable	In a Phase II trial, ERBB2 (HER2) mutations were only detected in  patients with muscle-invasive urothelial bladder cancer that responded to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	non-small cell lung carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival over 17 months in 2 patient with non-small cell lung cancer harboring ERBB2 (HER2) G778_P780dup (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	lung adenocarcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a clinical study, a lung adenocarcinoma patient harboring ERBB2 (HER2) G778_P780dup (also referred to as V747_G748insGSP and G748_P750dup), demonstrated a 13% regression of target lesions and stable disease for 11 months following treatment with pulse Gilotrif (afatinib) (PMID: 26964772).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	lung adenocarcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a clinical study, a patient with metastatic lung adenocarcinoma harboring ERBB2 (HER2) G778_P780dup (also referred to as V777_G778insGSP) demonstrated tumor shrinkage and clinical response for 7 months following treatment with Gilotrif (afatinib) (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	breast cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Tykerb (lapatinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	Advanced Solid Tumor	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G778_P780dup (reported P780insGSP) in culture (PMID: 29686424).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.5 months in one patient, and stable disease with a progression-free survival of 20.0 months in another patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) G778_P780dup (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	lung adenocarcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II trial, two lung adenocarcinoma patients harboring ERBB2 (HER2) P780_Y781insGSP (also referred to as G778_780dup) demonstrated partial response to treatment with dacomitinib (PMID: 25899785).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	breast cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Herceptin (trastuzumab) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) P780_Y781insGSP reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778_P780dup	breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), which included patients with ERBB2 G778_P780dup (1 complete response (referred to as V777_G778insGSP) and 1 patient with stable disease for more than 24 weeks (referred to as P780_Y781insGSP) (PMID: 28679771).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769N	cervical cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.5 months in a patient with cervical cancer harboring ERBB2 (HER2) D769N (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	APC Q1429fs BRAF N581S ERBB2 L755S	rectum adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Trastuzumab	Clinical Study	Actionable	In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L755S in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 L755S demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	colon cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response in a patient with ERBB2 (HER2) L755S, and 3 patients achieving stable disease for 24 weeks or more (PMID: 28679771).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease in one and stable disease in another patient with biliary tract cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Nerlynx (neratinib) resulted in growth inhibition in transformed human breast cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) in ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 28487443).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1 patient, partial response in 1 patient, stable disease in 2 patients, and progressive disease in 4 patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	non-small cell lung carcinoma	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 12.7 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	Advanced Solid Tumor	resistant	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755S demonstrated resistance to AEE788 in culture, except at very high doses (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	colon cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755S	Advanced Solid Tumor	sensitive	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 R678Q	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 R678Q demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 R678Q	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R678Q demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 R678Q	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 5.5 months in a patient with endometrial cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 R678Q	gastroesophageal junction adenocarcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 R678Q	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.6 months in a patient with colorectal cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D821N	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) D821N in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 E719G	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E719G in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 E719G	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) E719G demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	endometrial cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with endometrial cancer harboring ERBB2 (HER2) V842I (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	colon cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V842I demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	colorectal cancer	conflicting	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 2 patients and progressive disease in 1 patient with colorectal cancer harboring ERBB2 (HER2) V842I (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	colorectal cancer	conflicting	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V842I	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 act mut STK11 loss	breast cancer	sensitive	AZD8055	Preclinical	Actionable	In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	PIK3CA act mut ERBB2 act mut	breast cancer	sensitive	VS-5584	Preclinical	Actionable	In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 act mut	estrogen-receptor positive breast cancer	predicted - sensitive	Vistusertib	Phase I	Actionable	In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with ER-positive breast cancer harboring an ERBB2 activating mutation (PMID: 25805799).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 act mut	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) activation loop mutations demonstrated sensitivity to AEE788 in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 act mut	breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II clinical trial, Nerlynx (neratinib) treatment resulted in clinical benefit in 36% (5/14) of metastatic breast cancer patients harboring ERBB2 (HER2) activating mutations, with 1 complete response, 1 partial response, and 2 patients achieving stable disease for greater than 6 months, and a median progression-free survival of 5 months (J Clin Oncol 34, 2016 (suppl; abstr 516)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA E545K	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	sensitive	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study	Actionable	In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study	Actionable	In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA act mut	uterine cancer	sensitive	Taselisib	Preclinical	Actionable	In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	predicted - sensitive	BKM120 + Trastuzumab	Phase I	Actionable	In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA C420R	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA K111N	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	ovarian carcinoma	sensitive	SYD985	Preclinical - Cell culture	Actionable	In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive ovarian carcinoma cell line in culture (PMID: 25589493).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast cancer	predicted - sensitive	SYD985	Phase I	Actionable	In a Phase I trial, SYD985 treatment resulted in an overall response of 33% (33/99) and a median progression-free survival of 9.4 months in patients with ERBB2 (HER2)-positive (50) or ERBB2 (HER2)-low (49) metastatic breast cancer (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 1014-1014; NCT02277717).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach carcinoma	sensitive	SYD985	Preclinical - Cell culture	Actionable	In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture (PMID: 25589493).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Tucatinib	Phase I	Actionable	In a Phase I trial, treatment with Tucatinib (ARRY-380) resulted in a response rate of 14% (3/22; all partial responses (PR)) and a clinical benefit rate (PR plus stable disease for greater than or equal to 24 weeks) of 27% (6/22) in Erbb2 (Her2)-positive breast cancer patients (PMID: 28053022).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Capecitabine + Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) and Xeloda (capecitabine) combination therapy resulted in an overall 12-month survival rate of 63% (23/37) in patients with Erbb2 (Her2)-positive breast cancer brain metastases (J Clin Oncol 35, 2017 (suppl; abstr 1005)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Pertuzumab + Trastuzumab + Paclitaxel	Guideline	Actionable	Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxol (paclitaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-negative, ERBB2 (HER2) receptor-positive breast cancer (NCCN.org).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	BKM120 + Trastuzumab	Phase I	Actionable	In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated in patients with ERBB2 (HER2)-positive advanced or metastatic breast cancer that had progressed on Herceptin (trastuzumab) (PMID: 24470511).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	gastroesophageal junction adenocarcinoma	no benefit	Paclitaxel + Trastuzumab + MM-111	Phase II	Actionable	In a Phase II trial, Taxol (paclitaxel) and Herceptin (trastuzumab) treatment in combination with MM-111 did not improve progression free survival (9.6 weeks) and median overall survival (32.1 weeks) compared to without MM-111 (23.3 weeks, 56.1 weeks) in ERBB2 positive gastroesophageal junction cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4043)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	sensitive	HER2 Vaccine	Preclinical - Patient cell culture	Actionable	In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Capecitabine + Trastuzumab + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Tucatinib (ARRY-380), Herceptin (trastuzumab), and Capecitabine demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 50% (1/2) of evaluable patients achieving CNS partial response and 50% (1/2) achieving CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trodusquemine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Trodusquemine (MSI-1436) inhibited tumor growth and metastasis in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model (PMID: 24845231).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Lapatinib + MK2206	Phase I	Actionable	In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	sensitive	Trastuzumab + Oxaliplatin	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive gastric cancer cells in culture (PMID: 24300914).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	transitional cell carcinoma	no benefit	lapuleucel-T	Phase II	Actionable	In a Phase II trial, Neuvenge (lapuleucel-T) treatment did not result in statistically significant improvement of overall survival (37.0 vs 22.2 months, HR = 0.96) or disease recurrence-free survival (11.9 vs 10.1 months, HR = 0.99) compared to standard of care in ERBB2 (HER2) positive urothelial cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4513)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach carcinoma	sensitive	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tucatinib (ARRY-380) inhibited tumor growth in a ERBB2 (HER2)-positive gastric carcinoma cell line xenograft model (Cancer Res April 15, 2012 72:852).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	sensitive	Lapatinib + Paclitaxel	Phase III	Actionable	In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast cancer	sensitive	ADCT-502	Preclinical - Pdx	Actionable	In a preclinical study, ADCT-502 demonstrated anti-tumor activity in ERBB2 (HER2)-expressing breast cancer cell line and patient-derived xenograft (PDX) models, including PDX models expressing low levels of ERBB2 (HER2) (Eur J Cancer, 2016, Vol. 69, Supp1, S28).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Entinostat + Lapatinib + Trastuzumab	Phase I	Actionable	In a Phase I trial, combination treatment consisted of Entinostat, Tykerb (lapatinib) and Herceptin (trastuzumab) resulted in complete response in 9% (2/22), partial response in 14% (3/22), and stable disease in 27% (6/22) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	DS-8201a	Phase I	Actionable	In a Phase I trial, treatment with DS-8201a was well-tolerated and resulted in an overall response rate (ORR) of 38% (19/50) and disease control rate (DCR) of 90% (45/50) in patients with ERBB2 (HER2)-expressing solid tumors, and an ORR of 29% (4/14) and DCR of 93% (13/14) in patients with low ERBB2 (HER2) expression (J Clin Oncol 35, 2017 (suppl; abstr 108)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	uterine corpus serous adenocarcinoma	sensitive	SYD985	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-expressing primary uterine serous carcinoma (USC) cell lines in culture, including cell lines with both high and low levels of ERBB2 (HER2) expression, and inhibited tumor growth and improved survival in ERBB2 (HER2)-expressing USC primary cell line xenografts (PMID: 27256376).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast adenocarcinoma	sensitive	DS-8201a	Preclinical - Cell culture	Actionable	In a preclinical study, DS-8201 inhibited growth of an ERBB2 (HER2)-positive breast adenocarcinoma cell line in culture (PMID: 27026201).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	pancreatic cancer	sensitive	DS-8201a	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DS-8201a inhibited tumor growth in a pancreatic cancer cell line xenograft model with low ERBB2 (HER2) expression (PMID: 27026201).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	HER2 BATs	Preclinical - Cell culture	Actionable	In a preclinical study, HER2 BATs demonstrated enhanced toxicity comparing to unarmed T-cells against Erbb2 (Her2)-positive breast cancer cells in culture (PMID: 11359672).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trastuzumab + Lapatinib	Clinical Study	Actionable	In a meta-analysis of six randomized clinical trials, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in 13% absolute improvement in pathologic complete response rate in ERBB2 (HER2)-positive breast cancer patients compared to Herceptin (trastuzumab) single treatment (PMID: 27140927).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trastuzumab + Lapatinib	Phase II	Actionable	In a Phase II trial, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in complete response in the breast in 10.6% (7/66) and minimal residual disease in 16.7% (11/66) of ERBB2-positive breast cancer patients 11 days after receiving the treatment (European Breast Cancer Conference; Mar 2016; Abstract #6LBA).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Ibrutinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Imbruvica (ibrutinib) inhibited Her family receptor signaling, resulted in apoptosis and growth inhibition in ERBB2 (HER2)-positive breast cancer cell lines in culture and in cell line xenograft models (PMID: 27256378).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Neratinib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) plus Taxol (paclitaxel) demonstrated similar efficacy to Herceptin (trastuzumab) plus Taxol (paclitaxel), with an median progression-free survival of 12.9 months, however, potentially decreased CNS metastasis risk, with an incidence of 8.3% (20/242) compared to 17.3% (41/237) in the Herceptin (trastuzumab) plus Taxol (paclitaxel) group (PMID: 27078022).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast cancer	sensitive	MI130004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-receptor positive breast cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	sensitive	ARX-788	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2)-positive ovarian xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	salivary gland cancer	predicted - sensitive	DS-8201a	Phase I	Actionable	In a Phase I trial, treatment with DS-8201a resulted in a partial response in 50% (2/4) of evaluable patients with salivary gland cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide	Guideline	Actionable	Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	predicted - sensitive	MGAH22	Phase I	Actionable	In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	ovarian cancer	sensitive	ARX-788	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ERBB2 (HER2)-positive ovarian cancer xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trastuzumab + Docetaxel + Carboplatin	Guideline	Actionable	Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) therapy is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	CDX-3379	Preclinical	Actionable	In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-positive breast cancer (PMID: 26880266).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Pyrotinib	Phase I	Actionable	In a Phase I trial, Pyrotinib treatment resulted in an objective response rate of 50% (18/36, all partial responses), and a clinical benefit rate of 61.1% (22/36), and a median progression-free survival of 35.4 weeks in patients with ERBB2 (HER2)-positive breast cancer (PMID: 28498781, NCT01937689).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	MEDI4276	Phase I	Actionable	In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	S-222611	Phase I	Actionable	In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trastuzumab + Oxaliplatin	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive breast cancer cells in culture (PMID: 24300914).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast cancer	sensitive	ARX-788	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ERBB2 (HER2)-positive breast cancer xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	varlitinib	Phase I	Actionable	In a Phase I expansion trial, 36% (5/14) of metastatic breast cancer patients positive for ERBB2 (HER2) demonstrated stable disease for up to 16 weeks when treated with Varlitinib (ARRY-334543) (Cancer Res May 1, 2009 69; 3603).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Capecitabine + Trastuzumab	Phase II	Actionable	In Phase II clinical trials, the combination of Xeloda (capecitabine) and Herceptin (trastuzumab) demonstrated efficacy with a manageable toxicity profile in heavily pretreated patients with ERBB2 (HER2)-positive advanced breast cancer and earlier Herceptin (trastuzumab) exposure (PMID: 17679724).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	gastroesophageal junction adenocarcinoma	no benefit	trastuzumab emtansine	Phase III	Actionable	In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Pertuzumab + Trastuzumab + Carboplatin + Docetaxel	Guideline	Actionable	Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab) therapy, is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	sensitive	DS-8201a	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, DS-8201 inhibited growth of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture and in xenograft models, and induced tumor regression in a patient-derived xenograft (PDX) model of ERBB2 (HER2)-positive gastric cancer (PMID: 27026201).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	trastuzumab emtansine	Phase III	Actionable	In a Phase III trial, Kadclya (trastuzumab emtansine) demonstrated improved median progression free survival and overall survival compared to Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment in patients with ERBB2 (HER2) positive breast cancer, regardless of the expression level of Erbb2 (Her2), Egfr, and Her3, or PIK3CA mutation status (PMID: 26920887).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	trastuzumab emtansine	FDA approved	Actionable	In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast cancer	sensitive	Tucatinib + Trastuzumab emtansine	Phase Ib/II	Actionable	In a Phase Ib/II trial, ERBB2 (HER2)-positive breast cancer patients demonstrated an objective response rate of 47% (16/34), including one complete response and fifteen partial responses, and a progression-free survival of 8.2 months when treated with a combination of Tucatinib (ARRY-380) and Kadcyla (trastuzumab emtansine) compared to 6.5 months with Herceptin (trastuzumab) and Perjeta (pertuzumab) treatment (PMID: 29955792; NCT01983501).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	esophageal cancer	predicted - sensitive	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	gastric adenosquamous carcinoma	no benefit	trastuzumab emtansine	Phase III	Actionable	In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	MYL-1401O + Paclitaxel	Phase III	Actionable	In a Phase III trial, MYL-1401O demonstrated safety and efficacy comparable to Herceptin (trastuzumab) when given in combination with Taxol (paclitaxel), resulted in an objective response rate of 69.6% in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in partial response in 14% (2/14) and stable disease in 21% (3/14) of patients with ERBB2 (HER2)-positive tumors, including breast, gastric, esophageal, colorectal, and adnexal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	ductal carcinoma in situ	predicted - sensitive	HER2-pulsed DC1 vaccine	Phase Ib/II	Actionable	In a Phase I/Ib clinical trial, vaccination with a HER2-peptide pulsed dendritic cell vaccine was well-tolerated and resulted in immune response in patients with ERBB2 (HER2)-positive ductal carcinoma in situ (DCIS), and resulted in pathologic complete response rate of 28% (12/42), compared to 8.3% (1/12) in patients with invasive breast cancer (PMID: 27965306).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Afatinib + Trastuzumab	Phase I	Actionable	In a Phase I clinical trial, ERBB2 (HER2)-positive breast cancer patients treated with Gilotrif (afatinib), in combination with Herceptin (trastuzumab), demonstrated an overall objective response rate of 11% (2/18)  while 28% (5/18) attained a best response of stable disease (PMID: 25370464).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast carcinoma	sensitive	SYD985	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, SYD985 decreased survival of ERBB2 (HER2)-positive breast carcinoma cell lines in culture, and inhibited tumor growth and induced tumor remission in cell line and patient-derived xenograft models of ERBB2 (HER2)-positive breast carcinoma, including models with low ERBB2 (HER2) expression (PMID: 25589493).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	HER2 Vaccine	Phase II	Actionable	In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Capecitabine + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Tucatinib (ARRY-380) with other agents demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 1/1 evaluable patient treated with Tucatinib (ARRY-380) and Capecitabine achieving CNS partial response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	ABP 980	Phase III	Actionable	In a Phase III trial, ABP 980 treatment demonstrated safety and efficacy similar to Herceptin (trastuzumab), with pathologic complete response rates of 48% and 40.5%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 151PD; NCT01901146).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trastuzumab + TS-1	Phase II	Actionable	In a Phase II clinical trial, the combination of TS-1 (S-1) and Herceptin (trastuzumab) demonstrated safety and efficacy in patients with ERBB2 (HER2)-positive metastatic breast cancer, with an overall response rate of 53.6% (15/28), and a clinical benefit rate of 75.0% (21/28)  (PMID: 24982373).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Copanlisib	Preclinical	Actionable	In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2)-over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Trastuzumab + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib clinical trial, the combination of Tucatinib (ARRY-380) and Herceptin (trastuzumab) demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 100% (3/3) patients achieving CNS stable disease as best response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	ovarian cancer	sensitive	PRS-343	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRS-343 induced localized immune activation in cell line xenograft models of Erbb2 (Her2)-positive ovarian cancer, resulted in significant tumor growth inhibition (Eur J Cancer, Dec 2016, 69 (Suppl. 1): S99, abstract 301).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	MGAH22	Phase I	Actionable	In a Phase I trial, Margetuximab (MGAH22) treatment resulted in tumor reduction in 78% (18/23) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 28119295).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Pertuzumab + Trastuzumab + Docetaxel	FDA approved	Actionable	In a Phase III trial (CLEOPATRA) that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and Taxotere (docetaxel), improved median progression free survival to 18.5 months compared to 12.4 months with placebo plus Herceptin (trastuzumab) and Taxotere (docetaxel) in patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 23801166).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast cancer	sensitive	XMT-1522	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, XMT-1522 inhibited growth of Erbb2 (Her2)-positive breast cancer cells in culter, resulted in tumor regression in both cell line and patient-derived xenograft models (Cancer Res 2016;76(4 Suppl): Abstract nr P4-14-28).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	ovarian cancer	sensitive	Hertuzumab-vc-MMAE	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive ovarian cancer cell lines in culture and inhibited tumor growth in ERBB2 (HER2)-positive ovarian cancer cell line xenograft models (PMID: 27509865).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	glioblastoma multiforme	sensitive	HER2 CAR-T cells	Phase I	Actionable	In a Phase I trial, glioblastoma patients positive for ERBB2 (HER2) demonstrated antitumor activity when treated with ERBB2 (HER2)-CAR-T cell therapy including one patient with a partial response and seven patients with stable disease ranging from 8 weeks to 29 months (PMID: 28426845).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	SB3	Phase III	Actionable	In a Phase III trial, SB3 treatment demonstrated safety, immunogenicity, and survival result similar to Herceptin (trastuzumab), resulted in event-free-survival rates of 92.2% and 91.6%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD; NCT02149524).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	inflammatory breast carcinoma	predicted - sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Gilotrif (afatinib) resulted in a clinical benefit rate of 35% (9/26) in patients with ERBB2 (HER2)-positive inflammatory breast cancer, with 8 confirmed partial responses and 1 patient achieving stable disease for greater than 6 months (PMID: 27923043).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Metformin	Phase III	Actionable	In a Phase III trial, ERBB2 (HER2) positive breast cancer patients with diabetes demonstrated a greater disease free survival and overall survival when treated with Glucophage (metformin) compared to ERBB2 (HER2) positive breast cancer patients with diabetes not treated with Glucophage (metformin) (PMID: 28375706).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	ovarian cancer	sensitive	MI130004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive ovarian cancer cells in culture, and led to decreased tumor volume, reduced ERBB2 (HER2) expression, and improved survival in cell line xenograft models (PMID: 29440297).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	predicted - sensitive	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	AC480	Phase I	Actionable	In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Entinostat + Lapatinib	Phase I	Actionable	In a Phase I trial, Entinostat and Tykerb (lapatinib) combination treatment resulted in complete response in 7% (1/15) and stable disease in 27% (4/15) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in a median progression-free survival of 4.04 months, and a disease control rate of 75.49% (77/102; 20 partial responses) in heavily-treated Erbb2 (Her2)-positive breast cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 237O; NCT02418689).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Docetaxel + T-DM1	Phase Ib/II	Actionable	In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine) and Taxotere (docetaxel) combination treatment resulted in median progression-free survival of 13.8 months and objective response in 80.0% (20/25) of patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 27052654).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	colorectal cancer	predicted - sensitive	DS-8201a	Phase I	Actionable	In a Phase I trial, treatment with DS-8201a resulted in a partial response in 40% (2/5) of evaluable patients with colorectal cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	CT-P6	Phase III	Actionable	In a Phase III trial, CT-P6 demonstrated equivalence to reference Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive breast cancer, with 46.8% (116/248) of patients treated with CT-P6 achieving pathologic complete response compared to 50.4% (129/256) with Herceptin (trastuzumab) treatment (PMID: 28592386).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Lapatinib + Palbociclib	Preclinical	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and Ibrance (palbociclib) worked additively to suppress growth of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 25221644).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast cancer	sensitive	DS-8201a	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, DS-8201 inhibited growth of ERBB2 (HER2)-positive breast cancer cell lines in culture and xenograft models, and demonstrated antitumor activity in patient-derived xenograft (PDX) models of ERBB2 (HER2)-positive breast cancer, including models with low ERBB2 (HER2) expression (PMID: 27026201).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in partial response in 28.6% (2/7) and stable disease in 28.6% (2/7) of patients with ERBB2 (HER2)-positive breast cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	MM-302	Phase I	Actionable	In a Phase I study, MM-302 demonstrated safety in patients with ERBB2 (HER2) positive breast cancer (Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-09)
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	colorectal cancer	no benefit	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in disease progression in a patient with ERBB2 (HER2)-positive colorectal cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II clinical trial, Nerlynx (neratinib) demonstrated safety and efficacy as a monotherapy in patients with ERBB2 (HER2)-positive breast cancer (PMID: 23953056).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Neratinib	FDA approved	Actionable	In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Hertuzumab-vc-MMAE	Preclinical - Cell culture	Actionable	In a preclinical study, Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 27509865).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	sarcoma	predicted - sensitive	HER2 CAR-T cells	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with ERBB2 (HER2)-specific CAR-T cells resulted in stable disease for 12 weeks to 14 months in 4/17 evaluable patients with ERBB2 (HER2)-positive sarcomas and a median overall survival of 10.3 months (PMID: 25800760; NCT00902044).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Sunitinib + Trastuzumab	Phase II	Actionable	In a Phase II trial, Sutent (sunitinib), in combination with Herceptin (trastuzumab), demonstrated safety and efficacy in ERBB2 (HER2) positive advanced breast cancer patients (PMID: 24606768).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	breast cancer	sensitive	Withacnistin	Preclinical	Actionable	In a preclinical study, withacnistin induced tumor regression in transgenic mouse models of Erbb2 (Her2)-driven breast cancer (PMID: 24983364).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	sensitive	MI130004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive gastric cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Tucatinib + Trastuzumab emtansine	Phase Ib/II	Actionable	In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in partial response in 33% (11/33) and stable disease in 48% (16/33) and a clinical benefit rate of 58% (19/33) in patients with ERBB2 (HER2)-positive metastatic breast cancer (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-20).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Tucatinib + Trastuzumab emtansine	Phase Ib/II	Actionable	In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in an overall response rate of 47% (15/52) and median progression-free survival of 6.5 months in patients with ERBB2 (HER2)-positive metastatic breast cancer, including patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 513)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Tucatinib + Trastuzumab emtansine	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 12.5% (1/8) evaluable patients achieving CNS complete response, 25% (2/8) partial CNS response, and 62.5% (5/8) CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Docetaxel + T-DM1 + Pertuzumab	Phase Ib/II	Actionable	In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine), Taxotere (docetaxel) and Perjeta (pertuzumab) combination treatment resulted in pathologic complete response in 60.3% (44/73) of patients with ERBB2 (HER2)-positive locally advanced breast cancer (PMID: 27052654).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trastuzumab + Pertuzumab	Phase III	Actionable	In a Phase III trial, adjuvant Herceptin (trastuzumab), Perjeta (pertuzumab), plus chemotherapy resulted in improved invasive disease-free survival compared to Herceptin (trastuzumab) plus chemotherapy in patients with Erbb2 (Her2)-positive breast cancer (J Clin Oncol 35, 2017 (suppl; abstr LBA500)).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trastuzumab + Everolimus + Vinorelbine	Phase III	Actionable	In a Phase III trial (BOLERO-3), the combination of Afinitor (everolimus), Herceptin (trastuzumab), and Navelbine (vinorelbine) increased progression-free survival in patients with Herceptin (trastuzumab)-resistant, ERBB2 (HER2)-positive, advanced breast cancer who had prior taxane treatment (PMID: 24742739; NCT01007942).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	stomach cancer	predicted - sensitive	MEDI4276	Phase I	Actionable	In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab	Guideline	Actionable	Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study	Actionable	In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib + Capecitabine	Phase III	Actionable	In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib	Clinical Study	Actionable	In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PTEN mut	Her2-receptor positive breast cancer	predicted - sensitive	BKM120 + Trastuzumab	Phase I	Actionable	In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR pos ERBB2 pos	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR pos ERBB2 pos	breast cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR pos ERBB2 pos	lung cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR pos ERBB2 pos	colon cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR pos ERBB2 pos	stomach cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR pos ERBB2 pos	urinary bladder cancer	predicted - sensitive	Afatinib + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PTEN dec exp	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study	Actionable	In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 positive KRAS wild-type	colorectal cancer	sensitive	Trastuzumab + Lapatinib	Phase II	Actionable	In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PIK3CA I391M	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PTEN loss	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Phase I	Actionable	In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 pos PTEN loss	Her2-receptor positive breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	PIK3CA mutant ERBB2 pos	Her2-receptor positive breast cancer	decreased response	Trastuzumab + Lapatinib	Phase II	Actionable	In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	PIK3CA mutant ERBB2 pos	Her2-receptor positive breast cancer	decreased response	Trastuzumab + Lapatinib	Clinical Study	Actionable	In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 K753E	breast cancer	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Tykerb (lapatinib) in culture (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 K753E	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753 were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 K753E	breast cancer	resistant	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Herceptin (trastuzumab) in culture (PMID: 27697991).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V839G	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) V839G in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 N857S	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N857S in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 N857S	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2(HER2) N857S in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V659E	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) V659E in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V659E	breast cancer	sensitive	23814 + Tivozanib	Preclinical	Actionable	In a preclinical study, the combination of 23814 and Tivozanib (AV-951) inhibited tumor growth in several transgenic mouse models of breast cancer expressing ERBB2 (HER2) V659E, including those with resistance to VEGFR inhibitors (PMID: 25995436).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V659E	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) V659E did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V659E	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 11.1 months in a patient with biliary tract cancer harboring ERBB2 (HER2) V659E (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V659E	non-small cell lung carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in two patients with non-small cell lung cancer harboring ERBB2 (HER2) V659E (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 wild-type	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, Tagrisso (osimertinib) treatment resulted in antitumor efficacy in cells overexpressing wild-type ERBB2 (HER2), demonstrating inhibition of ERBB2 (HER2) phosphorylation and cell growth in culture and tumor regression in mouse models overexpressing wild-type ERBB2, with an 80% reduction in tumor volume (PMID: 29298799).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 wild-type	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 wild-type	Advanced Solid Tumor	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	EGFR exon 19 del ERBB2 wild-type	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, transgenic mouse models with ERBB2 (HER2)-wild-type cells expressing EGFR exon 19 deletion demonstrated tumor growth inhibition and an improved progression-free survival when treated with Tagrisso (osimertinib) compared to treatment with Tarceva (erlotinib) (PMID: 29298799).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 A775_G776insYVMA	Advanced Solid Tumor	sensitive	JQ1 + Osimertinib	Preclinical	Actionable	In a preclinical study, transgenic mouse models expressing ERBB2 (HER2) A775_G776insYVMA demonstrated greater tumor regression when treated with the combination of JQ1 and Tagrisso (osimertinib) compared to treatment with either agent alone, which resulted in little to no regression (PMID: 29298799).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 A775_G776insYVMA PIK3CA R425L	non-small cell lung carcinoma	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 K831N	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with colorectal cancer harboring ERBB2 (HER2) K831N (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G778A	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with colorectal cancer harboring ERBB2 (HER2) G778A (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V697L	Advanced Solid Tumor	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, a patient with cancer of unknown primary involving the head and neck that harbored ERBB2 (HER2) V697L demonstrated a response to treatment with Nerlynx (neratinib) that lasted 13 months (PMID: 29247016).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V697L	endometrial cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) V697L (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V697L	triple-receptor negative breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, a triple-negative breast cancer patient harboring ERBB2 V697L demonstrated a response to treatment with Nerlynx (neratinib) (PMID: 29247016).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755P	Advanced Solid Tumor	resistant	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755P	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755P	non-small cell lung carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 14.8 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755P (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755P	Advanced Solid Tumor	sensitive	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755P	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S783P	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) S783P were resistant to Tykerb (lapatinib) in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 S783P	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) S783P in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755_T759del	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Nerlynx (neratinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755_T759del	breast cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were resistant to treatment with Tykerb (lapatinib), resulting in decreased growth inhibition (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L755_T759del	breast cancer	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Iressa (gefitinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V773A	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 V773A	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769H	Her2-receptor negative breast cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.5 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) D769H (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769H	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769H	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with colorectal cancer harboring ERBB2 (HER2) D769H (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769H	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769H demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 D769H	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T862A	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N862A in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T862A	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T862A in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G309A	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) G309A demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G309A	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G309A	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G776delinsVV	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G776delinsVV in culture (PMID: 29686424).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 M774delinsWLV	lung adenocarcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II trial, a lung adenocarcinoma patient harboring ERBB2 (HER2) M774delinsWLV demonstrated a partial response to treatment with dacomitinib (PMID: 25899785).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 M774delinsWLV	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) M774delinsWLV in culture (PMID: 28363995).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	breast cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing the ERBB2 (HER2) T798M mutant were resistant to Erbitux (cetuximab)(PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	breast cancer	sensitive	XL147	Preclinical	Actionable	In a preclinical study, breast cancer cell lines expressing ERBB2 (HER2) T798M demonstrated sensitivity to XL147 (SAR245408) in cell culture (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	breast cancer	resistant	CI-1040	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 T798M demonstrated resistance to CI-1040 (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2  (HER2) T798M demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	Advanced Solid Tumor	resistant	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	breast cancer	sensitive	Trastuzumab + XL147	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) T798M were sensitive to the combination of Herceptin (trastuzumab) and XL147 (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	Her2-receptor positive breast cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	breast cancer	sensitive	Buparlisib	Preclinical	Actionable	In a preclinical study, human breast cancer cells expressing the ERBB2 (HER2) T798M mutation demonstrated sensitivity to BKM120 (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	breast cancer	sensitive	Cetuximab + Lapatinib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) inhibited cell growth of a human breast cancer cell line harboring ERBB2 T798M and synergized to inhibit tumor growth in xenograft models (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	Advanced Solid Tumor	sensitive	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	breast cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2(HER2) T798M were sensitive to Gilotrif (afatinib) (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798M	breast cancer	sensitive	Trastuzumab + Lapatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, human breast cancer cell lines and cell line xenografts expressing ERBB2 T798M demonstrated sensitivity to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23948973).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798I	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798I	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T798I in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 T798I	lung cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L785F	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L785F in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L785F	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) L785F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 G292R	urinary bladder cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with bladder cancer harboring both ERBB2 (HER2) G292R (PMID: 29420467; NCT01953926).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L866M	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L866M	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L866M	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L866M	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L866M	colon cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).
ERBB2	CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1	17q12	NM_004448	ERBB2 L866M	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 E317K	melanoma	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth and induced apoptosis in melanoma cells harboring ERBB4 E317K in culture (PMID: 19718025).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 mutant	lung squamous cell carcinoma	predicted - sensitive	Afatinib	Phase III	Actionable	In a Phase III trial (LUX-Lung 8), secondary analysis demonstrated favorable outcomes with Gilotrif (afatinib) treatment compared to Tarceva (erlotinib) in lung squamous cell carcinoma patients with ERBB (HER) family mutations, and ERBB4 (HER4) mutations predicted an OS (HR=0.22) and PFS (HR=0.21) benefit for Gilotrif (afatinib) over Tarceva (erlotinib) treatment (PMID: 29902295; NCT01523587).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 E452K	melanoma	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth and induced apoptosis in melanoma cells harboring ERBB4 E452K in culture (PMID: 19718025).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 G1109C	head and neck squamous cell carcinoma	no benefit	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C were insensitive to treatment with Erbitux (cetuximab) in culture (PMID: 27207775).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 G1109C	head and neck squamous cell carcinoma	no benefit	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C were insensitive to treatment with Tarceva (erlotinib) in culture (PMID: 27207775).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 G1109C	head and neck squamous cell carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) treatment induced apoptosis in head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 E563K	melanoma	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E563K in culture (PMID: 19718025).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 R393W	melanoma	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of melanoma cells harboring ERBB4 R393W in culture (PMID: 19718025).
ERBB4	ALS19 | HER4 | p180erbB4	2q34	NM_005235	ERBB4 R544W	melanoma	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) induced apoptosis in melanoma cells harboring ERBB4 R544W in culture (PMID: 19718025).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-FGFR4	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR4 (TEL-FGFR4) in culture (PMID: 27401245).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 inact mut	acute lymphocytic leukemia	not applicable	N/A	Clinical Study	Risk Factor	In multiple clinical studies, ETV6 inactivating germline mutations were shown to be a risk factor for the development of acute lymphocytic leukemia (PMID: 26522332, PMID: 26102509, PMID: 25807284).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-ALK	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-ALK demonstrated sensitivity  to Entrectinib (RXDX-101) in culture (PMID: 26939704).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	head and neck squamous cell carcinoma	sensitive	Merestinib	Preclinical - Pdx	Actionable	In a preclinical study, a head and neck squamous cell carcinoma patient-derived xenograft (PDX) model harboring ETV6-NTRK3 was sensitive to treatment with Merestinib (LY2801653) compared to vehicle, demonstrating decreased tumor growth (PMID: 29568395).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	congenital fibrosarcoma	not applicable	N/A	Guideline	Diagnostic	ETV6-NTRK3 fusions aid the diagnosis of congenital fibrosarcoma (NCCN.org).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation in culture (PMID: 26939704).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	breast cancer	sensitive	BMS-754807	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BMS-754807 inhibited tumor growth in cell line xenograft models of breast cancer cells overexpressing ETV6-NTRK3 (PMID: 21148487).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Lestaurtinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing the fusion, ETV6-NTRK3, were treated with Lestaurtinib (CEP-701), which resulted in inhibition of ETV6-NTRK3 autophosphorylation and restoration of Tgf-b1 signaling (PMID: 16258068).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	acute myeloid leukemia	sensitive	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited ETV6-NTRK3 activity, reduced cell growth in a human acute myeloid leukemia cell line harboring ETV6-NTRK3, and had anti-tumor activity in xenograft models (PMID: 23811600).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK3 demonstrated sensitivity to Altiratinib (DCC-2701) in culture, resulting in inhibition of Ntrk3 phosphorylation and decreased cell proliferation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 790).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	cancer	sensitive	Midostaurin	Preclinical	Actionable	In a preclinical study, the broad spectrum kinase inhibitor midostaurin inhibited growth of cells dependent on the fusion protein ETV6-NTRK3, reducing ETV6-NTRK3 kinase activity and downstream signaling and inducing apoptosis (PMID: 23131561).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	Advanced Solid Tumor	sensitive	BMS-536924	Preclinical	Actionable	In a preclinical study, transformed human cells expressing ETV6-NTRK3 were sensitive to BMS-536924, demonstrating a reduction in both cell survival and transformation activity in culture (PMID: 21804605).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	gastrointestinal stromal tumor	predicted - sensitive	Larotrectinib	Phase I	Actionable	In a Phase I trial, Larotrectinib treatment resulted in complete response in 1 and partial response in 2 patients with gastrointestinal stromal tumor harboring ETV6-NTRK3 fusions (PMID: 29466156, Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	small intestine neuroendocrine neoplasm	sensitive	Entrectinib	Clinical Study	Actionable	In a clinical study, Entrectinib (RXDX-101) treatment resulted in rapid response and tumor necrosis in a patient with small intestine neuroendocrine tumor who harbored a ETV6-NTRK3 fusion (PMID: 29118225).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	salivary gland cancer	sensitive	Entrectinib	Phase I	Actionable	In a Phase I clinical trial, treatment with Entrectinib (RXDX-101) resulted in a durable partial response in a patient with mammary analogue secretory carcinoma harboring ETV6-NTRK3 (PMID: 26884591).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	acute myeloid leukemia	sensitive	Larotrectinib	Preclinical	Actionable	In a preclinical study, LOXO-101 inhibited cell growth and downstream signaling in acute myeloid leukemia cells harboring ETV6-NTRK3 in culture and xenografts (PMID: 26216294).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	melanoma	sensitive	DS-6051a	Preclinical - Cell culture	Actionable	In a preclinical study, DS-6051a inhibited MAPK, PI3K, and PLCgamma-1 signaling in transformed melanocytes expressing ETV6-NTRK3 in culture (PMID: 27477320).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	fibrosarcoma	predicted - sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in an objective response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 fusion (J Clin Oncol 36, 2018 (suppl; abstr 10536); NCT02650401).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	congenital fibrosarcoma	sensitive	Larotrectinib	Clinical Study	Actionable	In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 demonstrated tumor regression by 90% when treated with LOXO-101 (PMID: 28578312).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	congenital fibrosarcoma	sensitive	Larotrectinib	Phase Ib/II	Actionable	In a Phase I/II trial, Larotrectinib treatment resulted in complete response in 33.3% (2/6) and partial response in 66.7% (4/6) of pediatric patients with congenital fibrosarcoma harboring ETV6-NTRK3 fusions (PMID: 29606586; NCT02637687).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK3	congenital fibrosarcoma	sensitive	Larotrectinib	Phase I	Actionable	In a Phase I clinical trial, treatment with LOXO-101 resulted in a partial response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 (PMID: 27093299).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 - JAK2 JAK2 G831R	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-JAK2 JAK2 V881A	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-JAK2	hematologic cancer	sensitive	NS-108	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing ETV6-JAK2 were sensitive to treatment with NS-108, demonstrating inhibition of cell growth in culture (PMID: 22829185).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-JAK2 JAK2 R975G	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 - JAK2 JAK2 R1127K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 - JAK2 JAK2 P1057S	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 - JAK2 JAK2 Y918H	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 - JAK2 JAK2 G935R	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-JAK2 JAK2 N909K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 - JAK2 JAK2 E864K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 - JAK2 JAK2 M929I	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-PDGFRA	chronic leukemia	sensitive	Imatinib	Clinical Study	Actionable	In a clinical case report, a patient with ETV6-PDGFRA positive chronic eosinophilic leukemia experienced complete cytogenic remission after treatment with Gleevec (imatinib) (PMID: 17555450).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-JAK3	hematologic cancer	predicted - resistant	NS-108	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing ETV6-JAK3 were insensitive to treatment with NS-108 in culture (PMID: 22829185).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-SYK	Advanced Solid Tumor	sensitive	HMPL-523	Preclinical - Cell culture	Actionable	In a preclinical study, HMPL-523 decreased viability of cells expressing ETV6-SYK in culture (Blood Dec 2016, 128 (22) 3970).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	ETV6 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, ETV6 mutations were associated with a shorter overall survival in patients with myelodysplastic syndrome (PMID: 21714648, PMID: 21877899, PMID: 26769228).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-NTRK2	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation in culture (PMID: 26939704).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-FGFR3	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR3 (TEL-FGFR3) in culture (PMID: 27401245).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-RUNX1	acute lymphocytic leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, the ETV6-RUNX1 fusion was associated with a favorable prognosis in acute lymphocytic leukemia patients (PMID: 8609706, PMID: 10086740, PMID: 11432885, Guidelines).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-RUNX1	acute lymphocytic leukemia	not applicable	N/A	Clinical Study	Diagnostic	ETV6-RUNX1 is used in the diagnosis of acute lymphocytic leukemia (PMID: 26711002, PMID: 15704129, PMID: 8609706, Guidelines).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-FGFR1	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR1 (TEL-FGFR1) in culture (PMID: 27401245).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-ROS1	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing ETV6-ROS1 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation in culture and decreased tumor growth in xenograft models (PMID: 26939704).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-ABL1	chronic myeloid leukemia	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical case study, a patient with chronic myeloid leukemia harboring ETV6-ABL1 achieved a complete haematological response after 4 weeks of Gleevec (imatinib mesylate) treatment, but the disease progressed at 6 months (PMID: 24053143).
ETV6	TEL | TEL/ABL | THC5	12p13.2	NM_001987	ETV6-ABL1	chronic myeloid leukemia	predicted - sensitive	Nilotinib	Clinical Study	Actionable	In a clinical case study, Tasigna (nilotinib)  treatment resulted in a complete haematological response after 4 weeks of treatment and sustained complete cytogenetic response and major molecular response at 22 months from diagnosis in a patient with chronic myeloid leukemia harboring ETV6-ABL1, whose disease progressed while on Gleevec (imatinib mesylate) at 6 months from diagnosis (PMID: 24053143).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y646N	melanoma	sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 treatment inhibited cell growth via suppression of downstream tumor suppressor gene targets and induced apoptosis in melanoma cells harboring EZH2 Y646N in culture (PMID: 26304929).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y646N	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell culture	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 F120L EZH2 Y111N	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell culture	Actionable	In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were sensitive to EED226, demonstrating inhibition of cell proliferation in culture (PMID: 28135235).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 F120L EZH2 Y111N	Advanced Solid Tumor	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, a cancer cell line co-expressing EZH2 F120L and EZH2 Y111N was resistant to Tazemetostat (EPZ-6438) in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 F120L EZH2 Y111N	diffuse large B-cell lymphoma	resistant	EI1	Preclinical - Cell culture	Actionable	In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were resistant to EI1 in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	EZH2 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 mutant	myelodysplastic/myeloproliferative neoplasm	not applicable	N/A	Guideline	Prognostic	EZH2 mutations are associated with a poor prognosis in patients with myelodysplastic/myeloproliferative neoplasm (NCCN.org).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	EZH2 mutations are associated with inferior overall survival in patients with myelofibrosis (NCCN.org).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 mutant	diffuse large B-cell lymphoma	sensitive	A-395	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring an EZH2 mutation demonstrated sensitivity to A-395, showing inhibition of tumor growth, however, due to its chemical properties A-395 will not proceed to clinical development (PMID: 28135237).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y646S	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell culture	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646S demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641S	diffuse large B-cell lymphoma	decreased response	DZNeP	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with DZNeP resulted in a slight increase in number of dead or sub-G1 cells and accumulation of DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641S	diffuse large B-cell lymphoma	sensitive	ACY-957 + DZNeP	Preclinical	Actionable	In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641S	diffuse large B-cell lymphoma	sensitive	ACY-957 + GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641S	diffuse large B-cell lymphoma	sensitive	ACY-957	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641S	diffuse large B-cell lymphoma	sensitive	Vorinostat	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641S	melanoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 reversed transcriptional silencing in human melanoma cells harboring wild-type EZH2 Y641S in culture (PMID: 26936398).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641S	diffuse large B-cell lymphoma	decreased response	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with GSK126 did not alter cell-cycle progression or decrease survival in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y646F	lymphoma	sensitive	Tazemetostat	Preclinical	Actionable	In a preclinical study, treatment with EPZ-6438 inhibited proliferation and promoted cell death in lymphoma cells expressing EZH2 Y646F (PMID: 24563539).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y646F	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell culture	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646F demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 T678_R679delinsKK	acute myeloid leukemia	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, a murine acute myeloid leukemia cell line expressing EZH2 T678_R679delinsKK were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 28231254).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y646H	non-Hodgkin lymphoma	sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in partial response for more than 16 weeks in a non-Hodgkin lymphoma patient harboring a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12C EZH2 pos	pancreatic cancer	sensitive	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12C EZH2 pos	lung adenocarcinoma	sensitive	DZNep + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C, in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12C EZH2 pos	lung adenocarcinoma	no benefit	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12C EZH2 pos	lung adenocarcinoma	no benefit	MK2206 + Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12C EZH2 pos	lung adenocarcinoma	sensitive	GSK343 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12C EZH2 pos	lung adenocarcinoma	no benefit	GSK343 + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12C EZH2 pos	pancreatic cancer	sensitive	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12C EZH2 pos	lung adenocarcinoma	sensitive	Selumetinib + Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	colon cancer	sensitive	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	lung adenocarcinoma	sensitive	DZNep + MK2206	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	lung adenocarcinoma	sensitive	MK2206 + Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	colon cancer	no benefit	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	pancreatic cancer	sensitive	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	lung adenocarcinoma	no benefit	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	lung adenocarcinoma	no benefit	Selumetinib + Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	lung adenocarcinoma	sensitive	GSK343 + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	pancreatic cancer	no benefit	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12D EZH2 pos	lung adenocarcinoma	no benefit	GSK343 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 positive	non-Hodgkin lymphoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a total response rate of 60% (9/15) in non-Hodgkin lymphoma patients harboring wild-type EZH2 (n=13/14 tested) or an EZH2 Y646H mutation (n=1/14 tested) (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 positive	follicular lymphoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) treatment in non-Hodgkin lymphoma (NHL) patients carrying wild-type EZH2 or an EZH2 Y646H mutation resulted in an objective response rate of 60% (3/5) among patients with follicular lymphoma (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 positive	diffuse large B-cell lymphoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) treatment in non-Hodgkin lymphoma (NHL) patients carrying wild-type EZH2 or an EZH2 Y646H mutation resulted in an objective response rate of 56% (5/9) among patients with diffuse large B-cell lymphoma (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12V EZH2 pos	lung adenocarcinoma	no benefit	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12V EZH2 pos	lung adenocarcinoma	no benefit	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12S EZH2 pos	lung adenocarcinoma	sensitive	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	KRAS G12S EZH2 pos	lung adenocarcinoma	sensitive	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y111D SMARCB1 inact mut	rhabdoid cancer	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y111D	Advanced Solid Tumor	resistant	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to GSK126 treatment in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y111D	Advanced Solid Tumor	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y111D EZH2 Y641F	Advanced Solid Tumor	decreased response	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y111D EZH2 Y641F	Advanced Solid Tumor	predicted - resistant	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to GSK126 in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 A677G EZH2 Y111D	Advanced Solid Tumor	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous A677G and Y111D mutations were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 A677G EZH2 Y111D	Advanced Solid Tumor	resistant	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous A677G and Y111D mutations were resistant to GSK126 in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 A677G EZH2 Y111D	B-cell lymphoma	resistant	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, EZH2 Y111D conferred resistance to GSK126 when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 A677G EZH2 Y111D	B-cell lymphoma	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, EZH2 Y111D conferred resistance to Tazemetostat (EPZ-6438) when occurring in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641F	lymphoma	sensitive	EPZ005687	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with EPZ005687 decreased proliferation and induced cell killing in a lymphoma cell line harboring EZH2 Y641F in culture (PMID: 23023262).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 wild-type	melanoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited H3K27 trimethylation in human melanoma cells harboring wild-type EZH2 in culture (PMID: 26936398).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641H	melanoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641H in culture (PMID: 26936398).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	EED226 + EI1	Preclinical - Cell culture	Actionable	In a preclinical study, EED226 and EI1 synergistically inhibited cell proliferation in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 28135235).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture and delayed tumor growth and tumor regression in a cell line xenograft model (PMID: 28135235).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	no benefit	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 alone did not alter cell-cycle progression in survival in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	ACY-957 + GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	melanoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641N in culture (PMID: 26936398).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	ACY-957	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	ACY-957 + Doxorubicin	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641N treated with the combination of ACY-957 and Adriamycin (doxorubicin) resulted in a greater sensitivity to cell death compared to treatment with either agent alone (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	UNC1999	Preclinical	Actionable	In a preclinical study, UNC1999 treatment reduced H3K27me3 levels, decreased proliferation, and increased cell death in diffuse large B-cell lymphoma cells harboring an EZH2 Y641N mutation in cell culture (PMID: 23614352).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	ACY-957 + DZNeP	Preclinical	Actionable	In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	Vorinostat	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 Y641N	diffuse large B-cell lymphoma	predicted - sensitive	DZNeP	Preclinical - Cell culture	Actionable	In a preclinical study, DZNeP treatment resulted in an increase in the number of dead or sub-G1 cells and increased DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 over exp	non-small cell lung carcinoma	sensitive	JQEZ5	Preclinical	Actionable	In a preclinical study, JQEZ5 inhibited proliferation of human EZH2-overexpressing non-small cell lung cancer cells in culture and induced tumor regression in mouse models of EZH2-overexpressing lung adenocarcinoma (PMID: 27312177).
EZH2	ENX-1 | ENX1 | EZH2b | KMT6 | KMT6A | WVS | WVS2	7q36.1	NM_001203247	EZH2 over exp	medulloblastoma	predicted - sensitive	MC3629	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MC3629 decreased proliferation and induced apoptosis in human and mouse primary SHH-subgroup medulloblastoma (SHH-MB) derived stem-cell like cells expressing high EZH2 levels in culture, decreased viability of a human SHH-MB cell line expressing high EZH2 in culture, and increased apoptosis and decreased growth of human SHH-MB cell line derived stem-cell like cells in culture and in xenograft models (PMID: 28978137).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 R505L	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R505L may conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 del	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, homozygous deletion of FBXW7 is conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 R479Q	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R479Q conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 R505C	colorectal cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cell lines with FBXW7 R505C demonstrated acquired resistance in regorafenib (PMID: 27399335).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 R505C	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R505C conferred resistance to gamma secretase inhibitor, MRK-300, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 R505C	head and neck squamous cell carcinoma	sensitive	Vorinostat	Preclinical	Actionable	In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring FBXW7 R505C in culture (PMID: 23274910).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	hematologic cancer	sensitive	Entinostat	Preclinical	Actionable	In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	hematologic cancer	sensitive	AR-42	Preclinical	Actionable	In a preclinical study, AR-42 inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	Advanced Solid Tumor	sensitive	AR-42	Preclinical	Actionable	In a preclinical study, AR-42 inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	Advanced Solid Tumor	sensitive	Belinostat	Preclinical	Actionable	In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	Advanced Solid Tumor	resistant	Docetaxel	Preclinical	Actionable	In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	hematologic cancer	sensitive	Belinostat	Preclinical	Actionable	In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	fibrolamellar carcinoma	sensitive	Sirolimus	Phase I	Actionable	In a Phase I study, Rapamune (sirolimus) resulted in prolonged stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring a FBXW7 mutation (PMID: 24586741).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	breast cancer	sensitive	Sirolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 inact mut	Advanced Solid Tumor	sensitive	Entinostat	Preclinical	Actionable	In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 loss	colon cancer	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) inhibited epithelial-mesenchymal transition, motility, and invasiveness in colon cancer cells lacking FBXW7 in culture (PMID: 23558291)
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 R465C	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R465C conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 R465H	lung adenocarcinoma	sensitive	Temsirolimus	Clinical Study	Actionable	In a clinical case report, a patient with lung adenocarcinoma harboring FBXW7 R465H demonstrated tumor shrinkage when treated with Torisel (temsirolimus) (PMID: 24360397).
FBXW7	AGO | CDC4 | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10	4q31.3	NM_033632	FBXW7 R465H	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R465H conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 dec exp KRAS mut	lung cancer	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 dec exp KRAS mut	pancreatic cancer	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 dec exp KRAS mut	colorectal cancer	no benefit	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 dec exp KRAS wild-type	lung cancer	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 wild-type	lung cancer	decreased response	AZD4547	Preclinical	Actionable	In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 wild-type	breast cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, ER-positive breast cancer cells with wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EGFR mutant FGFR1 wild-type	non-small cell lung carcinoma	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp KRAS G12V	non-small cell lung carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in FGFR1-amplified non-small cell lung carcinoma cells overexpressing KRAS G12V in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp KRAS G12V	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line harboring FGFR1 amplification and KRAS G13C demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp KRAS G12V	non-small cell lung carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of KRAS G12V in FGFR1-amplified non-small cell lung carcinoma cells resulted in decreased response to BGJ398 in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	breast cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling and growth of FGFR1-amplified non-small cell lung carcinoma cells in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	synovial sarcoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	adrenocortical carcinoma	sensitive	Derazantinib	Phase I	Actionable	In a Phase I trial, ARQ 087 treatment resulted in stable disease with a tumor reduction of 20% in an adrenocortical carcinoma patient harboring FGFR1 amplification, who remained on study for 3.5 years (PMID: 28972963; NCT01752920).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung squamous cell carcinoma	no benefit	Dovitinib	Phase II	Actionable	In a Phase II clinical trial, dovitinib treatment resulted in a objective response rate of 11.5% (3/26, all partial responses) and disease control rate of 50% (13/26), and a median progression-free survival of 2.9 months in lung squamous cell carcinoma patients with FGFR1 amplification, and FGFR1 amplification was not determined to be a predictive biomarker for sensitivity (PMID: 27315356).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	sensitive	GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified lung small cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in estrogen receptor (ER)-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung squamous cell carcinoma	no benefit	AZD4547	Phase I	Actionable	In a Phase Ib trial, AZD4547 demonstrated limited efficacy in patients with squamous cell lung cancer with FGFR1 amplification, resulting in an overall response rate of 8% (1/15) and a median overall survival of 4.9 months (PMID: 28615371; NCT00979134).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung squamous cell carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung cancer	predicted - sensitive	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Erdafitinib (JNJ-42756493) inhibited FGFR downstream signaling and proliferation of several lung cancer cell lines with FGFR1 amplification in culture, and inhibited tumor growth in an FGFR1-amplified lung cancer cell line xenograft model (PMID: 28341788).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of non-small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung carcinoma	sensitive	Lucitanib	Preclinical - Cell line xenograft	Actionable	in a preclinical study, Lucitanib (E-3810) preferentially inhibited growth of FGFR1-amplified lung carcinoma cell lines in culture and in cell line xenograft models (PMID: 27988457).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung adenocarcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 64.6% tumor growth inhibition in patient-derived xenograft models of FGFR1-amplified lung adenocarcinoma (PMID: 28978721).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	synovial sarcoma	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	sensitive	Cisplatin + Etoposide + GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, addition of GSK3052230 (FP-1039) to Platinol (cisplatin) and Vepesid (etoposide) resulted in improved tumor growth inhibition in cell line xenograft models of FGFR1 amplified lung small cell carcinoma (PMID: 23536011).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	estrogen-receptor positive breast cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-positive breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification (PMID: 7506125) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung squamous cell carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, patients with lung squamous cell carcinoma harboring an FGFR1 amplification demonstrated a disease control rate of 50% (18/36) when treated with BGJ398, resulting in 14 patients with stable disease and 4 patients with a partial response (PMID: 27870574).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	Ewing sarcoma	predicted - sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of Ewing’s sarcoma cell lines with FGFR1 copy number gain in culture (PMID: 26179511).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung large cell carcinoma	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of a large cell lung cancer cell line harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	Her2-receptor positive breast cancer	sensitive	Dovitinib	Phase I	Actionable	In a Phase I trial, Dovitinib (TKI258) promoted 6-month stable disease in Erbb2 (Her2)-positive breast cancer patients with FGFR1 amplification (PMID: 23658459).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	breast cancer	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, 28% (9/32) of breast cancer patients harboring FGFR1 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung cancer	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of lung cancer cell lines harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	transitional cell carcinoma	sensitive	AZD4547 + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line with FGFR1 amplification in culture, with increased efficacy over either agent alone (PMID: 28108151).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	sensitive	AZD4547 + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a small cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Lucitanib	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification demonstrated sensitivity to treatment with Lucitanib (E-3810) in culture (PMID: 27126994).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	predicted - sensitive	NGI-1	Preclinical - Cell culture	Actionable	In a preclinical study, NGI-1 inhibited FGFR1 phosphorylation and proliferation of a FGFR1-amplified cell line dependent on FGFR1 signaling in culture, however, did not inhibit proliferation of an FGFR1-amplified cell line not dependent on FGFR1 signaling (PMID: 27694802).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	sensitive	GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified non-small cell lung carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung squamous cell carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	sensitive	AZD4547	Preclinical - Pdx	Actionable	In a preclinical study, AZD4547 inhibited FGFR1 signaling and resulted in tumor regression in patient-derived xenograft models of non-small cell lung carcinoma harboring FGFR1 amplification, wild-type for EGFR, K-Ras and negative for EML4-ALK fusion (PMID: 23082000).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of lung cancer cells with FGFR1 amplification in culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	breast cancer	no benefit	AZD4547	Phase II	Actionable	In a Phase II clinical trial, treatment with AZD4547 resulted in a response rate of 12.5% (1/8) in patients with FGFR1-amplified breast cancer, and did not meet the predetermined criteria for efficacy (PMID: 27179038).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	estrogen-receptor positive breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring an FGFR1 amplification demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27126994).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung squamous cell carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung squamous cell carcinoma	sensitive	AZD4547 + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a squamous cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a non-small cell lung cancer cell line, harboring FGFR1 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of estrogen receptor (ER)-positive breast cancer cells with FGFR1 amplification in culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 96.1% tumor growth inhibition in patient-derived xenograft models of FGFR1-amplified non-small cell lung cancer (PMID: 28978721).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung cancer	sensitive	GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (56% vs 22%) in cell line xenograft models of FGFR1 amplified lung cancer compared to FGFR1 non-amplified models (PMID: 23536011).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	Her2-receptor negative breast cancer	sensitive	Pazopanib	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring FGFR1 amplification demonstrated antitumor activity when treated with Votrient (pazopanib), including a near complete loss of brain lesions and improved function of the liver (PMID: 29223982).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited Erk signaling and growth of FGFR1-amplified non-small cell lung carcinoma cells in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung squamous cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of squamous cell lung cancer cell lines harboring FGFR1 amplification (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of a small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 23082000).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (nintedanib) inhibited the growth of ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	lung small cell carcinoma	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, a small cell lung cancer cell line harboring FGFR1 amplification demonstrated sensitivity to E7090, resulting in decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	synovial sarcoma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp	non-small cell lung carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EML4-ALK FGFR1 amp	non-small cell lung carcinoma	predicted - resistant	Brigatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Alunbrig (brigatinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, FGFR1 amplification (PMID: 29636358).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET amp	lung squamous cell carcinoma	predicted - resistant	BGJ398	Phase I	Actionable	In a Phase I trial, MET amplification was detected in a squamous cell lung cancer patient harboring FGFR1 amplification whose disease relapsed after 17 months of BGJ398 treatment, supporting a role of MET amplification in drug resistance in FGFR1-amplified lung cancer (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET amp	lung cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, MET amplification was identified as the mechanism mediating acquired AZD4547 resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET amp	lung cancer	sensitive	AZD4547 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to AZD4547 through MET amplification in culture (PMID: 27429073).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp KRAS amp	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and KRAS demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET pos	lung cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to Rogaratinib (BAY 1163877)  in culture (PMID: 27429073).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET pos	lung cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to AZD4547 in culture (PMID: 27429073).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp NRAS amp	non-small cell lung carcinoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification were resistant to Mekinist (trametinib) in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp NRAS amp	non-small cell lung carcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of NRAS was identified in a non-small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp NRAS amp	non-small cell lung carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp FGFR2 amp	breast cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET dec exp	lung cancer	sensitive	Rogaratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET dec exp	lung cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EGFR amp FGFR1 amp KRAS G13C	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET over exp	lung cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, MET overexpression and activation was identified as the mechanism mediating acquired Rogaratinib (BAY 1163877) resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET over exp	lung small cell carcinoma	sensitive	BGJ398 + EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and EMD 1214063 synergistically inhibited growth of small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET over exp	lung small cell carcinoma	sensitive	BGJ398 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Xalkori (crizotinib) synergistically inhibited Erk signaling, resulted in growth inhibition in small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET over exp	lung small cell carcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression and activation of Met was identified in a small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp MET over exp	lung cancer	sensitive	Crizotinib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to Rogaratinib (BAY 1163877) through MET overexpression and activation in culture (PMID: 27429073).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EGFR over exp FGFR1 amp	head and neck squamous cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EGFR over exp FGFR1 amp	head and neck squamous cell carcinoma	sensitive	AZD4547 + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EGFR amp FGFR1 amp	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp NRAS over exp	non-small cell lung carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of Nras in FGFR1-amplified non-small cell lung carcinoma cells resulted in decreased response to BGJ398 in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 amp NRAS over exp	non-small cell lung carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in FGFR1-amplified non-small cell lung carcinoma cells overexpressing Nras in culture (PMID: 28630215).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 rearrange	lung small cell carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of small cell lung cancer cells harboring FGFR1 translocation in culture (PMID: 27550940).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 rearrange	leukemia	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 inhibited survival of leukemia cells harboring FGFR1 translocation in culture and in cell line xenograft models (PMID: 27550940).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 rearrange	myeloproliferative neoplasm	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, primary cells from 8p11 myeloproliferative syndrome patients harboring FGFR1 rearrangement were sensitive to Dovitinib (TKI258)-induced growth inhibition in culture (PMID: 17698633).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 pos FGFR2 pos	hepatocellular carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 pos FGFR2 pos	hepatocellular carcinoma	no benefit	PHA-665752	Preclinical - Cell culture	Actionable	In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	synovial sarcoma	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	lung adenocarcinoma	sensitive	AZD4547 + Vistusertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture and in cell line xenograft models (PMID: 26359452).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	uterus leiomyosarcoma	decreased response	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	synovial sarcoma	decreased response	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	lung large cell carcinoma	sensitive	AZD4547 + Vistusertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture and in cell line xenograft models (PMID: 26359452).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	leiomyosarcoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	lung large cell carcinoma	sensitive	AZD4547 + AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	uterus leiomyosarcoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	synovial sarcoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	uterus leiomyosarcoma	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	lung adenocarcinoma	sensitive	AZD4547 + Sirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	hemangioma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease with resolution of edema in a patient with FGFR1-positive hemangioendothelioma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	head and neck squamous cell carcinoma	sensitive	AZD4547 + Vistusertib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	lung large cell carcinoma	sensitive	AZD4547 + Sirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	salivary gland adenoid cystic carcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR1-positive adenoid cystic carcinoma of the tongue (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	lung adenocarcinoma	sensitive	AZD4547 + AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	leiomyosarcoma	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 positive	leiomyosarcoma	decreased response	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EGFR neg FGFR1 over exp	head and neck squamous cell carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp PIK3CA mut	estrogen-receptor positive breast cancer	sensitive	Alpelisib + Lucitanib	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Fgfr1 in culture (PMID: 27627808).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp	uterus leiomyosarcoma	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp	uterus leiomyosarcoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp	thyroid cancer	sensitive	Lenvatinib	Preclinical	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited FGFR1 phosphorylation and signaling in thyroid cancer cells overexpressing FGFR1 (PMID: 25295214).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp	uterus leiomyosarcoma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp	head and neck squamous cell carcinoma	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited cell growth and induced apoptosis in HNSCC cells over expressing Fgfr1 in culture and in xenograft models (PMID: 26015511).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp	renal cell carcinoma	not applicable	Sorafenib	Phase II	Emerging	In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 over exp	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing wild-type FGFR1 in culture (PMID: 28978721).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EGFR over exp FGFR1 over exp	esophageal cancer	sensitive	AZD4547	Preclinical - Pdx	Actionable	In a preclinical study, AZD4547 treatment resulted in tumor regression in patient-derived xenograft (PDX) models, with both Egfr and Fgfr1 overexpression (PMID: 28881608),
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EGFR over exp FGFR1 over exp	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment demonstrated decreased efficcacy in patient-derived xenograft (PDX) models of esophageal cancer with both Egfr and Fgfr1 overexpression compared to models with only Egfr overexpression (PMID: 28881608).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 mutant	Advanced Solid Tumor	sensitive	INCB054828	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 mutant	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 40% (6/16) of patients with advanced solid tumors harboring FGFR single nucleotide variants, with a 6-month progression-free survival rate of 8% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 mutant	transitional cell carcinoma	predicted - sensitive	Erdafitinib	Phase II	Actionable	In a Phase II trial, Erdafitinib (JNJ-42756493) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 V561M	Advanced Solid Tumor	sensitive	FIIN-01	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited Fgfr1 autophosphorylation in a human transformed embryonic kidney cell line harboring FGFR1 V561M mutation in culture (PMID: 20338520).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 V561M	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR1 V561M in culture (PMID: 28978721).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1-TACC1	malignant glioma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BJG398 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1-TACC1	malignant glioma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1-TACC1	malignant glioma	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 fusion	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited Erk, Stat5 signaling and survival of transformed cell lines overexpressing FGFR1 fusion proteins (ZMYM2-FGFR1 or BCR-FGFR1) in culture (PMID: 17698633).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 fusion	hematologic cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of hematologic cancer cells harboring FGFROP2-FGFR1 fusion in culture (PMID: 27627808).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 fusion	acute myeloid leukemia	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) increased apoptosis and inhibited survival of acute myelogenous leukemia cell lines harboring FGFR1OP2-FGFR1 fusion in culture (PMID: 17698633).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 fusion	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 42% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 act mut	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 act mut	Advanced Solid Tumor	sensitive	FF-284	Phase I	Actionable	In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 act mut	Advanced Solid Tumor	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 act mut	Advanced Solid Tumor	decreased response	Nintedanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 act mut	Advanced Solid Tumor	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 act mut	breast cancer	sensitive	FIIN-01	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520).
FGFR1	bFGF-R-1 | BFGFR | CD331 | CEK | ECCL | FGFBR | FGFR-1 | FLG | FLT-2 | FLT2 | HBGFR | HH2 | HRTFDS | KAL2 | N-SAM | OGD	8p11.23	NM_023110	FGFR1 act mut	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V565I	Advanced Solid Tumor	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Iclusig (ponatinib) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V565I	Advanced Solid Tumor	resistant	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V565I	Advanced Solid Tumor	resistant	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 E566G	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 E566G (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 E566G	Advanced Solid Tumor	resistant	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 E566G	Advanced Solid Tumor	resistant	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 - CIT	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells expressing FGFR2-CIT in culture (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp FGFR2-COL14A1	colorectal adenocarcinoma	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of colorectal adenocarcinoma cells harboring FGFR2 amplification and FGFR2-COL14A1 fusion in culture (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp FGFR2-COL14A1	colon cancer	sensitive	Derazantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of colon cancer cells harboring FGFR2 amplification and FGFR2-COL14A1 fusion in culture and in cell line xenograft models (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 M538I	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 M538I	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 M538I	Advanced Solid Tumor	decreased response	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	BRCA1 loss FGFR2-DNM3	triple-receptor negative breast cancer	predicted - sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring FGFR2-DNM3 were sensitive to treatment with BGJ398, demonstrating tumor regression, however, after 43 days on average, three out of six models developed resistance (PMID: 29203461).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	BRCA1 loss FGFR2-DNM3	triple-receptor negative breast cancer	decreased response	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models treated with BKM120 demonstrated only delayed tumor progression when compared to treatment with BGJ398, which resulted in tumor regression (PMID: 29203461).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	BRCA1 loss FGFR2-DNM3	triple-receptor negative breast cancer	sensitive	BGJ398 + Talazoparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models treated with a combination of BGJ398 and Talazoparib (BMN-673) demonstrated a complete response and no relapse within 80 days (PMID: 29203461).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	BRCA1 loss FGFR2-DNM3	triple-receptor negative breast cancer	sensitive	BGJ398 + Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring FGFR2-DNM3 treated with a combination of BGJ398 and Lynparza (olaparib) demonstrated a complete response and did not develop resistance as compared to those models treated with BGJ398 alone (PMID: 29203461).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-CASP7	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells expressing FGFR2-CASP7 in culture (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550S	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550S	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550S (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550S	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGR2 E565A FGFR2 K641R FGFR2 L617V FGFR2 N549H FGFR2 V564F FGFR2-OPTN	cholangiocarcinoma	predicted - resistant	BGJ398	Clinical Study	Actionable	In a clinical study, FGFR2 mutations E565A, K641R, L617V, N549H and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-OPTN fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 E565A FGFR2 K659M FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2-ZMYM4	cholangiocarcinoma	predicted - resistant	BGJ398	Clinical Study	Actionable	In a clinical study, FGFR2 mutations E565A, K659M, N549H, N549K and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-ZMYM4 fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660N	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660N	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660N	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR2 K660N in culture (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660N	Advanced Solid Tumor	sensitive	Lenvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660N	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR2 K660N in culture and inhibited tumor growth in xenograft models (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660N	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660N	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	sensitive	Lenvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response when treated with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR2 K660E in culture (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	resistant	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 K660E were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K660E	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion FGFR3 - TACC3	adrenal carcinoma	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion	intrahepatic cholangiocarcinoma	sensitive	Derazantinib	Phase I	Actionable	In a Phase I trial, Derazantinib (ARQ 087) treatment resulted in partial response in 2 and stable disease in 1 of the 5 intrahepatic cholangiocarcinoma patients harboring FGFR2 fusions, and progressive disease in 5 patients without FGFR aberrations (PMID: 28972963; NCT01752920).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion	urinary system cancer	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in partial response for more than 12 months in a urothelial cancer patient harboring FGFR2 - BICC1 and FGFR2 - CASP7 fusions (PMID: 26324363).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion	cholangiocarcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, two patients with cholangiocarcinoma harboring FGFR2 fusions demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion	biliary tract cancer	predicted - sensitive	TAS-120	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in stable disease over 24 weeks in two biliary tract cancer patients harboring FGFR2 fusions (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 42% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion	cholangiocarcinoma	predicted - sensitive	TAS-120	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in an objective response rate of 25% (7/28, 7 partial responses) in patients with cholangiocarcinoma harboring FGFR2 fusions, with 71% of patients experienced tumor shrinkage, 54% (15/28) achieved stable disease (Annals of Oncology, Volume 29, Issue suppl_5).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion	endometrial cancer	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in partial response in an endometrial cancer patient harboring FGFR2 - BICC1 and FGFR2 - OFD1 fusions (PMID: 26324363).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 fusion FGFR2 V564F	cholangiocarcinoma	predicted - resistant	BGJ398	Clinical Study	Actionable	In a clinical study, FGFR2 V564F was identified in the cell-free DNA of 3 cholangiocarcinoma patients harboring FGFR2 fusion after the patients progressed while on BGJ398 treatment (PMID: 28034880).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp FGFR2 fusion	stomach cancer	sensitive	Derazantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of gastric cancer cells harboring FGFR2 amplification and PDHX-FGFR2 fusion in culture, resulted in tumor regression in cell line xenograft models (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp FGFR2 fusion	breast cancer	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified breast cancer harboring FGFR2-GAB2 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V564L	Advanced Solid Tumor	resistant	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564L in culture (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 - TACC3	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 - TACC3 (PMID: 26048680).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 - TACC3	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing the fusion, FGFR2 - TACC3 (PMID: 26048680).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 C383R FGFR2 N550K	endometrial cancer	resistant	PD173074	Preclinical	Actionable	In a preclinical study, an endometrial cancer cell line harboring FGFR2 C383R and expressing FGFR2 N550K demonstrated resistance when treated with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550K	Advanced Solid Tumor	resistant	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550K	Advanced Solid Tumor	resistant	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550K	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR2 N550K in culture (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550K	endometrial cancer	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells harboring Fgfr2 N550K were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550K (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K310R FGFR2 N550K	endometrial cancer	sensitive	AZD4547	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AZD4547 inhibited proliferation of endometrial cells and delayed tumor growth in cell-line derived xenografts harboring the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 pos FGFR3 pos	breast carcinoma	sensitive	E7090	Preclinical	Actionable	In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR1 pos FGFR2 pos	hepatocellular carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR1 pos FGFR2 pos	hepatocellular carcinoma	no benefit	PHA-665752	Preclinical - Cell culture	Actionable	In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 positive	stomach cancer	sensitive	BAY1187982	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, BAY1187982 inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 positive	breast cancer	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR2-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 positive	breast cancer	sensitive	BAY1187982	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, BAY1187982 inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 positive	Advanced Solid Tumor	sensitive	BAY1187982	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, sensitivity to BAY1187982 positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-TNS1	triple-receptor negative breast cancer	no benefit	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated stable disease upon treatment with Buparlisib (BKM120), but also exhibited general toxicity (PMID: 29203461).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-TNS1	triple-receptor negative breast cancer	sensitive	BGJ398 + BKM120	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated rapid and complete tumor regression when treated with the combination of BGJ398 and Buparlisib (BKM120) (PMID: 29203461).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-TNS1	triple-receptor negative breast cancer	sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated tumor regression when treated with BGJ398 (PMID: 29203461).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T	olfactory neuroblastoma	sensitive	Cetuximab + Sunitinib	Clinical Study	Actionable	In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 I548V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 I548V (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 I548V	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 I548V	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K310R FGFR2 N549K	endometrial carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K310R FGFR2 N549K	endometrial carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K310R FGFR2 N549K	endometrial carcinoma	sensitive	FIIN-01	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K310R FGFR2 N549K	endometrial carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 K310R FGFR2 N549K	endometrial cancer	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial cancer	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 N549K mutation in culture (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial carcinoma	sensitive	FIIN-01	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K mutation in culture (PMID: 20338520).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial cancer	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) did not potently inhibit proliferation of endometrial cancer cell lines harboring FGFR2 N549K in cell culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial adenocarcinoma	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of endometrial adenocarcinoma cells harboring FGFR2 N549K in culture (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of endometrial cancer cell lines harboring FGFR2 N549K in culture (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial cancer	resistant	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (Nintedanib) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N549K	endometrial cancer	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in culture and in cell line xenograft models (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 L618M	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 L618M were sensitive to treatment with Iclusig (ponatinib) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 L618M	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 L618M	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 M536I	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 M536I	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 M536I (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 M536I	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-FAM76A	ovarian cancer	sensitive	BGJ398	Preclinical - Patient cell culture	Actionable	In a preclincal study, BGJ398 demonstrated enhanced inhibition of the survival in patient-derived ovarian cancer cells harboring FGFR2 - FAM76A in culture (PMID: 24563622).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 W290C	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR2 W290C in culture and inhibited tumor growth in xenograft models (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 W290C	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 W290C	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 W290C	Advanced Solid Tumor	sensitive	Lenvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 W290C	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 W290C	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	ERBB2 amp FGFR2 amp	esophagus adenocarcinoma	sensitive	AZD4547 + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	predicted - sensitive	TAS-120	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in clinical response in a gastric cancer patient harboring FGFR2 amplification (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	myxoid liposarcoma	sensitive	PD173074 + Trabectedin	Preclinical	Actionable	In a preclinical study, PD173034 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colon cancer	sensitive	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (nintedanib) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	non-small cell lung carcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 67.5% tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified non-small cell lung cancer (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	myxoid liposarcoma	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	breast cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified breast cancer cells in culture (PMID: 27550940).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD-6244) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colorectal adenocarcinoma	decreased response	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells demonstrated decreased response to RO4987655 in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colorectal adenocarcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	myxoid liposarcoma	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 increased apoptosis, and inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification  in culture (PMID: 26036639).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	Her2-receptor positive breast cancer	sensitive	Dovitinib	Phase I	Actionable	In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	breast cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-negative breast cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colon cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified colon cancer cells in culture (PMID: 27550940).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colon cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colorectal cancer	sensitive	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Erdafitinib (JNJ-42756493) inhibited tumor growth in an FGFR2-amplified colorectal cancer cell line xenograft model (PMID: 28341788).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	breast cancer	sensitive	Dovitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell growth of an FGFR2 amplified breast cancer cell line in culture and prevented tumor growth and induced tumor regression in FGFR2 amplified breast cancer patient derived xenograft (PDX) models (PMID: 23658459).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	myxoid liposarcoma	sensitive	Dovitinib + Trabectedin	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colon cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 reduced Myc expression, induced cell-cycle arrest, and inhibited growth of a colon cancer cell line with FGFR2 amplification in culture (PMID: 27401245).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, JNJ-42756493 (erdafitinib) inhibited proliferation of a gastric cancer cell line with FGFR2 amplification in culture, and inhibited tumor growth in xenograft models (PMID: 28341788).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of FGFR2-amplified gastric cancer cells in culture, and inhibited tumor growth in FGFR2-amplified gastric cancer cell line xenograft models (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	FIIN-01	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited Fgfr2-dependent cell proliferation of gastric cancer cell lines harboring FGFR2 amplification (PMID: 20338520).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2-amplified gastric cancer cell lines demonstrated sensitivity to PD173074 in culture, with cell lines with high-level FGFR2 amplification displaying higher sensitivity compared to cell lines with low-level amplification (PMID: 27179038).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited proliferation of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 26036639).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited FGFR signaling, and decreased proliferation and induced cell-cycle arrest in gastric cancer cells with amplification and over expression of FGFR2 in culture (PMID: 22869148).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	AZD4547	Phase II	Actionable	In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colorectal cancer	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of colorectal cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	estrogen-receptor negative breast cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-negative breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach carcinoma	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited tumor growth in cell line xenograft models of FGFR2 amplified gastric carcinoma (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	breast cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of breast cancer cells harboring FGFR2 amplification in culture (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	ovarian cancer	sensitive	BAY1187982	Preclinical - Pdx	Actionable	In a preclinical study, BAY1187982 inhibited tumor growth in patient-derived xenograft models of FGFR2 amplified ovarian cancer (PMID: 27543601).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	myxoid liposarcoma	sensitive	BGJ398 + Trabectedin	Preclinical	Actionable	In a preclinical study, BGJ398 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colon cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of FGFR-amplified gastric cancer cells in culture and inhibited tumor growth in cell line xenograft models of gastric cancer harboring FGFR2 amplification (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 26036639).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach carcinoma	sensitive	PRN1371	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1371 inhibited proliferation of FGFR2 amplified gastric carcinoma cells in culture and tumor growth in cell line xenograft models (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	myxoid liposarcoma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification  in culture (PMID: 26036639).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	gastric adenocarcinoma	no benefit	AZD4547	Phase II	Actionable	In a Phase II trial (SHINE), AZD4547 treatment did not improve progression-free survival compared to Taxol (paclitaxel) (1.8 vs 3.5 months, p=0.9581) in advanced gastric adenocarcinoma patients with FGFR2 amplification (PMID: 29177434; NCT01457846).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	predicted - sensitive	PRN1109	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1109 treatment resulted in tumor regression in gastric cancer cell line xenograft models harboring FGFR2 amplification (Eu J Cancer 2014 Vol 50, Suppl 6:157).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colon cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a gastric cancer cell line harboring FGFR2 amplification demonstrated decreased cell viability in culture and antitumor activity in xenograft models when treated with E7090 (PMID: 27535969).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	gastric signet ring cell adenocarcinoma	sensitive	M-COPA	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with M-COPA resulted in decreased Fgfr2 cell surface expression and phosphorylation and reduced growth of an FGFR2-amplified signet cell gastric cancer cell line in culture (PMID: 27197184).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	breast cancer	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of breast cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	breast cancer	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, a breast cancer patient harboring an FGFR2 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colon cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	stomach carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	colorectal adenocarcinoma	predicted - sensitive	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, RO5126766 inhibited proliferation of FGFR2 amplified colorectal adenocarcinoma cells in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp	endometrial cancer	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified endometrial cancer cells in cell line xenograft models (PMID: 27550940).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	EGFR over exp FGFR2 amp	head and neck squamous cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	EGFR over exp FGFR2 amp	head and neck squamous cell carcinoma	sensitive	AZD4547 + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp FGFR2 over exp	stomach cancer	sensitive	BGJ398	Preclinical - Pdx	Actionable	In a preclinical study, BGJ398 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp FGFR2 over exp	stomach cancer	sensitive	AZD4547	Preclinical - Pdx	Actionable	In a preclinical study, AZD4547 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp FGFR2-GAB2	breast cancer	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 60.6% tumor growth inhibition in patient-derived xenograft models of breast cancer harboring FGFR2 amplification and FGFR2-GAB2 fusion (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR1 amp FGFR2 amp	breast cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 amp FGFR2 rearrange	cholangiocarcinoma	predicted - sensitive	TAS-120	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in partial response in a patient with cholangiocarcinoma harboring FGFR2 rearrangement and FGFR2 amplification (Annals of Oncology, Volume 29, Issue suppl_5).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-AHCYL1	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-AHCYL1	Advanced Solid Tumor	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-BICC1	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-BICC1	Advanced Solid Tumor	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V564F FGFR2-BICC1	cholangiocarcinoma	predicted - resistant	BGJ398	Clinical Study	Actionable	In a clinical study, FGFR2 V564F was identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-BICC1 fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 rearrange	cholangiocarcinoma	predicted - sensitive	TAS-120	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in partial response in 2 patients with cholangiocarcinoma harboring FGFR2 rearrangements (Annals of Oncology, Volume 29, Issue suppl_5).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S267_D273dup	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 S267_D273dup (PMID: 26048680).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S267_D273dup	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 S267_D273dup (PMID: 26048680).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V564I	Advanced Solid Tumor	resistant	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564I in culture (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550H	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550H demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550H	Advanced Solid Tumor	resistant	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550H were resistant to treatment with PD173074 (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 N550H	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550H (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	sensitive	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (Nintedanib) inhibited cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells harboring Fgfr2 S252W were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring an FGFR2 S252W mutation in culture and inhibited tumor growth in FGFR2 S252W-positive endometrial cancer cell line xenograft models (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, an endometrial cancer cell line harboring FGFR2 S252W (PMID: 18552176) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) did not potently inhibit cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial carcinoma	sensitive	GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (95% vs 30%) in cell line xenograft models of endometrial carcinoma harboring FGFR2 S252W compared to FGFR2 wild-type models (PMID: 23536011).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and cell proliferation in endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial carcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased sensitivity to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 S252W were sensitive to Dovitinib (TKI258) (PMID: 23908597).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial carcinoma	decreased response	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased response to RO4987655 in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial cancer	sensitive	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 S252W	endometrial carcinoma	sensitive	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, RO5126766 inhibited proliferation of endometrial carcinoma cells harboring FGFR2 S252W in culture (PMID: 26438159).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V564F	Advanced Solid Tumor	resistant	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to AZD4547 in culture and in cell line xenograft models (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V564F	Advanced Solid Tumor	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR2 V564F in culture and inhibited tumor growth in cell line xenograft models (PMID: 25169980).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 V564F	Advanced Solid Tumor	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to BGJ398 in culture (PMID: 28034880).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 P253R	head and neck squamous cell carcinoma	predicted - sensitive	Pazopanib	Clinical Study	Actionable	In a case study, treatment with Votrient (pazopanib) resulted in reduced tumor size in a patient with head and neck squamous cell carcinoma harboring FGFR2 P253R (PMID: 23786770).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 dec exp	breast cancer	resistant	BAY1187982	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1187982 did not inhibit growth of breast cancer cells with very low Fgfr2 expression level in culture (PMID: 27543601).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 dec exp KRAS mut	lung cancer	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 W290_I291delinsC	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 W290_I291delinsC (PMID: 26048680).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 W290_I291delinsC	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 W290_I291delinsC (PMID: 26048680).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type	stomach cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, gastric cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type	endometrial cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, endometrial cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing wild-type Fgfr2 in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type	breast cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, ER-negative breast cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type	endometrial carcinoma	resistant	FIIN-01	Preclinical	Actionable	In a preclinical study, an endometrial carcinoma cell line harboring wild-type FGFR2 was resistant to FIIN-01-induced growth inhibition in culture (PMID: 20338520).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type	Advanced Solid Tumor	predicted - sensitive	AZ6089	Preclinical	Actionable	In a preclinical study, AZ12576089 (AZ6089) inhibited FGF2-induced ERK1/2 phosphorylation and cell proliferation in transformed fibroblasts in culture (PMID: 22869148).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type	endometrial cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells with Fgfr2 wild-type were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type	colon cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, colon cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 wild-type ERBB2 amp	stomach cancer	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, gastric cancer cells with wild-type FGFR2  and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2-CCDC6	liver cancer	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of liver cancer harboring FGFR2-CCDC6 fusion (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	Advanced Solid Tumor	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	stomach carcinoma	sensitive	S-49076	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring FGFR2 activating mutations in culture and in cell line xenograft models (PMID: 23804704).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	endometrial cancer	sensitive	Dovitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, both cell lines and cell line xenograft models of endometrial cancer with FGFR2 activating mutations showed greater sensitivity to Dovitinib (TKI258) as compared to FGFR2 wild-type (PMID: 23443805).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	Advanced Solid Tumor	decreased response	Brivanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Brivanib (BMS-540215) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	Advanced Solid Tumor	decreased response	Nintedanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 act mut	Advanced Solid Tumor	sensitive	FF-284	Phase I	Actionable	In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR2 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 over exp	breast cancer	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 over exp	breast cancer	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 over exp	colorectal cancer	sensitive	BAY1187982	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1187982 inhibited survival of colorectal cancer cells with over expressing Fgfr2 in culture, and suppressed tumor growth in cell line xenograft models (PMID: 27543601).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 over exp	endometrial cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells with Fgfr2 overexpression were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 over exp	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Fgfr2 in culture and in cell line xenograft models (PMID: 27627808).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 over exp	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing wild-type FGFR2 in culture (PMID: 28978721).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 over exp	breast cancer	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 mutant	endometrial cancer	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited the growth of FGFR2-mutated endometrial cancer cells in vitro and in xenograft models (PMID: 23443805).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 mutant	endometrial cancer	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of endometrial cancer cells harboring FGFR2 mutations in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 mutant	cholangiocarcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, a patient with cholangiocarcinoma harboring an FGFR2 mutation demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 mutant	Advanced Solid Tumor	sensitive	INCB054828	Preclinical - Cell culture	Actionable	In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 mutant	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 40% (6/16) of patients with advanced solid tumors harboring FGFR single nucleotide variants, with a 6-month progression-free survival rate of 8% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR2	BBDS | BEK | BFR-1 | CD332 | CEK3 | CFD1 | ECT1 | JWS | K-SAM | KGFR | TK14 | TK25	10q26.13	NM_000141	FGFR2 mutant	transitional cell carcinoma	predicted - sensitive	Erdafitinib	Phase II	Actionable	In a Phase II trial, Erdafitinib (JNJ-42756493) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	bladder urothelial carcinoma	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in a patient with BCG-unresponsive, non-muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 S249C (PMID: 27932416).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	renal pelvis transitional cell carcinoma	predicted - sensitive	Pazopanib	Clinical Study	Actionable	In a case study, a patient with urothelial carcinoma of the renal pelvis harboring FGFR3 S249C demonstrated a partial response lasting 9 months following treatment with Votrient (pazopanib) (PMID: 27271022).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary bladder cancer	resistant	Nintedanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3 S249C were resistant to Ofev (Nintedanib) induced inhibition of cell proliferation in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited proliferation of transformed cells expressing FGFR3 S249C in culture (PMID: 19381019).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary system cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture (PMID: 27401245).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary bladder cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary bladder cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 S249C in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary system cancer	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 decreased Myc expression and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture and in xenograft models (PMID: 27401245).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	bladder carcinoma	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab decreased dimer formation and constitutive activation of FGFR3 S249C, and inhibited growth of bladder cancer cell lines harboring FGFR3 S249C in culture and in xenograft models (PMID: 19381019).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary bladder cancer	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of bladder cancer cells harboring FGFR3 S249C in culture and in cell line xenograft models (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary bladder cancer	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cells harboring FGFR3 S249C in culture and inhibited tumor growth in FGFR3 S249C-positive bladder cancer cell line xenograft models (PMID: 25169980).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring FGFR3 S249C in culture, and resulted in tumor regression in xenograft models (Mol Cancer Ther December 2015 14; A170).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S249C FGFR3 over exp	transitional cell carcinoma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited growth of urothelial carcinoma (UC) cells expressing high levels of FGFR3 S249C, but had reduced efficacy against UC cells with low levels of FGFR3 S249C expression (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 N540K	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinicl study, Erdafitinib (JNJ-42756493) inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 N540K	Advanced Solid Tumor	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K were resistant to BGJ398 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 N540K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 N540K	Advanced Solid Tumor	decreased response	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 N540K	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 N540K	Advanced Solid Tumor	decreased response	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 N540K	Advanced Solid Tumor	decreased response	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 N540K	Advanced Solid Tumor	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K were reistant to growth inhibition by AZD4547 in culture (PMID: 26992226).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 L608V FGFR3 V555M	transitional cell carcinoma	resistant	BGJ398	Clinical Study	Actionable	In a clinical study, a patient with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555M (also corresponds to V443M) and FGFR3 L608V (also corresponds to L496V) (PMID: 29848605).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555M	Advanced Solid Tumor	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to AZD4547 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555M	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555M	Advanced Solid Tumor	decreased response	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555M	transitional cell carcinoma	resistant	BGJ398	Clinical Study	Actionable	In a clinical study, a patient with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555M (also corresponds to V443M) (PMID: 29848605).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555M	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555M	Advanced Solid Tumor	decreased response	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555M	Advanced Solid Tumor	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to BGJ398 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555M	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	Advanced Solid Tumor	sensitive	LY2874455	Preclinical	Actionable	In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	glioblastoma multiforme	sensitive	U0126	Preclinical	Actionable	In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells over-expressing Fgfr3 in culture (PMID: 23298836).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	transitional cell carcinoma	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	head and neck squamous cell carcinoma	sensitive	Rogaratinib	Preclinical	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) inhibited tumor growth in a head and neck squamous cell carcinoma xenograft model with FGFR3 overexpression (Cancer Res August 1, 2015 75:772).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	transitional cell carcinoma	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	urinary bladder cancer	sensitive	BGJ398	Preclinical - Pdx	Actionable	In a preclinical study, treatment with BGJ398 led to improved progression-free survival in a patient-derived xenograft (PDX) model of  bladder cancer with FGFR3 over expression (PMID: 26270481).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation in transformed cells overexpressing wild-type FGFR3 in culture (PMID: 28978721).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	urinary bladder cancer	sensitive	Sorafenib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, the combination of BEZ235 and Nexavar (sorafenib) resulted in improved progression-free survival in an FGFR3-over expressing patient-derived xenograft (PDX) model of bladder cancer with secondary resistance to BGJ398 due to reactivation of downstream signaling, as evidenced by increased activation of Akt and Erk (PMID: 26270481).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	multiple myeloma	sensitive	MFGR1877S	Phase I	Actionable	In a Phase I trial, MFGR1877S demonstrated safety and resulted in stable disease in 42% (6/14) of multiple myeloma patients overexpressing FGFR3 (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	urinary bladder cancer	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 8% (1/13) of non-muscle invasive bladder cancer patients over expressing FGFR3 (J Clin Oncol 34, 2016 (suppl; abstr 4526)).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 over exp	urinary bladder cancer	sensitive	SU5402	Preclinical	Actionable	In a preclinical study, SU5402 inhibited growth of bladder cancer cells over expressing wild-type FGFR3 in culture (PMID: 21119661).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mut FGFR3 over exp	urinary bladder cancer	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 33% (1/3) of non-muscle invasive bladder cancer patients harboring both FGFR3 mutations and FGFR3 over expression (J Clin Oncol 34, 2016 (suppl; abstr 4526)).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E FGFR3 over exp HRAS K117E	multiple myeloma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E FGFR3 over exp HRAS K117E	myeloid neoplasm	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y373C FGFR3 over exp	multiple myeloma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 signaling and decreased proliferation and survival of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y373C FGFR3 over exp	multiple myeloma	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	AZD4547	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZD4547 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	AZ8010	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZ8010 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to PD173074 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 G372C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent proliferation in cells expressing FGFR3 G372C (PMID: 19381019).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 R248C	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 R248C	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 R248C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-independent proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 R248C	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 F386L	myeloid neoplasm	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 F386L in culture (PMID: 25169980).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 L608V	Advanced Solid Tumor	decreased response	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 L608V	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 L608V	Advanced Solid Tumor	sensitive	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 L608V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 L608V	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 L608V	Advanced Solid Tumor	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to AZD4547 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 L608V	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 dec exp KRAS mut	lung cancer	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	decreased response	AZ8010	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	PD173074	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 rearrange	myeloid neoplasm	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of myeloma cells harboring FGFR3 rearrangements in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 rearrange	myeloid neoplasm	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 inhibited survival of myeloma cells harboring FGFR3 translocation in culture and in cell line xenograft models (PMID: 27550940).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 D788N	head and neck squamous cell carcinoma	no benefit	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D788N in culture, however, cells expressing FGFR3 D788N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 S131L	head and neck squamous cell carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650M	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR3 K650M in culture (PMID: 28978721).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 fusion	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 fusion in culture (PMID: 27550940).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 fusion	transitional cell carcinoma	predicted - sensitive	B-701 + Docetaxel	Phase Ib/II	Actionable	In a Phase I/II trial, B-701 in combination with Taxotere (docetaxel) demonstrated safety and preliminary efficacy, resulted in enhanced activity in patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 mutations or fusions comparing to wild-type patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534; NCT02401542).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 fusion	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 42% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 fusion	transitional cell carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 fusion	Advanced Solid Tumor	predicted - sensitive	TAS-120	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS-120 demonstrated growth inhibition and reduced FGFR phosphorylation in human cancer cell lines and xenograft models harboring FGFR mutations (Mol Cancer Ther 2013;12(11 Suppl):A270).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y373C	myeloid neoplasm	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 Y373C in culture (PMID: 25169980).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y373C	multiple myeloma	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, a multiple myeloma cell line harboring FGFR3 Y373C (PMID: 19901323) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y373C	myeloid neoplasm	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y373C	myeloid neoplasm	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y373C	myeloid neoplasm	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	AKT1 E17K FGFR3 Y373C	urinary bladder cancer	sensitive	AZD5363 + AZD4547	Preclinical	Actionable	In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555L	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555L demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 V555L	transitional cell carcinoma	resistant	BGJ398	Clinical Study	Actionable	In a clinical study, two patients with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555L (also corresponds to V443M) (PMID: 29848605).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K652E	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent cell proliferation in cells expressing FGFR3 K652E in culture (PMID: 19381019).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K652E	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cells harboring FGFR3 K652E in culture (PMID: 27627808).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	sensitive	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinicl study, Erdafitinib (JNJ-42756493) inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	myeloid neoplasm	no benefit	SSR128129E	Preclinical	Actionable	In a preclinical study, SSR128129E did not inhibit proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	sensitive	PD98059	Preclinical	Actionable	In a preclinical study, PD98059 inhibited FGFR3 K650E-induced transformation of cells in culture (PMID: 14534538).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	myeloid neoplasm	sensitive	SU5402	Preclinical - Cell culture	Actionable	In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	myeloid neoplasm	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 K650E in culture (PMID: 25169980).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to growth inhibition by AZD4547 in culture (PMID: 26992226).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 K650E	Advanced Solid Tumor	sensitive	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y375C	urinary bladder cancer	resistant	Nintedanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3 Y375C were resistant to growth inhibition by Ofev (Nintedanib) in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y375C	urinary bladder cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y375C	urinary bladder cancer	resistant	Cediranib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring an FGFR3 Y375C mutation were resistant to growth inhibition by Cediranib (AZD-2171) in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y375C	urinary bladder cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y375C	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 Y375C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent proliferation of cells expressing FGFR3 Y375C in culture (PMID: 19381019).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 decreased phosphorylation of ERK and FRS and inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture, and inhibited tumor growth in bladder cancer cell line xenograft models with FGFR3-BAIAP2L1 (PMID: 25589496)
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (PMID: 25169980).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells expressing FGFR3-BAIAP2L1 in culture (PMID: 27627808).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cells harboring FGFR3-BAIAP2L1 fusion in culture (PMID: 27627808).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell culture	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (Mol Cancer Ther December 2015 14; A170).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	bladder urothelial carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, patients with bladder urothelial carcinoma harboring an FGFR3 mutation demonstrated a disease control rate of 75% (6/8) when treated with BGJ398, including 3 patients with a partial response and 3 with stable disease (PMID: 27870574; NCT01004224).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	transitional cell carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	transitional cell carcinoma	sensitive	BGJ398	Clinical Study	Actionable	In a clinical study, BGJ398 treatment led to 25.4% (17/67) confirmed responses and a disease control rate of 64% (43/67), which included complete responses, partial responses, and stable disease, and resulted in a median progression-free survival of 3.75 months and a median overall survival of 7.75 months (PMID: 29848605).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	transitional cell carcinoma	predicted - sensitive	B-701 + Docetaxel	Phase Ib/II	Actionable	In a Phase I/II trial, B-701 in combination with Taxotere (docetaxel) demonstrated safety and preliminary efficacy, resulted in enhanced activity in patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 mutations or fusions comparing to wild-type patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534; NCT02401542).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	urinary system cancer	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in 25% tumor shrinkage at week 8 in an urothelial cancer patient harboring FGFR3 mutations (PMID: 26324363).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	Advanced Solid Tumor	sensitive	INCB054828	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, tumor cell lines with FGFR3 mutations demonstrated sensitivity to BGJ398 in culture (PMID: 23002168).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	transitional cell carcinoma	predicted - sensitive	Erdafitinib	Phase II	Actionable	In a Phase II trial, Erdafitinib (JNJ-42756493) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 40% (6/16) of patients with advanced solid tumors harboring FGFR single nucleotide variants, with a 6-month progression-free survival rate of 8% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 mutation in culture (PMID: 27550940).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 mutant	bladder urothelial carcinoma	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in 33% (1/3) of patients with BCG-unresponsive, non-muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 mutations (PMID: 27932416).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	PRN1109	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1109 treatment resulted in tumor regression in bladder cancer cell line xenograft models harboring FGFR3-TACC3 fusion (Eu J Cancer 2014 Vol 50, Suppl 6:157).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	transitional cell carcinoma	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with urothelial transitional cell carcinoma harboring FGFR3-TACC3 (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary system cancer	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I clinical trial, Erdafitinib (JNJ-42756493) treatment resulted in partial response in 2 urothelial cancer patients harboring FGFR3-TACC3 (PMID: 26324363).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of bladder cancer cell lines harboring a FGFR3-TACC3 fusion in culture, and resulted in tumor regression in a FGFR3-TACC3 positive bladder cancer cell line xenograft model (Mol Cancer Ther December 2015 14; A170).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	malignant glioma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BJG398 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cell lines harboring an FGFR3-TACC3 fusion in culture and inhibited tumor growth in FGFR3-TACC3-positive bladder cancer cell line xenograft models (PMID: 25169980).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	bladder transitional cell papilloma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO4987655 in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	glioblastoma multiforme	sensitive	U0126	Preclinical	Actionable	In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells expressing the FGFR3-TACC3 fusion in culture (PMID: 23298836).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinicl study, AZD4547 inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	no benefit	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3-TACC were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	lung adenocarcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatanib) inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	lung adenocarcinoma	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	non-small cell lung carcinoma	sensitive	Erdafitinib	Preclinical - Pdx	Actionable	In a preclinical study, Erdafitinib (JNJ-42756493) inhibited pERK signaling and tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring FGFR3-TACC3 (PMID: 28341788).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	malignant glioma	sensitive	Erdafitinib	Preclinical	Actionable	In a preclinical study, Erdafitinib (JNJ-42756493) inhibited proliferation of glioma cells harboring FGFR3 - TACC3 fusion in culture and xenograft tumor growth in animal models (PMID: 25609060).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	malignant glioma	sensitive	PD173074	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 kinase activity and growth in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture and in cell line xenograft models (PMID: 22837387).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinicl study, Erdafitinib (JNJ-42756493) inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ12908010 (AZ8010) induced cell cycle arrest and inhibited proliferation of urothelial cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 22869148, PMID: 23175443).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	transitional cell carcinoma	predicted - sensitive	BGJ398 + BYL719	Phase I	Actionable	In a Phase Ib trial, BGJ398 and Alpelisib (BYL719) combination treatment resulted in partial response and a complete shrinkage of target lesions lasting 4 months in one urothelial carcinoma patient harboring a FGFR3-TACC3 fusion (J Clin Oncol 34, 2016 (suppl; abstr 2500)).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, urinary bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability, and antitumor activity in xenograft models (PMID: 27535969).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	oligodendroglioma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of anaplastic oligodendroglioma harboring FGFR3-TACC3 fusion (PMID: 28978721).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	transitional cell carcinoma	sensitive	AZD4547 + BKM120	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line harboring FGFR3-TACC3 in culture, and inhibited tumor growth in xenograft models, with increased efficacy over either agent alone (PMID: 28108151).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	bladder urothelial carcinoma	sensitive	PRN1371	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1371 inhibited proliferation of bladder transitional cell carcinoma cell lines harboring FGFR3-TACC3 fusion in culture and tumor growth in cell line xenograft models (PMID: 28978721).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	FIIN-01	Preclinical	Actionable	In a preclinical study, FIIN-1 inhibited growth of the RT4 bladder cancer cell line, which has been demonstrated to harbor an FGFR3-TACC3 fusion, in culture (PMID: 20338520, PMID: 23175443).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	Pazopanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	predicted - sensitive	S-49076	Preclinical	Actionable	In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 23804704, PMID: 23175443).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cell lines harboring FGFR3-TACC3 fusion in culture (PMID: 27627808).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of bladder cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 24325461, PMID: 23175443).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	glioblastoma multiforme	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in tumor reduction and stable disease in 2 glioblastoma multiforme patients harboring FGFR3 - TACC3 fusion (PMID: 25609060).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	glioblastoma multiforme	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in partial response in a glioblastoma patient harboring FGFR3 - TACC3 fusion (PMID: 26324363).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	SU5402	Preclinical	Actionable	In a preclinical study, SU5402 induced cell-cycle arrest and inhibited proliferation of bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 21119661, PMID: 23175443).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	malignant glioma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	bladder transitional cell papilloma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO5126766 in culture (PMID: 26438159).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	cervical squamous cell carcinoma	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with squamous cell carcinoma of the cervix harboring FGFR3-TACC3 (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab inhibited FGFR3 signaling and tumor growth in bladder cancer cell line xenograft models harboring FGFR3-TACC3 (PMID: 25326231).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3-TACC3	urinary bladder cancer	sensitive	LY2874455	Preclinical	Actionable	In a preclinical study, LY2874455 induced tumor regression in bladder cancer xenograft models that have been demonstrated to harbor an FGFR3-TACC3 fusion (PMID: 21900693, PMID: 23175443).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR2 fusion FGFR3 - TACC3	adrenal carcinoma	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 D764N	head and neck squamous cell carcinoma	no benefit	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D764N in culture, however, cells expressing FGFR3 D764N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	ROS1 fusion ERBB2 amp FGFR3 amp RET amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of several tumor cell lines with FGFR alterations in culture (Cancer Res April 15, 2011 71:3560).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 amp	urinary system cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 amp	urinary system cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 demonstrated safety and preliminary efficacy in patients with select solid tumors harboring FGFR alterations (Cancer Res October 1, 2014 74:CT326).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 amp	non-small cell lung carcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 28.2% tumor growth inhibition in patient-derived xenograft models of FGFR3-amplified non-small cell lung cancer (PMID: 28978721).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 wild-type	myeloid neoplasm	sensitive	SU5402	Preclinical - Cell culture	Actionable	In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 wild-type	bladder carcinoma	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 wild-type	urinary bladder cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells with wild-type FGFR3 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 wild-type	myeloid neoplasm	sensitive	SSR128129E	Preclinical	Actionable	In a preclinical study, SSR128129E inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 act mut	Advanced Solid Tumor	sensitive	FF-284	Phase I	Actionable	In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR3 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 act mut	Advanced Solid Tumor	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 act mut	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 act mut	Advanced Solid Tumor	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 act mut	Advanced Solid Tumor	decreased response	Nintedanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 act mut	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 act mut	urinary bladder cancer	predicted - sensitive	S-49076	Preclinical	Actionable	In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells over expressing constitutively active FGFR3 in culture (PMID: 23804704).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR2 pos FGFR3 pos	breast carcinoma	sensitive	E7090	Preclinical	Actionable	In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 positive	stomach cancer	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive gastric cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 positive	lung adenocarcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung adenocarcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 positive	head and neck squamous cell carcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR3-positive head and neck squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).
FGFR3	ACH | CD333 | CEK2 | HSFGFR3EX | JTK4	4p16.3	NM_000142	FGFR3 positive	lung squamous cell carcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 L601_K602insREYEYDL	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited cell proliferation in cell culture and in mouse models carrying FLT3 L601_K602insREYEYDL (PMID: 12124172).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D839A	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839A were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D839A	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835A mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL in culture (PMID: 12124172).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 A848P	Advanced Solid Tumor	decreased response	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 A848P	Advanced Solid Tumor	decreased response	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 A848P	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and A848P were resistant to Sutent (sunitinib) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 N841K	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N841K mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 N841K	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 N841K were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835G	acute myeloid leukemia	sensitive	E6201	Preclinical - Cell culture	Actionable	In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835G in culture (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835G	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835G in culture (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835G were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D835G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835G mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 Y599_D600insGLYVDFREYEY	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 Y599_D600insGLYVDFREYEY in culture (PMID: 12124172).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD  along with FLT3 D835N were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D835N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835N mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835H	leukemia	resistant	Pexidartinib	Clinical Study	Actionable	In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 D835H mutation on the same allele as the FLT3-ITD mutation (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 D835H conferred resistance to PLX3397 in transformed cells when expressed as a compound mutation with FLT3-ITD in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Pdx	Actionable	In a preclinical study, FF-10101 inhibited cell growth in AML-patient-derived xenograft models with FLT3-ITD/D835H compound mutations (PMID: 29187377).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D835H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835H mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835H	acute myeloid leukemia	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, Crenolanib (CP-868596) inhibited Flt3 phosphorylation and induced apoptosis in leukemia cells expressing FLT3 D835H (PMID: 24623852).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y	acute promyelocytic leukemia	sensitive	Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin	Clinical Study	Actionable	In a clinical case study, a patient with acute promyelocytic leukemia harboring FLT3 D835Y demonstrated a complete molecular remission after treatment with Trisenox (arsenic trioxide) and Vesanoid (tretinoin) combined with Cytosar-U (cytarabine) and Methotrexate (PMID: 27626069).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y	hematologic cancer	sensitive	G-749	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FLT3 D835Y were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y	acute promyelocytic leukemia	resistant	Tretinoin	Clinical Study	Actionable	In a clinical case study, a patient with acute promyelocytic leukemia developed meningeal relapse after maintenance therapy with Vesanoid (tretinoid), which was found to be due to a FLT3 D835Y variant (PMID: 27626069).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Rydapt (midostaurin) inhibited FLT3 phosphorylation and resulted in decreased proliferation and viability of transformed cells expressing FLT3 D835Y in culture (PMID: 12124173).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835Y in culture (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y	acute myeloid leukemia	sensitive	E6201	Preclinical - Cell culture	Actionable	In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835Y in culture (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835Y in culture (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3 D835Y were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D835Y	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835Y mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835Y FLT3 N676D	hematologic cancer	sensitive	G-749	Preclinical - Cell culture	Actionable	In a preclinical study, cells co-expressing FLT3 D835Y and FLT3 N676D were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835Y in culture (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and growth of leukemic cell lines and inhibited growth of cell line xenografts with FLT3-ITD/D835Y compound mutations (PMID: 29187377).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 D835Y conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing FLT3 ITD and D835Y in culture (PMID: 27780853).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	MRX-2843	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and D835Y in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835Y	leukemia	resistant	Pexidartinib	Clinical Study	Actionable	In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397 therapy, but experienced relapse after emergence of FLT3 D835Y on the same allele as the FLT3-ITD mutation (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	decreased response	AGL2043	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated a decreased response to AGL2043 in culture when compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated sensitivity to Rydapt (midostaurin) in culture (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	decreased response	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated a decreased response to Sutent (sunitinib) in culture when compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	sensitive	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated sensitivity to Lestaurtinib (CEP-701) in culture (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated sensitivity to Nexavar (sorafenib) in culture (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 wild-type	acute myeloid leukemia	sensitive	Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited growth of human FLT3 wild-type human leukemia cells in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 wild-type	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Phase Ib/II	Actionable	In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in  complete remission in 74% (20 of 27) of acute myeloid leukemia patients carrying wild-type FLT3 (PMID: 22627678).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 wild-type	acute myeloid leukemia	sensitive	TCS 359	Preclinical	Actionable	In a preclinical study, TCS-359 inhibited growth of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 wild-type	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation in transformed cells expressing wild-type FLT3 in culture (PMID: 12124173).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 wild-type	acute myeloid leukemia	sensitive	Palbociclib + TCS 359	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 wild-type	acute myeloid leukemia	predicted - sensitive	CG'806	Preclinical - Cell culture	Actionable	In a preclinical study, CG'806 inhibited Btk and aurora kinase activation, induced G2/M arrest and autophagy in acute myeloid leukemia cells harboring wild-type FLT3 in culture (Blood 2017 130:4629).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib + SGI-1776	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and SGI-1776 were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	TCS 359	Preclinical	Actionable	In a preclinical study, TCS-359 inhibited growth of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	VS-5584	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a FLT3-ITD positive human acute myeloid leukemia cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23270925).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	Crenolanib	Phase II	Actionable	In a Phase II trial, relapsed or refractory acute myeloid leukemia patients harboring FLT3 activating mutations without a history of FLT3 therapy demonstrated a significantly greater overall survival and event free survival compared to those that had prior FLT3 therapy when treated with Crenolanib (ASH meeting, Dec 2014, abstract #389).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	leukemia	sensitive	Pexidartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX3397 inhibited FLT3 autophosphorylation in leukemia cells overexpressing FLT3 or harboring FLT3 activating mutations, and inhibited growth of leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (ASH Annual Meeting Abstracts 2011 118: 3632).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib + TCS 359	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib + Tandutinib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and tandutinib (MLN518) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) blocked growth, induced apoptosis, and inhibited STAT activation in human FLT3-ITD positive human acute myeloid leukemia cells in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	Sunitinib + Cytarabine + Daunorubicin	Phase Ib/II	Actionable	In a Phase Ib/II trial, 59% (13/22) of acute myeloid leukemia patients harboring FLT3 activating mutations achieved complete remission following treatment with Sutent (sunitinib) in combination with Cytarabine and Daunorubicin (PMID: 25818407).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib + Quizartinib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and Quizartinib (AC220) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 S451F	Advanced Solid Tumor	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 S451F demonstrated decreased sensitivity to inhibition of FLT3 phosphorylation and growth by Rydapt (midostaurin) in culture, when compared to cells expressing other FLT3 activating mutations (PMID: 18068628).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835V	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835V	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835V in culture (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835V	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835V in culture (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835V	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF in culture (PMID: 12124172).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 M837G FLT3 S838R FLT3 D839H	leukemia	resistant	Pexidartinib	Clinical Study	Actionable	In a clinical study, a leukemia patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a compound FLT3 M837G/S838R/D839H mutation on the FLT3-ITD allele (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 ITD FLT3 N676D FLT3 Y842C	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 N676D and Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 N676D	hematologic cancer	sensitive	G-749	Preclinical - Cell culture	Actionable	In a preclinical study, cells co-expressing a FLT3 internal tandem duplication and FLT3 N676D were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 N676D	Advanced Solid Tumor	decreased response	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and N676D demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 N676D	Advanced Solid Tumor	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and N676D were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 Y842C	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842C mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 Y842S	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842S mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 M664I FLT3 F691L	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/M664I mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D839N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D839N were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D835E	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3 ITD with R834Q and F691L were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 R834Q	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/R834Q mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 R845G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/R845G mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and growth of leukemic cell lines and inhibited growth of cell line xenografts with FLT3-ITD/F691L compound mutations (PMID: 29187377).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	Pexidartinib	Preclinical	Actionable	In a preclinical study, PLX3397 inhibited growth of transformed cells expressing a compound FLT3 F691L/FLT3-ITD mutation in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 F691L in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Quizartinib (AC220) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	G-749	Preclinical - Cell culture	Actionable	In a preclinical study, cells co-expressing a FLT3 internal tandem duplication and FLT3 F691L were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and F691L in culture (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	decreased response	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 F691L demonstrated a decreased response to Lestaurtinib (CEP-701) compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing FLT3 ITD and F691L in culture (PMID: 27780853).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 F691L demonstrated a decreased response to Lestaurtinib (CEP-701) compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	leukemia	sensitive	Pexidartinib	Preclinical	Actionable	In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring both FLT3-ITD and FLT3 F691L in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	MRX-2843	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and F691L in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 G846R	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/G846R mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D698N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D698N mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 D839G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD /F691L/D839G mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 N676S FLT3 F691L	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N676S mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691L FLT3 Y842H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842H mutation were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D839G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 D835G conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D839N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD  along with FLT3 D839N were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 amp	colorectal cancer	sensitive	Sorafenib	Clinical Study	Actionable	In a clinical case report, Nexavar (sorafenib) treatment targeting FLT3 amplification in a rectal adenocarcinoma patient who had progressed on all standard therapies resulted in rapid clinical improvement (PMID: 25848357).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 V592G	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 V592G in culture (PMID: 18068628).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	IDH2 R140W FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	Enasidenib + Quizartinib	Preclinical	Actionable	In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 induced cell death, inhibited cell growth, and decreased tumor burden in acute myeloid leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (Blood Nov 2013, 122 (21) 2683).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	Quizartinib	Phase I	Actionable	In a Phase I clinical trial, patients with refractory or relapsed acute myeloid leukemia positive for FLT3-ITD demonstrated a 53% (9/17) response rate compared to a 14% (5/37) response rate in those patients negative for FLT3-ITD when treated with Quizartinib (AC220) (PMID: 24002496).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	FLX925	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3-ITD secondary resistance mutation demonstrated sensitivity to FLX925 (Cancer Res, August 1, 2015 75; 787).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	Azacitidine + Sorafenib	Phase II	Actionable	In a Phase II trial, 93% (40/43) of acute myeloid leukemia patients harbored a FLT3-ITD and of the 37 patients that were evaluable, the combination therapy, Nexavar (sorafenib) and Vidaza (azacitidine), resulted in a 46% (17/37) response rate, which included 10 CRi, 6 CR, and 1 PR (PMID: 23613521).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 Y572C	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation of ERK1/2 and reduced cell growth in transformed cells expressing FLT3 Y572C in culture (PMID: 18068628).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 N676S	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 N676S were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 R834Q	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 R834Q in culture (PMID: 18068628).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 R834Q	Advanced Solid Tumor	sensitive	PD98059	Preclinical	Actionable	In a preclinical study, PD98059 inhibited ERK1/2 phosphorylation and reduced cell growth in transformed cells expressing FLT3 R834Q (PMID: 18068628).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 R834Q	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R834Q were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 R845G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R845G were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 G846R	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 G846R were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	predicted - sensitive	Gilteritinib	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with Gilteritinib (ASP2215) resulted in an overall response rate of 49% (93/191) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 mutations, compared to 12% (7/58) in patients with wild-type FLT3 (PMID: 28645776; NCT02014558).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	sensitive	Azacitidine + Midostaurin	Phase Ib/II	Actionable	In a Phase Ib/II trial, acute myeloid leukemia patients harboring a FLT3 mutation demonstrated an improved remission duration when treated with the combination therapy, Rydapt (midostaurin) and Vidaza (azacitidine) (PMID: 25530214).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	sensitive	Selinexor + Sorafenib	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Phase Ib/II	Actionable	In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in complete remission in 92% (12/13) of acute myeloid leukemia patients carrying FLT3 mutations, although overall survival rate was similar to patients with wild-type FLT3 (PMID: 22627678).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	FDA approved	Actionable	In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (HR=0.78, p=0.009) and event-free survival (HR=0.78, p=0.002) in patients with FLT3-mutant or FLT3-ITD acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114; NCT00651261).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	sensitive	UNC2025	Preclinical	Actionable	In a preclinical study, UNC2025 inhibited FLT3 activation and growth of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture (PMID: 25068800).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	sensitive	Crenolanib	Phase I	Actionable	In a Phase I trial, Crenolanib treatment resulted in complete response (CR) in 39% (7/18), partial response (PR) in 11% (2/18), and an overall survival (OS) of 234 days in AML patients harboring FLT3 mutations (D835X, ITD, or both) that received no prior therapy, and CR in 17% (6/36), PR in 14% (5/36), and OS of 94 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cell lines harboring FLT3 mutations demonstrated increased sensitivity to E6201 induced growth inhibition and apoptosis in culture compared to FLT3 wild-type cells (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 mutant	acute myeloid leukemia	sensitive	TG02	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TG02 inhibited growth of FLT3-mutated acute myeloid leukemia cells in culture, resulted in complete tumor regression in cell line xenograft animal models (PMID: 21860433).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	DNMT3A mut FLT3 mut NPM1 mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Emerging	In a retrospective analysis, the combination of DNMT3A, FLT3, and NPM1 mutations in patients with acute myeloid leukemia was highly associated with decreased event-free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 S652G	leukemia	resistant	Pexidartinib	Clinical Study	Actionable	In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 S652G mutation on the same allele as FLT3-ITD (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D698N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D698N were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated sensitivity to Rydapt (midostaurin) in culture (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Sutent (sunitinib) in culture (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated sensitivity to Lestaurtinib (CEP-701) in culture (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 Y842C conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101, as compared to Quizartinib, inhibited Flt3 autophosphorylation and cell proliferation of transformed 32Dcl3 murine myeloid cells expressing a human FLT3-ITD/Y842C compound mutation (PMID: 29187377).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	AGL2043	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to AGL2043 in culture (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842C in culture (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Nexavar (sorafenib) in culture (Blood 2009 114:3776).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842S	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842S were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835F	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835F in culture (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835F	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835F were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D839H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839H were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 ITD and F691I demonstrated reduced sensitivity to Alunbrig (brigatinib) compared to cells expressing FLT3 ITD in culture (PMID: 27780853).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	decreased response	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691I demonstrated reduced response to Sutent (sunitinib) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Quizartinib (AC220) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Cytarabine + Daunorubicin + Quizartinib	Phase I	Actionable	In a Phase I trial (QuANTUM-First), the combination therapy, Quizartinib (AC220) with Cytosar-U (cytarabine) and Cerubidine (daunorubicin), resulted in 67% (6/9) of acute myeloid leukemia patients harboring a FLT3-ITD achieving a composite complete response and two patients achieving morphologic leukemia-free state (PMID: 29139135; NCT01390337).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	leukemia	predicted - sensitive	GMI-1359 + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of GMI-1359 with Nexavar (sorafenib) enhanced apoptosis compared to Nexavar (sorafenib) alone (48.9% vs 36.6%) in leukemia cell lines harboring FLT3 internal tandem duplication (ITD) mutations (Blood 2015 126(23):3790).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Pacritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pacritinib (SB1518) induced apoptosis and inhibited proliferation of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture, and inhibited tumor growth and induced tumor regression in cell line xenograft models (PMID: 22829080).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	SHP099	Preclinical - Pdx	Actionable	In a preclinical study, treatment with SHP099 resulted in reduction of CD45-positive leukemic cells and decreased splenomegaly in a human primary tumor-derived xenograft model of acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 27362227).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Semaxanib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication were sensitive to Semaxanib (SU5416) in culture, demonstrating inhibition of cell proliferation and inhibition of Flt3, Mapk, and Stat5 phosphorylation (PMID: 12351406).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	E6201	Preclinical - Cell culture	Actionable	In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Altiratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Altiratinib (DCC-0701) inhibited proliferation of an acute myeloid leukemia cell harboring a FLT3-ITD mutation in culture (PMID: 26285778).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	G-749	Preclinical - Cell line xenograft	Actionable	In a preclinical study, G-749 induced apoptosis in acute myeloid leukemia cells harboring a FLT3 internal tandem duplication in culture, and inhibited tumor growth and induced tumor regression in cell line xenograft models (PMID: 24532805).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	no benefit	rebastinib	Phase I	Actionable	In a Phase I trial, acute myeloid leukemia patients harboring a FLT3 internal tandem duplication did not benefit from treatment with Rebastinib (DCC-2036) (PMID: 27927766).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	FLT3 internal tandem duplication (FLT3-ITD) mutations are associated with inferior prognosis in acute myeloid leukemia patients with normal karyotype (NCCN.org).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Cytarabine + Quizartinib	Phase Ib/II	Actionable	In a Phase I/II trial, Quizartinib (AC220) in combination with Cytosar-U (cytarabine) resulted in a median overall survival of 6.7 months and a median progression-free survival of 3 months in acute myeloid leukemia patients harboring FLT3 ITD mutations (ASH 59th Annual Meeting and Exposition, Dec 2017, Abstract 723).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	leukemia	sensitive	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 induced growth inhibition and apoptosis in leukemia cell lines harboring FLT3 internal tandem duplications (ITD) and reduced tumor burden in xenograft models (PMID: 26822154).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	GTP-14564	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication were sensitive to GTP-14564 treatment in culture, demonstrating growth inhibition (PMID: 12815052).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Phase III	Actionable	In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant or FLT3-ITD acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing FLT3 ITD in culture (PMID: 27780853).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	Advanced Solid Tumor	predicted - sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a FLT3-ITD mutation were sensitive to Cometriq (cabozantinib) in culture (PMID: 21926191).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Ponatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited viability of patient derived acute myeloid leukemia cells harboring FLT3 ITD mutations in culture, and inhibited growth of tumors in cell line xenograft models (PMID: 21482694).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Ponatinib	Phase I	Actionable	In a Phase I trial, Iclusig (ponatinib) resulted in a 25% (3/12) overall response rate, indicated as partial remission or better, in acute myeloid leukemia patients harboring FLT3-ITD (PMID: 23691988).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	CG'806	Preclinical - Cell culture	Actionable	In a preclinical study, CG'806 inhibited Flt3 downstream signaling, induced G1 cell cycle arrest and apoptosis in acute myeloid leukemia cells harboring FLT3 ITD mutations in culture (Blood 2017 130:4629).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	Advanced Solid Tumor	sensitive	Pexidartinib	Preclinical	Actionable	In a preclinical study, PLX3397 inhibited proliferation of transformed cells expressing FLT3-ITD in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Selinexor + Sorafenib	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	ENMD-2076	Phase I	Actionable	In a Phase I trial, an acute myeloid leukemia patient with a FLT3-ITD mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) demonstrated efficacy in inhibiting proliferation and viability of transformed cells expressing a FLT3-ITD mutation in culture (PMID: 12124173).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Cytarabine + G-749	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of G-749 and Cytosar-U (cytarabine) resulted in a synergistic effect, demonstrating greater inhibition of proliferation compared to G-749 alone in acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (PMID: 24532805).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Decitabine + Sorafenib	Guideline	Actionable	Nexavar (sorafenib) in combination with Dacogen (decitabine) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	leukemia	predicted - sensitive	GMI-1359	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GMI-1359 in combination with chemotherapy resulted in significant survival benefit compared to chemotherapy alone (67% vs 30%) in cell line xenograft models of FLT3-ITD leukemia (Blood 2015 126(23):3790).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Crenolanib	Phase I	Actionable	In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 238 days in AML patients harboring FLT3 exon 14 insertions (ITD) that received no prior therapy, and an OS of 158 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	MRX-2843	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 activation, resulted in growth inhibition in acute myeloid leukemia cell lines harboring FLT3 internal tandem duplication (ITD) in culture and in cell line xenograft models, and prolonged survival in patient-derived xenograft models (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	hematologic cancer	sensitive	GTP-14564	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a FLT3 internal tandem duplication were sensitive to GTP-14564 treatment in culture, demonstrating decreased Stat5 activity and growth inhibition (PMID: 12815052).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Ki23819	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication were sensitive to Ki23819 in culture, demonstrating inhibition of autophosphorylation and downstream signaling, and reduced cell proliferation (PMID: 15815726).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	leukemia	sensitive	Pexidartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring FLT3-ITD in culture and in cell line xenograft models (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Azacitidine + Quizartinib	Phase Ib/II	Actionable	In a Phase I/II trial, Quizartinib (AC220) in combination with Vidaza (azacitidine) resulted in a median overall survival of 13.4 months and a median progression-free survival of 6.9 months in acute myeloid leukemia patients harboring FLT3 ITD mutations (ASH 59th Annual Meeting and Exposition, Dec 2017, Abstract 723).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Azacitidine + Sorafenib	Guideline	Actionable	Nexavar (sorafenib) in combination with Vidaza (azacitidine) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Gilteritinib	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with Gilteritinib (ASP2215) at a dose of 80mg/day or higher resulted in an overall response rate of 55% (77/141) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 internal tandem duplication mutations (PMID: 28645776; NCT02014558).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Quizartinib	Phase I	Actionable	In a Phase I trial, acute myeloid leukemia (AML) pediatric patients harboring a FLT3-ITD mutation demonstrated a greater sensitivity to treatment with Quizartinib (AC220) when compared to AML patients with wild-type FLT3, resulting in three complete responses, four with stable disease, and a lower bone marrow blast cell count (PMID: 26920889).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and cell growth of leukemic cells in culture and in AML-patient-derived xenograft models with FLT3-ITD mutations (PMID: 29187377).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins NPM1 mutant	leukemia	predicted - sensitive	MI-503	Preclinical	Actionable	In a preclinical study, MI-503 inhibited growth of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins NPM1 mutant	leukemia	predicted - sensitive	EPZ004777	Preclinical	Actionable	In a preclinical study, EPZ004777 inhibited growth and induced differentiation of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	sensitive	ENMD-2076	Phase I	Actionable	In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835X FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Selinexor + Sorafenib	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835X FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Crenolanib	Phase I	Actionable	In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 128 days in AML patients harboring both FLT3 D835X and exon 14 insertion (ITD) that received no prior therapy, and an OS of 63 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842H were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842H	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101, as compared to Quizartinib, inhibited Flt3 autophosphorylation and cell proliferation of transformed 32Dcl3 murine myeloid cells expressing a human FLT3-ITD/Y842H compound mutation (PMID: 29187377).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842H	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842H in culture (PMID: 27158668).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842H	Advanced Solid Tumor	decreased response	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 Y842H	Advanced Solid Tumor	decreased response	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 M664I	Advanced Solid Tumor	decreased response	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 M664I displayed reduced sensitivity to PLX3397 relative to cells expressing FLT3-ITD in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 exon 14 ins FLT3 D835E	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835E were resistant to PLX3397 in culture (PMID: 25847190).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 Y842C	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) induced cell death and inhibited FLT3 activation and downstream STAT5 activation in primary acute myeloid leukemic blasts harboring FLT3 Y842C in culture (PMID: 15345593).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 Y842C	acute myeloid leukemia	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, primary AML blasts expressing FLT3 Y842C were resistant to Gleevec (imatinib) as demonstrated by constitutively phosphorylated FLT3 and STAT-5 (PMID: 15345593).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE in culture (PMID: 12124172).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 I836del	cancer	sensitive	Tandutinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tandutinib (CT53518) inhibited phosphorylation of FLT3 and activation of ERK and STAT5, and reduced growth of transformed cells expressing FLT3 I836del in culture (PMID: 15256420).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 I836del	cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited phosphorylation of FLT3, ERK, and STAT5, and growth of transformed cells expressing FLT3 I836del in culture (PMID: 17827387).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835X	acute myeloid leukemia	sensitive	Crenolanib	Phase I	Actionable	In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 185 days in AML patients harboring FLT3 D835X that received no prior therapy (J Clin Oncol 34, 2016 (suppl; abstr 7008)).
FLT3	CD135 | FLK-2 | FLK2 | STK1	13q12.2	NM_004119	FLT3 D835X	acute myeloid leukemia	sensitive	Selinexor + Sorafenib	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).
FOXL2	BPES | BPES1 | PFRK | PINTO | POF3	3q22.3	NM_023067	FOXL2 C134W	granulosa cell tumor	not applicable	N/A	Preclinical	Diagnostic	FOXL2 C134W mutations are used in the diagnosis of adult granulosa cell tumors of the ovary (PMID: 26791928, PMID: 22240241).
GATA1	ERYF1 | GATA-1 | GF-1 | GF1 | NF-E1 | NFE1 | XLANP | XLTDA | XLTT	Xp11.23	NM_002049	GATA1 mutant	megakaryocytic leukemia	not applicable	N/A	Clinical Study	Diagnostic	GATA1 mutations are used in the diagnosis of Down Syndrome related acute megakaryoblastic leukemia (PMID: 25266042, PMID: 14636651, PMID: 12586620).
GATA1	ERYF1 | GATA-1 | GF-1 | GF1 | NF-E1 | NFE1 | XLANP | XLTDA | XLTT	Xp11.23	NM_002049	GATA1 over exp	megakaryocytic leukemia	decreased response	Cytarabine	Preclinical - Cell culture	Actionable	In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cytosar-U (cytarabine) in an non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).
GATA1	ERYF1 | GATA-1 | GF-1 | GF1 | NF-E1 | NFE1 | XLANP | XLTDA | XLTT	Xp11.23	NM_002049	GATA1 over exp	megakaryocytic leukemia	decreased response	Daunorubicin	Preclinical - Cell culture	Actionable	In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cerubidine (daunorubicin) in a non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).
GATA2	DCML | IMD21 | MONOMAC | NFE1B	3q21.3	NM_032638	KRAS mut + GATA2 wild-type	non-small cell lung carcinoma	sensitive	bortezomib + fasudil	Preclinical	Actionable	In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434).
GATA2	DCML | IMD21 | MONOMAC | NFE1B	3q21.3	NM_032638	CEBPA mutant GATA2 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).
GATA2	DCML | IMD21 | MONOMAC | NFE1B	3q21.3	NM_032638	GATA2 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, GATA2 germline mutations were shown to be a risk factor for the development of acute myeloid leukemia following myelodysplastic syndrome (PMID: 21892162, PMID: 22271902, PMID: 22147895, PMID: 22533337).
GNA11	FBH | FBH2 | FHH2 | GNA-11 | HHC2 | HYPOC2	19p13.3	NM_002067	GNA11 mutant	uveal melanoma	predicted - sensitive	AEB071 + CGM097	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and CGM097 resulted in tumor regression or stasis in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, and induced apoptosis and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).
GNA11	FBH | FBH2 | FHH2 | GNA-11 | HHC2 | HYPOC2	19p13.3	NM_002067	GNA11 mutant	uveal melanoma	predicted - sensitive	MEK162 + AEB071	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).
GNA11	FBH | FBH2 | FHH2 | GNA-11 | HHC2 | HYPOC2	19p13.3	NM_002067	GNA11 mutant	uveal melanoma	predicted - sensitive	AEB071 + Everolimus	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and Afinitor (everolimus) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, including tumor regression, and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).
GNA11	FBH | FBH2 | FHH2 | GNA-11 | HHC2 | HYPOC2	19p13.3	NM_002067	GNA11 Q209L	uveal melanoma	sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNA11 Q209L in culture (PMID: 22515704).
GNA11	FBH | FBH2 | FHH2 | GNA-11 | HHC2 | HYPOC2	19p13.3	NM_002067	GNA11 Q209L	uveal melanoma	sensitive	MEK162 + AEB071	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) synergized to inhibit growth in a human uveal melanoma cancer cell line harboring a GNA11 Q209L mutation in culture and in xenograft models, and demonstrated improved efficacy over either agent alone (PMID: 24141786).
GNA11	FBH | FBH2 | FHH2 | GNA-11 | HHC2 | HYPOC2	19p13.3	NM_002067	GNA11 Q209L	uveal melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, uveal melanoma cell lines harboring GNA11 Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNA11 (PMID: 22733540).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ mutant	uveal melanoma	predicted - sensitive	MEK162 + AEB071	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ mutant	uveal melanoma	predicted - sensitive	AEB071 + CGM097	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and CGM097 resulted in tumor regression or stasis in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, and induced apoptosis and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ mutant	uveal melanoma	predicted - sensitive	AEB071 + Everolimus	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and Afinitor (everolimus) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, including tumor regression or stasis, and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L PTEN R173S	ocular melanoma	predicted - sensitive	Refametinib	Phase I	Actionable	In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	U0126	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with U0126 resulted in reduced cell numbers in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 19078957).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-733 inhibited growth of a uveal melanoma cell line harboring GNAQ Q209L in culture (PMID: 22515704).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	AEB071 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sotrastaurin (AEB071), in combination with PD-0325901, worked synergisitically to inhibit MAPK pathway activation and proliferation of a uveal melanoma cell line harboring GNAQ Q209L (PMID: 24141786).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, uveal melanoma cell lines harboring GNAQ Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNAQ (PMID: 22733540).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	GSK2126458 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and GSK2126458 induced apoptosis in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22733540).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	NAV-2729	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NAV-2729 inhibited signaling downstream of GNAQ Q209L in melanoma cells in culture, and inhibited initiation and growth of tumors in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27265506).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	Enzastaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22253748).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	Verteporfin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Visudyne (verteporfin) inhibited tumor formation in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27308390).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209L in culture (PMID: 22550165).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209L	uveal melanoma	sensitive	AEB071	Preclinical - Cell line xenograft	Actionable	In a preclinical study, human uveal melanoma cell lines harboring GNAQ Q209L demonstrated sensitivity to Sotrastaurin (AEB071) in culture, and Sotrastaurin (AEB071) decreased tumor growth in uveal melanoma cell line xenograft models harboring GNAQ Q209L (PMID: 24141786).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209P	uveal melanoma	sensitive	AEB071	Preclinical - Cell culture	Actionable	In a preclinical study, Sotrastaurin (AEB071) induced cell-cycle arrest and apoptosis, and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22653968).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209P	uveal melanoma	sensitive	Enzastaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22253748).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209P	uveal melanoma	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209P in culture (PMID: 22550165).
GNAQ	CMC1 | G-ALPHA-q | GAQ | SWS	9q21.2	NM_002072	GNAQ Q209P	uveal melanoma	sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNAQ Q209P in culture (PMID: 22515704).
GNAS	AHO | C20orf45 | GNAS1 | GPSA | GSA | GSP | NESP | PITA3 | POH | SCG6 | SgVI	20q13.32	NM_080425	EML4-ALK GNAS amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, GNAS amplification (PMID: 29636358).
HNF1A	HNF-1A | HNF1 | HNF4A | IDDM20 | LFB1 | MODY3 | TCF-1 | TCF1	12q24.31	NM_000545	HNF1A inact mut	hepatocellular adenoma	not applicable	N/A	Clinical Study	Diagnostic	Inactivating mutations in HNF1A (TCF1) are used in the diagnosis of the HCA-H subtype of hepatocellular adenoma (PMID: 25076298, PMID: 26961851, PMID: 25434466).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	decreased response	AZ8010	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	PD173074	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 22797062).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	sensitive	Pz-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pz-1 reduced tumor growth in xenograft models of transformed cells over expressing HRAS G12V in a dose-dependent manner (PMID: 26126987).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	malignant glioma	sensitive	SF1126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SF1126 inhibited Akt activation, proliferation, and migration of transgenic mouse glioma cells expressing HRAS G12V in culture, and suppressed tumor growth in xenograft models (PMID: 25425962).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	sensitive	rigosertib	Preclinical - Cell culture	Actionable	In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing HRAS G12V in culture (PMID: 27104980).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Vectibix (panitumumab) (PMID: 22797062).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	predicted - sensitive	SR9009	Preclinical - Cell culture	Actionable	In a preclinical study, SR9009 treatment resulted in apoptosis in HRAS G12V-induced senescent firbroblast cells in culture (PMID: 29320480).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	urinary bladder cancer	sensitive	Binimetinib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cell line harboring HRAS G12V in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	urinary bladder cancer	sensitive	Everolimus + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cancer cell line harboring HRAS G12V in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	sensitive	Binimetinib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS G12V in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	Advanced Solid Tumor	predicted - sensitive	SR9011	Preclinical - Cell culture	Actionable	In a preclinical study, SR9011 treatment resulted in apoptosis in HRAS G12V-induced senescent firbroblast cells in culture (PMID: 29320480).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12V	melanoma	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study CI-1040 (PD-184352) inhibited melanoma progression in a transgenic zebrafish model of melanoma expressing HRAS G12V (PMID: 26267534).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Dasatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Dasatinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	endometrial cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human endometrial cancer cells harboring mutant HRAS in culture (PMID: 26343583).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	breast cancer	decreased response	PI-273	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines harboring RAS mutations, including HRAS-mutant cell lines, demonstrated decreased sensitivity to growth inhibition by PI-273, in culture (PMID: 28827373).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	Advanced Solid Tumor	predicted - sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	Advanced Solid Tumor	predicted - sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by  Selumetinib (AZD6244) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	Advanced Solid Tumor	predicted - sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) inhibited growth and induced apoptosis in human solid tumor cell lines harboring HRAS mutations in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	transitional cell carcinoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human urinary transitional cell carcinoma cells harboring mutant HRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	ovarian cancer	predicted - sensitive	BYL719 + MEK162	Phase Ib/II	Actionable	In a Phase Ib study,  Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with RAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS mutant	urinary bladder cancer	sensitive	Metformin	Preclinical	Actionable	In a preclinical study, mouse models of bladder cancer harboring an HRAS mutation were sensitive to Glucophage (metformin), resulting in tumor growth reduction and prevention of hyperplasia regression (PMID: 26921394).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	BRAF G466E HRAS Q61K	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61R	Advanced Solid Tumor	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61R	Advanced Solid Tumor	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	EML4-ALK HRAS amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, HRAS amplification (PMID: 29636358).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G13R	thyroid cancer	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring HRAS G13R (PMID: 21289267).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	resistant	Dasatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	lung squamous cell carcinoma	sensitive	Binimetinib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	bladder carcinoma	sensitive	NS1	Preclinical - Cell culture	Actionable	In a preclinical study, bladder carcinoma cells expressing HRAS Q61L demonstrated sensitivity to NS1, resulting in inhibition of Mapk signaling and cell proliferation in culture (PMID: 27820802).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	Advanced Solid Tumor	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	skin squamous cell carcinoma	no benefit	PLX7904	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX7904 did not stimulate growth of Zelboraf (vemurafenib)-induced cutaneous squamous cell carcinoma cells harboring HRAS Q61L in culture or in cell line xenograft models (PMID: 26466569).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	Advanced Solid Tumor	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	lung squamous cell carcinoma	sensitive	AZD8055 + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and AZD8055 reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	lung squamous cell carcinoma	sensitive	Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	head and neck squamous cell carcinoma	sensitive	Sirolimus + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring HRAS Q61L in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	lung squamous cell carcinoma	sensitive	Everolimus + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models, with increased efficacy compared to either agent alone (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	Advanced Solid Tumor	sensitive	Binimetinib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS Q61L in culture (PMID: 26544513).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS Q61L	lung squamous cell carcinoma	no benefit	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, BKM120 did not inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513)
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	FGFR3 K650E FGFR3 over exp HRAS K117E	myeloid neoplasm	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	FGFR3 K650E FGFR3 over exp HRAS K117E	multiple myeloma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS inact mut	thyroid cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited growth of thyroid cancer cells harboring an HRAS pathway activating mutation in cell culture (PMID: 21831957).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS wild-type	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type HRAS (PMID: 23039341).
HRAS	C-BAS/HAS | C-H-RAS | C-HA-RAS1 | CTLO | H-RASIDX | HAMSV | HRAS1 | p21ras | RASH1	11p15.5	NM_001130442	HRAS wild-type	cancer	predicted - sensitive	FTI-277	Preclinical	Actionable	In a preclinical study, the farnesyltransferase inhibitor FTI-277 sensitized Hras transformed rat fibroblasts to radiation therapy (PMID: 8620483).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132S	intrahepatic cholangiocarcinoma	sensitive	Saracatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132S	intrahepatic cholangiocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132S	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Patient cell culture	Actionable	In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132S in culture (PMID: 28232670).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132G	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Patient cell culture	Actionable	In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132G in culture (PMID: 28232670).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	cholangiocarcinoma	sensitive	Ivosidenib	Phase I	Actionable	In a Phase I trial, AG-120 treatment resulted in partial response in 6% (4/72) and stable disease in 56% (40/72) of cholangiocarcinoma patients harboring IDH1 mutations (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 4015-4015; NCT02073994).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	astrocytoma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of grade II and grade III astrocytomas (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	chondrosarcoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, chondrosarcoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	lung adenocarcinoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	oligodendroglioma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of oligodendrogliomas (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	IDH1 mutations are associated with inferior leukemia-free survival in patients with myelofibrosis (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	malignant glioma	sensitive	Ivosidenib	Phase I	Actionable	In a Phase I trial, AG-120 demonstrated safety and preliminary efficacy in IDH1-mutant glioma patients (Neuro Oncol (2016) 18 (suppl 6): vi12).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	acute myeloid leukemia	predicted - sensitive	Venetoclax	Phase II	Actionable	In a Phase II trial, 33% (4/12) of acute myeloid leukemia patients harboring either IDH1 or IDH2 mutations responded to treatment with Venclexta (venetoclax), demonstrating a complete response or complete response with incomplete blood count recovery (PMID: 27520294).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	malignant glioma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of gliomas (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	malignant glioma	not applicable	N/A	Guideline	Prognostic	IDH1 mutations are associated with a favorable prognosis in patients with glioma, and are associated with a survival benefit for patients treated with radiation or alkylator therapy (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	malignant glioma	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with improved overall survival and progression free survival in patients with gliomas (PMID: 23817809, PMID: 26220714, PMID: 23894344).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	glioblastoma multiforme	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of secondary grade IV glioblastomas (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	glioblastoma multiforme	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with a greater overall survival and progression-free survival in patients with glioblastoma (PMID: 23904262, PMID: 26945349, PMID: 20560678).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In two meta-analyses, IDH1 mutations were associated with a worse overall survival in patients with acute myeloid leukemia (PMID: 22616558, PMID: 23226625).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment was well-tolerated and resulted in complete remission (CR) in 21.6% (27/125), complete remission with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring an IDH1 mutation, with a median duration of response of 8.2 months for CR+CRh, 9.3 months for CR, and 6.5 months for OR (PMID: 29860938; NCT02074839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	glioblastoma multiforme	predicted - sensitive	Bevacizumab + Lomustine	Phase II	Actionable	In a retrospective analysis of a Phase II trial, IDH1 mutation correlated with favorable overall survival in recurrent glioblastoma patients treated with a combination of  Avastin (bevacizumab) and Lomustine (PMID: 26762204).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 mutant	grade III astrocytoma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of grade III astrocytomas (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	ATRX loss IDH1 mut	astrocytoma	not applicable	N/A	Guideline	Diagnostic	ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	ATRX loss IDH1 mut	malignant glioma	predicted - sensitive	Gemcitabine + Radiotherapy	Phase I	Actionable	In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132L	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Patient cell culture	Actionable	In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132L in culture (PMID: 28232670).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132X	acute myeloid leukemia	sensitive	IDH305	Phase I	Actionable	In a Phase I trial, IDH305 treatment resulted in objective response in 33% (7/21) of acute myeloid leukemia patients harboring IDH1 R132 mutations, including complete remission in 3 (14%) and partial remission in 4 (19%) patients (Blood 2016 128 (22):1073).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, BAY1436032 decreased R-2HG levels and inhibited growth of primary acute myeloid leukemia (AML) cells harboring IDH1 R132C in culture, and decreased blast number and increased survival of two AML patient-derived xenograft (PDX) models, one which harbored additional alterations in FLT3, NPM1, and NRAS and one which harbored a KMT2A (MLL) alteration (PMID: 28232670).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	sarcoma	sensitive	Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lynparza (olaparib) treatment delayed tumor growth in cell line xenograft models of sarcoma harboring IDH1 R132C (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	sarcoma	decreased response	AGI-5198 + Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	malignant glioma	sensitive	AGI-5198	Preclinical	Actionable	In a preclinical study, AGI-5198 inhibited growth and promoted differentiation in glioma cells expressing IDH1 R132C (PMID: 23558169).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	sarcoma	decreased response	AGI-5198 + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	malignant glioma	sensitive	Talazoparib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived glioma cells harboring IDH1 R132C demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	intrahepatic cholangiocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib)  inhibited growth of intrahepatic cholangiocarcinoma cells harboring IDH1 R132C in culture, and suppressed tumor growth in PDX models (PMID: 27231123).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	fibrosarcoma	predicted - sensitive	AG-881	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AG-881 treatment decreased tumor 2HG levels in a fibrosarcoma cell line xenograft model harboring IDH1 R132C (Mol Cancer Ther Jan 1 2018 (17) (1 Supp) B126).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C	intrahepatic cholangiocarcinoma	sensitive	Saracatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132C demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C IDH1 S280F	acute myeloid leukemia	resistant	Enasidenib	Clinical Study	Actionable	In a clinical study, IDH1 S280F was identified as an acquired mutation in cis with the original IDH1 R132C in a patient with acute myeloid leukemia (AML) who developed resistance to Idhifa (enasidenib) after initial response (PMID: 29950729).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132C SRC T341I	intrahepatic cholangiocarcinoma	resistant	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	Advanced Solid Tumor	decreased response	AGI-5198 + Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198 reverted the sensitivity of transformed cells over expressing IDH1 R132H to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	Advanced Solid Tumor	sensitive	VX-970	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to VX-970-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	colon carcinoma	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	malignant glioma	not applicable	N/A	Guideline	Diagnostic	IDH1 R132H is diagnostic and aids in the diagnosis of gliomas (NCCN.org).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	Advanced Solid Tumor	sensitive	Cisplatin + Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, Talazoparib (BMN-673) and Cisplatin synergistically inhibited growth of transformed cells over expressing IDH1 R132H in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	Advanced Solid Tumor	sensitive	Niraparib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Zejula (niraparib)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	malignant glioma	predicted - sensitive	AG-881	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AG-881 treatment decreased brain tumor 2HG levels in an orthotopic glioma cell line xenograft model harboring IDH1 R132H (Mol Cancer Ther Jan 1 2018 (17) (1 Supp) B126).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	malignant glioma	sensitive	Talazoparib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived glioma cells harboring IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	oligodendroglioma	sensitive	Decitabine	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Dacogen (decitabine) decreased colony formation and tumor growth in patient derived xenograft (PDX) models of patient derived oligodendroglioma cells with IDH1 R132H mutations and co-deletion of 1p and 19q (PMID: 24077826).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	colorectal cancer	resistant	AGI-5198 + Radiotherapy	Preclinical	Actionable	In a preclinical study, colorectal cancer cells expressing IDH1 R132H were resistant to radiotherapy when treated with AGI-5198 (PMID: 26363012).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	Advanced Solid Tumor	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Rubraca (rucaparib)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	grade III astrocytoma	sensitive	Azacitidine	Preclinical	Actionable	In a preclinical study, long-term treatment with Vidaza (azacitidine) resulted in increased cellular differentiation, decreased proliferation, and tumor regression in a patient-derived xenograft (PDX) model of anaplastic astrocytoma harboring IDH1 R132H (PMID: 24077805).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	glioblastoma multiforme	sensitive	Vandetanib + Temozolomide	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetinib), in combination with Temodar (temozolomide) and radiation therapy, demonstrated a significant increase in PFS and OS in glioblastoma patients harboring IDH1 R132H compared to glioblastoma patients without IDH1 R132H (PMID: 25910950).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	colorectal cancer	sensitive	Metformin	Preclinical	Actionable	In a preclinical study, colorectal carcinoma cells expressing IDH1 R132H were sensitive to Glucophage (metformin), resulting in decreased cell proliferation in culture (PMID: 26363012).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	malignant glioma	sensitive	BPTES	Preclinical - Cell culture	Actionable	In a preclinical study, a glioma cell line expressing IDH1 R132H demonstrated increased sensitivity to growth inhibition by BPTES compared to a cell line expressing wild-type IDH1 in culture (PMID: 21045145).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	Advanced Solid Tumor	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	Advanced Solid Tumor	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Patient cell culture	Actionable	In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132H in culture (PMID: 28232670).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	malignant glioma	sensitive	AGI-5198	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AGI-5198 inhibited growth of a glioma cell line harboring IDH1 R132H in culture and in xenograft models (PMID: 23558169).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	colorectal cancer	resistant	Metformin + AGI-5198	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring IDH1 R132H demonstrated increased cell proliferation when treated with a combination of Glucophage (metformin) and AGI-5198 (PMID: 26363012).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 R132H	colon carcinoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).
IDH1	HEL-216 | HEL-S-26 | IDCD | IDH | IDP | IDPC | PICD	2q34	NM_005896	IDH1 wild-type	malignant glioma	not applicable	N/A	Guideline	Risk Factor	IDH1 wild-type is associated with increased risk of aggressive disease in patients with grade II or III infiltrative gliomas (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R140Q IDH2 Q316E	acute myeloid leukemia	resistant	Enasidenib	Clinical Study	Actionable	In a clinical study, IDH2 Q316E was identified as an acquired mutation in trans with the original IDH2 R140Q in a patient with acute myeloid leukemia (AML) who developed resistance to Idhifa (enasidenib) after initial response, coexpression of IDH2 Q316E in trans or in cis with IDH2 R140Q conferred resistance to Idhifa (enasidenib) in culture and in animal models of AML, supporting a mechanism of variants cooperating to confer resistance (PMID: 29950729).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R172X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	IDH2 R172X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R172K KRAS G12D	intrahepatic cholangiocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R172K KRAS G12D	intrahepatic cholangiocarcinoma	sensitive	Saracatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R172K	colorectal cancer	predicted - sensitive	Enasidenib	Preclinical - Cell culture	Actionable	In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a colorectal carcinoma cell line expressing IDH2 R172K in culture (PMID: 28193778).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R172K	acute myeloid leukemia	sensitive	Enasidenib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R172K in culture (PMID: 28193778).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R172K	glioblastoma multiforme	predicted - sensitive	Enasidenib	Preclinical - Cell culture	Actionable	In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R172K in culture (PMID: 28193778).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R140Q IDH2 I139M	acute myeloid leukemia	resistant	Enasidenib	Clinical Study	Actionable	In a clinical study, IDH2 I319M was identified as an acquired mutation in trans with the original IDH2 R140Q in a patient with acute myeloid leukemia (AML) who developed resistance to Idhifa (enasidenib) after initial response, coexpression of IDH2 I319M in trans or in cis with IDH2 R140Q conferred resistance to Idhifa (enasidenib) in culture, supporting a mechanism of variants cooperating to confer resistance (PMID: 29950729).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R140W FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	Enasidenib + Quizartinib	Preclinical	Actionable	In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R140Q	malignant glioma	predicted - sensitive	AG-881	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AG-881 treatment decreased tumor 2HG levels in a glioma cell line xenograft model harboring IDH2 R140Q (Mol Cancer Ther Jan 1 2018 (17) (1 Supp) B126).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R140Q	acute myeloid leukemia	sensitive	AGI-6780	Preclinical	Actionable	In a preclinical study, treatment with AGI-6780 resulted in the differentiation of erythroleukemia and AML cell lines expressing IDH2 R140Q (PMID: 23558173).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R140Q	acute myeloid leukemia	sensitive	Enasidenib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Enasidenib (AG-221) treatment reduced 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R140Q in culture, and decreased 2HG levels and blast percentage and improved survival relative to Cytosar-U (cytarabine) treatment in IDH2 R140Q-mutant primary AML xenograft models (PMID: 28193778).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R140Q	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	IDH2 R140Q is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 R140Q	glioblastoma multiforme	predicted - sensitive	Enasidenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R140Q in culture and in xenograft models (PMID: 28193778).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	ATRX loss IDH2 mut	astrocytoma	not applicable	N/A	Guideline	Diagnostic	ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	astrocytoma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of grade II and grade III astrocytomas (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	grade III astrocytoma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of grade III astrocytomas (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	IDH2 mutations are associated with inferior leukemia-free survival in patients with myelofibrosis (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	acute myeloid leukemia	predicted - sensitive	Venetoclax	Phase II	Actionable	In a Phase II trial, 33% (4/12) of acute myeloid leukemia patients harboring either IDH1 or IDH2 mutations responded to treatment with Venclexta (venetoclax), demonstrating a complete response or complete response with incomplete blood count recovery (PMID: 27520294).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	hematologic cancer	sensitive	Enasidenib	Phase I	Actionable	In a Phase I study, Enasidenib (AG-221) demonstrated safety and efficacy in patients with hematological cancer harboring IDH2 mutations and included 8 CR, 1 CRp, 3 CRi, and 8 PR (ASH Meeting, Dec 2014, abstract #115).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	glioblastoma multiforme	no benefit	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of secondary grade IV glioblastomas (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	oligodendroglioma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of oligodendrogliomas (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	malignant glioma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of gliomas (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	malignant glioma	not applicable	N/A	Guideline	Prognostic	IDH2 mutations are associated with a favorable prognosis in patients with glioma, and are associated with a survival benefit for patients treated with radiation or alkylator therapy (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	acute myeloid leukemia	sensitive	Enasidenib	Guideline	Actionable	Idhifa (enasidenib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring an IDH2 mutation (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 mutant	acute myeloid leukemia	sensitive	Enasidenib	FDA approved	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 wild-type	malignant glioma	not applicable	N/A	Guideline	Risk Factor	IDH2 wild-type is associated with increased risk of aggressive disease in patients with grade II or III infiltrative gliomas (NCCN.org).
IDH2	D2HGA2 | ICD-M | IDH | IDHM | IDP | IDPM | mNADP-IDH	15q26.1	NM_002168	IDH2 D76fs	acute myeloid leukemia	sensitive	Venetoclax	Phase II	Actionable	In a Phase II trial, an acute myeloid leukemia patient harboring IDH2 D76fs demonstrated sensitivity to treatment with Venclexta (venetoclax), achieving a complete response with incomplete blood count recovery after 24 weeks (PMID: 27520294).
IKZF1	CVID13 | Hs.54452 | IK1 | IKAROS | LyF-1 | LYF1 | PPP1R92 | PRO0758 | ZNFN1A1	7p12.2	NM_006060	IKZF1 wild-type	multiple myeloma	sensitive	Lenalidomide	Preclinical	Actionable	In a preclinical study, Revlimid (lenalidomide) treatment resulted in IKZF1 degradation and decreased proliferation of multiple myeloma cells in culture (PMID: 24292625).
IKZF1	CVID13 | Hs.54452 | IK1 | IKAROS | LyF-1 | LYF1 | PPP1R92 | PRO0758 | ZNFN1A1	7p12.2	NM_006060	IKZF1 del	acute lymphocytic leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, including a meta-analysis, IKZF1 deletion was associated with a worse event-free survival and overall survival in patients with acute lymphocytic leukemia (PMID: 25335741, PMID: 26194343, PMID: 27067989).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 Y931C	cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as  Jakafi (Ruxolitinib) (PMID: 21393331).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 Y931C	cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 M929I	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 M929I double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6 - JAK2 JAK2 M929I	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6 - JAK2 JAK2 P1057S	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6 - JAK2 JAK2 R1127K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6-JAK2 JAK2 R975G	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 amp	triple-receptor negative breast cancer	sensitive	NVP-BSK805	Preclinical - Pdx	Actionable	In a preclinical study, NVP-BSK805 inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models harboring JAK2 amplification (PMID: 27075627).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 amp	triple-receptor negative breast cancer	sensitive	NVP-BSK805 + paclitaxel	Preclinical - Pdx	Actionable	In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models with JAK2 amplification (PMID: 27075627).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 inact mut	melanoma	predicted - resistant	Pembrolizumab	Clinical Study	Actionable	In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon (PMID: 27433843).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	Momelotinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Momelotinib (CYT387) in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	AZD1480	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	SAR302503	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to fedratinib (SAR302503) in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	Lestaurtinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to lestauranib in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	CALR wild-type JAK2 wild-type MPL wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of concurrent wild-type JAK2, MPL, and CALR in myelofibrosis patients is associated with inferior leukemia-free survival compared to patients with JAK2 and/or CALR mutations, and is associated with inferior overall survival when compared to patients with CALR mutations (NCCN.org).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6-JAK2 JAK2 N909K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	SAR302503	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Fedratinib (SAR302503) in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	AZD1480	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	Lestaurtinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Lestauranib in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	Momelotinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 E864K	hematologic cancer	resistant	NVP-BSK805	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 E864K	hematologic cancer	resistant	NVP-BVB808	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 E985K	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E985K double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 G935R	hematologic cancer	resistant	NVP-BSK805	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 G935R	hematologic cancer	resistant	NVP-BVB808	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F JAK2 G935R	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	myelofibrosis	not applicable	N/A	Guideline	Prognostic	JAK2 V617F is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	bone marrow cancer	decreased response	SGI-1776	Preclinical	Actionable	In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to SGI-1776 induced growth inhibition in culture (PMID: 26472029).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	acute myeloid leukemia	sensitive	RP6530 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, RP6530 worked synergistically with Jakafi (ruxolitinib) to inhibit proliferation of Jakafi (ruxolitinib)-resistant erythroleukemia cell lines carrying JAK2 V617F mutation ( Cancer Res August 1, 2015 75; 2704 ).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	myeloproliferative neoplasm	predicted - sensitive	LY2784544	Phase I	Actionable	In a Phase I trial, treatment with Gandotinib (LY2784544) demonstrated safety in myeloproliferative neoplasm patients harboring JAK2 V617F and resulted in clinical improvement as best response in 29% (9/31) patients with myelofibrosis (PMID: 28934680).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	bone marrow cancer	sensitive	CHZ868	Preclinical	Actionable	In a preclinical study, CHZ868 inhibited proliferation of myeloproliferative neoplasm cells harboring JAK2 V617F , including cells with decreased response to Type I JAK inhibitors following chronic exposure, and decreased mutant allele burden in a mouse polycythemia vera model expressing JAK2 V617F (PMID: 26175413).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	acute myeloid leukemia	sensitive	Go 6976	Preclinical	Actionable	In a preclinical study, Go 6976 inhibited proliferation of cultured acute myeloid leukemia cells expressing the JAK2 V617F mutation (PMID: 16956345).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	bone marrow cancer	sensitive	AZD1208 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) worked synergistically with AZD1208 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F  in culture (PMID: 26472029).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	essential thrombocythemia	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited proliferation and induced apoptosis in an essential thrombocythemia cell line harboring JAK2 V617F in culture (PMID: 22015772).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	myeloid leukemia	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed mouse myeloid cells over expressing JAK2 V617F were resistant to Gleevec (imatinib) in culture (PMID: 21224473).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	bone marrow cancer	decreased response	AZD1208	Preclinical	Actionable	In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to AZD1208 induced growth inhibition in culture (PMID: 26472029).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	bone marrow cancer	sensitive	Ruxolitinib + SGI-1776	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) worked synergistically with SGI-1776 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F in culture (PMID: 26472029).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	hematologic cancer	sensitive	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 inhibited proliferation of a hematopoietic cancer cell line harboring JAK2 V617F in culture (PMID: 27362227).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	hematologic cancer	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited proliferation of transformed cells expressing JAK2 V617F in culture (PMID: 22015772).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	acute myeloid leukemia	sensitive	A-1155463	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells harboring JAK2 V617F demonstrated sensitivity to A-1155463 in culture (PMID: 25787766).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	myeloproliferative neoplasm	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited colony growth in myeloproliferative neoplasm patient-derived hematopoetic progenitor cells harboring JAK2 V617F in culture (PMID: 22015772).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	hematologic cancer	sensitive	NS-108	Preclinical	Actionable	In a preclinical study, cells expressing JAK2 V617F were sensitive to treatment with NS-108, demonstrating cell growth inhibition and increased apoptotic activity in culture and improved survival in transgenic mouse models (PMID: 22829185).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R683G JAK2 G935R	cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R683G JAK2 G935R	cancer	resistant	NVP-BSK805	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R683G JAK2 G935R	cancer	resistant	NVP-BVB808	Preclinical	Actionable	In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6 - JAK2 JAK2 G935R	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R867Q	hematologic cancer	decreased response	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R867Q	hematologic cancer	decreased response	AUY922	Preclinical	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AUY922 in culture (PMID: 24398328).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R867Q	hematologic cancer	decreased response	AZ960	Preclinical	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R867Q	hematologic cancer	decreased response	Momelotinib	Preclinical	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Momelotinib (CYT387) in culture (PMID: 24398328).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R867Q	hematologic cancer	decreased response	SAR302503	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Fedratinib (SAR302503) in culture (PMID: 24398328).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6 - JAK2 JAK2 Y918H	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6-JAK2 JAK2 V881A	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6 - JAK2 JAK2 E864K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R683G JAK2 E864K	cancer	resistant	NVP-BSK805	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 R683G JAK2 E864K	cancer	resistant	NVP-BVB808	Preclinical	Actionable	In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	ETV6 - JAK2 JAK2 G831R	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp	triple-receptor negative breast cancer	sensitive	NVP-BSK805 + paclitaxel	Preclinical - Pdx	Actionable	In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in patient-derived xenograft models of triple-negative breast cancer with JAK2 overexpression (PMID: 27075627).
JAK2	JTK10 | THCYT3	9p24.1	NM_004972	JAK2 over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 E183G	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing JAK3 E183G in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 I87T	Advanced Solid Tumor	sensitive	JANEX-1	Preclinical - Cell culture	Actionable	In a preclinical study, JANEX-1 (WHI-P131) inhibited proliferation of transformed cells expressing JAK3 I87T in culture (PMID: 18397343).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 R172Q	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing JAK3 R172Q in culture demonstrated decreased cell survival, reduced phosphorylation of Stat5a, and G1 arrest when treated with Xeljanz (tofacitinib) (PMID: 21821710).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 L857P JAK3 Y100A	Advanced Solid Tumor	decreased response	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing both JAK3 L857P and JAK3 Y100A demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 L857P JAK3 Y100A	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 L857P JAK3 Y100A	Advanced Solid Tumor	sensitive	NIBR3049	Preclinical - Cell culture	Actionable	In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 L857P	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 L857P	Advanced Solid Tumor	sensitive	NIBR3049	Preclinical - Cell culture	Actionable	In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 L857P	Advanced Solid Tumor	decreased response	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing JAK3 L857P demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 V722I	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical	Actionable	In a preclinical study, Xeljanz (tofacitinib) treatment converted cells expressing JAK3 V221I from factor-independent to factor-dependent growth in cell culture (PMID: 25146434).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 L156P	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing JAK3 L156P in culture demonstrated decreased cell survival, increased G1 arrest, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 A572V	acute myeloid leukemia	predicted - resistant	NS-108	Preclinical - Cell culture	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring JAK3 A572V was insensitive to treatment with NS-108 in culture (PMID: 22829185).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 A572V	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing JAK3 A572V in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 A572V	mature T-cell and NK-cell lymphoma	sensitive	Tofacitinib	Preclinical	Actionable	In a preclinical study, Xeljanz (tofacitinib), a pan-JAK inhibitor, reduced cell viability and increased apoptosis in a JAK3 A572V mutant natural killer/T-cell lymphoma cell line (PMID: 22705984).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 V674A	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 V674A	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793).
JAK3	JAK-3 | JAK3_HUMAN | JAKL | L-JAK | LJAK	19p13.11	NM_000215	JAK3 V674A	Advanced Solid Tumor	decreased response	NIBR3049	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing JAK3 V674A demonstrated reduced sensitivity to NIBR3049 in culture (PMID: 26446793).
KDM6A	bA386N14.2 | KABUK2 | UTX	Xp11.3	NM_021140	KDM6A loss	bladder urothelial carcinoma	sensitive	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, KDM6A-null urothelial bladder carcinoma cell lines demonstrated sensitivity to Tazemetostat (EPZ-6438), resulting in decreased proliferation in culture (PMID: 28228601).
KDM6A	bA386N14.2 | KABUK2 | UTX	Xp11.3	NM_021140	KDM6A loss	bladder urothelial carcinoma	sensitive	GSK343	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK343 inhibited proliferation of KDM6A-null urothelial bladder carcinoma cell lines in culture, and delayed tumor onset, improved survival, and inhibited tumor growth in xenograft models (PMID: 28228601).
KDM6A	bA386N14.2 | KABUK2 | UTX	Xp11.3	NM_021140	KDM6A loss	multiple myeloma	sensitive	GSK343	Preclinical - Cell culture	Actionable	In a preclinical study, a multiple myeloma cell line with KDM6A loss demonstrated sensitivity to treatment with GSK343, resulting in cell-cycle arrest and increased apoptosis in culture (PMID: 29045832).
KDM6A	bA386N14.2 | KABUK2 | UTX	Xp11.3	NM_021140	KDM6A loss	multiple myeloma	sensitive	GSK126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a multiple myeloma cell line demonstrated sensitivity to treatment with GSK126, resulting in decreased viability in culture and decreased tumor growth in xenograft models (PMID: 29045832).
KDM6A	bA386N14.2 | KABUK2 | UTX	Xp11.3	NM_021140	KDM6A loss	bladder urothelial carcinoma	sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, KDM6A-null urothelial bladder carcinoma cell lines demonstrated sensitivity to GSK126, resulting in decreased proliferation in culture (PMID: 28228601).
KDM6A	bA386N14.2 | KABUK2 | UTX	Xp11.3	NM_021140	KDM6A loss	bladder urothelial carcinoma	sensitive	GSK503	Preclinical - Pdx	Actionable	In a preclinical study, GSK503 inhibited tumor growth in a cell line xenograft model and in a patient-derived xenograft (PDX) model of KDM6A-null urothelial bladder carcinoma (PMID: 28228601).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR A1065T	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, cells expressing KDR A1065T were sensitive to Sutent (sunitinib) in culture (PMID: 19723655).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR positive	melanoma	predicted - sensitive	Anti-VEGFR2 CAR CD8 lymphocytes	Preclinical	Actionable	In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR positive	Advanced Solid Tumor	predicted - sensitive	Anti-VEGFR2 CAR CD8 lymphocytes	Preclinical	Actionable	In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR positive	Advanced Solid Tumor	predicted - sensitive	Tanibirumab	Phase I	Actionable	In a Phase I trial, Tanibirumab treatment demonstrated manageable toxicity and preliminary efficacy, resulted in increased circulating Kdr (Vegfr2), Vegf and Pigf, and stable disease in 61% (11/18) of patients with refractory solid tumors (PMID: 28391576; NCT01660360).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR positive	pancreatic cancer	sensitive	TAS-115	Preclinical	Actionable	In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR pos RET C634W	thyroid medullary carcinoma	predicted - sensitive	Motesanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T	olfactory neuroblastoma	sensitive	Cetuximab + Sunitinib	Clinical Study	Actionable	In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR Q472H	melanoma	sensitive	unspecified VEGFR2 antibody	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR wild-type	Advanced Solid Tumor	predicted - sensitive	Ramucirumab	Phase I	Actionable	In a Phase I trial, Cyramza (ramucirumab), an inhibitor of KDR (VEGFR2), demonstrated safety and efficacy (partial response or stable disease) in patients with advanced solid tumors (PMID: 20048182).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR wild-type	Advanced Solid Tumor	predicted - sensitive	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Kdr2 phosphorylation in transformed cells expressing KDR wild-type (PMID: 26126987).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR wild-type	pancreatic cancer	sensitive	VEGFR2-169 + Gemcitabine	Phase I	Actionable	In a Phase I trial, VEGFR2-169, in combination with Gemzar (gemcitabine), achieved a disease control rate of 67% (12/18) and an improved overall survival time to 8.7 months in pancreatic cancer patients expressing the HLA-A*2402 version of the KDR (VEGFR2) wild-type allele (PMID: 19930156).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR amp	non-small cell lung carcinoma	no benefit	Vandetanib	Phase III	Actionable	In a retrospective analysis of a Phase III trial, treatment with Caprelsa (vandetanib) did not correlate with an improved PFS, OS, or objective response rate in non-small cell lung carcinoma patients harboring a KDR amplification nor did it inhibit cell proliferation of the KDR amplified archived tumor cells in culture (PMID: 26578684).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	ROS1 fusion KDR amp KIT amp PDGFRA amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR over exp	breast cancer	predicted - resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, upregulation of Kdr (Vegfr2) was identified in tumors acquired resistance to Sutent (sunitinib) in allograft models of breast cancer (PMID: 28011623).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	APC mutant KRAS mutant KDR R961W	colorectal cancer	sensitive	Regorafenib	Clinical Study	Actionable	In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR D717V	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing KDR D717V were sensitive to Sutent (sunitinib) in culture (PMID: 19723655).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR act mut	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR act mut	bladder urothelial carcinoma	predicted - sensitive	Sunitinib	Phase II	Actionable	In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR act mut	Advanced Solid Tumor	predicted - sensitive	Lucitanib	Phase I	Actionable	In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991).
KDR	CD309 | FLK1 | VEGFR | VEGFR2	4q12	NM_002253	KDR act mut	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	resistant	Sunitinib	Preclinical - Pdx	Actionable	In a preclinical study, Sutent (sunitinib) demonstrated limited inhibition of Kit, Erk, and Mtor signaling and resulted in minimal (22.9%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited Kit, Erk, and Mtor signaling, resulted in tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	sensitive	Imatinib mesylate + LY294002	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) in combination with LY394002 resulted in enhanced tumor growth inhibition compared to monotherapy in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A829P	melanoma	sensitive	Nilotinib	Preclinical	Actionable	In a preclinical study, Tasigna (nilotinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A829P	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT A829P demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A829P	melanoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A829P	melanoma	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Sutent (sunitinib) (PMID: 23582185, PMID: 25594040).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A829P	melanoma	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11 KIT A829P	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 mutation and KIT A829P in culture (PMID: 27370604).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_Y578del KIT A829P	gastrointestinal stromal tumor	decreased response	Sunitinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT A829P demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A829P KIT V559D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT A829P and KIT V559D were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A829P KIT V559D	Advanced Solid Tumor	no benefit	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT A829P and KIT V559D were insensitive to Sutent (sunitinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT A829P	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816G ROS1 fusion	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion developed resistance to treatment with Xalkori (crizotinib) and was subsequently found to have acquired KIT D816G (PMID: 29636358).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D816G	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D816G	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D816G	Advanced Solid Tumor	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D816G	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT Y553S KIT V556_T574del KIT D820Y	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT D820Y was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring primary KIT V569_L576del and KIT Y553S mutations, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820N	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical case study, KIT D820N was identified as a secondary mutation in the metastatic lesions from a gastrointestinal stromal tumor patient whose disease progressed on Gleevec (imatinib mesylate) (PMID: 18628470).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V KIT V560G	mast-cell leukemia	sensitive	BPR1J373	Preclinical - Cell culture	Actionable	In a preclinical study, a mast-cell leukemia cell line simultaneously harboring KIT D816V and KIT V560G was sensitive to BPR1J373 in culture, demonstrating inhibition of Kit phosphorylation and apoptotic activity (PMID: 27512117).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V KIT V560G	mast cell neoplasm	resistant	Quizartinib	Preclinical	Actionable	In a preclinical study, KIT D816V conferred resistance to Quizartinib in a mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 23497317).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V KIT V560G	mast-cell leukemia	sensitive	BLU-285	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of a mast cell leukemia cell line harboring KIT D816V and V560G in culture (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V KIT V560G	mast-cell leukemia	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of a human mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 24552773).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V KIT V560G	mast-cell leukemia	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis in a mast-cell leukemia cell line harboring both KIT V560G and KIT D816V in culture (PMID: 18024392).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560G	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT V560G demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560G	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560G demonstrated inhibition of cell proliferation and tumor regression both in culture and in vivo when treated with Tasigna (nilotinib) (PMID: 20442311).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560G	mast-cell leukemia	sensitive	BLU-285	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of mast cell leukemia cells harboring KIT V560G in culture (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT L576P KIT W557R	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient co-harboring KIT L576P and KIT W557R demonstrating a partial response and a progression free survival of 5.3 months and overall survival of 14.7 months when treated with Tasigna (nilotinib) (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT L576P	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including three melanoma patients harboring KIT L576P demonstrating a partial response (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT L576P	melanoma	no benefit	Imatinib	Clinical Study	Actionable	In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in initial tumor reduction followed by disease progression in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT L576P	melanoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT L576P in culture (PMID: 29035277).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT L576P	melanoma	sensitive	Dasatinib	Clinical Study	Actionable	In two clinical case studies, patients with Gleevec (imatinib)-melanoma that harboring KIT L576P demonstrated initial clinical benefit following treatment with Sprycel (dasatinib), however progressed after 3-4 months of treatment (PMID: 19671763).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT L576P	melanoma	sensitive	Bevacizumab + Sorafenib	Clinical Study	Actionable	In a clinical case study, a melanoma patient harboring KIT L576P demonstrated sensitivity to the combination treatment of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in a partial response for 8 months (PMID: 25363205).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT L576P	melanoma	sensitive	SEL201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cells harboring KIT L576P in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557G	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT W557G in culture (PMID: 23567324).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560del KIT V654A	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V560del/V654A double mutation in culture (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560del	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560del KIT over exp	thymic carcinoma	sensitive	Imatinib	Clinical Study	Actionable	In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT V560del with KIT over expression initially demonstrated stable disease and reduction in metastatic lesions following treatment with Gleevec (imatinib), but progressed after 6 months (PMID: 15201427).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	ROS1 fusion KDR amp KIT amp PDGFRA amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT amp PDGFRA amp	glioblastoma multiforme	sensitive	DCC-2618	Phase I	Actionable	In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T417_D419delinsI	Advanced Solid Tumor	conflicting	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation in transformed cells over expressing KIT T417_D419delinsI in culture (PMID: 16015387).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T417_D419delinsI	Advanced Solid Tumor	conflicting	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT T417_D419delinsI were resistant to treatment with Gleevec (imatinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T417_D419delinsI	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT T417_D419delinsI were sensitive to treatment with Flumatinib, demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T417_D419delinsI	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT T417_D419delinsI were sensitive to treatment with Sutent (sunitinib), demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT mutant	gastrointestinal stromal tumor	predicted - sensitive	DCC-2618	Phase I	Actionable	In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT mutant	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT mutant	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT mutant	gastrointestinal stromal tumor	sensitive	BGJ398 + Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT mutant	gastrointestinal stromal tumor	not applicable	N/A	Clinical Study	Diagnostic	KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	RUNX1-RUNX1T1 KIT mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820Y KIT V559D	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820Y KIT V559D	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820Y KIT V559D	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture, with increased potency compared to Sprycel (dasatinib) or Nexavar (sorafenib) (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820Y	melanoma	predicted - sensitive	Sorafenib	Clinical Study	Actionable	In a clinical case report, Nexavar (sorafenib) treatment resulted in stable disease in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820Y	melanoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820Y	melanoma	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib mesylate) failed to inhibit MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820Y	melanoma	sensitive	SEL201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cell lines harboring KIT D820Y in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V555_L576del KIT D820G KIT D820Y	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT D820G and KIT D820Y were identified as secondary mutations in a patient with gastrointestinal stromal tumor harboring a primary KIT V555_L576del, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup KIT D820E	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal (7.4%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT A502_Y503dup and KIT D820E, which was established from a patient who did not respond to Gleevec (imatinib mesylate) and Sutent (sunitinib) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup KIT D820E	gastrointestinal stromal tumor	predicted - resistant	Sunitinib	Preclinical - Pdx	Actionable	In a preclinical study, Sutent (sunitinib) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal (26.2%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT A502_Y503dup and KIT D820E, which was established from a patient who did not respond to Gleevec (imatinib mesylate) and Sutent (sunitinib) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820E	thymic carcinoma	sensitive	Sorafenib	Clinical Study	Actionable	In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT D820E demonstrated a partial response to treatment with Nexavar (sorafenib) (PMID: 19461405).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820E	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT D820E demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K642E	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT K642E demonstrating a partial response and a progression free survival of 5.8 months and overall survival of 18.6 months (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K642E	gastrointestinal stromal tumor	sensitive	BGJ398 + Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 25673643).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K642E	vulvar melanoma	predicted - sensitive	Imatinib	Clinical Study	Actionable	In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with recurrent vulval melanoma harboring KIT K642E, reduced tumor mass by 35% (PMID: 20372153).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K642E	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line harboring KIT K642E demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K642E	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 21170960).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D KIT Y823D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical	Actionable	In a preclinical study, Flumatinib treatment in transformed cells co-expressing KIT N822K and KIT V559D demonstrated decreased cell proliferation and inhibition of Kit, Erk 1/2, and Stat3 phosphorylation in culture, and led to improved survival in mouse models (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D KIT Y823D	Advanced Solid Tumor	no benefit	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) treatment in a mouse model with cells expressing KIT V559D and KIT Y823D resulted in shortened survival (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D KIT Y823D	Advanced Solid Tumor	no benefit	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT Y823D and KIT V559D were insensitive to Sutent (sunitinib) in culture and in mouse models (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT Y823D	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT Y823D in culture (PMID: 20633291).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT Y823D	gastrointestinal stromal tumor	sensitive	DCC-2618	Preclinical - Pdx	Actionable	In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del and KIT Y823D (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT Y823D	gastrointestinal stromal tumor	sensitive	BLU-285	Preclinical - Pdx	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and resulted in tumor regression in patient-derived xenograft models of Gleevec (imatinib mesylate)-resistant gastrointestinal stromal tumor harboring KIT W557_K558del and Y823D (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT Y823D	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT W557_K558del and KIT Y823D demonstrated sensitivity to Iclusig (ponatinib) in a PDX model, resulting in complete tumor regression (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559_V560del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559_V560del were sensitive to Gleevec (imatinib), demonstrating decreased cell proliferation in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559_V560del	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559_V560del were sensitive to Sutent (sunitinib), demonstrating decreased cell proliferation in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559_V560del	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559_V560del were sensitive to Flumatinib, demonstrating decreased cell proliferation in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I KIT V560D	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/T670I double mutation in culture (PMID: 20633291).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I KIT V560D	Advanced Solid Tumor	resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V560D and KIT T670I were resistant to Flumatinib in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11 KIT T670I	gastrointestinal stromal tumor	predicted - sensitive	Sunitinib	Preclinical - Pdx	Actionable	In a preclinical study, Sutent (sunitinib) inhibited Kit signaling, resulted in 86.7% tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT exon 11 mutation (K550_splice) and KIT T670I, which was established from a patient who did not respond to Gleevec (imatinib mesylate) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11 KIT T670I	gastrointestinal stromal tumor	predicted - sensitive	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited Kit signaling, resulted in tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT exon 11 mutation (K550_splice) and KIT T670I, which was established from a patient who did not respond to Gleevec (imatinib mesylate) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11 KIT T670I	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) did not inhibit Kit, Erk signaling and resulted in limited (53.9%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT exon 11 mutation (K550_splice) and KIT T670I, which was established from a patient who did not respond to Gleevec (imatinib mesylate) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT T670I	Advanced Solid Tumor	no benefit	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT T670I	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited proliferation and induced apoptosis of transformed cells expressing a KIT W557_K558del/T670I double mutation in culture (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT T670I	Advanced Solid Tumor	resistant	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT T670I	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT T670I	Advanced Solid Tumor	resistant	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT T670I	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT T670I	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and decreased tumor volume (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT T670I demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I	melanoma	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I	gastrointestinal stromal tumor	resistant	Imatinib	Clinical Study	Actionable	In a clinical case report, a patient with a gastrointestinal stromal tumor developed disease progression while being treated with Gleevec (imatinib), demonstrating a KIT T670I mutation in the progressive lesion (PMID: 15236194).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I	melanoma	resistant	Nilotinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Tasigna (nilotinib) (PMID: 23582185, PMID: 25594040).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I	melanoma	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, Sutent (sunitinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT T670I (PMID: 23582185, PMID: 25594040).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I	melanoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Sprycel (dasatinib) (PMID: 23582185, PMID: 25594040).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT T670I KIT V559D	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V559D and KIT T670I were sensitive to treatment with Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_Y578del KIT T670I	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_Y578del KIT T670I	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816E KIT D820V	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT D816E and D820V were identified as secondary mutations in a patient with gastrointestinal stromal tumor who developed resistance to Gleevec (imatinib mesylate)(PMID: 18294292).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_Y578del KIT D816E	gastrointestinal stromal tumor	decreased response	Sunitinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT D816E demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P577del KIT W557Lfs*5 KIT D820G	gastrointestinal stromal tumor	sensitive	PLX9486	Preclinical - Pdx	Actionable	In a preclinical study, PLX9486 treatment decreased Mapk and Kit downstream signaling, resulted in tumor volume stabilization in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor harboring KIT P577del, W557Lfs*5, and D820G (18th Annual BSMO Meeting, Feb 2016, abstract O5).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P577del KIT W557Lfs*5 KIT D820G	gastrointestinal stromal tumor	sensitive	Cabozantinib	Preclinical - Pdx	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) slowed tumor growth and decreased mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G (PMID: 27777285).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P577del KIT W557Lfs*5 KIT D820G	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G, demonstrated resistance to treatment with Gleevec (imatinib) (PMID: 27777285).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 17	gastrointestinal stromal tumor	predicted - sensitive	PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 demonstrated safety and preliminary efficacy, resulted in a progression-free survival of more than 24 weeks and partial response in 8.3% (2/24) of patients with advanced solid tumors, 20 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 17	Advanced Solid Tumor	sensitive	BLU-285	Preclinical	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of various tumor cell lines harboring KIT exon 17 mutations in culture, and induced tumor regression in an allograft animal model (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 17	gastrointestinal stromal tumor	sensitive	BLU-285	Phase I	Actionable	In a Phase I trial, BLU-285 demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring KIT mutations, with reduced tumor burden in 38% (5/13) of patients, including 1 partial response and 4 stable diseases, and 3 of the 5 responding patients harbored KIT exon 17 mutations (EORTC-NCI-AACR 2016, Abs 6LBA).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 17	gastrointestinal stromal tumor	predicted - sensitive	Pexidartinib + PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 and Pexidartinib (PLX3397) combination therapy demonstrated safety and preliminary efficacy, resulted in a partial response rate of 8.3% (1/12) and progression-free survival not yet reached in patients with advanced solid tumors, 11 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11 KIT exon 17	gastrointestinal stromal tumor	predicted - sensitive	PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 treatment resulted in partial response with 33% decrease of tumor size after 4 cycles of therapy in a patient with gastrointestinal stromal tumor harboring a primary KIT exon 11 mutation and a secondary KIT exon 17 mutation, who progressed on prior Gleevec (imatinib mesylate) and Sutent (sunitinib) therapies (CTOS Annual Meeting, Nov 2017, abstract # 2771952).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820A KIT V560D	gastrointestinal stromal tumor	resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT D820A was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary KIT V560D mutation, who developed resistance to Gleevec (imatinib mesylate) (PMID: 16954519).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820A KIT V560D	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16954519).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820A KIT V560D	gastrointestinal stromal tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Sutent (sunitinib) in culture (PMID: 18955458).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D820A	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D820A	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing W557_K558del and KIT D820A were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D820A	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D820A	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559del	gastrointestinal stromal tumor	sensitive	G007-LK + Imatinib	Preclinical	Actionable	In a preclinical study, the combination of G007-LK and Gleevec (imatinib) demonstrated increased anti-tumor activity compared to either agent alone in a mouse model of gastrointestinal stromal tumor expressing Kit V558del (corresponding to human V559del) (PMID: 28611108).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P551_W557delinsL	gastrointestinal stromal tumor	sensitive	Ponatinib	Clinical Study	Actionable	In a clinical study, a GIST patient harboring KIT P551_W557delinsL, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity to Iclusig (ponatinib) treatment, which resulted in tumor regression and stable disease (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT act mut	gastrointestinal stromal tumor	sensitive	Cabozantinib	Preclinical	Actionable	In a preclinical study, Cometriq (cabozantinib) decreased cell viability in imatinib-sensitive and resistant gastrointestinal stromal tumor (GIST) cell lines harboring KIT activating mutations in culture, and induced tumor regression in KIT-mutant GIST mouse models (PMID: 25836719).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT act mut	gastrointestinal stromal tumor	not applicable	N/A	Guideline	Diagnostic	KIT activating mutations aid the diagnosis of gastrointestinal stromal tumor (NCCN.org).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT act mut	melanoma	sensitive	Imatinib	Guideline	Actionable	Gleevec (imatinib) is included in guidelines as second-line therapy for melanoma patients with KIT activating mutations (NCCN.org).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT act mut	gastrointestinal stromal tumor	sensitive	Pexidartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX3397 inhibited growth of gastrointestinal stromal tumor cell lines harboring KIT activating mutations in culture and in cell line xenograft models (PMID: 24583793).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT act mut	Advanced Solid Tumor	sensitive	PLX9486	Preclinical	Actionable	In a preclinical study, PLX9486 inhibited KIT mutations, including exon 17 mutations, and demonstrated in vivo and in vitro activity against tumors harboring KIT exon 17 mutations (Cancer Res February 1, 2016 76; IA32).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K550_W557del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K550_W557del	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K550_W557del	Advanced Solid Tumor	sensitive	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K550_W557del	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K558delinsNP	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K558delinsNP	Advanced Solid Tumor	sensitive	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K558delinsNP	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K558delinsNP	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT H697Y	Advanced Solid Tumor	decreased response	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cell lines overexpressing KIT H697Y demonstrated reduced sensitivity to Gleevec (imatinib mesylate)-induced growth inhibition in culture (PMID: 19861435).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT H697Y	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines overexpressing KIT H697Y in culture (PMID: 19861435).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D816H	Advanced Solid Tumor	decreased response	Sunitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D816H	Advanced Solid Tumor	decreased response	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Gleevec (imatinib) in both culture and xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D816H	Advanced Solid Tumor	decreased response	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Stivarga (regorafenib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D816H	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and tumor regression (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816H	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT D816H demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816H	Advanced Solid Tumor	predicted - sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816H were more sensitive to treatment with Sutent (sunitinib) in culture compared to Gleevec (imatinib) (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816H	Advanced Solid Tumor	predicted - sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816H were more sensitive to treatment with Flumatinib in culture compared to Gleevec (imatinib) (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816H	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, KIT D816H demonstrated resistance to Stivarga (regorafenib) in an in vitro assay, and conferred secondary resistance to Stivarga (regorafenib) in transformed cells expressing other KIT mutations (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_L576del	gastrointestinal stromal tumor	sensitive	Imatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Gleevec (imatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_L576del	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Iclusig (ponatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_L576del KIT V654A	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_L576del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820V	gastrointestinal stromal tumor	sensitive	BLU-285	Phase I	Actionable	In a Phase I trial, BLU-285 treatment resulted in tumor reduction lasting through 15 cycles of treatment in a patient with gastrointestinal stromal tumor harboring KIT D820V, whose disease had progressed on previous Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib) treatment (PMID: 29093181; NCT02508532).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558delinsCE KIT N822K	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT N822K was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary KIT W557_K558delinsCE, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P577_D579del	thymic carcinoma	sensitive	Sorafenib	Clinical Study	Actionable	In a clinical case report, a patient with advanced thymic carcinoma harboring KIT P577_D579del demonstrated response to treatment with Nexavar (sorafenib), with a decrease in tumor size (PMID: 20970876).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K558_V560del KIT W557C	gastrointestinal stromal tumor	sensitive	Ponatinib	Clinical Study	Actionable	In a clinical study, a GIST patient harboring KIT K558_V560del and KIT W557C, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity when treated with Iclusig (ponatinib), which resulted in a radiologic response and stabilization for six months (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K558_V560del KIT V654A	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT V654A was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary KIT K558_V560del, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K KIT V559D	Advanced Solid Tumor	no benefit	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT N822K and KIT V559D were insensitive to Sutent (sunitinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K KIT V559D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT N822K and KIT V559D were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation and inhibition of Kit, Erk 1/2, and Stat3 phosphorylation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559D were sensitive to Gleevec (imatinib), demonstrating decreased cell proliferation in culture and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT V559D demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V559D demonstrating a partial response and progression free survival of 28.3 months and overall survival of 28.3 months (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559D were sensitive to Sutent (sunitinib), demonstrating decreased cell proliferation in culture and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559D were sensitive to Flumatinib, demonstrating decreased cell proliferation in culture and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559D KIT V654A	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V559D and KIT V654A were sensitive to treatment with Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D820G KIT V559D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D820G and KIT V559D were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT positive	germ cell cancer	resistant	Imatinib	Phase II	Actionable	In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT positive	breast cancer	predicted - sensitive	Imatinib + Letrozole	Phase 0	Actionable	In a pilot trial, Gleevec (imatinib mesylate) and Femara (letrozole) combination treatment resulted in clinical partial response in 90% (9/10) and stable disease in 10% (1/10) of the evaluable patients with invasive hormone-sensitive breast cancer, 8 of the 13 enrolled patients had KIT-positive tumors (PMID: 18248884).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT positive	prostate neuroendocrine neoplasm	no benefit	Imatinib	Preclinical	Actionable	In a preclinical study, a prostate neuroendocrine tumor mouse model expressing Kit did not respond to Gleevec (imatinib), a result of impaired signaling of the Kit pathway (PMID: 27980106).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT positive	gastrointestinal stromal tumor	sensitive	Imatinib	FDA approved	Actionable	In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in an overall response rate of 38% (56/147) and a median duration of response of 13 weeks in patients with metastatic or unresectable KIT-positive GIST (PMID: 12374669).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_V559delinsF	gastrointestinal stromal tumor	sensitive	BLU-285	Preclinical - Pdx	Actionable	In a preclinical study, BLU-285 treatment resulted in tumor regression in patient-derived xenograft models of gastrointestinal stromal tumor harboring KIT W557_V559delinsF (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P551_V555delinsTL	gastrointestinal stromal tumor	sensitive	Sorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555delinsTL (PMID: 19139124).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT M552_K558del	gastrointestinal stromal tumor	resistant	Ponatinib	Clinical Study	Actionable	In a clinical study, a GIST patient harboring KIT M552_K558del, resistant to multiple tyrosine kinase inhibitors, demonstrated resistance to Iclusig (ponatinib) treatment as indicated by disease progression after 4 weeks of treatment (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 9	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 9	gastrointestinal stromal tumor	predicted - sensitive	Sunitinib	Clinical Study	Actionable	In a retrospective analysis, GIST patients with KIT exon 9 mutations showed improved progression-free survival (PFS), overall survival, and objective response rate (ORR) compared to patients with exon 11 mutations, with a median PFS of 12.3 months vs. 7.0 months, and an ORR of 19% (8/42) vs. 6% (9/143) following treatment with Sutent (sunitinib) (PMID: 26772734).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 9	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 9	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, Stivarga (regorafineb) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 9	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT over exp	seminoma	sensitive	Imatinib	Clinical Study	Actionable	In a clinical case report, Gleevec (imatinib) in conjunction with third-line chemotherapy resulted in a complete response in a patient with stage IV chemoresistant pure seminoma with KIT over expression (PMID: 18751412).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT over exp	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Kit in culture (PMID: 27627808).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P551_E554del	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT P551_E554del were resistant to treatment with Stivarga (regorafenib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P551_E554del	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT P551_E554del were resistant to treatment with Sutent (sunitinib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P551_E554del	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT P551_E554del were resistant to treatment with Gleevec (imatinib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P551_E554del	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT P551_E554del demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557C KIT Y578C	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing both KIT W557C and KIT Y578C in culture (PMID: 23567324).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT V654A	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and decreased tumor volume (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT V654A	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT V654A	gastrointestinal stromal tumor	sensitive	BLU-285	Preclinical - Pdx	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and resulted in tumor regression in patient-derived xenograft models of Gleevec (imatinib)-resistant gastrointestinal stromal tumor harboring KIT W557_K558del and V654A (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT V654A	Advanced Solid Tumor	no benefit	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT V654A	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V654A	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT V654A demonstrated some sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V654A	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT V654A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16751810).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D KIT V654A	Advanced Solid Tumor	resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V560D and KIT V654A were resistant to Flumatinib in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D KIT V654A	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/V654A double mutation in culture (PMID: 20633291).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11 KIT V654A	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion mutation and KIT V654A in culture (PMID: 27370604).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V569_L576del KIT V654A KIT N822K	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT V654A and KIT N822K were identified as secondary mutations in a patient with gastrointestinal stromal tumor harboring a primary KIT V569_L576del, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT M552_V559del	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT M552_V559del in culture (PMID: 20633291).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557R	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT W557R demonstrating a partial response and progression free survival of 35.4 months and overall survival of 35.4 months (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) did not inhibit growth of transformed cells expressing KIT D816V in culture (PMID: 22301675).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Gleevec (imatinib mesylate) in culture (PMID: 15790786).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	hematologic cancer	resistant	Sorafenib	Preclinical	Actionable	In a preclinical study, transformed hematopoietic cells expressing KIT D816V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 17229632).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	mast cell neoplasm	predicted - sensitive	BLU-285	Phase I	Actionable	In a Phase I trial, patients with either aggressive systemic mastocytosis, mast cell leukemia, or systemic mastocytosis with an associated hematologic neoplasm harboring KIT D816V demonstrated a reduction in mast cell burden and a decrease in KIT D816V allelic fraction when treated with BLU-285 (ASH Annual Meeting, Dec 2017, Plenary 2).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	acute myeloid leukemia	sensitive	Dasatinib + Cytarabine	Clinical Study	Actionable	In a clinical case study, a patient with acute myeloid leukemia harboring KIT D816V achieved long-term remission and loss of KIT D816V following treatment with the combination of Sprycel (dasatinib) and Cytosar-U (cytarabine) (PMID: 18986703).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Indication other than cancer	resistant	Imatinib	FDA approved	Actionable	Gleevec (imatinib) is not indicated for patients with aggressive systemic mastocytosis harboring KIT D816V (FDA.gov).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	hematologic cancer	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, a mouse myeloid cell line expressing KIT D816V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 12481435).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	decreased response	Nilotinib	Preclinical	Actionable	In a preclinical study, Tasigna (nilotinib) decreased viability of cells expressing KIT D816V in culture, but did not inhibit KIT phosphorylation or growth of KIT D816V-expressing tumors in mouse models (PMID: 20442311).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	resistant	Cabozantinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Cometriq (cabozantinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101, as compared to Quizartinib, inhibited cell proliferation of transformed 32Dcl3 murine myeloid cells expressing human Kit D816V (PMID: 29187377).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, KIT D816V mutations demonstrated resistance to Sutent (sunitinib) in a biochemical assay (PMID: 19164557).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Sutent (sunitinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	predicted - sensitive	BPR1J373	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were sensitive to BPR1J373, demonstrating inhibition of Kit phosphorylation (PMID: 27512117).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	resistant	Quizartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Quizartinib in culture (PMID: 23497317).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V	Advanced Solid Tumor	resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Flumatinib in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816V NRAS Q61R	melanoma	no benefit	Pembrolizumab + Trametinib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816Y	mast cell neoplasm	sensitive	DCC-2618	Preclinical - Cell culture	Actionable	In a preclinical study, DCC-2618 inhibited proliferation of a mouse mastocytosis cell line expressing KIT K816Y in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816Y	mast cell neoplasm	sensitive	BLU-285	Preclinical	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of murine mastocytoma cells harboring KIT D814Y (corresponding to human D816Y) in culture, and resulted in tumor regression in allograft animal models (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816Y	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816H were resistant to treatment with Gleevec (imatinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816Y	Advanced Solid Tumor	resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816Y were resistant to treatment with Flumatinib in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D816Y	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816Y were resistant to treatment with Sutent (sunitinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT D579del	thymic carcinoma	sensitive	Imatinib	Clinical Study	Actionable	In a clinical case report, a patient with thymic carcinoma harboring KIT D579del achieved disease stabilization following treatment with Gleevec (imatinib) (PMID: 24419427).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D820G	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D820G	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D820G	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT D820G	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K558_G565delinsR	gastrointestinal stromal tumor	sensitive	Cabozantinib	Preclinical - Pdx	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in tumor regression, decreased mitotic activity, and increased apoptotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT K558_G565delins (PMID: 27777285).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT K558_G565delinsR	gastrointestinal stromal tumor	sensitive	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib) treatment resulted in tumor regression and decreased mitotic activity in gastrointestinal stromal tumor patient derived xenograft (PDX) models harboring KIT K558_G565delinsR (PMID: 27777285).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT wild-type	acute myeloid leukemia	sensitive	BPR1J373	Preclinical - Cell culture	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring KIT wild-type was sensitive to BPR1J373 in culture, demonstrating apoptotic induction and inhibition of cell proliferation (PMID: 27512117).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT wild-type	megakaryocytic leukemia	decreased response	BLU-285	Preclinical - Cell culture	Actionable	In a preclinical study, KIT wild-type megakaryocytic leukemia cells were less sensitive to BLU-285 compared to cells harboring KIT mutations in culture (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_Y578del	gastrointestinal stromal tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line harboring KIT V560_Y578del demonstrated sensitivity to Gleevec (imatinib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_Y578del	gastrointestinal stromal tumor	sensitive	BGJ398 + Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT V560_Y578del in culture (PMID: 25673643).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560_Y578del	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line harboring KIT V560_Y578del demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup KIT N822K	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT N822K was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary KIT A502_Y503dup, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup	gastrointestinal stromal tumor	sensitive	Cabozantinib	Preclinical - Pdx	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in decreased tumor volume and reduced mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup (PMID: 27777285).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT A502_Y503dup (Y503_F504insAY) were sensitive to Gleevec (imatinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup demonstrated resistance to treatment with Gleevec (imatinib), resulting in increased tumor volume (PMID: 27777285).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT A502_Y503dup (Y503_F504insAY) were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT A502_Y503dup (Y503_F504insAY) were sensitive to Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup	gastrointestinal stromal tumor	predicted - sensitive	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Stivarga (regorafenib) did not significantly inhibit Kit, Erk, or Mtor signaling, but resulted in tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT A502_Y503dup and KIT D820E, which was established from a patient who did not respond to Gleevec (imatinib mesylate) and Sutent (sunitinib) (PMID: 29100343).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT A502_Y503dup PDGFRA H687Y	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, PDGFRA H687Y was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring primary KIT A502_Y503dup, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559A	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, KIT V559A was identified as a secondary mutation in a patient with gastrointestinal stromal tumor who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559A	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V559A demonstrating a partial response and progression free survival of 19.4 months and overall survival of 32.9 months (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V559A	melanoma	predicted - sensitive	Imatinib	Clinical Study	Actionable	In a clinical case study, Gleevec (imatinib) treatment in a patient with metastatic melanoma resulted in regression of the lung metastasis, which harbored KIT V559A, however, neither the primary tumor or lymph node metastasis responded, which had wild-type KIT (PMID: 19812602).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT I571_D579dup	Advanced Solid Tumor	predicted - resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Gleevec (imatinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT I571_D579dup	Advanced Solid Tumor	predicted - resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Sutent (sunitinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT I571_D579dup	Advanced Solid Tumor	predicted - resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Flumatinib in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT Y578C	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT Y578C in culture (PMID: 23567324).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 13	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a gastrointestinal stromal tumor cell line harboring a KIT exon 13 mutation in culture (PMID: 27370604).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 13	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response in 7.7% (1/13) of melanoma patients harboring KIT exon 13 mutations (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 13	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11 del	gastrointestinal stromal tumor	predicted - sensitive	Imatinib	Phase III	Actionable	In a Phase III trial, gastrointestinal stromal tumor patients harboring KIT exon 11 deletions or indels demonstrated improved improved recurrence-free survival (RFS) with 3-year adjuvant Gleevec (imatinib) treatment (5-year RFS, 70%), compared to patients receiving 1-year treatment (5-year RFS, 41.3%) (PMID: 28334365).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT Y553N	thymic carcinoma	sensitive	Imatinib	Clinical Study	Actionable	In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT Y553N demonstrated improved clinical performance and reduction in metastatic lesions following treatment with Gleevec (imatinib) (PMID: 21969494).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del	Advanced Solid Tumor	sensitive	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del	gastrointestinal stromal tumor	sensitive	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, PD-0325901 treatment inhibited Erk phosphorylation and decreased expression of ETV1 and CXCR4 in gastrointestinal stromal tumor cells harboring KIT W557_K558del (PMID: 26936919).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing W557_K558del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and near complete tumor regression (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT N822K	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT N822K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT N822K	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT W557_K558del KIT N822K	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D	Advanced Solid Tumor	sensitive	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT V560D in culture (PMID: 20633291).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D were sensitive to Nexavar (sorafenib) in culture (PMID: 22665524).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D were sensitive to Sprycel (dasatinib) in culture (PMID: 16397263).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V560D demonstrating a partial response and progression free survival of 8.6 months and overall survival of 23.5 months (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT V560D	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N505I	melanoma	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, KIT N505I induced phosphorylation of KIT, ERK, and AKT, and was inhibited by Nexavar (sorafenib) in cell culture of melanocytes, demonstrating sensitivity of N505I to sorafenib (PMID: 24317392).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N505I	melanoma	predicted - sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) decreased phosphorylation of KIT, AKT, and ERK in melanocytes expressing KIT N505I in culture (PMID: 24317392).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT C443S	mucosal melanoma	sensitive	Imatinib	Clinical Study	Actionable	In a case report study, a patient with mucosal melanoma harboring KIT C443S demonstrated a substantial response to Gleevec (imatinib) in the first two weeks and then developed progression at 15 weeks (PMID: 25003536).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT S476I	mast-cell leukemia	predicted - sensitive	Midostaurin	Preclinical - Patient cell culture	Actionable	In a preclinical study, treatment with Rydapt (midostaurin) decreased proliferation of patient-derived neoplastic mast cells harboring KIT S476I in culture (PMID: 25209843).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT S476I	mast-cell leukemia	predicted - sensitive	Nilotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, treatment with Tasigna (nilotinib) decreased proliferation of patient-derived neoplastic mast cells harboring KIT S476I in culture (PMID: 25209843).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT S476I MET R988C	gastrointestinal stromal tumor	sensitive	Bevacizumab + Sorafenib	Clinical Study	Actionable	In a clinical case study, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT M541L	chronic leukemia	sensitive	Imatinib	Phase I	Actionable	In Phase I trials, KIT M541L has been associated with response to Gleevec (imatinib) in chronic eosinophilic leukemia, NOS (PMID: 25015329) and mastocytosis (PMID: 18795925).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K	gastrointestinal stromal tumor	resistant	Imatinib	Clinical Study	Actionable	In a clinical case study, KIT N822K was identified in the tumor of a gastrointestinal stromal tumor patient that was resistant to Gleevec (imatinib mesylate) treatment. (PMID: 26316776).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K	acute myeloid leukemia	sensitive	DCC-2618	Preclinical - Pdx	Actionable	In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring KIT N822K (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K	acute myeloid leukemia	sensitive	BPR1J373	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring KIT N822K demonstrated sensitivity to treatment with BPR1J373, showing inhibition of Kit phosphorylation and apoptotic induction in culture, and tumor regression in xenograft models (PMID: 27512117).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K	acute myeloid leukemia	sensitive	BLU-285	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of acute myeloid leukemia cells harboring KIT N822K in culture (PMID: 29093181).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K	Advanced Solid Tumor	predicted - sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT N822K were more sensitive to treatment with Sutent (sunitinib) in culture compared to Gleevec (imatinib), demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K	Advanced Solid Tumor	predicted - sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT N822K were more sensitive to treatment with Flumatinib in culture compared to Gleevec (imatinib), demonstrating decreased cell proliferation (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT N822K were resistant to treatment with Gleevec (imatinib) in culture (PMID: 24205792).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822K	leukemia	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Kit signaling and viability in leukemia cells harboring KIT N822K in culture (PMID: 21482694).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT P551_V555del	gastrointestinal stromal tumor	sensitive	Sorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555del (PMID: 19139124).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 increased growth inhibition and decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations in culture, and improved survival and inhibited tumor growth in a KIT exon 11-mutant GIST cell line xenograft model, with increased efficacy compared to either agent alone (PMID: 27370604).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	melanoma	predicted - sensitive	Imatinib	Clinical Study	Actionable	In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with metastasized anal melanoma harboring a 21 base-pair duplication in exon 11 of KIT, reduced pulmonary metastasis by 60% (PMID: 20372153).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response of 38.5% (10/26) and a progression free survival of 5.4 months in melanoma patients harboring KIT exon 11 mutations (PMID: 28327988).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib	Phase III	Actionable	In a Phase III trial, Gleevec (imatinib) treatment resulted in longer overall survival (OS) (66 vs 40 months) in gastrointestinal stromal tumor (GIST) patients harboring KIT exon 11 mutations compared to KIT and PDGFRA wild-type patients, while subtypes of KIT exon  11 mutations (deletion, insertation/duplication, point mutation) did not affect OS outcome (PMID: 28196207; NCT00009906).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib	Phase III	Actionable	In a Phase III trial, a long-term analysis of gastrointestinal stromal tumor (GIST) patients treated with Gleevec (imatinib) demonstrated patients harboring KIT exon 11 mutations had a median progression-free survival of 39.4 months, and median overall survival was not reached, with 69.1% of patients with KIT exon 11 mutations alive at 5 years (PMID: 26687836; NCT00367861).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	sensitive	Nilotinib	Phase III	Actionable	In a Phase III trial, a 24 month progression free survival was observed in 69.6% of advanced GIST patients harboring KIT exon 11 mutations when treated with Tasigna (nilotinib) (J Clin Oncol May 2013 vol. 31 no. 15_suppl 10501).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	Dasatinib	Phase II	Actionable	In a Phase II clinical trial, Sprycel (dasatinib) demonstrated preliminary activity in patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor (GIST), including patients harboring KIT exon 11 mutations, with a partial response rate of 32% (15/47),  median progression-free survival of 2.0 months, and overall survival of 19 months (J Clin Oncol 29: 2011 (suppl; abstr 10006)).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 demonstrated safety and preliminary efficacy, resulted in a progression-free survival of more than 24 weeks and partial response in 8.3% (2/24) of patients with advanced solid tumors, 20 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib + XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of XAV939 and Gleevec (imatinib) resulted in decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations compared to Gleevec (imatinib) alone, in culture (PMID: 28611108).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib + PKF118-310	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of PKF118-310 and Gleevec (imatinib) resulted in decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations compared to Gleevec (imatinib) alone, in culture (PMID: 28611108).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	Pexidartinib + PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 and Pexidartinib (PLX3397) combination therapy demonstrated safety and preliminary efficacy, resulted in a partial response rate of 8.3% (1/12) and progression-free survival not yet reached in patients with advanced solid tumors, 11 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	DCC-2618	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DCC-2618 inhibited Kit phosphorylation and tumor growth in a gastrointestinal stromal tumor cell line xenograft model harboring a KIT exon 11 deletion mutation (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	decreased response	Sunitinib	Clinical Study	Actionable	In a retrospective analysis, GIST patients with KIT exon 11 mutations showed decreased benefit compared to patients with exon 9 mutations, with median PFS of 7.0 months with exon 11 mutations vs. 12.3 months with exon 9 mutations, and an ORR of 6% (9/143) vs. 19% (8/42) following treatment with Sutent (sunitinib) (PMID: 26772734).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	Ponatinib	Phase II	Actionable	In a Phase II trial, Iclusig (ponatinib) treatment resulted in partial response in 7% (2/27), stable disease in 59% (16/27), a median progression free survival of 4.3 months and a median overall survival of 15.0 months in gastrointestinal stromal tumor patients harboring KIT exon 11 mutations after prior tyrosine kinase inhibitor treatment failure (J Clin Oncol 33, 2015 (suppl; abstr 10535)).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT exon 11	gastrointestinal stromal tumor	sensitive	Regorafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with Stivarga (regorafenib) resulted in a clinical benefit rate of 76% (25/33), a median progression-free survival (PFS) of 13.2 months, and a median overall survival of 25 months in patients with gastrointestinal stromal tumors, with patients with KIT exon 11 mutations demonstrating the longest PFS of 13.4 months (PMID: 27371698).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822I	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT N822I in culture (PMID: 21689725).
KIT	C-Kit | CD117 | MASTC | PBT | SCFR	4q12	NM_000222	KIT N822I	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT N822I demonstrated resistance to Gleevec (imatinib) in culture (PMID: 21689725).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine + Panobinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Farydak (panobinostat) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cells harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine + Mocetinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Mocetinostat (MGCD0103) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine + Romidepsin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Istodax (romidepsin) enhanced the effects of Cytosar-U (cytarabine) in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 73% (PMID: 27443263).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cytosar-U (cytarabine) decreased leukemic cells by 66% in acute lymphocytic leukemia cell line xenograft models harboring a KMT2A rearrangement (PMID: 27443263).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	leukemia	predicted - sensitive	I-CBP112 + JQ1	Preclinical	Actionable	In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to JQ1, resulting in decreased cell growth in culture (PMID: 26552700).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	leukemia	predicted - sensitive	I-CBP112 + Doxorubicin	Preclinical	Actionable	In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to Doxorubicin, leading to decreased cell growth in culture (PMID: 26552700).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine + Dacinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Dacinostat (LAQ824) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, KMT2A rearrangements, specifically partial tandem duplications, were associated with a poor overall survival in acute myeloid leukemia patients (PMID: 24487413, PMID: 22915647, PMID: 22417203, PMID: 21881046).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A rearrange	acute lymphocytic leukemia	decreased response	romidepsin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Istodax (romidepsin) resulted in minimal activity in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 16% (PMID: 27443263).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-GAS7	leukemia	sensitive	AMI-408	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with AMI-408 decreased growth of leukemia cells expressing KMT2A-GAS7 (MLL-GAS7) in culture, and increased survival in xenograft models (PMID: 26766589).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-AFF1	acute myeloid leukemia	sensitive	Dinaciclib	Preclinical	Actionable	In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-AFF1 in culture (PMID: 26627013).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-AFF1	acute myeloid leukemia	sensitive	MI-503	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI-503 reduced expression of KMT2A (MLL) fusion target genes, inhibited growth of an acute myeloid leukemia (AML) cell lines harboring KMT2A-AFF1 (MLL-AF4) in culture, and inhibited tumor growth and progression in an AML cell line xenograft model harboring KMT2A-AFF1 (MLL-AF4) (PMID: 25817203).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-AFF1	acute myeloid leukemia	predicted - sensitive	AZD5153	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-AFF1	acute lymphocytic leukemia	predicted - sensitive	AZD5153	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD5153 inhibited proliferation of acute lymphocytic leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-AFF1	leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of leukemia cells harboring KMT2A-AFF1 in culture (PMID: 27294782).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-AFF1	leukemia	sensitive	IRAK1/4	Preclinical - Cell culture	Actionable	In a preclinical study, leukemia cells harboring KMT2A-AFF1 demonstrated sensitivity to IRAK1/4 in culture, resulting in decreased cell proliferation (PMID: 28065413).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT3 SRSF2 P95H	acute myeloid leukemia	sensitive	H3B-8800	Preclinical	Actionable	In a preclinical study, H3B-8800 inhibited tumor growth in transplant animal models of mouse acute myeloid leukemia cells harboring SRSF2 P95H and KMT2A-MLLT3 (MLL-AF9) while had no effect in SRSF2 wild-type controls (Blood 2016 128:966).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT3	leukemia	sensitive	IRAK1/4	Preclinical	Actionable	In a preclinical study, a transgenic leukemic mouse model harboring KMT2A-MLLT3 demonstrated sensitivity to IRAK1/4, resulting in delayed progression and improved survival (PMID: 28065413).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT3	acute myeloid leukemia	sensitive	MI-503	Preclinical - Patient cell culture	Actionable	In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia (AML) cell line and primary AML samples harboring KMT2A-MLLT3 (MLL-AF9) in culture (PMID: 25817203).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT3	acute myeloid leukemia	sensitive	Dinaciclib	Preclinical	Actionable	In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture (PMID: 26627013).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT3	leukemia	sensitive	MI-503	Preclinical	Actionable	In a preclinical study, MI-503 reduced progression and improved survival of a mouse leukemia model expressing KMT2A-MLLT3 (MLL-AF9) (PMID: 25817203).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT3	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture, and prolonged survival in animal models of mouse KMT2A-MLLT3-positive leukemia (PMID: 27294782).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT10	leukemia	sensitive	EPZ004777	Preclinical	Actionable	In a preclinical study, transformed cells expressing the fusion, KMT2A-MLLT10, demonstrated sensitivity to EPZ004777 in culture and in mouse models, resulting in cell cycle arrest, increased apoptotic activity, and inhibition of cell proliferation (PMID: 23138183).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT10	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT10 in culture (PMID: 27294782).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A - EP300	acute myeloid leukemia	sensitive	MI-503	Preclinical - Patient cell culture	Actionable	In a preclinical study, MI-503 inhibited growth of a primary acute myeloid sample harboring KMT2A-EP300 in culture (PMID: 25817203).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	predicted - sensitive	AZD0156	Preclinical	Actionable	In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	predicted - sensitive	AZ20	Preclinical	Actionable	In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	sensitive	Dinaciclib	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-MLLT1	acute myeloid leukemia	sensitive	MI-503	Preclinical - Cell culture	Actionable	In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line harboring KMT2A-MLLT1 (MLL-ENL) in culture (PMID: 25817203).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-ELL	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-ELL in culture (PMID: 27294782).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A fusion	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A fusions in culture (PMID: 27294782).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A fusion	acute myeloid leukemia	predicted - sensitive	MI-503	Preclinical - Cell culture	Actionable	In a preclinical study, MI-503 inhibited growth of several acute myeloid leukemia (AML) cell lines and primary AML samples harboring KMT2A (MLL) fusions in culture (PMID: 25817203).
KMT2A	ALL-1 | CXXC7 | HRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS	11q23.3	NM_005933	KMT2A-SEPT6	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-SEPT6 in culture (PMID: 27294782).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 2	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with KRAS exon 2 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 2	colorectal cancer	no benefit	Cetuximab + Selumetinib	Phase I	Actionable	In a Phase I trial, the combination of Erbitux (cetuximab) and Selumetinib (AZD6244) demonstrated safety, but minimal efficacy, in patients with metastatic colorectal cancer harboring KRAS exon 2 mutations, with no responses and 36% (5/14) of patients achieving stable disease (PMID: 26666244).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 2	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with KRAS exon 2 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 2	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 2 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 2	colorectal cancer	predicted - sensitive	Irinotecan + Selumetinib	Phase II	Actionable	In a Phase II study, Selumetinib (AZD6244), in combination with Camptosar (irinotecan), resulted in a partial response in 9.7% (3/31) and stable disease in 51.6% (16/31) of colorectal cancer patients with KRAS exon 2 mutations (PMID: 25322874).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 2	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with KRAS exon 2 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 3	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with KRAS exon 3 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 3	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 3 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 3	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with KRAS exon 3 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 3	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with KRAS exon 3 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR loss KRAS G12S	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGFR-deficient lung adenocarcinoma cells harboring KRAS G12S were sensitive to treatment with Gilotrif (afatinib), demonstrating decreased cell proliferation and inhibition of Erbb2 (Her2) and Erbb3 (Her3) in culture, and blocked tumor growth in cell line xenograft models (PMID: 29925635).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR loss KRAS G12S	lung adenocarcinoma	no benefit	Gefitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGFR-deficient lung adenocarcinoma cells harboring KRAS G12S did not respond to treatment with Iressa (gefitinib) in culture and in cell line xenograft models (PMID: 29925635).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	colorectal cancer	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring the KRAS G12S mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung carcinoma	sensitive	AZD4785	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cells harboring KRAS G12S (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung cancer	sensitive	APS-2-79 + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of APS-2-49 and Binimetinib (MEK162) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	pancreatic cancer	sensitive	Binimetinib	Preclinical	Actionable	In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung adenocarcinoma	decreased response	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, lung adenocarcinoma cells harboring KRAS G12S were sensitive to treatment with Gilotrif (afatinib), demonstrating decreased cell proliferation and reduced Erk, Mek, and Akt activity in culture, and decreased tumor growth in cell-line xenograft models (PMID: 29925635).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	non-small cell lung carcinoma	sensitive	Trametinib + Navitoclax	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung cancer	sensitive	APS-2-79 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung adenocarcinoma	no benefit	Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, lung adenocarcinoma cells harboring KRAS G12S were insensitive to treatment with Tarceva (erlotinib) in culture, demonstrating no change in Erk, Mek, and Akt activity and minimal inhibition of cell growth (PMID: 29925635).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	non-small cell lung carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	non-small cell lung carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring KRAS G12S in culture (PMID: 21325073, PMID: 23012248).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	non-small cell lung carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung adenocarcinoma	no benefit	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung adenocarcinoma cells harboring KRAS G12S were insensitive to treatment with Iressa (gefitinib) in culture, demonstrating minimal inhibition of cell growth (PMID: 29925635).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung cancer	sensitive	APS-2-79 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of APS-2-49 and PD-0325901 worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	non-small cell lung carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring KRAS G12S mutation in culture (PMID: 26090892).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	non-small cell lung carcinoma	sensitive	Trametinib + TW-37	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung cancer	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Mekinist (trametinib) in culture (PMID: 26582713).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung cancer	sensitive	APS-2-79 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of APS-2-49 and Selumetinib (AZD6244) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung adenocarcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung cancer	decreased response	PD-0325901	Preclinical	Actionable	In a preclinical study, a lung cancer cell line harboring KRAS G12S demonstrated a decreased response when treated with PD-0325901 in culture (PMID: 26582713).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung cancer	decreased response	Refametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Refametinib (BAY86-9766) in culture (PMID: 26582713).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	non-small cell lung carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S	lung cancer	sensitive	rigosertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of lung cancer harboring KRAS G12S (PMID: 27104980).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S STK11 inact mut	non-small cell lung carcinoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR exon 19 del KRAS G12S	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of KRAS G12S in lung adenocarcinoma cells harboring EGFR exon 19 deletion resulted in resistance to Tagrisso (osimertinib) in culture, consistent with KRAS G12S identified in tumor samples of a lung adenocarcinoma patient harboring EGFR exon 19 deletion who developed resistance to Tagrisso (osimertinib) (PMID: 27252416).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S EZH2 pos	lung adenocarcinoma	sensitive	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12S EZH2 pos	lung adenocarcinoma	sensitive	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C EZH2 pos	lung adenocarcinoma	sensitive	Selumetinib + Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C EZH2 pos	lung adenocarcinoma	no benefit	MK2206 + Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C EZH2 pos	lung adenocarcinoma	no benefit	GSK343 + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C EZH2 pos	lung adenocarcinoma	sensitive	GSK343 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C EZH2 pos	lung adenocarcinoma	no benefit	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C EZH2 pos	pancreatic cancer	sensitive	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C EZH2 pos	pancreatic cancer	sensitive	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C EZH2 pos	lung adenocarcinoma	sensitive	DZNep + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C, in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF dec exp KRAS G12C	lung cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Braf expression through shRNA knockdown in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	pancreatic cancer	sensitive	Cobimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring KRAS G12C (PMID: 23934108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	Advanced Solid Tumor	sensitive	SML-10-70-1	Preclinical	Actionable	In a preclinical study, SML-10-70-1 inhibited proliferation and Erk/Akt signaling in cells expressing KRAS G12C (PMID: 24259466).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	pancreatic adenocarcinoma	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by Selumetinib (AZD6244) in culture (PMID: 28957417).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	sensitive	ARS-853	Preclinical - Cell culture	Actionable	In a preclinical study, ARS-853 treatment in culture resulted in decreased cell proliferation and apoptotic induction in non-small cell lung carcinoma cells harboring KRAS G12C (PMID: 26841430).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	pancreatic adenocarcinoma	sensitive	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including PD-0325901, in culture (PMID: 28957417).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	pancreatic cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human pancreatic cancer cell lines harboring KRAS G12C in culture (PMID: 21325073, PMID: 12068308).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	sensitive	Trametinib + TW-37	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human lung cells harboring KRAS G12C in culture (PMID: 25665005).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	sensitive	AZD4785	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cell lines harboring KRAS G12C, and anti-tumor activity in cell line xenograft models (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	pancreatic adenocarcinoma	sensitive	Refametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including Refametinib (BAY86-9766), in culture (PMID: 28957417).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response (PR) in 8.8% (5/57) and stable disease (SD) in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer, including SD in 12 patients and PR in 3 patients with KRAS G12C (PMID: 23224737).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	sensitive	CID1067700	Preclinical	Actionable	In a preclinical study, CID1067700 inhibited growth and increased apoptosis of non-small cell lung cancer cells that harbor KRAS G12C in culture (PMID: 26247207, PMID: 19477428).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	predicted - sensitive	GLPG0634 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring KRAS G12C in culture that had, over time, acquired resistance to Selumetinib (AZD6244) showed decreased drug resistance when treatment was combined with Filgotinib (GLPG0634), demonstrating reduced expression of Osmr and phosphorylated-Stat3, and decreased cell viability (PMID: 28729401).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	predicted - sensitive	Docetaxel + Trametinib	Phase I	Actionable	In a Phase I/Ib trial, the subgroup of non-small cell lung cancer patients harboring KRAS G12C demonstrated a disease control rate (DCR) of 80% (8/10; 4 partial responses, 4 stable disease) following treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel), compared to a DCR of 60% (15/25) in the overall KRAS-mutant population (PMID: 27876675).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	sensitive	Trametinib + Navitoclax	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 25665005).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	pancreatic adenocarcinoma	sensitive	BI-847325	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BI-847325 induced sustained tumor regression in pancreatic adenocarcinoma cell line xenograft models harboring KRAS G12C (PMID: 27496137).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	lung adenocarcinoma	decreased response	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	predicted - sensitive	Selumetinib + Docetaxel	Phase I	Actionable	In a Phase I study, NSCLC patients harboring KRAS G12C or G12V mutations demonstrated a trend towards better overall survival, progression free survival, and objective response rate compared to NSCLC patients with other KRAS mutations when treated with the combination therapy, Selumetinib (AZD6244) and Taxotere (docetaxel) (PMID: 26125448).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	lung adenocarcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	non-small cell lung carcinoma	sensitive	Cobimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12C (PMID: 23934108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	lung cancer	sensitive	AZD4785	Preclinical - Pdx	Actionable	In a preclinical study, AZD4785 inhibited Kras expression and downstream signaling, resulted in tumor growth inhibition in patient-derived xenograft models of lung cancer harboring KRAS G12C (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	Advanced Solid Tumor	sensitive	ARS-853	Preclinical	Actionable	In a preclinical study, ARS-853 inhibited growth of several human tumor cell lines harboring KRAS G12C in 3-dimensional culture conditions (PMID: 26739882).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	pancreatic adenocarcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including Mekinist (trametinib), in culture (PMID: 28957417).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Pdx	Actionable	In a preclinical study, a lung adenocarcinoma patient-derived xenograft (PDX) model was sensitive to treatment with Gilotrif (afatinib), demonstrating inhibition of tumor growth (PMID: 29925635).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	lung cancer	sensitive	SCH772984 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) and SCH772984 combination treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	pancreatic cancer	sensitive	GDC-0623	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC-0623 induced tumor regression in pancreatic cancer cell line xenograft models harboring KRAS G12C (PMID: 23934108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	colorectal cancer	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring the KRAS G12C mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring KRAS G12C in culture (PMID: 28179366).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS G12C	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Pdx	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12C PIK3CA H1047R TP53 R248W	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EML4-ALK KRAS G12C	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK and KRAS G12C demonstrated a minimal response when treated with Xalkori (crizotinib), and eventually progressed (PMID: 29636358).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	decreased response	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	decreased response	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA wild-type	colorectal cancer	sensitive	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	resistant	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	resistant	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA E545K TP53 R335fs	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PTEN K6fs*4	prostate cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF mut KRAS G12V	melanoma	resistant	AZ628 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V TP53 del	lung cancer	resistant	7RH	Preclinical	Actionable	In a preclinical study, 7RH treatment had no effect on tumor cell apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V TP53 del	lung cancer	sensitive	7RH + LY411575	Preclinical	Actionable	In a preclinical study, 7RH and LY411575 combination treatment induced apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	sensitive	3144	Preclinical - Cell culture	Actionable	In a preclinical study, 3144 inhibited growth of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 28235199).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	lung adenocarcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	sensitive	Regorafenib + Cetuximab	Preclinical	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G12V in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	lung adenocarcinoma	decreased response	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring the KRAS G12V mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	ovarian serous carcinoma	sensitive	Selumetinib	Clinical Study	Actionable	In a clinical case study, treatment with Selumetinib (AZD6244)  resulted in lack of tumor progression for greater than 7 years in patient with low grade serous ovarian carcinoma harboring KRAS G12V (PMID: 27231576).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	Advanced Solid Tumor	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell culture	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing KRAS G12V in culture, while single agent inhibition had no effect (PMID: 26140595).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	sensitive	AZD4785	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of colorectal cancer cell lines harboring KRAS G12V (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	head and neck squamous cell carcinoma	sensitive	Sirolimus + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines overexpressing KRAS G12V in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colon cancer	sensitive	AUY922	Preclinical - Cell culture	Actionable	In a preclinical study, AUY922 inhibited growth of colon cancer cell lines harboring KRAS G12V in culture (PMID: 26832792).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	non-small cell lung carcinoma	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12V in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	decreased response	Neratinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring KRAS G12V were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colon cancer	sensitive	AZ-TAK1	Preclinical - Cell culture	Actionable	In a preclinical study, a colon cancer cell line harboring KRAS G12V demonstrated sensitivity to AZ-TAK1 in culture, resulting in inhibition of cell growth (PMID: 27655129).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 27602501).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	lung cancer	sensitive	7RH + LY411575	Preclinical	Actionable	In a preclinical study, 7RH and LY411575 combination treatment resulted in additive effect on apoptosis in KRAS G12V-driven animal models of lung cancer (PMID: 26855149).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	lung cancer	sensitive	Aurora Kinase Inhibitor II	Preclinical - Cell culture	Actionable	In a preclinical study, Aurora Kinase Inhibitor II (AI II) decreased viability of transformed lung cells expressing KRAS G12V  in culture (PMID: 26842935).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	colorectal cancer	sensitive	Oxaliplatin	Preclinical	Actionable	In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS G12V (PMID: 23209813).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V	non-small cell lung carcinoma	predicted - sensitive	Selumetinib + Docetaxel	Phase I	Actionable	In a Phase I study, NSCLC patients harboring KRAS G12C or G12V mutations demonstrated a trend towards better overall survival, progression free survival, and objective response rate compared to NSCLC patients with other KRAS mutations when treated with the combination therapy, Selumetinib (AZD6244) and Taxotere (docetaxel) (PMID: 26125448).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PIK3CA R88Q PTEN mut KRAS G12V	endometrial cancer	decreased response	BEZ235	Preclinical	Actionable	In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PIK3CA R88Q PTEN mut KRAS G12V	endometrial cancer	decreased response	Everolimus	Preclinical	Actionable	In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR1 amp KRAS G12V	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line harboring FGFR1 amplification and KRAS G13C demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR1 amp KRAS G12V	non-small cell lung carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of KRAS G12V in FGFR1-amplified non-small cell lung carcinoma cells resulted in decreased response to BGJ398 in culture (PMID: 28630215).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR1 amp KRAS G12V	non-small cell lung carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in FGFR1-amplified non-small cell lung carcinoma cells overexpressing KRAS G12V in culture (PMID: 28630215).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V EZH2 pos	lung adenocarcinoma	no benefit	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V EZH2 pos	lung adenocarcinoma	no benefit	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V MET amp	carcinoma	predicted - sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	predicted - sensitive	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	decreased response	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR L858R KRAS G12V	lung adenocarcinoma	resistant	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, KRAS G12V was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS G12V	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Pdx	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12V in patient-derived xenograft models (PMID: 19276360).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PIK3CA H1047X KRAS G12X	colorectal cancer	resistant	XL147 + Carboplatin + Paclitaxel	Clinical Study	Actionable	In a clinical study, the combination of XL147 plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PIK3CA mutant KRAS G12X KRAS G13X	colorectal cancer	sensitive	Temsirolimus + Bevacizumab	Clinical Study	Actionable	In a clinical study, a colorectal cancer patient harboring a PIK3CA mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PIK3CA E545X KRAS G12X	colorectal cancer	sensitive	Temsirolimus	Clinical Study	Actionable	In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	colorectal cancer	resistant	Panitumumab	Phase III	Actionable	In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	Advanced Solid Tumor	sensitive	PD-0325901	Preclinical	Actionable	In a preclinical study, transformed cell lines with various KRAS codon 12 mutations displayed differential inhibition by PD-0325901 (PMID: 26037647).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	colorectal cancer	no benefit	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan	Phase III	Actionable	In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	pancreatic cancer	sensitive	Cobimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	non-small cell lung carcinoma	sensitive	Cobimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	pancreatic cancer	resistant	PHT-427	Preclinical	Actionable	In a preclinical study, a pancreatic cancer cell line harboring a KRAS codon 12 mutation demonstrated resistance to PHT-427, resulting in increased Akt activity (PMID: 20197390, PMID: 20418756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	lung adenocarcinoma	predicted - resistant	Gefitinib	Clinical Study	Actionable	In a clinical study, KRAS codon 12 or 13 mutations were correlated with a lack of response to Iressa (gefitinib) in patients with lung adenocarcinoma (PMID: 15696205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	pancreatic cancer	sensitive	Binimetinib	Preclinical	Actionable	In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12X	colorectal adenocarcinoma	sensitive	Oxaliplatin	Preclinical	Actionable	In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12A MET amp	lung cancer	resistant	AMG 337	Preclinical - Cell culture	Actionable	In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12A MET amp	lung cancer	resistant	SAR125844	Preclinical - Cell culture	Actionable	In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12A	colorectal cancer	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells harboring KRAS G12A in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12A	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring KRAS G12A were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12A	multiple myeloma	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12A	multiple myeloma	sensitive	Panobinostat	Preclinical	Actionable	In a preclinical study, Farydak (panobinostat) induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMD: 19490892, PMID: 22693356).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR dec exp KRAS mut	non-small cell lung carcinoma	sensitive	ER2 + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model with low expression of wild-type EGFR, that also harbors a KRAS mutation (PMID: 27040853).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR dec exp KRAS mut	non-small cell lung carcinoma	sensitive	GA201	Preclinical	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR dec exp KRAS mut	lung adenocarcinoma	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS-mutant lung adenocarcinoma with low EGFR expression in culture and improved overall survival in low EGFR expressing, KRAS-mutant lung adenocarcinoma cell line xenograft models, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR dec exp KRAS mut	colorectal cancer	sensitive	GA201	Preclinical	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colorectal cancer	sensitive	AZD8055 + Selumetinib	Preclinical	Actionable	In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colorectal cancer	sensitive	CGM097 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of CGM097 and Mekinist (trametinib) treatment compared to treatment with either agent alone in a colorectal cancer cell line resulted in a greater decrease in colony formation in culture, and improved stable disease in xenograft models (PMID: 27659046).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colorectal cancer	no benefit	Taselisib	Phase I	Actionable	In a Phase I trial, a colorectal cancer patient co-harboring a PIK3CA mutation and KRAS mutation progressed on treatment with Taselisib (GDC-0032) (PMID: 28331003).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colon cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colon cancer	sensitive	Copanlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Aliqopa (copanlisib) inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	non-small cell lung carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	stomach cancer	predicted - sensitive	Deguelin	Preclinical	Actionable	In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	Advanced Solid Tumor	resistant	Everolimus	Preclinical	Actionable	In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance  (PMID: 20664172).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	Advanced Solid Tumor	sensitive	Alpelisib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colon cancer	sensitive	AT13148	Preclinical	Actionable	In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	non-small cell lung carcinoma	sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	non-small cell lung carcinoma	sensitive	Buparlisib	Phase II	Actionable	In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	stomach cancer	sensitive	Buparlisib	Preclinical	Actionable	In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	Advanced Solid Tumor	decreased response	Taselisib	Phase I	Actionable	In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, but preliminary data analysis suggested the presence of a KRAS mutation was associated with lack of response (Cancer Res October 1, 2014 74:915).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colon cancer	sensitive	A-443654	Preclinical	Actionable	In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colorectal cancer	resistant	BEZ235	Preclinical	Actionable	In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colorectal cancer	sensitive	SAR245409	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colorectal cancer	sensitive	ABT-263 + CGM097 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Navitoclax (ABT-263) improved the therapeutic effects of the combination of CGM097 and Mekinist (trametinib) in colorectal cancer cells, resulting in greater apoptotic activity and growth inhibition in culture, and tumor regression in xenograft models (PMID: 27659046).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	Advanced Solid Tumor	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	colon cancer	sensitive	GDC-0980	Preclinical - Cell line xenograft	Actionable	In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	non-small cell lung carcinoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut PIK3CA mut	non-small cell lung carcinoma	sensitive	Selumetinib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically prevented proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring KRAS and PIK3CA mutations in culture and in cell line xenograft models (PMID: 24939055).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant TP53 mutant	colorectal cancer	sensitive	ABT-263 + Alpelisib + Erlotinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant TP53 mutant	colorectal cancer	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant TP53 mutant	non-small cell lung carcinoma	predicted - sensitive	Nivolumab	Phase III	Actionable	In a Phase III trial, non-small cell lung carcinoma patients co-harboring a KRAS mutation and TP53 mutation demonstrated an objective response rate (ORR) of 57.1% (4/7) when treated with Opdivo (nivolumab) compared to an ORR of 0% (0/6) in patients co-harboring a KRAS mutation and STK11 mutation and an ORR of 18.2% (2/11) in patients with mutant KRAS only (PMID: 29773717; NCT01673867).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant TP53 mutant	non-small cell lung carcinoma	predicted - sensitive	Pembrolizumab	Phase I	Actionable	In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring  a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant TP53 mutant	lung adenocarcinoma	predicted - sensitive	unspecified PD-1 antibody	Clinical Study	Actionable	In a clinical study, lung adenocarcinoma patients co-harboring a KRAS mutation and TP53 mutation demonstrated a greater objective response rate (35.7% vs 7.4% vs 28.6%) compared to patients with KRAS and STK11 mutations and patients with KRAS mutations only when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut TP53 G105C TP53 V157fs	ovarian cancer	predicted - sensitive	MK-1775 + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 G105C, V157fs and mutations in Kras (PMID: 27998224).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	BMS-754807 + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-754807 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Panulisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Panulisib (P7170) demonstrated inhibition of tumor growth in cell line xenograft models of non-small cell lung cancer harboring KRAS mutations (Cancer Res 2012, 72(8 Suppl), Abstract  #3759).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Dinaciclib + MK2206	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Dinaciclib (SCH 727965) and MK-2206 inhibited tumor growth and metastasis in KRAS-mutant patient-derived xenograft models of pancreatic ductal adenocarcinoma, with some models achieving complete response (PMID: 25931518).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	decreased response	Pictilisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in pancreatic cell line xenograft models harboring KRAS mutations (PMID: 22952903).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Docetaxel + Trametinib	Phase I	Actionable	In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in an overall response rate (ORR) of 24% (6/25, all partial responses), and stable disease in 36% (9/25) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 18% (4/22) in patients with wild-type or unknown KRAS status (PMID: 27876675).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung cancer	no benefit	Gefitinib + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) and Iressa (gefitinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	leukemia	predicted - sensitive	Trametinib	Phase Ib/II	Actionable	In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Ridaforolimus + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Ridaforolimus (MK-8669) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	Cetuximab + LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring KRAS mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	multiple myeloma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human multiple myeloma cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Dasatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	endometrial cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human endometrial cancer cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung cancer	no benefit	Afatinib + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) and Gilotrif (afatinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	sensitive	GI-4000	Phase II	Actionable	In a Phase II clinical trial, GI-4000 was well-tolerated and resulted in some immune response to KRAS in lung adenocarcinoma patients carrying KRAS mutations (PMID: 25044103).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colon cancer	predicted - sensitive	OPB-111077	Phase I	Actionable	In a Phase I trial, a patient with colon cancer harboring a KRAS mutation demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Osimertinib	Guideline	Actionable	KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	Trametinib	Phase I	Actionable	In a Phase I trial, of eight patients with colorectal cancer, three patients harbored a KRAS mutation and demonstrated stable disease when treated with Mekinist (trametinib) (PMID: 22805291).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Navitoclax + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Navitoclax (ABT-263)  and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung cancer	predicted - sensitive	DT-061	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, resulted in growth inhibition and apoptosis in KRAS mutant lung cancer cell lines in culture, and in both cell line and patient-derived xenograft models (PMID: 28504649).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (12/17) lung adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	DEL-22379	Preclinical	Actionable	In a preclinical study, DEL-22379 induced tumor regression in colorectal cancer xenograft models harboring mutant KRAS (PMID: 26267534).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	gastric adenocarcinoma	conflicting	Trametinib	Preclinical	Actionable	In a preclinical study, the effect of Mekinist (trametinib) on human gastric adenocarcinoma cell lines harboring mutant KRAS is conflicting as cell lines were both sensitive and insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	predicted - sensitive	BEZ235 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of PD-0325901 to treatment with BEZ235 inhibited BEZ235-enhanced ERK activation, and the combination resulted in increased inhibition of cell proliferation in KRAS-mutant pancreatic ductal adenocarcinoma cell lines in culture compared to either agent alone (PMID: 25673820).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Trametinib	Phase I	Actionable	In a Phase I trial, two non-small cell lung carcinoma patients harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of non-small cell cancer cell lines harboring mutant KRAS in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a clinical study, KRAS mutations were associated with resistance to Tarceva (erlotinib) in patients with lung adenocarcinoma (PMID: 15696205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	CUDC-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CUDC-907 induced apoptosis and cell cycle arrest in several human solid tumor and hematological cancer cell lines in culture and inhibited tumor growth in tumor cell line xenograft models, including those harboring KRAS mutations (PMID: 22693356).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	SCH772984	Preclinical - Pdx	Actionable	In a preclinical study, SCH772984 inhibited tumor growth in both cell line and patient-derived xenograft models of KRAS mutant pancreatic ductal adenocarcinoma through down-regulation of Myc protein level (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Erlotinib + IRX4204	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tarceva (erlotinib) and IRX4204 inhibited proliferation of non-small cell lung cancer cell lines in culture, including cell lines harboring KRAS mutations, and resulted in increased inhibition of proliferation and Src, p-AKT, and ribosomal S6 compared to either agent alone (J Clin Oncol 35, 2017 (suppl; abstr e14095)).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - sensitive	Regorafenib	Phase III	Actionable	In a Phase III trial, Stivarga (regorafenib) treatment resulted in a median progression free survival (PFS) of 2.3 months in metastatic colorectal cancer patients harboring KRAS mutations, and a median PFS of 2.1 months in KRAS wild-type patients (J Clin Oncol 34, 2016 (suppl 4S; abstr 735), NCT01001377).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	resistant	Everolimus	Clinical Study	Actionable	In a clinical study, KRAS mutations were associated with resistance to Afinitor (everolimus) in patients with advanced solid tumors (PMID: 20664172).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	Metformin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glucophage (metformin) inhibited tumor growth in a variety of KRAS-mutant cancer cell line xenograft models (PMID: 23877793).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - resistant	SHP099	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines harboring KRAS mutations demonstrated resistance to SHP099 in culture (PMID: 27362227).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	predicted - sensitive	APS-2-79 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of several KRAS mutant cancer cell lines in culture (PMID: 27556948).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Danusertib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Danusertib (PHA-739358) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	no benefit	Salirasib	Phase II	Actionable	In a Phase II clinical trial, salirasib showed no benefit in KRAS-mutant lung adenocarcinoma patients (PMID: 21847063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	no benefit	MLN1117	Preclinical	Actionable	In a preclinical study, MLN1117 (INK1117) did not inhibit tumor growth in xenograft models harboring mutations in KRAS (American Association for Cancer Research; 2011:Abstract nr 4501).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	urinary bladder cancer	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant bladder cancer (PMID: 26140595).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Carboplatin + Erlotinib + Paclitaxel	Phase III	Actionable	In a Phase III trial, the combination therapy of Tarceva (erlotinib), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a worse overall response rate (8%) compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Tarceva (erlotinib) (23%) in non-small cell lung cancer patients harboring KRAS mutations (PMID: 16043828).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Ralimetinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Ralimetinib (LY2228820) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	BI-847325	Phase I	Actionable	In a Phase I trial, BI-847325 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Mol Cancer Ther 2013;12(11 Suppl):B281).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	no benefit	Cetuximab + FOLFIRI	Phase III	Actionable	In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	no benefit	Rigosertib + Gemcitabine	Phase II	Actionable	In a Phase II study, Estybon (rigosertib) in combination with, gemcitabine, did not demonstrate increased efficacy over gemcitabine alone and there was no correlation of reponse with Kras mutational status in pancreatic patients (PMID: 26091808).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	melanoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	SH-1242	Preclinical	Actionable	In a preclinical study, SH-1242 inhibited growth of non-small cell lung cancer cells expressing mutant KRAS in culture (PMID: 26645561).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	not applicable	N/A	Guideline	Prognostic	KRAS mutations are associated with shorter survival in patients with non-small cell lung carcinoma (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited growth of colorectal cancer cells harboring KRAS mutations in culture and in xenograft models (PMID: 23475782).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	decreased response	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	ovarian cancer	sensitive	CI-1040	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring a KRAS mutation in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	AZD8186 + Ulixertinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, AZD8186 and BVD-523 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung cancer	sensitive	Ponatinib + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture and induced tumor regression in xenograft models (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Linsitinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Linsitinib (OSI-906) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Volasertib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to volasertib than cells wild-type for KRAS (PMID: 26597303).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	no benefit	MEHD7945A + Cobimetinib	Phase I	Actionable	In a Phase I trial, Duligotuzumab (MEHD7945A) and Cotellic (cobimetinib) combination therapy demonstrated limited safety and efficacy, with stable disease as best response in 41% (9/22) of patients with KRAS-mutant solid tumors (PMID: 28592615; NCT01986166).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	NS1	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a KRAS mutation demonstrated sensitivity to NS1 in culture, resulting in decreased Mapk and Akt signaling and inhibition of cell transformation (PMID: 27820802).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	RAF709	Phase I	Actionable	In a preclinical study, cancer cell lines harboring KRAS mutations demonstrated increased sensitivity to RAF709 compared to KRAS wild-type cells in culture (PMID: 29343524).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Midostaurin + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung cancer	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant lung cancer (PMID: 26140595).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - sensitive	LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 resulted in a disease control rate of 11.4% (5/44) in KRAS mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Neratinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	resistant	AZD8835	Preclinical	Actionable	In a preclinical study, tumor cell lines harboring KRAS mutations were resistant to AZD8835 induced growth inhibition in culture (PMID: 26839307).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	hepatocellular carcinoma	sensitive	Refametinib + Sorafenib	Phase II	Actionable	In a Phase II trial, Refametinib (BAY86-9766), in combination with Nexavar (sorafenib), demonstrated more clinical benefit in hepatocellular carcinoma patients with mutant Kras than in patients with wild-type Kras (PMID: 25294897).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colon cancer	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant colon cancer (PMID: 26140595).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 resulted in tumor regression in KRAS-mutant non-small cell lung cancer cell line xenograft models (PMID: 21750219).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	predicted - sensitive	Gedatolisib	Preclinical - Cell culture	Actionable	In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of several human solid tumor cell lines in culture, including cell lines harboring KRAS mutations (PMID: 21325073).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	AZD8186 + SCH772984	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	Reolysin	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring a KRAS mutation demonstrated growth inhibition, cell membrane dysruption, induction of apoptosis, and G2/M arrest in culture when treated with Reolysin (pelareorep) (PMID: 24798549).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	melanoma	predicted - sensitive	MLN2480	Preclinical	Actionable	In a preclinical study, MLN2480 inhibited growth of RAS mutant melanoma and colorectal cancer cell lines in culture (Mol Cancer Ther November 2013 12; C146).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Afatinib	Guideline	Actionable	KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic adenocarcinoma	sensitive	BI-847325	Preclinical	Actionable	In a preclinical study, BI-847325 promoted tumor regression in mutant KRAS pancreatic adenocarcinoma models (Cancer Res 2012;72(8 Suppl):Abstract nr 1919).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	MK2206 + Romidepsin	Preclinical	Actionable	In a preclinical study, treatment with the combination of MK2206 and Istodax (romidepsin) resulted in greater cell death in tumor cell lines harboring Kras mutations compared to cell lines with wild-type Kras (Cancer Res April 15, 2012 72:4708)
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - sensitive	Binimetinib	Phase I	Actionable	In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival (PFS) of 1.5 months and overall survival (OS) of 4.7 months when dosed at 45mg, and PFS of 3.5 months and OS of 9.1 months when dosed at 60mg, in colorectal cancer patients harboring KRAS mutations (PMID: 28152546).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Erlotinib	Guideline	Actionable	KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Erlotinib	Phase II	Actionable	In a Phase II trial, Tarceva (erlotinib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (36%, 5/14) and KRAS mutated (20%, 1/5) patients with advanced non-small cell lung carcinoma (PMID: 27480147).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Pictilisib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	predicted - sensitive	unspecified PD-1 antibody	Clinical Study	Actionable	In a clinical study, lung adenocarcinoma patients harboring a KRAS mutation demonstrated an intermediate objective response rate (28.6% vs 35.7% vs 7.4%) compared to patients with co-occurring KRAS and TP53 mutations and patients with co-occurring KRAS and STK11 mutations when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (47%, 20/43) and KRAS mutated (44%, 8/18) patients with advanced non-small cell lung carcinoma (PMID: 27480147).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Sorafenib	Phase III	Actionable	In a Phase III trial, treatment with Nexavar (sorafenib) resulted in a longer progression free survival in patients with KRAS-mutant non-small cell lung cancer when compared to placebo, however, overall survival was similar between the two arms (PMID: 26743856).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response in 8.8% (5/57) and stable disease in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer (PMID: 23224737).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	PF-04691502 + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, PF-04691502 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	TVB-2640	Phase I	Actionable	In a Phase I trial, TVB-2640 treatment resulted in stable disease for more than 17 weeks in 100% (3/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colon cancer	decreased response	Ponatinib + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS mutant colon cancer cells in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	thyroid cancer	sensitive	HM95573	Preclinical - Cell culture	Actionable	In a preclinical study, HM95573 inhibited growth of KRAS mutant thyroid cancer cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung squamous cell carcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of squamous cell lung carcinoma cells harboring mutant KRAS in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	HM95573	Preclinical - Cell line xenograft	Actionable	In a preclinical study, HM95573 inhibited growth of KRAS mutant colorectal cancer cells in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	cervix carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colon cancer	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, colon cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	Ramucirumab + FOLFIRI	Phase III	Actionable	In a Phase III trial, Cyramza (ramucirumab) followed by FOLFIRI was equally efficacious in metastatic colorectal carcinoma patients with Kras exon 2 mutations as patients with wild-type Kras (PMID: 25877855).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colon cancer	predicted - sensitive	AUY922	Preclinical - Cell line xenograft	Actionable	In a preclinical study, colon cancer cell lines with KRAS codon 12 or 13 mutations demonstrated increased sensitivity to treatment with AUY922 in culture and in xenograft models (PMID: 26832792).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	ovarian cancer	sensitive	BYL719 + MEK162	Phase I	Actionable	In a Phase I clinical trial, Alpelisib (BYL719), in combination with Binimetinib (MEK162), demonstrated safety and preliminary efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	sensitive	GDC-0980 + PD-0325901	Preclinical	Actionable	In a preclinical study, the addition of PD-0325901 to treatment with GDC-0980 and inhibited GDC-0980-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic cancer cells harboring KRAS mutations in culture (PMID: 25673820).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical study, KRAS mutations were associated with resistance to Erbitux (cetuximab) in patients with colorectal cancer (PMID: 18202412).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical case report, an acquired KRAS mutation was associated with resistance to Erbitux (cetuximab) in a patient with metastatic colorectal cancer (PMID: 24304820).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung cancer	sensitive	AZD4547 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and AZD4547 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	Trametinib	Phase I	Actionable	In a Phase I trial, Mekinist (trametinib) reduced tumor formation in 36% (8/22) of solid tumor patients harboring KRAS mutations (PMID: 22805291).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	stomach cancer	resistant	Poziotinib	Preclinical	Actionable	In a preclinical study, a human gastric cancer cell line harboring a KRAS mutation demonstrated resistance to Poziotinib (PMID: 21306821).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Paclitaxel + TVB-2640	Phase I	Actionable	In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in 33% (1/3) and stable disease for more than 21 weeks in 67% (2/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - resistant	SYM004	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	sensitive	Ponatinib + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant pancreatic cancer cells in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Pembrolizumab	Phase I	Actionable	In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Pembrolizumab	Clinical Study	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P?=?0.24) non-small cell lung carcinoma patients (PMID: 29270615).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colon adenocarcinoma	not applicable	N/A	Phase III	Emerging	In a post-hoc analysis of a Phase III trial, KRAS mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that KRAS mutations may serve as a future prognostic biomarker in this patient population (PMID: 26768652).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic adenocarcinoma	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Patient cell culture	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from pancreas adenocarcinoma patients harboring KRAS mutations in culture (PMID: 26140595).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	HM95573	Preclinical - Cell line xenograft	Actionable	In a preclinical study, HM95573 inhibited growth of KRAS mutant non-small cell lung cancer cells in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	decreased response	Bevacizumab	Clinical Study	Actionable	In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	GDC-0623	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC-0623 demonstrated efficacy in several human tumor cell line xenograft models harboring KRAS mutations (PMID: 23934108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - sensitive	Atezolizumab + Cobimetinib	Phase I	Actionable	In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 17% (4/23) and stable disease in 22% (5/23) of colorectal cancer patients harboring KRAS mutations (Ann Oncol (2016) 27 (suppl 2): ii140).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung carcinoma	sensitive	AZD4785	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cell lines harboring KRAS mutations, and anti-tumor activity in cell line xenograft models (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	gastric adenocarcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, gastric cancer cell lines with Kras mutations were sensitive to Selumetinib (AZD6244) (PMID: 24935174).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	sensitive	Pictilisib + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in pancreatic cancer cell line xenograft models harboring KRAS mutations (PMID: 22952903).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Everolimus + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	no benefit	simtuzumab + FOLFIRI	Phase II	Actionable	In a Phase II trial, combination of Simtuzumab (GS-6634) with FOLFIRI did not improve median progression-free survival (5.5 vs 5.8 months) or median overall survival (11.4 vs 16.3 months) compared to FOLFIRI with placebo in patients with KRAS mutant colorectal cancer (PMID: 28246207; NCT01479465).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	endometrial cancer	predicted - sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 resulted in partial response in 1 endometrial cancer patient harboring harboring KRAS mutation, who remained on treatment for over 456 days (AACR Annual Meeting, Apr 2016, abstract # CT005).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal adenocarcinoma	no benefit	Dasatinib + FOLFOX	Phase Ib/II	Actionable	In a Phase Ib/II trial, the combination of Sprycel (dasatinib) and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma harboring KRAS codon 12/13 mutations, with no responses and a median time to treatment failure of 2.0 months (PMID: 28280091; NCT00501410).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Erlotinib + MK2206	Phase II	Actionable	In a Phase II trial, Tarceva (erlotinib) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (57%, 16/28) and KRAS mutated (25%, 2/8) patients with advanced non-small cell lung carcinoma (PMID: 27480147).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - sensitive	Necitumumab + FOLFOX	Phase II	Actionable	In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with an ORR of 56.5% (5/9; all partial responses), and stable disease in 44.4% (4/9) of KRAS-mutant patients (PMID: 26766738).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	sensitive	AT13148	Preclinical	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a human lung adenocarcinoma cell line xenograft model harboring mutant KRAS (PMID: 22781553).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Aurora Kinase Inhibitor II	Preclinical - Cell culture	Actionable	In a preclinical study, Aurora Kinase Inhibitor II (AI II) induced apoptosis and inhibited growth of KRAS-mutant non-small cell lung cancer cell lines in culture (PMID: 26842935).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Gefitinib	Guideline	Actionable	KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	endometrial cancer	no benefit	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, mutation status of KRAS was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring KRAS mutations in culture and in cell line xenograft models (PMID: 26140595).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	sensitive	BYL719 + MEK162	Phase Ib/II	Actionable	In a Phase Ib study, Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	stomach carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in objective response in PDX models of colorectal cancer cells  harboring KRAS mutations (PMID: 26369631).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	predicted - sensitive	Trametinib	Phase I	Actionable	In a Phase I trial, a pancreatic cancer patient harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	no benefit	CC-90003	Phase I	Actionable	In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	SCH772984 + Temsirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, Torisel (temsirolimus) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	ovarian cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring KRAS mutations (PMID: 21673091).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	no benefit	CH5132799	Preclinical	Actionable	In a preclinical study, human tumor cell lines harboring KRAS mutations did not demonstrate sensitivity to CH5132799 in culture (PMID: 22159814).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Selumetinib + Docetaxel	Phase III	Actionable	In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) did not significantly improve median progression-free survival (3.9 vs 2.8 months), median overall survival (8.7 vs 7.9 months), and overall response rate (20.1% vs 13.7%) compared to placebo in KRAS-mutant non-small cell lung cancer patients (PMID: 28492898).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	Selumetinib + Docetaxel	Phase II	Actionable	In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) improved progression-free survival in KRAS-mutant non-small cell lung cancer patients (PMID: 23200175).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring KRAS mutations demonstrated sensitivity to CI-1040 in culture (PMID: 19372556).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	stomach cancer	sensitive	BKM120 + AG490	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS mutations in culture (PMID: 22159814).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	KPT-185	Preclinical - Cell culture	Actionable	In a preclinical study, KPT-185 resulted in greater apoptotic activity and decreased cell viability in non-small cell lung cancer (NSCLC) cell lines harboring KRAS mutations compared to NSCLC cell lines with wild-type KRAS, suggesting a synthetic lethal effect via XPO1 inhibition (PMID: 27680702).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	SCH772984 + Vistusertib	Preclinical - Cell culture	Actionable	In a preclinical study, Vistusertib (AZD2014) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	predicted - sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	Irinotecan + Reolysin	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Reolysin (pelareorep) and Camptosar (irinotecan) resulted in a synergistic effect, demonstrating increased apoptotic activity and growth inhibition in colorectal cancer cells harboring a KRAS mutation in culture compared to either agent alone (PMID: 24798549).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant pancreatic cancer (PMID: 26140595).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	predicted - sensitive	Ixabepilone + Sunitinib	Phase I	Actionable	In a Phase I trial, Ixabepilone and Sutent (sunitinib) combination therapy resulted in an overall clinical benefit rate (complete response, partial response, or stable disease) of 53% (9/17) in colorectal cancer patients,  most of whom harbored KRAS mutations (PMID: 26864210).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	Advanced Solid Tumor	predicted - sensitive	Cobimetinib + GDC-0068	Phase I	Actionable	In a Phase I trial, the combination of Ipatasertib (GDC-0068) and Cobimetinib (GDC-0973) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Cancer Res, October 1, 2014 74; CT328).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	XMT-1536	Preclinical - Pdx	Actionable	In a preclinical study, XMT-1536 induced tumor regression in patient-derived-xenograft models of of non-small cell lung cancer harboring KRAS mutations (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung adenocarcinoma	predicted - sensitive	PF3644022 + PF-477736	Preclinical - Patient cell culture	Actionable	In a preclinical study, primary tumor cells isolated from lung adenocarcinoma patients harboring KRAS mutations demonstrated increased sensitivity to Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment in culture compared to cells lacking KRAS or BRAF mutations (PMID: 26140595).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	no benefit	MK2206 + Selumetinib	Phase II	Actionable	In a Phase II trial, Selumetinib (AZD6244) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (49%, 24/49) and KRAS mutated (62%, 13/21) patients with advanced non-small cell lung carcinoma (PMID: 27480147).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	OSI-027 + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, OSI-027 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Pictilisib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Ipatasertib (GDC-0068) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colon cancer	sensitive	AZ-TAK1 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZ-TAK1 and Selumetinib (AZD6244) resulted in an additive effect in colon cancer cells harboring KRAS mutant in culture, demonstrating a 90% growth reduction (PMID: 27655129).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	sensitive	SAR245409 + Pimasertib	Phase Ib/II	Actionable	In a Phase Ib trial, XL765 (SAR245409) in combination with, Pimasertib (MSC1936369B), demonstrated safety and preliminary efficacy in Kras mutant colorectal patients (Cancer Res 2013;73(8 Suppl):Abstract nr LB-147).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	MK2206 + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung cancer	sensitive	Crizotinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) and Xalkori (crizotinib) demonstrated additive effect at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	breast cancer	decreased response	PI-273	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines harboring RAS mutations, including KRAS-mutant cell lines, demonstrated decreased sensitivity to growth inhibition by PI-273 in culture (PMID: 28827373).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Ipatasertib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ipatasertib (GDC-0068) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	lung cancer	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and BGJ398 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	no benefit	RO4987655	Phase I	Actionable	In a Phase I trial, none of 30 colorectal cancer patients with KRAS mutations achieved favorable response after treatment with RO4987655 (PMID: 24947927).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Nilotinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Tasigna (nilotinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	AZD8055 + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, AZD8055 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Saracatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Saracatinib (AZD0530) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Saracatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Saracatinib (AZD0530) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colorectal cancer	no benefit	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan	Phase III	Actionable	In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with KRAS mutations (PMID: 26341920).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Atezolizumab	Clinical Study	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P?=?0.24) non-small cell lung carcinoma patients (PMID: 29270615).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal carcinoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human pancreatic ductal carcinoma cell lines harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	Panobinostat + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Farydak (panobinostat) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	BI2536	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to BI2536 than cells wild-type for KRAS (PMID: 26597303).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	colon cancer	sensitive	AZ-TAK1	Preclinical - Cell culture	Actionable	In a preclinical study, a colon cancer cell line harboring a KRAS mutation demonstrated sensitivity to AZ-TAK1 in culture, resulting in a 50% cell growth reduction (PMID: 27655129).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Pemetrexed + GSK1120212	Phase I	Actionable	In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Alimta (pemetrexed) resulted in an overall response rate (ORR) of 17% (4/23, all partial responses), and stable disease in 48% (11/23) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 11% (2/19) in patients with wild-type or unknown KRAS status (PMID: 27876675).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, treatment with Abemaciclib (LY2835219) in non-small cell lung carcinoma patients harboring a KRAS mutation resulted in a disease control rate of 55% (16/29) and a median PFS of 2.8 months (LY2835219) (PMID: 27217383).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 resulted in partial response in 1 non-small cell lung carcinoma patient harboring KRAS mutation, who remained on treatment for over 572 days (AACR Annual Meeting, Apr 2016, abstract # CT005).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic cancer	predicted - sensitive	GI-4000	Phase I	Actionable	In a Phase I clinical trial, GI-4000 was well-tolerated and led to some RAS-directed immune response in patients with RAS-mutant pancreatic cancer (PMID: 25585100).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (4/5) of human pancreatic adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	stomach cancer	decreased response	BAY1082439	Preclinical	Actionable	In a preclinical study, gastric cancer xenograft models harboring KRAS mutations demonstrated decreased sensitivity to BAY1082439 in culture (AACR; 2015. Abstract nr 2674).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	pancreatic ductal adenocarcinoma	sensitive	PD-0325901 + Gedatolisib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of combination PD-0325901 to treatment with Gedatolisib (PF-05212384) and PD-0325901 inhibited Gedatolisib (PF-05212384)-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic ductal adenocarcinoma cell lines harboring KRAS mutations in culture (PMID: 25673820).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	sensitive	RO4987655	Phase I	Actionable	In a Phase I trial, 11% (2/11) of NSCLC patients with Kras mutations achieved partial response after treatment with RO4987655 (PMID: 24947927).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Nivolumab	Phase III	Actionable	In a Phase III trial, non-small cell lung carcinoma patients harboring a KRAS mutation demonstrated an objective response rate (ORR) of 18.2% (2/11) when treated with Opdivo (nivolumab) compared to an ORR of 57.1% (4/7) in patients co-harboring a KRAS mutation and TP53 mutation and an ORR of 0% (0/6) in patients co-harboring a KRAS mutation and STK11 mutation (PMID: 29773717; NCT01673867).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant	non-small cell lung carcinoma	predicted - sensitive	Nivolumab	Clinical Study	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P=0.24) non-small cell lung carcinoma patients (PMID: 29270615).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 mut	lung adenocarcinoma	predicted - resistant	unspecified PD-1 antibody	Clinical Study	Actionable	In a clinical study, lung adenocarcinoma patients co-harboring a KRAS mutation and STK11 mutation demonstrated a lower objective response rate (7.4% vs 35.7% vs 28.6%) and shorter PFS (1.8mo vs 3.0 vs 2.7) and OS (6.4mo vs 16 vs 16.1) compared to patients with KRAS and TP53 mutations and patients with KRAS mutations only when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 mut	non-small cell lung carcinoma	sensitive	PKI-402	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 mut	non-small cell lung carcinoma	predicted - resistant	unspecified PD-1 antibody	Phase III	Actionable	In a Phase III trial, non-small cell lung carcinoma patients co-harboring a KRAS mutation and STK11 mutation demonstrated an objective response rate (ORR) of 0% (0/6) when treated with Opdivo (nivolumab) compared to an ORR of 57.1% (4/7) in patients co-harboring a KRAS mutation and TP53 mutation and an ORR of 18.2% (2/11) in patients with mutant KRAS only (PMID: 29773717; NCT01673867).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR2 dec exp KRAS mut	lung cancer	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut + TP53 wild-type	colorectal cancer	sensitive	ABT-263 + Alpelisib + CGM097 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut + TP53 wild-type	Advanced Solid Tumor	sensitive	Oxaliplatin + ABT-737	Preclinical	Actionable	In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut + TP53 wild-type	colorectal cancer	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut + TP53 wild-type	colorectal cancer	sensitive	AMG 232 + Irinotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AMG 232 and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA wild-type	colon cancer	sensitive	Buparlisib	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA wild-type	colon cancer	sensitive	BKM120 + Cetuximab	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture, and colorectal cancer patient-derived xenograft (PDX) models with KRAS or BRAF mutations and wild-type PIK3CA demonstrated a trend toward greater tumor growth inhibition (PMID: 26439693).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR1 dec exp KRAS mut	lung cancer	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR1 dec exp KRAS mut	colorectal cancer	no benefit	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR1 dec exp KRAS mut	pancreatic cancer	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 inact mut	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, MK-1775 and Platinol (cisplatin) combination treatment demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 inact mut	non-small cell lung carcinoma	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation and STK11 inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 inact mut	non-small cell lung carcinoma	predicted - sensitive	Adavosertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations demonstrated increased sensitivity to MK-1775 compared to cells expressing wild-type STK11 in culture (PMID: 28652249).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 inact mut	lung adenocarcinoma	sensitive	MLN0128 + Phenformin	Preclinical	Actionable	In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 inact mut	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, MK-1775 combined with radiation therapy demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR pos KRAS mut	triple-receptor negative breast cancer	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 resulted in increased tumor growth inhibition in EGFR-positive triple-negative breast cancer cell line xenograft models harboring KRAS mutations when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR pos KRAS mut	renal cell carcinoma	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR pos KRAS mut	pancreatic cancer	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA E545K	colon cancer	sensitive	BKM120 + Cetuximab	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA E545K	colon cancer	no benefit	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA E545K	colon cancer	decreased response	Buparlisib	Preclinical	Actionable	In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut + GATA2 wild-type	non-small cell lung carcinoma	sensitive	bortezomib + fasudil	Preclinical	Actionable	In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR3 dec exp KRAS mut	lung cancer	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	APC mutant KRAS mutant KDR R961W	colorectal cancer	sensitive	Regorafenib	Clinical Study	Actionable	In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA H1047R	colon cancer	sensitive	BKM120 + Cetuximab	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA H1047R	colon cancer	sensitive	Buparlisib	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mutant PIK3CA H1047R	colon cancer	no benefit	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF mut KRAS mut	melanoma	predicted - sensitive	BI-847325	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS mut STK11 loss TP53 loss	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF mut KRAS mut CDKN2A mut	triple-receptor negative breast cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS mutant	colorectal cancer	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS mutant	colorectal cancer	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PTEN loss TP53 V216M	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	lung adenocarcinoma	no benefit	Selumetinib + Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	colon cancer	no benefit	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	lung adenocarcinoma	sensitive	DZNep + MK2206	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	lung adenocarcinoma	sensitive	GSK343 + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	lung adenocarcinoma	no benefit	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	lung adenocarcinoma	no benefit	GSK343 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	colon cancer	sensitive	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	pancreatic cancer	sensitive	DZNep + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	lung adenocarcinoma	sensitive	MK2206 + Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D EZH2 pos	pancreatic cancer	no benefit	DZNep + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA E453K	stomach cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	predicted - sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	resistant	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D TP53 S127Y	lung adenocarcinoma	sensitive	Dasatinib + Demcizumab	Preclinical - Pdx	Actionable	In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12D and TP53 S127Y (PMID: 26855149).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS G12D	pancreatic cancer	resistant	GDC0879	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G12D	colorectal cancer	resistant	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G12D	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G12D	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G12D	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquisition of KRAS G12D (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	APC inact mut KRAS G12D	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	APC inact mut KRAS G12D	colorectal cancer	sensitive	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	APC inact mut KRAS G12D	colorectal cancer	sensitive	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA Q546L	colorectal cancer	sensitive	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	decreased response	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	predicted - sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D TP53 R175H	pancreatic cancer	sensitive	Pimasertib + Gemcitabine	Preclinical	Actionable	In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D TP53 R175H	pancreatic ductal adenocarcinoma	sensitive	Gemcitabine + SRA737	Preclinical	Actionable	In a preclinical study, Gemzar (gemcitabine) resulted in enhanced antitumor efficacy, including decreased tumor volume, when combined with SRA737 (CCT245737) in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H (PMID: 27167172).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D TP53 R175H	pancreatic ductal adenocarcinoma	conflicting	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) treatment in transgenic animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H resulted in proliferation of tumor cells in interior, hypovascularized tumor regions, but inhibited proliferation in outer, vascularized tumor regions, despite inhibition of mTORC signaling in both regions (PMID: 26144316).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D TP53 R175H	pancreatic ductal adenocarcinoma	sensitive	SRA737	Preclinical	Actionable	In a preclinical study, SRA737 (CCT245737) resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PTEN dec exp TP53 R306*	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA Q546R	colorectal cancer	sensitive	Bevacizumab + Sorafenib	Clinical Study	Actionable	In a clinical case study, a patient with colorectal cancer harboring KRAS G12D and PIK3CA Q546R demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for more than 6 months (PMID: 25363205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D STK11 inact mut	lung cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D PIK3CA G1049R	endometrial cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PIK3CA G1049R KRAS G12D PIK3CA amp	endometrial cancer	sensitive	BEZ235 + PD98509	Preclinical	Actionable	In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colorectal cancer	sensitive	ST-162	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ST-162 treatment inhibited tumor growth of colorectal cancer cell line xenograft models harboring KRAS G12D (PMID: 28775144).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	biliary tract cancer	sensitive	Copanlisib + Refametinib	Preclinical	Actionable	In a preclinical study, Aliqopa (copanlisib) and Refametinib (BAY86-9766) worked synergistically to inhibit proliferation and increase apoptosis of biliary tract cancer cells harboring KRAS G12D in culture (Cancer Res April 15, 2012 72:869).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	stomach cancer	sensitive	BKM120 + AG490	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS G12D in culture (PMID: 22159814).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	myelodysplastic/myeloproliferative neoplasm	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated efficacy in a mouse model of chronic myelomonocytic leukemia expressing KRAS G12D (ASH Annual Meeting Abstracts 2012 120: 2862).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	lung adenocarcinoma	sensitive	PD-0325901	Preclinical	Actionable	In a preclinical study, PD-0325901 inhibited growth of lung adenocarcinomas in mouse models expressing Kras G12D (PMID: 22684718).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	lung cancer	predicted - sensitive	AR-mTOR-26	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in lung cancer cell line xenograft models harboring KRAS G12D (Cancer Res 2010;70(8 Suppl):Abstract nr 4484).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic adenocarcinoma	sensitive	RAF709 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RAF709 and Mekinist (trametinib) synergistically inhibited Erk signaling and growth of pancreatic adenocarcinoma cells in culture, resulted in tumor regression in cell line xenograft models (PMID: 29343524).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	lung adenocarcinoma	sensitive	PX-866	Preclinical	Actionable	In a preclinical study, the treatment of KRAS G12D mutant mouse lung cancer with PX-866, a PI3K inhibitor, resulted in inhibition of tumor growth (PMID: 18493606).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	lung cancer	sensitive	Selumetinib + BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 in combination with Selumetinib (AZD6244) induced tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	sensitive	AZD4785	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of pancreatic cancer cells harboring KRAS G12D (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	decreased response	Pictilisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in a pancreatic cell line xenograft model harboring KRAS G12D (PMID: 22952903).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	lung adenocarcinoma	sensitive	Selumetinib + BEZ235	Preclinical	Actionable	In a preclinical study, a mouse lung adenocarcinoma model harboring the KRAS G12D mutation treated with a combination of the MEK inhibitor selumetinib (AZD6244) and the PI3K inhibitor BEZ235 resulted in significant tumor regression (PMID: 19029981).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	lung adenocarcinoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, the treatment of a mouse model lung adenocarcinoma harboring the KRAS G12D mutant with selumetinib, a MEK inhibitor, resulted in modest tumor regression (PMID: 19029981).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colorectal cancer	sensitive	PD-0325901 + ZSTK474	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination treatment of PD-0325901 and ZSTK474 inhibited tumor growth of colorectal cancer cell line xenograft models harboring KRAS G12D (PMID: 28775144).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colorectal cancer	resistant	Neratinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	predicted - sensitive	Aphanin	Preclinical - Cell culture	Actionable	In a preclinical study, Aphanin inhibited proliferation and induced apoptosis in pancreatic cancer cells harboring KRAS G12D in culture (PMID: 27333990).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	lung cancer	no benefit	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 did not induce tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colon cancer	sensitive	AUY922	Preclinical - Cell culture	Actionable	In a preclinical study, AUY922 inhibited growth of a colon cancer cell line harboring KRAS G12D in culture (PMID: 26832792).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colorectal cancer	sensitive	Cetuximab + LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in patient-derived xenograft models of colorectal cancer harboring KRAS G12D (PMID: 28611205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colorectal cancer	resistant	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colorectal cancer	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring the KRAS G12D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	Advanced Solid Tumor	sensitive	LY294002	Preclinical	Actionable	In a preclinical study, LY294002 reduced phosphorylation of Akt in pancreatic epithelial cells expressing Kras G12D (PMID: 22871572).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	sensitive	Ponatinib + Trametinib	Preclinical	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Iclusig (ponatinib) induced cell death in tumors and prolonged survival in an animal model of pancreatic cancer harboring KRAS G12D (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colorectal cancer	sensitive	KRAS mutant-specific TIL	Clinical Study	Actionable	In a clinical case study, a patient with metastatic colorectal cancer harboring KRAS G12D demonstrated regression of metastatic lung lesions and a partial response for 9 months following infusion of autologous tumor-infiltrating lymphocytes containing cytotoxic T-cells that specifically recognize KRAS G12D (PMID: 27959684).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	cholangiocarcinoma	sensitive	TAK-733	Preclinical - Pdx	Actionable	In a preclinical study, TAK-733 induce tumor regression in patient derived xenografts of cholangiocarcinoma with Kras G12D mutations (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2523).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	resistant	UC-773587	Preclinical	Actionable	In a preclinical study, UC-773587 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	sensitive	Pictilisib + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in a pancreatic cancer cell line xenograft model harboring KRAS G12D (PMID: 22952903).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	resistant	UC-857993	Preclinical	Actionable	In a preclinical study, UC-857993 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	lung cancer	sensitive	SH-1242	Preclinical	Actionable	In a preclinical study, SH-1242 inhibited lung tumor growth in a KRAS G12D-expressing transgenic mouse model that forms spontaneous lung tumors (PMID: 26645561).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	Advanced Solid Tumor	sensitive	AZD8055 + MK-1775	Preclinical	Actionable	In a preclinical study, AZD8055 worked synergistically with MK-1775 to inhibit proliferation and promote apoptosis in transformed cells expressing KRAS G12D in culture (PMID: 24791855).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	sensitive	Reolysin + Gemcitabine	Clinical Study	Actionable	In a clinical case report, treatment with Reolysin (pelareorep) in combination with Gemzar (gemcitabine) resulted in stable disease in a patient with pancreatic cancer harboring KRAS G12D (PMID: 26156229).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	pancreatic cancer	sensitive	rigosertib	Preclinical	Actionable	In a preclinical study, Estybon (rigosertib) inhibited tumorigenesis in transgenic animal model of pancreatic cancer driven by KRAS G12D (PMID: 27104980).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D	colorectal cancer	predicted - sensitive	LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 resulted in tumor regression in a patient-derived xenograft model of colorectal cancer harboring KRAS G12D, but relapse upon discontinuation of treatment (PMID: 28611205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PTEN pos KRAS G12D	endometrial cancer	sensitive	Metformin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D MET amp	esophageal carcinoma	resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	IDH2 R172K KRAS G12D	intrahepatic cholangiocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	IDH2 R172K KRAS G12D	intrahepatic cholangiocarcinoma	sensitive	Saracatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	sensitive	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	no benefit	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR L858R KRAS G12D	lung adenocarcinoma	resistant	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D MET over exp	stomach cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	ATM del KRAS G12D	lung adenocarcinoma	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	ATM del KRAS G12D	lung adenocarcinoma	sensitive	VX-970	Preclinical	Actionable	In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to VX-970, demonstrating decreased tumor volume and greater overall survival compared to control treated models (PMID: 28363999).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12D STK11 loss	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Cisplatin	Preclinical	Actionable	In a preclinical study,  MK-1775 and Platinol (cisplatin) combination treatment resulted in improved survival in transgenic animal models of non-small cell lung carcinoma harboring KRAS G12D and STK11 loss compared to Platinol (cisplatin) alone (PMID: 28652249).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PTEN loss KRAS G12D	pancreatic adenocarcinoma	sensitive	MK2206	Phase I	Actionable	In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Dasatinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Dasatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G12R KRAS G13R	thyroid cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12F PIK3CA H1047R	lung adenocarcinoma	sensitive	Dasatinib + Demcizumab	Preclinical - Pdx	Actionable	In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12F and PIK3CA H1047R (PMID: 26855149).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PIK3CA mutant KRAS Q61X	ovarian carcinoma	sensitive	Bevacizumab + Temsirolimus + Doxil	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian carcinoma harboring both a PIK3CA mutation and a KRAS Q61 mutation (PMID: 21216929).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS Q61K	non-small cell lung carcinoma	resistant	GDC0879	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS Q61K in culture and in cell line xenograft models (PMID: 19276360).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61K	lung adenocarcinoma	decreased response	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61K	non-small cell lung carcinoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth and vascularization in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K (PMID: 25637314).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61K	lung adenocarcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61K	non-small cell lung carcinoma	sensitive	BI-847325	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BI-847325 inhibited MEK phosphorylation and proliferation and disrupted cell cycle progression in a non-small cell lung cancer cell line harboring KRAS Q61K in culture, and induced tumor stasis or regression in KRAS Q61K mutant non-small cell lung cancer cell line xenograft models (PMID: 27496137).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61K	non-small cell lung carcinoma	sensitive	XL147 + Carboplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of XL147 and Paraplatin (carboplatin) inhibited tumor growth and angiogenesis in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K, with increased efficacy compared to either agent alone (PMID: 25637314).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS G13D	colon cancer	resistant	GDC0879	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA E545K	endometrial cancer	resistant	Everolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, expression of KRAS G13D in an endometrial cancer cell line harboring PIK3CA E545K conferred resistance to Afinitor (everolimus) in xenograft models (PMID: 20664172).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA E545K	colorectal adenocarcinoma	sensitive	Cobimetinib + Pictilisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Pictilisib (GDC-0941) and Cobimetinib (GDC-0973) inhibited tumor growth in a colorectal adenocarcinoma xenograft model harboring KRAS G13D and PIK3CA E545K mutations, and demonstrated improved efficacy over either agent alone (PMID: 22084396).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	ERBB2 over exp KRAS G13D	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS G13D in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF G464V KRAS G13D	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF G464V KRAS G13D	triple-receptor negative breast cancer	sensitive	DHM25	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF G464V KRAS G13D	breast cancer	decreased response	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF G464V KRAS G13D	breast cancer	sensitive	Regorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA E545K PIK3CA D549N	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA E545K PIK3CA D549N	colon cancer	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA E545K PIK3CA D549N	colorectal cancer	sensitive	Regorafenib + Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N in culture and reduced tumor growth in cell line xenograft models (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	PD-0325901 + Gedatolisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	AT-7867	Preclinical	Actionable	In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	Gedatolisib + Camptothecin	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistictically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	CC-223	Preclinical	Actionable	In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	Gedatolisib + Irinotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colorectal cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 27602501).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	Irinotecan	Preclinical	Actionable	In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA H1047R	colorectal cancer	sensitive	Regorafenib + Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D and PIK3CA H1047R in culture, and reduced tumor growth in cell line xenograft models (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EML4-ALK KRAS G13D	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK eventually progressed while on treatment with Xalkori (crizotinib) and was subsequently found to harbor a presumed resistance mutation, KRAS G13D (PMID: 29636358).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquisition of KRAS G13D (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS G13D	colorectal cancer	resistant	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and SCH772984 in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA E545k TP53 S241F	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	breast cancer	sensitive	3144	Preclinical - Cell line xenograft	Actionable	In a preclinical study, 3144 inhibited growth of a breast cancer cell line harboring KRAS G13D in culture and reduced tumor growth in xenograft models (PMID: 28235199).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	non-small cell lung carcinoma	sensitive	AZD4785	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cells harboring KRAS G13D, and anti-tumor activity in cell line xenograft models (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	Advanced Solid Tumor	sensitive	GDC-0623	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC-0623 demonstrated efficacy against both KRAS-mutant and BRAF-mutant cancer models in cell based assays and cell line xenografts (PMID: 23934108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	Cobimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of human colorectal cancer cell lines harboring KRAS G13D (PMID: 23934108).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colon cancer	sensitive	APS-2-79 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a colon cancer cell line harboring KRAS G13D in culture (PMID: 27556948).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	Palbociclib + Trametinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) synergistically inhibited growth of colorectal cancer cells harboring KRAS G13D in culture and resulted in partial tumor regression in patient-derived xenograft models (PMID: 26369631).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited growth of, and blocked MAPK signaling in human colorectal cancer cells harboring KRAS G13D in culture (PMID: 26343583).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal adenocarcinoma	predicted - sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD-6244) inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal adenocarcinoma	sensitive	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, RO5126766 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	rigosertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of colorectal cancer harboring KRAS G13D (PMID: 27104980).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	Regorafenib + Cetuximab	Preclinical	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis in human colorectal cancer cell lines harboring KRAS G13D in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	Oxaliplatin	Preclinical	Actionable	In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colon tumor cell lines carrying KRAS G13D (PMID: 23209813).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	decreased response	Neratinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring KRAS G13D were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, RAF709 inhibited Erk signaling and proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 29343524).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colon cancer	sensitive	AUY922	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colon cancer cell line harboring KRAS G13D demonstrated increased sensitivity to AUY922 compared to cell lines with wild-type KRAS, resulting in decreased viability and increased apoptosis in culture and reduced tumor growth in xenograft models (PMID: 26832792).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring the KRAS G13D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colon cancer	no benefit	Buparlisib	Preclinical	Actionable	In a preclinical studu, BKM120 alone failed to induce tumor regression in mouse xenograft models of Kras G13D mutant colorectal cancer (PMID: 24576621).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring KRAS G13D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring KRAS G13D were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D	colorectal adenocarcinoma	sensitive	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, RO4987655 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	sensitive	Pimasertib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture and in cell line xenograft models (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 4	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with KRAS exon 4 mutation (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 4	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with KRAS exon 4 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 4	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with KRAS exon 4 mutations (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS exon 4	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with KRAS exon 4 mutation (NCCN.org).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13X	lung adenocarcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a clinical study, KRAS codon 12 or 13 mutations correlated with a lack of response to Iressa (gefitinib) in patients with lung adenocarcinoma (PMID: 15696205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13X	colorectal cancer	no benefit	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan	Phase III	Actionable	In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13X	colorectal cancer	resistant	Panitumumab	Phase III	Actionable	In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13X	colorectal cancer	sensitive	Oxaliplatin	Preclinical	Actionable	In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61L PIK3CA E542K TP53 T118Qfs*5	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS act mut	colorectal cancer	sensitive	AZ628 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cell lines harboring KRAS activating mutations in culture (PMID: 26351322).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS act mut	colorectal cancer	no benefit	Venetoclax + VX-11e	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS act mut	lung cancer	predicted - sensitive	Dinaciclib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring activating KRAS mutations demonstrated increased sensitivity to Dinaciclib (SCH 727965) in culture (PMID: 27550941).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS act mut	non-small cell lung carcinoma	sensitive	RAF709	Preclinical - Pdx	Actionable	In a preclinical study, RAF709 inhibited tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring KRAS activating mutations (PMID: 29343524).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS act mut	ovarian cancer	predicted - sensitive	PD-0325901 + Gedatolisib	Phase I	Actionable	In a Phase I trial, treatment with the combination of Gedatolisib (PF-05212384) and PD-0325901 resulted in an overall response rate of 11.1% (4/44) and clinical benefit rate of 16.3% (7/44) in patients with a variety of solid tumors, with responses seen in 3 patients with KRAS-mutant ovarian cancer and 1 patient with KRAS-mutant endometrial cancer (PMID: 29067643).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS act mut	colorectal cancer	predicted - sensitive	VX-11e + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	MAP2K1 Y134C KRAS Q61H	lung adenocarcinoma	no benefit	Refametinib	Preclinical	Actionable	In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	MAP2K1 Y134C KRAS Q61H	lung adenocarcinoma	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H PIK3CA E542K	colorectal cancer	sensitive	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H	non-small cell lung carcinoma	sensitive	AZD4785	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cell lines harboring KRAS Q61H (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H	ovarian carcinoma	sensitive	Bevacizumab + Sorafenib	Clinical Study	Actionable	In a clinical case study, a patient with ovarian carcinoma harboring KRAS Q61H demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in 62% tumor regression (PMID: 25363205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H	lung adenocarcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H	lung adenocarcinoma	decreased response	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H	non-small cell lung carcinoma	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited growth and repressed RAF-MEK-MAPK signaling as indicated by reduced phosphorylation of Craf, Mek, and Mapk in a human non-small cell lung cancer cell line harboring KRAS Q61H in culture (PMID: 19165201, PMID: 22693356).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H	non-small cell lung carcinoma	resistant	Pictilisib	Preclinical	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring KRAS Q61H (PMID: 19165201) were insensitive to pictilisib (GDC-0941) growth inhibition in culture (PMID: 22693356).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H PIK3CA E545K	non-small cell lung carcinoma	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H PIK3CA E545K	non-small cell lung carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H PIK3CA E545K	non-small cell lung carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS Q61H PIK3CA E545K	non-small cell lung carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E ERBB2 over exp KRAS A146V	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS A146V and BRAF V600E in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to combination treatment consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture, likely due to the acquisition of KRAS A146V and A146T secondary resistance mutations (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T KRAS A146V	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFOX	Phase II	Actionable	In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	AKT1 E17K KRAS wild-type BRAF wild-type	colorectal cancer	resistant	Cetuximab + Irinotecan	Clinical Study	Actionable	In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR over exp KRAS wild-type	pancreatic adenocarcinoma	sensitive	Trametinib + Triciribine	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Triciribine (API-2) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR over exp KRAS wild-type	pancreatic adenocarcinoma	sensitive	Afatinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gilotrif (afatinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS wild-type	colorectal cancer	decreased response	LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 demonstrated limited efficacy in BRAF and KRAS wild-type patient-derived xenograft models of colorectal cancer, resulted in a disease control rate of 3.8% (1/26) (PMID: 28611205).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Bevacizumab	Clinical Study	Actionable	In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) resulted in improved objective response rate (54.8% vs 48.3%, OR=1.42, p=0.02), median progression-free survival (HR=0.85, p=0.02), and median overall survival (HR=0.65, p=0.01) in KRAS wild-type patients compared to KRAS mutant patients (PMID: 23828442).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Bevacizumab	Phase III	Actionable	In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p?=?0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFIRI	Phase III	Actionable	In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	lung carcinoma	decreased response	AZD4785	Preclinical - Cell culture	Actionable	In a preclinical study, KRAS wild-type lung carcinoma cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	vaginal squamous tumor	sensitive	GDC-0623	Phase I	Actionable	In a Phase I trial, GDC-0632 treatment resulted in stable disease for more than 5 months in 13% (6/45) of patients with advanced solid tumors and 1 partial response in a squamous cell vaginal carcinoma patient carrying wild-type KRAS (Mol Cancer Ther 2013;12(11 Suppl):B75).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	decreased response	AZD4785	Preclinical - Cell culture	Actionable	In a preclinical study, KRAS wild-type colorectal cancer cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab	Phase III	Actionable	In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p=0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab	Clinical Study	Actionable	In a clinical study, KRAS wild-type colorectal cancer patients demonstrated a greater response to Erbitux (cetuximab) treatment compared to KRAS mutant colorectal cancer patients, including an objective response of 41% (27/66) vs 0% (0/42), a median overall survival of 43 weeks vs 27.3 weeks, and an overall survival of 74.9 weeks vs 30.6 weeks, respectively (PMID: 17998284).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan	Phase III	Actionable	In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with KRAS exon 2 wild-type colorectal cancer compared to FOLFIRI treatment alone, with an overall response rate of 35% (105/297) with the combination versus 10% (28/285) with FOLFIRI alone (PMID: 26341920).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan	Phase III	Actionable	In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	non-small cell lung carcinoma	no benefit	Selumetinib + Docetaxel	Phase II	Actionable	In a Phase II trial, the combination of Selumetinib (AZD6244) and Taxotere (docetaxel) did not result in a greater clinical benefit in KRAS wild-type patients with non-small cell lung carcinoma when compared to Taxotere (docetaxel) plus placebo (PMID: 29045535; NCT01750281).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	lung cancer	decreased response	Ponatinib + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS wild-type lung cancer cells in culture (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	predicted - sensitive	Bevacizumab + Capecitabine	Phase III	Actionable	In a Phase III trial, Avastin (bevacizumab) and Xeloda (capecitabine) maintenance treatment resulted in better time to first progression (HR = 0.27), time to second progression (HR = 0.42) and overall survival (HR = 0.64) in KRAS wild-type colorectal cancer patients compared to patients harboring KRAS mutations (HR = 0.40, 0.75, 1.07 respectively) (J Clin Oncol 34, 2016 (suppl; abstr 3525)).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	no benefit	SYM004	Phase II	Actionable	In a Phase II trial, SYM004 treatment did not improve overall survival compared to standard of care in patients with metastatic colorectal cancer harboring no KRAS exon 2 mutations, and acquired resistance to anti-EGFR therapy (PMID: 29423521).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	predicted - sensitive	Napabucasin + Panitumumab	Phase Ib/II	Actionable	In a Phase Ib/II clinical trial, BBI608 and Vectibix (panitumumab) combination therapy resulted in PR in 22.2% (2/9), SD in 22.2% (2/9), and median PFS of 9 weeks in colorectal cancer patients carrying wild-type Kras naive for anti-EGFR therapy; compared to SD in 53.3% (8/15), and median PFS of 16.4 weeks in patients failed anti-EGFR treatment (J Clin Oncol 33, 2015 (suppl; abstr 3617)).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	non-small cell lung carcinoma	sensitive	Erlotinib	Phase I	Actionable	In a Phase I trial, Tarceva (erlotinib) treatment resulted in a greater survival benefit in non-small cell lung cancer patients with wild-type KRAS compared to treatment in those patients harboring KRAS mutations (PMID: 18626007).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Rilotumumab + Panitumumab	Phase Ib/II	Actionable	In a Phase Ib/II trial, the combination of HGF inhibitor, rilotumumab, with Vectibix (panitumumab) demonstrated efficacy in previously treated patients with wild-type KRAS metastatic colorectal cancer (PMID: 24919569).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Panitumumab + cabozantinib	Phase Ib/II	Actionable	In a Phase Ib trial, Cometriq (cabozantinib) and Vectibix (panitumumab) combination treatment resulted in a median progression free survival of 3.7 months, median overall survival of 7.5 months, and partial response in 14% (2/14) of KRAS wild-type colorectal patients (J Clin Oncol 34, 2016 (suppl; abstr 3548)).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	head and neck squamous cell carcinoma	predicted - sensitive	Cetuximab + lenalidomide	Phase I	Actionable	In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in stable disease in 67% (2/3) of KRAS wild-type head and neck squamous cell cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal adenocarcinoma	no benefit	Cetuximab + Dasatinib + FOLFOX	Phase Ib/II	Actionable	In a Phase Ib/II trial, the combination of Erbitux (cetuximab), Sprycel (dasatinib), and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma, with an overall response rate of 20% (6/30) in the Phase Ib portion, and 13% (3/24) in KRAS codon 12/13 wild-type patients in the Phase II portion (PMID: 28280091; NCT00501410).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	non-small cell lung carcinoma	decreased response	AZD4785	Preclinical - Pdx	Actionable	In a preclinical study, AZD4785 inhibited Kras expression in tumors, but had no effect on tumor growth in patient-derived xenograft models of KRAS wild-type non-small cell lung carcinoma (PMID: 28615361).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	gastric adenocarcinoma	sensitive	GA201	Preclinical	Actionable	In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS wild-type gastric adenocarcinoma in culture, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	pancreatic cancer	decreased response	Aphanin	Preclinical - Cell culture	Actionable	In a preclinical study, KRAS wild-type pancreatic cancer cells were less sensitive to Aphanin induced growth inhibition and apoptosis in culture (PMID: 27333990).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	predicted - sensitive	Necitumumab + FOLFOX	Phase II	Actionable	In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with KRAS wild-type patients achieving an ORR of 87.5% (14/16), including complete response in 25% (4/16), and partial response in 62.5% (10/16) of patients (PMID: 26766738).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	pancreatic cancer	predicted - sensitive	Gemcitabine + Refametinib	Phase Ib/II	Actionable	In a Phase I/II trial, Refametinib (BAY86-9766) and Gemzar (gemcitabine) combination treatment resulted in improved overall response rate, disease control rate, progression-free survival, and overall survival (48% vs. 28%, 81% vs. 69%, 8.8 vs. 5.3 months,18.2 vs. 6.6 months, respectively) in pancreatic cancer patients without detectable KRAS mutations in circulating tumor DNA (PMID: 27975152).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	non-small cell lung carcinoma	no benefit	Sorafenib	Phase III	Actionable	In a Phase III trial, Nexavar (sorafenib) treatment in KRAS wild-type non-small cell lung carcinoma patients did not meet its primary endpoint when compared to placebo, resulting in a similar overall survival, however, did meet its secondary endpoint, showing a longer progression free survival (PMID: 26743856).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	squamous cell carcinoma	no benefit	Metformin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glucophage (metformin) did not induce growth inhibition or apoptosis in a KRAS wild-type squamous cell carcinoma cell line in culture and did not inhibit tumor growth in xenograft models (PMID: 23877793).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + lenalidomide	Phase I	Actionable	In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in partial response in 5% (1/19) and stable disease in 32% (6/19) of KRAS wild-type colorectal cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	Advanced Solid Tumor	sensitive	GDC-0623	Phase I	Actionable	In a Phase I trial, GDC-0632 treatment resulted in stable disease for more than 5 months in 13% (6/45) of patients with advanced solid tumors and 1 partial response in a squamous cell vaginal carcinoma patient carrying wild-type KRAS (Mol Cancer Ther 2013;12(11 Suppl):B75).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	biliary tract cancer	predicted - sensitive	Panitumumab + Gemcitabine + Oxaliplatin	Phase II	Actionable	In a Phase II clinical trial, a PFS difference was not observed between KRAS wild-type biliary tract cancer patients when treated with a combination of Vectibix (panitumumab), Gemzar (gemcitabine), and Eloxatin (oxaliplatin) versus Gemzar (gemcitabine) and Eloxatin (oxaliplatin) only (PMID: 26540314).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Panitumumab	Phase III	Actionable	In a Phase III trial, Vectibix (panitumumab) treatment resulted in better overall survival (HR = 0.65) compared to Erbitux (cetuximab) in colorectal cancer patients harboring KRAS with wild-type exon 2 who received prior Avastin (bevacizumab) treatment (J Clin Oncol 34, 2016 (suppl; abstr 3538); NCT01001377).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Panitumumab	FDA approved	Actionable	In a Phase III trial that supported FDA approval, Vectibix (panitumumab) demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS, resulting in a median progression-free survival of 12.3 weeks, compared to 7.3 weeks with best supportive care (BSC), improved overall survival (HR=0.67), and a response rate of 17% (21/141) (PMID: 18316791; NCT00113763).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type	colorectal cancer	sensitive	Panitumumab	Phase III	Actionable	In a post-hoc analysis of a Phase III trial, colorectal cancer patients with KRAS wild-type demonstrated a greater overall survival (8.1 mo) upon treatment with Vectibix (panitumumab) compared to overall survival (4.4 mo) of patients with KRAS mutations randomized to best supportive care only (PMID: 23625191; NCT00113763).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	ERBB2 positive KRAS wild-type	colorectal cancer	sensitive	Trastuzumab + Lapatinib	Phase II	Actionable	In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS wild-type	colorectal cancer	no benefit	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring BRAF V600E (PMID: 26369631).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR dec exp KRAS wild-type	colorectal cancer	sensitive	GA201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR dec exp KRAS wild-type	colorectal cancer	sensitive	GA201 + Irinotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS wild-type PIK3CA mutant	colorectal cancer	sensitive	Cetuximab	Clinical Study	Actionable	In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	CDKN2A loss KRAS wild-type	non-small cell lung carcinoma	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR1 dec exp KRAS wild-type	lung cancer	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR pos KRAS wild-type	colorectal cancer	sensitive	Cetuximab + FOLFIRI	Phase III	Actionable	In a Phase III trial that supported FDA approval, the combination of Erbitux (cetuximab) and FOLFIRI resulted in a greater tumor response rate in EGFR positive, KRAS wild-type colorectal cancer patients (59% (102/172)) compared to EGFR positive, KRAS mutant colorectal cancer patients (36.2% (38/105)) (PMID: 19339720; NCT00154102).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS wild-type NRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFIRI	Phase II	Actionable	In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Erbitux (cetuximab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 33.2 mo and response rate of 68% (40/59), however, resulted in a 10-mo PFS rate of 50.8% (30/59), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF wild-type KRAS wild-type NRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFIRI + Bevacizumab	Phase II	Actionable	In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by  Avastin (bevacizumab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 32.2 mo and response rate of 75% (43/57), however, resulted in a 10-mo PFS rate of 40.4% (23/57), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS wild-type PIK3CA H1047R	colorectal cancer	no benefit	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR L858R KRAS G12R	lung adenocarcinoma	resistant	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, KRAS G12R was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12R TP53 R248L	lung adenocarcinoma	sensitive	Dasatinib + Demcizumab	Preclinical - Pdx	Actionable	In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12R and TP53 R248L (PMID: 26855149).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12R	colorectal cancer	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study,  colorectal cancer cells harboring a KRAS G12R mutation demonstrated resistance to Sutent (sunitinib) treatment (PMID: 23455880).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12R	thyroid cancer	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12R	lung adenocarcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12R mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12R	thyroid cancer	sensitive	Pazopanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Votrient (pazopanib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12R	thyroid cancer	sensitive	Pazopanib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination of Mekinist (trametinib) and Votrient (pazopanib) significantly delayed tumor progression in cell line xenograft models of thyroid cancer harboring KRAS G12R (PMID: 26324075).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G12R	lung adenocarcinoma	decreased response	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12R mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	resistant	Dasatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS A59T	colon cancer	sensitive	Panitumumab + FOLFIRI	Clinical Study	Actionable	In a clinical case study, a colon cancer patient harboring KRAS A59T demonstrated sensitivity to the combination treatment of Vectibix (panitumumab) and FOLFIRI, which resulted in an objective response of a 36% decrease according to RECIST (PMID: 28404754).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS amp	colorectal cancer	resistant	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired KRAS amplification (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS amp	colorectal cancer	resistant	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS amp	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS amp	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS amp	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR exon 19 del KRAS amp	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR exon 19 del KRAS amp	non-small cell lung carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS amp	melanoma	sensitive	Sorafenib + Carboplatin + Paclitaxel	Phase III	Actionable	In retrospective study of a Phase III trial, melanoma patients harboring KRAS amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater overall survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR exon 19 del EGFR T790M KRAS amp	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR exon 19 del EGFR T790M KRAS amp	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR exon 19 del EGFR T790M KRAS amp	non-small cell lung carcinoma	sensitive	Osimertinib + Selumetinib	Preclinical	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib increased Parp cleavage, and highly suppressed phosphorylated Erk in human non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and a gain in KRAS in culture (PMID: 25870145).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	PIK3CA amp KRAS amp	endometrial cancer	sensitive	BEZ235 + PD98509	Preclinical	Actionable	In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	FGFR1 amp KRAS amp	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and KRAS demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9	ovarian clear cell adenocarcinoma	sensitive	DS-7423	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	EGFR amp FGFR1 amp KRAS G13C	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to Erdafitinib (JNJ-42756493) in culture (PMID: 28341788).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13C	lung adenocarcinoma	decreased response	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G13C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS G13C	lung adenocarcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G13C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T	colorectal cancer	resistant	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T	colorectal cancer	resistant	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	BRAF V600E KRAS A146T	colorectal cancer	resistant	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS A146T	colorectal cancer	sensitive	PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring KRAS A146T in culture and in cell line xenograft models (PMID: 20570890).
KRAS	C-K-RAS | c-Ki-ras2 | CFC2 | K-Ras | K-RAS2A | K-RAS2B | K-RAS4A | K-RAS4B | KI-RAS | KRAS1 | KRAS2 | NS | NS3 | RALD | RASK2	12p12.1	NM_033360	KRAS A146T	colorectal cancer	resistant	Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colorectal cancer cell line harboring KRAS A146T demonstrated resistance to tumor growth inhibition by Erbitux (cetuximab) in xenograft models (PMID: 20570890).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 G128V	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 G128V	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 G128V	melanoma	resistant	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 G128V	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P124S	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P124S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P124S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P124S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Y134C KRAS Q61H	lung adenocarcinoma	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Y134C KRAS Q61H	lung adenocarcinoma	no benefit	Refametinib	Preclinical	Actionable	In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal-regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID: 24463458).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 Q56P	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 Q56P	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 Q56P	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G EGFR G719S	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	stomach cancer	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, selumetinib (AZD6244) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	lymphatic system cancer	sensitive	Cobimetinib	Clinical Study	Actionable	In a clinical study, a patient with refractory Erdheim-Chester disease harboring a MAP2K1 Q56P mutation had a reduction of lymphatic infiltrates to background within a month of receiving Cotellic (cobimetinib) therapy (PMID: 26566875).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	lung adenocarcinoma	sensitive	Refametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Refametinib (BAY86-9766), resulting in decreased cell viability (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	lung adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	lung adenocarcinoma	sensitive	PD-0325901	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to PD-0325901, resulting in decreased cell viability (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	stomach cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a gastric cancer cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	lung adenocarcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Selumetinib (AZD6244), resulting in decreased cell viability (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P BRAF V600E	melanoma	sensitive	Selumetinib + PLX4720	Preclinical	Actionable	In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P BRAF V600E	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor selumetinib (AZD6244) cell culture.
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 Q56P BRAF V600E	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	resistant	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	LGX818 + Cetuximab + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Vemurafenib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 L115P	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 L115P	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 L115P	Advanced Solid Tumor	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of Map2k1 L115P expressed in transformed human kidney cells (PMID: 12370306).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 P124L	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, transformed human melanoma cells expressing MAP2K1 P124L demonstrated resistance to the MEK inhibitor, Selumetinib (AZD6244) (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600K MAP2K1 P124L	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600K MAP2K1 P124L	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600K MAP2K1 P124L	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P124L	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P124L	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 V60E	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V60E	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57T	colorectal cancer	sensitive	Panitumumab + Trametinib	Clinical Study	Actionable	In a clinical case study, a combination of Vectibix (panitumumab) and Mekinist (trametinib) caused tumor regression in a patient’s colorectal cancer metastases harboring MAP2K1 K57T after being identified pre-clinically as a combination likely to inhibit MAP2K1 K57T expressing colorectal cancer (PMID: 26644315).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57T	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57T	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57T	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 I111N	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N  in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 I111N	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 K59del	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 K59del	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 K59del	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 K59del	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 K59del	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 K59del	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 K59del	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 V211D	melanoma	resistant	CI-1040	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 V211D	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 V211D	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 V211D	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 V211D	Advanced Solid Tumor	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 V211D	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 V211D	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53S	Advanced Solid Tumor	sensitive	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited kinase activity of Map2k1 F53S expressed in transformed human kidney cells (PMID: 12370306).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 E203K	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 E203K	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 E203K	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I111S	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I111S	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I111S	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I111S	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I111S	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I111S	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 L115A	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 L115A expressed in transformed human kidney cells (PMID: 12370306).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F53L	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 H119P	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600K MAP2K1 P124Q	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600K MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600K MAP2K1 P124Q	melanoma	sensitive	VX-11e	Preclinical - Cell culture	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	conflicting	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	no benefit	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I103N	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I103N	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 I103N expressed in transformed human kidney cells (PMID: 12370306).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 I103N	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 I103N	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 I103N	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 C121S	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 C121S	melanoma	resistant	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 C121S	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 C121S	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 C121S	melanoma	decreased response	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Zelboraf (vemurafenib)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 C121S	melanoma	decreased response	Vemurafenib	Clinical Study	Actionable	In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 C121S	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	BRAF V600E MAP2K1 C121S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 C121S	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 C121S	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 C121S	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 C121S	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 C121S in culture (PMID: 28179366).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 C121S	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 C121S	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 C121S	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 C121S	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	colorectal cancer	sensitive	Panitumumab + Trametinib	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	lymphatic system cancer	sensitive	Trametinib	Clinical Study	Actionable	In a clinical study, a patient with refractory Erdheim-Chester disease harboring a MAP2K1 K57N mutation had a sustained clinical response to Mekinist (trametinib) for over 6 months (PMID: 26566875).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	lung adenocarcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, selumetinib (AZD6244) inhibited phosphorylation of ERK in cells expressing MAP2K1 K57N and inhibited MAP2K1 K57N-dependent growth in cell culture (PMID: 18632602).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 K57N	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	ALK rearrange MAP2K1 K57N	non-small cell lung carcinoma	sensitive	Ceritinib + Selumetinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of AZD6244, resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F129L	colorectal cancer	sensitive	RO4927350	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F129L demonstrated sensitivity to treatment with RO4927350 in culture and in cell line xenograft models, demonstrating inhibition of tumor growth (PMID: 21705440).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F129L	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F129L	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F129L	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F129L	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F129L	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).
MAP2K1	CFC3 | MAPKK1 | MEK1 | MKK1 | PRKMK1	15q22.31	NM_002755	MAP2K1 F129L	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230D	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230D in an in vitro kinase assay (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S	lung adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring MET del exon14 and MET amplification demonstrated resistance to Xalkori (crizotinib), and the patient was found to have acquired MET Y1230H, MET D1228N, MET Y1230S, and MET G1163R (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S	lung adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring MET del exon14 responded to Xalkori (crizotinib), demonstrating a near complete response at 3 months, however, after 9 months progression ensued and a re-biospy identified MET del exon14, MET amplification, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R (PMID: 28522754).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp MET del exon14 MET D1228N MET G1163R MET L1195V	lung adenocarcinoma	resistant	Glesatinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient previously harboring MET amp, MET del exon14, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R demonstrated a decrease in lesion size when treated with Glesatinib (MGCD265), however, progression ensued and plasma testing indicated the patient lost Y1230H and Y1230S, but acquired MET L1195V (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET M1268T	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET M1268T demonstrated sensitivity to SU11274 treatment (PMID: 15064724).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET M1268T	cancer	sensitive	K252a	Preclinical	Actionable	In preclinical studies, cell lines transformed by MET M1268T were sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET V1206L	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET V1206I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H	lung adenocarcinoma	predicted - resistant	Crizotinib + Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M and MET amplification demonstrated progressive disease after 3 months of treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) and was found to have acquired 4 MET mutations: MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y (PMID: 29128427).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H	lung adenocarcinoma	unknown	Cabozantinib + Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M, MET amplification and MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement, decreased pleural effusion, and lung nodule shrinkage following treatment with the combination of Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) (PMID: 29128427).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228N	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET D1228N in culture (PMID: 23275061).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228N	Advanced Solid Tumor	predicted - sensitive	Cabozantinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228N	Advanced Solid Tumor	predicted - resistant	Capmatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228N	Advanced Solid Tumor	predicted - resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228N	Advanced Solid Tumor	predicted - sensitive	BMS-777607	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to D1228N in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228N	Advanced Solid Tumor	predicted - resistant	Crizotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Xalkori (crizotinib), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228N	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228N in an in vitro kinase assay (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14 MET D1228N	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing MET del exon14 and MET D1228N were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 21% tumor regression in xenograft models (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14 MET D1228N	lung squamous cell carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with squamous cell lung cancer harboring a MET exon 14 skipping mutation was determined to have acquired MET D1228N after progression on Xalkori (crizotinib) therapy (PMID: 27343442).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET T1010I	lung carcinoma	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung carcinoma cell lines harboring MET T1010I showed sensitivity to Xalkori (crizotinib) in cell culture (PMID: 17483355).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET N375S	ovarian carcinoma	sensitive	Bevacizumab + Sorafenib	Clinical Study	Actionable	In a clinical case study, a patient with ovarian cancer harboring MET N375S demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for greater than six months (PMID: 25363205).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET N375S	oral cavity cancer	no benefit	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with oral cavity cancer harboring MET N375S demonstrated progressive disease and overall survival of five weeks when treated with Xalkori (crizotinib) (PMID: 28514312).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET N375S	Advanced Solid Tumor	decreased response	SU11274	Preclinical	Actionable	In a preclinical study, cells expressing MET N375S had decreased sensitivity to SU11274 in culture compared to cells expressing wild-type MET (PMID: 19723643).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET E168D	Advanced Solid Tumor	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, SU11274 induced apoptosis of cells expressing MET E168D, which demonstrated increased sensitivity compared to cells expressing wild-type MET (PMID: 19723643).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET M1250T	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET M1250T in an in vitro kinase assay (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR wild-type MET over exp	non-small cell lung carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	BRCA2 dec exp MET over exp	triple-receptor negative breast cancer	no benefit	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Brca2 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met overexpression to Rubraca (rucaparib) in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	INC280 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET over exp	lung cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, MET overexpression and activation was identified as the mechanism mediating acquired Rogaratinib (BAY 1163877) resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET over exp	lung small cell carcinoma	sensitive	BGJ398 + EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and EMD 1214063 synergistically inhibited growth of small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET over exp	lung small cell carcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression and activation of Met was identified in a small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET over exp	lung small cell carcinoma	sensitive	BGJ398 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Xalkori (crizotinib) synergistically inhibited Erk signaling, resulted in growth inhibition in small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET over exp	lung cancer	sensitive	Crizotinib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to Rogaratinib (BAY 1163877) through MET overexpression and activation in culture (PMID: 27429073).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	melanoma	sensitive	XL147	Preclinical	Actionable	In a preclinical study, XL147 inhibited migration and growth of mouse melanoma cells with MET over expression in culture (PMID: 25637314).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	lung papillary adenocarcinoma	sensitive	Telisotuzumab vedotin	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with ABBV-399 resulted in complete response in a MET-over expressing papillary lung adenocarcinoma cell line xenograft model (PMID: 27573171).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	hepatocellular carcinoma	sensitive	Tepotinib	Preclinical - Pdx	Actionable	In a preclinical study, Tepotinib (MSC2156119J) treatment resulted in tumor regression in patient-derived xenograft models of hepatocellular cancer with high Met expression level (PMID: 25256830).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	glioblastoma multiforme	predicted - sensitive	Altiratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and viability of several Met over expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	lung cancer	sensitive	Crizotinib + Rucaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human lung cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	lung cancer	sensitive	SYM015	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in both cell line xenograft and patient-derived xenograft (PDX) models of lung cancer with high Met expression (PMID: 28679766).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	cholangiocarcinoma	predicted - sensitive	Cabozantinib	Phase II	Actionable	In a Phase II trial, a cholangiocarcinoma patient with high Met expression in tumor stayed on Cometriq (cabozantinib) treatment for 278 days (PMID: 28192597).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	hepatocellular carcinoma	sensitive	SCC244	Preclinical - Pdx	Actionable	In a preclinical study, hepatocellular carcinoma patient-derived xenograft (PDX) models overexpressing MET were sensitive to SCC244, demonstrating a complete response in one and partial response in eleven (PMID: 29237805).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	non-small cell lung carcinoma	sensitive	Telisotuzumab vedotin	Phase I	Actionable	In a Phase I trial, ABBV-399 resulted in a partial response in 19% (3/16) of patients with non-small cell lung carcinoma while 37.5% (6/16) of patients experienced disease control at 12 weeks (J Clin Oncol 35, 2017 (suppl; abstr 2509)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	non-small cell lung carcinoma	sensitive	Telisotuzumab vedotin	Preclinical - Cell culture	Actionable	In a preclinical study, ABBV-399 inhibited growth of MET over expressing non-small cell lung cancer cell lines in culture (PMID: 27573171).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	triple-receptor negative breast cancer	unknown	BKM120 + Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer xenograft models overexpressing MET demonstrated stable disease when treated with the combination therapy, BKM120 and Xalkori (crizotinib) (PMID: 29203461).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	non-small cell lung carcinoma	sensitive	Erlotinib + Telisotuzumab vedotin	Phase I	Actionable	In a Phase I trial, the combination of ABBV-399 and Tarceva (erlotinib) resulted in a partial response in 31% (4/13) of non-small cell lung carcinoma patients and disease control at 12 weeks in 61.5% (8/13) of patients (J Clin Oncol 35, 2017 (suppl; abstr 2509)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	lung adenocarcinoma	sensitive	Merestinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of lung adenocarcinoma with Met over expression (PMID: 23275061).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	colorectal cancer	sensitive	JNJ 38877605 + Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of JNJ-38877605 to Vectibix (panitumumab) treatment overcame Vectibix (panitumumab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	stomach cancer	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of a human gastric cancer cell line with high levels of MET expression in culture (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	stomach cancer	sensitive	KRC-00509	Preclinical	Actionable	In a preclinical study, KRC-00509 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	lung small cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines over-expressing MET (PMID: 25122427).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	stomach cancer	sensitive	KRC-00715	Preclinical	Actionable	In a preclinical study, KRC-00715 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture and in xenograft models, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	non-small cell lung carcinoma	sensitive	SCC244	Preclinical - Pdx	Actionable	In a preclinical study, non-small cell lung carcinoma patient-derived xenograft (PDX) models harboring MET overexpression were sensitive to SCC244, demonstrating inhibition of tumor growth and nine partial responses (PMID: 29237805).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of MET conferred resistance to Erbitux (cetuximab) in colorectal cancer cell lines in culture (PMID: 23729478).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	lung squamous cell carcinoma	sensitive	EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing lung squamous cell carcinoma cells in culture (PMID: 26358474).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	colorectal cancer	resistant	Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of MET conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	colorectal cancer	sensitive	Cetuximab + JNJ 38877605	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of JNJ-38877605 to Erbitux (cetuximab) treatment overcame Erbitux (cetuximab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	triple-receptor negative breast cancer	sensitive	Foretinib + Veliparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Foretinib (GSK1363089) and Veliparib (ABT-888) worked synergistically to inhibit growth of Met-over expressing triple-receptor negative breast cancer cells in culture, and reduced tumor growth in xenograft models (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	stomach cancer	sensitive	Merestinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY2801653 blocked tumor growth in a gastric cancer cell line xenograft model over expressing Met (PMID: 23275061).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	lung adenocarcinoma	predicted - sensitive	Telisotuzumab vedotin	Preclinical - Pdx	Actionable	In a preclinical study, ABBV-399 demonstrated efficacy in MET-expressing lung adenocarcinoma patient-derived xenograft (PDX) models, with the PDX model with higher MET expression levels showing improved tumor growth delay (PMID: 27573171).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	triple-receptor negative breast cancer	sensitive	Foretinib + Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Foretinib (GSK1363089) and Rubraca (rucaparib) combination treatment resulted in enhanced growth inhibition in Met-over expressing triple-receptor negative breast cancer cells in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	triple-receptor negative breast cancer	decreased response	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines overexpressing Met demonstrated decreased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	stomach cancer	sensitive	SYM015	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in patient-derived xenograft (PDX) models of gastric cancer with high Met expression (PMID: 28679766).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	stomach carcinoma	sensitive	EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing gasric carcinoma cell lines in culture, regardless of their TP53 status (PMID: 26358474).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	breast cancer	sensitive	Crizotinib + Rucaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human breast cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp	triple-receptor negative breast cancer	sensitive	Crizotinib + Rucaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of Met-over expressing human triple-receptor negative breast cancer cell lines in culture, and reduced tumor growth in xenograft models (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp MET Y1230C MET Y1230H	stomach cancer	resistant	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, acquired MET Y1230C and MET Y1230H mutations were associated with secondary resistance to Xalkori (crizotinib) in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this model demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21266357).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	BRCA1 dec exp MET over exp	triple-receptor negative breast cancer	no benefit	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp MET Y1230C	stomach cancer	resistant	PHA-665752	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acquired MET Y1230C mutation was associated with resistance to PHA-665752 in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this xenograft model demonstrated sustained MET activation following treatment with PHA-665752 in culture (PMID: 21266357).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	KRAS G12D MET over exp	stomach cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp TP53 dec exp	stomach carcinoma	sensitive	EMD 1214063 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET over exp MET Y1230H	stomach cancer	resistant	PHA-665752	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MET Y1230H was associated with resistance to PHA-665752 in a gastric cancer cell line with MET over expression in culture (PMID: 21266357).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp over exp	non-small cell lung carcinoma	sensitive	Altiratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and proliferation of a non-small cell lung cancer cell line with MET amplification and overexpression in culture (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp over exp	stomach carcinoma	sensitive	K252a	Preclinical	Actionable	In preclinical studies, a MET amplified, gastric carcinoma cell over expressing Met was sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp over exp	stomach cancer	sensitive	Altiratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Altiratinib (DCC-0701) inhibited Met phosphorylation and proliferation of a gastric cancer cell line with MET amplification and over expression in culture, and inhibited tumor growth and induced tumor regression in xenograft models (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET V1110I	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET V1110I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR L858R EGFR T790M MET amp MET D1231Y	lung adenocarcinoma	predicted - resistant	Cabozantinib + Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R, EGFR T790M, MET amplification, MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement and lung nodule shrinkage following treatment Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) in combination, but progressed after 1 month and was found to have lost MET D1228H, MET D1228N, and MET Y1230H, and to have an increased allele fraction of MET D1231Y (PMID: 29128427).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET H1112Y	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET H1112Y demonstrated sensitivity to SU11274 treatment (PMID: 19783361).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET L1213V	cancer	resistant	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET L1213V showed resistance to SU11274 treatment (PMID: 15064724).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	KRAS G12A MET amp	lung cancer	resistant	SAR125844	Preclinical - Cell culture	Actionable	In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	KRAS G12A MET amp	lung cancer	resistant	AMG 337	Preclinical - Cell culture	Actionable	In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp TP53 del	breast cancer	sensitive	Crizotinib	Preclinical	Actionable	In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR L858R EGFR T790M MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib + Osimertinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient with EGFR L858R, EGFR T790M, and MET amplification demonstrated a partial response in her lung lesions and an approximately 90% reduction in the retroperitoneal lymph node and right adrenal gland, and progression-free survival lasting 3 months following treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) (PMID: 29128427).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR L858R EGFR T790M MET amp	lung adenocarcinoma	predicted - resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M progressed after 19 months on Tagrisso (osimertinib), and was found to have acquired MET amplification (PMID: 29128427).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET amp	non-small cell lung carcinoma	sensitive	JNJ-61186372	Preclinical - Cell line xenograft	Actionable	In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Erlotinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET amp	lung adenocarcinoma	sensitive	Osimertinib + Savolitinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib), however, after 36 weeks presented with progression (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET amp	lung adenocarcinoma	sensitive	Afatinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR amp MET amp	esophagus adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR mut MET amp	lung adenocarcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of MET was identified in a lung adenocarcinoma cell line harboring EGFR mutation that acquired resistance to Tarceva (erlotinib) in culture (PMID: 28630215).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR mut MET amp	lung adenocarcinoma	sensitive	Erlotinib + EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) and EMD 1214063 synergistically inhibited growth of lung carcinoma cells harboring EGFR mutation and Met amplification in culture (PMID: 28630215).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	sensitive	Emibetuzumab	Preclinical	Actionable	In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with MET amplification in culture, and inhibited growth in MET-amplified tumor xenograft models (PMID: 25231402).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	not applicable	N/A	Clinical Study	Emerging	In a retrospective study, advanced solid tumor patients harboring MET amplification demonstrated worse overall survival (7.23 months) comparing to patients without MET amplification (8.62 months) (PMID: 25326232), suggesting that this may serve as a future prognostic biomarker.
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	liver cancer	sensitive	Crizotinib	Preclinical - Pdx	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified liver cancer (PMID: 26483207).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	SCC244	Preclinical - Pdx	Actionable	In a preclinical study, non-small cell lung carcinoma patient-derived xenograft models harboring MET amplification were sensitive to SCC244, demonstrating inhibition of tumor growth and stable disease (PMID: 29237805).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	lung cancer	sensitive	AMG 337	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	predicted - sensitive	SAR125844	Phase I	Actionable	In a Phase I trial, SAR125844 treatment in advanced solid tumor patients harboring a MET amplification was well-tolerated and resulted in a partial response in 17% (5/29) of patients, including patients with non-small cell lung carcinoma, and stable disease in 59% (17/29) of patients (PMID: 29145039; NCT01391533).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	predicted - sensitive	PP-121	Preclinical - Cell culture	Actionable	In a preclinical study, the multitarget kinase inhibitor PP-121 inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	lung cancer	sensitive	SAR125844	Preclinical - Cell culture	Actionable	In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	SGX523	Preclinical - Cell culture	Actionable	In a preclinical study, SGX523 inhibited survival of MET-amplified non-small cell lung cancer cells in culture (PMID: 26483207).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach carcinoma	sensitive	EMD 1214063	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	lung cancer	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth of MET-amplified lung cancer cells in culture (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	predicted - sensitive	Alvespimycin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Alvespimycin inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture and in cell line xenograft models (PMID: 26483207).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	Golvatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	SAR125844	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines  in culture and in xenograft models (PMID: 25504634).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	ARGX-111	Phase I	Actionable	In a Phase I trial, a gastric cancer patient harboring MET amplification was sensitive to treatment with ARGX-111, demonstrating stable disease, a metabolic response, and a decrease in circulating tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2580-2580).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	predicted - sensitive	Merestinib	Preclinical - Pdx	Actionable	In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition in patient-derived xenograft (PDX) models of MET-amplified non-small cell lung carcinoma that were resistant to Egfr inhibitors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	predicted - sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, INC280 displayed safety and preliminary efficacy in patients with MET dependent solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2520)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in MET-amplified gastric cancer cell line xenograft models (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	KTN0073-IgG2	Preclinical - Cell line xenograft	Actionable	In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	sensitive	SYM015	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sym015 inhibited growth of cancer cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified patient-derived xenograft (PDX) models (Cancer Res July 15 2016 (76) (14 Supplement) 1219).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	AMG 337	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	Telisotuzumab vedotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	KTN0073-IgG2	Preclinical - Cell culture	Actionable	In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited proliferation of a MET-amplified non-small cell lung cancer cell line in culture (PMID: 27550450).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring MET amplification in culture (PMID: 26090892).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	EMD 1214063	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of non-small cell lung carcinoma harboring MET amplification (PMID: 23553846).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	papillary renal cell carcinoma	sensitive	Savolitinib	Phase II	Actionable	In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET amplification, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	papillary renal cell carcinoma	sensitive	Savolitinib	Preclinical - Pdx	Actionable	In a preclinical study, Savolitinib (AZD6094) demonstrated antitumor activity in patient-derived papillary renal cell carcinoma xenograft models harboring MET amplification (PMID: 25779944).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	no benefit	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	SGX523	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines for non-small cell lung cancer patients with high level MET amplification (NCCN.org).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	Crizotinib	Preclinical - Pdx	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified non-small cell lung cancer (PMID: 26483207).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	predicted - sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the multitarget kinase inhibitor Sprycel (dasatinib) inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	SCC244	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in gastric cancer cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	lung squamous cell carcinoma	sensitive	SCC244	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in lung squamous cell carcinoma cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	colorectal cancer	resistant	Cetuximab	Clinical Study	Actionable	In a clinical study, MET amplification was associated with resistance to Erbitux (cetuximab) in 2 colorectal cancer patients, and in patient-derived xenograft (PDX) models (PMID: 23729478).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	colorectal cancer	sensitive	JNJ 38877605	Preclinical - Pdx	Actionable	In a preclinical study, JNJ-38877605 inhibited tumor growth in colorectal cancer patient-derived xenograft models with MET amplification (PMID: 23729478).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	sensitive	ABT-700	Phase I	Actionable	In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	TAS-115	Preclinical	Actionable	In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	predicted - sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Ganetespib inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	stomach cancer	sensitive	M-COPA	Preclinical - Cell line xenograft	Actionable	In a preclinical study, M-COPA reduced Met cell surface expression and downstream signaling and decreased growth of MET-amplified gastric cancer cell lines in culture, and demonstrated antitumor activity in MET-amplified gastric cancer cell line xenograft models (PMID: 27197184).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	decreased response	AMG 337	Clinical Study	Actionable	In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	sensitive	Tepotinib	Phase I	Actionable	In a Phase I study, Tepotinib (MSC2156119J) demonstrated safety and preliminary efficacy in advanced solid tumor patients with MET amplification (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2591).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	Advanced Solid Tumor	decreased response	EMD 1204831	Clinical Study	Actionable	In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	esophagus adenocarcinoma	sensitive	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	Selumetinib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring MET amplification in culture and in cell line xenograft models (PMID: 24939055).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	lung cancer	sensitive	Golvatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	esophageal cancer	sensitive	AMG 337	Clinical Study	Actionable	In clinical case studies, patients with MET amplified esophageal cancer responded to AMG 337 therapy (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	hepatocellular carcinoma	sensitive	AMG 337	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp	non-small cell lung carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	KRAS G12V MET amp	carcinoma	predicted - sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	lung adenocarcinoma	no benefit	Afatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	lung adenocarcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	lung adenocarcinoma	resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841)
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	non-small cell lung carcinoma	sensitive	Gefitinib + NPS-1034	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	non-small cell lung carcinoma	resistant	CO1686	Preclinical - Cell line xenograft	Actionable	In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	non-small cell lung carcinoma	sensitive	CO1686 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	non-small cell lung carcinoma	sensitive	Gefitinib + PHA-665752	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR E746_A750del MET amp	lung adenocarcinoma	sensitive	Afatinib + Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 over exp MET amp MET R988C	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study, assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR L858R MET amp	non-small cell lung carcinoma	sensitive	CO1686 + Crizotinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	KRAS G12D MET amp	esophageal carcinoma	resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	BRAF V600E EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET amp	lung cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, MET amplification was identified as the mechanism mediating acquired AZD4547 resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET amp	lung squamous cell carcinoma	predicted - resistant	BGJ398	Phase I	Actionable	In a Phase I trial, MET amplification was detected in a squamous cell lung cancer patient harboring FGFR1 amplification whose disease relapsed after 17 months of BGJ398 treatment, supporting a role of MET amplification in drug resistance in FGFR1-amplified lung cancer (PMID: 28630215).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET amp	lung cancer	sensitive	AZD4547 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to AZD4547 through MET amplification in culture (PMID: 27429073).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del EGFR T790M MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with Xalkori (crizotinib) treatment (PMID: 27393507).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del EGFR T790M MET amp	lung adenocarcinoma	resistant	Osimertinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	esophageal carcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	gastroesophageal junction adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) inhibited the growth of gastroesophageal adenocarcinoma cells with ERBB2 (HER2) and MET amplification in culture (PMID: 25350844).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	gastric adenocarcinoma	resistant	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	esophageal carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	esophageal carcinoma	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	gastric adenocarcinoma	resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	gastric adenocarcinoma	resistant	Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	esophagus adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 amp MET amp	gastric adenocarcinoma	sensitive	Crizotinib + Trastuzumab + Paclitaxel	Clinical Study	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR act mut MET amp	lung cancer	sensitive	SYM015	Preclinical - Pdx	Actionable	In a preclinical study, SYM015 treatment resulted in tumor growth inhibition in patient-derived xenograft (PDX) models of MET-amplified lung cancer harboring EGFR activating mutations (PMID: 28679766).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp MET del exon14	lung cancer	sensitive	Glesatinib	Preclinical - Pdx	Actionable	In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET del exon14 demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp MET del exon14	lung adenocarcinoma	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient co-harboring MET del exon14 and MET amp was sensitive to Xalkori (crizotinib), demonstrating a partial response for 8 months (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp MET del exon14	non-small cell lung carcinoma	sensitive	Glesatinib	Preclinical - Pdx	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring MET exon 14 deletion and varying degrees of MET amplification (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET amp MET del exon14	non-small cell lung carcinoma	sensitive	SCC244	Preclinical - Pdx	Actionable	In a preclinical study, non-small cell lung carcinoma patient derived xenograft (PDX) models co-harboring MET amplification and MET del exon 14 were sensitive to SCC244 treatment, demonstrating a complete response in four and a partial response in another four (PMID: 29237805).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR T790M MET amp	non-small cell lung carcinoma	resistant	CO1686	Clinical Study	Actionable	In an analysis of EGFR T790M-positive non-small cell lung cancer patients, emergence of MET amplification was identified in 26% (28/43) of patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR T790M MET amp	lung adenocarcinoma	resistant	CO1686	Preclinical	Actionable	In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR T790M MET amp	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 over exp MET amp	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tissue from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified MET amplification in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ALK rearrange MET amp	lung adenocarcinoma	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement who developed resistance to Alecensa (alectinib) likely due to acquisition of MET amplification, responded well to treatment with Xalkori (crizotinib), demonstrating a radiological response after 12 days (PMID: 24128725, PMID: 24518097).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ALK rearrange MET amp	lung adenocarcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement developed resistance to Alecensa (alectinib)treatment, and subsequently was found to harbor amplification of MET (PMID: 24128725, PMID: 24518097).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET amp MET D1228V	lung adenocarcinoma	sensitive	Cabozantinib + Erlotinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR del exon19 MET amp	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET dec exp	lung cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET dec exp	lung cancer	sensitive	Rogaratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	BRCA2 dec exp MET dec exp	triple-receptor negative breast cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	BRCA1 dec exp MET dec exp	triple-receptor negative breast cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET dec exp	triple-receptor negative breast cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Lynparza (olaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET dec exp	triple-receptor negative breast cancer	sensitive	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Veliparib (ABT-888) induced growth and colony formation inhibition in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET dec exp	triple-receptor negative breast cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET F1200I	papillary renal cell carcinoma	predicted - sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, a patient with papillary renal cell carcinoma harboring MET G1163T demonstrated a partial response with a duration of 37.3 months when treated with Xalkori (crizotinib) (PMID: 29149761; NCT01524926).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET wild-type	colorectal cancer	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in  only partial growth inhibition in cell line xenograft models of MET wild-type colorectal cancer (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET wild-type	pancreatic cancer	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type pancreatic cancer (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET wild-type	bladder carcinoma	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type urinary bladder carcinoma (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET wild-type	cholangiocarcinoma	sensitive	Merestinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, LY2801653 inhibited phosphorylation of Met, resulting in inhibition of cholangiocarcinoma proliferation in cell culture and growth of tumors in Pdx models (PMID: 26757360).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET wild-type	prostate cancer	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type prostate caner (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET wild-type	prostate cancer	sensitive	BMS-777607	Preclinical	Actionable	In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in inhibiting migration and invasion of cultured prostate cancer cells expressing wild-type Met (PMID: 20515943).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET wild-type	breast cancer	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment only resulted in partial growth inhibition in cell line xenograft models of MET wild-type breast cancer (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET wild-type	Advanced Solid Tumor	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in MET wild-type cell line xenograft models of various tumor types (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14 MET Y1230C	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing MET del exon14 and MET Y1230C were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 52% tumor regression in xenograft models (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230C	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230C in an in vitro kinase assay (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230C	stomach cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a Capmatinib (INC280)-resistant gastric cancer cell line (PMID: 15494073) harboring MET Y1230C also demonstrated resistance when treated with Xalkori (crizotinib) (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230C	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a transformed cell line expressing MET Y1230C was sensitive to Glesatinib (MGCD265), demonstrating inhibition of cell growth in culture and 88% tumor regression in xenograft models (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230C	stomach cancer	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Capmatinib (INC280) in culture for several months developed resistance and was found to harbor MET Y1230C (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230C	stomach cancer	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) harboring MET Y1230C was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230C	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET Y1230C in culture (PMID: 23275061).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET negative	triple-receptor negative breast cancer	no benefit	Cabozantinib	Preclinical	Actionable	In a preclinical study, Cometriq (cabozantinib) treatment had no effect on the cellular outgrowth or tumor volume of a TNBC cell line negative for MET expression in culture (PMID: 26432786).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	Advanced Solid Tumor	sensitive	Emibetuzumab	Preclinical	Actionable	In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with constitutive MET activation in culture, and inhibited tumor growth in xenograft models (PMID: 25231402).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical	Actionable	In a preclinical study, cells harboring MET activating mutations demonstrated sensitivity to treatment with Glesatinib (MGCD265) in cell-based assays (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3609).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	sarcoma	sensitive	BMS-777607	Preclinical	Actionable	In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in blocking Met phosphorylation and inhibiting cell proliferation and metastasis in cultured cells and murine models with activating Met mutations (PMID: 22286523).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	malignant glioma	sensitive	Merestinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of glioma with autocrine activation of Met signaling (PMID: 23275061).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	non-small cell lung carcinoma	predicted - sensitive	Crizotinib	Phase I	Actionable	In a Phase I clinical trial, Xalkori (crizotinib) was generally well-tolerated and demonstrated preliminary efficacy in patients with non-small cell lung cancer harboring MET exon 14 alterations, with anti-tumor activity demonstrated in 10/15 evaluable patients (J Clin Oncol 34, 2016 (suppl; abstr 108)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	Advanced Solid Tumor	sensitive	Altiratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited MET activity, including MET activating mutations, and inhibited proliferation of MET-driven tumor cell lines in culture (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	stomach carcinoma	sensitive	S-49076	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring MET activating mutations in culture and in cell line xenograft models (PMID: 23804704).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	hepatocellular carcinoma	sensitive	Tepotinib	Preclinical	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited tumor growth in hepatocellular cancer (HCC) mouse xenograft models with MET overexpression or activation (Cancer Res April 15, 2013; 73(8 Supplement): 925)
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET act mut	papillary renal cell carcinoma	predicted - sensitive	Savolitinib	Phase II	Actionable	In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET kinase domain mutations, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - sensitive	Afatinib + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in MET, leading to increased Met phosphorylation, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Xalkori (crizotinib) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - sensitive	Osimertinib + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Tagrisso (osimertinib) and Saracatinib (AZD0530) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Tagrisso (osimertinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Gilotrif (afatinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased expression and phosphorylation of Met, were associated with resistance to Tarceva (erlotinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228H	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228H in an in vitro kinase assay (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228H	papillary renal cell carcinoma	predicted - sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, a patient with papillary renal cell carcinoma harboring MET D1228H demonstrated a partial response with a duration of 21.8 months when treated with Xalkori (crizotinib) (PMID: 29149761; NCT01524926).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230H	Advanced Solid Tumor	predicted - sensitive	BMS-777607	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to Y1230H in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230H	Advanced Solid Tumor	predicted - resistant	Capmatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230H	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230H in an in vitro kinase assay (PMID: 26285778).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230H	Advanced Solid Tumor	predicted - resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230H	Advanced Solid Tumor	predicted - sensitive	Cabozantinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1230H	Advanced Solid Tumor	predicted - resistant	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Xalkori (crizotinib), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in cell line xenograft mouse models (PMID: 28396313).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET F1200L MET Y1230H	stomach cancer	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET F1200L MET Y1230H	stomach cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Xalkori (crizotinib) in culture for several months developed resistance and was found to co-harbor MET Y1230H and MET F1200L(PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET F1200L MET Y1230H	stomach cancer	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L demonstrated resistance when treated with Capmatinib (INC280) in culture (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	glioblastoma multiforme	predicted - sensitive	Altiratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	triple-receptor negative breast cancer	sensitive	Cabozantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cometriq (cabozantinib) inhibited Met activity, cell growth, and invasive cellular characteristics in a human MET positive TNBC cell line in culture, and reduced tumor volume in xenograft models (PMID: 26432786).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	Advanced Solid Tumor	sensitive	ARGX-111	Phase I	Actionable	In a Phase I trial, ARGX-111 demonstrated safety and resulted in some efficacy in patients with advanced solid tumors expressing MET, including a decrease in circulating tumor cells positive for MET (Journal of Clinical Oncology 33, no. 15_suppl, May 2015, 2580-2580).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	clear cell sarcoma	predicted - sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial (CREATE), Xalkori (crizotinib) treatment in MET-positive clear cell sarcoma patients resulted in an objective response rate of 3.8% (1/26) and a median progression-free survival of 131 days, similar to results achieved with first-line Adriamycin (doxorubicin) in non-selected metastatic soft tissue sarcomas (PMID: 28950372; NCT01524926).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	multiple myeloma	predicted - sensitive	Ficlatuzumab	Phase I	Actionable	In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	myeloid neoplasm	predicted - sensitive	Amuvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Amuvatinib (MP470) demonstrated efficacy in reducing Met phosphorylation and inducing apoptosis in cultured myeloma cells (PMID: 24326130).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	cholangiocarcinoma	predicted - sensitive	Cabozantinib	Phase II	Emerging	In a Phase II trial, higher baseline soluble Met level correlated with longer overall survival in cholangiocarcinoma patients treated with Cometriq (cabozantinib) (PMID: 28192597).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	Advanced Solid Tumor	predicted - sensitive	Merestinib	Preclinical - Pdx	Actionable	In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition correlating with Met expression level in a panel of patient-derived xenograft models of solid tumors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	non-small cell lung carcinoma	conflicting	Onartuzumab + Erlotinib	Phase III	Actionable	In a Phase II clinical trial, Onartuzumab (RO5490258), in combination with Tarceva (erlotinib) demonstrated efficacy in patients with Met-positive NSCLC (PMID: 24101053). However, a subsequent Phase III clinical trial has been unable to confirm this efficacy (J Clin Oncol 32:5s, 2014 (suppl; abstr 8000)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	Advanced Solid Tumor	sensitive	INCB028060	Phase I	Actionable	In a Phase I trial, INCB028060 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, as indicated by decreased whole blood Met phosphorylation level (J Clin Oncol 29: 2011 (suppl; abstr 3091)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	non-small cell lung carcinoma	sensitive	Emibetuzumab + Erlotinib	Phase I	Actionable	In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 14.3% (2/14) of patients with non-small cell lung carcinoma, with both responders being Met positive (PMID: 27803065).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	non-small cell lung carcinoma	sensitive	Emibetuzumab + Erlotinib	Phase I	Actionable	In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 15% (2/13) of Met-positive patients with non-small cell lung carcinoma (J Clin Oncol 31, 2013 (suppl; abstr 8093)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	non-small cell lung carcinoma	sensitive	Telisotuzumab vedotin	Phase I	Actionable	In a Phase I clinical trial, ABBV-399 was well-tolerated and demonstrated preliminary efficacy in patients with MET-positive non-small cell lung cancer, with 30% (3/10) of patients demonstrating a partial response (J Clin Oncol 34, 2016 (suppl; abstr 2510)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	glioblastoma multiforme	sensitive	Ningetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ningetinib inhibited Met phosphorylation in tumor tissue, resulted in prolonged median survival time and significantly increased life-span in cell line xenograft models of glioblastoma (Cancer Res 2014;74(19 Suppl):Abstract nr 1755).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	ovarian cancer	predicted - sensitive	Altiratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited MET activation, decreased viability and migration of c-MET positive ovarian cancer cells in culture, and reduced tumor growth in ovarian cancer cell line xenograft models (PMID: 24362531).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	Advanced Solid Tumor	no benefit	AMG208	Phase I	Actionable	In a Phase I trial, Met expression and mutation status were not associated with response to AMG208 treatment in patients with advanced solid tumor (PMID: 26155941; NCT00813384).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	Advanced Solid Tumor	sensitive	Emibetuzumab	Phase I	Actionable	In a Phase I trial, Emibetuzumab (LY2875358) treatment resulted in durable partial response in 4% (1/23) of Met-positive patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 8093)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	non-small cell lung carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 19% (5/26) of MET-positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET positive	glioblastoma multiforme	sensitive	Altiratinib + Bevacizumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Altiratinib (DCC-2701) and Avastin (bevacizumab) inhibited tumor growth and invasiveness, decreased blood vessel formation, and prolonged survival in cell line xenograft models of MET-expressing glioblastoma (PMID: 26965451).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET pos	lung cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to AZD4547 in culture (PMID: 27429073).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	FGFR1 amp MET pos	lung cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to Rogaratinib (BAY 1163877)  in culture (PMID: 27429073).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Onartuzumab + mFOLFOX6	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 neg MET pos	gastroesophageal junction adenocarcinoma	no benefit	AMG102	Phase III	Actionable	In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 neg MET pos	gastroesophageal junction adenocarcinoma	no benefit	Onartuzumab	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 neg MET pos	esophagus adenocarcinoma	no benefit	Onartuzumab + mFOLFOX6	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	AMG102	Phase III	Actionable	In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Onartuzumab	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	KIT S476I MET R988C	gastrointestinal stromal tumor	sensitive	Bevacizumab + Sorafenib	Clinical Study	Actionable	In a clinical case study, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET R988C	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MET R998C demonstrated sensitivity to Xalkori (crizotinib) in culture (PMID: 17483355).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET M1149T	papillary renal cell carcinoma	predicted - sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, a patient with papillary renal cell carcinoma harboring MET M1149T demonstrated stable disease when treated with Xalkori (crizotinib) (PMID: 29149761; NCT01524926).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET Y1248H	cancer	resistant	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET Y1248H showed resistance to SU11274 treatment (PMID: 15064724).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET V1238I	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET V1238I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET H1112L	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET H1112L demonstrated sensitivity to SU11274 treatment (PMID: 19783361).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14 TP53 R175H	histiocytic and dendritic cell cancer	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET del exon14 and TP53 R175H (PMID: 25971938).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	Advanced Solid Tumor	sensitive	SYM015	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sym015 inhibited growth of cancer cell lines harboring MET exon 14 deletion in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models with MET exon 14 deletion (Cancer Res July 15 2016 (76) (14 Supplement) 1219).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	lung cancer	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in lung cancer cells harboring MET exon 14 deletion and loss of the wild-type MET allele in culture (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Xalkori (crizotinib) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	lung squamous cell carcinoma	sensitive	Capmatinib	Clinical Study	Actionable	In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring MET del exon14 (PMID: 25971938).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	stomach cancer	sensitive	SYM015	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in cell line xenograft models of gastric cancer harboring MET exon 14 skipping (PMID: 28679766).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	lung cancer	sensitive	SYM015	Preclinical - Pdx	Actionable	In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping (PMID: 28679766).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Capmatinib (INC280) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	lung adenocarcinoma	sensitive	Glesatinib	Clinical Study	Actionable	In a clinical study, a patient with lung adenocarcinoma harboring MET del exon14 demonstrated a 66% reduction in target lesion size and maintained a partial response for 7 months when treated with Glesatinib (MGCD265) (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	non-small cell lung carcinoma	sensitive	KTN0073-IgG1	Preclinical - Cell culture	Actionable	In a preclinical study, KTN0073-IgG1 inhibited growth of a non-small cell lung cancer cell line harboring deletion of MET exon 14 in culture (PMID: 27550450).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	lung adenocarcinoma	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, three patients with lung adenocarcinoma harboring MET del exon14 demonstrated partial responses when treated with Xalkori (crizotinib) (PMID: 25971939).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	non-small cell lung carcinoma	sensitive	Onartuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Onartuzumab inhibited tumor growth and decreased MET expression in a non-small cell lung cancer xenograft model harboring MET exon 14 deletion (PMID: 23882082).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	stomach cancer	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in gastric cancer cells harboring MET exon 14 deletion and amplification of the mutant allele in culture, and resulted in tumor regression in cell line xenograft models (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Glesatinib (MGCD265) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	stomach cancer	decreased response	Emibetuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	lung cancer	decreased response	Emibetuzumab	Preclinical - Pdx	Actionable	In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14	lung adenocarcinoma	sensitive	Cabozantinib	Clinical Study	Actionable	In a clinical study, a patient with lung adenocarcinoma harboring MET del exon14 demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H	melanoma	sensitive	Imatinib + Carboplatin + Paclitaxel	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET del exon14 TP53 N30fs*14	lung large cell carcinoma	sensitive	Capmatinib	Clinical Study	Actionable	In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET del exon14 and TP53 N30fs*14 (PMID: 25971938).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET exon 14	non-small cell lung carcinoma	predicted - sensitive	Tepotinib	Phase II	Actionable	In a Phase II trial, Tepotinib (MSC2156119J) treatment resulted in partial response in 60.0% (9/15) and stable disease in 20% (3/15) of patients with non-small cell lung cancer harboring MET exon 14 skipping mutations (J Clin Oncol 36, 2018 (suppl; abstr 9016); NCT02864992).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET exon 14	non-small cell lung carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 100% (2/2) of non-small cell lung carcinoma patients harboring MET exon 14 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9067)).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET exon 14	non-small cell lung carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines for non-small cell lung cancer patients with MET exon 14 mutations (NCCN.org).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228V	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Merestinib (LY2801653) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228V	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Capmatinib (INC280) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228V	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Glesatinib (MGCD265) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228V	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Xalkori (crizotinib) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228V	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Savolitinib (AZD6094) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).
MET	AUTS9 | c-Met | DFNB97 | HGFR | RCCP2	7q31.2	NM_000245	MET D1228V	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Cometriq (Cabometyx, cabozantinib) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).
MLH1	COCA2 | FCC2 | hMLH1 | HNPCC | HNPCC2	3p22.2	NM_000249	MLH1 mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MLH1 result in Lynch syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).
MLH1	COCA2 | FCC2 | hMLH1 | HNPCC | HNPCC2	3p22.2	NM_000249	MLH1 mutant	stomach cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MLH1 result in Lynch syndrome, which is associated with increased risk of early onset of gastric cancer (NCCN.org).
MLH1	COCA2 | FCC2 | hMLH1 | HNPCC | HNPCC2	3p22.2	NM_000249	MLH1 mutant	endometrial cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MLH1 result in Lynch syndrome, which is associated with increased risk of developing endometrial cancer (NCCN.org).
MLH1	COCA2 | FCC2 | hMLH1 | HNPCC | HNPCC2	3p22.2	NM_000249	MLH1 inact mut	colorectal cancer	not applicable	N/A	Preclinical	Emerging	In a preclinical study, MLH1 inactivation through hypermethylation was associated with high microsatellite instability (MSI-H) colorectal carcinoma by whole genome sequencing of tumor samples (PMID: 22810696), suggesting it may be a potential biomarker.
MLH1	COCA2 | FCC2 | hMLH1 | HNPCC | HNPCC2	3p22.2	NM_000249	MLH1 loss	colon cancer	sensitive	KU60648	Preclinical - Cell culture	Actionable	In a preclinical study, MLH1 deficient colon cancer cell lines were sensitive to KU60648 in culture, demonstrating decreased cell viability and reduced colony formation (PMID: 28224663).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515K	myelofibrosis	not applicable	N/A	Guideline	Prognostic	MPL W515K is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515K	myelofibrosis	sensitive	Everolimus	Phase II	Actionable	In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	CALR wild-type JAK2 wild-type MPL wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of concurrent wild-type JAK2, MPL, and CALR in myelofibrosis patients is associated with inferior leukemia-free survival compared to patients with JAK2 and/or CALR mutations, and is associated with inferior overall survival when compared to patients with CALR mutations (NCCN.org).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	myelofibrosis	sensitive	CHZ868	Preclinical	Actionable	In a preclinical study, CHZ868 demonstrated efficacy in a mouse model of MPL W515L induced myelofibrosis (PMID: 26175413).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	myelofibrosis	not applicable	N/A	Guideline	Prognostic	MPL W515L is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	myelofibrosis	sensitive	Everolimus	Phase II	Actionable	In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	myeloproliferative neoplasm	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited colony growth in myeloproliferative neoplasm patient-derived hematopoetic progenitor cells harboring MPL W515L in culture (PMID: 22015772).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	hematologic cancer	sensitive	NS-108	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing MPL W515L were sensitive to treatment with NS-108, demonstrating inhibition of cell growth in culture (PMID: 22829185).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	hematologic cancer	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited proliferation of transformed cells expressing MPL W515L in culture (PMID: 22015772).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	hematologic cancer	sensitive	CHZ868	Preclinical	Actionable	In a preclinical study, CHZ868 inhibited proliferation of bone marrow cell lines expressing MPL W515L in culture, including cells with decreased response to Type I JAK inhibitors due to chronic exposure (PMID: 26175413).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	myelofibrosis	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 treatment reduced disease burden in MPL W515L transduced mouse models of myelofibrosis (PMID: 23748344).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	MPL W515L	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).
MPL	C-MPL | CD110 | MPLV | THCYT2 | TPOR	1p34.2	NM_005373	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).
MSH6	GTBP | GTMBP | HNPCC5 | HSAP | p160	2p16.3	NM_000179	MSH6 mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MSH6 result in Lynch syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).
MSH6	GTBP | GTMBP | HNPCC5 | HSAP | p160	2p16.3	NM_000179	MSH6 mutant	colorectal cancer	not applicable	N/A	Clinical Study	Diagnostic	Germline mutations in MSH6 are associated with microsatellite instability in colorectal cancer (CRC), and are diagnostic for Lynch syndrome (hereditary nonpolyposis colorectal cancer) in colorectal cancer patients (PMID: 26582061; PMID: 19125127).
MSH6	GTBP | GTMBP | HNPCC5 | HSAP | p160	2p16.3	NM_000179	MSH6 mutant	endometrial cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MSH6 result in Lynch syndrome, which is associated with increased risk of developing endometrial cancer (NCCN.org).
MSH6	GTBP | GTMBP | HNPCC5 | HSAP | p160	2p16.3	NM_000179	MSH6 T1219I	glioblastoma multiforme	resistant	Temozolomide	Preclinical	Actionable	In a preclinical study, glioblastoma cells harboring a MSH6 T1219I mutation were resistant to Temodar (temozolomide) in cell culture (PMID: 19584161).
MSH6	GTBP | GTMBP | HNPCC5 | HSAP | p160	2p16.3	NM_000179	MSH6 loss	colon cancer	no benefit	KU60648	Preclinical - Cell culture	Actionable	In a preclinical study, MSH6 deficient colon cancer cells did not respond to treatment with KU60648 in culture (PMID: 28224663).
MSH6	GTBP | GTMBP | HNPCC5 | HSAP | p160	2p16.3	NM_000179	MSH6 loss	colon carcinoma	not applicable	N/A	Preclinical	Emerging	Preclinical shRNA mediated-inhibition of PTEN-induced putative kinase 1 (PINK1) in colon carcinoma cells with MSH6 loss resulted in synthetic lethality, suggesting PINK1 may be a promising therapeutic target for MSH6 deficient cancer cells (PMID: 21242281).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 mutant	lymphoplasmacytic lymphoma	not applicable	N/A	Clinical Study	Diagnostic	MYD88 mutations are used in the diagnosis of lymphoplasmacytic lymphoma (Guidelines, PMID: 22944768).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 mutant	Waldenstroem's macroglobulinemia	not applicable	N/A	Guideline	Diagnostic	MYD88 mutations are used to differentiate Waldenstroem's macroglobulinemia from marginal zone B-cell lymphoma in the presence of plasmacytic differentiation (NCCN.org).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 mutant	marginal zone B-cell lymphoma	not applicable	N/A	Guideline	Diagnostic	MYD88 mutations are used to differentiate Waldenstroem's macroglobulinemia from marginal zone B-cell lymphoma in the presence of plasmacytic differentiation (NCCN.org).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 act mut	diffuse large B-cell lymphoma	predicted - sensitive	eFT508	Preclinical - Cell line xenograft	Actionable	In a preclinical study, eFT508 demonstrated anti-tumor activity in two diffuse large B-cell lymphoma cell line xenograft models, both harboring MYD88 activating mutations (Blood Dec 2015, 126 (23) 1554).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 L265P	Waldenstroem's macroglobulinemia	not applicable	N/A	Guideline	Diagnostic	MYD88 L265P is diagnostic and aids distinguishing Waldenstroem's macroglobulinemia from non-IgM lymphoplasmacytic lymphoma, B-cell lymphomas, and plasma cell myeloma (NCCN.org).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 L265P	diffuse large B-cell lymphoma	resistant	Ibrutinib	Phase II	Actionable	In a Phase II trial, all of diffuse large B-cell lymphoma patients harboring MYD88 L265P (n=4) did not respond to Imbruvica (ibrutinib) treatment (Blood 2012, 120 (21): 686).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 L265P	diffuse large B-cell lymphoma	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, MYD88 L265P was associated with a worse overall survival in patients with diffuse large B-cell lymphoma when compared to MYD88 wild-type (PMID: 24903481, PMID: 25055137, PMID: 26792260).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 L265P	non-Hodgkin lymphoma	no benefit	Ibrutinib	Preclinical - Pdx	Actionable	In a preclinical study, a non-Hodgkin lymphoma (NHL) patient derived xenograft (PDX) model harboring both CD79B Y197N and MYD88 L265P demonstrated sensitivity to Ibruvica (ibrutinib) while an NHL patient derived xenograft (PDX) model harboring only MYD88 L265P did not respond to Ibruvica (ibrutinib) (ASH 57th Annual Meeting, 2015, abstract #2759).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 L265P	B-cell lymphoma	sensitive	IMO-8400	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with IMO-8400 resulted in decreased survival of B-cell lymphoma cell lines harboring MYD88 L265P in culture, and decreased tumor growth in a MYD88 L265P-positive B-cell lymphoma cell line xenograft models (Cancer Res October 1, 2014 74:2570).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 L265P	diffuse large B-cell lymphoma	sensitive	Vorinostat	Preclinical - Cell culture	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 L265P	central nervous system lymphoma	sensitive	Ibrutinib	Phase I	Actionable	In a Phase I trial, two patients with primary central nervous system lymphoma each harboring MYD88 L265P demonstrated a complete response when treated with Imbruvica (ibrutinib) (PMID: 28619981).
MYD88	MYD88D	3p22.2	NM_002468	MYD88 wild-type	diffuse large B-cell lymphoma	predicted - sensitive	ST2825	Preclinical	Actionable	In a preclinical study, STS2825 demonstrated effective inhibition of MYD88 homodimerization and signalling in cultured cells and is currently being evaluated in preclinical studies of B cell lymphoma  (Blood Lymph Canc 2013; 3: 53-61).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type	triple-receptor negative breast cancer	decreased response	MRK-003	Preclinical	Actionable	In a preclinical study, triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 demonstrated reduced sensitivity to MRK-003 induced tumor growth inhibition (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type	triple-receptor negative breast cancer	no benefit	MRK-003 + Paclitaxel	Preclinical	Actionable	In a preclinical study, the combination of MRK-003 and Taxol (paclitaxel) did not potentiate the anti-tumor effects compared to single agent therapy in triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Mercaptopurine	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	conflicting	Ribociclib + Dexamethasone	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + JQ1	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Prednisolone	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Methotrexate	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Bortezomib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Everolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Asparaginase	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 wild-type RB1 loss	T-cell adult acute lymphocytic leukemia	resistant	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 V1676I	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1676I in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 rearrange	triple-receptor negative breast cancer	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited growth of triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture and reduced tumor growth in xenograft models (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 rearrange	triple-receptor negative breast cancer	no benefit	MRK-003 + SCH772984	Preclinical	Actionable	In a preclinical study, SCH772984 did not potentiate the growth inhibition effect of MRK-003 in triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 rearrange	triple-receptor negative breast cancer	sensitive	MRK-003 + Paclitaxel	Preclinical	Actionable	In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH1 rearrangement, resulting in tumor regression (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	EML4-ALK NOTCH1 D1533A	non-small cell lung carcinoma	predicted - resistant	Ceritinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated resistance to treatment with Zykadia (ceritinib), and was subsequently found to have acquired NOTCH1 D1533A (PMID: 29636358).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mutant	triple-receptor negative breast cancer	sensitive	PF-03084014	Preclinical - Pdx	Actionable	In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient-derived xenograft models of triple receptor negative breast cancer harboring NOTCH1 mutations (PMID: 25564152).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Methotrexate	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Bortezomib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Dexamethasone	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + JQ1	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Mercaptopurine	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Prednisolone	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Asparaginase	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 C478F	head and neck squamous cell carcinoma	sensitive	LGK974	Preclinical	Actionable	In a preclinical study, LGK974 inhibited growth of head and neck squamous cell carcinoma cells harboring NOTCH1 C478F in culture and xenograft models (PMID: 24277854).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 A1570G	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1570G in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 act mut	acute lymphocytic leukemia	sensitive	Brontictuzumab	Preclinical - Pdx	Actionable	In a preclinical study, xenograft models of patient-derived acute lymphocytic leukemia cells harboring NOTCH1 activating muatations demonstrated better response to Brontictuzumab (OMP-52M51) compared to NOTCH1 wild-type models (PMID: 23774673).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 act mut	T-cell adult acute lymphocytic leukemia	predicted - sensitive	Ribociclib + Dexamethasone	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) resulted in reduced leukemia burden and a greater survival benefit in a NOTCH1 activated T-cell acute lymphoblastic leukemia patient derived xenograft (PDX) model when compared to control or either agent alone (PMID: 28151717).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 act mut	colorectal cancer	sensitive	PF-03084014	Preclinical - Cell culture	Actionable	In a preclinical study, the gamma secretase inhibitor PF-03084014 reduced Notch1 cleavage, decreased activation of Notch targets, and increased apoptosis in colorectal cancer cell lines exhibiting increased Notch activation (PMID: 23868008).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 act mut	breast cancer	sensitive	Brontictuzumab	Preclinical - Pdx	Actionable	In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth and reduced cancer stem cells in xenograft models of tumor derived from a breast cancer patient harboring activating NOTCH1 mutations (Cancer Res 2013;73(8 Suppl):Abstract nr 3728).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 A1552G	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552G in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 A1707T	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1707T in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 A1707T	Advanced Solid Tumor	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, transformed cells expressing NOTCH1 A1707T demonstrated sensitivity to MRK-003 in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 V1575A	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1575A in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 R1683W	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 R1683W in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 positive	ovarian cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of ovarian cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 positive	glioblastoma multiforme	sensitive	Radiotherapy + RO4929097 + Temozolomide	Phase I	Actionable	In a Phase I trial, addition of RO4929097 to Temodar (temozolomide) and radiation therapy inhibited Notch signaling and cell proliferation in patient tumor samples, resulted in a median overall survival of 21 months and a median progression free survival of 13 months in glioblastoma patients (PMID: 27154916).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 positive	lung cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of lung cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 positive	breast cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of breast cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 positive	stomach cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of gastric cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 positive	colon cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of colon cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 positive	glioblastoma multiforme	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of glioblastoma (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 positive	prostate cancer	predicted - sensitive	PF-03084014 + Docetaxel	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-03084014 and Taxotere (docetaxel) in combination inhibited growth of Notch1-expressing Taxotere (docetaxel)-resistant prostate cancer cell lines in culture, and inhibited both soft tissue and bony tumor growth in Taxotere (docetaxel)-resistant prostate cancer cell line xenograft models, with increased efficacy over either agent alone (PMID: 26202948).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 V1599M	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1599M in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	EML4-ALK NOTCH1 D1538A	non-small cell lung carcinoma	predicted - resistant	Brigatinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated resistance to treatment with Alunbrig (brigatinib), and was subsequently found to have acquired NOTCH1 D1538A (PMID: 29636358).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 A1552V	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552V in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 E1567K	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 E1567K in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 S2449fs	triple-receptor negative breast cancer	sensitive	PF-03084014	Preclinical - Pdx	Actionable	In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient derived xenograft animal models of triple receptor negative breast cancer harboring NOTCH1 S2449fs (PMID: 25564152).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 I1680S	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 I1680S in culture (PMID: 25104330).
NOTCH1	AOS5 | AOVD1 | hN1 | TAN1	9q34.3	NM_017617	NOTCH1 over exp	Advanced Solid Tumor	sensitive	Brontictuzumab	Phase I	Actionable	In a Phase I trial, Brontictuzumab (OMP-52M51) treatment resulted in stable disease in 43% (3/7) of advanced solid tumor patients with elevated levels of Notch1 intracellular domain (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C42).
NPM1	B23 | NPM	5q35.1	NM_002520	DNMT3A mut FLT3 mut NPM1 mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Emerging	In a retrospective analysis, the combination of DNMT3A, FLT3, and NPM1 mutations in patients with acute myeloid leukemia was highly associated with decreased event-free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 mutant	acute myeloid leukemia	predicted - sensitive	MI-503	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line and primary AML samples harboring NPM1 mutations in culture, and reduced tumor burden and improved survival in an NPM1-mutant AML cell line xenograft model (PMID: 27535106).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in NPM1, in the absence of a FLT3 ITD mutation, were associated with favorable prognosis in acute myeloid leukemia patients with normal karyotype (PMID: 26239249, PMID: 26586702, PMID: 26676635, PMID: 16109776).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, an NPM1 mutation without FLT3 internal tandem duplication (ITD) mutation was associated with favorable prognosis in acute myeloid leukemia (AML) patients, compared to AML patients harboring an NPM1 mutation and FLT3 ITD mutation (PMID: 19047294, PMID: 24573385, PMID: 25713434).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 mutant	acute myeloid leukemia	sensitive	NSC348884	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a NPM1 mutation were sensitive to NSC348884 as demonstrated by induced apoptosis (PMID: 21719597).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 mutant	leukemia	predicted - sensitive	EPZ004777	Preclinical	Actionable	In  preclinical study, treatment with EPZ004777 resulted in reduced proliferation and increased differentiation of murine leukemia cells expressing an NPM1 mutation, and improved survival in NPM1-mutant murine leukemia models (PMID: 27535106).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 mutant	acute myeloid leukemia	predicted - sensitive	EPZ004777	Preclinical - Patient cell culture	Actionable	In a preclinical study, EPZ004777 decreased HOX gene expression, and reduced proliferation and increased differentiation of a human acute myeloid leukemia (AML) cell line and primary AML samples harboring NPM1 mutations in culture (PMID: 27535106).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 mutant	acute myeloid leukemia	sensitive	ENMD-2076	Phase I	Actionable	In a Phase I trial, three acute myeloid leukemia patient harboring an NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088).
NPM1	B23 | NPM	5q35.1	NM_002520	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	sensitive	ENMD-2076	Phase I	Actionable	In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088).
NPM1	B23 | NPM	5q35.1	NM_002520	FLT3 exon 14 ins NPM1 mutant	leukemia	predicted - sensitive	MI-503	Preclinical	Actionable	In a preclinical study, MI-503 inhibited growth of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).
NPM1	B23 | NPM	5q35.1	NM_002520	FLT3 exon 14 ins NPM1 mutant	leukemia	predicted - sensitive	EPZ004777	Preclinical	Actionable	In a preclinical study, EPZ004777 inhibited growth and induced differentiation of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 exon12	acute myeloid leukemia	predicted - sensitive	Ixazomib	Clinical Study	Actionable	In a clinical study, Ixazomib (MLN9708) treatment resulted in significantly reduced peripheral blast cells in a NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia (AML) patient, and demonstrated selective toxicity towards NPMc+ AML cell lines in culture (PMID: 26634271).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 exon12	acute myeloid leukemia	sensitive	Ixazomib + Vorinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Ixazomib (MLN9708) and Zolinza (vorinostat) synergistically induced apoptosis in NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia cells in culture (PMID: 26634271).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1 exon12	acute myeloid leukemia	sensitive	Deguelin	Preclinical	Actionable	In preclinical studies, deguelin treatment of an AML cell line harboring NPM1 exon12 mutation resulted in reduced levels of mutant Npm1 protein and induced differentiation of the cells (PMID: 25242579, PMID: 25348016).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK amp	anaplastic large cell lymphoma	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK demonstrated a decreased response compared to parental cell lines harboring NPM1-ALK when treated with Alecensa (alectinib) in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171T	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, an anaplastic large-cell lymphoma cell line expressing ALK I1171T in the context of NPM1-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171T	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1128S	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1128S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171N	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK N1178H	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK N1178H	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK N1178H	Advanced Solid Tumor	decreased response	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK N1178H	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK S1206C	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK S1206C	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK S1206C	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	anaplastic large cell lymphoma	sensitive	CEP-28122	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, CEP-28122 inhibited Alk activation, resulting in growth inhibition in culture, and tumor regression in both cell line and patient-derived xenograft models of NPM1-ALK positive anaplastic large cell lymphoma (PMID: 22203728).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited proliferation of transformed cells expressing NPM1-ALK in culture (PMID: 20207848).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited cell growth, Alk phosphorylation, downstream signaling and induced apoptosis in human anaplastic large cell lymphoma cell lines harboring a NPM1-ALK fusion in culture and in xenograft models (PMID: 18089725).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Crizotinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 83% (5/6, all complete responses), at the 165 mg dose, and 90% (18/20, with complete response in 80% (16/20), at the recommended phase 2 dose of 280 mg, in patients with anaplastic large cell lymphoma harboring an ALK fusion, with 72% of tested patients harboring NPM1-ALK (PMID: 28787259; NCT00939770).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Entrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, anaplastic large cell lymphoma cells harboring NPM1-ALK were sensitive to Entrectinib (RXDX-101) in culture and in cell line xenograft models, resulting in inhibition of NPM1-ALK autophosphorylation and near complete tumor regression (PMID: 26939704).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	anaplastic large cell lymphoma	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited Alk phosphorylation and growth in anaplastic large cell lymphoma cell lines harboring NPM1-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174I	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174I	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156Y	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK E1210K	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with  ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK T1151M	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171S	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK I1171S	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1122V ALK L1196M	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196Q	anaplastic large cell lymphoma	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK L1196Q	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F ALK D1203N	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK P1139S in the context of NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK P1139S	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1269A	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK R1192P	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK R1192P	Advanced Solid Tumor	decreased response	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture compared to cells expressing wild-type NPM1-ALK (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V	Advanced Solid Tumor	predicted - sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V, but to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK C1156F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174L	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V ALK L1198F	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).
NPM1	B23 | NPM	5q35.1	NM_002520	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 2	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 2 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 2	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 2	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 2 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 2	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	AKT1 E17K NRAS Q61R	bladder carcinoma	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	ATM mut NRAS Q61R	melanoma	sensitive	Binimetinib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61R	thyroid cancer	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring NRAS Q61R (PMID: 21289267).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61R	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	KIT D816V NRAS Q61R	melanoma	no benefit	Pembrolizumab + Trametinib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	NRAS Q61X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G13X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	NRAS G13X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	FGFR1 amp NRAS over exp	non-small cell lung carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of Nras in FGFR1-amplified non-small cell lung carcinoma cells resulted in decreased response to BGJ398 in culture (PMID: 28630215).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	FGFR1 amp NRAS over exp	non-small cell lung carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in FGFR1-amplified non-small cell lung carcinoma cells overexpressing Nras in culture (PMID: 28630215).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G13V	adult T-cell leukemia	sensitive	3144	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13V in culture, and reduced tumor burden in xenograft models (PMID: 28235199).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K NRAS A146T	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	no benefit	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS wild-type	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type NRAS (PMID: 23039341).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS wild-type	colorectal cancer	predicted - sensitive	Panitumumab	Phase III	Actionable	In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS wild-type	melanoma	sensitive	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS wild-type	melanoma	decreased response	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, an NRAS wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS wild-type	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, an NRAS wild-type melanoma cell line demonstrated inhibition of cell growth when treated with Mekinist (trametinib) in culture (PMID: 27488531).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFIRI	Phase III	Actionable	In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF mut NRAS wild-type	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFOX	Phase II	Actionable	In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type NRAS wild-type	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type NRAS wild-type	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type NRAS wild-type	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type NRAS wild-type	melanoma	resistant	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type NRAS wild-type	melanoma	sensitive	Binimetinib + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type NRAS wild-type	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type KRAS wild-type NRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFIRI	Phase II	Actionable	In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by Erbitux (cetuximab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 33.2 mo and response rate of 68% (40/59), however, resulted in a 10-mo PFS rate of 50.8% (30/59), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type KRAS wild-type NRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFIRI + Bevacizumab	Phase II	Actionable	In a Phase II trial (MACBETH), first-line treatment with the combination of Erbitux (cetuximab) and FOLFIRI, followed by  Avastin (bevacizumab) maintenance, demonstrated activity in BRAF/KRAS/NRAS wild-type metastatic colorectal cancer patients, resulting in a median overall survival in the intent-to-treat population of 32.2 mo and response rate of 75% (43/57), however, resulted in a 10-mo PFS rate of 40.4% (23/57), which did not meet the primary endpoint of 70% (PMID: 29450468; NCT02295930).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 4	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 4 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 4	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 4 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 4	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 4	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF G596V NRAS G13R	colorectal cancer	sensitive	Cetuximab + LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 3	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 3	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 3 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 3	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 3 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS exon 3	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G13D	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring NRAS G13D were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G13D	adult T-cell leukemia	sensitive	3144	Preclinical - Cell culture	Actionable	In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13D in culture (PMID: 28235199).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G13D	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS G13D in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G13D	melanoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring NRAS G13D in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS G12V	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS G12V	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G12V	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring NRAS G12V in culture (PMID: 28179366).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G12V	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring NRAS G12V demonstrated resistance to Erbitux (cetuximab) in culture (PMID: 28179366).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS G12V	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G12X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	NRAS G12X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	AKT1 E17K NRAS G12D	prostate cancer	sensitive	BAY1125976	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G12D	acute myeloid leukemia	sensitive	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) inhibited growth of acute myeloid leukemia cells that have been demonstrated to harbor NRAS G12D in culture and decreased disease burden in xenograft models with NRAS G12D (PMID: 24569456, PMID: 11238126).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G12D	acute myeloid leukemia	sensitive	BYL719 + MEK162	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Alpelisib (BYL719) inhibited proliferation in a human acute myeloid leukemia (AML) cell line harboring NRAS G12D in culture, and decreased disease burden in xenograft models (PMID: 24569456).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS G12D	Advanced Solid Tumor	sensitive	N-Arachidonoyl Dopamine	Preclinical - Cell culture	Actionable	In a preclinical study, N-Arachidonoyl Dopamine (NADA) disrupted NRAS protein membrane localization and decreased NRAS downstream signaling, and inhibited proliferation and induced cell death in transformed cells expressing NRAS G12D in culture (PMID: 27760835).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF D594G NRAS G12D	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF D594G NRAS G12D	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF D594G NRAS G12D	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF D594G NRAS G12D	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF D594G NRAS G12D	melanoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	sensitive	Dinaciclib	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	predicted - sensitive	AZD0156	Preclinical	Actionable	In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	predicted - sensitive	AZ20	Preclinical	Actionable	In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS G12R	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS G12R	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF amp BRAF V600X NRAS Q61K	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	conflicting	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	non-small cell lung carcinoma	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human non-small cell lung cancer cells harboring NRAS Q61K had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 12068308).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring NRAS Q61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	non-small cell lung carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61K in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	melanoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cell lines harboring NRAS Q61K in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	melanoma	predicted - sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, RAF709 inhibited Erk signaling in melanoma cells harboring NRAS Q61K in culture (PMID: 29343524).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	non-small cell lung carcinoma	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	non-small cell lung carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	non-small cell lung carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K	lung cancer	sensitive	RAF709	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RAF709 inhibited Erk signaling and proliferation of lung cancer cells harboring NRAS Q61K in culture, and resulted in tumor regression in cell line xenograft models (PMID: 29343524).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF L597V NRAS Q61K	non-small cell lung carcinoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR L858R EGFR T790M NRAS Q61K	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600K NRAS Q61K	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600K NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600K NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600K NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600K NRAS Q61K	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600K NRAS Q61K	melanoma	sensitive	GSK2126458	Preclinical	Actionable	In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K CDKN2A loss	melanoma	sensitive	Palbociclib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61K CDKN2A loss	melanoma	sensitive	SBI-0640756	Preclinical	Actionable	In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF G466V NRAS Q61K	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del EGFR T790M NRAS Q61K	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type NRAS Q61K	melanoma	resistant	GDC0879	Preclinical - Pdx	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K	melanoma	sensitive	XL888	Preclinical	Actionable	In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K	melanoma	sensitive	Trametinib + Dabrafenib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF V600E NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF G469R NRAS Q61K	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF G469R NRAS Q61K	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF G469R NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS Q61K	non-small cell lung carcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS Q61K	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS Q61K	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61L	melanoma	resistant	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 did not inhibit growth of melanoma cells harboring NRAS Q61L in culture or in cell line xenograft models (PMID: 25500121, PMID: 23431193).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61L	melanoma	sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, RAF709 inhibited Erk signaling and proliferation of melanoma cells harboring NRAS Q61L in culture (PMID: 29343524).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61L	melanoma	sensitive	CCT196969	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CCT196969 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61L	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring NRAS Q61L were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61L	melanoma	sensitive	CCT241161	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CCT241161 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61L	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61L	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring NRAS Q61L in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61L	melanoma	decreased response	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61L in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS E63K	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS E63K	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS E63K	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mut STAG2 dec exp	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	lung adenocarcinoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human lung adenocarcinoma cell lines harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	Binimetinib + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring an NRAS mutation (PMID: 27307593).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	no benefit	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ibrance (palbociclib) treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrated a lack of benefit (PMID: 27488531).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	colorectal cancer	no benefit	Cetuximab + FOLFIRI	Phase III	Actionable	In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	CCT241161	Preclinical	Actionable	In a preclinical study, CCT241161 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	leukemia	predicted - sensitive	Trametinib	Phase Ib/II	Actionable	In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	CCT196969	Preclinical	Actionable	In a preclinical study, CCT196969 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	Advanced Solid Tumor	sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, cancer cell lines harboring NRAS mutations demonstrated increased sensitivity to RAF709 compared to NRAS wild-type cells in culture (PMID: 29343524).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	transitional cell carcinoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human urinary tract transitional cell carcinoma cells harboring mutant NRAS were moderately sensitive to Mekinist (trametinib) growth inhibition in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	S63845 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in NRAS-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	Advanced Solid Tumor	sensitive	Obatoclax	Preclinical	Actionable	In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with NRAS mutation in culture (PMID: 22460902).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	multiple myeloma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant NRAS in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	Binimetinib + Ribociclib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a median progression-free survival of 6.7 months, a partial response in 25% (4/16), and stable disease in 44% (7/16) of NRAS mutant melanoma patients (J Clin Oncol 35, 2017 (suppl; abstr 9519)).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	Binimetinib + Ribociclib	Phase Ib/II	Actionable	In a Phase Ib/II trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a partial response in 43% (6/14) and stable disease in 43% (6/14) of NRAS mutant melanoma patients (J Clin Oncol 32:5s, 2014 (Suppl;abstr 9009)).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	hematologic cancer	predicted - resistant	SHP099	Preclinical	Actionable	In a preclinical study, hematopoietic cancer cell lines harboring NRAS mutations demonstrated resistance to SHP099 in cell culture (PMID: 27362227).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	thyroid cancer	sensitive	Selumetinib	Phase I	Actionable	In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	central nervous system cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human central nervous system cancer cells harboring mutant NRAS in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	sarcoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human sarcoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	no benefit	PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PD-0325901 treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrates a lack of benefit (PMID: 27488531).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	Advanced Solid Tumor	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	SBI-0640726	Preclinical	Actionable	In a preclinical study, SBI-0640726 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	acute myeloid leukemia	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited proliferation of human NRAS mutant acute myeloid leukemia cell lines in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	lymphoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human lymphoma cells harboring mutant NRAS in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	HM95573	Phase I	Actionable	In a Phase I trial, HM95573 treatment resulted in an unconfirmed partial response in a patient with NRAS mutant melanoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2570-2570; NCT02405065).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	Adavosertib	Preclinical	Actionable	In a preclinical study, MK-1775 showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID: 24791855).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring a mutation in NRAS were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	PD-0325901 + Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in tumor regression in 33% (2/6) of melanoma xenograft models harboring an NRAS mutation (PMID: 27488531).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	leukemia	sensitive	BYL719 + MEK162	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in leukemia cells harboring mutant NRAS, demonstrating cell death in culture (PMID: 29437705).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	liver cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of liver cancer cell lines harboring mutant NRAS in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	predicted - sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a best response of stable disease in six melanoma patients and a partial response in three melanoma patients all harboring an NRAS mutation (PMID: 29247021).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	cervix carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	non-small cell lung carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	acute myeloid leukemia	predicted - sensitive	AZD5153	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring NRAS mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	predicted - sensitive	Trametinib	Phase I	Actionable	In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease in 29% (2/7) of patients with NRAS mutated melanoma (PMID: 22805292).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring an NRAS mutation resulted in inhibition of brain tumor growth and an improved survival benefit (PMID: 27307593).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	BI-69A11	Preclinical	Actionable	In a preclinical study, BI-69A11 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	Tubastatin A	Preclinical	Actionable	In a preclinical study, Tubastatin A inhibited proliferation of NRAS mutant melanoma cell lines in culture (PMID: 25957812).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	acute myeloid leukemia	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human acute myeloid leukemia cell lines harboring mutant NRAS in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	pancreatic cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	leukemia	sensitive	HM95573	Preclinical - Cell culture	Actionable	In a preclinical study, HM95573 inhibited growth of NRAS mutant leukemia cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	conflicting	Binimetinib	Phase III	Actionable	In a Phase III clinical trial, treatment with Binimetinib (MEK162) improved median progression-free survival compared to treatment with Deticene (dacarbazine) (2.8 mo. vs. 1.5 mo.), but did not improve overall survival in patients with NRAS-mutant melanoma (PMID: 28284557).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	conflicting	Binimetinib	Phase II	Actionable	In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	non-Hodgkin lymphoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human non-Hodgkin lymphoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	colorectal cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	Advanced Solid Tumor	no benefit	CC-90003	Phase I	Actionable	In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited growth of NRAS mutant human melanoma cell lines in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	stomach carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	sensitive	SBI-0640756	Preclinical	Actionable	In a preclinical study, SBI-0640756 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	ovarian cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of ovarian cancer cells harboring mutant NRAS in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	colorectal cancer	predicted - resistant	SYM004	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	melanoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	autonomic nervous system neoplasm	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human autonomic ganglia cancer cells harboring mutant NRAS in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	colon cancer	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, colon cancer cells harboring NRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	Advanced Solid Tumor	no benefit	NS1	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an NRAS mutation did not respond to treatment with NS1 in culture, resulting in sustained downstream signaling and cell transformation (PMID: 27820802).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	Advanced Solid Tumor	predicted - sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	skin melanoma	sensitive	Binimetinib	Phase III	Actionable	In a Phase III trial, Binimetinib (MEK162) treatment resulted in improved progression free survival (2.8 months), objective response rate (15%, 40/269) and disease control rate (58%, 156/269) compared to Deticene (dacarbazine) (1.5 months, 7%, 25%, respectively) in NRAS-mutant cutaneous melanoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9500)).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	biliary tract cancer	predicted - sensitive	Binimetinib	Phase I	Actionable	In a Phase I trial, Binimetinib (MEK162) treatment resulted in partial response in a biliary tract cancer patient harboring NRAS mutation (PMID: 28152546)
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mutant	neuroblastoma	sensitive	BYL719 + MEK162	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in neuroblastoma cells harboring mutant NRAS, demonstrating cell death in culture (PMID: 29437705).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	CTNNB1 mut NRAS mut	liver cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF wild-type NRAS mutant	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	CDKN2A loss NRAS mutant	melanoma	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mut PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF mut NRAS mut	melanoma	predicted - sensitive	BI-847325	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	BRAF mut NRAS mut	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS Q61H	rhabdomyosarcoma	sensitive	BYL719 + MEK162	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in rhabdomyosarcoma cells harboring NRAS Q61H, demonstrating cell death in culture (PMID: 29437705).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS act mut	non-small cell lung carcinoma	sensitive	RAF709	Preclinical - Pdx	Actionable	In a preclinical study, RAF709 inhibited tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring NRAS activating mutations (PMID: 29343524).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	NRAS mut CDKN2A mut	acute lymphocytic leukemia	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	FGFR1 amp NRAS amp	non-small cell lung carcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of NRAS was identified in a non-small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	FGFR1 amp NRAS amp	non-small cell lung carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification in culture (PMID: 28630215).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	FGFR1 amp NRAS amp	non-small cell lung carcinoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification were resistant to Mekinist (trametinib) in culture (PMID: 28630215).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS amp	non-small cell lung carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS amp	non-small cell lung carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).
NRAS	ALPS4 | CMNS | N-ras | NCMS | NRAS1 | NS6	1p13.2	NM_002524	EGFR exon 19 del NRAS amp	non-small cell lung carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA V561D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, cells expressing PDGFRA V561D demonstrated sensitivity to Gleevec (imatinib) in cell culture (PMID: 15928335).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA V561D	Advanced Solid Tumor	sensitive	BLU-285	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation in transformed cells overexpressing PDGFRA V561D in culture (PMID: 29093181).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V PDGFRA V561D	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, PDGFRA D842V conferred resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in cells expressing PDGFRA V561D in culture (PMID: 18955458).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA R841_D842delinsKI	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing PDGFRA R841_D842delinsKI were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA Y849S	myeloid leukemia	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA Y849S in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA Y849S	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA Y849S in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842_I843delinsIM	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing PDGFRA D842_I843delinsIM were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA H650Q	leukemia	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, mice injected with transformed cells harboring PDGFRA H650Q developed leukemia-like disease that is sensitive to Gleevec (imatinib) (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D846Y	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA D846Y in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842X	gastrointestinal stromal tumor	sensitive	BLU-285	Phase I	Actionable	In a Phase I trial, BLU-285 demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring PDGFRA D842 mutations, with partial responses in 50% (6/12) and stable disease in 50% (6/12) of patients (EORTC-NCI-AACR 2016, Abs 6LBA).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA I843del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) decreased phosphorylation of Pdgfra in cell lines expressing PDGFRA I843del mutation in culture (PMID: 14645423).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA H845Y	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA H845Y	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA N659S	myeloid leukemia	decreased response	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed mouse myeloid cells over expressing PDGFRA N659S demonstrated reduced sensitivity to Gleevec (imatinib) in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H	melanoma	sensitive	Imatinib + Carboplatin + Paclitaxel	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA mutant	gastrointestinal stromal tumor	not applicable	N/A	Clinical Study	Diagnostic	PDGFRA mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 26276366, PMID: 25729899).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA G853D	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA G853D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA L221F	gastrointestinal stromal tumor	sensitive	Imatinib	Phase I	Actionable	In a Phase I retrospective study, treatment with Gleevec (imatinib) demonstrated a prolonged response in a patient with a gastrointestinal stromal tumor harboring a PDGFRA L221F mutation (PMID: 22718859).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA S566_E571delinsR	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA S566_E571delinsR in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA P577S	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA P577S	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA act mut	gastrointestinal stromal tumor	not applicable	N/A	Guideline	Diagnostic	PDGFRA activating mutations aid the diagnosis of gastrointestinal stromal tumor (NCCN.org).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA act mut	pancreatic cancer	predicted - sensitive	Vistusertib	Phase I	Actionable	In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with pancreatic cancer harboring a PDGFRA activating mutation (PMID: 25805799).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA R748G	myeloid leukemia	sensitive	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA R748G in culture and prolonged survival in xenograft models (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	gastrointestinal stromal tumor	sensitive	BLU-285	Phase I	Actionable	In a Phase I trial, BLU-285 treatment resulted in partial response lasted for more than 15 cycles of treatment, and sustained reduction of plasma PDGFRA D842V in a patient with gastrointestinal stromal tumor harboring PDGFRA D842V, whose disease had progressed on previous Gleevec (imatinib mesylate), Sprycel (dasatinib), and Crenolanib treatment (PMID: 29093181; NCT02508532).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, expression of PDGFRA D842V conferred resistance to Gleevec (imatinib) in cell culture (PMID: 15928335).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	Advanced Solid Tumor	resistant	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 18794084).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	Advanced Solid Tumor	sensitive	BLU-285	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation in transformed cells overexpressing PDGFRA D842V in culture (PMID: 29093181).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 22745105).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	gastrointestinal stromal tumor	predicted - sensitive	Dasatinib	Phase 0	Actionable	In a clinical trial, Sprycel (dasatinib) treatment resulted in a partial response in 25% (12/48) of patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor, with decreased tumor size in 2 of those patients, 1 of which harbored PDGFRA D842V (PMID: 29710216).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	gastrointestinal stromal tumor	sensitive	Crenolanib	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with Crenolanib (CP-868596) resulted in a clinical benefit rate of 31% (5/16) in gastronintestinal stromal tumor patients harboring PDGFRA D842V, with partial response in 2/16 and stable disease in 3/16 patients (J Clin Oncol 34, 2016 (suppl; abstr 11010)).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing PDGFRA D842V demonstrated resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in culture (PMID: 18955458).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842V	gastrointestinal stromal tumor	predicted - sensitive	Regorafenib	Clinical Study	Actionable	In a clinical study, Stivarga (regorafenib) treatment resulted in partial response in 11% (2/18) of patients and stable disease in 39% (7/18) of gastrointestinal stromal tumor patients, including prolonged stable disease for 12 months in a patient harboring PDGFRA D842V (PMID: 25905001).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA R841K	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA R841K	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA V561_I562insER	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA V561_I562insER in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA N659K	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA N659K	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA H845_N848delinsP	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA H845_N848delinsP in culture (PMID: 21224473).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA amp EGFR amp	glioblastoma multiforme	sensitive	Gefitinib + Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	KIT amp PDGFRA amp	glioblastoma multiforme	sensitive	DCC-2618	Phase I	Actionable	In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA amp	lung small cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA amp	non-small cell lung carcinoma	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, Sutent (sunitinib) decreased cell proliferation and inhibited downstream signaling in a NSCLC cell line harboring a PDGFRA amplification (PMID: 19366796).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA amp	lung squamous cell carcinoma	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA amp	lung squamous cell carcinoma	sensitive	Dasatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell cancer (SCC) cell line with amplification of PDGFRA in culture, and inhibited tumor growth in PDGFRA-amplified lung SCC xenograft models (PMID: 22328973).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA amp	malignant peripheral nerve sheath tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, a malignant peripheral nerve sheath tumor cell line harboring a PDGFRA amplification demonstrated cell growth inhibition when treated with Gleevec (imatinib) (PMID: 16357008).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	ROS1 fusion KDR amp KIT amp PDGFRA amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA rearrange	myelodysplastic/myeloproliferative neoplasm	sensitive	Imatinib	FDA approved	Actionable	Gleevec (imatinib) is FDA approved for myelodysplastic/myeloproliferative cancers that are associated with PDGFR rearrangements (FDA.gov).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA V658A	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA V658A in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA V658A	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA V658A in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	KIT A502_Y503dup PDGFRA H687Y	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Clinical Study	Actionable	In a clinical study, PDGFRA H687Y was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring primary KIT A502_Y503dup, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842Y	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921).
PDGFRA	CD140A | PDGFR-2 | PDGFR2	4q12	NM_006206	PDGFRA D842Y	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA E545K PIK3CA K567R	Her2-receptor positive breast cancer	sensitive	Gedatolisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9	ovarian clear cell adenocarcinoma	sensitive	DS-7423	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047Y	glioblastoma multiforme	sensitive	YM-024	Preclinical	Actionable	In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-204 induced growth inhibition (PMID: 24718026).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047Y	endometrial cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth in a human endometrial cancer cell line harboring a PIK3CA H1047Y mutation, and inhibited tumor growth in xenograft models (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA H1047R	colon cancer	no benefit	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA H1047R	colon cancer	sensitive	BKM120 + Cetuximab	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA H1047R	colon cancer	sensitive	Buparlisib	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA P539R PIK3CA H1047R	breast cancer	sensitive	PF-04691502	Preclinical - Cell culture	Actionable	In a preclinical study, PF-04691502 inhibited Akt phosphorylation and proliferation of breast cancer cells harboring both PIK3CA P539R and H1047R in culture (PMID: 21750219).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA P539R PIK3CA H1047R	breast cancer	sensitive	ARQ092	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA P539R and H1047R were sensitive to ARQ092 in culture, demonstrating inhibition of cell growth (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA P539R PIK3CA H1047R	breast cancer	sensitive	ARQ 751	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA P539R and PH1047R was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12F PIK3CA H1047R	lung adenocarcinoma	sensitive	Dasatinib + Demcizumab	Preclinical - Pdx	Actionable	In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12F and PIK3CA H1047R (PMID: 26855149).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R TP53 S90fs*33	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	lung adenocarcinoma	no benefit	Sirolimus	Preclinical	Actionable	In a preclinical study, Sirolimus (rapamycin) failed to inhibit tumor growth in a mouse lung adenocarcinoma model expressing the PIK3CA H1047R mutation (PMID: 19029981).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	Advanced Solid Tumor	sensitive	rigosertib	Preclinical - Cell culture	Actionable	In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA H1047R in culture (PMID: 27104980).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	stomach cancer	sensitive	Capivasertib	Preclinical - Pdx	Actionable	In a preclinical study, AZD5363 inhibited growth in a patient-derived xenograft model of gastric cancer harboring a PIK3CA H1047R mutation (PMID: 24088382).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	urinary bladder cancer	sensitive	Pictilisib	Preclinical - Pdx	Actionable	In a preclinical study, Pictilisib (GDC-0941) inhibited Akt phosphorylation and tumor growth, prolonged survival in patient-derived xenograft (PDX) models of bladder cancer harboring PIK3CA H1047R (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	ovarian cancer	sensitive	A66	Preclinical - Cell line xenograft	Actionable	In a preclinical study, A66 delayed tumor growth in an ovarian cancer cell line xenograft model harboring PIK3CA H1047R (PMID: 21668414).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	ARQ092	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ092 in culture, resulting in inhibition of cell proliferation (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	lung cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 reduced tumor size in mouse models of lung cancer carrying PIK3CA H1047R (PMID: 19029981).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	lung adenocarcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 promoted tumor regression in a mouse lung adenocarcinoma model expressing PIK3CA H1047R (PMID: 19029981).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	Metformin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glucophage (metformin) inhibited cell proliferation of a dietary restriction-resistant PIK3CA H1047R-harboring human breast cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23986086).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	ovarian cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited tumor growth in mouse xenografts of ovarian cancer with a Pik3ca H1047R mutation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2830).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, transformed cells expressing PIK3CA H1047R were sensitive to Rapamune (sirolimus), resulting in inhibition of transformation in culture (PMID: 15647370).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	lung squamous cell carcinoma	sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	lung cancer	no benefit	Sirolimus	Preclinical	Actionable	In a preclinical study, Sirolimus (rapamycin) did not induce tumor shrinkage in mouse lung cancer models carrying PIK3CA H1047R (PMID: 19029981).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	colorectal cancer	sensitive	Metformin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human colorectal cancer cell line xenograft tumors harboring PIK3CA H1047R (PMID: 23986086).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	head and neck squamous cell carcinoma	sensitive	Radiotherapy + Taselisib	Preclinical	Actionable	In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis of head and neck squamous carcinoma cells harboring PIK3CA H1047R (PMID: 26589432).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	Taselisib	Phase I	Actionable	In a Phase I trial, four patients with breast cancer harboring PIK3CA H1047R demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	colorectal cancer	resistant	Fluorouracil + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells over expressing PIK3CA H1047R were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	Advanced Solid Tumor	sensitive	A66	Preclinical	Actionable	In a preclinical study, A66 delayed tumor growth in human tumor xenograft models harboring PIK3CA H1047R mutations (PMID: 21668414).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	thyroid cancer	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring PIK3CA H1047R (PMID: 21289267).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	head and neck squamous cell carcinoma	sensitive	Sirolimus + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring PIK3CA H1047R in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	colorectal cancer	sensitive	Cetuximab	Clinical Study	Actionable	In a retrospective study, Erbitux (cetuximab) combined with radiation therapy resulted in stable disease for 6 months in a colorectal carcinoma patient harboring a PIK3CA H1047R mutation (PMID: 25714871).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	head and neck squamous cell carcinoma	sensitive	Gedatolisib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cell lines harboring PIK3CA H1047R demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) in culture (PMID: 25977343).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	thyroid cancer	sensitive	MK2206 + Temsirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of an anaplastic thyroid cancer cell line harboring PIK3CA H1047R in culture (PMID: 21289267).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in breast cancer cell lines harboring PIK3CA H1047R in culture (PMID: 26237138).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	urinary bladder cancer	sensitive	Cisplatin + Pictilisib	Preclinical - Pdx	Actionable	In a preclinical study, combination of or sequential treatment with Pictilisib (GDC-0941) and Platinol (cisplatin) significantly delayed tumor growth and prolonged survival in patient-derived xenograft (PDX) models of bladder cancer harboring PIK3CA H1047R (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	ovarian cancer	sensitive	CH5132799	Phase I	Actionable	In a Phase I trial, CH5132799 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with ovarian cancer harboring PIK3CA H1047R (PMID: 25231405).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line xenograft model harboring PIK3CA H1047R demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	MSC2363318A	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model harboring PIK3CA H1047R was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth (PMID: 27186432).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	BAY1125976	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of  breast cancer cell lines harboring PIK3CA H1047R in culture, and inhibited AKT signaling and tumor growth in a PIK3CA H1047R-mutant cell line xenograft model (PMID: 27699769).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	Alpelisib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	ovarian cancer	sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited Pi3k signaling, resulted in growth inhibition of ovarian cancer cells harboring PIK3CA H1047R in culture and in cell line xenograft models (PMID: 21750219).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	breast cancer	sensitive	ARQ 751	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ 751 in culture, resulting in inhibition of cell proliferation (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R	urinary bladder cancer	sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 inhibited tumor growth in a patient-derived xenograft (PDX) model of bladder cancer harboring PIK3CA H1047R (PMID: 26270481).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R PIK3CA K111R PTEN wild-type	lung small cell carcinoma	sensitive	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA H1047R, PIK3CA K111R, and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Ponatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	BKM120 + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Trastuzumab + Pertuzumab	Preclinical	Actionable	In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Trastuzumab + Lapatinib	Preclinical	Actionable	In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	BKM120 + Trastuzumab + Pertuzumab	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	BKM120 + Bevacizumab	Preclinical	Actionable	In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	no benefit	BKM120 + Trastuzumab + Lapatinib	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS wild-type PIK3CA H1047R	colorectal cancer	no benefit	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600X PIK3CA H1047R PTEN Y86fs	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	resistant	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	predicted - sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	AT-7867	Preclinical	Actionable	In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	Gedatolisib + Irinotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	CC-223	Preclinical	Actionable	In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	Irinotecan	Preclinical	Actionable	In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colorectal cancer	sensitive	Regorafenib + Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D and PIK3CA H1047R in culture, and reduced tumor growth in cell line xenograft models (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	PD-0325901 + Gedatolisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colorectal cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 27602501).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA H1047R	colon cancer	sensitive	Gedatolisib + Camptothecin	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistictically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CH5132799 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA H1047R	ovarian cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	decreased response	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	predicted - sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA H1047R	thyroid carcinoma	sensitive	Dabrafenib + Everolimus + Trametinib	Clinical Study	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA H1047R	thyroid carcinoma	resistant	Trametinib + Dabrafenib	Clinical Study	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA H1047R	thyroid carcinoma	resistant	Everolimus	Clinical Study	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R PTEN loss	breast cancer	no benefit	BEZ235 + Venetoclax	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R PTEN loss	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	ABT-737 + MLN0128	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	ABT-737 + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12C PIK3CA H1047R TP53 R248W	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047R PTEN E307K	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	AKT1 over exp PIK3CA H1047R	breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA V955G	colorectal cancer	resistant	Fluorouracil + Cetuximab	Clinical Study	Actionable	In a clinical study, PIK3CA V955G was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955G (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA K944N	colorectal cancer	resistant	Fluorouracil + Cetuximab	Clinical Study	Actionable	In a clinical study, PIK3CA K944N was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA K944N (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA H1047L	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047L	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047L	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047L	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047L	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047L	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047L	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	predicted - sensitive	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	decreased response	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA Q546K	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA Q546K	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA Q546K	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA Q546K	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA Q546K	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA Q546K	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA Q546K	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA C420R	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA C420R	ovarian clear cell adenocarcinoma	sensitive	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA C420R was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA C420R	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, cells expressing PIK3CA C420R were sensitive to Rapamune (sirolimus) in culture (PMID: 17376864).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA C420R	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA V344G	glioblastoma multiforme	no benefit	YM-024	Preclinical	Actionable	In a preclinical study, YM-024 did not inhibit proliferation of glioblastoma cell lines harboring PIK3CA V344G in culture (PMID: 24718026).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA Q546R	prostate cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells harboring PIK3CA Q546R in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA Q546R	colorectal cancer	sensitive	Bevacizumab + Sorafenib	Clinical Study	Actionable	In a clinical case study, a patient with colorectal cancer harboring KRAS G12D and PIK3CA Q546R demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for more than 6 months (PMID: 25363205).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA P124L PTEN del	urinary bladder cancer	decreased response	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited  inhibition of Akt phosphorylation and growth in bladder cancer cells harboring PIK3CA P124L and PTEN deletion in culture (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H450_P458del	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed breast epithelial cells expressing PIK3CA H450_P458del were sensitive to treatment with Alpelisib (BYL719) in culture, demonstrating growth inhibition and decreased invasiveness of acini (PMID: 29284706).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA V952A	colorectal cancer	resistant	Fluorouracil + Cetuximab	Clinical Study	Actionable	In a clinical study, PIK3CA V952A was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V952A (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA N345T	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA N345T (PMID: 29208673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA K966E	colorectal cancer	resistant	Fluorouracil + Cetuximab	Clinical Study	Actionable	In a clinical study, PIK3CA K966E was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA K966E (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E453del PIK3CA T1025K PIK3CA R88L PTEN mut PTEN loss	endometrial carcinoma	sensitive	Copanlisib	Phase I	Actionable	In a Phase I clinical trial, an endometrial carcinoma patient harboring PIK3CA T1052K, R88L, and E453del, as well as a PTEN mutation and loss of PTEN protein expression demonstrated a complete response to treatment with Aliqopa (copanlisib) (PMID: 27672108).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R88Q PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R88Q PTEN mut	endometrial cancer	sensitive	Everolimus	Preclinical	Actionable	In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R88Q	colorectal cancer	sensitive	Cetuximab + Fluorouracil + Irinotecan + Floxuridine	Clinical Study	Actionable	In a retrospective study, treatment with the combination of Erbitux (cetuximab), Adrucil (fluorouracil), Camptosar (irinotecan), and Floxuridine resulted in at least 24 months without evidence of disease in a colorectal carcinoma patient harboring a PIK3CA R88Q mutation (PMID: 25714871).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R88Q	malignant pleural mesothelioma	sensitive	GDC-0980	Phase I	Actionable	In a Phase I trial, treatment with Apitolisib (GDC-0980) resulted in a partial response in a patient with malignant pleural mesothelioma harboring PIK3CA R88Q (PMID: 26787751).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R88Q PTEN mut KRAS G12V	endometrial cancer	decreased response	Everolimus	Preclinical	Actionable	In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R88Q PTEN mut KRAS G12V	endometrial cancer	decreased response	BEZ235	Preclinical	Actionable	In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA D1029Y PTEN inact mut	lung small cell carcinoma	resistant	PF-4989216	Preclinical - Cell culture	Actionable	In a preclinical study, small cell lung carcinoma cells harboring PIK3CA D1029Y and PTEN inactivating mutation were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA P447_L455del	estrogen-receptor positive breast cancer	sensitive	Letrozole + BYL719	Clinical Study	Actionable	In a clinical case study, a patient with estrogen-receptor positive breast cancer harboring PIK3CA P447_L455del demonstrated an 11 month sustained response to the combination therapy of Femara (letrozole) and Alpelisib (BYL719) (PMID: 29284706).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E78K PIK3CA D939G PIK3CA E726K	estrogen-receptor positive breast cancer	no benefit	Letrozole + BYL719	Phase Ib/II	Actionable	In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA mutations, E78K, D939G, and E726K, demonstrated progressive disease when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047X	small intestine adenocarcinoma	resistant	Bortezomib + Temsirolimus + Topotecan	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Velcade (bortezomib) and Hycamtin (topotecan) resulted in progressive disease in a patient with small intestine adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047X	colorectal cancer	resistant	Temsirolimus + Bevacizumab	Clinical Study	Actionable	In a clinical study, a colorectal cancer patient harboring a mutation at PIK3CA H1047 demonstrated progressive disease when treated with Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047X	endometrial adenocarcinoma	sensitive	Temsirolimus	Clinical Study	Actionable	In a clinical study, a patient with endometrial adenocarcinoma harboring a PIK3CA H1047 mutation demonstrated a partial response when treated with Torisel (temsirolimus) (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047X	non-small cell lung carcinoma	sensitive	Taselisib	Phase I	Actionable	In a Phase I trial, a non-small cell lung carcinoma patient harboring a mutation at PIK3CA H1047 demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047X BRAF V600X	ovarian carcinoma	sensitive	Bevacizumab + Temsirolimus + Doxil	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA H1047X KRAS G12X	colorectal cancer	resistant	XL147 + Carboplatin + Paclitaxel	Clinical Study	Actionable	In a clinical study, the combination of XL147 plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA I391M	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA I391M	uterine cancer	sensitive	Sirolimus	Clinical Study	Actionable	In a clinical study, a uterine cancer patient harboring PIK3CA I391M demonstrated stable disease when treated with Rapamune (sirolimus) (PMID: 28514312).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	sensitive	Pimasertib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	EGFR L858R EGFR T790M PIK3CA G118D	non-small cell lung carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G118D	non-small cell lung carcinoma	sensitive	LY3023414	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY3023414 inhibited proliferation of non-small cell lung cancer cells harboring PIK3CA G118D in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G106_R108del PTEN wild-type	lung small cell carcinoma	sensitive	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA G106_R108del and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R108H PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA D549Y	urinary bladder cancer	decreased response	Pictilisib	Preclinical - Pdx	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited tumor growth inhibition and survival benefit in patient-derived xenograft (PDX) models of bladder cancer harboring PIK3CA D549Y (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA mut	breast cancer	sensitive	ARQ092 + Paclitaxel	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA mut	breast cancer	sensitive	ARQ092 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 over exp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	PKI-179	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA mut	colorectal cancer	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF wild-type KRAS wild-type PIK3CA mutant	colorectal cancer	sensitive	Cetuximab	Clinical Study	Actionable	In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	Ipatasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA mut	breast cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	Copanlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA mut	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant KRAS G12X KRAS G13X	colorectal cancer	sensitive	Temsirolimus + Bevacizumab	Clinical Study	Actionable	In a clinical study, a colorectal cancer patient harboring a PIK3CA mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	FGFR1 over exp PIK3CA mut	estrogen-receptor positive breast cancer	sensitive	Alpelisib + Lucitanib	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	Advanced Solid Tumor	sensitive	Alpelisib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	non-small cell lung carcinoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colorectal cancer	no benefit	Taselisib	Phase I	Actionable	In a Phase I trial, a colorectal cancer patient co-harboring a PIK3CA mutation and KRAS mutation progressed on treatment with Taselisib (GDC-0032) (PMID: 28331003).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	stomach cancer	predicted - sensitive	Deguelin	Preclinical	Actionable	In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	non-small cell lung carcinoma	sensitive	Selumetinib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically prevented proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring KRAS and PIK3CA mutations in culture and in cell line xenograft models (PMID: 24939055).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colon cancer	sensitive	Copanlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Aliqopa (copanlisib) inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colon cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	Advanced Solid Tumor	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colon cancer	sensitive	GDC-0980	Preclinical - Cell line xenograft	Actionable	In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	non-small cell lung carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	stomach cancer	sensitive	Buparlisib	Preclinical	Actionable	In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colon cancer	sensitive	AT13148	Preclinical	Actionable	In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colorectal cancer	sensitive	ABT-263 + CGM097 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Navitoclax (ABT-263) improved the therapeutic effects of the combination of CGM097 and Mekinist (trametinib) in colorectal cancer cells, resulting in greater apoptotic activity and growth inhibition in culture, and tumor regression in xenograft models (PMID: 27659046).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	Advanced Solid Tumor	resistant	Everolimus	Preclinical	Actionable	In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance  (PMID: 20664172).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	non-small cell lung carcinoma	sensitive	Buparlisib	Phase II	Actionable	In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	Advanced Solid Tumor	decreased response	Taselisib	Phase I	Actionable	In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, but preliminary data analysis suggested the presence of a KRAS mutation was associated with lack of response (Cancer Res October 1, 2014 74:915).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colorectal cancer	sensitive	AZD8055 + Selumetinib	Preclinical	Actionable	In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colorectal cancer	sensitive	CGM097 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of CGM097 and Mekinist (trametinib) treatment compared to treatment with either agent alone in a colorectal cancer cell line resulted in a greater decrease in colony formation in culture, and improved stable disease in xenograft models (PMID: 27659046).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colorectal cancer	sensitive	SAR245409	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colorectal cancer	resistant	BEZ235	Preclinical	Actionable	In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	non-small cell lung carcinoma	sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mut PIK3CA mut	colon cancer	sensitive	A-443654	Preclinical	Actionable	In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	endometrial cancer	no benefit	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, mutation status of PIK3CA was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	ovarian cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells with PIK3CA mutations in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast adenocarcinoma	sensitive	GS-9820	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of breast adenocarcinoma harboring a PIK3CA mutation (Mol Cancer Ther 2009;8(12 Suppl):B136).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	Carboxyamidotriazole Orotate	Phase I	Actionable	In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors, including patients harboring PIK3CA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	colorectal cancer	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in a disease control rate of 34.3% (12/35, 0 complete response (CR), 2 partial response (PR), 10 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 8.6% (3/35) in patients with colorectal cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited growth of human breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 22693356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	endometrial cancer	sensitive	GDC-0980	Phase II	Actionable	In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	predicted - sensitive	GDC-0077	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, GDC-0077 inhibited proliferation and induced apoptosis in PIK3CA-mutant breast cancer cell lines in culture, and induced apoptosis and tumor regression in PIK3CA-mutant breast cancer cell line and patient-derived xenograft models (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 156).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	Taselisib	Phase I	Actionable	In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, in the absence of alterations in the MAPK or PTEN pathways (Cancer Res October 1, 2014 74:915).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	A-443654	Preclinical	Actionable	In a preclinical study, cells expressing mutant PIK3CA demonstrated increased sensitivity to A-443654 compared to cells expressing wild-type PIK3CA (PMID: 19208828).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	colon cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of colon cancer cells harboring a PIK3CA mutation in culture  (PMID: 22543857).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	predicted - sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, AZD5363 inhibited growth in breast cancer cell lines and xenograft models expressing PIK3CA mutations (PMID: 22294718).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	predicted - sensitive	Capivasertib	Phase I	Actionable	In a Phase I trial, treatment with AZD5363 was well-tolerated and resulted in tumor shrinkage in 46% (12/26) patients with PIK3CA-mutant breast cancer, with confirmed RECIST responses in 4% (1/28) of patients (PMID: 29066505; NCT01226316).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	head and neck cancer	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in a disease control rate of 68.4% (13/19, 0 complete response (CR), 0 partial response (PR), 13 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 10.5% (2/19) in patients with head and neck cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	squamous cell carcinoma	sensitive	Carboxyamidotriazole Orotate	Phase I	Actionable	In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors including squamous cell carcinomas (tonsil) with PI3KCA and NRAS mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited tumor growth in breast cancer xenograft models harboring PIK3CA mutations (AACR; 2015. Abstract nr 2665).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	endometrial cancer	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to GDC-0941 (Pictilisib) induced growth inhibition comparing to PIK3CA wild-type cells in culture (PMID: 23674493).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	VS-5584	Preclinical	Actionable	In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	XL147	Phase I	Actionable	In a Phase I clinical trial, XL147 (SAR24508) was shown to be safe and potentially efficacious, with clinical activity seen irrespective of tumor PI3K pathway molecular alterations (PMID: 24166903).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	XL147	Preclinical	Actionable	In a preclinical study, tumor cell lines with PIK3CA mutations demonstrated sensitivity to XL147 in culture (PMID: 25637314).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	Bevacizumab + Temsirolimus + Doxil	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	Bevacizumab + Temsirolimus + Doxil	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temisirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxirubicin) resulted in stable disease in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	cervical cancer	decreased response	Cetuximab	Phase II	Actionable	In a Phase II clinical trial, Erbitux (cetuximab) treatment, in addition to radiochemotherapy, did not result in any complete responses (0/8) and demonstrated a worse disease free survival when compared to radiochemotherapy alone in cervical cancer patients harboring PIK3CA mutations (PMID: 25724520).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 induced tumor regression in breast cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	estrogen-receptor positive breast cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA mutations in culture and suppressed tumor growth in xenograft models (PMID: 26839307).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, GDC-0941 inhibited growth and induced apoptosis in breast cancer cells expressing PIK3CA mutations (PMID: 24601221).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	MLN1117	Preclinical	Actionable	In a preclinical study, MLN1117 inhibited proliferation of tumor cells harboring oncogenic PIK3CA mutations in culture and inhibited tumor growth in PIK3CA mutant xenograft models (Cancer Ther 2011;10(11 Suppl):Abstract nr A171).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	MLN1117	Phase I	Actionable	In a Phase I trial, MLN1117 demonstrated safety and preliminary efficacy in a variety of patients with advanced solid tumors carrying PIK3CA mutations (Journal of Clinical Oncology, 2015 ASCO Annual Meeting Vol 33, No 15_suppl., 2015: 2501).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	triple-receptor negative breast cancer	predicted - sensitive	Ipatasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	estrogen-receptor positive breast cancer	predicted - sensitive	Letrozole	Phase III	Actionable	In a Phase III trial, estrogen-receptor positive breast cancer patients harboring a PIK3CA mutation demonstrated a greater benefit when treated with Femara (letrozole) compared to Nolvadex (tamoxifen) (PMID: 29902286; NCT00004205).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Her2-receptor positive breast cancer	sensitive	CCT128930	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CCT128930 induced growth arrest and inhibited tumor growth in a xenograft model of a ERBB2 (HER2)-positive human breast cancer cell line harboring a PIK3CA mutation (PMID: 21191045).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	prostate cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells with PIK3CA mutations in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	non-small cell lung carcinoma	sensitive	PWT33597	Preclinical	Actionable	In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in non-small cell lung cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	estrogen-receptor positive breast cancer	no benefit	Fulvestrant	Phase II	Actionable	In a Phase II trial, Falsodex (fulvestrant) treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	triple-receptor negative breast cancer	sensitive	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit the survival of triple-receptor negative breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	stomach cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of gastric cancer cells harboring a PIK3CA mutation in culture (PMID: 22543857).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Her2-receptor negative breast cancer	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in a disease control rate of 60.9% (14/23, 0 complete response (CR), 1 partial response (PR), 13 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 17.4% (4/23) in patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	colorectal cancer	predicted - sensitive	MS417 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in colorectal cancer cell lines harboring PIK3CA mutations in culture (PMID: 26058079).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	VS-5584	Preclinical	Actionable	In a preclinical study, PIK3CA mutant breast cancer cells showed increased sensitivity to VS-5584 compared to PIK3CA wild-type cells in culture (PMID: 23270925).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	stomach cancer	predicted - sensitive	MLN1117	Clinical Study	Actionable	In a Phase I trial, MLN1117 treatment resulted in partial response in 3 patients with gastric cancer harboring PI3CA mutations (PMID: 28490463).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	female reproductive organ cancer	predicted - sensitive	Capivasertib	Phase I	Actionable	In a Phase I trial, treatment with AZD5363 was well-tolerated and resulted in tumor shrinkage in 56% (14/25) patients with PIK3CA-mutant gynecological cancers, however, the response rate was modest with confirmed RECIST responses in 8% (2/26) of patients (PMID: 29066505; NCT01226316).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	AT-7867	Preclinical	Actionable	In a preclinical study, AT-7867 inhibited proliferation in several human tumor cell lines harboring PIK3CA mutations in culture (PMID: 20423992).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	Letrozole + Taselisib	Phase Ib/II	Actionable	In a Phase Ib trial, Taselisib (GDC-0032) and Femara (letrozole) combination therapy resulted in an overall response rate of 38% in breast cancer patients with PIK3CA mutations, compared to 9% in patients with wild-type PIK3CA (Cancer Res May 1, 2015 75; PD5-2).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, human cancer cell lines harboring PIK3CA mutations were sensitive to Sapanisertib (MLN0128) as demonstrated by significant growth inhibition (PMID: 25261369).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	endometrial cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells with PIK3CA mutations in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	hematologic cancer	sensitive	CUDC-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CUDC-907 inhibited PIK3CA, blocked downstream AKT pathway activation, and induced apoptosis and cell cycle arrest in both PIK3CA wild-type and PIK3CA mutant human cancer cell lines and xenograft models of multiple solid and hematologic cancers (PMID: 22693356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, breast cancer cells with PIK3CA mutations, both with and without ERBB2 (HER2) amplification, demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	BAY1082439	Preclinical	Actionable	In a preclinical study, BAY1082439 induced regression in xenograft models of advanced solid tumors with PIK3CA mutations (Cancer Res April 15, 2012 72; 2799).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	PX-866	Phase I	Actionable	In a Phase I trial, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	non-small cell lung carcinoma	sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21750219).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited growth of a variety of advanced solid tumor models with Pik3ca mutations in culture (PMID: 26839307).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	endometrioid ovary carcinoma	sensitive	Capivasertib	Phase I	Actionable	In a Phase I clinical trial, AZD5363 demonstrated safety and efficacy in patients with advanced solid tumors, including prolonged stable disease in one patient with a PIK3CA-mutant endometrioid ovarian cancer (American Association for Cancer Research; 06 Apr 2013-10 Apr 2013; Abstract LB-66).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	endometrial cancer	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in complete response in 1 and partial response in 1patient with endometrial cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	CC-223	Phase I	Actionable	In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	stomach cancer	sensitive	BAY1082439	Preclinical	Actionable	In a preclinical study, BAY1082439 inhibited growth of gastric cancer cells harboring PIK3CA mutations in culture and xenograft models (AACR; 2015. Abstract nr 2674).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Her2-receptor negative breast cancer	no benefit	Capivasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, the addition of AZD5363 to Taxol (paclitaxel) therapy did not improve progression-free survival compared to placebo (10.9 vs 10.8 months) in patients with PIK3CA-mutant, Esr1-positive, Erbb2 (Her2)-negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #241PD; NCT01625286).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	estrogen-receptor positive breast cancer	no benefit	Fulvestrant + Pictilisib	Phase II	Actionable	In a Phase II trial, Falsodex (fulvestrant) and Pictilisib (GDC-0941) combination treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	no benefit	GSK2126458	Phase I	Actionable	In a Phase I trial, GSK2126458 was well-tolerated and resulted in some efficacy in patients with breast cancer harboring a PIK3CA mutation including stable disease in 22% (2/9), however, objective response rate was not associated with PIK3CA mutations when compared to those without PIK3CA mutations (PMID: 26603258).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	ovarian cancer	sensitive	Temsirolimus	Phase I	Actionable	In a Phase I clinical trial, Torisel (temsirolimus) demonstrated limited efficacy in ovarian cancer patients with PIK3CA mutations (PMID: 22271473).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	MSC2363318A	Preclinical	Actionable	In a preclinical study, MSC2363318A demonstrated anti-proliferative activity against many solid tumor cell lines with PI3K pathway genomic alterations, and inhibited tumor growth in several human cancer xenograft models of breast, pancreatic, glioblastoma and ovarian cancers (Mol Cancer Ther 2013;12(11 Suppl):A162).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	ovarian cancer	sensitive	BKM120 + Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Lynparza (olaparib) worked synergistically to induce apoptosis and inhibit growth of ovarian cancer cell lines harboring PIK3CA mutations in culture, and induced apoptosis and decreased proliferation of PIK3CA-mutant ovarian cancer cell line xenograft models (PMID: 26909613).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	invasive bladder transitional cell carcinoma	predicted - resistant	Cisplatin + Gemcitabine + Sorafenib	Phase II	Actionable	In a Phase II trial, PIK3CA mutations were more frequent in  muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	cervical cancer	predicted - sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in partial response in 3 patients with cervical cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	Alpelisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PIK3CA mutations were associated with sensitivity to Alpelisib (BYL719) in human tumor cell lines in culture and in xenograft models (PMID: 24608574).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) demonstrated safety and efficacy in patients with advanced solid tumor harboring PIK3CA mutations, resulted in a disease control rate of 58.2% (78/134, 1 complete response (CR), 7 partial response (PR), 70 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 15.7% (21/134) (PMID: 29401002; NCT01219699).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	head and neck squamous cell carcinoma	predicted - sensitive	Carboplatin + Paclitaxel + Temsirolimus	Phase II	Actionable	In a Phase II trial, two patients with head and neck squamous cell carcinoma harboring a PIK3CA mutation who had stable disease demonstrated some tumor regression when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	no benefit	Temsirolimus	Phase II	Actionable	In a Phase II trial, Torisel (temsirolimus) treatment resulted in stable disease in 9.7% (3/31) of breast cancer patients positive for ER, PR or ERBB2 (HER2), however there was no association between PIK3CA mutational status and clinical benefits (PMID: 22245973).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	GDC-0980	Phase I	Actionable	In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in partial response in 21% (3/14) and stable disease in 57% (8/14) of patients with advanced solid tumors harboring PIK3CA mutations (PMID: 26787751).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	predicted - sensitive	GSK2141795	Phase I	Actionable	In a Phase I clinical trial, GSK2141795 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with 4 patients with PIK3CA mutations and/or PTEN loss achieving stable disease for greater than 6 months (J Clin Oncol 29: 2011 (suppl; abstr 3003)).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	gastric adenocarcinoma	sensitive	PI-103 + 5-FU	Preclinical	Actionable	In a preclinical study, PI-103 enhanced sensitivity to 5-FU in gastric cancer cells with mutant PIK3CA (PMID: 22336586).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	Advanced Solid Tumor	sensitive	CUDC-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CUDC-907 inhibited PIK3CA, blocked downstream AKT pathway activation, and induced apoptosis and cell cycle arrest in both PIK3CA wild-type and PIK3CA mutant human cancer cell lines and xenograft models of multiple tumor types (PMID: 22693356).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	Alpelisib + GSK2334470	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK2334470 resensitized Alpelisib (BYL719)-resistant breast cancer cell lines harboring PIK3CA mutations to Alpelisib (BYL719) in culture and in cell line xenograft models (PMID: 27451907).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a ERBB3 (HER3) positive breast cancer cell line xenograft model harboring a PIK3CA mutation was demonstrated decreased tumor growth when treated with AT13148 (PMID: 22781553).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	colon cancer	sensitive	PWT33597	Preclinical	Actionable	In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in colon cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	predicted - sensitive	MLN1117	Phase I	Actionable	In a Phase I trial, MLN1117 treatment resulted in partial response in 3 patients with breast cancer harboring PI3CA mutations (PMID: 28490463).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	breast cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, Sapanisertib (MLN0128) demonstrated efficacy in PIK3CA mutant breast cancer xenograft models (PMID: 23085766).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	triple-receptor negative breast cancer	sensitive	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to Pictilisib (GDC-0941) in culture (PMID: 27196766).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	ovarian cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant	head and neck squamous cell carcinoma	sensitive	Radiotherapy + Taselisib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines, cell line xenograft models, and a patient derived xenograft (PDX) model, all with PIK3CA mutations (PMID: 26589432).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study	Actionable	In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib + Capecitabine	Phase III	Actionable	In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib	Clinical Study	Actionable	In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant PTEN loss	breast cancer	sensitive	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant PTEN loss	breast cancer	resistant	Alpelisib	Clinical Study	Actionable	In a case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN (Cancer Res October 1, 2014 74; LB-327).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant PTEN loss	breast cancer	resistant	Alpelisib	Preclinical - Pdx	Actionable	In a preclinical study, a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss was resistant to Alpelisib (BYL719)-induced inhibition of Akt signaling and growth (Cancer Res October 1, 2014 74; LB-327).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant PTEN loss	prostate cancer	sensitive	PKI-179	Preclinical - Cell culture	Actionable	In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant PTEN loss	breast cancer	sensitive	AZD6482 + BYL719	Preclinical - Pdx	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant KRAS Q61X	ovarian carcinoma	sensitive	Bevacizumab + Temsirolimus + Doxil	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian carcinoma harboring both a PIK3CA mutation and a KRAS Q61 mutation (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant CDKN2A mutant	breast cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant ERBB2 pos	Her2-receptor positive breast cancer	decreased response	Trastuzumab + Lapatinib	Phase II	Actionable	In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA mutant ERBB2 pos	Her2-receptor positive breast cancer	decreased response	Trastuzumab + Lapatinib	Clinical Study	Actionable	In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA N345K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA N345K	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA N345K	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA N345K	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA N345K	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA N345K	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA N345K	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA N345K	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542V	colorectal cancer	sensitive	Cetuximab	Clinical Study	Actionable	In a retrospective study, Erbitux (cetuximab) treatment resulted in stable disease in a colorectal carcinoma patient harboring a PIK3CA E542V mutation (PMID: 25714871).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA over exp	head and neck squamous cell carcinoma	sensitive	Gedatolisib	Preclinical - Cell culture	Actionable	In a preclinical study, some head and neck squamous cell carcinoma cell lines over expressing PIK3CA demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) (PMID: 25977343).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA over exp	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA over exp	lung squamous cell carcinoma	sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA over exp	glioblastoma multiforme	sensitive	YM-024	Preclinical	Actionable	In a preclinical study, YM-024 inhibited proliferation and anchorage-independent growth of glioblastoma cell lines with elevated Pik3ca protein level in culture (PMID: 24718026).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA over exp	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type PIK3CA in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA V955I	colorectal cancer	resistant	Fluorouracil + Cetuximab	Clinical Study	Actionable	In a clinical study, PIK3CA V955I was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955I (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545X KRAS G12X	colorectal cancer	sensitive	Temsirolimus	Clinical Study	Actionable	In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA E545K PIK3CA D549N	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA E545K PIK3CA D549N	colon cancer	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA E545K PIK3CA D549N	colorectal cancer	sensitive	Regorafenib + Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N in culture and reduced tumor growth in cell line xenograft models (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture and in cell line xenograft models (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	sensitive	Pimasertib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA D549N PIK3CA E545K	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA wild-type	colorectal cancer	sensitive	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type PTEN inact mut	lung small cell carcinoma	decreased response	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN inactivating mutations were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	NRAS mut PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	predicted - sensitive	Cetuximab + FOLFOX	Phase II	Actionable	In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type PTEN Y27fs*1	lung small cell carcinoma	resistant	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN Y27fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Neratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF mut PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type PTEN R55fs*1	lung small cell carcinoma	resistant	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN R55fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type	Advanced Solid Tumor	sensitive	PX-866	Phase I	Actionable	In a Phase I study, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type	Her2-receptor positive breast cancer	sensitive	Paclitaxel + Lapatinib + Trastuzumab	Phase II	Actionable	In a Phase II trial, the combination of Taxol (paclitaxel) plus Herceptin (trastuzumab) and Tykerb (lapatinib) resulted in a higher pathologic complete remission rate in ERBB2 (HER2)-receptor positive breast cancer patients with PIK3CA wild-type compared to those harboring a PIK3CA mutation (PMID: 26245675).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type	Her2-receptor negative breast cancer	no benefit	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in no clinical benefit in 4 patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type	triple-receptor negative breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in PIK3CA wild-type, triple-receptor negative breast cancer cell lines in culture (PMID: 27020857).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type	breast cancer	no benefit	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize PIK3CA wild-type breast cancer cell lines to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type	breast cancer	predicted - sensitive	A-1210477 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, combination of WEHI-539 and A-1210477 resulted in enhanced apoptosis in PIK3CA wild-type breast cancer cell lines in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	A66	Preclinical	Actionable	In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	Idelalisib	Preclinical	Actionable	In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Vemurafenib + ZSTK474	Preclinical	Actionable	In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + ZSTK474	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	BEZ235 + Vemurafenib	Preclinical	Actionable	In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	TGX-221	Preclinical	Actionable	In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type PTEN loss	breast cancer	no benefit	Everolimus + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type PTEN loss	breast cancer	no benefit	Everolimus + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type PTEN loss	breast cancer	resistant	AZD8835	Preclinical	Actionable	In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type PTEN loss	breast cancer	sensitive	Selumetinib + Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and Selumetinib (AZD6244) in culture (PMID: 21358673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA wild-type PTEN loss	breast cancer	sensitive	Torkinib + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA wild-type	colon cancer	sensitive	BKM120 + Cetuximab	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture, and colorectal cancer patient-derived xenograft (PDX) models with KRAS or BRAF mutations and wild-type PIK3CA demonstrated a trend toward greater tumor growth inhibition (PMID: 26439693).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA wild-type	colon cancer	sensitive	Buparlisib	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E365K PTEN mut	endocervical carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E365K PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA D350G PIK3CA R93W PTEN R130G	endometrial cancer	sensitive	ARQ092	Preclinical - Pdx	Actionable	In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to ARQ092, demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R KRAS G12D PIK3CA amp	endometrial cancer	sensitive	BEZ235 + PD98509	Preclinical	Actionable	In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA G1049R	endometrial cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA G1049R demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R	breast cancer	sensitive	Alpelisib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA G1049R	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA H1047K	melanoma	sensitive	ARQ092 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of ARQ092 and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA F930S	colorectal cancer	resistant	Fluorouracil + Cetuximab	Clinical Study	Actionable	In a clinical study, PIK3CA F930S was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA F930S (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA Q546L	colorectal cancer	sensitive	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA E545K	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K PTEN loss	stomach cancer	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including 2 gastric cancer patients harboring PIK3CA E545K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF G596R PIK3CA E545K	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA E545K	colorectal adenocarcinoma	sensitive	Cobimetinib + Pictilisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Pictilisib (GDC-0941) and Cobimetinib (GDC-0973) inhibited tumor growth in a colorectal adenocarcinoma xenograft model harboring KRAS G13D and PIK3CA E545K mutations, and demonstrated improved efficacy over either agent alone (PMID: 22084396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA E545K	endometrial cancer	resistant	Everolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, expression of KRAS G13D in an endometrial cancer cell line harboring PIK3CA E545K conferred resistance to Afinitor (everolimus) in xenograft models (PMID: 20664172).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	resistant	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	resistant	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	AKT1 over exp PIK3CA E545K	breast cancer	resistant	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA E545K	colon cancer	decreased response	Buparlisib	Preclinical	Actionable	In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA E545K	colon cancer	no benefit	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS mutant PIK3CA E545K	colon cancer	sensitive	BKM120 + Cetuximab	Preclinical	Actionable	In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	estrogen-receptor positive breast cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA E545K in culture and suppressed tumor growth in xenograft models (PMID: 26839307).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	colorectal cancer	sensitive	Cetuximab + Irinotecan	Clinical Study	Actionable	In a retrospective study, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in stable disease in 50% (1/2) and 14 months without evidence of disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E545K mutation (PMID: 25714871).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	esophagus squamous cell carcinoma	sensitive	LY294002	Preclinical	Actionable	In a preclinical study, LY294002 inhibited cell proliferation of esophagus squamous cell carcinoma cells expressing PIK3CA E545K (PMID: 18262558).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	Advanced Solid Tumor	resistant	A66	Preclinical	Actionable	In a preclinical study, cancer cell lines harboring PIK3CA E545K did not demonstrate sensitivity to A66 in culture, in contrast with cells harboring PIK3CA H1047R (PMID: 21668414).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	Advanced Solid Tumor	sensitive	GDC-0980	Phase I	Actionable	In a Phase I trial, Apitolisib (GDC-0980) resulted in a partial response in two patients, one with head and neck squamous cell carcinoma and another with ovarian cancer, both harboring PIK3CA E545K (PMID: 26787751).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E545K mutations (PMID: 15647370).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	urinary bladder cancer	sensitive	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) inhibited Akt phosphorylation, resulted in growth inhibition in bladder cancer cells harboring PIK3CA E545K in culture (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA E545K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	Everolimus	Preclinical	Actionable	In a preclinical study, breast cancer cell lines harboring a PIK3CA E545K mutation had increased sensitivity to Afinitor (everolimus) in culture (PMID: 20664172).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 26237138).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	thyroid cancer	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, expression of PIK3CA E545K in a thyroid cancer cell line resulted in increased sensitivity to MK2206 in culture (PMID: 21289267).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 decreased cell proliferation in colorectal cancer cells harboring a PIK3CA E545K mutation in cell culture (PMID: 21966435).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	ARQ092	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with ARQ092 resulted in growth inhibition in hormone receptor positive breast cancer cells harboring PIK3CA E545K in culture (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	no benefit	BEZ235 + Venetoclax	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA E545K to Venclexta (venetoclax) in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	WYE-125132	Preclinical	Actionable	In a preclinical study, WYE-125132 inhibited proliferation of breast cancer cells with a PIK3CA E545K mutation (PMID: 20068177).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	lung squamous cell carcinoma	sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	head and neck squamous cell carcinoma	sensitive	rigosertib	Preclinical - Pdx	Actionable	In a preclinical study, head and neck squamous cell carcinoma patient-derived xenograft models harboring a PIK3CA E545K mutation demonstrated increased sensitivity to Estybon (rigosertib) (PMID: 23873848).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	ovarian cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells harboring PIK3CA E545K in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	ARQ 751	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	BAY1125976	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K in culture, and inhibited AKT signaling and tumor growth in xenograft models (PMID: 27699769).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	cervical cancer	sensitive	PW12	Preclinical	Actionable	In a preclinical study, PW12 inhibited proliferation of cervical cancer cells with a PIK3CA E545K mutation (PMID: 22391131).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	gastrointestinal system cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, gastric cancer cells harboring PI3KCA E545K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast carcinoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a human breast carcinoma cell line harboring PIK3CA E545K in culture and inhibited tumor growth in xenograft models (PMID: 25637314).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	hilar cholangiocellular carcinoma	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1; harboring PIK3CA E545K), with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation and colony formation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E545K to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	urinary bladder cancer	sensitive	Pictilisib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Nexavar (sorafenib) synergistically decreased Erk and Akt phosphorylation, inhibited survival of bladder cancer cells harboring PIK3CA E545K in culture (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	Advanced Solid Tumor	sensitive	rigosertib	Preclinical - Cell culture	Actionable	In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA E545K in culture (PMID: 27104980).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	head and neck squamous cell carcinoma	predicted - sensitive	Carboplatin + Paclitaxel + Temsirolimus	Phase II	Actionable	In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PIK3CA E545K demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	PKI-402	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with PKI-402 resulted in decreased Akt phosphorylation and tumor regression in ERBB2 (HER2)-positive breast cancer cell line xenograft models harboring PIK3CA E545K (PMID: 20371716).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	urinary bladder cancer	sensitive	Cisplatin + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Platinol (cisplatin) synergistically inhibited Akt phosphorylation and growth of bladder cancer cells harboring PIK3CA E545K in culture (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	Advanced Solid Tumor	sensitive	Alpelisib	Preclinical - Pdx	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited PIK3CA E545K and showed anti-tumor activity in patient-derived xenograft models harboring a PIK3CA E545K mutation (PMID: 24608574).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	colon cancer	sensitive	LY2780301	Phase I	Actionable	In a Phase I trial, a colon cancer patient harboring PIK3CA E545K was sensitive to LY2780301, demonstrating stable disease for approximately 125 days (PMID: 25902900).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	leukemia	sensitive	LY3023414	Preclinical	Actionable	In a preclinical study, LY3023414 inhibited tumor growth in a transgenic animal model of leukemia driven by PIK3CA E545K (PMID: 27439478).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	non-small cell lung carcinoma	sensitive	Copanlisib + Paclitaxel	Preclinical - Pdx	Actionable	In a preclinical study, Aliqopa (copanlisib), in combination with Taxol (paclitaxel), induced tumor regression in PIK3CA E545K-mutant patient-derived non-small cell lung cancer xenografts (PMID: 24170767).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	colorectal cancer	resistant	Fluorouracil + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells over expressing PIK3CA E545K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells expressing PIK3CA E545K (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	urinary bladder cancer	sensitive	Gemcitabine + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Gemzar (gemcitabine) synergistically inhibited Akt phosphorylation and growth of bladder cancer cells harboring PIK3CA E545K in culture (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545K	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA E545K in culture (PMID: 21325073, PMID: 17314276).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G13D PIK3CA E545k TP53 S241F	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA E545K TP53 R335fs	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA E545K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA E545K	breast cancer	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	decreased response	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	decreased response	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS Q61H PIK3CA E545K	non-small cell lung carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS Q61H PIK3CA E545K	non-small cell lung carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS Q61H PIK3CA E545K	non-small cell lung carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS Q61H PIK3CA E545K	non-small cell lung carcinoma	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E545V	ovarian clear cell adenocarcinoma	sensitive	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA E545V was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA P449T	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Regorafenib + Cetuximab	Preclinical	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA P449T	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	BRAF V600E PIK3CA P449T TP53 R273H	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA P539R	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA P539R in culture (PMID: 27699769).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 A775_G776insYVMA PIK3CA R425L	non-small cell lung carcinoma	predicted - resistant	Trastuzumab	Clinical Study	Actionable	In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E39K	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA E39K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA N345I	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA N345I demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA T1025A	lung small cell carcinoma	sensitive	PF-4989216	Preclinical - Cell culture	Actionable	In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA T1025A in culture (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R38C PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA R38C  PTEN loss	endometrial cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp KRAS amp	endometrial cancer	sensitive	BEZ235 + PD98509	Preclinical	Actionable	In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	lung small cell carcinoma	resistant	PF-4989216	Preclinical - Cell culture	Actionable	In a preclinical study, small cell lung carcinoma cells harboring amplification of wild-type PIK3CA were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	nasopharynx carcinoma	sensitive	MK2206	Phase II	Actionable	In a Phase II study, MK2206 increased stable disease to 12 months in a nasopharyngeal carcinoma patient with Pik3ca amplification (PMID: 26084990).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	ovarian cancer	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a PIK3CA amplified human ovarian cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 25637314).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	triple-receptor negative breast cancer	sensitive	NVP-AEW541 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, NVP-AEW541 enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	urinary bladder cancer	sensitive	Gemcitabine + Pictilisib	Preclinical - Pdx	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Gemzar (gemcitabine) combination treatment resulted in inhibition of Akt phosphorylation and improved tumor growth inhibition and survival compared to single agent therapy in patient-derived xenograft (PDX) models of PIK3CA amplified bladder cancer (PMID: 28808038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	ovarian cancer	sensitive	Panulisib	Preclinical	Actionable	In a preclinical study, Panulisib (P7170) downregulated mTOR pathway signaling in ovarian cancer cells with amplified PIK3CA (PMID: 25700704).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	triple-receptor negative breast cancer	sensitive	Linsitinib + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Linsitinib (OSI-906) enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	head and neck squamous cell carcinoma	sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	head and neck squamous cell carcinoma	predicted - sensitive	AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	head and neck squamous cell carcinoma	sensitive	Radiotherapy + Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines and cell line xenograft models with PIK3CA amplification (PMID: 26589432).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA amp	ovarian cancer	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ovarian cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA K111N	Her2-receptor positive breast cancer	sensitive	trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA K111N	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 27699769).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA K111N	estrogen-receptor positive breast cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and induced tumor regression in xenograft models (PMID: 26839307).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA K111N	breast cancer	sensitive	ARQ092	Preclinical - Cell culture	Actionable	In a preclinical study, hormone receptor positive breast cancer cells harboring PIK3CA K111N were sensitive to ARQ092 in culture, demonstrating inhibition of cell growth (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA K111N	breast cancer	sensitive	ARQ 751	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA K111N was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA K111N	breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 26237138).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 amp PIK3CA K111N	breast cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA M1043V	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) inhibited proliferation in cultured cells expressing PIK3CA M1043V (PMID: 17376864).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS G12D PIK3CA E453K	stomach cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E453K	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA E453K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	sensitive	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study	Actionable	In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study	Actionable	In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA act mut	uterine cancer	sensitive	Taselisib	Preclinical	Actionable	In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	predicted - sensitive	BKM120 + Trastuzumab	Phase I	Actionable	In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut ERBB2 act mut	breast cancer	sensitive	VS-5584	Preclinical	Actionable	In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut PTEN dec exp	renal cell carcinoma	no benefit	GDC-0980	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=15) of PIK3CA activating mutation or loss of Pten expression (PMID: 26951309).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut PTEN dec exp	renal cell carcinoma	no benefit	Everolimus	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=17) of PIK3CA activating mutations (PMID: 26951309).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut PTEN wild-type	breast cancer	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut PTEN wild-type	breast cancer	sensitive	Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	Advanced Solid Tumor	sensitive	Ipatasertib + Paclitaxel	Phase Ib/II	Actionable	In a Phase Ib trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) demonstrated safety and anti-tumor activity in patients with advanced solid tumors, including patients with PIK3CA activating mutations (Annals of Oncology (2014) 25 (suppl_4): iv146-iv164. 10.1093/annonc/mdu331).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	predicted - sensitive	Torin 1 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, the ATP-competitive mTORC1/2 inhibitor Torin1 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	sensitive	Copanlisib	Preclinical	Actionable	In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2) over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	sensitive	Copanlisib	Phase I	Actionable	In a Phase I clinical trial, treatment with Aliqopa (copanlisib) resulted in partial response in one and stable disease in another patient with breast cancer harboring activating PIK3CA mutations (PMID: 27672108; NCT00962611).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	ovarian clear cell adenocarcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 demonstrated efficacy in mouse xenograft models of ovarian clear cell adenocarcinoma with PIK3CA mutations (PMID: 24927217).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	triple-receptor negative breast cancer	predicted - sensitive	Bevacizumab + Doxorubicin + Everolimus	Phase I	Actionable	In a Phase I trial, triple-receptor negative breast cancer patients, including those with PIK3CA activating mutations, demonstrated an overall response rate of 21% (11/52) and clinical benefit rate of 40% (21/52) when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	Advanced Solid Tumor	conflicting	Taselisib	Phase II	Actionable	In a Phase II (MATCH) trial, Taselisib (GDC-0032) treatment resulted in no objective response (0/65) in patients with advanced solid tumors harboring PIK3CA activating mutations (J Clin Oncol 36, 2018 (suppl; abstr 101); NCT02465060).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	Advanced Solid Tumor	conflicting	Taselisib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, Taselisib (GDC-0032) effectively suppressed growth of multiple tumor types in a cell line xenograft models, with greater selectivity for PIK3CA activating mutants (PMID: 23662903).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	no benefit	BKM120 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	lung small cell carcinoma	predicted - sensitive	Navitoclax + Pictilisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263) and GDC-0941 resulted in increased tumor growth delay and apoptosis in a small cell lung cancer cell line xenograft model harboring a PIK3CA activating mutation compared to either drug alone (PMID: 27197306).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	predicted - sensitive	Vistusertib + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, the ATP-competitive mTORC1/2 inhibitor Vistusertib (AZD2014) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	lung small cell carcinoma	sensitive	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cell lines harboring activating PIK3CA mutations in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	predicted - sensitive	MLN0128 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, the ATP-competitive mTORC1/2 inhibitor Sapanisertib (MLN0128) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	non-small cell lung carcinoma	sensitive	Pictilisib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in culture and in xenograft models harboring alterations in the PI3K pathway (PMID: 23136191).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	estrogen-receptor positive breast cancer	predicted - sensitive	AZD5363 + Tamoxifen	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD5363 and 4-hydroxytamoxifen (4-OHT) worked synergistically or additively to inhibit growth of several estrogen receptor-positive breast cancer cell lines in culture, including cell lines with PIK3CA activating mutations, and overcame tamoxifen resistance in a resistant cell line (PMID: 26116361).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	head and neck squamous cell carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, PF-05212384 decreased viability of head and neck squamous carcinoma cells harboring a PIK3CA activating mutation in cell culture (PMID: 24823695).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	Advanced Solid Tumor	sensitive	Afuresertib	Preclinical	Actionable	In a preclinical study, various tumor cell lines harboring PI3KCA activating mutations demonstrated increased sensitivity to Afuresertib (GSK2110183) in cultured cells (PMID: 24978597).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, breast cancer cell lines harboring activating mutations in PIK3CA had increased sensitivity to MK2206 in cell culture (PMID: 22932669).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	head and neck squamous cell carcinoma	predicted - sensitive	AZD8055 + Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, two head and neck squamous cell carcinoma patient-derived xenograft (PDX) models harboring a PIK3CA activating mutation demonstrated greater delayed tumor growth when treated with a combination of AZD8055 and Erbitux (cetuximab) compared to either agent alone (PMID: 28446642).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	predicted - sensitive	Ridaforolimus + MK2206	Phase I	Actionable	In a Phase I clinical trial, Ridaforolimus in combination with MK-2206 demonstrated clinical activity in breast cancer patients expressing a PI3K pathway dependent gene expression signature, with complete response in 14.3% (2/14), partial response in 12.5% (2/16), and 2 patients achieving stable disease (PMID: 26187616).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	no benefit	BEZ235 + Venetoclax	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	Advanced Solid Tumor	sensitive	GSK1059615	Preclinical	Actionable	In a preclinical study, solid tumor cell lines harboring PIK3CA activating mutations demonstrated increased sensitivity to GSK1059615 in culture (Clin Cancer Res October 1, 2008 14; B37).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	Advanced Solid Tumor	sensitive	Metformin	Preclinical	Actionable	In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human xenograft tumors harboring a PIK3CA-activating mutation (PMID: 23986086).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	breast cancer	no benefit	Alpelisib + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	Advanced Solid Tumor	sensitive	Everolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Afinitor (everolimus) demonstrated efficacy in multiple cancer cell lines in culture and xenograft models with PIK3CA activating mutations (PMID: 20664172).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	Advanced Solid Tumor	sensitive	BAY1125976	Preclinical	Actionable	In a preclinical study, BAY1125976 demonstrated anti-tumor efficacy in multiple xenograft tumor models of different cancers with PIK3CA mutations or PTEN deletions and displayed synergy with other anti-cancer therapies (Cancer Res 2013;73(8 Suppl):Abstract nr 2050).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA act mut	triple-receptor negative breast cancer	predicted - sensitive	Bevacizumab + Doxorubicin + Temsirolimus	Phase I	Actionable	In a Phase I trial, triple-receptor negative breast cancer patients, including those with PIK3CA activating mutations, demonstrated an overall response rate of 21% (11/52) and clinical benefit rate of 40% (21/52) when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS Q61H PIK3CA E542K	colorectal cancer	sensitive	Palbociclib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K PTEN loss	stomach cancer	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including a gastric cancer patient harboring PIK3CA E542K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K PTEN loss	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	colon adenocarcinoma	sensitive	VS-5584	Preclinical	Actionable	In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	papillary thyroid carcinoma	sensitive	MK2206 + Temsirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 suppressed activation of AKT induced by Torisel (temsirolimus), and MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of a papillary thyroid cancer cell line harboring PIK3CA E542K in culture (PMID: 21289267).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	head and neck squamous cell carcinoma	sensitive	GDC-0980	Phase I	Actionable	In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in a partial response in a patient with head and neck squamous cell carcinoma harboring a PIK3CA E542K mutation (PMID: 26787751).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	colorectal cancer	resistant	Fluorouracil + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells over expressing PIK3CA E542K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	colorectal cancer	sensitive	Cetuximab + Irinotecan	Clinical Study	Actionable	In a retrospective study, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E542K mutation (PMID: 25714871).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	gastrointestinal system cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, gastric cancer cells harboring PI3KCA E542K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	sensitive	ARQ092	Preclinical - Cell culture	Actionable	In a preclinical study, a hormone breast cancer cell line harboring PIK3CA E542K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E542K in culture (PMID: 21558396).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA E542K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E542K mutations (PMID: 15647370).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	papillary thyroid carcinoma	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including a papillary thyroid cancer cell line harboring PIK3CA E542K (PMID: 21289267).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	colorectal cancer	sensitive	PD-0325901 + Pictilisib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, the combination of GDC-0941 and PD-0325901 (PI3K and MEK inhibitors, respectively) inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24339963).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	cervical squamous cell carcinoma	sensitive	Gemcitabine + LY2780301	Phase Ib/II	Actionable	In a Phase Ib trial, a patient with cervical squamous cell carcinoma harboring PIK3CA E542K demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	PIK3CA E542K	ovarian cancer	predicted - sensitive	Temsirolimus	Phase I	Actionable	In a Phase I trial, an ovarian cancer patient harboring a PIK3CA E542 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	KRAS Q61L PIK3CA E542K TP53 T118Qfs*5	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).
PIK3CA	CLOVE | CWS5 | MCAP | MCM | MCMTC | p110-alpha | PI3K | PI3K-alpha	3q26.32	NM_006218	EGFR over exp PIK3CA E542K	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment demonstrated decreased efficcacy in patient-derived xenograft (PDX) models of esophageal cancer with Egfr overexpression and PIK3CA E542K compared to models with only Egfr overexpression (PMID: 28881608).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN R130*	follicular thyroid carcinoma	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an follicular thyroid cancer cell line harboring PTEN R130* and loss of one PTEN allele (PMID: 21289267).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	AKT1 Q79K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	AKT1 Q79K BRAF V600X PTEN pos	melanoma	sensitive	MK2206 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN pos KRAS G12D	endometrial cancer	sensitive	Metformin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN positive	melanoma	sensitive	Pembrolizumab	Clinical Study	Actionable	In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN positive	melanoma	sensitive	Nivolumab	Clinical Study	Actionable	In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Opdivo (nivolumab) (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	AKT1 E17K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN A126G	prostate cancer	sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 inhibited Akt signaling and cell migration in prostate cancer cell lines overexpressing PTEN A126G (PMID: 26504226).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN A126G	prostate cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited Akt signaling and cell migration in prostate cancer cells expressing PTEN A126G in culture (PMID: 26504226).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN A72fs*5	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PTEN A72fs*5 in culture (PMID: 21325073, PMID: 17314276).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN A72fs*5	triple-receptor negative breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in a triple-negative breast cancer cell line harboring PTEN A72fs*5 in culture (PMID: 26237138).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA H1047R PTEN E307K	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN V54fs	glioblastoma multiforme	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human glioblastoma cell line harboring PTEN V54fs (PMID: 25637314).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	EGFR act mut EGFR A289T PTEN I253N PTEN N69D	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	EGFR act mut EGFR A289T PTEN I253N PTEN N69D	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA act mut PTEN dec exp	renal cell carcinoma	no benefit	Everolimus	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=17) of PIK3CA activating mutations (PMID: 26951309).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA act mut PTEN dec exp	renal cell carcinoma	no benefit	GDC-0980	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=15) of PIK3CA activating mutation or loss of Pten expression (PMID: 26951309).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	ERBB2 amp PTEN dec exp	Her2-receptor positive breast cancer	decreased response	CDX-3379	Preclinical	Actionable	In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN dec exp	Advanced Solid Tumor	predicted - sensitive	Pemetrexed + Sorafenib	Phase I	Actionable	In a Phase I clinical trial, low Pten expression or lack of Pten expression was associated with better response to treatment with the combination of Alimta (pemetrexed) and Nexavar (sorafenib) in patients with advanced solid tumors (PMID: 27213589).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN dec exp	Advanced Solid Tumor	sensitive	GSK2636771	Phase Ib/II	Actionable	In a Phase I/II trial, GSK2636771 treatment inhibited Akt signaling, and resulted in partial response in 2% (1/53) and stable disease in 25% (13/53) of patients with PTEN-deficient advanced solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2514)).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN dec exp	renal cell carcinoma	no benefit	Everolimus	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by high expression (n=17) and low expression (n=21) of Pten (PMID: 26951309).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN dec exp	renal cell carcinoma	no benefit	GDC-0980	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by high expression (n=17) and low expression (n=19) of Pten (PMID: 26951309).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN dec exp	melanoma	sensitive	SAR260301	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 inhibited tumor growth in xenograft models of melanoma cell lines harboring PTEN deficiency (PMID: 24387221).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN dec exp	triple-receptor negative breast cancer	predicted - sensitive	Ipatasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients with low Pten expression (J Clin Oncol 35, 2017 (suppl; abstr 1009)).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	ERBB2 pos PTEN dec exp	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study	Actionable	In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KRAS G12D PTEN dec exp TP53 R306*	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN T319fs*1	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN T319fs*1 in culture (PMID: 27699769).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600X PTEN H93D	melanoma	sensitive	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited Kit, Erk, and Mtor signaling, resulted in tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	sensitive	Imatinib mesylate + LY294002	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) in combination with LY394002 resulted in enhanced tumor growth inhibition compared to monotherapy in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	resistant	Sunitinib	Preclinical - Pdx	Actionable	In a preclinical study, Sutent (sunitinib) demonstrated limited inhibition of Kit, Erk, and Mtor signaling and resulted in minimal (22.9%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN V275*	triple-receptor negative breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring PTEN V275* in culture (PMID: 26237138).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600X PIK3CA H1047R PTEN Y86fs	melanoma	resistant	Vemurafenib	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN N48I	urinary bladder cancer	decreased response	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited  inhibition of Akt phosphorylation and growth in bladder cancer cells harboring PTEN N48I in culture (PMID: 28808038).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA R38C  PTEN loss	endometrial cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600E/K PTEN loss	Advanced Solid Tumor	predicted - sensitive	PX-866 + Vemurafenib	Phase I	Actionable	In a Phase I trial, the combination therapy of PX-866 and Zelboraf (vemurafenib) demonstrated safety and resulted in an objective response in 28% (5/18) of advanced solid tumor patients harboring BRAF V600E or K, and of those five patients, 80% (4/5) also demonstrated loss of PTEN (PMID: 29051322).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss STK11 loss	endometrial cancer	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA H1047R PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	ABT-737 + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA H1047R PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	ABT-737 + MLN0128	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA H1047R PTEN loss	breast cancer	no benefit	BEZ235 + Venetoclax	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA H1047R PTEN loss	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA E545K PTEN loss	stomach cancer	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including 2 gastric cancer patients harboring PIK3CA E545K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss VHL loss	renal carcinoma	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA mutant PTEN loss	prostate cancer	sensitive	PKI-179	Preclinical - Cell culture	Actionable	In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA mutant PTEN loss	breast cancer	sensitive	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA mutant PTEN loss	breast cancer	sensitive	AZD6482 + BYL719	Preclinical - Pdx	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA mutant PTEN loss	breast cancer	resistant	Alpelisib	Clinical Study	Actionable	In a case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN (Cancer Res October 1, 2014 74; LB-327).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA mutant PTEN loss	breast cancer	resistant	Alpelisib	Preclinical - Pdx	Actionable	In a preclinical study, a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss was resistant to Alpelisib (BYL719)-induced inhibition of Akt signaling and growth (Cancer Res October 1, 2014 74; LB-327).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	EGFR amp PTEN loss	glioblastoma multiforme	decreased response	Dacomitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Dacomitinib induced growth inhibition in culture and in xenograft models (PMID: 25939761).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss RB1 loss	triple-receptor negative breast cancer	resistant	Pictilisib	Preclinical	Actionable	In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss RB1 loss	triple-receptor negative breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss RB1 loss	triple-receptor negative breast cancer	resistant	Palbociclib	Preclinical	Actionable	In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss TP53 loss	prostate cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of  prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600D PTEN loss	melanoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	ERBB2 pos PTEN loss	Her2-receptor positive breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	ERBB2 pos PTEN loss	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Phase I	Actionable	In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss KRAS G12D	pancreatic adenocarcinoma	sensitive	MK2206	Phase I	Actionable	In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA wild-type PTEN loss	breast cancer	no benefit	Everolimus + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA wild-type PTEN loss	breast cancer	resistant	AZD8835	Preclinical	Actionable	In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA wild-type PTEN loss	breast cancer	sensitive	Selumetinib + Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and Selumetinib (AZD6244) in culture (PMID: 21358673).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA wild-type PTEN loss	breast cancer	no benefit	Everolimus + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA wild-type PTEN loss	breast cancer	sensitive	Torkinib + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN loss	melanoma	sensitive	SAR260301 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN loss	melanoma	no benefit	GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN loss	melanoma	no benefit	Pembrolizumab	Preclinical	Actionable	In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN loss	melanoma	sensitive	SAR260301	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN loss	melanoma	sensitive	SAR260301 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN loss	melanoma	sensitive	GSK2636771 + Pembrolizumab	Preclinical	Actionable	In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA E542K PTEN loss	stomach cancer	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including a gastric cancer patient harboring PIK3CA E542K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA E542K PTEN loss	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600E PTEN loss TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KRAS G12D PTEN loss TP53 V216M	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA E453del PIK3CA T1025K PIK3CA R88L PTEN mut PTEN loss	endometrial carcinoma	sensitive	Copanlisib	Phase I	Actionable	In a Phase I clinical trial, an endometrial carcinoma patient harboring PIK3CA T1052K, R88L, and E453del, as well as a PTEN mutation and loss of PTEN protein expression demonstrated a complete response to treatment with Aliqopa (copanlisib) (PMID: 27672108).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600E PTEN loss	melanoma	sensitive	GSK2636771 + unspecified PD-1 antibody	Preclinical	Actionable	In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600E PTEN loss	melanoma	sensitive	Pictilisib + PLX4720	Preclinical	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600E PTEN loss	melanoma	sensitive	GDC0879 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600E PTEN loss	melanoma	resistant	Everolimus	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600E PTEN loss	melanoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	Ipatasertib	Phase I	Actionable	In a Phase I trial, a patient with castration resistant prostate cancer harboring a loss of PTEN demonstrated an improved prostate specific antigen when treated with Ipatasertib (GDC-0068) (PMID: 27872130).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	uterine corpus sarcoma	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human uterine sarcoma cell line xenograft model (PMID: 22781553).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Talazoparib	Preclinical	Actionable	In a preclinical study, the combination of Talazoparib (BMN-673) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res, Feb 2016 14; B12).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, treatment with AZD5363 decreased AKT phosphorylation and downstream signaling and reduced tumor burden in mouse models of PTEN-deficient prostate cancer, including both castration-naive and castration resistant models (PMID: 26910118).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	predicted - sensitive	CX-5461 + CX-6258	Preclinical	Actionable	In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in decreased tumor burden in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	head and neck squamous cell carcinoma	predicted - sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	AZD8186	Phase I	Actionable	In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including triple negative breast cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	predicted - sensitive	AR-mTOR-26	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in prostate cancer xenograft models with PTEN loss (Cancer Res 2010;70(8 Suppl):Abstract nr 4484).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	triple-receptor negative breast cancer	sensitive	MSC2363318A	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a triple-receptor negative breast cancer xenograft model harboring PTEN loss was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth and tumor regression (PMID: 27186432).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	sarcoma	sensitive	YU238259	Preclinical	Actionable	In a preclinical study, YU238259 demonstrated increased cytotoxicity in PTEN-deficient sarcoma cell lines in culture (PMID: 26116172).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Rubraca (rucaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	Abiraterone + Ipatasertib	Clinical Study	Actionable	In a clinical study, the combination of Ipatasertib (GDC-0068) and Zytiga (abiraterone) resulted in a better progression free survival in metastatic castration resistant prostate cancer patients with PTEN loss when compared to placebo combined with Zytiga (abiraterone) (Ann Oncol (2016) 27 (suppl_6): 718O).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	ovarian mucinous neoplasm	decreased response	KX2-391	Preclinical	Actionable	In a preclincal study, mucinous ovarian carcinoma cell lines harboring PTEN loss were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	melanoma	sensitive	DETD-35 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DETD-35 and Zelboraf (vemurafenib) combination treatment resulted in further reduction of tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss when compared to single agent treatment (PMID: 27048951).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	renal carcinoma	sensitive	Capivasertib	Preclinical - Pdx	Actionable	In a preclinical study, AZD5363 inhibited growth of renal cancer Pdx models with Pten loss (PMID: 22294718).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	head and neck squamous cell carcinoma	predicted - sensitive	rigosertib	Phase I	Actionable	In a Phase I trial in patients with advanced solid tumors, Estybon (rigosertib) treatment resulted in responses in 2 patients with head and neck squamous cell carcinoma (1 complete response and 1 partial response), 1 harboring PIK3CA amplification and the other harboring PTEN loss (Cancer Res April 15 2013 (73) (8 Supplement) LB-198).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	predicted - sensitive	CX-6258	Preclinical	Actionable	In a preclinical study, CX-6258 treatment resulted in decreased carcinoma in situ in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	lung squamous cell carcinoma	predicted - sensitive	AZD8186	Phase I	Actionable	In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including squamous non-small cell lung cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	melanoma	sensitive	DETD-35	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DETD-35 treatment resulted in reduced tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss (PMID: 27048951).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	Advanced Solid Tumor	no benefit	SAR260301	Phase I	Actionable	In a Phase I trial, SAR260301 demonstrated acceptable safety but undesirable pharmacokinetics, and resulted in no response in patients with advanced solid tumors harboring PTEN loss (J Clin Oncol 33, 2015 (suppl; abstr 2564)).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	breast cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 induced tumor regression in PTEN-null breast cancer cell line xenograft models (PMID: 21673091).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	colon cancer	sensitive	KU-55933	Preclinical	Actionable	In a preclinical study, KU-55933 induced cell cycle arrest and caspase activation in PTEN deficient human colon cancer cells in culture (PMID: 25870146).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	glioblastoma multiforme	sensitive	PKI-402	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PKI-402 inhibited tumor growth in PTEN-negative glioblastoma multiforme cell line xenograft models (PMID: 20371716).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	glioblastoma multiforme	sensitive	LY3023414	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY3023414 inhibited Pi3k/mTor signaling and proliferation in PTEN deficient glioblastoma cells in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	glioblastoma multiforme	sensitive	CCT128930	Preclinical - Cell line xenograft	Actionable	In preclinical studies, CCT128930 prevented tumor growth in a PTEN-null human glioblastoma cell line xenograft model (PMID: 21191045).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	ovarian cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 inhibited tumor growth in PTEN-null ovarian cancer cell line xenograft models (PMID: 21673091).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	SF1126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a glioblastoma cell line harboring PTEN loss (PMID: 24634413) was sensitive to SF1126, demonstrating a 76% decrease in tumor growth in cell line xenograft models (PMID: 18172313).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	AZD8186	Preclinical	Actionable	In a preclinical study, AZD8186 inhibited tumor growth of PTEN deficient prostate xenografts models (PMID: 25514658).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	no benefit	MK2206	Phase I	Actionable	In a Phase I clinical trial, 8 patients with metastatic, castration-resistant prostate cancer harboring a loss of PTEN did not respond to MK-2206 therapy, but prolonged stable disease was observed in 2 patients (PMID: 26187616).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	glioblastoma multiforme	resistant	A66	Preclinical - Cell line xenograft	Actionable	In a preclinical study, A66 did not inhibit tumor growth in a PTEN-null cell line xenograft model of glioblastoma (PMID: 21668414).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Niraparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zejula (niraparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	Advanced Solid Tumor	no benefit	Everolimus	Phase II	Actionable	In a Phase II trial, Afinitor (everolimus) treatment in patients with advanced solid tumors harboring PTEN loss did not reach its primary endpoint, resulting in only stable disease or progressive disease (PMID: 28330462).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	head and neck squamous cell carcinoma	predicted - sensitive	AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	non-small cell lung carcinoma	sensitive	Pictilisib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in both culture and xenograft models harboring alterations in the PI3K pathway (PMID: 23136191).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Lynparza (olaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	breast adenocarcinoma	sensitive	SAR245409	Preclinical - Cell culture	Actionable	In a preclinical study, a breast adenocarcinoma cell line harboring PTEN loss was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	colorectal cancer	sensitive	AZD8186 + Vistusertib	Phase I	Actionable	In a Phase I trial, the combination of AZD8186 and Vistusertib (AZD2014) resulted in a partial response in a patient with PTEN-deficient colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2570)).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	Panulisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Panulisib (P7170) inhibited tumor growth in PTEN null prostate cancer cell xenograft models (PMID: 25700704).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate carcinoma	decreased response	SAR260301	Preclinical - Cell line xenograft	Actionable	In a precliinical study, PTEN deficient prostate carcinoma cells demonstrated reduced response to SAR260301 in cell culture and in cell line xenograft models (PMID: 27196754).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	breast cancer	sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	glioblastoma multiforme	sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited Akt phosphorylation, resulted in growth inhibition of PTEN-null glioblastoma cells in culture and in cell line xenograft models (PMID: 21750219).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PTEN loss demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	breast cancer	resistant	Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines with PTEN loss demonstrated resistance to Torkinib (PP242) in culture (PMID: 21358673).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	ovarian mucinous neoplasm	no benefit	KX2-391 + Oxaliplatin	Preclinical	Actionable	In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) combination treatment did not show improved tumor suppression in xenograft models of ovarian mucinous carcinoma harboring PTEN loss when compared to single agent treatment (PMID: 24100628).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a prostate cancer cell line with PTEN loss was sensitive to XL765 (SAR245409) treatment, demonstrating inhibition of the PI3K pathway and decreased colony formation in culture, and inhibition of tumor growth and reduced tumor vascularization in cell line xenograft models (PMID: 24634413).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	OP449	Preclinical	Actionable	In a preclinical study, prostate cancer mouse models deficient for Pten demonstrated inhibition of the PI3K/Akt signaling pathway and a decrease in both tumor size and cell proliferation when treated with OP449 (PMID: 26563471).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	diffuse large B-cell lymphoma	predicted - sensitive	GSK2334470 + Idelalisib	Preclinical - Cell culture	Actionable	In a preclinical study, GSK2334470 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss that acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	acute lymphocytic leukemia	sensitive	BGT226	Preclinical - Cell culture	Actionable	In a preclinical study, BGT226 treatment in PTEN-deficient acute lymphoblastic leukemia cells resulted in inhibition of PI3K/Akt signaling and apoptotic activity in culture (PMID: 23705826).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human prostate cancer cell line xenograft model (PMID: 22781553).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	melanoma	sensitive	GSK2636771	Preclinical	Actionable	In a preclinical study, human melanoma cells with PTEN loss were sensitive to GSK2636771, resulting in decreased activation of Akt and some inhibition of tumor growth (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	GS-9820	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of prostate cancer with PTEN deficiency (Mol Cancer Ther 2009;8(12 Suppl):B136).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	melanoma	decreased response	Nivolumab	Clinical Study	Actionable	In a clinical study, melanoma patients with PTEN loss demonstrated decreased response to anti-PD-1 antibodies, including Opdivo (nivolumab), as compared to patients in which PTEN is present (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	glioblastoma multiforme	no benefit	BLZ945	Preclinical	Actionable	In a preclinical study, BLZ945 resulted in limited benefit in transgenic mouse models of glioblastoma harboring a loss of PTEN (PMID: 27199435).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	breast cancer	sensitive	GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	brain glioma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human glioma cells with PTEN loss in culture (PMID: 21325073).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	breast adenocarcinoma	sensitive	Gemcitabine + LY2780301	Phase Ib/II	Actionable	In a Phase Ib trial, a breast adenocarcinoma patient harboring PTEN loss demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	renal carcinoma	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human renal carcinoma cells with PTEN loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	glioblastoma multiforme	sensitive	GDC-0084	Preclinical - Cell line xenograft	Actionable	In a preclinical study, two PTEN-deficient glioblastoma cell line xenograft models were sensitive to GDC-0084 treatment, resulting in decreased tumor volumes by 70% and 40%, and inhibition of PI3K pathway signaling (PMID: 27638506).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	Advanced Solid Tumor	sensitive	Capivasertib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with loss of Pten (PMID: 22294718).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	breast cancer	resistant	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, 10/12 breast cancer cell lines with PTEN loss demonstrated resistance to Afinitor (everolimus) in culture (PMID: 21358673).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	Advanced Solid Tumor	sensitive	BAY1125976	Preclinical	Actionable	In a preclinical study, BAY1125976 demonstrated anti-tumor efficacy in multiple xenograft tumor models of different cancers with PIK3CA mutations or PTEN deletions and displayed synergy with other anti-cancer therapies (Cancer Res 2013;73(8 Suppl):Abstract nr 2050).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	transitional cell carcinoma	resistant	Everolimus	Phase II	Actionable	In a Phase II trial, 57% (8/14) of transitional cell carcinoma patients that demonstrated uncontrolled disease after treatment with Afinitor (everolimus) harbored PTEN loss compared to 0% of patients with controlled disease demonstrating no evidence of PTEN loss (PMID: 22473592).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	sensitive	KU-60019	Preclinical	Actionable	In a preclinical study, KU-60019 blocked tumor growth in PTEN-deficient human prostate cancer xenograft models (PMID: 25870146).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	diffuse large B-cell lymphoma	predicted - sensitive	Idelalisib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss with acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	prostate cancer	no benefit	CX-5461	Preclinical	Actionable	In a preclinical study, CX-5461 treatment did not result in histological change in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	melanoma	decreased response	Pembrolizumab	Clinical Study	Actionable	In a clinical study, melanoma patients with PTEN loss demonstrated decreased response to anti-PD-1 antibodies, including Keytruda (pembrolizumab), compared to patients in which PTEN is present (PMID: 26645196).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Veliparib (ABT-888) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23	endometrial cancer	sensitive	BGJ398 + BKM120	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KRAS G12V PTEN K6fs*4	prostate cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KRAS G12D PIK3CA H1047R PTEN R130G	endometrial cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA D350G PIK3CA R93W PTEN R130G	endometrial cancer	sensitive	ARQ092	Preclinical - Pdx	Actionable	In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to ARQ092, demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA wild-type PTEN Y27fs*1	lung small cell carcinoma	resistant	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN Y27fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9	ovarian clear cell adenocarcinoma	sensitive	DS-7423	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN R130Q	head and neck squamous cell carcinoma	predicted - sensitive	Carboplatin + Paclitaxel + Temsirolimus	Phase II	Actionable	In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PTEN R130Q demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN L108R	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN L108R in culture (PMID: 27699769).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN L108R	breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PTEN L108R in culture (PMID: 26237138).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600X PTEN neg	melanoma	sensitive	GSK2141795	Preclinical - Cell culture	Actionable	In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN negative	lung squamous cell carcinoma	sensitive	Buparlisib	Phase II	Actionable	In a Phase II trial, one patient with Pten negative squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN negative	glioblastoma multiforme	no benefit	Vandetanib + Temozolomide	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS when compared between glioblastoma patients negative for PTEN versus those positive for PTEN (PMID: 25910950).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN negative	Advanced Solid Tumor	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, PTEN-deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, Talazoparib (BMN-673) (PMID: 23881923).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA R88Q PTEN mut	endometrial cancer	sensitive	Everolimus	Preclinical	Actionable	In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA R88Q PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA R88Q PTEN mut KRAS G12V	endometrial cancer	decreased response	Everolimus	Preclinical	Actionable	In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA R88Q PTEN mut KRAS G12V	endometrial cancer	decreased response	BEZ235	Preclinical	Actionable	In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA R38C PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF V600E PTEN mut	melanoma	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant TP53 mutant	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant TP53 mutant	glioblastoma multiforme	sensitive	Navitoclax + ONC201	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA R108H PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA E365K PTEN mut	endocervical carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA E365K PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mut RB1 mut SMAD4 mut TP53 mut	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	melanoma	sensitive	BI-69A11	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BI-69A11 resulted in antitumor activity in a melanoma cell line harboring a PTEN mutation, including induction of cell death in culture, and in xenograft models, tumor growth inhibition and tumor regression (PMID: 19175524).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	sensitive	Everolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Afinitor (everolimus) inhibited growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	sensitive	A66 + GSK2636771	Preclinical	Actionable	In a preclinical study, A66 and GSK2636771 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	no benefit	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, mutation status of PTEN was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	sensitive	GDC-0980	Phase II	Actionable	In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	resistant	A66	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to A66 induced growth inhibition in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	resistant	AZD6482	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to AZD6482 induced growth inhibition in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	resistant	TGX-221	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to TGX-221 induced growth inhibition in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	triple-receptor negative breast cancer	predicted - sensitive	Ipatasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	sensitive	A66 + AZD6482	Preclinical	Actionable	In a preclinical study, A66 and AZD6482 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	uterine cancer	sensitive	GSK2256098 + Paclitaxel	Preclinical	Actionable	In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Taxol (paclitaxel) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	uterine cancer	sensitive	GSK2256098	Preclinical	Actionable	In a preclinical study, uterine cancer cells harboring a PTEN mutation demonstrated sensitivity to GSK2256098, resulting in inhibition of Ptk2 (Fak) phosphorylation, decreased tumor growth, and apoptosis both in culture and in mouse models (PMID: 25833835).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	breast cancer	predicted - sensitive	MS417 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in a PTEN-mutant breast cancer cell line in culture (PMID: 26058079).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	head and neck squamous cell carcinoma	resistant	Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, head and neck squamous cell carcinoma cell lines and cell line xenograft models with PTEN alterations were resistant to the apoptotic effects of Taselisib (GDC-0032) (PMID: 26589432).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	breast cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, Sapanisertib (MLN0128) induced apoptosis and inhibited MTORC1 signaling in breast cancer cells harboring a PTEN mutation (PMID: 25261369).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	resistant	GSK2636771	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to GSK2636771 induced growth inhibition in culture (PMID: 23674493).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	breast cancer	sensitive	CUDC-907	Preclinical - Cell culture	Actionable	In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN mutant	uterine cancer	sensitive	GSK2256098 + Topotecan	Preclinical	Actionable	In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Hycamtin (topotecan) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	ERBB2 pos PTEN mut	Her2-receptor positive breast cancer	predicted - sensitive	BKM120 + Trastuzumab	Phase I	Actionable	In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN mut	melanoma	decreased response	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN mut	melanoma	predicted - sensitive	ST-162	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ST-162 resulted in tumor regression in a melanoma cell line xenograft model co-harboring mutations in BRAF and PTEN (PMID: 28775144).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN C136Y	breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PTEN C136Y demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA D1029Y PTEN inact mut	lung small cell carcinoma	resistant	PF-4989216	Preclinical - Cell culture	Actionable	In a preclinical study, small cell lung carcinoma cells harboring PIK3CA D1029Y and PTEN inactivating mutation were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	no benefit	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	APC inact mut KRAS G12D PTEN inact mut	colorectal cancer	sensitive	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	APC inact mut PTEN inact mut	colorectal cancer	no benefit	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	APC inact mut PTEN inact mut	colorectal cancer	no benefit	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	APC inact mut PTEN inact mut	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN inact mut	estrogen-receptor positive breast cancer	sensitive	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, a PTEN deficient estrogen-receptor (ER) positive breast cancer cell line demonstrated increased sensitivity to treatment in culture when Pictilisib (GDC-0941) was given at a higher dose for a shorter duration, resulting in inhibition of cell growth (PMID: 26733612).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN inact mut	glioblastoma multiforme	sensitive	SF1126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation (PMID: 24634413) was sensitive to SF1126, demonstrating inhibition of tumor growth in cell line xenograft models (PMID: 18172313).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN inact mut	estrogen-receptor positive breast cancer	sensitive	Fulvestrant + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Faslodex (fulvestrant) and PIctilisib (GDC-0941) resulted in decreased cell viability and increased apoptotic activity in PTEN deficient estrogen-receptor (ER) positive breast cancer cells in culture (PMID: 26733612).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN inact mut	kidney cancer	sensitive	LY3023414	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY3023414 inhibited proliferation of renal cancer cells harboring PTEN inactivating mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN inact mut	prostate adenocarcinoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited PI3K signaling, growth, and migration of a human prostate adenocarcinoma cell line harboring a PTEN inactivating mutation in culture, and inhibited tumor growth and vascularization in xenograft models (PMID: 25637314).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN inact mut	glioblastoma multiforme	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN inact mut	Advanced Solid Tumor	sensitive	Capivasertib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with inactivating Pten mutations (PMID: 22294718).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN inact mut	prostate adenocarcinoma	sensitive	XL147 + Paclitaxel	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of XL147 and Taxol (paclitaxel) inhibited tumor growth and angiogenesis in xenograft models of a human prostate adenocarcinoma cell line harboring an inactivating mutation in PTEN, with increased efficacy compared to either agent alone (PMID: 25637314).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + BYL719	Preclinical	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + BYL719	Preclinical - Cell culture	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + LGX818 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + LGX818 + BYL719	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	TGX-221	Preclinical	Actionable	In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	Binimetinib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	no benefit	BYL719 + MEK162	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	NVP-AEW541 + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	decreased response	Alpelisib	Preclinical	Actionable	In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	no benefit	BYL719 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	no benefit	BYL719 + LGX818	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + Binimetinib	Preclinical	Actionable	In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	BYL719 + GSK2636771 + LGX818	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + LGX818	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + LGX818	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	LGX818 + unspecified IGF-1R antibody	Preclinical	Actionable	In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	BYL719 + GSK2636771	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + LGX818 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + LGX818 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	Pictilisib	Preclinical	Actionable	In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482	Preclinical	Actionable	In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + LGX818 + BYL719	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA wild-type PTEN inact mut	lung small cell carcinoma	decreased response	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN inactivating mutations were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA wild-type PTEN R55fs*1	lung small cell carcinoma	resistant	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN R55fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	GNAQ Q209L PTEN R173S	ocular melanoma	predicted - sensitive	Refametinib	Phase I	Actionable	In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	EGFR amp EGFR act mut PTEN R308C	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	EGFR amp EGFR act mut PTEN R308C	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN G129R	ovarian mucinous neoplasm	decreased response	KX2-391	Preclinical	Actionable	In a preclincal study, mucinous ovarian carcinoma cell lines over-expressing PTEN G129R were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN wild-type	ovarian mucinous neoplasm	sensitive	KX2-391	Preclinical	Actionable	In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN wild-type	glioblastoma multiforme	sensitive	2-Methoxyestradiol	Preclinical	Actionable	In a preclinical study, 2-Methoxyestradiol (2ME2) inhibited tumor-induced angiogenesis and reduced tumor growth in PTEN reconstituted GBM cell lines and mouse models (PMID: 24162827).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN wild-type	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and sensitivity was associated with wild-type PTEN (PMID: 23039341).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN wild-type	uterine cancer	decreased response	GSK2256098	Preclinical	Actionable	In a preclinical study, GSK2256098 treatment resulted in a decreased response in uterine cancer cells with PTEN wild-type versus uterine cancer cells harboring a PTEN mutation (PMID: 25833835).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN wild-type	ovarian mucinous neoplasm	sensitive	KX2-391 + Oxaliplatin	Preclinical	Actionable	In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) synergistically inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN wild-type	melanoma	sensitive	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + LGX818	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + LGX818	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + Binimetinib	Preclinical	Actionable	In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA act mut PTEN wild-type	breast cancer	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA act mut PTEN wild-type	breast cancer	sensitive	Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA H1047R PIK3CA K111R PTEN wild-type	lung small cell carcinoma	sensitive	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA H1047R, PIK3CA K111R, and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA G106_R108del PTEN wild-type	lung small cell carcinoma	sensitive	PF-4989216	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA G106_R108del and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	Pictilisib + vorinostat	Preclinical	Actionable	In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	non-small cell lung carcinoma	predicted - sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited tumor growth in PTEN-deleted non-small cell lung cancer cell line xenograft models (PMID: 21750219).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	Advanced Solid Tumor	no benefit	GSK2636771	Phase I	Actionable	In a Phase I trial, patients with advanced solid tumors deficient in PTEN lacked benefit from GSK2636771 (PMID: 26117819).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	VS-5584	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a human prostate cancer cell line harboring a PTEN deletion in culture, and inhibited PI3K/MTOR signaling and tumor growth in xenograft models (PMID: 23270925).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	head and neck squamous cell carcinoma	resistant	Taselisib	Preclinical	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells homozygous for PTEN deletion were resistant to Taselisib (GDC-0032) in culture (PMID: 26589432).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	urinary bladder cancer	sensitive	Metformin	Preclinical	Actionable	In a preclinical study, bladder cancer cells with PTEN deletion were sensitive to Glucophage (metformin) in culture, resulting in inhibition of cell growth (PMID: 26921394).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human prostate cancer cells harboring PTEN deletion in culture (PMID: 21325073, PMID: 14737113).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human prostate cancer cell line with deletion of PTEN (PMID: 21558396).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	AZD8186 + BYL719	Preclinical	Actionable	In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in minor inhibition of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	breast cancer	sensitive	CUDC-907	Preclinical - Cell culture	Actionable	In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	Advanced Solid Tumor	sensitive	CC-223	Phase I	Actionable	In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	Ipatasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, prostate cancer cell line xenograft models with PTEN deletion demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	predicted - sensitive	AZD8186	Phase I	Actionable	In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including prostate cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	AZD8186 + Enzalutamide	Preclinical	Actionable	In a preclinical study, AZD8186 and Xtandi (enzalutamide) combination treatment resulted in suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	prostate cancer	sensitive	AZD8186 + BYL719 + Enzalutamide	Preclinical	Actionable	In a preclinical study, AZD8186, Alpelisib (BYL719), and Xtandi (enzalutamide) combination treatment resulted in near-complete suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PTEN del	stomach cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 induced tumor regression in xenograft models of a human stomach cancer cell line with deletion of PTEN (PMID: 21558396).
PTEN	10q23del | BZS | CWS1 | DEC | GLM2 | MHAM | MMAC1 | PTEN1 | PTENbeta | TEP1	10q23.31	NM_000314	PIK3CA P124L PTEN del	urinary bladder cancer	decreased response	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited  inhibition of Akt phosphorylation and growth in bladder cancer cells harboring PIK3CA P124L and PTEN deletion in culture (PMID: 28808038).
PTPN11	BPTP3 | CFC | JMML | METCDS | NS1 | PTP-1D | PTP2C | SH-PTP2 | SH-PTP3 | SHP2	12q24.13	NM_001330437	PTPN11 E76K	hematologic cancer	sensitive	II-B08	Preclinical	Actionable	In a preclinical study, hematopoietic progenitor cells expressing PTPN11 E76K were sensitive to II-B08, resulting in decreased cell proliferation (PMID: 20170098).
PTPN11	BPTP3 | CFC | JMML | METCDS | NS1 | PTP-1D | PTP2C | SH-PTP2 | SH-PTP3 | SHP2	12q24.13	NM_001330437	PTPN11 E76K	leukemia	sensitive	PD98059	Preclinical	Actionable	In a preclinical study, PD98059 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).
PTPN11	BPTP3 | CFC | JMML | METCDS | NS1 | PTP-1D | PTP2C | SH-PTP2 | SH-PTP3 | SHP2	12q24.13	NM_001330437	PTPN11 E76K	leukemia	sensitive	U0126	Preclinical	Actionable	In a preclinical study, U0126 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).
PTPN11	BPTP3 | CFC | JMML | METCDS | NS1 | PTP-1D | PTP2C | SH-PTP2 | SH-PTP3 | SHP2	12q24.13	NM_001330437	PTPN11 E76K	juvenile myelomonocytic leukemia	sensitive	cryptotanshinone	Preclinical	Actionable	In a preclinical study, myeloid cells harboring PTPN11 E76K were sensitive to cryptotanshinone in culture, resulting in decreased cell growth (PMID: 23957426).
PTPN11	BPTP3 | CFC | JMML | METCDS | NS1 | PTP-1D | PTP2C | SH-PTP2 | SH-PTP3 | SHP2	12q24.13	NM_001330437	PTPN11 act mut	non-small cell lung carcinoma	sensitive	Refametinib	Preclinical	Actionable	In a preclinical study, Rafemetinib (BAY86-9766) inhibited growth of NSCLC cells harboring activating PTPN11 mutations in culture (J Clin Oncol 33, 2015(Suppl; abstr 11077)).
PTPN11	BPTP3 | CFC | JMML | METCDS | NS1 | PTP-1D | PTP2C | SH-PTP2 | SH-PTP3 | SHP2	12q24.13	NM_001330437	BRAF mut PTPN11 dec exp	colorectal cancer	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).
PTPN11	BPTP3 | CFC | JMML | METCDS | NS1 | PTP-1D | PTP2C | SH-PTP2 | SH-PTP3 | SHP2	12q24.13	NM_001330437	PTPN11 mutant	juvenile myelomonocytic leukemia	not applicable	N/A	Clinical Study	Emerging	In two clinical studies, PTPN11 mutations were frequently identified in patients with juvenile myelomonocytic leukemia and were found to be associated with poor survival (PMID: 19047918, PMID: 21901340), suggesting that this may serve as a future prognostic biomarker.
RAD21	CDLS4 | hHR21 | HR21 | HRAD21 | MCD1 | NXP1 | SCC1	8q24.11	NM_006265	RAD21 wild-type	breast cancer	not applicable	N/A	Preclinical	Emerging	In a preclinical study, siRNA inhibition of RAD21 in breast cancer cells resulted in increased sensitivity to Toposaur (etoposide) in culture, suggesting RAD21 may be a potential therapeutic target for enhanced sensitivity to chemotherapeutics (PMID: 15767545).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 K240Sfs*22 TP53 R248W	Her2-receptor negative breast cancer	predicted - resistant	Fulvestrant + Palbociclib	Clinical Study	Actionable	In a clinical case study, RB1 K240Sfs*22 and TP53 R248W were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 5 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 mut TP53 mut	prostate carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 mut TP53 mut	breast carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 mut TP53 mut	cervical cancer	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 mutant	osteosarcoma	sensitive	VCN-01	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VCN-01 decreased viability of a human RB1-mutant primary osteosarcoma cell line in culture, and inhibited tumor growth and decreased lung metastases in xenograft models (PMID: 26603261).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	PTEN mut RB1 mut SMAD4 mut TP53 mut	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	PTEN loss RB1 loss	triple-receptor negative breast cancer	resistant	Palbociclib	Preclinical	Actionable	In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	PTEN loss RB1 loss	triple-receptor negative breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	PTEN loss RB1 loss	triple-receptor negative breast cancer	resistant	Pictilisib	Preclinical	Actionable	In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 loss	T-cell adult acute lymphocytic leukemia	resistant	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	BRAF mut RB1 loss	melanoma	decreased response	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	BRAF mut RB1 loss	melanoma	decreased response	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	BRAF mut RB1 loss	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	retinoblastoma	sensitive	Trichostatin A	Preclinical - Cell culture	Actionable	In a preclinical study, Trichostatin A (TSA) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	lung small cell carcinoma	resistant	Trilaciclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to Trilaciclib (G1T28) in culture and in xenograft models (PMID: 26826116).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	lung small cell carcinoma	sensitive	Trilaciclib + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Trilaciclib (G1T28) and Hycamtin (topotecan) inhibited tumor growth in RB1-deficient small cell lung cancer cell line xenograft models, with greater efficacy than Hycamtin (topotecan) alone (PMID: 26826116).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	retinoblastoma	sensitive	Vorinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Zolinza (vorinostat) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	neuroendocrine tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	retinoblastoma	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Sirolimus (rapamycin) decreased tumor occurrence, tumor hypoxia and  tumor vascularization in a retinoblastoma mouse model with functionally inactivated Rb protein (PMID: 21468343, PMID: 1689463).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	Advanced Solid Tumor	no benefit	Palbociclib	Preclinical	Actionable	In preclinical studies, the CDK4/6 inhibitor, Ibrance (palbociclib), was not effective in a variety of solid tumors with Rb1-deficiency (PMID: 26649278).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	estrogen-receptor positive breast cancer	resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, RB1 loss was associated with acquired resistance to Ibrance (palbociclib) in an estrogen-receptor positive breast cancer cell line in culture (PMID: 27020857).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 loss	retinoblastoma	sensitive	Entinostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Entinostat (MS-275) inhibited growth of retinoblastoma cell lines in culture and inhibited tumor growth in a retinoblastoma cell line xenograft model (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	CDKN2A pos RB1 inact mut	glioblastoma multiforme	resistant	Palbociclib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 inact mut	retinoblastoma	sensitive	Fostamatinib	Preclinical	Actionable	In a preclinical study, retinoblastoma cell lines demonstrated sensitivity to Fostamatinib resulting in cell death (PMID: 22237022).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 inact mut	retinoblastoma	sensitive	BAY 61-3606	Preclinical	Actionable	In a preclinical study, a retinoblastoma cell line was sensitive to BAY 61-3606 in cell culture and in xenograft models, demonstrating increased apoptosis (PMID: 22237022).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 inact mut	glioblastoma multiforme	resistant	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ibrance (palbociclib) failed to inhibit growth of RB1-deficient glioblastoma cell lines in culture and in intracranial cell line xenograft models (PMID: 20354191).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 inact mut	retinoblastoma	sensitive	Nutlin-3a	Preclinical	Actionable	In a preclinical study, Nutlin-3a induced p53 pathway signaling in MDMX mouse models with retinoblastoma and 69% (70/102) of the eyes harvested from the mouse models demonstrated complete response or stable disease after 18 weeks of therapy (PMID: 21515735).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 E268* RB1 I101fs RB1 T738_R775del RB1 V654fs	Her2-receptor negative breast cancer	predicted - resistant	Fulvestrant + Palbociclib	Clinical Study	Actionable	In a clinical case study, RB1 mutations including E268*, I101fs, T738_R775del, and V654fs were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 8 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 H483Y	Her2-receptor negative breast cancer	predicted - resistant	Letrozole + Ribociclib	Clinical Study	Actionable	In a clinical case study, RB1 H48Y was identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 13 months of Kisqali (ribociclib) and Femara (letrozole) combination treatment (PMID: 29236940).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 positive	glioblastoma multiforme	predicted - sensitive	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited proliferation of RB1-proficient glioblastoma cell lines in culture and inhibited tumor growth in intracranial cell line xenograft models (PMID: 20354191).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 positive	Advanced Solid Tumor	predicted - sensitive	Ribociclib	Phase I	Actionable	In a Phase I clinical trial, Kisqali (ribociclib) demonstrated safety and preliminary efficacy in patients with RB1-positive solid tumors and lymphomas, resulting in partial responses in 2.3% (3/132) of patients and stable disease in 32.6% (41/132) of patients, including 8 patients demonstrating stable disease for greater than 6 months (PMID: 27542767).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	RB1 positive	medulloblastoma	sensitive	Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited Rb1 phosphorylation in tumor tissues and improved survival in patient-derived intracranial xenograft models of medulloblastoma (PMID: 27012813).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	ALK rearrange RB1 C706F TP53 loss	lung small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study	Actionable	In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 wild-type RB1 wild-type	mantle cell lymphoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 wild-type RB1 wild-type	melanoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 wild-type RB1 wild-type	lung carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 wild-type RB1 wild-type	colon carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 wild-type RB1 wild-type	breast carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Mercaptopurine	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + JQ1	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Dexamethasone	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Bortezomib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Methotrexate	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Prednisolone	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Asparaginase	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 mutant RB1 wild-type	mantle cell lymphoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 mutant RB1 wild-type	osteosarcoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 mutant RB1 wild-type	breast carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	TP53 mutant RB1 wild-type	colon carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Methotrexate	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Asparaginase	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Everolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Bortezomib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + JQ1	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	conflicting	Ribociclib + Dexamethasone	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib + Prednisolone	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
RB1	OSRC | p105-Rb | pp110 | PPP1R130 | pRb | RB	13q14.2	NM_000321	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Ribociclib + Mercaptopurine	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	ROS1 fusion ERBB2 amp FGFR3 amp RET amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET A883F	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET A883F in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET A883F	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET A883F in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET over exp	breast cancer	sensitive	Y078-DM1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Y078-DM1 induced cytotoxicity in a human breast cancer cell line with high levels of RET expression in culture and inhibited tumor growth in xenograft models (PMID: 26240273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C630X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C630X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C618X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C618X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET A883X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET A883X mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C620X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C620X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET V804X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid medullary carcinoma	sensitive	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid medullary carcinoma	sensitive	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid carcinoma	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture (PMID: 17664273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid medullary carcinoma	sensitive	CEP-32496	Preclinical - Cell culture	Actionable	In a preclinical study, RXDX-105 (CEP-32496) reduced phosphorylation of RET and downstream signaling and inhibited proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture (PMID: 28011461).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid carcinoma	sensitive	Cabozantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cometriq (cabozantinib) inhibited phosphorylation of RET C634W and decreased tumor growth in xenograft models of a human thyroid carcinoma cell line harboring RET C634W mutation (PMID: 23705946).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid medullary carcinoma	sensitive	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid medullary carcinoma	sensitive	Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and inhibited tumor growth in cell line xenograft models of medullary thyroid carcinoma harboring RET C634W (PMID: 16507829).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid cancer	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of thyroid cancer cells harboring RET C634W in culture (PMID: 21170960).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid carcinoma	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture and in cell line xenograft models (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid medullary carcinoma	sensitive	BLU-667	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BLU-667 inhibited Ret signaling and proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture, and inhibited tumor growth in xenograft models (PMID: 29657135).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid medullary carcinoma	sensitive	LOXO-292	Preclinical - Cell line xenograft	Actionable	In a preclinical study, thyroid medullary carcinoma cells harboring RET C634W were sensitive to treatment with LOXO-292, demonstrating decreased cell proliferation in culture and inhibition of tumor growth in cell line xenograft models (PMID: 29912274).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid cancer	sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a thyroid cancer cell line harboring RET C634W in culture (PMID: 23056499).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634W	thyroid cancer	sensitive	Lenvatinib	Preclinical	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited RET phosphorylation and signaling in thyroid cancer cells expressing RET C634W (PMID: 25295214).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	KDR pos RET C634W	thyroid medullary carcinoma	predicted - sensitive	Motesanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET E768X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET E768X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET S891X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET S891X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET fusion	non-small cell lung carcinoma	sensitive	Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetanib) treatment resulted in partial remission in 17% (3/18) and stable disease in 44% (8/18) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9013)).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET fusion	non-small cell lung carcinoma	sensitive	Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetanib) treatment resulted in a disease control rate of 88% (15/17), median progression-free survival (PFS) of 4.7 months, and partial response in 53% (9/17) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9012)).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET fusion	non-small cell lung carcinoma	sensitive	LOXO-292	Phase I	Actionable	In a Phase I trial, LOXO-292 treatment resulted in an objective response rate of 65% (17/26) in RET fusion-positive non-small cell lung cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET fusion	papillary thyroid carcinoma	sensitive	LOXO-292	Phase I	Actionable	In a Phase I trial, LOXO-292 treatment resulted in an objective response rate of 83% (5/6) in RET fusion-positive papillary thyroid cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET Y791X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET Y791X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634Y	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634Y (PMID: 20368568).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634Y	Advanced Solid Tumor	sensitive	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634Y	Advanced Solid Tumor	sensitive	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634Y	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells harboring RET C634Y in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634Y	Advanced Solid Tumor	sensitive	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET S891A	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation in cells expressing RET S891A in culture (PMID: 17664273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET S891A	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET S891A in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET S891A	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET S891A in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	non-small cell lung carcinoma	predicted - sensitive	Alectinib	Clinical Study	Actionable	In a clinical study, Alecensa (alectinib) treatment resulted in objective radiographic response in 50% (2/4) and stable disease in 25% (1/4) of non-small cell lung carcinoma patients harboring RET rearrangement (PMID: 27544060).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	non-small cell lung carcinoma	sensitive	CEP-32496	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring a RET rearrangement demonstrated a sustained partial response following treatment with RXDX-105 (CEP-32496) on a Phase Ib clinical trial (PMID: 28011461).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	papillary thyroid carcinoma	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and activation of downstream signaling, and decreased growth of papillary thyroid carcinoma cells harboring the RET/PTC1 oncogene in culture (PMID: 17664273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	Advanced Solid Tumor	sensitive	CEP-32496	Preclinical - Pdx	Actionable	In a preclinical study, CEP-32496 (RXDX-105) induced tumor regression in patient-derived xenograft models of several advanced solid tumor type with RET rearrangements (2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Abstract A174).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	non-small cell lung carcinoma	sensitive	Vandetanib	Guideline	Actionable	Caprelsa (vandetanib) is in guidelines for non-small cell lung cancer patients with RET rearrangements (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	non-small cell lung carcinoma	sensitive	Vandetanib	Clinical Study	Actionable	In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/11, all partial responses) and stable disease in 27% (3/11) of patients following Caprelsa (vandetanib) treatment (PMID: 28447912).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	non-small cell lung carcinoma	sensitive	Cabozantinib	Clinical Study	Actionable	In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 37% (7/19), with complete response in 5% (1/19) and partial response in 32% (6/19) of patients, and stable disease in 26% (5/19) of patients following Cometriq (cabozantinib) treatment (PMID: 28447912).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	non-small cell lung carcinoma	sensitive	Cabozantinib	Guideline	Actionable	Cometriq (cabozantinib) is in guidelines for non-small cell lung cancer patients with RET rearrangements (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	papillary thyroid carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) decreased proliferation of papillary thyroid carcinoma cells harboring the RET/PTC1 rearrangement in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	lung cancer	sensitive	Cabozantinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Cometriq (cabozantinib) resulted in an overall response rate of 28% (7/25) in patients with RET-rearranged lung cancer (PMID: 27825636).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET rearrange	non-small cell lung carcinoma	sensitive	Sunitinib	Clinical Study	Actionable	In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/9, all partial responses), and stable disease in 33% (3/9) of patients following Sutent (sunitinib) treatment (PMID: 28447912).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C611X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C611X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C609X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C609X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804M + RET E805K	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Compound germline RET V840M and E805K mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804M + RET S904C	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Compound germline RET V840M and S904C mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804M	Advanced Solid Tumor	predicted - sensitive	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804M (PMID: 26126987).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804M	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET V804M in culture (PMID: 16507829).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804M	Advanced Solid Tumor	resistant	Vandetanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing RET V804M demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804M	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed human cell lines expressing RET V804M demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804M	thyroid medullary carcinoma	sensitive	LOXO-292	Phase I	Actionable	In a Phase I trial, LOXO-292 treatment resulted in partial response in a thyroid medullary cancer patientharboring RET V804M (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R RET V804M	Advanced Solid Tumor	resistant	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells co-expressing RET C634R and RET V804M were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804M + RET Y806C	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Compound germline RET V840M and Y806C mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T RET V804M	thyroid medullary carcinoma	resistant	Vandetanib + Everolimus	Clinical Study	Actionable	In a clinical case study, a patient with thyroid medullary carcinoma harboring RET M918T progressed on multiple therapies, including Nexavar (sorafenib), Caprelsa (vandetanib), Cometriq (cabozantinib), MGCD-516 (sitravatinib), and RXDX-105 (CEP-32496), and upon progression with the combination therapy, Vandetanib and Afinitor (everolimus), cell-free DNA testing revealed RET M918T and acquisition of a secondary drug resistant mutation, RET V804M (PMID: 29912274; NCT03157128).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T RET V804M	thyroid medullary carcinoma	sensitive	LOXO-292	Clinical Study	Actionable	In a clinical case study, a patient with thyroid medullary cancer harboring RET M918T and RET V804M demonstrated an initial response to LOXO-292, which included a decrease in allelic fraction of RET M918T and RET V804M over 8 weeks and a radiographic response of nearly 54% post 6.9 months of treatment (PMID: 29912274; NCT03157128).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T RET V804M	lung adenocarcinoma	resistant	Alectinib	Clinical Study	Actionable	In a clinical case study, a patient with lung adenocarcinoma initially treated with chemotherapy and immunotherapy was found to harbor KIF5B-RET, and was then treated with Alecensa (alectinib), which resulted in an intracranial response, but eventually led to further progression (PMID: 29912274; NCT03157128).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804L	Advanced Solid Tumor	predicted - sensitive	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804L (PMID: 26126987).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804L	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed human cell lines expressing RET V804L demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET V804L	Advanced Solid Tumor	resistant	Vandetanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing RET V804L demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R RET Y806F	Advanced Solid Tumor	predicted - sensitive	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806F in culture demonstrated inhibition of Ret phosphorylation and activity in kinase assays when treated with Caprelsa (vandetanib) (PMID: 19029224).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C634X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET L790X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET L790X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET D898V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET D898V in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R RET Y806E	Advanced Solid Tumor	resistant	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806E were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T	olfactory neuroblastoma	sensitive	Cetuximab + Sunitinib	Clinical Study	Actionable	In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET E768D	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E768D in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET E768D	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET E768D in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET Y791F	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y971F in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET Y791F	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET Y791F in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C618R	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C618R (PMID: 20368568).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET D631_R635delinsG RET L629P RET V637R	thyroid medullary carcinoma	predicted - sensitive	BLU-667	Phase I	Actionable	In a Phase I trial, a patient with medullary thryoid cancer harboring RET D631_R635delinsG, L629P, and V637R demonstrated a partial response, with maximal tumor reduction of 47% at 10 months, following treatment with BLU-667 (PMID: 29657135; NCT03037385).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634F	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634F (PMID: 20368568).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET C634R in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET kinase activity and proliferation in transformed cells expressing RET C634R in culture (PMID: 16507829).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of cells expressing RET C634R in culture (PMID: 17664273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R	Advanced Solid Tumor	sensitive	Pz-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pz-1 inhibited Ret signaling in transformed cells over expressing RET C634R and inhibited tumor growth in cell line xenografts models (PMID: 26126987).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed human cell lines expressing RET C634R demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of patients with medullary thyroid carcinoma harboring RET C634R (PMID: 20368568).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R RET Y806C	Advanced Solid Tumor	resistant	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C634R RET V804G	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing Ret protein carrying both C634R and V804G mutations were more sensitive to Vandetanib induced inhibition of Ret activity than cells expressing Ret C634R alone in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET mutant	colorectal cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) demonstrated efficacy in RET mutant positive colorectal cancer cell lines (PMID: 23811235).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET mutant	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cancer cell lines harboring RET mutations in cultured and in cell line xenograft models (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET mutant	thyroid medullary carcinoma	sensitive	LOXO-292	Phase I	Actionable	In a Phase I trial, LOXO-292 treatment resulted in partial response in 14% (2/14) and tumor reduction in 79% (11/14) of RET mutant thyroid medullary cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET mutant	thyroid medullary carcinoma	sensitive	Everolimus	Phase II	Actionable	In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, including patients harboring RET mutations, with median progression-free survival of 33 weeks (PMID: 26294908).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET mutant	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (60 vs 20 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET mutations (PMID: 27525386).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET mutant	cancer	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited wild-type RET and RET mutations to prevent cell proliferation in cell culture (PMID: 17664273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET Y806C	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y806C in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET act mut	non-small cell lung carcinoma	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited RET phosphorylation and reduced viability of non-small cell lung cancer cells with RET activating mutations (Cancer Res April 15, 2013 73; 2084).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET E884K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E884K in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET G691S	Advanced Solid Tumor	sensitive	Dovitinib	Phase I	Actionable	In a Phase I clinical trial, two patients with germline RET G691S mutations demonstrated sensitivity to Dovitinib (TKI258) treatment (PMID: 25103625).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET positive	thyroid medullary carcinoma	sensitive	Y078-DM4	Preclinical	Actionable	In a preclinical study, Y078-DM4 induced cytotoxicity in a RET-expressing medullary thyroid cell line in culture (PMID: 26240273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET positive	breast cancer	sensitive	Y078-DM4	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Y078-DM4 induced cytotoxicity in RET-expressing human breast cancer cell lines in culture and inhibited tumor growth in xenograft models (PMID: 26240273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET L790F	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET L790F in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET L790F	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET L790F in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET wild-type	lung small cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET wild-type	lung small cell carcinoma	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET M918X mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	ATM L804fs*4 ATM S978fs*12 RET M918T	thyroid medullary carcinoma	predicted - sensitive	Vandetanib + Everolimus	Clinical Study	Actionable	In a clinical case study, addition of Afinitor (everolimus)  to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased proliferation of cells expressing RET M918T in culture (PMID: 17664273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a medullary thyroid cancer cell line harboring RET M918T in culture (PMID: 23056499).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	lung small cell carcinoma	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	colorectal cancer	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of colorectal cancer cells harboring a RET M918T mutation in culture (PMID: 17664273).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) increased overall survival to 25.4 months in medullary thyroid carcinoma patients with RET M918T (J Clin Oncol 33, 2015, suppl; abstr 6012).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (61 vs 17 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET M918T (PMID: 27525386).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	lung small cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	Advanced Solid Tumor	sensitive	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	sensitive	Everolimus	Phase II	Actionable	In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7)  of medullary thyroid cancer patients, and 4 of the 7 patients carried a RET M918T mutation (PMID: 26294908).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	predicted - sensitive	BLU-667	Phase I	Actionable	In a Phase I trial, a patient with sporadic medullary thryoid cancer harboring RET M918T demonstrated a partial response, with maximal tumor reduction of 47% following treatment with BLU-667 (PMID: 29657135; NCT03037385).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET M918T in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	sensitive	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased proliferation of thyroid carcinoma cells harboring a RET M918T mutation in culture (PMID: 23526464).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	sensitive	LOXO-292	Preclinical - Cell culture	Actionable	In a preclinical study, thyroid medullary carcinoma cells harboring RET M918T were sensitive to treatment with LOXO-292 in culture, demonstrating decreased cell proliferation (PMID: 29912274).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	Advanced Solid Tumor	sensitive	LOXO-292	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing RET M918T were sensitive to treatment with LOXO-292 in culture, demonstrating decreased cell proliferation (PMID: 29912274).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation and transforming activity in cells expressing RET M918T in culture (PMID: 15184865).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	Advanced Solid Tumor	predicted - sensitive	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET M918T (PMID: 26126987).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	sensitive	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thryoid carcinoma cells harboring RET M918T in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	Advanced Solid Tumor	sensitive	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 10% (1/10) and stable disease in 90% (9/10) of patients with medullary thyroid carcinoma harboring RET M918T (PMID: 20368568).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	thyroid medullary carcinoma	sensitive	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET M918T	Advanced Solid Tumor	sensitive	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).
RET	CDHF12 | CDHR16 | HSCR1 | MEN2A | MEN2B | MTC1 | PTC | RET-ELE1	10q11.21	NM_020975	RET C620R	thyroid medullary carcinoma	sensitive	Everolimus	Phase II	Actionable	In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease of 116 weeks in a MEN2A patient with medullary thyroid cancer carrying a RET C620R mutation (PMID: 26294908).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	KIT D816G ROS1 fusion	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion developed resistance to treatment with Xalkori (crizotinib) and was subsequently found to have acquired KIT D816G (PMID: 29636358).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion KDR amp KIT amp PDGFRA amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 fusion proteins in culture (PMID: 27780853).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion	Advanced Solid Tumor	predicted - sensitive	Ropotrectinib	Phase I	Actionable	In a Phase I (TRIDENT-1) trial, Ropotrectinib (TPX-0005) treatment resulted in partial response in 21.6% (8/37) of patients with advanced solid tumors harboring ROS1 or NTRK fusions (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion	non-small cell lung carcinoma	predicted - sensitive	DS6051b	Phase I	Actionable	In a Phase I clinical trial, DS-6051b was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with non-small cell lung cancer liver metastases harboring a ROS1 fusion (Cancer Res July 15 2016 (76) (14 Supplement) CT024).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion	non-small cell lung carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I clinical trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion ERBB2 amp FGFR3 amp RET amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion ROS1 L2026M ROS1 L1951R	non-small cell lung carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion progressed after 17 months of treatment with Xalkori (crizotinib) and was found to have acquired two additional mutations, ROS1 L2026M and ROS1 L1951R (PMID: 29636358).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion ROS1 L2026M ROS1 L1951R	non-small cell lung carcinoma	resistant	Ceritinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient co-harboring a ROS1 fusion, ROS1 L2026M, and ROS1 L1951R demonstrated resistance to treatment with Zykadia (ceritinib) (PMID: 29636358).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	predicted - sensitive	Cabozantinib	Clinical Study	Actionable	In a clinical case study, a patient with ROS1-rearranged non-small cell lung cancer with acquired resistance to Xalkori (crizotinib) demonstrated partial response to treatment with Cometriq (cabozantinib) prior to progressing after approximately 10 weeks (PMID: 27370605).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	Advanced Solid Tumor	sensitive	Entrectinib	Phase I	Actionable	In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in an objective response rate of 86% (12/14) in patients with ROS-1 rearranged advanced solid tumors that were treatment-naive, but no response (0/6) in patients received prior Xalkori (crizotinib) (PMID: 28183697).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	Advanced Solid Tumor	sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in complete response in 13% (1/12) and objection response in 75% (6/8) of patients with advanced solid tumors harboring rearrangement in ROS1 gene (AACR Apr 2016, Abstract # CT007).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	no benefit	Erlotinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	no benefit	Alectinib	Guideline	Actionable	Alecensa (alectinib) is not indicated for use in ROS1 rearranged non-small cell lung cancer patients whose disease became resistant to Xalkori (crizotinib) (NCCN.org).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	lung adenocarcinoma	sensitive	Crizotinib	Phase I	Actionable	In a retrospective analysis of Phase I clinical data, Xalkori (crizotinib) resulted in an objective response rate of 80% (24/30) and a median PFS of 9.1 months in patients with ROS1 rearranged lung adenocarcinoma (PMID: 25667280).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I trial, Lorlatinib (PF-06463922) treatment resulted in an objective response in 50% (6/12) of patients with non-small cell lung carcinoma harboring a ROS1 rearrangement (PMID: 29074098; NCT03052608).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	sensitive	NPS-1034	Preclinical - Cell culture	Actionable	In a preclinical study, NPS-1034 inhibited ROS1 activity and proliferation of a non-small cell lung cancer cell line harboring a ROS1 rearrangement in culture (PMID: 24165158).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	sensitive	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is included in guidelines as first-line therapy for ROS1 rearranged non-small cell lung cancer, but is not indicated after patients became resistant to Xalkori (crizotinib) (NCCN.org).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	sensitive	Ceritinib	Phase II	Actionable	In a Phase II trial, treatment with Zykadia (ceritinib) resulted in an overall response rate of 62% (20/32, including 1 complete response), a disease control rate of 81% (26/32), and a progression-free survival of 9.3 months in all patients and 19.3 months in Xalkori (crizotinib)-naive patients with non-small cell lung cancer harboring a ROS1 rearrangement (PMID: 28520527; NCT01964157).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	no benefit	Gefitinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	sensitive	Entrectinib	Phase I	Actionable	In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in complete response in 2 and partial response in 10 patients with ROS-1 rearranged non-small cell lung carcinoma that were treatment-naive (PMID: 28183697).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	sensitive	Crizotinib	FDA approved	Actionable	In a Phase I trial that supported FDA approval, non-small cell lung cancer patients with ROS1 rearrangements treated with Xalkori (crizotinib) demonstrated an objective response rate of 72% (36/50), with 3 complete responses and 33 partial responses, a median duration of response of 17.6 months, and a median progression-free survival of 19.2 months (PMID: 25264305; NCT00585195).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines as the preferred first-line therapy for ROS1 rearranged non-small cell lung cancer (NCCN.org).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	no benefit	Afatinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 rearrange	non-small cell lung carcinoma	no benefit	Osimertinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 positive	pancreatic cancer	predicted - sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in stable disease in a patient with ROS1-positive pancreatic cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ALK neg ROS1 pos	non-small cell lung carcinoma	sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022); NCT01945021).
ROS1	c-ros-1 | MCF3 | ROS	6q22.1	NM_002944	ROS1 G2032R	Advanced Solid Tumor	predicted - sensitive	Ropotrectinib	Phase I	Actionable	In a Phase I (TRIDENT-1) trial, Ropotrectinib (TPX-0005) treatment resulted in partial response in a patient with advanced solid tumor harboring ROS1 G2032R in the context of ROS1 fusion (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116).
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, RUNX1 mutations were associated with adverse clinical outcome in acute myeloid leukemia patients (PMID: 21343560, PMID: 22689681, PMID: 22753902, PMID: 25652455).
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, RUNX1 mutations were associated with poor overall survival in patients with myelodysplastic syndrome (PMID: 21714648, PMID: 22869879).
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	RUNX1 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1-RUNX1T1 KIT mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	RN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RN-1 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture, and inhibited tumor growth in xenograft models (PMID: 26837761).
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1-RUNX1T1	leukemia	sensitive	I-CBP112 + Doxorubicin	Preclinical	Actionable	In a preclinical study, the combination of I-CBP112 and Doxorubicin worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1-RUNX1T1	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, the t(8;21) cytogenetic abnormality, which leads to the RUNX1-RUNX1T1 fusion, is associated with core-binding factor acute myeloid leukemia and favorable prognosis (PMID: 22180162, PMID: 9746770, PMID: 25111512).
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1-RUNX1T1	leukemia	sensitive	I-CBP112	Preclinical	Actionable	In a preclinical study, I-CBP112 inhibited clonogenic growth in a leukemia cell line harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700).
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1-RUNX1T1	leukemia	sensitive	I-CBP112 + JQ1	Preclinical	Actionable	In a preclinical study, the combination of I-CBP112 and JQ1 worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)
RUNX1	AML1 | AML1-EVI-1 | AMLCR1 | CBF2alpha | CBFA2 | EVI-1 | PEBP2aB | PEBP2alpha	21q22.12	NM_001001890	RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	GSK690	Preclinical - Cell culture	Actionable	In a preclinical study, GSK690 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture (PMID: 26837761).
SETBP1	MRD29 | SEB	18q12.3	NM_015559	SETBP1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in SETBP1 were associated with poor prognosis in patients with myelodysplastic syndrome (PMID: 28447248, PMID: 28158286, PMID: 24127063, PMID: 23889083, PMID: 23832012).
SETBP1	MRD29 | SEB	18q12.3	NM_015559	SETBP1 mutant	myelodysplastic/myeloproliferative neoplasm	not applicable	N/A	Preclinical	Emerging	In a preclinical study, SETPB1 missense mutations conferred a predicted gain-of-function, resulting in transformation of murine myeloid progenitors and increased Pp2ac phosphorylation compared to wild-type SETBP1 in culture, suggesting that Setbp1 may serve as a potential therapeutic target (PMID: 23832012).
SETBP1	MRD29 | SEB	18q12.3	NM_015559	SETBP1 mutant	chronic myelomonocytic leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in SETBP1 were associated with poor prognosis in patients with chronic myelomonocytic leukemia (PMID: 29225884, PMID: 28158286, PMID: 28209919, PMID: 23558523, PMID: 23832012).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 G742X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 G742X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 R1074H	Advanced Solid Tumor	resistant	H3B-8800	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing SF3B1 R1074H were resistant to H3B-8800 in culture (Blood 2016 128:966).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 N626X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 N626X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 G740X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 G740X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 Y623X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 Y623X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 K666N	endometrial cancer	sensitive	Spliceostatin A	Preclinical	Actionable	In a preclinical study, Spliceostatin A inhibited survival of endometrial cancer cells harboring SF3B1 K666N in culture (PMID: 25424858).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 K700E	acute myeloid leukemia	sensitive	H3B-8800	Preclinical - Cell culture	Actionable	In a preclinical study, H3B-8800 preferentially inhibited growth of mouse acute myeloid leukemia cells harboring SF3B1 K700E compared to SF3B1 wild-type cells in culture (Blood 2016 128:966).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 K700E	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 K700E is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 K700E	hematologic cancer	sensitive	E7107	Preclinical - Cell culture	Actionable	In a preclinical study, mouse cells expressing SF3B1 K700E demonstrated sensitivity to E7107 in culture, resulting in decreased viability of cells (PMID: 27622333).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 K700E	pancreatic cancer	sensitive	Spliceostatin A	Preclinical	Actionable	In a preclinical study, Spliceostatin A inhibited survival of pancreatic cancer cells harboring SF3B1 K700E in culture (PMID: 25424858).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 K700E	chronic myeloid leukemia	sensitive	H3B-8800	Preclinical - Cell line xenograft	Actionable	In a preclinical study, H3B-8800 inhibited tumor growth in cell line xenograft models of chronic myeloid leukemia harboring SF3B1 K700E while had no effect in SF3B1 wild-type controls (Blood 2016 128:966).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 K666X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 K666X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 E622X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 E622X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 I704X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 I704X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 H662X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 H662X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, SF3B1 mutations were associated with better overall survival in patients with myelodysplastic syndrome (PMID: 21998214, PMID: 22096241, PMID: 24220272), but may not have independent prognostic significance (PMID: 22096241).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 R625X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 R625X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 T663X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 T663X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SF3B1	Hsh155 | MDS | PRP10 | PRPF10 | SAP155 | SF3b155	2q33.1	NM_012433	SF3B1 D781X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 D781X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - sensitive	Alectinib	Clinical Study	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 del	pancreatic cancer	decreased response	Gemcitabine	Preclinical	Actionable	In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were half as sensitive to gemcitabine in vitro as wild-type cells (PMID: 22753594).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 del	pancreatic cancer	sensitive	Cisplatin	Preclinical	Actionable	In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were twice as sensitive to cisplatin in vitro as wild-type cells (PMID: 22753594).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 del	pancreatic cancer	sensitive	Irinotecan	Preclinical	Actionable	In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	PTEN mut RB1 mut SMAD4 mut TP53 mut	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 mutant	stomach cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in SMAD4 or BMPR1A result in juvenile polyposis syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 mutant	colorectal cancer	no benefit	Cetuximab	Clinical Study	Actionable	In a clinical study, Chinese metastatic colorectal cancer patients harboring either a SMAD4 mutation or NF1 mutation did not respond to treatment with Erbitux (cetuximab) and showed a shorter progression-free survival compared to patients with wild-type SMAD4 or wild-type NF1 (PMID: 29703253).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 dec exp	head and neck squamous cell carcinoma	decreased response	SP600125	Preclinical - Cell culture	Actionable	In a preclinical study, SP600125 demonstrated modest inhibition of Jnk activity and transient growth inhibition in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 dec exp	colorectal cancer	not applicable	N/A	Clinical Study	Prognostic	In clinical and meta-analyses, decreased expression of Smad4 was correlated with poor prognosis in colorectal cancer (PMID: 25749173, PMID: 19478385, PMID: 25681512, PMID: 26861460).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 dec exp	head and neck squamous cell carcinoma	sensitive	Cetuximab + SP600125	Preclinical - Cell culture	Actionable	In a preclinical study, addition of SP600125 to Erbitux (cetuximab) restored sensitivity to Erbitux (cetuximab) in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 dec exp	pancreatic cancer	not applicable	N/A	Clinical Study	Prognostic	In clinical and meta-analyses, loss of Smad4 expression and SMAD4 inactivating mutations were associated with decreased survival in patients with pancreatic cancer (PMID: 26947875, PMID: 25760429, PMID: 22504380, PMID: 19584151).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 dec exp	head and neck squamous cell carcinoma	decreased response	U0126	Preclinical - Cell culture	Actionable	In a preclinical study, U0126 demonstrated modest inhibition of Mapk activity and transient growth inhibition in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 dec exp	head and neck squamous cell carcinoma	sensitive	Cetuximab + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, addition of U0126 to Erbitux (cetuximab) restored sensitivity to Erbitux (cetuximab) in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 dec exp	head and neck squamous cell carcinoma	resistant	Cetuximab	Clinical Study	Actionable	In a clinical study, decreased Smad4 expression level correlated with Erbitux (cetuximab) resistance in head and neck squamous cell carcinoma (HNSCC) patients, which is consistent with cell culture studies demonstrating Erbitux (cetuximab) resistance induced by knocking-down of Smad4 expression in HNSCC cell lines (PMID: 28522603).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 loss	pancreatic carcinoma	sensitive	SD-093	Preclinical	Actionable	In a preclinical study, SD-093 reduced the migration and invasiveness of pancreatic carcinoma cell lines lacking Smad4 (PMID: 15289325).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	SMAD4 inact mut	pancreatic cancer	sensitive	Irinotecan	Preclinical	Actionable	In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594).
SMAD4	DPC4 | JIP | MADH4 | MYHRS	18q21.2	NM_005359	CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H	melanoma	sensitive	Imatinib + Carboplatin + Paclitaxel	Clinical Study	Actionable	In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	EZH2 Y111D SMARCB1 inact mut	rhabdoid cancer	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 inact mut	epithelioid sarcoma	not applicable	N/A	Guideline	Diagnostic	SMARCB1 inactivating mutations aid the diagnosis of epithelioid sarcoma (NCCN.org).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 del	epithelioid sarcoma	not applicable	N/A	Guideline	Diagnostic	SMARCB1 deletion aids the diagnosis of epithelioid sarcoma (NCCN.org).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 loss	rhabdoid cancer	sensitive	Tazemetostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tazemetostat (EPZ-6438) inhibited growth of SMARCB1-deficient malignant rhabdoid tumor cell lines in culture, and inhibited H3K27 trimethylation and induced tumor regression in a SMARCB1-deleted human malignant rhabdoid tumor cell line xenograft model (PMID: 23620515).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 loss	atypical teratoid rhabdoid tumor	sensitive	CFI-400945	Preclinical - Cell culture	Actionable	In a preclinical study, CFI-400945 inhibited proliferation and decreased survival and migration of SMARCB1-deficient atypical teratoid rhabdoid tumor cells in culture (PMID: 28398638).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 negative	atypical teratoid rhabdoid tumor	sensitive	DZNeP	Preclinical	Actionable	In a preclinical study, DZNep induced apoptosis and cell-cycle arrest and inhibited growth of SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 negative	rhabdoid cancer	sensitive	Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited growth of  SMARCB1-negative malignant rhabdoid tumor cell lines in culture, and sensitivity was associated with low levels of p16 expression (PMID: 21871868).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 negative	rhabdoid cancer	sensitive	Alvocidib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alvocidib (flavopiridol) induced cell-cycle arrest and inhibited growth of human rhabdoid tumor cell lines with SMARCB1 biallelic deficiency in culture and inhibted tumor growth in SMARCB1-deficient cell line xenograft models (PMID: 18223228).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 negative	rhabdoid cancer	sensitive	Fenretinide + Vorinostat	Preclinical	Actionable	In a preclinical study, the combination of Zolinza (vorinostat) and fenretinide induced apoptosis and inhibited growth of rhabdoid tumor cell lines in culture (PMID: 23764045).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 negative	atypical teratoid rhabdoid tumor	sensitive	DZNeP + radiotherapy	Preclinical	Actionable	In a preclinical study, DZNep increased radiosensitivity in SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 negative	chordoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 negative	atypical teratoid rhabdoid tumor	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	SMARCB1 negative	epithelioid sarcoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).
SMARCB1	BAF47 | CSS3 | hSNFS | INI1 | MRD15 | PPP1R144 | RDT | RTPS1 | Sfh1p | SNF5 | SNF5L1 | Snr1 | SWNTS1	22q11	NM_003073	CDKN2A over exp SMARCB1 negative	rhabdoid cancer	decreased response	Palbociclib	Preclinical	Actionable	In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO H231R	basal cell carcinoma	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO H231R was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO L325F	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO L325F displayed reduced binding to MRT-92 (PMID: 25636740).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D384N	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D384N	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D384N	Advanced Solid Tumor	resistant	Sonidegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D384N	sarcoma	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, mouse sarcoma cell lines over expressing SMO D384N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D384N	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO Q477E	basal cell carcinoma	no benefit	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO Q477E with resistance to Erivedge (vismodegib) (PMID: 26546616).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO Q477E	basal cell carcinoma	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO Q477E was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO S387N	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO S387N	sarcoma	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, mouse sarcoma cell lines over expressing SMO S387N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO S387N	Advanced Solid Tumor	resistant	Sonidegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO S387N	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO S387N	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473H	Advanced Solid Tumor	sensitive	Taladegib	Preclinical	Actionable	In a preclinical study, LY2940680, inhibited the activity of SMO D473H, which is a mutant that confers resistance to the treatment of vismodegib (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473H	basal cell carcinoma	resistant	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473H with resistance to Erivedge (vismodegib) (PMID: 26546616).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473H	medulloblastoma	resistant	Vismodegib	Clinical Study	Actionable	In a single patient study, the SMO D473H mutant conferred secondary resistance to the hedgehog pathway inhibitor Erivedge (vismodegib) in a medulloblastoma patient (PMID: 19726788).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473H	Advanced Solid Tumor	predicted - sensitive	TAK-441	Preclinical	Actionable	In a preclinical study, TAK-441 inhibited Gli-reporter activation in cells transfected with SMO D473H in culture (PMID: 24291104).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO C469Y	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO C469Y	Advanced Solid Tumor	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO C469Y	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO C469Y	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO S533N	basal cell carcinoma	resistant	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient with resistance to Erivedge (vismodegib) harboring SMO D533N (PMID: 26546616).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO Y394A	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO Y394A displayed reduced binding to MRT-92 (PMID: 25636740).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D384A	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO D384A displayed reduced binding to MRT-92 (PMID: 25636740).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO T466F	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO T466F displayed reduced binding to MRT-92 (PMID: 25636740).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO L412F	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO L412F demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	EGFR E746_A750del SMO amp	non-small cell lung carcinoma	no benefit	Sonidegib	Preclinical	Actionable	In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	EGFR E746_A750del SMO amp	non-small cell lung carcinoma	sensitive	PHA-665752 + Sonidegib	Preclinical	Actionable	In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	EGFR E746_A750del SMO amp	non-small cell lung carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	EGFR E746_A750del SMO amp	non-small cell lung carcinoma	sensitive	Gefitinib + Sonidegib	Preclinical	Actionable	In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO N219D	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO N219D	sarcoma	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, mouse sarcoma cell lines over expressing SMO N219D demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO N219D	Advanced Solid Tumor	resistant	Sonidegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO N223D (corresponding to human SMO N219D) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO N219D	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO F460L	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO F460L demonstrated resistance to Erivedge (vismodegib) as compared to wild-type (PMID: 25759020).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO E518K	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO E518K displayed reduced binding to MRT-92 (PMID: 25636740).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO E518K	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO E518K	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO E518K	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) demonstrated decreased response to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO E518K	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO V329F	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO V329F displayed reduced binding to MRT-92 (PMID: 25636740).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO W535L	Advanced Solid Tumor	resistant	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole did not inhibit Hedghog signaling in mouse fibroblasts over expressing murine SMO W539L (corresponding to human SMO W535L) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO W535L	medulloblastoma	sensitive	Arsenic trioxide	Preclinical	Actionable	In a preclinical study, treatment with arsenic trioxide resulted in improved survival in a transgenic mouse model of medulloblastoma expressing SMO W535L (PMID: 21183792).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO W535L	basal cell carcinoma	predicted - sensitive	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in stable disease in a basal cell carcinoma patient harboring SMO W535L with resistance to Erivedge (vismodegib) (PMID: 26546616).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO W535L	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO W535L demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO dec exp	osteosarcoma	predicted - sensitive	SANT1	Preclinical	Actionable	In a preclinical study, SANT1 inhibited survival of osteosarcoma cell lines with reduced SMO mRNA level in culture (PMID: 26781311).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO T241M	Advanced Solid Tumor	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO T241M	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO T241M	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO T241M	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473G	basal cell carcinoma	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO D473G was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473G	basal cell carcinoma	resistant	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473G with resistance to Erivedge (vismodegib) (PMID: 26546616).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473G	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D477G (corresponding to human SMO D473G) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473G	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO D473G	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO V321M	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO V321M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO V321M	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO V321M	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO V321M	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO V321M demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO M525G	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO M525G displayed reduced binding to MRT-92 (PMID: 25636740).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO R400A	Advanced Solid Tumor	predicted - sensitive	MRT-92	Preclinical	Actionable	In a preclincal, transformed human cells expressing SMO R400A displayed reduced binding to MRT-92 (PMID: 25636740).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO A459V	Advanced Solid Tumor	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO A459V	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO A459V	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO A459V	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO W281C	basal cell carcinoma	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO W281C was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO W281C	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO W281C	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO W281C	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO I408V	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO I408V	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO I408V	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO I408V	Advanced Solid Tumor	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO wild-type	stomach cancer	predicted - sensitive	Vismodegib	Preclinical	Actionable	In a preclinical study, Vismodegib (GDC-0449) inhibited Hedgehog pathway signaling, increased apoptosis, and decreased proliferation of a gastric cancer cell line in culture (PMID: 26676867).
SMO	CRJS | FZD11 | Gx | SMOH	7q32.1	NM_005631	SMO wild-type	medulloblastoma	sensitive	Taladegib	Preclinical	Actionable	In a preclinical study, LY2940680 was demonstrated to bind to the Smo receptor and inhibit hedgehog signaling in a human medulloblastoma tumor cell line (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC over exp	clear cell renal cell carcinoma	no benefit	Cediranib + Saracatinib	Phase II	Actionable	In a Phase II clinical trial, baseline expression of SRC was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Ponatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	ERBB2 amp SRC E527K	gastroesophageal junction adenocarcinoma	sensitive	Lapatinib + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and Saracatinib (AZD0530) inhibited growth of ERBB2 (HER2)-amplified gastroesophageal adenocarcinoma cells harboring SRC E527K in culture (PMID: 25350844).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	ERBB2 amp SRC E527K	gastroesophageal junction adenocarcinoma	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, an ERBB2 (HER2)-amplified gastroesophageal cancer cell line initially sensitive to treatment with Tykerb (lapatinib) in culture developed resistance and was subsequently found to have acquired a secondary drug resistant mutation, SRC E527K (PMID: 25350844).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	EML4-ALK SRC pos	lung cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	EML4-ALK SRC pos	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Zykadia (ceritinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	EML4-ALK SRC pos	lung cancer	sensitive	Ropotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	biliary tract cancer	sensitive	Bosutinib + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Bosulif (bosutinib) and Platinol (cisplatin) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	biliary tract cancer	sensitive	Bosutinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Bosulif (bosutinib) inhibited Src signaling, resulted in cell cycle arrest and decreased invasion of biliary tract cancer cell lines in culture, and delayed tumor growth in cell line xenograft models (PMID: 27196758).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	glioblastoma multiforme	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) treatment resulted in a strong antitumoral effect in GBM cell lines with high levels of Src phosphorylation (PMID: 19098899).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	biliary tract cancer	sensitive	Bosutinib + Gemcitabine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Bosulif (bosutinib) and Gemzar (gemcitabine) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	triple-receptor negative breast cancer	predicted - sensitive	UM-164	Preclinical - Cell line xenograft	Actionable	In a preclinical study, UM-164 inhibited proliferation and induced apoptosis in human triple-receptor negative breast cancer cell lines with elevated Src activity in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27154914).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	Advanced Solid Tumor	predicted - sensitive	Bosutinib	Preclinical - Cell culture	Actionable	In a preclinical study, Bosulif (bosutinib) inhibited invasion and migration of Src-positive cells in culture (PMID: 18483306).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	triple-receptor negative breast cancer	sensitive	KX2-391	Preclinical - Cell line xenograft	Actionable	In a preclinical study, KX2-392 inhibited Src signaling and proliferation in triple-receptor negative breast cancer cell lines in culture, and suppressed tumor growth in xenograft models (PMID: 22784709).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	triple-receptor negative breast cancer	sensitive	BIRB-796 + Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, BIRB-796 in combination with Sprycel (dasatinib) resulted in improved growth inhibition in both 2D and 3D cultures of triple-receptor negative breast cancer cell lines with elevated Src activity compared to single agent treatment (PMID: 27154914).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	non-small cell lung carcinoma	predicted - sensitive	AC-93253 iodide	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AC-93253 iodide reduced the expression and phosphorylation of Src in non-small cell lung carcinoma cells, which led to antitumor activity, including decreased cell proliferation, cell migration, cell invasion, and colony formation in culture and inhibition of tumor growth in cell line xenograft models (PMID: 29132432).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	glioblastoma multiforme	sensitive	Si306 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Si306 in combination with radiotherapy decreased growth of radiotherapy-sensitive SRC-positive glioblastoma cells in culture and decreased tumor growth in cell line xenograft models, with increased efficacy compared to Si306 or radiotherapy alone (PMID: 27196762).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	triple-receptor negative breast cancer	sensitive	KX2-391 + Paclitaxel	Preclinical - Cell line xenograft	Actionable	In a preclinical study, KX2-392 and Taxol (paclitaxel) worked synergistically to inhibit Src signaling and proliferation of triple-receptor negative breast cancer cell lines in culture, and induced tumor regression and suppressed metastasis in xenograft models (PMID: 22784709).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC positive	glioblastoma multiforme	sensitive	Si306	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Si306 inhibited SRC phosphorylation and proliferation of SRC-expressing glioblastoma cell lines in culture, and inhibited tumor growth and increased survival in cell line xenograft models (PMID: 27196762).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	ALK rearrange SRC pos	non-small cell lung carcinoma	sensitive	Saracatinib + Ceritinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Zykadia (ceritinib) demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	sensitive	Dasatinib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	HRAS G13R KRAS G12R SRC T341M	thyroid cancer	resistant	Dasatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	IDH1 R132C SRC T341I	intrahepatic cholangiocarcinoma	resistant	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).
SRC	ASV | c-SRC | p60-Src | SRC1 | THC6	20q11.23	NM_198291	SRC amp	non-small cell lung carcinoma	sensitive	Derazantinib	Phase I	Actionable	In a Phase I trial, ARQ 087 treatment resulted in 25% tumor reduction and stable disease for 36 weeks in a squamous non-small cell lung carcinoma patient harboring SRC amplification (PMID: 28972963; NCT01752920).
SRSF2	PR264 | SC-35 | SC35 | SFRS2 | SFRS2A | SRp30b	17q25.1	NM_001195427	KMT2A-MLLT3 SRSF2 P95H	acute myeloid leukemia	sensitive	H3B-8800	Preclinical	Actionable	In a preclinical study, H3B-8800 inhibited tumor growth in transplant animal models of mouse acute myeloid leukemia cells harboring SRSF2 P95H and KMT2A-MLLT3 (MLL-AF9) while had no effect in SRSF2 wild-type controls (Blood 2016 128:966).
SRSF2	PR264 | SC-35 | SC35 | SFRS2 | SFRS2A | SRp30b	17q25.1	NM_001195427	SRSF2 P95X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SRSF2 P95X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
SRSF2	PR264 | SC-35 | SC35 | SFRS2 | SFRS2A | SRp30b	17q25.1	NM_001195427	SRSF2 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	SRSF2 mutations are associated with inferior overall survival and leukemia-free survival in patients with myelofibrosis (NCCN.org).
SRSF2	PR264 | SC-35 | SC35 | SFRS2 | SFRS2A | SRp30b	17q25.1	NM_001195427	SRSF2 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, SRSF2 mutations were associated with shortened survival in patients with myelodysplastic syndrome (PMID: 26769228, PMID: 26508027).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	STAG2 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 S653*	glioblastoma multiforme	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 S653*	glioblastoma multiforme	sensitive	Camptothecin	Preclinical - Cell culture	Actionable	In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 N357fs	glioblastoma multiforme	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505)  demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture, resulting in decreased proliferation and colony formation, and increased DNA damage compared to isogenic cells with wild-type STAG2 (PMID: 24356817).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 N357fs	glioblastoma multiforme	sensitive	Olaparib + Temozolomide	Preclinical - Cell culture	Actionable	In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and Temodar (temozolomide) compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 N357fs	glioblastoma multiforme	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505), demonstrated increased sensitivity to treatment with Rubraca (rucaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 N357fs	glioblastoma multiforme	sensitive	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Veliparib (ABT-888) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 N357fs	glioblastoma multiforme	sensitive	Camptothecin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	BRAF mut STAG2 dec exp	melanoma	decreased response	Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	BRAF mut STAG2 dec exp	melanoma	decreased response	Trametinib + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	BRAF mut STAG2 dec exp	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	BRAF mut STAG2 dec exp	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	NRAS mut STAG2 dec exp	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).
STAG2	bA517O1.1 | SA-2 | SA2 | SCC3B	Xq25	NM_001282418	STAG2 dec exp	colorectal cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells with knockdown of STAG2 expression demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture (PMID: 24356817).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 dec exp	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, knockdown of STK11 increased sensitivity to Mekinist (trametinib) in non-small cell lung cancer cell lines in culture and in xenograft models (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 wild-type	Advanced Solid Tumor	sensitive	Metformin	Preclinical	Actionable	In a preclinical studies, Glucophage (metformin) inhibited cancer cell growth by activating the AMP kinase pathway in a variety of cancer cell lines that retained one functional allele of STK11 (PMID: 17062558, 18006825).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 W332*	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 W332*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 D194E STK11 loss	pancreatic cancer	sensitive	Everolimus	Clinical Study	Actionable	In a clinical case study, a pancreatic cancer patient with Peutz-Jeghers syndrome harboring STK11 D194E and loss of heterozygosity of the other STK11 allele in the tumor achieved a partial response following treatment with Afinitor (everolimus), but progressed after 9 months (PMID: 21189378).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	PTEN loss STK11 loss	endometrial cancer	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	ERBB2 act mut STK11 loss	breast cancer	sensitive	AZD8055	Preclinical	Actionable	In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS G12D STK11 loss	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Cisplatin	Preclinical	Actionable	In a preclinical study,  MK-1775 and Platinol (cisplatin) combination treatment resulted in improved survival in transgenic animal models of non-small cell lung carcinoma harboring KRAS G12D and STK11 loss compared to Platinol (cisplatin) alone (PMID: 28652249).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 loss TP53 loss	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 loss	lung cancer	resistant	unspecified PD-1 antibody	Preclinical	Actionable	In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 loss	Advanced Solid Tumor	no benefit	Metformin	Preclinical	Actionable	In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, 18006825).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 Q37*	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 Q37*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 E57fs	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E57fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 K48fs	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 K48fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in STK11 result in Peutz Jeghers syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 mutant	non-small cell lung carcinoma	decreased response	Nivolumab	Clinical Study	Actionable	In a clinical study, mutant STK11 correlated with a worse response to Opdivo (nivolumab) compared to wild-type STK11 in non-small cell lung carcinoma patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 1138PD).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 mutant	non-small cell lung carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of human non-small cell lung carcinoma cells harboring an STK11 mutation in culture (PMID: 21325073).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 mutant	stomach cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in STK11 result in Peutz Jeghers syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 mut	non-small cell lung carcinoma	sensitive	PKI-402	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 mut	non-small cell lung carcinoma	predicted - resistant	unspecified PD-1 antibody	Phase III	Actionable	In a Phase III trial, non-small cell lung carcinoma patients co-harboring a KRAS mutation and STK11 mutation demonstrated an objective response rate (ORR) of 0% (0/6) when treated with Opdivo (nivolumab) compared to an ORR of 57.1% (4/7) in patients co-harboring a KRAS mutation and TP53 mutation and an ORR of 18.2% (2/11) in patients with mutant KRAS only (PMID: 29773717; NCT01673867).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 mut	lung adenocarcinoma	predicted - resistant	unspecified PD-1 antibody	Clinical Study	Actionable	In a clinical study, lung adenocarcinoma patients co-harboring a KRAS mutation and STK11 mutation demonstrated a lower objective response rate (7.4% vs 35.7% vs 28.6%) and shorter PFS (1.8mo vs 3.0 vs 2.7) and OS (6.4mo vs 16 vs 16.1) compared to patients with KRAS and TP53 mutations and patients with KRAS mutations only when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 E199*	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E199*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS G12D STK11 inact mut	lung cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS G12S STK11 inact mut	non-small cell lung carcinoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 inact mut	endometrial cancer	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) reduced S6K phosphorylation and inhibited tumor growth in mouse models of STK11 (LKB1)-deficient endometrial cancer, including models with advanced tumors (PMID: 20142330).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 inact mut	pituitary carcinoma	sensitive	Everolimus + Radiotherapy	Clinical Study	Actionable	In a clinical case study, a patient with adenocorticotropic pituitary carcinoma harboring an STK11 inactivating mutation demonstrated clinical efficacy for greater than 6 months when treated with a combination of Afinitor (everolimus) and radiotherapy (PMID: 27615706).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 inact mut	Advanced Solid Tumor	sensitive	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, the presence an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to CI-1040 (PD184352) in human tumor cell lines in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 inact mut	Advanced Solid Tumor	sensitive	RDEA119	Preclinical - Cell culture	Actionable	In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to RDEA119 in human tumor cell lines in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 inact mut	non-small cell lung carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 inact mut	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the presence of an STK11 loss expression signature, which correlated to STK11 inactivating mutations, was associated with increased sensitivity to Mekinist (trametinib) in human tumor cell lines in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 inact mut	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the presence of an STK11 inactivating mutation and STK11 loss expression signature was associated with increased sensitivity to Selumetinib (AZD6244) in human tumor cell lines in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	STK11 inact mut	Advanced Solid Tumor	sensitive	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to PD-0325901 in human tumor cell lines in culture (PMID: 27821489).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 inact mut	non-small cell lung carcinoma	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation and STK11 inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 inact mut	lung adenocarcinoma	sensitive	MLN0128 + Phenformin	Preclinical	Actionable	In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 inact mut	non-small cell lung carcinoma	predicted - sensitive	Adavosertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations demonstrated increased sensitivity to MK-1775 compared to cells expressing wild-type STK11 in culture (PMID: 28652249).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 inact mut	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, MK-1775 and Platinol (cisplatin) combination treatment demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).
STK11	hLKB1 | LKB1 | PJS	19p13.3	NM_000455	KRAS mut STK11 inact mut	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, MK-1775 combined with radiation therapy demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).
TET2	KIAA1546 | MDS	4q24	NM_001127208	TET2 mutant	acute myeloid leukemia	predicted - sensitive	Azacitidine	Phase I	Actionable	In a retrospective analysis, presence of a TET2 mutation correlated with higher overall response rate (ORR) in patients with myelodysplastic syndrome and acute myeloid leukemia following treatment with Vidaza (azacitidine), with an ORR of 85% (11/3) in TET2-mutated patients, compared to 47% (34/47) in patients with wild-type TET2, but did not correlate with overall survival (PMID: 21494260).
TET2	KIAA1546 | MDS	4q24	NM_001127208	TET2 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, including a meta-analysis, TET2 mutations were associated with shorter overall survival in patients with acute myeloid leukemia (PMID: 24524305, PMID: 25412851, PMID: 24994606).
TET2	KIAA1546 | MDS	4q24	NM_001127208	ASXL1 wild-type TET2 mutant	myelodysplastic/myeloproliferative neoplasm	sensitive	Decitabine	Clinical Study	Actionable	In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65%  vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).
TET2	KIAA1546 | MDS	4q24	NM_001127208	ASXL1 wild-type TET2 mutant	myelodysplastic/myeloproliferative neoplasm	sensitive	Azacitidine	Clinical Study	Actionable	In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65%  vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P98fs TP53 R175C TP53 S215G	ovarian cancer	predicted - resistant	MK-1775 + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in disease progression in an ovarian cancer patient harboring TP53 P98fs, R175C, and S215G (PMID: 27998224).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	resistant	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	resistant	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA E545K TP53 R273*	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 Y163H	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 Y163H in culture (PMID: 27179933).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 S241F	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 S241F	lung small cell carcinoma	sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, APR-246 demonstrated efficacy in xenograft models of small cell lung cancer harboring TP53 S241F (PMID: 21415220).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 S241F	ovarian cancer	sensitive	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib inhibited growth of human ovarian cancer cells harboring TP53 S241F in culture (PMID: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G13D PIK3CA E545k TP53 S241F	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P223L TP53 V274F	prostate cancer	resistant	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib inhibited growth of human prostate cancer cells harboring TP53 P223L and V274F in culture (PMID: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 S215G	non-small cell lung carcinoma	resistant	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 S215G were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P72R TP53 Y220C	breast cancer	no benefit	Epirubicin + Cyclophosphamide	Phase I	Actionable	In a Phase I clinical trial, a breast cancer patient carrying TP53 P72R and Y220C mutations demonstrated incomplete response to treatment with an Ellence (epirubicin)-Cytoxan (cyclophosphamide) combination regimen (PMID: 17388661).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P72R	breast cancer	predicted - sensitive	Doxil	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P72R	estrogen-receptor negative breast cancer	sensitive	Doxorubicin + Flourouracil + Cyclophosphamide	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R who were estrogen receptor negative had a more favorable response to Doxil (doxorubicin) in combination with Adrucil (fluorouracil) and Cytoxan (cyclophosphamide) (PMID: 16243804).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P72R	breast cancer	predicted - sensitive	Daunorubicin	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P72R	non-small cell lung carcinoma	sensitive	Camptosar + Cisplatin	Phase I	Actionable	In phase I clinical studies, NSCLC patients with TP53 P72R mutations had a longer progression-free survival than wild-type TP53 patients, after combined treatment with Camptosar (irinotecan) and  Platinol (cisplatin) (PMID: 18618574).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P72R	sarcoma	sensitive	Doxorubicin + Ifosfamide	Phase I	Actionable	In a Phase I clinical trial, sarcoma patients harboring TP53 P72R mutations had longer progression-free survival after treatment with Cyfos (ifosfamide) and Adriamycin (doxorubicin) (PMID: 23165797).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P72R	breast cancer	predicted - sensitive	Daunoxome	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P72R	breast cancer	sensitive	epirubicin	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations, who were also hormone receptor negative, demonstrated a favorable response to Ellence (epirubicin) in combination with other chemotherapeutic agents (PMID: 22903472).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 V173M	acute myeloid leukemia	predicted - sensitive	APR-246	Phase I	Actionable	In a Phase I clinical trial, APR-246 demonstrated safety and preliminary clinical activity in patients with hematological cancers, including an acute myeloid leukemia patient harboring TP53 V173M that achieved a decrease in bone marrow blast percentage from 46% to 26% (PMID: 22965953).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK	wild-type TP53 H168R	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	EGFR mut TP53 exon 8	non-small cell lung carcinoma	decreased response	unspecified EGFR tyrosine kinase inhibitor	Clinical Study	Actionable	In a clinical study, EGFR-mutant non-small cell lung cancer patients with TP53 exon 8 mutations demonstrated a disease control rate (DCR) of 42% (5/12), median progression-free survival (mPFS) of 4.2 mo and median overall survival (mOS) of 16.2 mo with first-line EGFR tyrosine kinase inhibitor treatment (such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Dacomitinib), vs a DCR of 87% (97/111), mPFS of 12.5 mo, and mOS of 32.3 mo in TP53 exon 8 wild-type patients (PMID: 27780855).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 Y163*	ovarian cancer	predicted - sensitive	MK-1775 + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 Y163* (PMID: 27998224).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 L111Q	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 L111Q in culture (PMID: 27179933).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R273H TP53 P309S	colorectal cancer	sensitive	Cisplatin + NSC59984	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Platinol (cisplatin) and NSC59984 worked synergistically to decrease viability of a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R273H TP53 P309S	colorectal cancer	sensitive	NSC59984	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	MET over exp TP53 dec exp	stomach carcinoma	sensitive	EMD 1214063 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 Y327L	ovarian carcinoma	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y327L in culture (PMID: 26748848).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	PIK3CA H1047R TP53 S90fs*33	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R273W	breast cancer	resistant	NSC319726	Preclinical - Cell culture	Actionable	In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of breast cancer harboring TP53 R273W (PMID: 22624712).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R249S	hepatocellular carcinoma	sensitive	CP-31398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 R249S in culture, and inhibited tumor growth in xenograft models (PMID: 26250460).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	MET amp TP53 del	breast cancer	sensitive	Crizotinib	Preclinical	Actionable	In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 del	colorectal cancer	predicted - sensitive	Doxorubicin + Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-null colorectal cancer cells in culture (PMID: 26826118).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 del	ovarian cancer	sensitive	Nutlin-3 + Etoposide	Preclinical	Actionable	In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 del	ovarian clear cell carcinoma	predicted - sensitive	thioureidobutyronitrile	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment resulted in Tp53-independent increase of Cdkn1a expression and apoptosis of ovarian clear cell carcinoma cells harboring TP53 deletion in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 del	colorectal cancer	predicted - sensitive	TC-A2317	Preclinical - Cell culture	Actionable	In a preclinical study, MK-8745 treatment resulted in polyploidy in TP53-null colorectal cancer cells in culture (PMID: 22293494).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 del	ovarian cancer	no benefit	Nutlin-3a	Preclinical	Actionable	In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with deletion of TP53 in culture (PMID: 25964101).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 del	ovarian cancer	sensitive	Nutlin-3 + Cisplatin	Preclinical	Actionable	In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V TP53 del	lung cancer	sensitive	7RH + LY411575	Preclinical	Actionable	In a preclinical study, 7RH and LY411575 combination treatment induced apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V TP53 del	lung cancer	resistant	7RH	Preclinical	Actionable	In a preclinical study, 7RH treatment had no effect on tumor cell apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175L	colorectal cancer	sensitive	NSC59984	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175L in culture (PMID: 26294215).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175L	lung large cell carcinoma	sensitive	NSC319726	Preclinical - Cell culture	Actionable	In a preclinical study, lung large cell carcinoma cells harboring TP53 R175L demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	ovarian cancer	sensitive	MK-1775 + Carboplatin + Paclitaxel	Phase I	Actionable	In a Phase I trial, ovarian patients with TP53 deficiency had a 78.6% response rate to MK-1775 in combination with carboplatin and paclitaxel (J Clin Oncol 31, 2013 (suppl; abstr 5518)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	ovarian carcinoma	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death and decreased proliferation of ovarian carcinoma cells harboring TP53 mutations in culture, but did not effect viability of ovarian carcinoma cells with wild-type TP53 (PMID: 26748848).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	breast carcinoma	predicted - sensitive	CHIR-124 + SN-38	Preclinical - Cell culture	Actionable	In a preclinical study, SN-38 and CHIR-124 demonstrated synergy in a breast carcinoma cell line with defective TP53, resulting in increased cell cycle arrest and apoptosis in culture (PMID: 17255282).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	lung small cell carcinoma	sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, APR-246 induced apoptosis in small-cell lung cancer (SCLC) cell lines and decreased tumor growth in SCLC cell line xenograft models harboring Tp53 inactivating mutations (PMID: 21415220).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	breast cancer	sensitive	AMG 900	Preclinical	Actionable	In a preclinical study, breast cancer cell lines with TP53 loss of function mutations had more pronounced apoptosis after treatment with AMG 900 in culture (PMID: 24091768).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	breast carcinoma	predicted - sensitive	CHIR-124 + Irinotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, sequential treatment with Camptosaur (irinotecan) and CHIR-124 enhanced tumor growth inhibition compared to either agent alone in a breast carcinoma cell line xenograft model with defective TP53 (PMID: 17255282).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	chronic lymphocytic leukemia	sensitive	AZD6738 + Ibrutinib	Preclinical	Actionable	In a preclinical study, AZD6738 sensitized TP53-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	chronic lymphocytic leukemia	predicted - sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 induced cell death in TP53-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	ovarian cancer	sensitive	Nutlin-3 + Cisplatin	Preclinical	Actionable	In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	breast cancer	sensitive	MK-1775 + Radiotherapy	Preclinical	Actionable	In a preclinical study, MK-1775 increased the efficacy of radiation in breast cancer cells with defective TP53 in culture (PMID: 21799033).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 inact mut	ovarian cancer	sensitive	LB-100 + Cisplatin	Preclinical	Actionable	In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in a cisplatin-resistant ovarian cancer cell line harboring a TP53 inactivating mutation in culture (PMID: 25376608).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P151H	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P151H in culture (PMID: 27179933).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12R TP53 R248L	lung adenocarcinoma	sensitive	Dasatinib + Demcizumab	Preclinical - Pdx	Actionable	In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12R and TP53 R248L (PMID: 26855149).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 C135Y	peritoneum cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived peritoneum cancer cells harboring TP53 C135Y in culture (PMID: 27179933).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS Q61L PIK3CA E542K TP53 T118Qfs*5	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 negative	breast cancer	sensitive	Avastin + Doxorubicin + Docetaxel	Phase I	Actionable	In a pilot trial, TP53-negative breast cancer patients demonstrated increased survival following treatment with Avastin (bevacizumab) in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel), compared to patients with TP53-positive tumors (PMID: 21399868).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 negative	non-small cell lung carcinoma	decreased response	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, TP53-null non-small cell lung carcinoma cells demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R273L	lung small cell carcinoma	sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, APR-246 demonstrated efficacy in cell line xenograft models of small cell lung cancer harboring TP53 R273L (PMID: 21415220).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R158G	non-small cell lung carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring TP53 R138G in culture (PMID: 21325073, PMID: 23980093).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 E258Q	osteosarcoma	resistant	Nutlin-3a	Preclinical	Actionable	In a preclinical study, TP53 E258Q resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 A159V	non-small cell lung carcinoma	decreased response	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 A159V demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRCA1 mut TP53 E298*	ovarian cancer	predicted - sensitive	MK-1775 + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 E298* and mutations in BRCA1 (PMID: 27998224).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRCA1 mut TP53 Y220C	ovarian cancer	sensitive	Carboplatin + VX-970	Phase I	Actionable	In a Phase I trial, VX-970 and Paraplatin (carboplatin) combination treatment resulted in partial response for 6 months in a PARP inhibitor-resistant ovarian cancer patient harboring a germline BRCA1 mutation and TP53 Y220C (J Clin Oncol 34, 2016 (suppl; abstr 2504)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 Y220C	hepatocellular carcinoma	sensitive	CP-31398	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture (PMID: 26250460).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 Y220C	non-small cell lung carcinoma	resistant	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y220C were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R280M	osteosarcoma	resistant	Nutlin-3a	Preclinical	Actionable	In a preclinical study, TP53 R280M resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 D259Y	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring TP53 D259Y in culture (PMID: 26343583).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 D259Y	melanoma	sensitive	Vemurafenib	Preclinical	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of human melanoma cells TP53 D259Y in culture (PMID: 26343583).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 D259Y	melanoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring TP53 D259Y in culture (PMID: 26343583).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant RB1 wild-type	osteosarcoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant RB1 wild-type	breast carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant RB1 wild-type	mantle cell lymphoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant RB1 wild-type	colon carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	RB1 mut TP53 mut	prostate carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	RB1 mut TP53 mut	breast carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	RB1 mut TP53 mut	cervical cancer	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mutant TP53 mutant	non-small cell lung carcinoma	predicted - sensitive	Nivolumab	Phase III	Actionable	In a Phase III trial, non-small cell lung carcinoma patients co-harboring a KRAS mutation and TP53 mutation demonstrated an objective response rate (ORR) of 57.1% (4/7) when treated with Opdivo (nivolumab) compared to an ORR of 0% (0/6) in patients co-harboring a KRAS mutation and STK11 mutation and an ORR of 18.2% (2/11) in patients with mutant KRAS only (PMID: 29773717; NCT01673867).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mutant TP53 mutant	colorectal cancer	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mutant TP53 mutant	lung adenocarcinoma	predicted - sensitive	unspecified PD-1 antibody	Clinical Study	Actionable	In a clinical study, lung adenocarcinoma patients co-harboring a KRAS mutation and TP53 mutation demonstrated a greater objective response rate (35.7% vs 7.4% vs 28.6%) compared to patients with KRAS and STK11 mutations and patients with KRAS mutations only when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mutant TP53 mutant	non-small cell lung carcinoma	predicted - sensitive	Pembrolizumab	Phase I	Actionable	In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring  a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mutant TP53 mutant	colorectal cancer	sensitive	ABT-263 + Alpelisib + Erlotinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	PTEN mut RB1 mut SMAD4 mut TP53 mut	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	EGFR mut TP53 mut	non-small cell lung carcinoma	decreased response	unspecified EGFR tyrosine kinase inhibitor	Clinical Study	Actionable	In a clinical study, non-small cell lung cancer patients harboring both EGFR and TP53 mutations demonstrated a disease control rate of 70.3% (26/37) following first-line treatment with an EGFR inhibitor such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Dacomitinib, compared to a DCR of 88.2% (75/85) in TP53 wild-type, EGFR-mutant patients (PMID: 27780855).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRAF mut TP53 mut	colorectal cancer	sensitive	ABT-263 + Alpelisib + Dabrafenib + Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	PTEN mutant TP53 mutant	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	PTEN mutant TP53 mutant	glioblastoma multiforme	sensitive	Navitoclax + ONC201	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	sarcoma	sensitive	Pazopanib	Clinical Study	Actionable	In a retrospective study, advanced sarcoma patients with TP53 mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with Votrient (pazopanib) (PMID: 26646755).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	colorectal cancer	predicted - sensitive	NSC59984	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NSC59984 treatment resulted in increased Tp53 signaling and cell death in colorectal cancer cell lines harboring TP53 mutations, and inhibited tumor growth in TP53-mutant cell line colorectal cancer xenograft models (PMID: 26294215).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	osteosarcoma	not applicable	N/A	Guideline	Risk Factor	Germline mutations in TP53 result in Li-Fraumeni syndrome, which is associated with increased risk of developing osteosarcoma (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	non-small cell lung carcinoma	predicted - sensitive	Pembrolizumab	Phase I	Actionable	In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	neuroblastoma	resistant	Nutlin-3a	Preclinical	Actionable	In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to nutlin-3 mediated growth inhibition (PMID: 21725357).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	ovarian cancer	no benefit	Nutlin-3a	Preclinical	Actionable	In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with TP53 mutations in culture (PMID: 25964101).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	hypopharynx cancer	predicted - sensitive	unspecified EGFR antibody + unspecified IGF-1R antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	neuroblastoma	resistant	MI-63	Preclinical	Actionable	In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to MI-63 mediated growth inhibition (PMID: 21725357).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	leukemia	decreased response	RG7112	Phase I	Actionable	In a Phase I clinical trial, the majority of 19 leukemia patients with identified TP53 mutations did not demonstrate response to treatment with RG7112, with 2 acute myeloid leukemia patients harboring TP53 mutations showing clinical activity, but not improvement, and 1 sCLL/CLL patient achieving stable disease (PMID: 26459177).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	glioblastoma multiforme	sensitive	Adavosertib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with MK-1775 decreased CDK1 phosphorylation and reduced tumor growth in patient-derived xenograft models of glioblastoma multiforme that harbor TP53 mutations (PMID: 27196784).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	Advanced Solid Tumor	sensitive	Adavosertib	Phase I	Actionable	In a retrospective analysis of a Phase I trial, MK-1775 combined with a chemotherapy resulted in a 21% (4/19) response rate in advanced solid tumor patients harboring a TP53 mutation and in those without a TP53 mutation, a 12% (4/33) response rate was observed (PMID: 27601554).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	TP53 mutations are associated with inferior leukemia-free survival in patients with essential thrombocythemia (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	chronic lymphocytic leukemia	predicted - sensitive	Ibrutinib + Venetoclax	Phase II	Actionable	In a Phase II trial, Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy resulted in a response rate of 100% (14/14, 9 complete response, 5 partial response) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients, and a response rate of 100% (16/16, 9 complete response, 7 partial response) in untreated patients with high-risk features including del 17p, TP53 mutations, and del 11q (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 429; NCT02756897).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	hypopharynx cancer	predicted - sensitive	EGFR antibody + ERBB3 antibody + IGF-1R antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	ovarian serous carcinoma	sensitive	thioureidobutyronitrile	Preclinical - Cell culture	Actionable	In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment decreased mutant Tp53 level, resulted in apoptosis of ovarian serous carcinoma cells harboring TP53 mutations in culture (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	breast carcinoma	predicted - sensitive	Camptothecin + CHIR-124	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Camptothecin and CHIR-124 demonstrated synergy in TP53-mutant breast carcinoma cell lines in culture, resulting in increased growth inhibition (PMID: 17255282).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	colon carcinoma	predicted - sensitive	Camptothecin + CHIR-124	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Camptothecin and CHIR-124 demonstrated synergy in TP53-mutant colon carcinoma cell lines in culture, resulting in increased growth inhibition (PMID: 17255282).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	ovarian cancer	predicted - sensitive	MK-1775 + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in an overall response rate of 43% (9/21), a median progression-free survival of 5.3 months and a median overall survival of 12.6 months in ovarian cancer patients harboring TP53 mutations (PMID: 27998224).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	CLL/SLL	sensitive	Venetoclax	Guideline	Actionable	Venclexta (venetoclax) is indicated in the guidelines for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	ovarian cancer	sensitive	Nutlin-3 + Etoposide	Preclinical	Actionable	In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	colorectal cancer	sensitive	Bevacizumab	Phase III	Actionable	In a Phase III trial, Avastin (bevacizumab), in combination with chemotherapy, provided a significant survival benefit in patients with colorectal cancers regardless of mutational status in KRAS, BRAF, and TP53 (PMID: 17145525).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	sarcoma	sensitive	Pazopanib + Vorinostat	Phase I	Actionable	In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	triple-receptor negative breast cancer	predicted - sensitive	Doxorubicin + Seliciclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-mutant triple-receptor negative breast cancer cell lines in culture, and inhibited tumor growth, prolonged survival in cell line xenograft models (PMID: 26826118).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical	Actionable	In a preclinical study, ovarian clear cell adenocarcinoma cell lines harboring TP53 mutations demonstrated reduced sensitivity to DS-7423 induced apoptosis in culture compared to TP53 wild-type cells (PMID: 24504419).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	fibrous histiocytoma	predicted - sensitive	GDC-0575 + Gemcitabine	Preclinical - Pdx	Actionable	In a preclinical study, GDC-0575 and Gemzar (gemcitabine) combination treatment inhibited tumor growth, prolonged progression-free survival in patient-derived xenogrft (PDX) models of undifferentiated pleomorphic sarcoma (fibrous histiocytoma) (PMID: 29409053).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	glioblastoma multiforme	sensitive	AZD1390	Preclinical - Cell culture	Actionable	In a preclinical study, TP53 mutant glioblastoma cells demonstrated increased sensitivity to radiosensitization by AZD1390 treatment compared to TP53 wild-type cells in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	chronic lymphocytic leukemia	predicted - sensitive	Duvelisib	Phase I	Actionable	In a Phase I trial, Duvelisib (IPI-145) treatment inhibited Akt phosphorylation, resulted in complete response in 2% (1/49), partial response in 53% (26/49), and stable disease in 43% (21/49) of chronic lymphocytic leukemia patients, of which 49% (23/47) carried TP53 mutations (Blood 124 (21): 3334).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	head and neck squamous cell carcinoma	sensitive	AZD7762 + Cisplatin	Preclinical	Actionable	In a preclinical study, the treatment of a head and neck squamous cell carcinoma cell line with mutant TP53 (C176F and A161S) with AZD7762, a pan Chk1/2 inhibitor, sensitizes the cells to Platinol (cisplatin) (PMID: 23839309).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	Advanced Solid Tumor	sensitive	Bevacizumab	Clinical Study	Actionable	In a retrospective study, Avastin (bevacizumab) treatment was associated with increased progression-free survival in cancer patients carrying TP53 mutations (PMID: 23670029).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	Advanced Solid Tumor	sensitive	Bevacizumab	Clinical Study	Actionable	In a clinical study, 106 advanced solid tumor patients harboring a TP53 mutation demonstrated a greater sensitivity to VEGF/VEGFR inhibitors, such as Avastin (bevacizumab), when compared to 82 treated patients harboring TP53 wild-type, resulting in improved rates of SD, PR, and CR, better time-to-treatment failure, and overall survival (PMID: 27466356).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	neuroblastoma	resistant	GSK2830371	Preclinical	Actionable	In a preclinical study, neuroblastoma cell lines harboring TP53 mutations were resistant to GSK2830371 induced growth inhibition in culture (PMID: 25658463).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	Advanced Solid Tumor	sensitive	CTX-1	Preclinical	Actionable	In a preclinical study, CTX-1 induced increased Tp53 protein levels and cell death in human tumor cell lines with mutant Tp53 in culture (PMID: 26883273).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	pharynx squamous cell carcinoma	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a pharynx squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	colorectal cancer	sensitive	Prodigiosin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 26759239).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	glioblastoma multiforme	sensitive	MK-1775 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of MK-1775 and radiation therapy synergized to inhibit tumor growth in a human glioblastoma multiforme cell line xenograft model harboring mutant TP53 (PMID: 21992793).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	CLL/SLL	sensitive	Idelalisib + Rituximab	Guideline	Actionable	Zydelig (idelalisib) combined with Rituxan (rituximab) is indicated in the guidelines for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	TP53 mutations except P47S and P72R are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	Advanced Solid Tumor	sensitive	Pazopanib + Vorinostat	Phase I	Actionable	In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) improved progression-free survival and overall survival in advanced solid tumor patients harboring TP53 hotspot mutations, and resulted in an increased stable disease rate of 45% (5/11), compared to a stable disease rate of 16% (4/25) in patients without detected TP53 mutations (PMID: 25669829).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	head and neck squamous cell carcinoma	predicted - sensitive	Buparlisib + Paclitaxel	Phase II	Actionable	In a Phase II (BERIL-1) trial, Buparlisib (BKM120) and Taxol (paclitaxel) combination treatment resulted in improved overall survival (HR=0.52)  and prolonged progression-free survival (HR=0.45) in head and neck squamous cell carcinoma patients harboring TP53 mutations compared to TP53 wild-type patients (PMID: 29490986; NCT01852292).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	Advanced Solid Tumor	resistant	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 did not inhibit growth of human tumor cell lines harboring TP53 mutations in culture (PMID: 25567130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	hypopharynx cancer	resistant	unspecified EGFR antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr did not inhibit proliferation of Tp53 mutated hypopharyngeal carcinoma cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	CLL/SLL	sensitive	Ibrutinib	Guideline	Actionable	Imbruvica (ibrutinib) is indicated in the guidelines for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	colorectal cancer	sensitive	Pazopanib + Vorinostat	Phase I	Actionable	In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	triple-receptor negative breast cancer	predicted - sensitive	Carboplatin + Nutlin-3	Preclinical - Cell culture	Actionable	In a preclinical study, Nutlin-3 and Paraplatin (carboplatin) synergistically inhibited growth in TP53 mutated triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26494859).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	triple-receptor negative breast cancer	predicted - sensitive	GDC-0425 + Gemcitabine	Phase I	Actionable	In a Phase I trial, treatment with GDC-0425 followed by Gemzar (gemcitabine) resulted in a partial response in a patient with triple-receptor negative breast cancer harboring a TP53 mutation (PMID: 27815358).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	medulloblastoma	decreased response	JQ1	Preclinical	Actionable	In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	colorectal cancer	sensitive	PD0166285	Preclinical	Actionable	In a preclinical study, PD0166285 sensitizes colorectal cancer cells with TP53 mutation to radiation induced cell death (PMID: 11719452).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	breast cancer	sensitive	PK11007	Preclinical - Cell culture	Actionable	In a preclinical study, TP53-mutated breast cancer cell lines demonstrated increased sensitivity to PK11007 compared to TP53-wild type cells in culture, regardless of Esr1 and Erbb2 (Her2) status (J Clin Oncol 35, 2017 (suppl; abstr e14099)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	hypopharynx cancer	predicted - sensitive	unspecified EGFR antibody + unspecified ERBB3 antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	CLL/SLL	sensitive	GDC-0199 + Rituximab	Guideline	Actionable	Venclexta (venetoclax) combined with Rituxan (rituximab) is indicated in the guidelines for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	sarcoma	predicted - sensitive	GDC-0575 + Gemcitabine	Clinical Study	Actionable	In a preclinical study, GDC-0575 and Gemzar (gemcitabine) combination treatment resulted in prolonged tumor response in 2 soft tissue sarcoma patients harboring TP53 mutations, and no response in a patient with TP53 wild-type tumor (PMID: 29409053).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	tongue squamous cell carcinoma	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a tongue squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 mutant	non-small cell lung carcinoma	sensitive	CEP-8983 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK	wild-type TP53 mutant	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P177T	osteosarcoma	resistant	Nutlin-3a	Preclinical	Actionable	In a preclinical study, TP53 P177T resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK	wild-type TP53 P177T	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	predicted - sensitive	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA Q546K TP53 R282W	colorectal cancer	decreased response	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D TP53 R175H	pancreatic ductal adenocarcinoma	sensitive	SRA737	Preclinical	Actionable	In a preclinical study, SRA737 (CCT245737) resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D TP53 R175H	pancreatic ductal adenocarcinoma	sensitive	Gemcitabine + SRA737	Preclinical	Actionable	In a preclinical study, Gemzar (gemcitabine) resulted in enhanced antitumor efficacy, including decreased tumor volume, when combined with SRA737 (CCT245737) in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H (PMID: 27167172).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D TP53 R175H	pancreatic cancer	sensitive	Pimasertib + Gemcitabine	Preclinical	Actionable	In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D TP53 R175H	pancreatic ductal adenocarcinoma	conflicting	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) treatment in transgenic animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H resulted in proliferation of tumor cells in interior, hypovascularized tumor regions, but inhibited proliferation in outer, vascularized tumor regions, despite inhibition of mTORC signaling in both regions (PMID: 26144316).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	MET del exon14 TP53 R175H	histiocytic and dendritic cell cancer	sensitive	Crizotinib	Clinical Study	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET del exon14 and TP53 R175H (PMID: 25971938).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	Advanced Solid Tumor	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, treatment with ReACp53 induced cell death in primary human uterine fibroblasts expressing TP53 R175H in culture (PMID: 26748848).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	breast cancer	sensitive	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R175H in culture (PIMD: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	Advanced Solid Tumor	sensitive	Alvespimycin + Vorinostat	Preclinical	Actionable	In a preclinical study, Alvespimycin (17-DMAG) and Zolinza (vorinostat) extended survival by 59% in mice with tumors expressing Tp53 R172H (which corresponds to R175H in the human Tp53 protein) (PMID: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	head and neck cancer	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death and decreased proliferation of head and neck carcinoma cells harboring TP53 R175H in culture (PMID: 26748848).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	breast cancer	sensitive	NSC319726	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	colorectal cancer	sensitive	NSC59984	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175H in culture (PMID: 26294215).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	non-small cell lung carcinoma	resistant	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 R175H were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R175H	ovarian cancer	sensitive	NSC319726	Preclinical - Cell culture	Actionable	In a preclinical study, ovarian cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726-induced growth inhibition in culture and in cell line xenograft models (PMID: 22624712).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRAF V600E TP53 Q192K	colon cancer	sensitive	Vemurafenib + Panitumumab	Clinical Study	Actionable	In a clinical study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P278R	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P278R in culture (PMID: 27179933).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PTEN loss TP53 V216M	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 L194F	breast cancer	sensitive	Vorinostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zolinza (vorinostat) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 L194F	breast cancer	sensitive	Tanespimycin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 L194F	breast cancer	sensitive	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PIMD: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 L194F	breast cancer	sensitive	Tanespimycin + Vorinostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tanespimycin (17-AAG) and Zolinza (vorinostat) were synergistic towards tumor growth inhibition in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	EGFR exon 19 del TP53 wild-type	non-small cell lung carcinoma	sensitive	unspecified EGFR tyrosine kinase inhibitor	Clinical Study	Actionable	In a clinical study, non-small cell lung carcinoma patients harboring an EGFR exon 19 deletion and TP53 wild-type exon 8 demonstrated a median progression-free survival of 16.8 months following first-line treatment with an EGFR tyrosine kinase inhibitor, such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Dacomitinib, compared with 4.2 months in patients harboring a TP53 exon 8 mutation and EGFR exon 19 deletion (PMID: 27780855).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK wild-type TP53 wild-type	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mut + TP53 wild-type	colorectal cancer	sensitive	AMG 232 + Irinotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AMG 232 and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mut + TP53 wild-type	colorectal cancer	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mut + TP53 wild-type	colorectal cancer	sensitive	ABT-263 + Alpelisib + CGM097 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mut + TP53 wild-type	Advanced Solid Tumor	sensitive	Oxaliplatin + ABT-737	Preclinical	Actionable	In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK act mut TP53 wild-type	neuroblastoma	predicted - sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRAF mut + TP53 wild-type	melanoma	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRAF mut + TP53 wild-type	melanoma	sensitive	CGM097 + LGX818	Preclinical	Actionable	In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRAF mut + TP53 wild-type	colorectal cancer	sensitive	ABT-263 + CGM097 + Dabrafenib + PF-04217903	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRAF V600E PTEN loss TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	breast cancer	predicted - sensitive	SAR405838	Preclinical - Pdx	Actionable	In a preclinical study, SAR405838 (MI-77301) induced p53 signaling and inhibited tumor growth in patient-derived xenograft models of endocrine therapy-resistant breast cancer  with wild-type TP53, and induced cell-cycle arrest and inhibited growth of patient-derived  endocrine therapy-resistant breast cancer cells in culture (PMID: 27765850).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	lung large cell carcinoma	resistant	NSC319726	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	neuroblastoma	predicted - sensitive	GSK2830371	Preclinical	Actionable	In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	sarcoma	sensitive	MK-1775 + Gemcitabine	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the combination of MK-1775 and Gemzar (gemcitabine) induced cell death in a variety of sarcoma cell lines and inhibited tumor growth in a patient-derived sarcoma xenograft model, independent of TP53 mutational status (PMID: 23520471).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	breast cancer	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type breast cancer cells in culture (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colon carcinoma	sensitive	MPI-0479605	Preclinical	Actionable	In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	non-small cell lung carcinoma	sensitive	AMG 232 + Carboplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AMG 232 and Paraplatin (carboplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	breast cancer	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type breast cancer cells in culture (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	papillary thyroid carcinoma	sensitive	APG-115	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with APG-115 demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	non-small cell lung carcinoma	sensitive	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, Roscovotine (seliciclib) induced substantial apoptosis in non-small cell lung carcinoma cells overexpressing wild-type TP53 in culture (PMID: 22862161).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	endometrioid ovary carcinoma	sensitive	thioureidobutyronitrile	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	Merkel cell carcinoma	sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	ovarian cancer	no benefit	p53-SLP vaccine	Phase II	Actionable	In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	lymphoma	predicted - sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	Advanced Solid Tumor	sensitive	CTX-1	Preclinical	Actionable	In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	lung carcinoma	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a lung carcinoma cell line harboring wild-type TP53 in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colon cancer	sensitive	MK-1775 + PF-00477736	Preclinical	Actionable	In a preclinical study, MK-1775, in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	neuroblastoma	predicted - sensitive	Carboplatin + GSK2830371	Preclinical	Actionable	In a preclinical study, GSK283071 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colorectal cancer	predicted - sensitive	MLN0128 + PD-0325901	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	Advanced Solid Tumor	sensitive	HDM201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, HDM201 treatment resulted in tumor regression in various cell line xenograft models of Tp53 wild-type tumors (Cancer Res 2016;76(14 Suppl):Abstract nr 4855).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	melanoma	sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	osteosarcoma	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colorectal cancer	sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2505)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	Advanced Solid Tumor	predicted - sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colon cancer	sensitive	SAR405838	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	lung cancer	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	acute myeloid leukemia	sensitive	Cytarabine + RO6839921	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RO6839921 and Cytosar-U (cytarabine) combination treatment demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	melanoma	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	melanoma	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	peripheral T-cell lymphoma	sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colorectal cancer	sensitive	Prodigiosin	Preclinical	Actionable	In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	non-small cell lung carcinoma	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a non-small cell lung cancer (NSCLC) cell line with wild-type TP53 in culture and inhibited tumor growth in a TP53 wild-type NSCLC cell line xenograft model (PMID: 25567130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colon cancer	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	acute leukemia	sensitive	SAR405838	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR405838 inhibited growth of TP53 wild-type acute leukemia cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	Advanced Solid Tumor	unknown	MK-8242	Phase I	Actionable	In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with TP53 wild-type advanced solid tumors, particularly those with liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and 75.6% (31/41) of patients achieving stable disease (PMID: 28240971).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	ovarian cancer	predicted - sensitive	Ad.p53-DC vaccine	Phase I	Actionable	In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	non-small cell lung carcinoma	sensitive	CEP-8983 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colon cancer	sensitive	CPUY201112	Preclinical	Actionable	In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	lung cancer	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	Advanced Solid Tumor	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of several human tumor cell lines with wild-type TP53 in culture and in cell line xenograft models (PMID: 25567130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	liposarcoma	predicted - sensitive	MK-8242	Phase I	Actionable	In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors, particularly those with TP53 wild-type liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and a median progression-free survival in LPS of 237 days (PMID: 28240971).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	osteosarcoma	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	acute myeloid leukemia	sensitive	CTX-1 + Nutlin-3	Preclinical	Actionable	In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	medulloblastoma	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	neuroblastoma	predicted - sensitive	Doxorubicin + GSK2830371	Preclinical	Actionable	In a preclinical study, GSK283071 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	prostate cancer	sensitive	SAR405838	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	Advanced Solid Tumor	decreased response	Pazopanib + Vorinostat	Phase I	Actionable	In a Phase I study, patients with advanced solid tumor harboring TP53 mutations had increased progression-free survival and overall survival than TP53 wild-type patients after treatment with Votrient (pazopanib) in combination with Zolinza (vorinostat) (J Clin Oncol 32:5s, 2014 (suppl; abstr 2576)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	osteosarcoma	sensitive	CPUY201112	Preclinical	Actionable	In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	liposarcoma	sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (J Clin Oncol 35, 2017 (suppl; abstr 2505)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	Advanced Solid Tumor	sensitive	CTX-1 + Nutlin-3	Preclinical	Actionable	In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	salivary gland adenoid cystic carcinoma	predicted - sensitive	Cisplatin + SAR405838	Preclinical - Pdx	Actionable	In a preclinical study, the combination of SAR405838 (MI-773) and Platinol (cisplatin) resulted in increased Tp53 and Mdm2 expression, and demonstrated improved efficacy over either agent alone in TP53 wild-type patient-derived xenograft (PDX) models of salivary gland adenoid cystic carcinoma, resulting in tumor regression without tumor rebound after cessation of therapy (PMID: 27550999).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	salivary gland adenoid cystic carcinoma	predicted - sensitive	SAR405838	Preclinical - Pdx	Actionable	In a preclinical study, treatment with SAR405838 (MI-773) resulted in activation of Mdm2 and Tp53 in patient-derived salivary gland adenoid cystic carcinoma (ACC) cells in culture, and led to induction of apoptosis and tumor regression in ACC patient-derived xenograft (PDX) models with wild-type TP53 (PMID: 26936915).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	fibrosarcoma	sensitive	Doxil + RO6839921	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RO6839921 and Doxil combination treatment demonstrated sustained survival benefit in TP53 wild-type fibrosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colon cancer	sensitive	Trifluridine	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colon cancer	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	acute myeloid leukemia	sensitive	ALRN-6924	Preclinical - Patient cell culture	Actionable	In a preclinical study, ALRN-6924 inhibited growth of cells derived from patients with TP53 wild-type acute myeloid leukemia in culture, and inhibited leukemia cell growth, prolonged survival in cell line xenograft models (PMID: 29643228).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	colorectal cancer	predicted - sensitive	MK-8745	Preclinical - Cell culture	Actionable	In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	non-small cell lung carcinoma	sensitive	AMG 232 + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AMG 232 and Platinol (cisplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone, resulting in tumor stasis (PMID: 25567130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	acute myeloid leukemia	sensitive	CTX-1	Preclinical	Actionable	In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type	acute myeloid leukemia	sensitive	RO6839921	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK mut TP53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type RB1 wild-type	colon carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type RB1 wild-type	breast carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type RB1 wild-type	mantle cell lymphoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type RB1 wild-type	lung carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 wild-type RB1 wild-type	melanoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK	F1174L TP53	wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRAF V600E PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	decreased response	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	predicted - sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PIK3CA H1047R TP53 wild-type	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G13D PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	sensitive	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	decreased response	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA E545K TP53 wild-type	colorectal cancer	decreased response	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK	F1245C TP53	wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Pdx	Actionable	In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK amp Tp53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12C PIK3CA H1047R TP53 R248W	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R248W	non-small cell lung carcinoma	sensitive	APR-246 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R248W VHL inact mut	clear cell renal cell carcinoma	resistant	PT2399	Preclinical - Cell culture	Actionable	In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	resistant	Selumetinib	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	no benefit	Selumetinib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PIK3CA H1047R TP53 R248W	colorectal cancer	predicted - sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	RB1 K240Sfs*22 TP53 R248W	Her2-receptor negative breast cancer	predicted - resistant	Fulvestrant + Palbociclib	Clinical Study	Actionable	In a clinical case study, RB1 K240Sfs*22 and TP53 R248W were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 5 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ERBB2 amp TP53 R158H	gastric adenocarcinoma	predicted - resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D PTEN dec exp TP53 R306*	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R280K	triple-receptor negative breast cancer	sensitive	YW3-56	Preclinical - Cell line xenograft	Actionable	In a preclinical study, YW3-56 inhibited proliferation of a human triple-negative breast cancer (TNBC) cell line harboring TP53 R280K in culture and inhibited tumor growth in TP53 R280K-mutant TNBC cell line xenograft models (PMID: 25612620).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R280K	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically in culture, resulting in reduced cell viability in patient derived ovarian cancer cells harboring TP53 R280K (PMID: 27179933).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R280K	breast cancer	sensitive	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R280K in culture (PMID: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	MET del exon14 TP53 N30fs*14	lung large cell carcinoma	sensitive	Capmatinib	Clinical Study	Actionable	In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET del exon14 and TP53 N30fs*14 (PMID: 25971938).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 I195* TP53 R248Q	ovarian carcinoma	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death and decreased proliferation of human primary ovarian carcinoma cells harboring both TP53 I195* and TP53 R248Q in culture (PMID: 26748848).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12D TP53 S127Y	lung adenocarcinoma	sensitive	Dasatinib + Demcizumab	Preclinical - Pdx	Actionable	In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12D and TP53 S127Y (PMID: 26855149).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 I232S	osteosarcoma	resistant	Nutlin-3a	Preclinical	Actionable	In a preclinical study, TP53 I232S resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS G12V PIK3CA E545K TP53 R335fs	colorectal cancer	no benefit	MLN0128 + PD-0325901	Preclinical - Pdx	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mut TP53 G105C TP53 V157fs	ovarian cancer	predicted - sensitive	MK-1775 + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 G105C, V157fs and mutations in Kras (PMID: 27998224).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 Y163C	lung small cell carcinoma	sensitive	APR-246 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of small lung cancer cells harboring TP53 Y163C in culture (PMID: 26086967).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRAF V600E PIK3CA P449T TP53 R273H	colorectal cancer	sensitive	MLN0128 + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R273H	non-small cell lung carcinoma	sensitive	APR-246 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRCA1 loss TP53 loss	breast cancer	sensitive	AZD2461	Preclinical	Actionable	In a preclinical study, a breast cancer model lacking both BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	BRCA1 C61G TP53 loss	breast cancer	decreased response	Olaparib	Preclinical	Actionable	In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	KRAS mut STK11 loss TP53 loss	non-small cell lung carcinoma	predicted - sensitive	MK-1775 + Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	glioblastoma multiforme	sensitive	BLZ945	Preclinical	Actionable	In a preclinical study, treatment with BLZ945 demonstrated some efficacy, specifically a 56% tumor reduction, in transgenic mouse models of glioblastoma with a loss of TP53 (PMID: 27199435).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	pancreatic cancer	sensitive	MK-1775 + Gemcitabine	Preclinical - Pdx	Actionable	In a preclinical study, the combination of MK-1775 and Gemzar (gemcitabine) inhibited Wee1 expression, Cdc2 phosphorylation, and tumor growth in several patient-derived xenograft models of pancreatic cancer harboring TP53 mutations (PMID: 21389100).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	ovarian cancer	no benefit	ReACp53	Preclinical	Actionable	In a preclincial study, ReACp53 did not induce cell death in ovarian cancer cells with loss of TP53 in culture (PMID: 26748848).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	colon cancer	decreased response	CPUY201112	Preclinical	Actionable	In a preclinical study, colon cancer cells lacking TP53 had a decreased response to CPUY201112 in culture, when compared to colon cancer cells with wild-type TP53 (PMID: 26743233).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	colorectal cancer	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD6738 increased sensitivity to radiotherapy in colorectal cancer xenograft models harboring a loss of TP53, resulting in a greater delay of tumor growth compared to radiation alone and an improved survival compared to control or either agent alone (PMID: 28062704).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	CLL/SLL	sensitive	Idelalisib + Rituximab	Guideline	Actionable	Zydelig (idelalisib) combined with Rituxan (rituximab) is indicated in the guidelines for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	Advanced Solid Tumor	decreased response	CTX-1	Preclinical	Actionable	In a preclinical study, CTX-1 induced cell death in TP53-deficient human tumor cell lines in culture, but had a greater effect on cell lines with wild-type TP53 compared to isogenic cell lines with TP53 loss (PMID: 26883273).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	colorectal cancer	sensitive	PHA-680632 + Radiotherapy	Preclinical - Pdx	Actionable	In a preclinical study, PHA-680632 synergized with radiotherapy to decrease tumor growth in Pdx models deficient in Tp53 (PMID: 18026198).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	CLL/SLL	sensitive	Ibrutinib	Guideline	Actionable	Imbruvica (ibrutinib) is indicated in the guidelines for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	Advanced Solid Tumor	sensitive	Adavosertib	Preclinical	Actionable	In a preclinical study, tumor cell lines carrying deficient TP53 were sensitized to DNA-damaging agents upon MK-1775 administration (PMID: 19887545).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	CLL/SLL	sensitive	Venetoclax	Guideline	Actionable	Venclexta (venetoclax) is indicated in the guidelines for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	colon carcinoma	sensitive	MPI-0479605	Preclinical	Actionable	In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	lung cancer	resistant	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 did not enhance radiation-induced cytotoxicity in TP53-null lung cancer cells in culture and in cell line xenograft models (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	colorectal cancer	sensitive	Prodigiosin	Preclinical	Actionable	In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 loss in culture (PMID: 26759239).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	colorectal cancer	predicted - sensitive	Ad5CMV-p53 gene	Preclinical	Actionable	In a preclinical study, Ad5CMV-p53 gene therapy suppressed growth of allograft colorectal cancer in rat models (PMID: 15608394).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	lung cancer	resistant	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, TP53-null lung cancer cells were resistant to AMG 232 induced growth inhibition in culture (PMID: 26162687).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	thymoma	predicted - resistant	Selinexor	Preclinical - Cell culture	Actionable	In a preclinical study, a thymoma cell line with TP53 loss demonstrated primary resistance to Selinexor (KPT-330) in  culture, and reconstitution of TP53 expression resulted in increased Selinexor sensitivity (PMID: 28819023).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	colon cancer	sensitive	CHIR-124 + SN-38	Preclinical - Cell culture	Actionable	In a preclinical study, a colon cancer cell line deficient in TP53 demonstrated increased sensitivity to sequential treatment with SN-38 and CHIR-124 compared to cells with wild-type TP53, resulting in increased apoptosis and micronucleation in culture (PMID: 17255282).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	CLL/SLL	sensitive	GDC-0199 + Rituximab	Guideline	Actionable	Venclexta (venetoclax) combined with Rituxan (rituximab) is indicated in the guidelines for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	colon carcinoma	sensitive	SP600125	Preclinical	Actionable	In a preclinical study, SP600125 induced cell death in colon carcinoma cells deficient for p53 (PMID: 22438244).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	ovarian cancer	sensitive	LB-100 + Cisplatin	Preclinical	Actionable	In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in cisplatin-resistant ovarian cancer cells with TP53 loss in culture and in xenograft models (PMID: 25376608).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	acute myeloid leukemia	resistant	ALRN-6924	Preclinical - Cell culture	Actionable	In a preclinical study, ALRN-6924 did not inhibit the growth of TP53-null acute myeloid leukemia cells in culture (PMID: 29643228).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 loss	osteosarcoma	decreased response	CPUY201112	Preclinical	Actionable	In a preclinical study, an osteosarcoma cell line lacking TP53 demonstrated a decreased response to CPUY201112 in culture, when compared to osteosarcoma cells with wild-type TP53 (PMID: 26743233).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	PTEN loss TP53 loss	prostate cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of  prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK rearrange RB1 C706F TP53 loss	lung small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study	Actionable	In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 C238F	fallopian tube cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived fallopian tube cancer cells harboring TP53 C238F in culture (PMID: 27179933).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	ALK	wild-type TP53 C176F	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 Y234C	ovarian carcinoma	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y234C in culture (PMID: 26748848).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 Y234C	non-small cell lung carcinoma	decreased response	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y234C demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 P98A	non-small cell lung carcinoma	decreased response	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 P98A demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R248Q	Advanced Solid Tumor	sensitive	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib extended survival by 48% in mice with tumors expressing TP53 R248Q (PMID: 26009011).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R248Q	acute myeloid leukemia	resistant	ALRN-6924	Preclinical - Cell culture	Actionable	In a preclinical study, ALRN-6924 did not inhibit the growth of acute myeloid leukemia cells harboring TP53 R248Q in culture (PMID: 29643228).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R248Q	ovarian cancer	sensitive	ReACp53	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, ReACp53 rescued p53 activity and decreased viability of ovarian cancer cells harboring TP53 R248Q in culture, and induced tumor regression in patient-derived ovarian cancer xenograft models harboring TP53 R248Q (PMID: 26748848).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 R248Q	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of a Platinol (cisplatin)-resistant ovarian cancer cell line harboring TP53 R248Q in culture and inhibited tumor growth in TP53 R248Q-carrying ovarian cancer cell line xenograft models (PMID: 26086967).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 positive	breast cancer	sensitive	Serdemetan	Phase I	Actionable	In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 positive	Advanced Solid Tumor	sensitive	MVAp53	Phase I	Actionable	In a phase I study, Ankara (MVAp53) demonstrated safety and efficacy in patients with metastatic colon, gastric and pancreas cancer stained positive for p53 (J Clin Oncol 31, 2013 (suppl; abstr 3089)).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 positive	Advanced Solid Tumor	predicted - sensitive	p28	Phase I	Actionable	In a Phase I trial, treatment with p28 was well-tolerated and demonstrated preliminary efficacy in patients with Tp53-positive advanced solid tumors, with complete response in 6% (1/15), partial response in 20% (3/15), and stable disease in 46% (7/15) of patients (PMID: 23449360).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 positive	Advanced Solid Tumor	sensitive	Serdemetan	Phase I	Actionable	In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 positive	ovarian cancer	predicted - sensitive	NU6027 + Temozolomide	Preclinical - Cell culture	Actionable	In a preclinical study, NU6027 enhanced the efficacy of Temodar (temozolomide) in ovarian cancer cells with mismatch repair activity and positive for TP53 in culture, demonstrating a 50% greater decrease in cell survival compared to Temodar (temozolomide) alone (PMID: 21730979).
TP53	BCC7 | LFS1 | P53 | TRP53	17p13.1	NM_000546	TP53 over exp	ovarian cancer	predicted - sensitive	p53:264-272 vaccine	Phase I	Actionable	In a Phase I trial, the HLA-A2 p53:264-272 vaccine demonstrated safety and preliminary efficacy in patients with TP53 overexpressing ovarian cancer, resulting in a progression-free survival of 5.5 months and an overall survival of 40.4 months (PMID: 21927947).
U2AF1	FP793 | RN | RNU2AF1 | U2AF35 | U2AFBP	21q22.3	NM_006758	U2AF1 S34X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	U2AF1 S34X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
U2AF1	FP793 | RN | RNU2AF1 | U2AF35 | U2AFBP	21q22.3	NM_006758	U2AF1 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	U2AF1 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
U2AF1	FP793 | RN | RNU2AF1 | U2AF35 | U2AFBP	21q22.3	NM_006758	U2AF1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Emerging	In multiple clinical studies, the presence of U2AF1 mutations was associated with a trend toward risk of progression to acute myeloid leukemia, however, the prognostic significance of U2AF1 mutations is still unclear (PMID: 25465125, PMID: 22158538, PMID: 22389253).
U2AF1	FP793 | RN | RNU2AF1 | U2AF35 | U2AFBP	21q22.3	NM_006758	U2AF1 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).
U2AF1	FP793 | RN | RNU2AF1 | U2AF35 | U2AFBP	21q22.3	NM_006758	U2AF1 S34F	lung cancer	sensitive	H3B-8800	Preclinical - Cell line xenograft	Actionable	In a preclinical study, H3B-8800 preferentially inhibited growth of lung cancer cells harboring U2AF1 S34F compared to U2AF1 wild-type cells in culture and in cell line xenograft models (Cancer Res 2017;77(13 Suppl):Abstract nr 1185).
U2AF1	FP793 | RN | RNU2AF1 | U2AF35 | U2AFBP	21q22.3	NM_006758	U2AF1 Q157X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	U2AF1 Q157X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL over exp	clear cell renal cell carcinoma	no benefit	Cediranib + Saracatinib	Phase II	Actionable	In a Phase II clinical study, baseline expression of VHL was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL del	renal cell carcinoma	predicted - sensitive	Regorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited angiogenesis and tumor growth in cell line xenograft models of renal cell carcinoma harboring VHL gene deletion (PMID: 21170960).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL V155fs	kidney cancer	predicted - sensitive	Sunitinib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Sutent (sunitinib) inhibited tumor growth in patient-derived xenograft models of renal cancer harboring VHL V155fs (referred to as V155fs*4) (PMID: 26487278).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	PTEN loss VHL loss	renal carcinoma	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL loss	renal cell carcinoma	sensitive	ELR510444	Preclinical - Cell line xenograft	Actionable	In a preclinical study, renal cell carcinoma cells deficient for VHL were sensitive to ELR510444 both in culture and in cell line xenograft models (PMID: 22295124).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL loss	renal cell carcinoma	sensitive	Bevacizumab	Preclinical	Actionable	In a preclinical study, clear cell renal cell carcinoma xenograft models with VHL loss demonstrated sensitivity to Avastin (bevacizumab) (PMID: 22931246).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL loss	renal cell carcinoma	sensitive	CB-839	Preclinical - Cell culture	Actionable	In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition in culture when treated with CB-839 (PMID: 28346230).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL loss	renal cell carcinoma	sensitive	BPTES	Preclinical - Cell culture	Actionable	In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition and suppression of DNA synthesis in culture when treated with BPTES (PMID: 28346230).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL loss	renal cell carcinoma	sensitive	CB-839 + Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of CB-839 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating greater reduction in tumor volume compared to either agent alone in renal carcinoma cell xenograft models deficient for VHL (PMID: 28346230).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL loss	renal cell carcinoma	sensitive	BPTES + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BPTES and Lynparza (olaparib) resulted in a synergistic effect, demonstrating growth inhbition of VHL-deficient renal cell carcinoma cells in culture (PMID: 28346230).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL negative	renal cell carcinoma	sensitive	STF-62247	Preclinical	Actionable	In a preclinical study, STF-62247 induced selective cytotoxicity and inhibited tumor growth of renal cell carcinoma cells lacking VHL (PMID: 18769110, PMID: 18598947).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL mut	renal cell carcinoma	sensitive	Everolimus	Phase I	Actionable	In a Phase I study, Afinitor (everolimus), as compared to Apitolisib (GDC-0980), resulted in a greater progression free survival and overall survival in patients with renal cell carcinoma harboring VHL mutations (J Clin Oncol 32:5s, 2014 (suppl; abstr 4525)).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL mut	renal cell carcinoma	no benefit	N/A	Clinical Study	Prognostic	In a meta-analysis of 6 clinical studies, VHL mutation status was not associated with overall response rate (relative risk=1.47, p=0.20), progression-free survival (HR=1.02, p=0.91), or overall survival (HR=0.80, p=0.21) in a total of 633 patients with renal cell carcinoma who received anti-VEGF therapy (PMID: 28103578).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL mut	renal cell carcinoma	sensitive	Sunitinib	Phase I	Actionable	In a Phase I study, 33% (6/18) of renal cell carcinoma archived patient samples with VHL mutations demonstrated partial response when treated with Sutent (sunitinib) (PMID: 22105611).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL inact mut	renal cell carcinoma	predicted - sensitive	Everolimus	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had a trend towards improved in progression free survival when stratified by the presence (median PFS=8.6 months, n=15) or absence (median PFS=5.5 months, n=16) of deleterious VHL mutations (PMID: 26951309).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL inact mut	clear cell renal cell carcinoma	conflicting	PT2399	Preclinical - Pdx	Actionable	In a preclinical study, PT2399 had variable impact on tumor growth in clear cell renal cell carcinoma (ccRCC) cell line and patient-derived xenograft (PDX) models with defective VHL, with decreased tumor growth in a VHL-defective ccRCC PDX model and some VHL-defective ccRCC cell line xenograft models, and no tumor suppression in other cell line xenograft models (PMID: 27595393).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL inact mut	renal cell carcinoma	predicted - sensitive	Bevacizumab + Alpha 2 Interferon	Clinical Study	Actionable	In a retrospective analysis, VHL alterations did not impact overall survival or objective response in renal cell carcinoma patients treated with a VEGF-targeted therapy,including Avastin (bevacizumab) and Alpha 2 Interferon combination therapy, but were associated with a prolonged time to progression (PMID: 16827904).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	VHL inact mut	renal cell carcinoma	no benefit	GDC-0980	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=5) or absence (n=17) of deleterious VHL mutations (PMID: 26951309).
VHL	HRCA1 | pVHL | RCA1 | VHL1	3p25.3	NM_000551	TP53 R248W VHL inact mut	clear cell renal cell carcinoma	resistant	PT2399	Preclinical - Cell culture	Actionable	In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).
ZRSR2	U2AF1-RS2 | U2AF1L2 | U2AF1RS2 | URP | ZC3H22	Xp22.2	NM_005089	ZRSR2 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	ZRSR2 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).
